3560096
D013467_D006947 CID sulindac_3\NN\3828465| (r_compound) therapy_4\NN\657604|with|sulindac (r_nmod) associated_1\VBN\628491|therapy (r_acl) hyperkalemia_0\NN\14299637|associated|.
D013467_D006947 CID sulindac_20\NN\3828465| (r_compound) administration_21\NN\1133281|of|sulindac (r_nmod) days_18\NNS\15140892|within|8|administration (r_nmod) developed_13\VBD\1753788|whom|hyperkalemia|days (l_nsubj) hyperkalemia_6\NN\14299637|ranging
D013467_D006947 CID sulindac_25\NN\3828465|between|and|hyperkalemia (l_conj) hyperkalemia_27\NN\14299637|
D007213_D006947 CID indomethacin_17\NN\3828465|such (r_nmod) agents_11\NNS\7347|of|nonsteroidal|antiinflammatory|nsaid|indomethacin (r_nmod) complication_7\NN\1073995|as|a|agents (r_nmod) recognized_4\VBN\686447|hyperkalemia|has|recently|been|complication|. (l_nsubjpass) hyperkalemia_0\NN\14299637|
D011188_D006947 NONE potassium_8\NN\14625458|serum (r_dobj) effect_6\VB\1645601|to|potassium (r_xcomp) known_4\VBN\2110220|effect (r_acl) medications_3\NNS\3247620|no|other|known (r_nsubjpass) given_11\VBN\2327200|as|medications|had|been|concomitantly (r_advcl) suggestive_19\JJ\1740|given|,|course|is|relationship|. (l_nmod) relationship_23\NN\31921|of|a|cause-and-effect|sulindac (l_nmod) sulindac_25\NN\3828465|between|and|hyperkalemia (l_conj) hyperkalemia_27\NN\14299637|
1130930
D002512_D007674 NONE cephalothin-gentamicin_3\NN\1740| (r_compound) regimen_4\NN\5898568|of|combined|cephalothin-gentamicin (r_nmod) nephrotoxicity_0\NN\1740|regimen|.
D005839_D007674 NONE cephalothin-gentamicin_3\NN\1740| (r_compound) regimen_4\NN\5898568|of|combined|cephalothin-gentamicin (r_nmod) nephrotoxicity_0\NN\1740|regimen|.
D002512_D007683 CID sodium_23\NN\14625458|of|cephalothin|and|sulfate (r_nmod) combination_20\NN\7951464|a|sodium|therapy (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized
D002512_D009846 NONE sodium_23\NN\14625458|of|cephalothin|and|sulfate (r_nmod) combination_20\NN\7951464|a|sodium|therapy (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
D002512_D051437 NONE sodium_23\NN\14625458|of|cephalothin|and|sulfate (r_nmod) combination_20\NN\7951464|a|sodium|therapy (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
D005839_D007683 CID sulfate_26\NN\15010703|gentamicin (r_conj) sodium_23\NN\14625458|of|cephalothin|and|sulfate (r_nmod) combination_20\NN\7951464|a|sodium|therapy (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized
D005839_D009846 NONE sulfate_26\NN\15010703|gentamicin (r_conj) sodium_23\NN\14625458|of|cephalothin|and|sulfate (r_nmod) combination_20\NN\7951464|a|sodium|therapy (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
D005839_D051437 NONE sulfate_26\NN\15010703|gentamicin (r_conj) sodium_23\NN\14625458|of|cephalothin|and|sulfate (r_nmod) combination_20\NN\7951464|a|sodium|therapy (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
2951327
D009638_D013610 NONE norepinephrine_72\NN\14807929| (r_compound) rate_74\NN\13815152|of|the|norepinephrine|release (r_nmod) augmentation_69\NN\7356676|no|rate (r_conj) tachycardia_66\NN\14110674|no|and|augmentation|microgram/kg/min
D009638_D007022 NONE norepinephrine_72\NN\14807929| (r_compound) rate_74\NN\13815152|of|the|norepinephrine|release (r_nmod) augmentation_69\NN\7356676|no|rate (r_conj) tachycardia_66\NN\14110674|no|and|augmentation|microgram/kg/min (r_conj) 99_26\CD\1740|pressure|was|+/-|1|,|95|,|93|,|or|%|,|respectively|,|but|tachycardia|observed (l_dep) observed_82\VBN\2163746|were|,|contrast|. (l_dep) contrast_87\NN\13854649|which|is|in|hypotension (l_nmod) hypotension_90\NN\14057371|to|comparable|induced
D006830_D013610 NONE hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|to|comparable|induced (r_nmod) contrast_87\NN\13854649|which|is|in|hypotension (r_dep) observed_82\VBN\2163746|were|,|contrast|. (r_dep) 99_26\CD\1740|pressure|was|+/-|1|,|95|,|93|,|or|%|,|respectively|,|but|tachycardia|observed (l_conj) tachycardia_66\NN\14110674|no|and|augmentation|microgram/kg/min
D006830_D007022 CID hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|to|comparable|induced
D005996_D013610 NONE nitroglycerin_95\NN\15015501| (r_conj) hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|to|comparable|induced (r_nmod) contrast_87\NN\13854649|which|is|in|hypotension (r_dep) observed_82\VBN\2163746|were|,|contrast|. (r_dep) 99_26\CD\1740|pressure|was|+/-|1|,|95|,|93|,|or|%|,|respectively|,|but|tachycardia|observed (l_conj) tachycardia_66\NN\14110674|no|and|augmentation|microgram/kg/min
D005996_D007022 CID nitroglycerin_95\NN\15015501| (r_conj) hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|to|comparable|induced
11166519
D003042_D012640 CID cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|acute|cocaine-induced|:|sensitivity
D003042_D012640 CID cocaine_22\NN\3492717|of (r_nmod) injection_20\NN\320852|by|a|single|cocaine (r_nmod) induced_16\VBN\1627355|injection (r_acl) seizures_15\NNS\14081375|to|behavioral|induced
D003042_D012640 CID cocaine-induced_14\JJ\1740| (r_amod) seizures_15\NNS\14081375|on|cocaine-induced
11642480
D015283_D004409 CID citalopram_7\NN\1740|on (r_nmod) twitching_1\NN\14360459|palpebral|adolescent|citalopram|.
D015283_D004409 CID citalopram_8\NN\1740|with (r_nmod) treatment_6\NN\654885|to|citalopram (r_nmod) response_4\NN\11410625|a|favorable|treatment|boy (l_nmod) boy_12\NN\9624168|by|a|15-year-old|depression|exhibited (l_acl:relcl) exhibited_17\VBD\2632167|who|twitching|weeks (l_dobj) twitching_19\NN\14360459|palpebral
D015283_D003866 NONE citalopram_7\NN\1740|on (r_nmod) twitching_1\NN\14360459|palpebral|adolescent|citalopram|. (l_nmod) adolescent_5\NN\9622049|in|a|depressed (l_amod) depressed_4\JJ\1740|
D015283_D003865 NONE citalopram_8\NN\1740|with (r_nmod) treatment_6\NN\654885|to|citalopram (r_nmod) response_4\NN\11410625|a|favorable|treatment|boy (l_nmod) boy_12\NN\9624168|by|a|15-year-old|depression|exhibited (l_nmod) depression_15\NN\14373582|with|major
3693336
D014229_D001714 CID triazolam-induced_0\NN\1740| (r_amod) episodes_2\NNS\7283608|triazolam-induced|brief|mania|patient|. (l_nmod) mania_5\NN\9180259|of|secondary
D014229_D001714 CID triazolam_3\NN\2830852|of (r_nmod) doses_1\NNS\3740161|large|triazolam (r_nsubj) induced_5\VBD\1627355|doses|repeatedly|episodes|woman|. (l_dobj) episodes_7\NNS\7283608|brief|mania (l_nmod) mania_9\NN\9180259|of
D014229_D001714 CID triazolam_10\NN\2830852|of (r_nmod) action_8\NN\30358|of|triazolam (r_nmod) duration_6\NN\15113229|with|the|action (r_nmod) coincident_3\JJ\1740|excitement|was|duration|. (l_nsubj) excitement_1\NN\7527352|manic (l_amod) manic_0\JJ\1740|
D014229_D003866 NONE triazolam-induced_0\NN\1740| (r_amod) episodes_2\NNS\7283608|triazolam-induced|brief|mania|patient|. (l_nmod) patient_9\NN\9898892|in|a|depressed (l_amod) depressed_8\JJ\1740|
D014229_D003866 NONE triazolam_3\NN\2830852|of (r_nmod) doses_1\NNS\3740161|large|triazolam (r_nsubj) induced_5\VBD\1627355|doses|repeatedly|episodes|woman|. (l_nmod) woman_14\NN\9605289|in|a|depressed|elderly (l_amod) depressed_12\JJ\1740|
18996674
D004837_D011317 NONE epinephrine_1\NN\14807929|intracavernous|:|treatment|. (l_appos) treatment_6\NN\654885|a|invasive|priapism (l_nmod) priapism_8\NN\14204950|for|department
D003042_D011317 CID cocaine_7\NN\3492717| (r_compound) user_8\NN\7846|an|admitted|frequent|cocaine (r_appos) man_2\NN\9605289|a|45-year-old|,|user|, (r_nsubj) presented_10\VBD\2137132|man|department|occasions|history|. (l_nmod) history_24\NN\15120823|with|a|priapism (l_nmod) priapism_26\NN\14204950|of|use
D003042_D011317 CID cocaine_28\NN\3492717| (r_compound) use_29\NN\407535|after|cocaine (r_nmod) priapism_26\NN\14204950|of|use
17919553
C106791_D056486 CID telithromycin_6\NN\1740|to (r_nmod) exposure_4\NN\5042871|after|telithromycin (r_nmod) attack_2\NN\955060|acute|hepatitis|exposure|. (l_compound) hepatitis_1\NN\14127211|
C106791_D056486 CID telithromycin_19\NN\1740| (r_compound) usage_20\NN\407535|after|telithromycin (r_nmod) occurred_17\VBD\2623529|that|usage (r_acl:relcl) hepatitis_10\NN\14127211|of|"|acute|origin|,|"|occurred
C106791_D056486 CID telithromycin_15\NN\1740| (r_nsubj) cause_19\NN\7323922|score|,|telithromycin|was|the|probable|hepatitis|,|and|suggested (l_nmod) hepatitis_22\NN\14127211|of|acute|patient
C106791_D056486 CID telithromycin_15\NN\1740| (r_nsubj) cause_19\NN\7323922|score|,|telithromycin|was|the|probable|hepatitis|,|and|suggested (l_conj) suggested_30\VBD\1010118|findings|hepatitis|. (l_dobj) hepatitis_33\NN\14127211|drug-induced|toxic
C106791_D056486 CID telithromycin_21\NN\1740| (r_dobj) prescribed_20\VBD\748282|who|telithromycin|time (r_acl:relcl) physician_18\NN\10305802|to|the|attending|prescribed (r_nmod) communicated_14\VBN\2231661|if|incident|had|been|physician (r_advcl) avoided_7\VBN\2452885|recurrence|might|have|been|communicated|. (l_nsubjpass) recurrence_0\NN\7342049|attack (l_nmod) attack_3\NN\955060|of|hepatitis (l_compound) hepatitis_2\NN\14127211|
C106791_D056486 CID telithromycin_16\NN\1740|of (r_nmod) administration_14\NN\1133281|with|the|telithromycin (r_nmod) associated_11\VBN\628491|probably|administration (r_acl) hepatitis_9\NN\14127211|of|acute|associated
C106791_D012141 NONE telithromycin_4\NN\1740|mg/d (r_dobj) prescribed_3\VBN\748282|he|had|been|telithromycin|treat|. (l_xcomp) treat_9\VB\2376958|to|infection|prior (l_dobj) infection_14\NN\14052046|an|tract
C106791_D064420 NONE telithromycin_15\NN\1740| (r_nsubj) cause_19\NN\7323922|score|,|telithromycin|was|the|probable|hepatitis|,|and|suggested (l_nmod) score_3\NN\5736149|based|on|a|8|scale (l_nmod) scale_13\NN\7260623|on|the|naranjo|probability (l_compound) probability_12\NN\33615|reaction (l_compound) reaction_11\NN\13446390|adverse|drug
6692345
D001241_D001749 NONE aspirin_3\NN\2707683|of (r_nmod) co-administration_1\NN\1740|the|aspirin|fanft|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_nmod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D001241_D013274 NONE aspirin_3\NN\2707683|of (r_nmod) co-administration_1\NN\1740|the|aspirin|fanft|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D001749 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740| (r_compound) fanft_7\NN\1740|with|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|(|) (r_nmod) co-administration_1\NN\1740|the|aspirin|fanft|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_nmod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D005200_D001749 CID fanft_7\NN\1740|with|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|(|) (r_nmod) co-administration_1\NN\1740|the|aspirin|fanft|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_nmod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D005200_D001749 CID fanft-induced_17\JJ\1740| (r_amod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D005200_D013274 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740| (r_compound) fanft_7\NN\1740|with|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|(|) (r_nmod) co-administration_1\NN\1740|the|aspirin|fanft|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D013274 CID fanft_7\NN\1740|with|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|(|) (r_nmod) co-administration_1\NN\1740|the|aspirin|fanft|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D013274 CID fanft-induced_17\JJ\1740| (r_amod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder (r_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D063646 NONE fanft_16\NN\1740| (r_compound) carcinogenesis_17\NN\1740|in|fanft|bladder
D005200_D063646 NONE fanft_30\NN\1740|on|forestomach (r_nmod) effect_28\NN\34213|aspirin|fanft (r_nsubj) effect_40\NN\34213|that|effect|is|not|due|an|irritant|associated (r_conj) involved_14\VBN\2676054|that|mechanisms|are|carcinogenesis|,|and|effect (l_nmod) carcinogenesis_17\NN\1740|in|fanft|bladder
D001241_D063646 NONE aspirin_26\NN\2707683|'s (r_nmod:poss) effect_28\NN\34213|aspirin|fanft (r_nsubj) effect_40\NN\34213|that|effect|is|not|due|an|irritant|associated (r_conj) involved_14\VBN\2676054|that|mechanisms|are|carcinogenesis|,|and|effect (l_nmod) carcinogenesis_17\NN\1740|in|fanft|bladder
2476560
D001556_D012532 NONE lindane_12\NN\14919948|hexachloride (r_nsubj) treatment_19\NN\654885|lindane|the|choice (r_ccomp) consider_11\VBP\689344|initiated|;|most|treatment|. (l_ccomp) initiated_5\VBN\1617192|treatment|is|usually|practitioners (l_nsubjpass) treatment_0\NN\654885|scabies (l_nmod) scabies_2\NNS\14174549|for
D001556_D012532 NONE hexachloride_16\NN\1740|(|gamma|benzene|) (r_appos) lindane_12\NN\14919948|hexachloride (r_nsubj) treatment_19\NN\654885|lindane|the|choice (r_ccomp) consider_11\VBP\689344|initiated|;|most|treatment|. (l_ccomp) initiated_5\VBN\1617192|treatment|is|usually|practitioners (l_nsubjpass) treatment_0\NN\654885|scabies (l_nmod) scabies_2\NNS\14174549|for
D001556_D002493 CID lindane_4\NN\14919948| (r_nsubj) toxic_7\JJ\1740|that|lindane|can|be|system|and|associated (l_nmod) system_12\NN\3575240|to|the|central|nervous
D001556_D000741 CID lindane_4\NN\14919948| (r_nsubj) toxic_7\JJ\1740|that|lindane|can|be|system|and|associated (l_conj) associated_16\VBN\628491|may|be|anaemia (l_nmod) anaemia_19\NN\14299637|with|aplastic
9495837
C087567_D000647 NONE (+/-)-pg-9_0\NN\1740|kg-1 (r_nsubj) able_10\JJ\1740|(+/-)-pg-9|was|prevent|. (l_xcomp) prevent_12\VB\1740|to|amnesia|test (l_dobj) amnesia_13\NN\5669934|induced
C087567_D000647 NONE (+/-)-pg-9_3\NN\1740|of (r_nmod) profiles_1\NNS\6999802|affinity|(+/-)-pg-9|subtypes|,|determined|, (r_nsubj) shown_42\VBN\2137132|profiles|have|ratio|. (l_dobj) ratio_46\NN\13815152|an|m4/m1|selectivity|10.2|responsible (l_acl:relcl) responsible_52\JJ\1740|that|might|be|antinociception|increase (l_nmod) antinociception_55\NN\1740|for|the|and|effect|induced (l_conj) effect_59\NN\34213|the|anti-amnesic (l_amod) anti-amnesic_58\JJ\1740|
C087567_D000647 NONE (+/-)-pg-9_62\NN\1740|by (r_nmod) induced_60\VBN\1627355|(+/-)-pg-9 (r_acl) antinociception_55\NN\1740|for|the|and|effect|induced (l_conj) effect_59\NN\34213|the|anti-amnesic (l_amod) anti-amnesic_58\JJ\1740|
D012601_D000647 CID scopolamine_16\NN\14712692|by|kg-1|i.p.|)|and|dicyclomine (r_nmod) induced_14\VBN\1627355|scopolamine (r_acl) amnesia_13\NN\5669934|induced
D004025_D000647 CID dicyclomine_24\NN\1740|kg-1|i.p.|) (r_conj) scopolamine_16\NN\14712692|by|kg-1|i.p.|)|and|dicyclomine (r_nmod) induced_14\VBN\1627355|scopolamine (r_acl) amnesia_13\NN\5669934|induced
D000109_D000647 NONE acetylcholine_67\NN\14807558| (r_compound) levels_69\NNS\4916342|in|acetylcholine|extracellular (r_nmod) increase_65\NN\13576355|through|an|levels (r_nmod) responsible_52\JJ\1740|that|might|be|antinociception|increase (l_nmod) antinociception_55\NN\1740|for|the|and|effect|induced (l_conj) effect_59\NN\34213|the|anti-amnesic (l_amod) anti-amnesic_58\JJ\1740|
19957053
D010656_D002534 CID phenylephrine_0\NN\2682038|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_dobj) oxygenation_7\NN\13518963|lobe
D010656_D007022 NONE phenylephrine_0\NN\2682038|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_nmod) hypotension_10\NN\14057371|following|anesthesia-induced
D010656_D007022 NONE phenylephrine_5\NN\2682038|of|and|ephedrine (r_nmod) effect_3\NN\34213|the|phenylephrine|oxygenation|hypotension (l_nmod) hypotension_18\NN\14057371|following|anesthesia-induced
D010656_D007022 NONE phenylephrine_5\NN\2682038|of (r_nmod) utilization_3\NN\407535|the|phenylephrine|correct (l_acl) correct_7\VB\138508|to|hypotension (l_dobj) hypotension_8\NN\14057371|induced
D004809_D002534 NONE ephedrine_3\NN\14712692|not (r_appos) phenylephrine_0\NN\2682038|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_dobj) oxygenation_7\NN\13518963|lobe
D004809_D007022 NONE ephedrine_3\NN\14712692|not (r_appos) phenylephrine_0\NN\2682038|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_nmod) hypotension_10\NN\14057371|following|anesthesia-induced
D004809_D007022 NONE ephedrine_7\NN\14712692| (r_conj) phenylephrine_5\NN\2682038|of|and|ephedrine (r_nmod) effect_3\NN\34213|the|phenylephrine|oxygenation|hypotension (l_nmod) hypotension_18\NN\14057371|following|anesthesia-induced
D004809_D007022 NONE ephedrine_20\NN\14712692| (r_nsubj) maintains_21\VBZ\2202928|while|ephedrine|oxygenation (r_advcl) has_12\VBZ\2108377|utilization|impact|s(c)o(2|)|maintains (l_nsubj) utilization_3\NN\407535|the|phenylephrine|correct (l_acl) correct_7\VB\138508|to|hypotension (l_dobj) hypotension_8\NN\14057371|induced
9406968
D014667_D003919 NONE vasopressin_5\NN\5407119| (r_compound) gene_6\NN\8459252|of|vasopressin (r_nmod) expression_3\NN\4679549|of|the|gene|nuclei (l_nmod) nuclei_12\NNS\5445668|in|the|paraventricular|rat (l_nmod) rat_18\NN\2329401|of|the|lithium-induced|diabetes|insipidus (l_compound) insipidus_17\NN\1740|
D008094_D003919 NONE lithium-induced_15\JJ\1740| (r_amod) rat_18\NN\2329401|of|the|lithium-induced|diabetes|insipidus (l_compound) insipidus_17\NN\1740|
D008094_D003919 NONE li-induced_35\JJ\1740| (r_amod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (l_compound) insipidus_37\NN\1740|
D001127_D011141 NONE vasopressin_4\NN\5407119| (r_compound) gene_8\NN\8459252|of|arginine|vasopressin|(|avp|) (r_nmod) expression_1\NN\4679549|the|gene|pvn (r_nsubjpass) investigated_22\VBN\644583|expression|was|rats|,|using|. (l_nmod) rats_24\NNS\2329401|in|polyuria (l_nmod) polyuria_28\NN\14113228|with|lithium
D001127_D011141 NONE avp_6\NN\1740| (r_compound) gene_8\NN\8459252|of|arginine|vasopressin|(|avp|) (r_nmod) expression_1\NN\4679549|the|gene|pvn (r_nsubjpass) investigated_22\VBN\644583|expression|was|rats|,|using|. (l_nmod) rats_24\NNS\2329401|in|polyuria (l_nmod) polyuria_28\NN\14113228|with|lithium
D008094_D011141 NONE lithium_26\NN\14625458|(li)-induced (r_compound) polyuria_28\NN\14113228|with|lithium
D008094_D011141 NONE (li)-induced_27\NN\1740| (r_dep) lithium_26\NN\14625458|(li)-induced (r_compound) polyuria_28\NN\14113228|with|lithium
D018021_D011141 CID licl_9\NN\1740|mmol/kg (r_dobj) contained_8\VBD\2632940|that|licl|weeks (r_acl:relcl) diet_6\NN\7560652|a|contained (r_dobj) consuming_4\VBG\1168468|diet (r_acl) rats_3\NNS\2329401|the|male|wistar|consuming (r_nsubj) developed_17\VBD\1753788|rats|polyuria|. (l_dobj) polyuria_19\NN\14113228|marked
D001127_D003681 NONE avp_19\NN\1740|of|plasma (r_nmod) elevation_16\NN\7445480|to|the|avp|and|upregulation (r_nmod) contribute_13\VB\126264|that|dehydration|may|elevation (l_nsubj) dehydration_4\NN\14536438|and/or|activation
D001127_D003681 NONE avp_24\NN\1740| (r_compound) expression_26\NN\4679549|of|avp|gene (r_nmod) upregulation_22\NN\1740|the|expression|pvn (r_conj) elevation_16\NN\7445480|to|the|avp|and|upregulation (r_nmod) contribute_13\VB\126264|that|dehydration|may|elevation (l_nsubj) dehydration_4\NN\14536438|and/or|activation
D001127_D003919 NONE avp_19\NN\1740|of|plasma (r_nmod) elevation_16\NN\7445480|to|the|avp|and|upregulation (l_conj) upregulation_22\NN\1740|the|expression|pvn (l_nmod) pvn_29\NN\1740|in|the|and|son (l_conj) son_32\NN\10285938|the|rat (l_nmod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (l_compound) insipidus_37\NN\1740|
D001127_D003919 NONE avp_24\NN\1740| (r_compound) expression_26\NN\4679549|of|avp|gene (r_nmod) upregulation_22\NN\1740|the|expression|pvn (l_nmod) pvn_29\NN\1740|in|the|and|son (l_conj) son_32\NN\10285938|the|rat (l_nmod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (l_compound) insipidus_37\NN\1740|
D008094_D003681 NONE li-induced_35\JJ\1740| (r_amod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (r_nmod) son_32\NN\10285938|the|rat (r_conj) pvn_29\NN\1740|in|the|and|son (r_nmod) upregulation_22\NN\1740|the|expression|pvn (r_conj) elevation_16\NN\7445480|to|the|avp|and|upregulation (r_nmod) contribute_13\VB\126264|that|dehydration|may|elevation (l_nsubj) dehydration_4\NN\14536438|and/or|activation
1835291
D009241_D029424 NONE bromide_5\NN\14904359|of|ipratropium|and|theophylline (r_nmod) effects_2\NNS\13245626|acute|bronchodilating|bromide|disease|. (l_nmod) disease_12\NN\14061805|in|chronic|obstructive|pulmonary
D009241_D029424 NONE bromide_9\NN\14904359|ipratropium (r_compound) aerosol_10\NN\11439690|of|bromide (r_nmod) dose_6\NN\3740161|of|a|single|aerosol|micrograms|and|tablets (r_nmod) effects_2\NNS\13245626|the|bronchodilator|dose (r_nsubjpass) compared_33\VBN\644583|effects|(|dose|were|study|. (l_nmod) study_40\NN\635850|in|a|double-blind|,|placebo-controlled|crossover|patients (l_nmod) patients_43\NNS\9898892|in|21|disease (l_nmod) disease_50\NN\14061805|with|stable|,|chronic|obstructive|pulmonary
D009241_D029424 NONE ipratropium_4\NN\1740| (r_nsubj) bronchodilator_9\NN\3740161|that|ipratropium|is|a|potent|theophylline|patients (l_nmod) patients_14\NNS\9898892|in|obstruction (l_nmod) obstruction_18\NN\4341686|with|chronic|airflow
D013806_D029424 NONE theophylline_7\NN\2905612| (r_conj) bromide_5\NN\14904359|of|ipratropium|and|theophylline (r_nmod) effects_2\NNS\13245626|acute|bronchodilating|bromide|disease|. (l_nmod) disease_12\NN\14061805|in|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_17\NN\2905612| (r_compound) tablets_18\NNS\4233405|short-acting|theophylline (r_conj) dose_6\NN\3740161|of|a|single|aerosol|micrograms|and|tablets (r_nmod) effects_2\NNS\13245626|the|bronchodilator|dose (r_nsubjpass) compared_33\VBN\644583|effects|(|dose|were|study|. (l_nmod) study_40\NN\635850|in|a|double-blind|,|placebo-controlled|crossover|patients (l_nmod) patients_43\NNS\9898892|in|21|disease (l_nmod) disease_50\NN\14061805|with|stable|,|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_12\NN\2905612|than|oral (r_nmod) bronchodilator_9\NN\3740161|that|ipratropium|is|a|potent|theophylline|patients (l_nmod) patients_14\NNS\9898892|in|obstruction (l_nmod) obstruction_18\NN\4341686|with|chronic|airflow
D013806_D002318 CID theophylline_9\NN\2905612| (r_compound) use_10\NN\407535|after|theophylline (r_nmod) experienced_7\VBN\2108377|use (r_acl) those_6\DT\1740|experienced (r_nsubj) involve_12\VB\2676054|rare|,|those|did|systems|. (l_dobj) systems_17\NNS\3575240|the|cardiovascular
D013806_D005767 CID theophylline_9\NN\2905612| (r_compound) use_10\NN\407535|after|theophylline (r_nmod) experienced_7\VBN\2108377|use (r_acl) those_6\DT\1740|experienced (r_nsubj) involve_12\VB\2676054|rare|,|those|did|systems|. (l_dobj) systems_17\NNS\3575240|the|cardiovascular
19058010
D010936_D009203 NONE tea_3\NN\7881800|green|and|e (r_compound) combination_7\NN\7951464|of|tea (r_nmod) effect_0\NN\34213|combination|infarction|. (l_nmod) infarction_12\NN\14204950|in|induced|myocardial|rats
D010936_D009203 NONE tea_12\NN\7881800|of|green|and|e (r_nmod) effects_9\NNS\13245626|the|combined|tea|weight (l_nmod) weight_18\NN\5009170|on|heart|,|weight|,|enzymes|,|peroxidation|,|antioxidants|infarction (l_nmod) infarction_40\NN\14204950|in|isoproterenol|myocardial|rats
D010936_D009203 NONE tea_9\NN\7881800|of|green|and|e (r_nmod) effect_6\NN\34213|the|synergistic|protective|tea|infarction (l_nmod) infarction_17\NN\14204950|during|induced|myocardial|rats
D014810_D009203 NONE e_6\NN\14724645|vitamin (r_conj) tea_3\NN\7881800|green|and|e (r_compound) combination_7\NN\7951464|of|tea (r_nmod) effect_0\NN\34213|combination|infarction|. (l_nmod) infarction_12\NN\14204950|in|induced|myocardial|rats
D014810_D009203 NONE e_15\NN\14724645|vitamin (r_conj) tea_12\NN\7881800|of|green|and|e (r_nmod) effects_9\NNS\13245626|the|combined|tea|weight (l_nmod) weight_18\NN\5009170|on|heart|,|weight|,|enzymes|,|peroxidation|,|antioxidants|infarction (l_nmod) infarction_40\NN\14204950|in|isoproterenol|myocardial|rats
D014810_D009203 NONE e_12\NN\14724645|vitamin (r_conj) tea_9\NN\7881800|of|green|and|e (r_nmod) effect_6\NN\34213|the|synergistic|protective|tea|infarction (l_nmod) infarction_17\NN\14204950|during|induced|myocardial|rats
D007545_D009203 CID isoproterenol_9\NN\3740161| (r_nmod:npmod) induced_10\JJ\1740|isoproterenol (r_amod) infarction_12\NN\14204950|in|induced|myocardial|rats
D007545_D009203 CID isoproterenol_37\NN\3740161|(iso)-induced (r_compound) infarction_40\NN\14204950|in|isoproterenol|myocardial|rats
D007545_D009203 CID (iso)-induced_38\JJ\1740| (r_dep) isoproterenol_37\NN\3740161|(iso)-induced (r_compound) infarction_40\NN\14204950|in|isoproterenol|myocardial|rats
D007545_D009203 CID iso_14\NN\1740| (r_nmod:npmod) induced_15\JJ\1740|iso (r_amod) infarction_17\NN\14204950|during|induced|myocardial|rats
7199841
C004616_D010243 CID 2-chloroprocaine-ce_9\NN\1740|of (r_nmod) injection_7\NN\320852|subarachnoid|2-chloroprocaine-ce (r_dobj) received_5\VBD\2210855|that|injection (r_acl:relcl) animals_3\NNS\4475|of|the|20|received (r_nmod) developed_15\VBD\1753788|animals|seven|paralysis|. (l_dobj) paralysis_17\NN\14557898|hind-limb
D002045_D010243 NONE bupivacaine_6\NN\1740|,|saline (r_dobj) received_5\VBD\2210855|that|bupivacaine (r_acl:relcl) animals_3\NNS\4475|of|the|received (r_nmod) none_0\NN\15228378|animals|titrated (r_nsubj) developed_19\VBD\1753788|none|paralysis|. (l_dobj) paralysis_21\NN\14557898|hind-limb
C004616_D013118 CID 2-chloroprocaine-ce_10\NN\1740| (r_dobj) received_9\VBD\2210855|that|2-chloroprocaine-ce (r_acl:relcl) animals_7\NNS\4475|of|the|received (r_nmod) cords_4\NNS\4489008|of|the|15|spinal|animals (r_nmod) showed_13\VBD\2137132|cords|,|13|necrosis (l_dobj) necrosis_15\NN\11444117|subpial
19843802
D004837_D006973 CID epinephrine_5\NN\14807929|of (r_nmod) bolus_3\NN\13899404|a|epinephrine|injected (r_nsubj) provoked_11\VBD\1617192|however|,|bolus|crisis|. (l_dobj) crisis_14\NN\14411243|a|hypertensive (l_amod) hypertensive_13\JJ\1740|
20667451
D003474_D003072 NONE curcumin_0\NN\1740| (r_nsubj) ameliorates_1\VBZ\126264|curcumin|dysfunction|. (l_dobj) dysfunction_3\NN\14204950|cognitive|and|damage|rats
D003474_D003072 NONE curcumin_14\NN\1740| (r_compound) administration_15\NN\1133281|of|chronic|curcumin (r_nmod) effect_11\NN\34213|the|administration|impairment (l_nmod) impairment_21\NN\7296428|on|phenobarbitone-|cognitive|and|stress
D003474_D003072 NONE curcumin_1\NN\1740| (r_compound) administration_2\NN\1133281|concomitant|curcumin (r_nsubj) prevented_3\VBD\1740|administration|impairment|and|decreased|. (l_dobj) impairment_6\NN\7296428|the|cognitive
D003474_D003072 NONE curcumin_4\NN\1740| (r_nsubj) has_5\VBZ\2108377|that|curcumin|effect|mitigating (l_advcl) mitigating_9\VBG\894738|in|deterioration|altering (l_dobj) deterioration_11\NN\14560612|the|functions|and|damage (l_nmod) functions_14\NNS\13783581|of|cognitive
D003474_D003072 NONE curcumin_4\NN\1740| (r_nsubjpass) considered_7\VBN\689344|that|curcumin|can|be|adjuvant (l_nmod) adjuvant_14\NN\2679788|as|a|potential|safe|therapy|preventing (l_advcl) preventing_21\VBG\1740|in|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
D010634_D003072 CID phenobarbitone_8\NN\2792049|and|carbamazepine (r_nmod:npmod) administered_11\VBN\2436349|phenobarbitone (r_amod) rats_12\NNS\2329401|in|administered (r_nmod) dysfunction_3\NN\14204950|cognitive|and|damage|rats
D010634_D003072 CID phenobarbitone_4\NN\2792049|and|carbamazepine (r_appos) drugs_2\NNS\14778436|the|antiepileptic|,|phenobarbitone (r_nsubjpass) known_9\VBN\2110220|drugs|are|well|cause|. (l_xcomp) cause_11\VB\1617192|to|impairment (l_dobj) impairment_13\NN\7296428|cognitive|use
D010634_D003072 CID phenobarbitone-_17\NN\1740|and|carbamazepine-induced (r_amod) impairment_21\NN\7296428|on|phenobarbitone-|cognitive|and|stress
D010634_D003072 CID phenobarbitone_3\NN\2792049|of|and|carbamazepine (r_nmod) administration_1\NN\1133281|the|phenobarbitone|21days (r_nsubj) caused_8\VBD\1617192|administration|impairment|. (l_dobj) impairment_11\NN\7296428|a|significant|learning|as|stress (l_nmod) learning_13\NN\5701944|of|and|memory (l_conj) memory_15\NN\5926676|
D010634_D003072 CID phenobarbitone_22\NN\2792049|with|and|carbamazepine (r_nmod) treated_20\VBN\2376958|phenobarbitone (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) damage_17\NN\7296428|oxidative|rats (r_conj) deterioration_11\NN\14560612|the|functions|and|damage (l_nmod) functions_14\NNS\13783581|of|cognitive
D010634_D003072 CID phenobarbitone_16\NN\2792049|and|carbamazepine (r_compound) therapy_19\NN\657604|to|phenobarbitone (r_nmod) adjuvant_14\NN\2679788|as|a|potential|safe|therapy|preventing (l_advcl) preventing_21\VBG\1740|in|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
D002220_D003072 CID carbamazepine_10\NN\1740| (r_conj) phenobarbitone_8\NN\2792049|and|carbamazepine (r_nmod:npmod) administered_11\VBN\2436349|phenobarbitone (r_amod) rats_12\NNS\2329401|in|administered (r_nmod) dysfunction_3\NN\14204950|cognitive|and|damage|rats
D002220_D003072 CID carbamazepine_6\NN\1740| (r_conj) phenobarbitone_4\NN\2792049|and|carbamazepine (r_appos) drugs_2\NNS\14778436|the|antiepileptic|,|phenobarbitone (r_nsubjpass) known_9\VBN\2110220|drugs|are|well|cause|. (l_xcomp) cause_11\VB\1617192|to|impairment (l_dobj) impairment_13\NN\7296428|cognitive|use
D002220_D003072 CID carbamazepine-induced_19\JJ\1740| (r_conj) phenobarbitone-_17\NN\1740|and|carbamazepine-induced (r_amod) impairment_21\NN\7296428|on|phenobarbitone-|cognitive|and|stress
D002220_D003072 CID carbamazepine_5\NN\1740| (r_conj) phenobarbitone_3\NN\2792049|of|and|carbamazepine (r_nmod) administration_1\NN\1133281|the|phenobarbitone|21days (r_nsubj) caused_8\VBD\1617192|administration|impairment|. (l_dobj) impairment_11\NN\7296428|a|significant|learning|as|stress (l_nmod) learning_13\NN\5701944|of|and|memory (l_conj) memory_15\NN\5926676|
D002220_D003072 CID carbamazepine_24\NN\1740| (r_conj) phenobarbitone_22\NN\2792049|with|and|carbamazepine (r_nmod) treated_20\VBN\2376958|phenobarbitone (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) damage_17\NN\7296428|oxidative|rats (r_conj) deterioration_11\NN\14560612|the|functions|and|damage (l_nmod) functions_14\NNS\13783581|of|cognitive
D002220_D003072 CID carbamazepine_18\NN\1740| (r_conj) phenobarbitone_16\NN\2792049|and|carbamazepine (r_compound) therapy_19\NN\657604|to|phenobarbitone (r_nmod) adjuvant_14\NN\2679788|as|a|potential|safe|therapy|preventing (l_advcl) preventing_21\VBG\1740|in|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
19356307
D012601_D003704 NONE scopolamine_9\NN\14712692|by (r_nmod) induced_7\VBN\1627355|scopolamine (r_acl) dementia_6\NN\14395018|induced
C008281_D003704 NONE s-limonene_4\NN\1740|of|and|alcohol (r_nmod) effects_2\NNS\13245626|the|anti-dementia|s-limonene (l_amod) anti-dementia_1\JJ\1740|
C032208_D003704 NONE alcohol_7\NN\7881800|s-perillyl (r_conj) s-limonene_4\NN\1740|of|and|alcohol (r_nmod) effects_2\NNS\13245626|the|anti-dementia|s-limonene (l_amod) anti-dementia_1\JJ\1740|
D012601_D008569 CID scopolamine_12\NN\14712692|by (r_nmod) impaired_10\JJ\1740|scopolamine
D012601_D008569 CID scopolamine_12\NN\14712692|by (r_nmod) impaired_10\JJ\1740|scopolamine (r_amod) memory_9\NN\5926676|impaired (r_dobj) improve_8\VB\126264|to|memory (r_acl) ability_6\NN\4723816|strong|improve (r_dobj) showed_4\VBD\2137132|oils|ability (r_ccomp) relieved_18\VBD\205885|showed|;|however|,|alcohol|deficit|pa|,|and|improve|. (l_dobj) deficit_20\NN\5113133|the|memory (l_nmod) memory_23\NN\5926676|of|associative
C032208_D008569 NONE alcohol_17\NN\7881800|s-perillyl (r_nsubj) relieved_18\VBD\205885|showed|;|however|,|alcohol|deficit|pa|,|and|improve|. (l_ccomp) showed_4\VBD\2137132|oils|ability (l_dobj) ability_6\NN\4723816|strong|improve (l_acl) improve_8\VB\126264|to|memory (l_dobj) memory_9\NN\5926676|impaired (l_amod) impaired_10\JJ\1740|scopolamine
C032208_D008569 NONE alcohol_17\NN\7881800|s-perillyl (r_nsubj) relieved_18\VBD\205885|showed|;|however|,|alcohol|deficit|pa|,|and|improve|. (l_dobj) deficit_20\NN\5113133|the|memory (l_nmod) memory_23\NN\5926676|of|associative
12921865
D013256_D012640 NONE steroids_4\NNS\14727670|of|neuroactive (r_nmod) efficacy_1\NN\5199286|protective|steroids|kindled-seizures|. (l_nmod) kindled-seizures_7\NN\1740|against|cocaine|mice
D013256_D012640 NONE steroid_13\NN\14727670|neuroactive|modulate (r_dobj) evaluate_6\VB\670261|to|endogenous|steroid|increase (l_nmod) increase_27\NN\13576355|against|the|sensitivity (l_nmod) sensitivity_29\NN\5651971|in|effects (l_nmod) effects_33\NNS\13245626|to|the|convulsant|cocaine (l_nmod) cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|kindling (l_appos) kindling_43\NN\15101361|(|seizure|) (l_compound) seizure_42\NN\14081375|
D003042_D012640 CID cocaine_6\NN\3492717| (r_compound) kindled-seizures_7\NN\1740|against|cocaine|mice
D003042_D012640 CID cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|kindling (l_appos) kindling_43\NN\15101361|(|seizure|) (l_compound) seizure_42\NN\14081375|
D003042_D012640 CID cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|by|repeated|cocaine|kindling (l_appos) kindling_43\NN\15101361|(|seizure|) (l_compound) seizure_42\NN\14081375|
D003042_D012640 CID cocaine-kindled_39\JJ\1740| (r_amod) seizures_40\NNS\14081375|of|cocaine-kindled
D003042_D012640 CID cocaine_10\NN\3492717|of|mg/kg (r_nmod) administration_6\NN\1133281|by|daily|cocaine|days (r_nmod) induced_3\VBN\1627355|seizures|were|administration|. (l_nsubjpass) seizures_1\NNS\14081375|kindled
D013256_D009422 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) demonstrate_2\VBP\2137132|steroids|actions|. (l_dobj) actions_4\NNS\30358|pharmacological|have (l_acl:relcl) have_6\VBP\2108377|that|relevance (l_dobj) relevance_7\NN\13791389|host (l_nmod) host_10\NN\9605289|for|a|disorders (l_nmod) disorders_15\NNS\14034177|of|neurological
D013256_D001523 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) demonstrate_2\VBP\2137132|steroids|actions|. (l_dobj) actions_4\NNS\30358|pharmacological|have (l_acl:relcl) have_6\VBP\2108377|that|relevance (l_dobj) relevance_7\NN\13791389|host (l_nmod) host_10\NN\9605289|for|a|disorders (l_nmod) disorders_15\NNS\14034177|of|neurological
D005680_D012640 NONE acid_19\NN\14818238| (r_compound) receptor_24\NN\5225602|the|gamma-aminobutyric|acid|(|gaba(a|)|) (r_dobj) modulate_16\VBP\1724459|that|positively|receptor (r_acl:relcl) steroid_13\NN\14727670|neuroactive|modulate (r_dobj) evaluate_6\VB\670261|to|endogenous|steroid|increase (l_nmod) increase_27\NN\13576355|against|the|sensitivity (l_nmod) sensitivity_29\NN\5651971|in|effects (l_nmod) effects_33\NNS\13245626|to|the|convulsant|cocaine (l_nmod) cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|kindling (l_appos) kindling_43\NN\15101361|(|seizure|) (l_compound) seizure_42\NN\14081375|
D005680_D012640 NONE gaba(a_21\NN\1740| (r_compound) receptor_24\NN\5225602|the|gamma-aminobutyric|acid|(|gaba(a|)|) (r_dobj) modulate_16\VBP\1724459|that|positively|receptor (r_acl:relcl) steroid_13\NN\14727670|neuroactive|modulate (r_dobj) evaluate_6\VB\670261|to|endogenous|steroid|increase (l_nmod) increase_27\NN\13576355|against|the|sensitivity (l_nmod) sensitivity_29\NN\5651971|in|effects (l_nmod) effects_33\NNS\13245626|to|the|convulsant|cocaine (l_nmod) cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|kindling (l_appos) kindling_43\NN\15101361|(|seizure|) (l_compound) seizure_42\NN\14081375|
D005680_D012640 NONE gaba(a_4\NN\1740| (r_compound) modulators_6\NNS\1740|of|these|positive|gaba(a|) (r_nmod) all_0\DT\1740|modulators (r_nsubj) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|seizures (l_nmod) seizures_12\NNS\14081375|of|kindled
D011280_D012640 NONE allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740|(|) (r_appos) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one|and|ganaxolone (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740|(|) (r_appos) pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one|and|ganaxolone (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE allopregnanolone_16\NN\1740| (r_compound) 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\NN\1740|of|allopregnanolone|) (r_nmod) derivative_14\NN\5802185|(|a|synthetic|3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one (r_appos) ganaxolone_10\NN\1740|derivative (r_conj) pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one|and|ganaxolone (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE allopregnanolone_16\NN\1740|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\2510337|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|seizures (l_nmod) seizures_12\NNS\14081375|of|kindled
C105051_D012640 NONE ganaxolone_10\NN\1740|derivative (r_conj) pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one|and|ganaxolone (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
C105051_D012640 NONE 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\NN\1740|of|allopregnanolone|) (r_nmod) derivative_14\NN\5802185|(|a|synthetic|3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one (r_appos) ganaxolone_10\NN\1740|derivative (r_conj) pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one|and|ganaxolone (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
C105051_D012640 NONE ganaxolone_18\NN\1740| (r_conj) allopregnanolone_16\NN\1740|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\2510337|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|seizures (l_nmod) seizures_12\NNS\14081375|of|kindled
2375138
D008874_D006323 CID midazolam-associated_2\NN\1740|intramuscular (r_nummod) arrest_4\NN\88481|possible|midazolam-associated|cardiorespiratory|and|death|.
D008874_D006323 CID midazolam_17\NN\2830852|of (r_nmod) administration_15\NN\1133281|with|intramuscular|midazolam (r_nmod) associated_12\VBN\628491|administration (r_acl) arrest_9\NN\88481|of|cardiorespiratory|and|death|associated
D008874_D003643 NONE midazolam-associated_2\NN\1740|intramuscular (r_nummod) arrest_4\NN\88481|possible|midazolam-associated|cardiorespiratory|and|death|. (l_conj) death_6\NN\7296428|
D008874_D003643 NONE midazolam_17\NN\2830852|of (r_nmod) administration_15\NN\1133281|with|intramuscular|midazolam (r_nmod) associated_12\VBN\628491|administration (r_acl) arrest_9\NN\88481|of|cardiorespiratory|and|death|associated (l_conj) death_11\NN\7296428|
3780846
D009020_D009127 CID morphine_14\NN\2707683|by (r_nmod) produced_12\VBN\1617192|morphine|rats (r_acl) rigidity_11\NN\5023233|to|the|muscular|produced
D009020_D009127 CID morphine_10\NN\2707683|by (r_nmod) produced_8\VBN\1617192|morphine (r_acl) rigidity_7\NN\5023233|to|the|muscular|produced
D009020_D009127 CID morphine_7\NN\2707683|of (r_nmod) dose_5\NN\3740161|a|test|morphine|mg/kg (r_dobj) given_2\VBN\2327200|dose (r_acl) controls_1\NNS\5190804|saline-pretreated|given (r_nsubj) showed_13\VBD\2137132|controls|rigidity|. (l_dobj) rigidity_16\NN\5023233|a|pronounced|recorded
D009020_D009127 CID morphine_6\NN\2707683|with (r_nmod) treated_1\VBN\2376958|days|morphine|and|withdrawn (r_acl) rats_0\NNS\2329401|treated (r_nsubj) showed_14\VBD\2137132|rats|differences (r_ccomp) showed_27\VBD\2137132|showed|:|half|rigidity|dose|. (l_dobj) rigidity_29\NN\5023233|a
D009020_D009127 CID morphine_35\NN\2707683|of (r_nmod) dose_33\NN\3740161|after|the|test|morphine|less (r_nmod) showed_27\VBD\2137132|showed|:|half|rigidity|dose|. (l_dobj) rigidity_29\NN\5023233|a
D009020_D009127 CID morphine_16\NN\2707683|of (r_nmod) action_14\NN\30358|an|morphine|striatum (r_dobj) due_11\JJ\1740|to|be|to|action (r_xcomp) assumed_8\VBN\719734|which|is|due (r_acl:relcl) rigidity_4\NN\5023233|,|assumed|,
D009020_D018476 CID morphine_6\NN\2707683|with (r_nmod) treated_1\VBN\2376958|days|morphine|and|withdrawn (r_acl) rats_0\NNS\2329401|treated (r_nsubj) showed_14\VBD\2137132|rats|differences (r_ccomp) showed_27\VBD\2137132|showed|:|half|rigidity|dose|. (l_nmod) dose_33\NN\3740161|after|the|test|morphine|less (l_acl:relcl) less_40\JJR\1740|that|was|not|significantly|than|and|akinetic (l_conj) akinetic_47\JJ\1740|were|group
D009020_D018476 CID morphine_35\NN\2707683|of (r_nmod) dose_33\NN\3740161|after|the|test|morphine|less (l_acl:relcl) less_40\JJR\1740|that|was|not|significantly|than|and|akinetic (l_conj) akinetic_47\JJ\1740|were|group
D006220_D009127 CID haloperidol_7\NN\3713736|mg/kg (r_nsubjpass) used_14\VBN\1156834|series|,|haloperidol|was|order|block|. (l_xcomp) block_18\VB\1476483|to|activation|and|estimate (l_conj) estimate_24\VB\637259|to|degree|interference (l_dobj) degree_27\NN\4916342|the|real|tolerance (l_nmod) tolerance_30\NN\5032565|of|the|rigidity (l_nmod) rigidity_33\NN\5023233|to|the
D006220_D009127 CID haloperidol_0\NN\3713736| (r_nsubj) enhanced_1\VBD\227165|haloperidol|rigidity|. (l_dobj) rigidity_3\NN\5023233|the|group
3496378
D014217_D002779 CID troleandomycin-induced_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|after|troleandomycin-induced|acute (r_nmod) cholestasis_1\NN\14052403|prolonged|hepatitis|.
D014217_D002779 CID troleandomycin-induced_9\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced (r_nsubjpass) followed_12\VBN\1835496|whom|hepatitis|was|cholestasis (l_nmod) cholestasis_16\NN\14052403|by|prolonged|anicteric
D014217_D002779 CID troleandomycin-induced_8\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced|acute (r_dobj) follow_7\VB\1835496|that|cholestasis|can|hepatitis (l_nsubj) cholestasis_5\NN\14052403|prolonged
D014217_D056486 CID troleandomycin-induced_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|after|troleandomycin-induced|acute
D014217_D056486 CID troleandomycin-induced_9\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced
D014217_D056486 CID troleandomycin-induced_8\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced|acute
D014217_D007565 CID troleandomycin_5\NN\1740|of (r_nmod) administration_3\NN\1133281|after|troleandomycin|days (r_nmod) occurred_1\VBD\2623529|jaundice|administration|and|associated|. (l_nsubj) jaundice_0\NN\14299637|
D014217_D004802 CID troleandomycin_5\NN\1740|of (r_nmod) administration_3\NN\1133281|after|troleandomycin|days (r_nmod) occurred_1\VBD\2623529|jaundice|administration|and|associated|. (l_conj) associated_11\VBN\628491|was|hypereosinophilia (l_nmod) hypereosinophilia_13\NN\1740|with
6538499
D011092_D064420 NONE 400_4\CD\1740| (r_nummod) glycol_3\NN\14766364|of|polyethylene|400 (r_nmod) effect_0\NN\34213|glycol|toxicity|. (l_nmod) toxicity_7\NN\13576101|on|adriamycin|mice
D004317_D064420 NONE adriamycin_6\NN\1740| (r_compound) toxicity_7\NN\13576101|on|adriamycin|mice
D004317_D009202 CID adr-induced_8\JJ\1740| (r_amod) alterations_11\NNS\7283608|against|adr-induced|cardiac|morphological
D004317_D007939 NONE adr_6\NN\1740| (r_compound) activity_8\NN\30358|the|adr|antitumor|leukemia (l_nmod) leukemia_11\NN\14239918|in|l1210|and|tumor
D004317_D002286 NONE adr_6\NN\1740| (r_compound) activity_8\NN\30358|the|adr|antitumor|leukemia (l_nmod) leukemia_11\NN\14239918|in|l1210|and|tumor (l_conj) tumor_16\NN\14234074|in|ehrlich|ascites
20528871
C104457_D015458 NONE nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
C104457_D015458 NONE nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D015458 NONE arag_8\NN\1740|(|) (r_appos) nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D016399 NONE nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
C104457_D016399 NONE nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D016399 NONE arag_8\NN\1740|(|) (r_appos) nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D015458 NONE etoposide_5\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D005047_D015458 NONE etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D015458 NONE vp_16\NN\1740|(|) (r_appos) etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D016399 NONE etoposide_5\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D005047_D016399 NONE etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D016399 NONE vp_16\NN\1740|(|) (r_appos) etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D015458 NONE cyclophosphamide_8\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D003520_D015458 NONE cyclophosphamide_19\NN\1740|cpm (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D015458 NONE cpm_21\NN\1740|(|) (r_appos) cyclophosphamide_19\NN\1740|cpm (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D016399 NONE cyclophosphamide_8\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D003520_D016399 NONE cyclophosphamide_19\NN\1740|cpm (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D016399 NONE cpm_21\NN\1740|(|) (r_appos) cyclophosphamide_19\NN\1740|cpm (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) d_4\NN\15089472|of|5|nelarabine|d|and|chemotherapy (r_nmod) combination_1\NN\7951464|a|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|children|. (l_nmod) children_34\NNS\9622049|in|seven|leukaemia (l_nmod) leukaemia_40\NN\14239918|with|refractory|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D009422 CID arag_8\NNP\1740|to|the (r_nmod) attributable_5\JJ\1740|arag (r_amod) effects_4\NNS\13245626|the|common|side|attributable (r_nsubj) included_9\VBD\690614|effects|grade|neuropathy|. (l_dobj) neuropathy_17\NN\14204950|sensory|and|pain
C104457_D009422 CID arag_7\NN\1740| (r_dobj) giving_6\VBG\2327200|of|arag|therapy|synchrony (r_advcl) safety_4\NN\13920835|the|giving (r_dobj) supports_2\VBZ\2199590|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
C104457_D059352 CID arag_8\NNP\1740|to|the (r_nmod) attributable_5\JJ\1740|arag (r_amod) effects_4\NNS\13245626|the|common|side|attributable (r_nsubj) included_9\VBD\690614|effects|grade|neuropathy|. (l_dobj) neuropathy_17\NN\14204950|sensory|and|pain (l_conj) pain_20\NN\14299637|musculoskeletal
C104457_D006402 CID arag_8\NN\1740|than|alone (r_nmod) greater_3\JJR\1740|toxicity|was|combination|arag|,|consistent|. (l_nsubj) toxicity_1\NN\13576101|haematological
D005047_D009422 NONE etoposide_14\NN\1740|with|and|cyclophosphamide (r_nmod) synchrony_12\NN\13844690|in|etoposide (r_nmod) giving_6\VBG\2327200|of|arag|therapy|synchrony (r_advcl) safety_4\NN\13920835|the|giving (r_dobj) supports_2\VBZ\2199590|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
D003520_D009422 NONE cyclophosphamide_16\NN\1740| (r_conj) etoposide_14\NN\1740|with|and|cyclophosphamide (r_nmod) synchrony_12\NN\13844690|in|etoposide (r_nmod) giving_6\VBG\2327200|of|arag|therapy|synchrony (r_advcl) safety_4\NN\13920835|the|giving (r_dobj) supports_2\VBZ\2199590|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
11206082
C036150_D012640 CID beta-carboline-induced_8\JJ\1740| (r_amod) seizures_9\NNS\14081375|to|beta-carboline-induced
C036150_D012640 CID beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|by|a|single|i.p.|beta-carboline-3-carboxylate (r_nmod) induced_22\VBN\1627355|injection (r_acl) seizures_21\NNS\14081375|to|induced
C036150_D012640 CID beta-ccm_32\NN\1740|(|) (r_appos) beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|by|a|single|i.p.|beta-carboline-3-carboxylate (r_nmod) induced_22\VBN\1627355|injection (r_acl) seizures_21\NNS\14081375|to|induced
D005680_D012640 NONE gaba(a_20\NN\1740| (r_compound) ligands_23\NNS\20090|of|other|gaba(a|)|receptor (r_nmod) effects_17\NNS\13245626|to|various|pharmacological|ligands (r_nmod) sensitive_13\JJ\1740|lines|are|also|differentially|effects|. (l_nsubj) lines_2\NNS\8426461|two|mouse|selected (l_acl) selected_3\VBN\697589|sensitivities (l_nmod) sensitivities_6\NNS\5651971|for|differential|seizures (l_nmod) seizures_9\NNS\14081375|to|beta-carboline-induced
D005680_D012640 NONE gaba(a_40\NN\1740| (r_compound) site_44\NN\8673395|of|the|gaba(a|)|receptor|benzodiazepine (r_nmod) agonist_37\NN\9613191|an|inverse|site (r_appos) beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|by|a|single|i.p.|beta-carboline-3-carboxylate (r_nmod) induced_22\VBN\1627355|injection (r_acl) seizures_21\NNS\14081375|to|induced
D001569_D012640 NONE benzodiazepine_43\NN\3771443| (r_compound) site_44\NN\8673395|of|the|gaba(a|)|receptor|benzodiazepine (r_nmod) agonist_37\NN\9613191|an|inverse|site (r_appos) beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|by|a|single|i.p.|beta-carboline-3-carboxylate (r_nmod) induced_22\VBN\1627355|injection (r_acl) seizures_21\NNS\14081375|to|induced
D003975_D012640 NONE diazepam-induced_2\JJ\1740| (r_amod) anxiolysis_3\NN\1740|diazepam-induced|test|,|sedation (l_conj) sedation_11\NN\14034177|diazepam-induced|recording|,|and|seizures (l_conj) seizures_22\NNS\14081375|picrotoxin-
D003975_D012640 NONE diazepam-induced_10\JJ\1740| (r_amod) sedation_11\NN\14034177|diazepam-induced|recording|,|and|seizures (l_conj) seizures_22\NNS\14081375|picrotoxin-
D010852_D012640 CID picrotoxin-_19\NN\1740|and|pentylenetetrazol-induced (r_compound) seizures_22\NNS\14081375|picrotoxin-
D010433_D012640 CID pentylenetetrazol-induced_21\JJ\1740| (r_conj) picrotoxin-_19\NN\1740|and|pentylenetetrazol-induced (r_compound) seizures_22\NNS\14081375|picrotoxin-
12202650
D002211_D063806 NONE capsaicin-induced_0\JJ\1740| (r_amod) pain_2\NN\14299637|capsaicin-induced|muscle
D002211_D010146 CID capsaicin_0\NN\15032661|g (r_nsubjpass) injected_7\VBN\81072|capsaicin|was|muscle|induce|. (l_advcl) induce_13\VB\1627355|to|pain|volunteers (l_dobj) pain_14\NN\14299637|
3031535
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN\1740|by|delta (r_nmod) induced_4\VBN\1627355|9-tetrahydrocannabinol (r_acl) catalepsy_3\NN\14023236|in|induced
D013759_D002375 CID thc_17\NN\4017137|by (r_nmod) induced_15\VBN\1627355|thc (r_acl) catalepsy_14\NN\14023236|of|induced
D013759_D002375 CID thc_17\NN\4017137|by (r_nmod) induced_15\VBN\1627355|thc (r_acl) catalepsy_14\NN\14023236|of|induced (r_nmod) manifestation_12\NN\7321772|in|the|catalepsy (r_nmod) have_6\VBP\2108377|that|neurons|role|manifestation|,|whereas|important (l_parataxis) important_23\JJ\1740|neurons|are|catalepsy (l_nmod) catalepsy_25\NN\14023236|in|induced
D006220_D002375 CID haloperidol_28\NN\3713736|by (r_nmod) induced_26\VBN\1627355|haloperidol (r_acl) catalepsy_25\NN\14023236|in|induced (r_nmod) important_23\JJ\1740|neurons|are|catalepsy (r_parataxis) have_6\VBP\2108377|that|neurons|role|manifestation|,|whereas|important (l_nmod) manifestation_12\NN\7321772|in|the|catalepsy (l_nmod) catalepsy_14\NN\14023236|of|induced
D006220_D002375 CID haloperidol_28\NN\3713736|by (r_nmod) induced_26\VBN\1627355|haloperidol (r_acl) catalepsy_25\NN\14023236|in|induced
9746003
D002220_D004832 CID carbamazepine_3\NN\1740|of|and|vigabatrin (r_nmod) use_1\NN\407535|inappropriate|carbamazepine|seizures|. (l_nmod) seizures_9\NNS\14081375|in|typical|absence
D002220_D004832 CID carbamazepine_0\NN\1740|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\872886|carbamazepine|are|seizures|. (l_nmod) seizures_8\NNS\14081375|in|typical|absence
D020888_D004832 CID vigabatrin_5\NN\1740| (r_conj) carbamazepine_3\NN\1740|of|and|vigabatrin (r_nmod) use_1\NN\407535|inappropriate|carbamazepine|seizures|. (l_nmod) seizures_9\NNS\14081375|in|typical|absence
D020888_D004832 CID vigabatrin_2\NN\1740| (r_conj) carbamazepine_0\NN\1740|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\872886|carbamazepine|are|seizures|. (l_nmod) seizures_8\NNS\14081375|in|typical|absence
D002220_D009207 CID carbamazepine_9\NN\1740|with (r_nmod) treated_7\VBN\2376958|carbamazepine (r_acl) children_6\NNS\9622049|in|four|treated (r_nmod) increased_3\VBD\169651|frequency|children|and|developed (l_conj) developed_14\VBD\1753788|two|jerks|. (l_dobj) jerks_16\NNS\10322238|myoclonic|,|resolved
D002220_D009207 CID carbamazepine_23\NN\1740|of (r_nmod) withdrawal_21\NN\7206096|on|carbamazepine (r_nmod) resolved_19\VBD\352826|which|withdrawal (r_acl:relcl) jerks_16\NNS\10322238|myoclonic|,|resolved
12757899
D004958_D012640 NONE estradiol_0\NN\14749794| (r_nsubj) reduces_1\VBZ\441445|estradiol|injury|female|. (l_dobj) injury_4\NN\14052046|seizure-induced|hippocampal (l_amod) seizure-induced_2\JJ\1740|
D004958_D012640 NONE estradiol_7\NN\14749794|of (r_nmod) effects_5\NNS\13245626|the|estradiol|threshold (l_dep) threshold_10\NN\15265518|seizure|and|damage (l_compound) seizure_9\NN\14081375|on
D004958_D001930 NONE estradiol_0\NN\14749794| (r_nsubj) reduces_1\VBZ\441445|estradiol|injury|female|. (l_dobj) injury_4\NN\14052046|seizure-induced|hippocampal
D007608_D001930 NONE acid-induced_10\JJ\1740|kainic (r_amod) epilepticus_12\NN\1740|by|acid-induced|status|se (r_nmod) induced_7\VBN\1627355|epilepticus (r_acl) injury_6\NN\14052046|from|hippocampal|induced
D007608_D013226 NONE acid-induced_10\JJ\1740|kainic (r_amod) epilepticus_12\NN\1740|by|acid-induced|status|se
D007608_D013226 NONE acid-induced_10\JJ\1740|kainic (r_amod) epilepticus_12\NN\1740|by|acid-induced|status|se (l_appos) se_14\NN\14724645|(|)
D004958_D013226 NONE 17beta-estradiol_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|the|17beta-estradiol|rats (l_nmod) rats_12\NNS\2329401|in|male|female|subjected (l_acl) subjected_13\VBN\137313|se (l_nmod) se_16\NN\14724645|to|lithium-pilocarpine-induced
D008094_D013226 CID lithium-pilocarpine-induced_15\JJ\1740| (r_amod) se_16\NN\14724645|to|lithium-pilocarpine-induced
D010862_D013226 CID lithium-pilocarpine-induced_15\JJ\1740| (r_amod) se_16\NN\14724645|to|lithium-pilocarpine-induced
D012834_D013226 NONE silver-stained_3\JJ\1740| (r_amod) ca3_4\NN\1740|of|silver-stained|and|ca1 (r_nmod) extent_1\NN\13939892|the|ca3|neurons (r_nsubjpass) evaluated_10\VBN\670261|extent|was|se|. (l_dobj) se_14\NN\14724645|days
8302922
D000527_D007022 CID e1_5\NN\1740|during|prostaglandin|or|trimethaphan (r_nmod) flow_2\NN\7311115|epidural|blood|e1|hypotension|. (l_dep) hypotension_9\NN\14057371|induced
D000527_D007022 CID e1_6\NN\1740|prostaglandin|pge1|or|tmp (r_compound) hypotension_16\NN\14057371|of|e1|induced
D000527_D007022 CID pge1_8\NN\1740|(|) (r_appos) e1_6\NN\1740|prostaglandin|pge1|or|tmp (r_compound) hypotension_16\NN\14057371|of|e1|induced
D000527_D007022 CID pge1_2\NN\1740|or|tmp (r_dobj) starting_1\VBG\2009433|after|pge1 (r_advcl) decreased_14\VBD\169651|starting|,|map|significantly|values|,|and|remained (l_conj) remained_34\VBD\2604760|degree|constant|. (l_nsubj) degree_28\NN\4916342|the|hypotension (l_nmod) hypotension_30\NN\14057371|of|pge1
D000527_D007022 CID pge1_33\NN\1740|due (r_nmod) hypotension_30\NN\14057371|of|pge1
D000527_D007022 CID pge1_4\NN\1740| (r_nsubj) preferable_7\JJ\1740|that|pge1|may|be|tmp|anaesthesia|decreased (l_nmod) anaesthesia_12\NN\14034177|for|hypotensive|surgery (l_amod) hypotensive_11\JJ\1740|
D014294_D007022 CID trimethaphan_7\NN\1740| (r_conj) e1_5\NN\1740|during|prostaglandin|or|trimethaphan (r_nmod) flow_2\NN\7311115|epidural|blood|e1|hypotension|. (l_dep) hypotension_9\NN\14057371|induced
D014294_D007022 CID trimethaphan_11\NN\1740| (r_compound) tmp_13\NN\1740|trimethaphan|(|) (r_conj) e1_6\NN\1740|prostaglandin|pge1|or|tmp (r_compound) hypotension_16\NN\14057371|of|e1|induced
D014294_D007022 CID tmp_13\NN\1740|trimethaphan|(|) (r_conj) e1_6\NN\1740|prostaglandin|pge1|or|tmp (r_compound) hypotension_16\NN\14057371|of|e1|induced
D014294_D007022 CID tmp_4\NN\1740| (r_conj) pge1_2\NN\1740|or|tmp (r_dobj) starting_1\VBG\2009433|after|pge1 (r_advcl) decreased_14\VBD\169651|starting|,|map|significantly|values|,|and|remained (l_conj) remained_34\VBD\2604760|degree|constant|. (l_nsubj) degree_28\NN\4916342|the|hypotension (l_nmod) hypotension_30\NN\14057371|of|pge1
D014294_D007022 CID tmp_9\NN\1740|to (r_nmod) preferable_7\JJ\1740|that|pge1|may|be|tmp|anaesthesia|decreased (l_nmod) anaesthesia_12\NN\14034177|for|hypotensive|surgery (l_amod) hypotensive_11\JJ\1740|
D014294_D007022 CID tmp_17\NN\1740| (r_nsubj) decreased_18\VBD\169651|because|tmp|ebf (r_advcl) preferable_7\JJ\1740|that|pge1|may|be|tmp|anaesthesia|decreased (l_nmod) anaesthesia_12\NN\14034177|for|hypotensive|surgery (l_amod) hypotensive_11\JJ\1740|
D007530_D007022 NONE isoflurane_45\NN\3570838| (r_compound) anaesthesia_46\NN\14034177|under|isoflurane (r_nmod) underwent_40\VBD\109660|who|fusion|anaesthesia (r_acl:relcl) patients_38\NNS\9898892|in|30|underwent (r_nmod) using_31\VBG\1156834|method|patients (r_xcomp) measured_30\VBN\697589|evaluate|,|ebf|was|using|. (l_advcl) evaluate_1\VB\670261|to|effect (l_dobj) effect_3\NN\34213|the|hypotension|flow|surgery (l_nmod) hypotension_16\NN\14057371|of|e1|induced
12639165
D013988_D002779 CID ticlopidine-induced_0\JJ\1740| (r_amod) hepatitis_2\NN\14127211|ticlopidine-induced|cholestatic|.
D013988_D002779 CID ticlopidine-induced_7\JJ\1740| (r_amod) hepatitis_9\NN\14127211|of|ticlopidine-induced|cholestatic
D013988_D002779 CID ticlopidine_11\NN\1740| (r_dobj) receiving_10\VBG\2210855|after|ticlopidine|angioplasty (r_advcl) developed_5\VBD\1753788|:|patients|hepatitis|receiving|,|remission|. (l_dobj) hepatitis_8\NN\14127211|prolonged|cholestatic
D013988_D002779 CID ticlopidine_12\NN\1740|agent (r_dobj) complication_7\NN\1073995|:|hepatitis|is|a|rare|ticlopidine (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D002779 CID ticlopidine_7\NN\1740|with (r_nmod) treatment_5\NN\654885|following|ticlopidine (r_nmod) developed_2\VBD\1753788|patients|jaundice|treatment|and|showed|. (l_conj) showed_9\VBD\2137132|characteristics (l_dobj) characteristics_14\NNS\5849040|the|clinical|hepatitis (l_nmod) hepatitis_17\NN\14127211|of|cholestatic|,|resolved
D013988_D002779 CID ticlopidine-induced_4\JJ\1740| (r_amod) cholestasis_5\NN\14052403|of|this|ticlopidine-induced
D013988_D002779 CID ticlopidine_10\NN\1740|of (r_nmod) effect_8\NN\34213|:|hepatitis|is|a|rare|adverse|ticlopidine|mediated (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine-induced_0\JJ\1740| (r_amod) hepatitis_2\NN\14127211|ticlopidine-induced|cholestatic|.
D013988_D056486 CID ticlopidine-induced_7\JJ\1740| (r_amod) hepatitis_9\NN\14127211|of|ticlopidine-induced|cholestatic
D013988_D056486 CID ticlopidine_11\NN\1740| (r_dobj) receiving_10\VBG\2210855|after|ticlopidine|angioplasty (r_advcl) developed_5\VBD\1753788|:|patients|hepatitis|receiving|,|remission|. (l_dobj) hepatitis_8\NN\14127211|prolonged|cholestatic
D013988_D056486 CID ticlopidine_12\NN\1740|agent (r_dobj) complication_7\NN\1073995|:|hepatitis|is|a|rare|ticlopidine (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine_7\NN\1740|with (r_nmod) treatment_5\NN\654885|following|ticlopidine (r_nmod) developed_2\VBD\1753788|patients|jaundice|treatment|and|showed|. (l_conj) showed_9\VBD\2137132|characteristics (l_dobj) characteristics_14\NNS\5849040|the|clinical|hepatitis (l_nmod) hepatitis_17\NN\14127211|of|cholestatic|,|resolved
D013988_D056486 CID ticlopidine_10\NN\1740|of (r_nmod) effect_8\NN\34213|:|hepatitis|is|a|rare|adverse|ticlopidine|mediated (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D007565 CID ticlopidine_7\NN\1740|with (r_nmod) treatment_5\NN\654885|following|ticlopidine (r_nmod) developed_2\VBD\1753788|patients|jaundice|treatment|and|showed|. (l_dobj) jaundice_3\NN\14299637|
8595686
D013874_D010146 NONE thiopentone_0\NN\1740| (r_compound) pretreatment_1\NN\1740|thiopentone|pain|. (l_nmod) pain_5\NN\14299637|for|injection|patients
D013874_D010146 NONE thiopentone_17\NN\1740| (r_nsubj) reduces_19\VBZ\441445|whereas|thiopentone|only|severity (r_advcl) reduces_4\VBZ\441445|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\13821570|the|and|severity|pain|patients (l_nmod) pain_12\NN\14299637|of|propofol|injection
D015742_D010146 CID propofol_3\NN\1740| (r_compound) injection_4\NN\320852|propofol (r_compound) pain_5\NN\14299637|for|injection|patients
D015742_D010146 CID propofol_3\NN\1740| (r_compound) injection_4\NN\320852|propofol (r_compound) pain_5\NN\14299637|injection|patients
D015742_D010146 CID propofol_10\NN\1740| (r_compound) pain_12\NN\14299637|of|propofol|injection
D008012_D010146 NONE lidocaine_3\NN\3681148| (r_nsubj) reduces_4\VBZ\441445|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\13821570|the|and|severity|pain|patients (l_nmod) pain_12\NN\14299637|of|propofol|injection
10901305
D007649_D050723 NONE ketamine_0\NN\3054098| (r_compound) sedation_1\NN\14034177|ketamine|reduction|. (l_nmod) reduction_4\NN\351485|for|the|fractures|department (l_nmod) fractures_8\NNS\14285662|of|children
D007649_D050723 NONE ketamine_14\NN\3054098|of (r_nmod) safety_10\NN\13920835|the|and|efficacy|ketamine|sedation|treatment|department (l_nmod) treatment_19\NN\654885|in|the|fractures (l_nmod) fractures_23\NNS\14285662|of|children
D007649_D050723 NONE ketamine_9\NN\3054098|of (r_nmod) administration_7\NN\1133281|from|intravenous|ketamine (r_nmod) time_4\NN\7308889|the|average|administration|manipulation (l_nmod) manipulation_11\NN\157081|to|fracture (l_nmod) fracture_14\NN\14285662|of|the|or|dislocation
D007649_D050723 NONE ketamine_2\NN\3054098| (r_nsubj) provided_9\VBD\2199590|ketamine|reliably|safely|sedation (l_dobj) sedation_11\NN\14034177|adequate|facilitate (l_acl:relcl) facilitate_14\VB\2547586|to|effectively|reduction|department (l_dobj) reduction_16\NN\351485|the|fractures (l_nmod) fractures_20\NNS\14285662|of|children
D007649_D004204 NONE ketamine_9\NN\3054098|of (r_nmod) administration_7\NN\1133281|from|intravenous|ketamine (r_nmod) time_4\NN\7308889|the|average|administration|manipulation (l_nmod) manipulation_11\NN\157081|to|fracture (l_nmod) fracture_14\NN\14285662|of|the|or|dislocation (l_conj) dislocation_16\NN\7367812|
12041669
D000961_D000741 NONE globulin_1\NN\14736972|antithymocyte|treatment|. (l_nmod) treatment_4\NN\654885|in|the|anemia (l_nmod) anemia_8\NN\14189204|of|d-penicillamine-induced|aplastic
D000961_D000741 NONE globulin_5\NN\14736972| (r_compound) therapy_6\NN\657604|antithymocyte|globulin|anemia (l_nmod) anemia_9\NN\14189204|for|aplastic
D000961_D000741 NONE globulin_3\NN\14736972|of|antithymocyte (r_nmod) use_0\NN\407535|globulin (r_nsubj) treatment_8\NN\654885|use|may|be|the|optimal|anemia|. (l_nmod) anemia_12\NN\14189204|of|d-penicillamine-induced|aplastic
D010396_D000741 CID d-penicillamine-induced_6\JJ\1740| (r_amod) anemia_8\NN\14189204|of|d-penicillamine-induced|aplastic
D010396_D000741 CID d-penicillamine_12\NN\1740| (r_compound) therapy_13\NN\657604|due|d-penicillamine (r_nmod) received_3\VBD\2210855|who|therapy|therapy (l_dobj) therapy_6\NN\657604|antithymocyte|globulin|anemia (l_nmod) anemia_9\NN\14189204|for|aplastic
D010396_D000741 CID d-penicillamine-induced_10\JJ\1740| (r_amod) anemia_12\NN\14189204|of|d-penicillamine-induced|aplastic
9034419
C047426_D012640 CID venlafaxine_4\NN\1740| (r_compound) overdose_5\NN\1740|from|a|venlafaxine (r_nmod) resulting_1\VBG\2633881|overdose (r_acl) seizure_0\NN\14081375|resulting|.
C047426_D012640 CID venlafaxine_5\NN\1740| (r_compound) tablets_7\NNS\4233405|of|26|venlafaxine|50-mg (r_nmod) ingestion_2\NN\13440063|after|the|tablets (r_nmod) experienced_11\VBD\2108377|ingestion|,|patient|seizure|. (l_dobj) seizure_15\NN\14081375|a|witnessed|generalized
C047426_D012640 CID venlafaxine_13\NN\1740| (r_compound) overdose_14\NN\1740|of|venlafaxine (r_nmod) case_11\NN\7283608|:|knowledge|,|this|is|the|first|reported|overdose|resulted (l_acl:relcl) resulted_16\VBD\2633881|that|seizure (l_nmod) seizure_20\NN\14081375|in|a|generalized
C047426_D012640 CID venlafaxine_3\NN\1740| (r_compound) overdose_4\NN\1740|the|venlafaxine|patient (r_nsubj) resulted_8\VBD\2633881|overdose|episode|but|elicited|. (l_nmod) episode_12\NN\7283608|in|a|single|seizure (l_nmod) seizure_15\NN\14081375|of|generalized
C047426_D062787 CID venlafaxine_4\NN\1740| (r_compound) overdose_5\NN\1740|from|a|venlafaxine
C047426_D062787 CID venlafaxine_7\NN\1740| (r_compound) overdose_8\NN\1740|of|venlafaxine
C047426_D062787 CID venlafaxine_13\NN\1740|of (r_nmod) overdose_11\NN\1740|an|venlafaxine
C047426_D062787 CID venlafaxine_13\NN\1740| (r_compound) overdose_14\NN\1740|of|venlafaxine
C047426_D062787 CID venlafaxine_3\NN\1740| (r_compound) overdose_4\NN\1740|the|venlafaxine|patient
C047426_D003865 NONE venlafaxine_13\NN\1740|of (r_nmod) overdose_11\NN\1740|an|venlafaxine (r_dobj) took_9\VBD\2367363|woman|overdose|attempt|. (l_nsubj) woman_5\NN\9605289|a|40-year-old|depression (l_nmod) depression_8\NN\14373582|with|major
6861444
D009638_D006973 CID noradrenaline_3\NN\14807929|of (r_nmod) infusion_1\NN\14589223|intrarenal|noradrenaline (r_nsubj) caused_4\VBD\1617192|infusion|hypertension|doses|. (l_dobj) hypertension_5\NN\14057371|
D009638_D006973 CID noradrenaline_8\NN\14807929| (r_compound) infusion_9\NN\14589223|after|chronic|intrarenal|noradrenaline (r_nmod) hypertension_4\NN\14057371|infusion
D009638_D006973 CID noradrenaline_18\NN\14807929|of|circulating (r_nmod) levels_15\NNS\4916342|by|higher|noradrenaline|and|triggering (r_nmod) produced_11\VBN\1617192|that|hypertension|is|levels (l_nsubjpass) hypertension_4\NN\14057371|infusion
16181582
D014635_D001927 CID valproate-induced_0\NN\1740| (r_amod) encephalopathy_1\NN\14084880|valproate-induced|.
D014635_D001927 CID valproate-induced_0\JJ\1740| (r_amod) encephalopathy_1\NN\14084880|valproate-induced
D014635_D001927 CID valproate-induced_3\JJ\1740| (r_amod) encephalopathy_4\NN\14084880|of|valproate-induced
D014635_D004827 NONE valproate-induced_0\JJ\1740| (r_amod) encephalopathy_1\NN\14084880|valproate-induced (r_nsubj) syndrome_5\NN\5870365|encephalopathy|is|a|rare|manifest|. (l_acl:relcl) manifest_8\VB\1015244|that|may|individuals (l_nmod) individuals_13\NNS\7347|in|otherwise|normal|epileptic (l_amod) epileptic_12\JJ\1740|
17343925
D012906_D034381 CID smoking_3\NN\831191|of|pregnancy|cochlea (r_nmod) influence_1\NN\5190804|the|smoking (r_nsubjpass) estimated_13\VBN\637259|influence|has|not|been|,|associated|. (l_advcl) associated_20\VBN\628491|although|smoking|has|been|positively|loss (l_nmod) loss_23\NN\13252973|with|hearing|adults
D012906_D034381 CID smoking_16\NN\831191| (r_nsubjpass) associated_20\VBN\628491|although|smoking|has|been|positively|loss (l_nmod) loss_23\NN\13252973|with|hearing|adults
18442015
D014700_D006471 NONE verapamil_3\NN\2938514|of (r_nmod) effect_1\NN\34213|protective|verapamil|ulcers|. (l_nmod) ulcers_7\NNS\14211294|on|gastric|hemorrhagic|rats (l_amod) hemorrhagic_6\JJ\1740|
D014700_D006471 NONE verapamil_13\NN\2938514|by|daily|intragastric (r_nmod) ameliorated_9\VBN\126264|ulcer|were|dose-dependently|verapamil|. (l_nsubjpass) ulcer_2\NN\14211294|this|hemorrhagic|and|parameters (l_amod) hemorrhagic_1\JJ\1740|
D014700_D006471 NONE verapamil_26\NN\2938514|by|rats (r_nmod) ameliorated_24\VBN\126264|that|could|be|verapamil (r_acl:relcl) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability|ameliorated (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\1740|
D014700_D014456 NONE verapamil_3\NN\2938514|of (r_nmod) effect_1\NN\34213|protective|verapamil|ulcers|. (l_nmod) ulcers_7\NNS\14211294|on|gastric|hemorrhagic|rats
D014700_D014456 NONE verapamil_6\NN\2938514|of (r_nmod) effect_4\NN\34213|the|protective|verapamil|model (l_nmod) model_10\NN\5888929|on|this|ulcer (l_compound) ulcer_9\NN\14211294|
D014700_D014456 NONE verapamil_13\NN\2938514|by|daily|intragastric (r_nmod) ameliorated_9\VBN\126264|ulcer|were|dose-dependently|verapamil|. (l_nsubjpass) ulcer_2\NN\14211294|this|hemorrhagic|and|parameters
D014700_D014456 NONE verapamil_26\NN\2938514|by|rats (r_nmod) ameliorated_24\VBN\126264|that|could|be|verapamil (r_acl:relcl) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability|ameliorated (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic
D014700_D050197 NONE verapamil_3\NN\2938514|of (r_nmod) effect_1\NN\34213|protective|verapamil|ulcers|. (l_nmod) ulcers_7\NNS\14211294|on|gastric|hemorrhagic|rats (l_nmod) rats_11\NNS\2329401|in|severe|atherosclerotic (l_amod) atherosclerotic_10\JJ\1740|
D014700_D050197 NONE verapamil_26\NN\2938514|by|rats (r_nmod) ameliorated_24\VBN\126264|that|could|be|verapamil (r_acl:relcl) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability|ameliorated (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_nsubj) atherosclerosis_0\NN\14108324|
D006632_D006471 NONE histamine_17\NN\14739004| (r_compound) release_18\NN\3748886|mast|cell|histamine (r_conj) back-diffusion_13\NN\1740|of|gastric|acid|,|release|,|generation|and|permeability (r_nmod) role_9\NN\719494|the|back-diffusion (r_dobj) examine_7\VB\789138|to|role|modulating (l_advcl) modulating_31\VBG\1724459|in|hemorrhage (l_dobj) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats
D006632_D006471 NONE histamine_6\NN\14739004|of (r_nmod) correlation_4\NN\13841213|a|positive|histamine|hemorrhage (l_nmod) hemorrhage_9\NN\14285662|to|gastric|and|ulcer
D006632_D006471 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability|ameliorated (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\1740|
D006632_D014456 NONE histamine_17\NN\14739004| (r_compound) release_18\NN\3748886|mast|cell|histamine (r_conj) back-diffusion_13\NN\1740|of|gastric|acid|,|release|,|generation|and|permeability (r_nmod) role_9\NN\719494|the|back-diffusion (r_dobj) examine_7\VB\789138|to|role|modulating (l_advcl) modulating_31\VBG\1724459|in|hemorrhage (l_dobj) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats (l_conj) ulcer_35\NN\14211294|
D006632_D014456 NONE histamine_8\NN\14739004| (r_compound) concentration_9\NN\4916342|histamine (r_conj) generation_6\NN\7942152|mucosal|lpo|,|concentration|,|permeability|,|content (l_conj) content_16\NN\7951464|luminal|hemoglobin|and|areas (l_conj) areas_19\NNS\8630985|ulcer (l_compound) ulcer_18\NN\14211294|
D006632_D014456 NONE histamine_14\NN\14739004| (r_compound) release_15\NN\3748886|histamine (r_conj) back-diffusion_12\NN\1740|including|gastric|acid|,|release|,|generation|and|content (r_nmod) factors_7\NNS\7326557|with|increased|ulcerogenic|,|back-diffusion (r_nmod) accompanied_3\VBN\1835496|factors (r_acl) ulcers_2\NNS\14211294|severe|gastric|accompanied
D006632_D014456 NONE histamine_6\NN\14739004|of (r_nmod) correlation_4\NN\13841213|a|positive|histamine|hemorrhage (l_nmod) hemorrhage_9\NN\14285662|to|gastric|and|ulcer (l_conj) ulcer_12\NN\14211294|to
D006632_D014456 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability|ameliorated (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic
D006632_D050197 NONE histamine_17\NN\14739004| (r_compound) release_18\NN\3748886|mast|cell|histamine (r_conj) back-diffusion_13\NN\1740|of|gastric|acid|,|release|,|generation|and|permeability (r_nmod) role_9\NN\719494|the|back-diffusion (r_dobj) examine_7\VB\789138|to|role|modulating (l_advcl) modulating_31\VBG\1724459|in|hemorrhage (l_dobj) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats (l_nmod) rats_37\NNS\2329401|in|atherosclerosis (l_nmod) atherosclerosis_39\NN\14108324|with|induced
D006632_D050197 NONE histamine_6\NN\14739004|of (r_nmod) correlation_4\NN\13841213|a|positive|histamine|hemorrhage (r_nsubjpass) found_14\VBN\2426171|moreover|,|correlation|was|rats|. (l_nmod) rats_18\NNS\2329401|in|those|atherosclerotic (l_amod) atherosclerotic_17\JJ\1740|
D006632_D050197 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability|ameliorated (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_nsubj) atherosclerosis_0\NN\14108324|
D004872_D006471 CID d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats
D004872_D014456 CID d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats (l_conj) ulcer_35\NN\14211294|
D004872_D050197 CID d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced
D004872_D050197 CID d2_19\NN\1740|vitamin|and|cholesterol (r_dobj) containing_17\VBG\2632940|d2 (r_acl) oil_16\NN\14938907|of|corn|containing (r_nmod) ml/kg_13\NN\1740|with|1.0|oil (r_nmod) challenged_4\VBN\869596|rats|were|intragastrically|once|daily|days|ml/kg|induce|. (l_advcl) induce_23\VB\1627355|to|atherosclerosis (l_dobj) atherosclerosis_24\NN\14108324|
D002784_D006471 CID cholesterol_47\NN\15058310| (r_conj) d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats
D002784_D014456 CID cholesterol_47\NN\15058310| (r_conj) d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) hemorrhage_33\NN\14285662|gastric|and|ulcer|rats (l_conj) ulcer_35\NN\14211294|
D002784_D050197 CID cholesterol_47\NN\15058310| (r_conj) d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced
D002784_D050197 CID cholesterol_21\NN\15058310| (r_conj) d2_19\NN\1740|vitamin|and|cholesterol (r_dobj) containing_17\VBG\2632940|d2 (r_acl) oil_16\NN\14938907|of|corn|containing (r_nmod) ml/kg_13\NN\1740|with|1.0|oil (r_nmod) challenged_4\VBN\869596|rats|were|intragastrically|once|daily|days|ml/kg|induce|. (l_advcl) induce_23\VB\1627355|to|atherosclerosis (l_dobj) atherosclerosis_24\NN\14108324|
D002784_D050197 CID cholesterol_10\NN\15058310|total (r_conj) calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (l_amod) atherosclerotic_1\JJ\1740|
D002784_D050197 CID cholesterol_10\NN\15058310|total (r_conj) calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (r_nsubjpass) obtained_16\VBN\2210855|parameters|were|rats|. (l_nmod) rats_19\NNS\2329401|in|atherosclerotic (l_amod) atherosclerotic_18\JJ\1740|
D010634_D014456 NONE luminal_14\JJ\1740| (r_amod) content_16\NN\7951464|luminal|hemoglobin|and|areas (l_conj) areas_19\NNS\8630985|ulcer (l_compound) ulcer_18\NN\14211294|
D010634_D014456 NONE luminal_20\JJ\1740| (r_amod) content_22\NN\7951464|luminal|hemoglobin (r_conj) back-diffusion_12\NN\1740|including|gastric|acid|,|release|,|generation|and|content (r_nmod) factors_7\NNS\7326557|with|increased|ulcerogenic|,|back-diffusion (r_nmod) accompanied_3\VBN\1835496|factors (r_acl) ulcers_2\NNS\14211294|severe|gastric|accompanied
D002118_D050197 NONE calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (l_amod) atherosclerotic_1\JJ\1740|
D002118_D050197 NONE calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (r_nsubjpass) obtained_16\VBN\2210855|parameters|were|rats|. (l_nmod) rats_19\NNS\2329401|in|atherosclerotic (l_amod) atherosclerotic_18\JJ\1740|
3101906
D007654_D003643 NONE ketoconazole_9\NN\1740| (r_compound) treatment_10\NN\654885|with|ketoconazole (r_nmod) associated_7\VBN\628491|probably|treatment (r_acl) deaths_5\NNS\7296428|of|the|three|associated
D007654_D007565 CID ketoconazole_9\NN\1740| (r_compound) treatment_10\NN\654885|with|ketoconazole (r_nmod) associated_7\VBN\628491|probably|treatment (r_acl) deaths_5\NNS\7296428|of|the|three|associated (r_nmod) two_1\CD\13741022|in|deaths (r_nmod) continued_15\VBN\2367363|two|drug|had|been|onset|. (l_nmod) onset_18\NN\7325190|after|the|jaundice (l_nmod) jaundice_20\NN\14299637|of|and|symptoms
D007654_D056486 CID ketoconazole_9\NN\1740| (r_compound) treatment_10\NN\654885|with|ketoconazole (r_nmod) associated_7\VBN\628491|probably|treatment (r_acl) deaths_5\NNS\7296428|of|the|three|associated (r_nmod) two_1\CD\13741022|in|deaths (r_nmod) continued_15\VBN\2367363|two|drug|had|been|onset|. (l_nmod) onset_18\NN\7325190|after|the|jaundice (l_nmod) jaundice_20\NN\14299637|of|and|symptoms (l_conj) symptoms_23\NNS\5823932|other|hepatitis (l_nmod) hepatitis_25\NN\14127211|of
D007654_D056486 CID ketoconazole_18\NN\1740|with (r_nmod) treatment_16\NN\654885|during|term|ketoconazole (r_nmod) advised_12\VBN\813978|monitoring|is|treatment|prevent|. (l_nsubjpass) monitoring_3\NN\879759|clinical|intervals|evidence (l_nmod) evidence_8\NN\5816287|for|hepatitis (l_nmod) hepatitis_10\NN\14127211|of
D007654_D056486 CID ketoconazole_18\NN\1740|with (r_nmod) treatment_16\NN\654885|during|term|ketoconazole (r_nmod) advised_12\VBN\813978|monitoring|is|treatment|prevent|. (l_advcl) prevent_20\VB\1740|to|injury (l_dobj) injury_24\NN\14052046|possible|serious|hepatic
20882060
D009496_D002375 NONE neurotensin_3\NN\1740|of|pallidal (r_nmod) effects_0\NNS\13245626|neurotensin|catalepsy|:|studies (l_nmod) catalepsy_7\NN\14023236|on|haloperidol-induced|parkinsonian
D009496_D002375 NONE neurotensin_5\NN\1740|of (r_nmod) infusions_3\NNS\14589223|bilateral|neurotensin|pallidus (r_nsubj) reversed_10\VBD\109660|results|infusions|catalepsy|. (l_dobj) catalepsy_13\NN\14023236|haloperidol-induced|parkinsonian|rats
D006220_D002375 CID haloperidol-induced_5\JJ\1740| (r_amod) catalepsy_7\NN\14023236|on|haloperidol-induced|parkinsonian
D006220_D002375 CID haloperidol-induced_11\JJ\1740| (r_amod) catalepsy_13\NN\14023236|haloperidol-induced|parkinsonian|rats
D009496_D010302 NONE neurotensin_10\NN\1740|of|pallidal (r_nmod) effects_7\NNS\13245626|the|neurotensin|symptoms (l_nmod) symptoms_14\NNS\5823932|on|haloperidol-induced|parkinsonian
D006220_D010302 NONE haloperidol-induced_12\JJ\1740| (r_amod) symptoms_14\NNS\5823932|on|haloperidol-induced|parkinsonian
6387529
D003975_D016584 NONE diazepam_3\NN\2830852|of|and|propranolol (r_nmod) effects_1\NNS\13245626|behavioral|diazepam|patients|. (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia
D003975_D016584 NONE diazepam_6\NN\2830852|of|dose|and|propranolol (r_nmod) doses_4\NNS\3740161|of|oral|diazepam (r_nmod) effects_1\NNS\13245626|the|doses|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia
D003975_D000379 NONE diazepam_3\NN\2830852|of|and|propranolol (r_nmod) effects_1\NNS\13245626|behavioral|diazepam|patients|. (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_12\NN\14381416|
D003975_D000379 NONE diazepam_6\NN\2830852|of|dose|and|propranolol (r_nmod) doses_4\NNS\3740161|of|oral|diazepam (r_nmod) effects_1\NNS\13245626|the|doses|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_52\NN\14381416|
D011433_D016584 NONE propranolol_5\NN\1740| (r_conj) diazepam_3\NN\2830852|of|and|propranolol (r_nmod) effects_1\NNS\13245626|behavioral|diazepam|patients|. (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia
D011433_D016584 NONE propranolol_25\NN\1740|dose (r_conj) diazepam_6\NN\2830852|of|dose|and|propranolol (r_nmod) doses_4\NNS\3740161|of|oral|diazepam (r_nmod) effects_1\NNS\13245626|the|doses|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia
D011433_D000379 NONE propranolol_5\NN\1740| (r_conj) diazepam_3\NN\2830852|of|and|propranolol (r_nmod) effects_1\NNS\13245626|behavioral|diazepam|patients|. (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_12\NN\14381416|
D011433_D000379 NONE propranolol_25\NN\1740|dose (r_conj) diazepam_6\NN\2830852|of|dose|and|propranolol (r_nmod) doses_4\NNS\3740161|of|oral|diazepam (r_nmod) effects_1\NNS\13245626|the|doses|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_52\NN\14381416|
D003975_D008569 CID diazepam_12\NN\2830852|for (r_nmod) greater_10\JJR\1740|decrease|was|diazepam|propranolol|. (r_conj) impaired_2\VBD\258857|drugs|recall|but|greater (l_dobj) recall_5\NN\7185325|immediate|free
D011433_D008569 CID propranolol_14\NN\1740|than (r_nmod) greater_10\JJR\1740|decrease|was|diazepam|propranolol|. (r_conj) impaired_2\VBD\258857|drugs|recall|but|greater (l_dobj) recall_5\NN\7185325|immediate|free
16755009
D003975_D000647 CID diazepam-_0\NN\1740|,|scopolamine-|and|ageing-induced (r_compound) amnesia_5\NN\5669934|diazepam-
D003975_D000647 CID diazepam_16\NN\2830852|mg/kg (r_conj) scopolamine_8\NN\14712692|by|mg/kg|i.p.|)|and|diazepam (r_nmod) induced_6\VBN\1627355|scopolamine (r_acl) amnesia_5\NN\5669934|the|induced
D012601_D000647 CID scopolamine-_2\NN\1740| (r_conj) diazepam-_0\NN\1740|,|scopolamine-|and|ageing-induced (r_compound) amnesia_5\NN\5669934|diazepam-
D012601_D000647 CID scopolamine_8\NN\14712692|by|mg/kg|i.p.|)|and|diazepam (r_nmod) induced_6\VBN\1627355|scopolamine (r_acl) amnesia_5\NN\5669934|the|induced
D010936_D000647 NONE dce_2\NN\1740| (r_nsubj) reversed_3\VBD\109660|furthermore|,|dce|amnesia|. (l_dobj) amnesia_5\NN\5669934|the|induced
D010936_D003072 NONE dce_2\NN\1740| (r_nsubj) prove_4\VB\2604760|therefore|,|dce|may|remedy|. (l_xcomp) remedy_9\NN\258854|to|be|a|useful|management|account (l_nmod) management_12\NN\1123598|for|the|dysfunctions (l_nmod) dysfunctions_15\NNS\14204950|of|cognitive
D002784_D003072 NONE cholesterol_30\NN\15058310| (r_compound) property_32\NN\32613|cholesterol|lowering|and|activity (r_conj) property_28\NN\32613|such|memory|improving|,|property (r_nmod) effects_22\NNS\13245626|of|its|multifarious|beneficial|property (r_nmod) account_17\NN\6647206|on|effects (r_nmod) remedy_9\NN\258854|to|be|a|useful|management|account (l_nmod) management_12\NN\1123598|for|the|dysfunctions (l_nmod) dysfunctions_15\NNS\14204950|of|cognitive
3371379
D014700_D020258 CID verapamil-induced_0\JJ\1740| (r_amod) neurotoxicity_2\NN\1740|verapamil-induced|carbamazepine|.
D014700_D020258 CID verapamil_11\NN\2938514|with (r_nmod) treatment_9\NN\654885|after|combined|verapamil (r_nmod) signs_3\NNS\6643763|with|neurotoxicity|treatment (l_nmod) neurotoxicity_6\NN\1740|of|carbamazepine
D002220_D020258 CID carbamazepine_1\NN\1740| (r_compound) neurotoxicity_2\NN\1740|verapamil-induced|carbamazepine|.
D002220_D020258 CID carbamazepine_5\NN\1740| (r_compound) neurotoxicity_6\NN\1740|of|carbamazepine
D002118_D020258 NONE calcium_19\NN\14625458| (r_compound) blocker_21\NN\10101634|of|the|calcium|entry (r_nmod) discontinuation_16\NN\209943|after|blocker (r_nmod) recovery_14\NN\7357388|complete|discontinuation (r_dobj) showed_12\VBD\2137132|patients|recovery|. (l_nsubj) patients_1\NNS\9898892|two|signs (l_nmod) signs_3\NNS\6643763|with|neurotoxicity|treatment (l_nmod) neurotoxicity_6\NN\1740|of|carbamazepine
2559236
D004317_D007674 NONE adriamycin-induced_9\JJ\1740| (r_amod) nephropathy_10\NN\14573196|of|adriamycin-induced
D004317_D007674 NONE adriamycin_24\NN\1740| (r_compound) nephrosis_25\NN\14304060|in|adriamycin (r_nmod) injury_22\NN\14052046|of|renal|nephrosis
D004656_D009401 NONE enalapril_10\NN\2673637|of|the|inhibitor|cei|) (r_nmod) effect_1\NN\34213|the|enalapril (r_nsubjpass) assessed_12\VBN\670261|effect|was|rats|. (l_nmod) rats_15\NNS\2329401|in|munich-wistar|nephrosis (l_nmod) nephrosis_19\NN\14304060|with|established|adriamycin
D004656_D009401 NONE enalapril_17\NN\2673637|of (r_nmod) effect_15\NN\34213|the|enalapril|progression (l_nmod) progression_19\NN\8457976|on|injury (l_nmod) injury_22\NN\14052046|of|renal|nephrosis (l_nmod) nephrosis_25\NN\14304060|in|adriamycin
D004317_D009401 CID adriamycin_18\NN\1740| (r_compound) nephrosis_19\NN\14304060|with|established|adriamycin
D004317_D009401 CID adriamycin_24\NN\1740| (r_compound) nephrosis_25\NN\14304060|in|adriamycin
D004317_D000419 CID adriamycin_7\NN\1740|of (r_nmod) dose_5\NN\3740161|a|single|adriamycin (r_dobj) given_2\VBN\2327200|rats|were|dose|and|divided|. (l_conj) divided_12\VBN\140123|later|groups (l_nmod) groups_15\NNS\2137|into|four|matched (l_acl) matched_16\VBN\2664769|albuminuria (l_nmod) albuminuria_18\NN\14299637|for|,|pressure|,|and|concentration
D004656_D000419 NONE enalapril_5\NN\2673637| (r_nsubj) reduced_6\VBD\441445|that|enalapril|pressure|reducing (l_advcl) reducing_52\VBG\441445|without|albuminuria (l_dobj) albuminuria_53\NN\14299637|mg/day|or|gfr
D004656_D000419 NONE enalapril_1\NN\2673637| (r_compound) treatment_2\NN\654885|chronic|enalapril (r_nsubj) reduced_3\VBD\441445|treatment|pressure|reducing|. (l_advcl) reducing_7\VBG\441445|without|albuminuria|group (l_dobj) albuminuria_8\NN\14299637|
D004656_D007674 NONE enalapril_17\NN\2673637|of (r_nmod) effect_15\NN\34213|the|enalapril|progression (l_nmod) progression_19\NN\8457976|on|injury (l_nmod) injury_22\NN\14052046|of|renal|nephrosis
2484011
D000547_D003866 NONE amantadine_4\NN\1740|of (r_nmod) dose_2\NN\3740161|the|initial|amantadine (r_nsubj) depressed_5\VBD\1819147|dose|activity|sensitive|.
D000547_D011596 CID amantadine_2\NN\1740|of (r_nmod) readministration_0\NN\1740|amantadine (r_nsubj) increased_10\VBD\169651|readministration|,|period|,|motility|control|strains|exception|. (l_nmod) exception_20\NN\5706954|with|mice (l_nmod) mice_24\NNS\2329401|of|the|balb/c|occurred (l_acl:relcl) occurred_29\VBD\2623529|where|suppression (l_nsubj) suppression_26\NN\13489037|motility (l_nmod) motility_28\NN\4773351|of
D000547_D011596 CID amantadine_41\NN\1740|by|mice (r_nmod) caused_39\VBN\1617192|amantadine (r_acl) depression_38\NN\14373582|for|a|behavioral|caused
D000588_D011596 NONE amines_6\NNS\14951377|of|brain|biogenic|strain (r_nmod) results_2\NNS\34213|the|biochemical|amines (r_nsubj) suggest_11\VBP\1010118|results|decrease|. (l_dobj) decrease_14\NN\7296428|a|probable|rate|and/or|metabolism|and|increase (l_conj) increase_27\NN\13576355|a|resulting|o-methylation|account (l_acl:relcl) account_34\VB\2604760|which|may|depression (l_nmod) depression_38\NN\14373582|for|a|behavioral|caused
D002395_D011596 NONE catecholamine_16\NN\5407119| (r_compound) rate_18\NN\13815152|of|catecholamine|turnover (r_nmod) decrease_14\NN\7296428|a|probable|rate|and/or|metabolism|and|increase (l_conj) increase_27\NN\13576355|a|resulting|o-methylation|account (l_acl:relcl) account_34\VB\2604760|which|may|depression (l_nmod) depression_38\NN\14373582|for|a|behavioral|caused
D009638_D011596 NONE norepinephrine_31\NN\14807929|of (r_nmod) o-methylation_29\NN\1740|in|norepinephrine (r_nmod) increase_27\NN\13576355|a|resulting|o-methylation|account (l_acl:relcl) account_34\VB\2604760|which|may|depression (l_nmod) depression_38\NN\14373582|for|a|behavioral|caused
19767176
C020972_D013226 NONE dithiocarbamate_1\NN\1740|pyrrolidine (r_nsubj) protects_2\VBZ\1127795|dithiocarbamate|cortex|model|. (l_nmod) model_11\NN\5888929|in|the|epilepticus (l_compound) epilepticus_10\NN\1740|pilocarpine|status
C020972_D013226 NONE pdtc_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|pdtc|loss (l_nmod) loss_8\NN\13252973|on|epilepticus-associated|cell|hippocampus (l_amod) epilepticus-associated_6\JJ\1740|status
C020972_D013226 NONE pdtc_4\NN\1740|with|mg/kg (r_nmod) treatment_0\NN\654885|pdtc|before|epilepticus (l_appos) epilepticus_9\NN\1740|status
C020972_D013226 NONE pdtc_4\NN\1740|of|mg/kg|low-dose (r_nmod) administration_0\NN\1133281|pdtc (r_nsubj) exert_10\VB\1158872|administration|did|not|effects|development|. (l_nmod) development_15\NN\248977|on|the|epilepticus|or|rate (l_nmod) epilepticus_19\NN\1740|of|a|status
C020972_D013226 NONE pdtc-treated_16\JJ\1740| (r_conj) vehicle-_14\NN\1740|and|pdtc-treated (r_amod) rats_17\NNS\2329401|in|vehicle- (r_nmod) identified_12\VBN\699815|decrease|was|rats|epilepticus|. (l_nmod) epilepticus_20\NN\1740|following|status
D010862_D013226 CID pilocarpine_8\NN\14712692| (r_compound) epilepticus_10\NN\1740|pilocarpine|status
D010862_D013226 CID pilocarpine_21\NN\14712692| (r_compound) model_22\NN\5888929|in|the|rat|fractionated|pilocarpine (r_nmod) evaluated_16\VBN\670261|effect|was|model|. (l_nsubjpass) effect_1\NN\34213|the|pdtc|loss (l_nmod) loss_8\NN\13252973|on|epilepticus-associated|cell|hippocampus (l_amod) epilepticus-associated_6\JJ\1740|status
D010100_D009410 NONE oxygen_5\NN\14622893| (r_compound) species_6\NNS\7992450|of|reactive|oxygen (r_nmod) production_2\NN\30358|species|as|activation (r_nsubjpass) implicated_15\VBN\2677097|both|,|production|have|been|damage|. (l_nmod) damage_19\NN\7296428|in|severe|neuronal|sub-regions
D010100_D009410 NONE oxygen_9\NN\14622893| (r_compound) species_10\NNS\7992450|of|reactive|oxygen (r_nmod) generation_6\NN\7942152|the|species|and|activation (r_nsubj) plays_15\VBZ\1072262|that|generation|role|damage|compared (l_nmod) damage_23\NN\7296428|in|seizure-associated|neuronal|cortex
C020972_D009410 NONE pdtc_8\NN\1740|antioxidant (r_conj) inhibitor_5\NN\20090|the|nf-kappab|and|pdtc (r_nsubj) protected_9\VBD\1127795|conclusion|,|inhibitor|cortex|,|affect|. (l_advcl) affect_18\VB\126264|whereas|it|did|not|loss (l_dobj) loss_21\NN\13252973|hilar|neuronal
D010100_D012640 NONE oxygen_9\NN\14622893| (r_compound) species_10\NNS\7992450|of|reactive|oxygen (r_nmod) generation_6\NN\7942152|the|species|and|activation (r_nsubj) plays_15\VBZ\1072262|that|generation|role|damage|compared (l_nmod) damage_23\NN\7296428|in|seizure-associated|neuronal|cortex (l_amod) seizure-associated_21\JJ\1740|
15737522
D002443_D001660 CID ceftriaxone-associated_0\NN\1740| (r_compound) pseudolithiasis_2\NN\1740|ceftriaxone-associated|biliary|patients|.
D002443_D001660 CID ceftriaxone_5\NN\2996840| (r_nsubj) leads_6\VBZ\1752884|that|ceftriaxone|pseudolithiasis (l_nmod) pseudolithiasis_8\NN\1740|to|patients
D002443_D001660 CID ceftriaxone_19\NN\2996840| (r_compound) treatment_20\NN\654885|ceftriaxone (r_dobj) receiving_18\VBG\2210855|treatment (r_acl) patients_17\NNS\9898892|in|paediatric|surgical|receiving|,|had (r_nmod) incidence_8\NN\13821570|the|and|importance|pseudolithiasis|patients (l_nmod) pseudolithiasis_13\NN\1740|of
809711
D010656_D009203 NONE phenylephrine_2\NN\2682038|by (r_nmod) reversal_0\NN\199130|phenylephrine|effects|. (l_nmod) effects_6\NNS\13245626|of|the|beneficial|nitroglycerin|patients (l_nmod) patients_11\NNS\9898892|in|infarction (l_nmod) infarction_15\NN\14204950|with|acute|myocardial
D010656_D009203 NONE phenylephrine_6\NN\2682038|of (r_nmod) addition_4\NN\3081021|phenylephrine|nitroglycerin (r_nsubj) beneficial_11\JJ\1740|that|addition|is|not|treatment (l_nmod) treatment_14\NN\654885|in|the|patients (l_nmod) patients_16\NNS\9898892|of|infarction (l_nmod) infarction_20\NN\14204950|with|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\15015501|of|intravenous (r_nmod) effects_6\NNS\13245626|of|the|beneficial|nitroglycerin|patients (l_nmod) patients_11\NNS\9898892|in|infarction (l_nmod) infarction_15\NN\14204950|with|acute|myocardial
D005996_D009203 NONE nitroglycerin_0\NN\15015501| (r_nsubjpass) shown_3\VBN\2137132|nitroglycerin|has|been|reduce|. (l_xcomp) reduce_5\VB\441445|to|elevation|,|effect (l_dobj) elevation_7\NN\7445480|st-segment|infarction (l_nmod) infarction_11\NN\14204950|during|acute|myocardial
D005996_D009203 NONE nitroglycerin-induced_23\JJ\1740| (r_amod) hypotension_24\NN\14057371|nitroglycerin-induced (r_dobj) reverse_22\VBP\109660|that|hypotension (r_acl:relcl) agents_20\NNS\7347|by|reverse (r_nmod) potentiated_15\VBN\229605|dog|agents (r_acl) effect_14\NN\34213|an|potentiated (r_dobj) reduce_5\VB\441445|to|elevation|,|effect (l_dobj) elevation_7\NN\7445480|st-segment|infarction (l_nmod) infarction_11\NN\14204950|during|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\15015501|intravenous|,|sufficient|, (r_dobj) received_7\VBD\2210855|patients|nitroglycerin|minutes|. (l_nsubj) patients_1\NNS\9898892|ten|infarctions (l_nmod) infarctions_6\NNS\14204950|with|acute|transmural|myocardial
D005996_D009203 NONE nitroglycerin_8\NN\15015501|to (r_nmod) addition_4\NN\3081021|phenylephrine|nitroglycerin (r_nsubj) beneficial_11\JJ\1740|that|addition|is|not|treatment (l_nmod) treatment_14\NN\654885|in|the|patients (l_nmod) patients_16\NNS\9898892|of|infarction (l_nmod) infarction_20\NN\14204950|with|acute|myocardial
D005996_D007022 CID nitroglycerin_0\NN\15015501| (r_nsubjpass) shown_3\VBN\2137132|nitroglycerin|has|been|reduce|. (l_xcomp) reduce_5\VB\441445|to|elevation|,|effect (l_dobj) effect_14\NN\34213|an|potentiated (l_acl) potentiated_15\VBN\229605|dog|agents (l_nmod) agents_20\NNS\7347|by|reverse (l_acl:relcl) reverse_22\VBP\109660|that|hypotension (l_dobj) hypotension_24\NN\14057371|nitroglycerin-induced
D005996_D007022 CID nitroglycerin-induced_23\JJ\1740| (r_amod) hypotension_24\NN\14057371|nitroglycerin-induced
150790
D011736_D002653 NONE pyridoxine-dependent_1\NN\1740| (r_amod) disorder_3\NN\14034177|a|pyridoxine-dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_6\NN\2716205|by (r_nmod) unmasked_4\VBN\853195|isoniazid (r_acl) disorder_3\NN\14034177|a|pyridoxine-dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) had_3\VBD\2108377|girl|deterioration|administration|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis
D007538_D006948 CID isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) had_3\VBD\2108377|girl|deterioration|administration|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis (l_nmod) hyperkinesis_8\NN\1740|with|,|irritability
D007538_D001523 NONE isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) had_3\VBD\2108377|girl|deterioration|administration|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis (l_nmod) hyperkinesis_8\NN\1740|with|,|irritability (l_conj) irritability_10\NN\7552087|,|and|difficulties
D007538_D012893 NONE isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) had_3\VBD\2108377|girl|deterioration|administration|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis (l_nmod) hyperkinesis_8\NN\1740|with|,|irritability (l_conj) irritability_10\NN\7552087|,|and|difficulties (l_conj) difficulties_14\NNS\621627|sleeping
D011736_D006948 NONE pyridoxine_3\NN\15090742|of (r_nmod) withdrawal_1\NN\7206096|periodic|pyridoxine (r_nsubjpass) associated_5\VBN\628491|withdrawal|was|return|. (l_nmod) return_7\NN\6479665|with|hyperkinesis (l_nmod) hyperkinesis_10\NN\1740|of|the
20722491
-1_D009369 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|,
-1_D015179 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
-1_D001943 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
-1_D006258 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
D005472_D009369 NONE 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|,
D005472_D009369 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|,
D005472_D015179 NONE 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
D005472_D015179 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
D005472_D001943 NONE 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
D005472_D001943 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
D005472_D006258 NONE 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
D005472_D006258 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil (r_nsubj) mainstay_17\NN\10677713|fluoropyrimidines|,|have|been|the|treatment|years|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|cancers|, (l_nmod) cancers_33\NNS\14239425|including|colorectal
C110904_D007674 NONE capecitabine_16\NN\1740|of (r_nmod) safety_14\NN\13920835|into|the|capecitabine|populations (l_nmod) populations_19\NNS\7942152|in|special|patients (l_nmod) patients_22\NNS\9898892|such|age (l_nmod) age_25\NN\4916342|with|advanced|,|renal|disease (l_dep) disease_30\NN\14061805|
C110904_D007674 NONE capecitabine_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|capecitabine|profile|and|given|. (l_conj) given_9\VBN\2327200|can|be|safely|patients (l_nmod) patients_12\NNS\9898892|to|age (l_nmod) age_15\NN\4916342|with|advanced|,|dysfunctions (l_conj) dysfunctions_20\NNS\14204950|hepatic
C110904_D003967 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|reported|toxic|capecitabine (r_nsubj) diarrhea_9\NN\14299637|effects|are|,|nausea|.
C110904_D009325 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|reported|toxic|capecitabine (r_nsubj) diarrhea_9\NN\14299637|effects|are|,|nausea|. (l_conj) nausea_11\NN\14299637|,|vomiting|,|stomatitis
C110904_D014839 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|reported|toxic|capecitabine (r_nsubj) diarrhea_9\NN\14299637|effects|are|,|nausea|. (l_conj) nausea_11\NN\14299637|,|vomiting|,|stomatitis (l_conj) vomiting_13\NN\116687|
C110904_D013280 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|reported|toxic|capecitabine (r_nsubj) diarrhea_9\NN\14299637|effects|are|,|nausea|. (l_conj) nausea_11\NN\14299637|,|vomiting|,|stomatitis (l_conj) stomatitis_15\NN\14336539|and|syndrome
C110904_D060831 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|reported|toxic|capecitabine (r_nsubj) diarrhea_9\NN\14299637|effects|are|,|nausea|. (l_conj) nausea_11\NN\14299637|,|vomiting|,|stomatitis (l_conj) stomatitis_15\NN\14336539|and|syndrome (l_conj) syndrome_18\NN\5870365|hand-foot
C110904_D008107 NONE capecitabine_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|capecitabine|profile|and|given|. (l_conj) given_9\VBN\2327200|can|be|safely|patients (l_nmod) patients_12\NNS\9898892|to|age (l_nmod) age_15\NN\4916342|with|advanced|,|dysfunctions (l_conj) dysfunctions_20\NNS\14204950|hepatic
2950248
D004176_D017202 NONE dipyridamole-induced_0\NN\1740| (r_compound) ischemia_2\NN\14195315|dipyridamole-induced|myocardial|.
D004176_D017202 NONE dipyridamole_16\NN\1740| (r_compound) therapy_17\NN\657604|of|preoperative|dipyridamole (r_nmod) effect_13\NN\34213|as|a|side|therapy (r_nmod) reported_9\VBN\831651|knowledge|,|this|has|not|previously|been|effect|,|demonstrated|. (l_advcl) demonstrated_25\VBN\2137132|although|ischemia|has|been|occur (l_nsubjpass) ischemia_22\NN\14195315|dipyridamole-induced|myocardial
D004176_D017202 NONE dipyridamole-induced_20\JJ\1740| (r_amod) ischemia_22\NN\14195315|dipyridamole-induced|myocardial
D004176_D000787 CID dipyridamole_10\NN\1740|of|oral (r_nmod) administration_7\NN\1133281|after|dipyridamole|patients (r_nmod) occurred_5\VBD\2623529|angina|administration|. (l_nsubj) angina_0\NN\14171682|and|changes
D004176_D003324 NONE dipyridamole_16\NN\1740| (r_compound) therapy_17\NN\657604|of|preoperative|dipyridamole (r_nmod) effect_13\NN\34213|as|a|side|therapy (r_nmod) reported_9\VBN\831651|knowledge|,|this|has|not|previously|been|effect|,|demonstrated|. (l_advcl) demonstrated_25\VBN\2137132|although|ischemia|has|been|occur (l_xcomp) occur_27\VB\2623529|to|animals (l_nmod) animals_29\NNS\4475|in|and|humans|disease (l_nmod) disease_35\NN\14061805|with|coronary|artery
D004176_D003324 NONE dipyridamole-induced_20\JJ\1740| (r_amod) ischemia_22\NN\14195315|dipyridamole-induced|myocardial (r_nsubjpass) demonstrated_25\VBN\2137132|although|ischemia|has|been|occur (l_xcomp) occur_27\VB\2623529|to|animals (l_nmod) animals_29\NNS\4475|in|and|humans|disease (l_nmod) disease_35\NN\14061805|with|coronary|artery
D004176_D007511 NONE dipyridamole-induced_23\JJ\1740| (r_amod) ischemia_24\NN\14195315|of|the|dipyridamole-induced|observed
12596116
D015282_D000860 NONE octreotide-induced_0\JJ\1740| (r_amod) hypoxemia_1\NN\1740|octreotide-induced|and|hypertension|neonates|.
D015282_D006976 CID octreotide-induced_0\JJ\1740| (r_amod) hypoxemia_1\NN\1740|octreotide-induced|and|hypertension|neonates|. (l_conj) hypertension_4\NN\14057371|pulmonary
D015282_D006976 CID octreotide_10\NN\1740| (r_appos) analogue_8\NN\4743605|of|a|somatostatin|,|octreotide|, (r_nmod) administration_4\NN\1133281|after|analogue|enhance (r_nmod) developed_2\VBD\1753788|hypertension|administration|. (l_nsubj) hypertension_1\NN\14057371|pulmonary
D015282_D005402 NONE octreotide_10\NN\1740| (r_appos) analogue_8\NN\4743605|of|a|somatostatin|,|octreotide|, (r_nmod) administration_4\NN\1133281|after|analogue|enhance (l_acl) enhance_13\VB\227165|to|resolution (l_dobj) resolution_14\NN\6470073|fistula (l_nmod) fistula_17\NN\14253124|of|the
7420681
D014031_D007674 NONE tobramycin_3\NN\2716866|of|and|gentamicin (r_nmod) nephrotoxicity_1\NN\1740|clinical|tobramycin|.
D014031_D007674 NONE sulfate_4\NN\15010703|tobramycin (r_conj) sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity|studies (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity (l_conj) nephrotoxicity_10\NN\1740|
D005839_D007674 NONE gentamicin_5\NN\2716866| (r_conj) tobramycin_3\NN\2716866|of|and|gentamicin (r_nmod) nephrotoxicity_1\NN\1740|clinical|tobramycin|.
D005839_D007674 NONE sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity|studies (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity (l_conj) nephrotoxicity_10\NN\1740|
D005839_D006311 NONE sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity|studies (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity
D014031_D006311 NONE sulfate_4\NN\15010703|tobramycin (r_conj) sulfate_1\NN\15010703|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity|studies (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity
D005839_D051437 CID sulfate_21\NN\15010703|of|gentamicin|or|sulfate (r_nmod) mg/kg/day_18\NN\1740|with|5|sulfate (r_nmod) treated_13\VBN\2376958|mg/kg/day|minimum (r_acl) patients_5\NNS\9898892|62|function|treated (r_nsubjpass) followed_32\VBN\1835496|study|,|patients|were|up|prospectively|development|. (l_nmod) development_37\NN\248977|for|the|failure (l_nmod) failure_41\NN\66216|of|aminoglycoside-related|renal|,|defined
D005839_D051437 CID gentamicin-treated_21\JJ\1740| (r_amod) patients_22\NNS\9898892|of|the|gentamicin-treated (r_nmod) %_5\NN\1740|(|15|)|patients|and|29|%|patients (r_appos) 33_2\CD\1740|five|of|% (r_nsubj) had_23\VBD\2108377|33|failure|. (l_dobj) failure_25\NN\66216|renal
D005839_D051437 CID gentamicin_2\NN\2716866| (r_nsubjpass) associated_4\VBN\628491|thus|,|gentamicin|was|failure|often|. (l_nmod) failure_7\NN\66216|with|renal
D014031_D051437 CID sulfate_24\NN\15010703|tobramycin (r_conj) sulfate_21\NN\15010703|of|gentamicin|or|sulfate (r_nmod) mg/kg/day_18\NN\1740|with|5|sulfate (r_nmod) treated_13\VBN\2376958|mg/kg/day|minimum (r_acl) patients_5\NNS\9898892|62|function|treated (r_nsubjpass) followed_32\VBN\1835496|study|,|patients|were|up|prospectively|development|. (l_nmod) development_37\NN\248977|for|the|failure (l_nmod) failure_41\NN\66216|of|aminoglycoside-related|renal|,|defined
D014031_D051437 CID tobramycin-treated_9\JJ\1740| (r_amod) patients_10\NNS\9898892|of|the|tobramycin-treated (r_nmod) %_5\NN\1740|(|15|)|patients|and|29|%|patients (r_appos) 33_2\CD\1740|five|of|% (r_nsubj) had_23\VBD\2108377|33|failure|. (l_dobj) failure_25\NN\66216|renal
D014031_D051437 CID tobramycin_16\NN\2716866|as|was (r_advcl) often_13\RB\1740|times|as|tobramycin (r_advmod) associated_4\VBN\628491|thus|,|gentamicin|was|failure|often|. (l_nmod) failure_7\NN\66216|with|renal
D000617_D051437 NONE aminoglycoside-related_39\JJ\1740| (r_amod) failure_41\NN\66216|of|aminoglycoside-related|renal|,|defined
19631624
D018817_D007859 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|in|ecstasy (r_nmod) deficits_3\NNS\5113133|learning|users|and|correlates
D018817_D007859 CID ecstasy_6\JJ\1740| (r_amod) users_7\NNS\7846|ecstasy (r_nsubj) display_8\VBP\2137132|that|users|impairments|performance (l_dobj) impairments_9\NNS\7296428|learning (l_nmod) learning_11\NN\5701944|in|and|memory (l_conj) memory_13\NN\5926676|
D018817_D008569 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|in|ecstasy (r_nmod) deficits_3\NNS\5113133|learning|users|and|correlates
D018817_D008569 CID ecstasy_6\JJ\1740| (r_amod) users_7\NNS\7846|ecstasy (r_nsubj) display_8\VBP\2137132|that|users|impairments|performance (l_dobj) impairments_9\NNS\7296428|learning (l_nmod) learning_11\NN\5701944|in|and|memory (l_conj) memory_13\NN\5926676|
D002188_D007859 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|in|cannabis (r_nmod) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity|users (r_dep) deficits_0\NNS\5113133|learning|:|hyperactivity|. (l_nmod) learning_2\NN\5701944|in|and|memory (l_conj) memory_4\NN\5926676|
D002188_D008569 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|in|cannabis (r_nmod) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity|users (r_dep) deficits_0\NNS\5113133|learning|:|hyperactivity|. (l_nmod) learning_2\NN\5701944|in|and|memory (l_conj) memory_4\NN\5926676|
D002188_D006948 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|in|cannabis (r_nmod) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity|users
D018817_D006948 NONE ecstasy-specific_13\JJ\1740| (r_amod) hyperactivity_14\NN\14052403|ecstasy-specific|regions
D018817_D020258 NONE ecstasy-specific_1\JJ\1740| (r_amod) effects_2\NNS\13245626|these|ecstasy-specific (r_nsubj) related_5\JJ\1740|effects|may|be|vulnerability|. (l_nmod) vulnerability_8\NN\14540765|to|the|regions|effects (l_nmod) effects_17\NNS\13245626|to|the|neurotoxic|ecstasy (l_amod) neurotoxic_16\JJ\1740|
D018817_D020258 NONE ecstasy_19\NN\13985818|of (r_nmod) effects_17\NNS\13245626|to|the|neurotoxic|ecstasy (l_amod) neurotoxic_16\JJ\1740|
137340
D009020_D006948 CID morphine-induced_5\JJ\1740| (r_amod) increase_6\NN\13576355|of|morphine-induced|activity (l_nmod) activity_9\NN\30358|in|locomotor|mice
D009020_D006948 CID morphine-induced_7\JJ\1740| (r_amod) increase_8\NN\13576355|on|the|morphine-induced|activity (l_nmod) activity_11\NN\30358|in|locomotor|mice
D009020_D006948 CID morphine-hc1_7\NN\1740|of (r_nmod) mg/kg_5\NN\1740|of|10|morphine-hc1 (r_nmod) administration_2\NN\1133281|the|subcutaneous|mg/kg (r_nsubj) produced_8\VBD\1617192|administration|increase|. (l_dobj) increase_11\NN\13576355|a|marked|activity (l_nmod) activity_14\NN\30358|in|locomotor|mice
D009020_D006948 CID morphine-induced_1\JJ\1740| (r_amod) hyperactivity_2\NN\14052403|the|morphine-induced
D009020_D006948 CID morphine_24\NN\2707683|by (r_nmod) produced_22\VBN\1617192|morphine (r_acl) hyperactivity_21\NN\14052403|on|the|produced
D012601_D006948 CID scopolamine_6\NN\14712692|by (r_nmod) potentiated_4\VBN\229605|hyperactivity|was|scopolamine|and|attenuated|. (l_nsubjpass) hyperactivity_2\NN\14052403|the|morphine-induced
D010830_D006948 NONE physostigmine_10\NN\14712692|by (r_nmod) attenuated_8\VBN\224901|physostigmine (r_conj) potentiated_4\VBN\229605|hyperactivity|was|scopolamine|and|attenuated|. (l_nsubjpass) hyperactivity_2\NN\14052403|the|morphine-induced
D019832_D006948 NONE methscopolamine_4\NN\1740|both|and|neostigmine|,|penetrate|, (r_nsubj) had_16\VBD\2108377|contrast|,|methscopolamine|effect|. (l_dobj) effect_18\NN\34213|no|hyperactivity (l_nmod) hyperactivity_21\NN\14052403|on|the|produced
D009388_D006948 NONE neostigmine_6\NN\2718084| (r_conj) methscopolamine_4\NN\1740|both|and|neostigmine|,|penetrate|, (r_nsubj) had_16\VBD\2108377|contrast|,|methscopolamine|effect|. (l_dobj) effect_18\NN\34213|no|hyperactivity (l_nmod) hyperactivity_21\NN\14052403|on|the|produced
D010134_D006948 NONE p-chlorophenylalamine_7\NN\1740|with|mg/kg|,|depletor|, (r_nmod) pretreatment_5\NN\1740|p-chlorophenylalamine (r_nsubj) caused_23\VBD\1617192|hand|,|pretreatment|change|. (l_dobj) change_26\NN\7283608|no|significant|hyperactivity (l_nmod) hyperactivity_29\NN\14052403|in|the
D012701_D006948 NONE serotonin_20\NN\14807737| (r_compound) depletor_21\NN\1740|a|serotonin (r_appos) p-chlorophenylalamine_7\NN\1740|with|mg/kg|,|depletor|, (r_nmod) pretreatment_5\NN\1740|p-chlorophenylalamine (r_nsubj) caused_23\VBD\1617192|hand|,|pretreatment|change|. (l_dobj) change_26\NN\7283608|no|significant|hyperactivity (l_nmod) hyperactivity_29\NN\14052403|in|the
17437408
D010862_D012640 CID pilocarpine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|after|pilocarpine-induced|rats
16904497
D013256_D011128 NONE steroid_5\NN\14727670| (r_compound) injection_6\NN\320852|after|epidural|steroid (r_nmod) syndrome_2\NN\5870365|equina|injection|:|report
D013256_D011843 NONE steroid_13\NN\14727670| (r_compound) injections_14\NNS\320852|epidural|steroid|,|medications|,|and|therapy (r_conj) therapy_10\NN\657604|methods|are|physical|,|injections|. (l_nsubj) methods_4\NNS\5616786|conventional|treatment|radiculopathy (l_nmod) radiculopathy_7\NN\1740|of|lumbusacral
D014221_D011128 NONE triamcinolone_16\NN\14751417|of|and|bupivacaine (r_nmod) injection_14\NN\320852|by|epidural|triamcinolone (r_nmod) caused_11\VBN\1617192|possibly|injection (r_acl) syndrome_9\NN\5870365|of|equina|caused
D002045_D011128 CID bupivacaine_18\NN\1740| (r_conj) triamcinolone_16\NN\14751417|of|and|bupivacaine (r_nmod) injection_14\NN\320852|by|epidural|triamcinolone (r_nmod) caused_11\VBN\1617192|possibly|injection (r_acl) syndrome_9\NN\5870365|of|equina|caused
D013256_D017116 NONE steroid_17\NN\14727670| (r_compound) injection_18\NN\320852|for|epidural|steroid (r_nmod) scheduled_14\VBN\704690|woman|was|injection|. (l_nsubjpass) woman_5\NN\9605289|a|50-year-old|pain (l_nmod) pain_12\NN\14299637|with|back
D013256_D010146 NONE steroid_17\NN\14727670| (r_compound) injection_18\NN\320852|for|epidural|steroid (r_nmod) scheduled_14\VBN\704690|woman|was|injection|. (l_nsubjpass) woman_5\NN\9605289|a|50-year-old|pain (l_nmod) pain_12\NN\14299637|with|back
D013256_D009422 NONE steroid_10\NN\14727670| (r_compound) injections_11\NNS\320852|after|epidural|steroid (r_nmod) deterioration_7\NN\14560612|for|neurologic|injections
18768591
D004317_D009404 CID doxorubicin-induced_6\JJ\1740| (r_amod) syndrome_8\NN\5870365|in|doxorubicin-induced|nephrotic
D004317_D009404 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|. (l_nmod) proteinuria_5\NN\14299637|in|heavy|crea|15/44|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites
D004317_D007674 NONE doxorubicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|doxorubicin-induced
D004317_D016055 NONE doxorubicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|doxorubicin-induced (r_nsubj) leads_2\VBZ\1752884|nephropathy|retention|. (l_nmod) retention_9\NN\809465|to|(enac)-dependent|volume|and|fibrosis
D004317_D005355 NONE doxorubicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|doxorubicin-induced (r_nsubj) leads_2\VBZ\1752884|nephropathy|retention|. (l_nmod) retention_9\NN\809465|to|(enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_12\NN\14204950|renal
D012964_D007674 NONE sodium_5\NN\14625458| (r_compound) channel_6\NN\6251781|epithelial|sodium (r_compound) (enac)-dependent_7\NN\1740|channel (r_nummod) retention_9\NN\809465|to|(enac)-dependent|volume|and|fibrosis (r_nmod) leads_2\VBZ\1752884|nephropathy|retention|. (l_nsubj) nephropathy_1\NN\14573196|doxorubicin-induced
D012964_D016055 NONE sodium_5\NN\14625458| (r_compound) channel_6\NN\6251781|epithelial|sodium (r_compound) (enac)-dependent_7\NN\1740|channel (r_nummod) retention_9\NN\809465|to|(enac)-dependent|volume|and|fibrosis
D012964_D005355 NONE sodium_5\NN\14625458| (r_compound) channel_6\NN\6251781|epithelial|sodium (r_compound) (enac)-dependent_7\NN\1740|channel (r_nummod) retention_9\NN\809465|to|(enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_12\NN\14204950|renal
D000450_D005355 NONE aldosterone-sensitive_1\JJ\1740| (r_amod) serum-_2\NN\1740|aldosterone-sensitive|and|glucocorticoid-inducible (r_amod) sgk1_6\NN\1740|the|serum-|kinase (r_nsubjpass) shown_9\VBN\2137132|sgk1|has|been|participate|. (l_xcomp) participate_11\VB\2367363|to|stimulation|and|mediate (l_conj) mediate_19\VB\761713|to|fibrosis (l_dobj) fibrosis_21\NN\14204950|renal|excess
D004317_D011507 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|. (l_nmod) proteinuria_5\NN\14299637|in|heavy|crea|15/44|leading
D004317_D001201 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|. (l_nmod) proteinuria_5\NN\14299637|in|heavy|crea|15/44|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites (l_nmod) ascites_30\NN\14204950|with|,|lipidemia|,|and|hypoalbuminemia|genotypes
D004317_D006949 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|. (l_nmod) proteinuria_5\NN\14299637|in|heavy|crea|15/44|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites (l_nmod) ascites_30\NN\14204950|with|,|lipidemia|,|and|hypoalbuminemia|genotypes (l_conj) lipidemia_32\NN\14299637|
D004317_D034141 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|. (l_nmod) proteinuria_5\NN\14299637|in|heavy|crea|15/44|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites (l_nmod) ascites_30\NN\14204950|with|,|lipidemia|,|and|hypoalbuminemia|genotypes (l_conj) hypoalbuminemia_35\NN\1740|
D000450_D009404 NONE aldosterone_1\NN\14751863| (r_compound) levels_2\NNS\4916342|plasma|aldosterone (r_nsubj) increased_3\VBD\169651|levels|mice|and|followed|. (l_nmod) mice_6\NNS\2329401|in|nephrotic|genotypes (l_amod) nephrotic_5\JJ\1740|
D012964_D015430 NONE sodium_1\NN\14625458| (r_compound) excretion_2\NN\13466586|urinary|sodium (r_nsubj) reached_3\VBD\2005948|excretion|values|mice|crea|than|crea|and|associated|. (l_conj) associated_32\VBN\628491|was|gain|mice (l_nmod) gain_39\NN\13576355|with|a|higher|body|weight|sgk1(+/+
D014508_D009404 NONE urea_8\NN\14727670| (r_compound) concentrations_9\NNS\4916342|serum|urea (r_nsubj) increased_10\VBD\169651|course|,|concentrations|faster|than|leading|. (l_nmod) course_2\NN\883297|during|the|syndrome (l_nmod) syndrome_5\NN\5870365|of|nephrotic
D014508_D014511 NONE urea_8\NN\14727670| (r_compound) concentrations_9\NNS\4916342|serum|urea (r_nsubj) increased_10\VBD\169651|course|,|concentrations|faster|than|leading|. (l_xcomp) leading_22\VBG\1752884|uremia (l_nmod) uremia_24\NN\14204950|to|and|survival
3173179
D014700_D009203 CID verapamil_0\NN\2938514| (r_compound) withdrawal_1\NN\7206096|verapamil|cause|. (l_nmod) cause_5\NN\7323922|as|a|possible|infarction|woman (l_nmod) infarction_8\NN\14204950|of|myocardial
D014700_D009203 CID verapamil_18\NN\2938514|of (r_nmod) withdrawal_16\NN\7206096|the|verapamil|woman (r_conj) introduction_11\NN\235435|with|the|captopril|and|withdrawal (r_nmod) coincided_8\VBD\2604477|which|infarction|introduction (l_nsubj) infarction_7\NN\14204950|myocardial
D014700_D006973 NONE verapamil_0\NN\2938514| (r_compound) withdrawal_1\NN\7206096|verapamil|cause|. (l_nmod) cause_5\NN\7323922|as|a|possible|infarction|woman (l_nmod) woman_12\NN\9605289|in|a|hypertensive|angiogram (l_amod) hypertensive_11\JJ\1740|
D014700_D006973 NONE verapamil_18\NN\2938514|of (r_nmod) withdrawal_16\NN\7206096|the|verapamil|woman (l_nmod) woman_23\NN\9605289|in|a|asymptomatic|hypertension (l_nmod) hypertension_26\NN\14057371|with|severe
D002216_D009203 NONE captopril_13\NN\2673637|of (r_nmod) introduction_11\NN\235435|with|the|captopril|and|withdrawal (r_nmod) coincided_8\VBD\2604477|which|infarction|introduction (l_nsubj) infarction_7\NN\14204950|myocardial
D002216_D006973 NONE captopril_13\NN\2673637|of (r_nmod) introduction_11\NN\235435|with|the|captopril|and|withdrawal (l_conj) withdrawal_16\NN\7206096|the|verapamil|woman (l_nmod) woman_23\NN\9605289|in|a|asymptomatic|hypertension (l_nmod) hypertension_26\NN\14057371|with|severe
15233872
C007145_D009203 NONE crataegus_5\NN\11585340|of (r_nmod) tincture_3\NN\14984973|of|crataegus (r_nmod) effect_1\NN\34213|cardioprotective|tincture|infarction|. (l_nmod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
C007145_D009203 NONE tcr_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|protective|tcr|infarction (l_nmod) infarction_16\NN\14204950|on|induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_7\JJ\1740| (r_amod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
6727060
D008787_D004409 CID metoclopramide_7\NN\1740|by (r_nmod) caused_5\VBN\1617192|metoclopramide (r_acl) dyskinesia_4\NN\14084880|of|tardive|caused
D008787_D004409 CID metoclopramide_21\NN\1740| (r_dobj) took_20\VBD\2367363|after|he|metoclopramide|disorder|regimen|total (r_advcl) appeared_3\VBD\2604760|movements|mouth|took|. (l_nsubj) movements_2\NNS\191142|abnormal|involuntary
D008787_D004409 CID metoclopramide_2\NN\1740| (r_compound) administration_3\NN\1133281|the|metoclopramide (r_nsubjpass) discontinued_5\VBN\2609764|when|administration|was (r_advcl) improved_11\VBD\126264|discontinued|,|movements|gradually|extent|. (l_nsubj) movements_9\NNS\191142|the|abnormal
D008787_D005767 NONE metoclopramide_21\NN\1740| (r_dobj) took_20\VBD\2367363|after|he|metoclopramide|disorder|regimen|total (l_nmod) disorder_24\NN\14034177|for|gastrointestinal
1009330
C004658_D003556 NONE p-choloroaniline_8\NN\1740|product (r_nsubj) factor_13\NN\7326557|that|p-choloroaniline|is|not|a|significant|cystitis (l_nmod) cystitis_18\NN\14566129|in|associated|erosive
C010882_D003556 CID chlorhexidine-digluconate_15\NN\1740| (r_nmod:npmod) associated_16\JJ\1740|chlorhexidine-digluconate (r_amod) cystitis_18\NN\14566129|in|associated|erosive
D007612_D003556 CID kanamycin-colistin_4\NN\1740|and (r_compound) irrigations_7\NNS\1057200|of|kanamycin-colistin|povidone-iodine (r_nmod) percentage_2\NN\13815742|a|high|irrigations (r_nsubjpass) associated_9\VBN\628491|percentage|were|cystitis|and|suggested|. (l_nmod) cystitis_12\NN\14566129|with|erosive
D003091_D003556 CID kanamycin-colistin_4\NN\1740|and (r_compound) irrigations_7\NNS\1057200|of|kanamycin-colistin|povidone-iodine (r_nmod) percentage_2\NN\13815742|a|high|irrigations (r_nsubjpass) associated_9\VBN\628491|percentage|were|cystitis|and|suggested|. (l_nmod) cystitis_12\NN\14566129|with|erosive
D011206_D003556 CID povidone-iodine_6\NN\1740| (r_compound) irrigations_7\NNS\1057200|of|kanamycin-colistin|povidone-iodine (r_nmod) percentage_2\NN\13815742|a|high|irrigations (r_nsubjpass) associated_9\VBN\628491|percentage|were|cystitis|and|suggested|. (l_nmod) cystitis_12\NN\14566129|with|erosive
C005253_D003556 NONE picloxydine_0\NN\1740| (r_compound) irrigations_1\NNS\1057200|picloxydine (r_nsubj) appeared_2\VBD\2604760|irrigations|have|but|have (l_xcomp) have_4\VB\2108377|to|incidence (l_dobj) incidence_7\NN\13821570|a|lower|cystitis (l_nmod) cystitis_10\NN\14566129|of|erosive
9522152
D002045_D009461 NONE bupivacaine_11\NN\1740|of|%|hyperbaric (r_nmod) injection_6\NN\320852|following|intrathecal|bupivacaine|anaesthesia (r_nmod) deficit_3\NN\5113133|a|transient|neurological|injection|.
D002045_D009461 NONE bupivacaine_21\NN\1740|of|%|hyperbaric (r_nmod) mg_16\NN\13717155|with|8|bupivacaine|injected (r_nmod) anaesthesia_13\NN\14034177|after|unilateral|spinal|mg (r_nmod) occurred_9\VBD\2623529|that|anaesthesia (r_acl:relcl) deficit_7\NN\5113133|of|transient|neurological|occurred
20080419
D010862_D004827 CID pilocarpine_24\NN\14712692|by|rats (r_nmod) induced_22\VBN\1627355|pilocarpine (r_acl) epilepsy_21\NN\14085708|of|induced
2348231
D010431_D006940 NONE pentoxifylline_0\NN\3247620|trental (r_nsubj) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D010431_D006940 NONE trental_2\NN\3247620|(|) (r_appos) pentoxifylline_0\NN\3247620|trental (r_nsubj) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D010431_D006940 NONE pentoxifylline_1\NN\3247620| (r_nsubj) inhibits_2\VBZ\2510337|whether|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D010431_D006940 NONE pentoxifylline_3\NN\3247620|of (r_nmod) dose_1\NN\3740161|neither|pentoxifylline (r_nsubj) decreased_5\VBD\169651|dose|significantly|hyperemia|,|lower|. (l_dobj) hyperemia_8\NN\14320394|the|dipyridamole-induced
D010431_D006940 NONE pentoxyifylline_3\NN\1740| (r_nsubj) inhibit_6\VB\2510337|that|pentoxyifylline|does|not|hyperemia|doses (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D004176_D006940 CID dipyridamole-induced_7\JJ\1740| (r_amod) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D004176_D006940 CID dipyridamole-thallium-201_13\NN\1740| (r_compound) imaging_15\NN\5765159|for|dipyridamole-thallium-201|myocardial (r_nmod) implications_11\NNS\5774614|imaging (r_dep) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D004176_D006940 CID dipyridamole-induced_3\JJ\1740| (r_amod) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D004176_D006940 CID dipyridamole-thallium-201_18\NN\1740| (r_compound) imaging_19\NN\5765159|dipyridamole-thallium-201 (r_nmod) stopped_15\VBN\2452885|should|be|prior|imaging (r_conj) inhibits_2\VBZ\2510337|whether|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D004176_D006940 CID dipyridamole-induced_7\JJ\1740| (r_amod) hyperemia_8\NN\14320394|the|dipyridamole-induced
D004176_D006940 CID dipyridamole-induced_7\JJ\1740| (r_amod) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D013793_D006940 NONE dipyridamole-thallium-201_13\NN\1740| (r_compound) imaging_15\NN\5765159|for|dipyridamole-thallium-201|myocardial (r_nmod) implications_11\NNS\5774614|imaging (r_dep) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D013793_D006940 NONE dipyridamole-thallium-201_18\NN\1740| (r_compound) imaging_19\NN\5765159|dipyridamole-thallium-201 (r_nmod) stopped_15\VBN\2452885|should|be|prior|imaging (r_conj) inhibits_2\VBZ\2510337|whether|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D004176_D016491 NONE dipyridamole-thallium-201_0\NN\1740| (r_compound) imaging_1\NN\5765159|dipyridamole-thallium-201 (r_nsubjpass) performed_4\VBN\2367363|imaging|is|often|patients|disease|. (l_nmod) disease_14\NN\14061805|because|peripheral|vascular
D013793_D016491 NONE dipyridamole-thallium-201_0\NN\1740| (r_compound) imaging_1\NN\5765159|dipyridamole-thallium-201 (r_nsubjpass) performed_4\VBN\2367363|imaging|is|often|patients|disease|. (l_nmod) disease_14\NN\14061805|because|peripheral|vascular
D010431_D007383 CID pentoxifylline_6\NN\3247620|trental|,|derivative (l_appos) derivative_13\NN\5802185|a|methylxanthine|improve (l_acl:relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
D010431_D007383 CID trental_8\NN\3247620|(|) (r_appos) pentoxifylline_6\NN\3247620|trental|,|derivative (l_appos) derivative_13\NN\5802185|a|methylxanthine|improve (l_acl:relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
C008514_D007383 NONE methylxanthine_12\NN\1740| (r_compound) derivative_13\NN\5802185|a|methylxanthine|improve (l_acl:relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
C008514_D006940 NONE methylxanthines_8\NNS\1740|like|other|theophylline (r_nmod) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D013806_D006940 NONE theophylline_11\NN\2905612|such (r_nmod) methylxanthines_8\NNS\1740|like|other|theophylline (r_nmod) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D013806_D006940 NONE theophylline_19\NN\2905612|after (r_nmod) lower_17\JJR\1740|while|flow|was|significantly|theophylline|p (r_advcl) decreased_5\VBD\169651|dose|significantly|hyperemia|,|lower|. (l_dobj) hyperemia_8\NN\14320394|the|dipyridamole-induced
3187073
D005472_D002637 CID 5-fu_6\NN\1740| (r_compound) treatment_7\NN\654885|on|5-fu (r_nmod) patients_4\NNS\9898892|treatment (r_nsubj) that_3\IN\1740|patients|should|be|supervision|and|discontinued (l_conj) discontinued_19\VBN\2609764|that|treatment|should|be|observed (l_advcl) observed_26\VBN\2163746|if|pain|is (l_nsubjpass) pain_22\NN\14299637|chest|or|tachyarrhythmia
D005472_D013610 NONE 5-fu_6\NN\1740| (r_compound) treatment_7\NN\654885|on|5-fu (r_nmod) patients_4\NNS\9898892|treatment (r_nsubj) that_3\IN\1740|patients|should|be|supervision|and|discontinued (l_conj) discontinued_19\VBN\2609764|that|treatment|should|be|observed (l_advcl) observed_26\VBN\2163746|if|pain|is (l_nsubjpass) pain_22\NN\14299637|chest|or|tachyarrhythmia (l_conj) tachyarrhythmia_24\NN\1740|
19308880
D014635_D003221 CID acid_10\NN\14818238|with|valproic (r_nmod) reaction_7\NN\13446390|a|serious|adverse|drug|acid (r_appos) confusion_0\NN\13972797|,|reaction|:|review|.
D014635_D003221 CID acid_12\NN\14818238|with|valproic (r_nmod) observed_9\VBN\2163746|frequently|acid (r_acl) reaction_7\NN\13446390|:|confusion|is|an|adverse|drug|observed (l_nsubj) confusion_2\NN\13972797|
D014635_D003221 CID acid_19\NN\14818238|with|valproic (r_nmod) reported_14\VBN\831651|1985|acid (r_acl) confusion_13\NN\13972797|of|reported
D014635_D003221 CID acid_10\NN\14818238|with|valproic (r_nmod) reported_7\VBN\831651|results|were|acid|:|women (l_nsubjpass) results_0\NNS\34213|:|cases (l_appos) cases_3\NNS\7283608|272|confusion (l_nmod) confusion_5\NN\13972797|of
D014635_D003221 CID acid_10\NN\14818238|valproic (r_compound) exposure_11\NN\5042871|following|acid (r_nmod) weeks_7\NNS\15113229|during|the|two|first|exposure (r_nmod) occurred_2\VBD\2623529|confusion|mostly|weeks|%|. (l_nsubj) confusion_0\NN\13972797|
D014635_D003221 CID acid_9\NN\14818238|with|valproic (r_nmod) confusion_6\NN\13972797|acid
1833784
D004298_D006948 NONE dopamine_8\NN\14807737| (r_compound) receptors_9\NNS\5225602|dopamine (r_nmod) involvement_3\NN\1080366|for|an|d1|receptors|mediating (l_advcl) mediating_11\VBG\761713|in|hyperactivity (l_dobj) hyperactivity_13\NN\14052403|nicotine-induced|rats
D009538_D006948 CID nicotine-induced_12\JJ\1740| (r_amod) hyperactivity_13\NN\14052403|nicotine-induced|rats
D009538_D006948 CID nicotine_0\NN\14712692|mg/kg (r_nsubj) caused_5\VBD\1617192|nicotine|increase|rats|,|but|had|. (l_dobj) increase_8\NN\13576355|a|significant|activity (l_nmod) activity_11\NN\30358|in|locomotor
D009538_D006948 CID nicotine-induced_0\JJ\1740| (r_amod) hyperactivity_1\NN\14052403|nicotine-induced
D009538_D006948 CID nicotine-induced_7\JJ\1740| (r_amod) hyperactivity_8\NN\14052403|nicotine-induced
D009538_D006948 CID nicotine_5\NN\14712692| (r_compound) injection_6\NN\320852|acute|nicotine (r_nsubj) induces_7\VBZ\1627355|that|injection|hyperactivity (l_dobj) hyperactivity_10\NN\14052403|a|pronounced|rats
C534628_D006948 NONE 23390_10\NN\1740|sch|,|raclopride (r_dobj) blocked_3\VBN\1476483|hyperactivity|was|23390|and|fluphenazine|. (l_nsubjpass) hyperactivity_1\NN\14052403|nicotine-induced
D020891_D006948 NONE raclopride_16\NN\1740|the|selective|d2|antagonist (r_conj) 23390_10\NN\1740|sch|,|raclopride (r_dobj) blocked_3\VBN\1476483|hyperactivity|was|23390|and|fluphenazine|. (l_nsubjpass) hyperactivity_1\NN\14052403|nicotine-induced
D005476_D006948 NONE fluphenazine_21\NN\3713736|the|d1/d2|antagonist (r_conj) blocked_3\VBN\1476483|hyperactivity|was|23390|and|fluphenazine|. (l_nsubjpass) hyperactivity_1\NN\14052403|nicotine-induced
-1_D006948 NONE phno_5\NN\1740|with|the|d2|agonist (r_nmod) pretreatment_0\NN\1740|phno (r_nsubj) enhanced_6\VBD\227165|pretreatment|hyperactivity|,|whereas|had|. (l_dobj) hyperactivity_8\NN\14052403|nicotine-induced
D015647_D006948 NONE 38393_15\NN\1740|skf (r_nsubj) had_16\VBD\2108377|38393|effect (r_parataxis) enhanced_6\VBD\227165|pretreatment|hyperactivity|,|whereas|had|. (l_dobj) hyperactivity_8\NN\14052403|nicotine-induced
11263551
D016572_D010146 CID cyclosporine-_3\NN\1740|of|or|tacrolimus (r_nmod) reduction_1\NN\351485|the|cyclosporine-|levels|and|administration (r_nsubj) led_15\VBD\1752884|reduction|relief|. (l_nmod) relief_17\NN\7492516|to|pain (l_nmod) pain_19\NN\14299637|of
D016572_D010146 CID cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|syndrome|is|a|rare|side|cyclosporine|and|diagnosed|. (l_nsubj) syndrome_4\NN\5870365|the|calcineurin-inhibitor|induced|pain|cips (l_compound) pain_3\NN\14299637|
D016559_D010146 CID tacrolimus_5\NN\1740| (r_conj) cyclosporine-_3\NN\1740|of|or|tacrolimus (r_nmod) reduction_1\NN\351485|the|cyclosporine-|levels|and|administration (r_nsubj) led_15\VBD\1752884|reduction|relief|. (l_nmod) relief_17\NN\7492516|to|pain (l_nmod) pain_19\NN\14299637|of
D016559_D010146 CID tacrolimus_18\NN\1740| (r_conj) cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|syndrome|is|a|rare|side|cyclosporine|and|diagnosed|. (l_nsubj) syndrome_4\NN\5870365|the|calcineurin-inhibitor|induced|pain|cips (l_compound) pain_3\NN\14299637|
D002118_D010146 NONE calcium_12\NN\14625458| (r_compound) blockers_14\NNS\10101634|of|calcium|channel (r_nmod) administration_10\NN\1133281|the|blockers (r_conj) reduction_1\NN\351485|the|cyclosporine-|levels|and|administration (r_nsubj) led_15\VBD\1752884|reduction|relief|. (l_nmod) relief_17\NN\7492516|to|pain (l_nmod) pain_19\NN\14299637|of
D016572_-1 NONE cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|syndrome|is|a|rare|side|cyclosporine|and|diagnosed|. (l_nsubj) syndrome_4\NN\5870365|the|calcineurin-inhibitor|induced|pain|cips (l_appos) cips_6\NN\1740|(|)
D016559_-1 NONE tacrolimus_18\NN\1740| (r_conj) cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|syndrome|is|a|rare|side|cyclosporine|and|diagnosed|. (l_nsubj) syndrome_4\NN\5870365|the|calcineurin-inhibitor|induced|pain|cips (l_appos) cips_6\NN\1740|(|)
2673163
D003042_D020521 NONE cocaine_3\NN\3492717| (r_compound) use_4\NN\407535|with|cocaine (r_nmod) associated_1\VBN\628491|stroke|use|. (l_nsubj) stroke_0\NN\556313|
D003042_D020521 NONE cocaine_6\NN\3492717| (r_compound) use_7\NN\407535|cocaine (r_nsubj) related_9\JJ\1740|whom|use|was|stroke (l_nmod) stroke_11\NN\556313|to
D003042_D020521 NONE cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine (r_dobj) followed_1\VBD\1835496|stroke|use|inhalation|. (l_nsubj) stroke_0\NN\556313|
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_conj) follow_35\VB\1835496|3|stroke|may|route|; (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nsubjpass) stroke_45\NN\556313|use
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_conj) follow_35\VB\1835496|3|stroke|may|route|; (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nsubjpass) stroke_45\NN\556313|use
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nsubjpass) stroke_45\NN\556313|use
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (r_dep) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (r_dep) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (r_dep) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_conj) follow_35\VB\1835496|3|stroke|may|route|; (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (r_conj) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (r_dep) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (r_conj) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (r_dep) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (r_conj) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (r_dep) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (l_conj) follow_35\VB\1835496|3|stroke|may|route|; (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (r_conj) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nsubjpass) stroke_45\NN\556313|use
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated
D003042_D002532 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (r_conj) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D001165 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (r_conj) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D020300 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nsubj) frequency_68\NN\15286249|the|hemorrhage (l_nmod) hemorrhage_71\NN\14285662|of|intracranial
D003042_D020300 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nsubj) frequency_68\NN\15286249|the|hemorrhage (l_nmod) hemorrhage_71\NN\14285662|of|intracranial
D003042_D020300 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nsubj) frequency_68\NN\15286249|the|hemorrhage (l_nmod) hemorrhage_71\NN\14285662|of|intracranial
D003042_D020300 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nsubj) frequency_68\NN\15286249|the|hemorrhage (l_nmod) hemorrhage_71\NN\14285662|of|intracranial
D003042_D020300 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_nsubj) frequency_68\NN\15286249|the|hemorrhage (l_nmod) hemorrhage_71\NN\14285662|of|intracranial
D003042_D002544 CID cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_dobj) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_dobj) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route|; (r_conj) occurs_24\VBZ\2623529|2|stroke|adults|;|follow (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|associated (l_dep) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_dobj) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|use (r_nsubjpass) associated_51\VBN\628491|4|stroke|is|frequently|aneurysms|;|and|exceeds (l_conj) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_dobj) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) exceeds_72\VBZ\2673965|5|stroke|,|frequency|that (l_dobj) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
12584269
D020123_D007674 CID srl_5\NN\1740| (r_nsubj) seems_6\VBZ\2604760|srl|act|,|open|. (r_conj) nephrotoxic_2\JJ\1740|these|are|,|but|seems
D020123_D007674 CID srl_5\NN\1740| (r_nsubj) seems_6\VBZ\2604760|srl|act|,|open|. (l_xcomp) act_8\VB\1619354|to|differently|displaying (l_advcl) displaying_10\VBG\2137132|effects (l_dobj) effects_14\NNS\13245626|only|minor|nephrotoxic (l_amod) nephrotoxic_13\JJ\1740|
D020123_D007674 CID srl_7\NN\1740| (r_nsubjpass) combined_9\VBN\2630189|where|srl|was|inhibitor (r_acl:relcl) protocols_5\NNS\6652242|of|treatment|combined (r_nmod) number_2\NN\5107765|in|a|protocols (r_nmod) described_21\VBN\1001294|number|indications|were|. (l_nsubjpass) indications_14\NNS\33020|effect (l_nmod) effect_19\NN\34213|of|a|synergistic|nephrotoxic (l_amod) nephrotoxic_18\JJ\1740|
D020123_D007674 CID srl_13\NN\1740| (r_conj) csa_11\NN\1740|of|plus|srl (r_nmod) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
D020123_D007674 CID srl_18\NN\1740| (r_conj) fk506_16\NN\1740|plus|srl (r_nsubjpass) tolerated_21\VBN\802318|fk506|was|better|. (r_dep) conclusion_0\NN\5837957|demonstrated|whereas|tolerated (l_dep) demonstrated_5\VBD\2137132|:|study|effect|, (l_dobj) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
D016572_D005355 NONE csa_11\NN\1740|with|plus|srl (r_nmod) treated_9\VBN\2376958|csa (r_acl) group_8\NN\2137|in|the|treated (r_nmod) worst_5\JJS\1740|scoring|was|significantly|group|p<0.001|compared|)|and|showed (l_conj) showed_30\VBD\2137132|analysis|also|proportion|and|different|. (l_nsubj) analysis_22\NN\633864|the|grade (l_nmod) grade_26\NN\7975026|of|the|total|fibrosis (l_nmod) fibrosis_28\NN\14204950|of
D020123_D005355 NONE srl_13\NN\1740| (r_conj) csa_11\NN\1740|with|plus|srl (r_nmod) treated_9\VBN\2376958|csa (r_acl) group_8\NN\2137|in|the|treated (r_nmod) worst_5\JJS\1740|scoring|was|significantly|group|p<0.001|compared|)|and|showed (l_conj) showed_30\VBD\2137132|analysis|also|proportion|and|different|. (l_nsubj) analysis_22\NN\633864|the|grade (l_nmod) grade_26\NN\7975026|of|the|total|fibrosis (l_nmod) fibrosis_28\NN\14204950|of
D020123_D005355 NONE srl_3\NN\1740| (r_conj) fk506_1\NN\1740|plus|srl (r_compound) combination_4\NN\7951464|the|fk506 (r_nsubj) showed_5\VBD\2137132|combination|degree|compared|. (l_dobj) degree_10\NN\4916342|only|a|higher|fibrosis (l_nmod) fibrosis_12\NN\14204950|of
D016559_D005355 NONE fk506_1\NN\1740|plus|srl (r_compound) combination_4\NN\7951464|the|fk506 (r_nsubj) showed_5\VBD\2137132|combination|degree|compared|. (l_dobj) degree_10\NN\4916342|only|a|higher|fibrosis (l_nmod) fibrosis_12\NN\14204950|of
D016572_D007674 CID csa_11\NN\1740|of|plus|srl (r_nmod) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
D016559_D007674 CID fk506_16\NN\1740|plus|srl (r_nsubjpass) tolerated_21\VBN\802318|fk506|was|better|. (r_dep) conclusion_0\NN\5837957|demonstrated|whereas|tolerated (l_dep) demonstrated_5\VBD\2137132|:|study|effect|, (l_dobj) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
15859940
D016572_D064420 NONE cyclosporine_5\NN\1740| (r_compound) tacrolimus_7\NN\1740|drug-related|(|cyclosporine|,|) (r_dobj) include_2\VBP\690614|causes|tacrolimus|toxicity|. (l_dobj) toxicity_9\NN\13576101|,|status
D016559_D064420 NONE tacrolimus_7\NN\1740|drug-related|(|cyclosporine|,|) (r_dobj) include_2\VBP\690614|causes|tacrolimus|toxicity|. (l_dobj) toxicity_9\NN\13576101|,|status
D016572_D057049 CID cyclosporine_16\NN\1740|to (r_nmod) secondary_13\JJ\1740|cyclosporine (r_dep) related_11\JJ\1740|that|cause|was|drug|,|secondary (l_nsubj) cause_5\NN\7323922|the|most-frequent|microangiopathy (l_nmod) microangiopathy_8\NN\1740|of|thrombotic
8319760
D019808_D009401 NONE 753_1\CD\1740| (r_nummod) dup_0\NN\1740|753 (r_nsubj) prevents_2\VBZ\1740|dup|development|. (l_dobj) development_4\NN\248977|the|nephrosis (l_nmod) nephrosis_8\NN\14304060|of|aminonucleoside-induced
D011692_D009401 NONE aminonucleoside-induced_7\JJ\1740|puromycin (r_amod) nephrosis_8\NN\14304060|of|aminonucleoside-induced
D011692_D009401 NONE aminonucleoside-induced_15\JJ\1740| (r_amod) nephrosis_16\NN\14304060|of|puromycin|aminonucleoside-induced
D001806_D009404 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\NN\13576355|urea (r_conj) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (r_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D001806_D011507 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\NN\13576355|urea (r_conj) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced
D001806_D034141 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\NN\13576355|urea (r_conj) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypoalbuminemia_9\NN\1740|
D001806_D006937 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\NN\13576355|urea (r_conj) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypercholesterolemia_11\NN\14299637|
D011692_D009404 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (r_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D011692_D011507 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced
D011692_D034141 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypoalbuminemia_9\NN\1740|
D011692_D006937 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypercholesterolemia_11\NN\14299637|
D019808_D009404 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D019808_D009404 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D019808_D011507 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced
D019808_D011507 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced
D019808_D034141 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypoalbuminemia_9\NN\1740|
D019808_D034141 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypoalbuminemia_9\NN\1740|
D019808_D006937 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypercholesterolemia_11\NN\14299637|
D019808_D006937 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypercholesterolemia_11\NN\14299637|
D000804_D009404 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D000804_D011507 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced
D000804_D034141 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypoalbuminemia_9\NN\1740|
D000804_D006937 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_appos) dup_34\NN\1740|of|753|losartan|,|antagonist|, (r_nmod) administration_32\NN\1133281|by|oral|dup|dose (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia|,|hypercholesterolemia|and|increase|,|induced (l_conj) hypercholesterolemia_11\NN\14299637|
D000809_D009401 NONE renin-angiotensin_8\JJ\1740| (r_amod) system_9\NN\3575240|of|the|renin-angiotensin (r_nmod) involvement_5\NN\1080366|a|possible|system|development (l_nmod) development_12\NN\248977|in|the|nephrosis (l_nmod) nephrosis_16\NN\14304060|of|puromycin|aminonucleoside-induced
10706004
D012964_D006973 NONE sodium_2\NN\14625458|and|atp (r_compound) affinities_5\NNS\11426530|of|sodium|k)-atpase (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|deficient
D012964_D006973 NONE (na_9\NN\1740| (r_compound) k)-atpase_11\NN\1740|of|the|cardiac|(na|, (r_nmod) affinities_5\NNS\11426530|of|sodium|k)-atpase (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|deficient
D012964_D006973 NONE sodium_9\NN\14625458| (r_compound) level_10\NN\4916342|of|intracellular|sodium (r_nmod) elevation_6\NN\7445480|level (r_nsubjpass) documented_12\VBN\1000214|models|,|elevation|was|tissue|. (l_nmod) models_2\NNS\5888929|in|several|hypertension (l_nmod) hypertension_4\NN\14057371|of
D012964_D006973 NONE na+_11\NN\1740|of (r_nmod) transport_9\NN\3575240|in|transmembraneous|na+ (r_nmod) disturbances_6\NNS\407535|of|transport (r_nmod) basis_4\NN\13790712|the|molecular|disturbances (r_dobj) assess_1\VB\670261|to|basis (r_advcl) studied_14\VBD\630380|assess|,|we|response|weeks|. (l_dobj) response_16\NN\11410625|the|k)-atpase|hypertension (l_nmod) hypertension_24\NN\14057371|to|no-deficient|induced
D012964_D006973 NONE (na_19\NN\1740|cardiac (r_compound) k)-atpase_21\NN\1740|of|(na|, (r_nmod) response_16\NN\11410625|the|k)-atpase|hypertension (l_nmod) hypertension_24\NN\14057371|to|no-deficient|induced
D012964_D006973 NONE (na_8\NN\1740| (r_compound) k)-atpase_10\NN\1740|of|(na|, (r_nmod) activity_6\NN\30358|the|k)-atpase (r_nsubj) increased_11\VBD\169651|recovery|,|activity|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D012964_D006973 NONE na+-extrusion_10\NN\1740|by|depressed|cells (r_nmod) accompanied_7\VBN\1835496|na+-extrusion (r_acl) hypertension_6\NN\14057371|a|reversible|accompanied
D012964_D006973 NONE na+-binding_19\JJ\1740| (r_amod) properties_20\NNS\32613|of|deteriorated|na+-binding|k)-atpase (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied
D012964_D006973 NONE (na_23\NN\1740| (r_compound) k)-atpase_25\NN\1740|of|the|(na|, (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|k)-atpase (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied
D000255_D006973 NONE atp_4\NN\14964590| (r_conj) sodium_2\NN\14625458|and|atp (r_compound) affinities_5\NNS\11426530|of|sodium|k)-atpase (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|deficient
D000255_D006973 NONE atp-binding_19\JJ\1740| (r_amod) site_20\NN\8673395|of|the|atp-binding (r_nmod) affinity_16\NN\11426530|due|higher|site (r_nmod) increased_11\VBD\169651|recovery|,|activity|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D000255_D006973 NONE atp_30\NN\14964590|for (r_nmod) value_28\NN\5856066|from|the|lowered|km|atp (r_nmod) revealed_23\VBN\2137132|as|value (r_advcl) increased_11\VBD\169651|recovery|,|activity|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D011188_D006973 NONE k)-atpase_11\NN\1740|of|the|cardiac|(na|, (r_nmod) affinities_5\NNS\11426530|of|sodium|k)-atpase (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|deficient
D011188_D006973 NONE k)-atpase_21\NN\1740|of|(na|, (r_nmod) response_16\NN\11410625|the|k)-atpase|hypertension (l_nmod) hypertension_24\NN\14057371|to|no-deficient|induced
D011188_D006973 NONE k)-atpase_10\NN\1740|of|(na|, (r_nmod) activity_6\NN\30358|the|k)-atpase (r_nsubj) increased_11\VBD\169651|recovery|,|activity|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D011188_D006973 NONE k)-atpase_25\NN\1740|of|the|(na|, (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|k)-atpase (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied
D009569_D006973 CID oxide_16\NN\14818238|nitric (r_nmod:npmod) deficient_17\JJ\1740|oxide (r_amod) hypertension_18\NN\14057371|deficient
D009569_D006973 CID no_2\NN\7204911| (r_compound) synthesis_3\NN\13446390|of|no (r_nmod) inhibition_0\NN\1068773|synthesis (r_nsubj) induces_4\VBZ\1627355|inhibition|hypertension|. (l_dobj) hypertension_6\NN\14057371|sustained
D009569_D006973 CID no-deficient_23\JJ\1740| (r_amod) hypertension_24\NN\14057371|to|no-deficient|induced
D009569_D006973 CID no-synthase_29\NN\1740| (r_compound) inhibition_30\NN\1068773|by|no-synthase|ester (r_nmod) induced_25\VBN\1627355|rats|inhibition (r_acl) hypertension_24\NN\14057371|to|no-deficient|induced
D009569_D006973 CID no-synthase_2\NN\1740|of (r_nmod) inhibition_0\NN\1068773|no-synthase (r_nsubj) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied
D019331_D006973 NONE ester_36\NN\14727670|with|mg/kg/day|n(g)-nitro-l-arginine|methyl|l-name (r_nmod) inhibition_30\NN\1068773|by|no-synthase|ester (r_nmod) induced_25\VBN\1627355|rats|inhibition (r_acl) hypertension_24\NN\14057371|to|no-deficient|induced
D019331_D006973 NONE l-name_38\NN\1740|(|) (r_appos) ester_36\NN\14727670|with|mg/kg/day|n(g)-nitro-l-arginine|methyl|l-name (r_nmod) inhibition_30\NN\1068773|by|no-synthase|ester (r_nmod) induced_25\VBN\1627355|rats|inhibition (r_acl) hypertension_24\NN\14057371|to|no-deficient|induced
D009569_D003866 NONE no-synthase_2\NN\1740|of (r_nmod) inhibition_0\NN\1068773|no-synthase (r_nsubj) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied (l_acl) accompanied_7\VBN\1835496|na+-extrusion (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\VBN\1819147|
D012964_D003866 NONE na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\VBN\1819147|
D012964_D003866 NONE na+-binding_19\JJ\1740| (r_amod) properties_20\NNS\32613|of|deteriorated|na+-binding|k)-atpase (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied (l_acl) accompanied_7\VBN\1835496|na+-extrusion (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\VBN\1819147|
D012964_D003866 NONE (na_23\NN\1740| (r_compound) k)-atpase_25\NN\1740|of|the|(na|, (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|k)-atpase (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied (l_acl) accompanied_7\VBN\1835496|na+-extrusion (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\VBN\1819147|
D011188_D003866 NONE k)-atpase_25\NN\1740|of|the|(na|, (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|k)-atpase (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) induced_3\VBD\1627355|inhibition|hypertension|consequence|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied (l_acl) accompanied_7\VBN\1835496|na+-extrusion (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\VBN\1819147|
20470218
D008727_D056784 NONE methotrexate_30\NN\2722166| (r_compound) toxicity_31\NN\13576101|high-dose|methotrexate|=|,|syndrome|,|and|events (r_conj) epilepsy_22\NN\14085708|lobe|=|,|toxicity (r_conj) stroke_13\NN\556313|=|,|epilepsy (r_conj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|=|,|stroke (l_compound) leukoencephalopathy_5\NN\1740|
D008727_D020521 NONE methotrexate_30\NN\2722166| (r_compound) toxicity_31\NN\13576101|high-dose|methotrexate|=|,|syndrome|,|and|events (r_conj) epilepsy_22\NN\14085708|lobe|=|,|toxicity (r_conj) stroke_13\NN\556313|=|,|epilepsy
D008727_D004833 NONE methotrexate_30\NN\2722166| (r_compound) toxicity_31\NN\13576101|high-dose|methotrexate|=|,|syndrome|,|and|events (r_conj) epilepsy_22\NN\14085708|lobe|=|,|toxicity
D008727_D064420 NONE methotrexate_30\NN\2722166| (r_compound) toxicity_31\NN\13576101|high-dose|methotrexate|=|,|syndrome|,|and|events
D008727_D007177 NONE methotrexate_30\NN\2722166| (r_compound) toxicity_31\NN\13576101|high-dose|methotrexate|=|,|syndrome|,|and|events (l_conj) syndrome_38\NN\5870365|secretion|= (l_nmod) secretion_43\NN\13526110|of|inappropriate|antidiuretic|hormone
8372922
15804801
D017239_D003323 CID paclitaxel-eluting_6\JJ\1740| (r_amod) stent_7\NN\4493505|of|a|paclitaxel-eluting (r_nmod) implantation_3\NN\13526110|after|stent (r_nmod) aneurysm_1\NN\14057371|coronary|implantation|.
D017239_D003323 CID paclitaxel-eluting_20\JJ\1740| (r_amod) stent_21\NN\4493505|a|paclitaxel-eluting (r_dobj) receiving_18\VBG\2210855|after|stent (r_advcl) developed_6\VBD\1753788|who|aneurysm|receiving (l_dobj) aneurysm_9\NN\14057371|a|coronary|artery
8864707
D010672_D004827 NONE phenytoin_10\NN\3550533| (r_compound) overdosages_11\NNS\1740|after|phenytoin (r_nmod) volumetry_2\NN\1740|resonance|cerebellum|overdosages|. (l_nmod) cerebellum_5\NN\5462674|of|the|patients (l_nmod) patients_8\NNS\9898892|in|epileptic (l_amod) epileptic_7\JJ\1740|
D010672_D062787 CID phenytoin_10\NN\3550533| (r_compound) overdosages_11\NNS\1740|after|phenytoin
D010672_D062787 CID phenytoin_3\NN\3550533| (r_compound) overdosage_4\NN\1740|phenytoin
D010672_D062787 CID phenytoin_17\NN\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) cause_22\NN\7323922|that|medication|was|the|only|atrophy (r_ccomp) unlikely_15\JJ\1740|it|is|cause (r_conj) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and|unlikely (l_nsubj) overdosage_4\NN\1740|phenytoin
D010672_D002526 NONE phenytoin_11\NN\3550533| (r_compound) medication_12\NN\3247620|between|phenytoin|and|atrophy (l_conj) atrophy_15\NN\14299637|cerebellar
D010672_D002526 NONE phenytoin_3\NN\3550533| (r_compound) overdosage_4\NN\1740|phenytoin (r_nsubj) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and|unlikely (l_nmod) atrophy_11\NN\14299637|in|cerebellar
D010672_D002526 NONE phenytoin_3\NN\3550533| (r_compound) overdosage_4\NN\1740|phenytoin (r_nsubj) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and|unlikely (l_conj) unlikely_15\JJ\1740|it|is|cause (l_ccomp) cause_22\NN\7323922|that|medication|was|the|only|atrophy (l_nmod) atrophy_25\NN\14299637|of|cerebellar|patients
D010672_D002526 NONE phenytoin_17\NN\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) cause_22\NN\7323922|that|medication|was|the|only|atrophy (r_ccomp) unlikely_15\JJ\1740|it|is|cause (r_conj) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and|unlikely (l_nmod) atrophy_11\NN\14299637|in|cerebellar
D010672_D002526 NONE phenytoin_17\NN\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) cause_22\NN\7323922|that|medication|was|the|only|atrophy (l_nmod) atrophy_25\NN\14299637|of|cerebellar|patients
D010672_D012640 NONE phenytoin_15\NN\3550533| (r_compound) levels_17\NNS\4916342|of|phenytoin|serum (r_nmod) elevation_13\NN\7445480|levels (r_conj) duration_11\NN\15113229|between|seizure|,|elevation|and|volume (l_compound) seizure_10\NN\14081375|
18004067
D000431_D017114 NONE alcohol_8\NN\7881800| (r_compound) consumption_9\NN\13440063|with|regular|alcohol (r_nmod) patients_5\NNS\9898892|in|two|consumption (r_nmod) failure_2\NN\66216|acute|liver|patients|ingesting|.
D000082_D017114 NONE paracetamol_11\NN\1740| (r_dobj) ingesting_10\VBG\597915|paracetamol|dosage (r_acl) failure_2\NN\66216|acute|liver|patients|ingesting|.
D000431_D056486 NONE alcohol_6\NN\7881800|of (r_nmod) role_4\NN\719494|the|possible|alcohol|development (l_nmod) development_9\NN\248977|in|the|hepatotoxicity (l_nmod) hepatotoxicity_11\NN\1740|of|associated
D000082_D056486 CID paracetamol_17\NN\1740|of|acetaminophen (r_nmod) doses_15\NNS\3740161|with|therapeutic|paracetamol (r_nmod) associated_12\VBN\628491|doses (r_acl) hepatotoxicity_11\NN\1740|of|associated
D000082_D056486 CID acetaminophen_19\NN\2707683|(|) (r_appos) paracetamol_17\NN\1740|of|acetaminophen (r_nmod) doses_15\NNS\3740161|with|therapeutic|paracetamol (r_nmod) associated_12\VBN\628491|doses (r_acl) hepatotoxicity_11\NN\1740|of|associated
D000082_D056486 CID paracetamol_15\NN\1740|of (r_nmod) doses_13\NNS\3740161|with|therapeutic|paracetamol (r_nmod) treated_10\VBN\2376958|doses (r_acl) patients_9\NNS\9898892|in|treated (r_nmod) development_5\NN\248977|for|the|hepatotoxicity|patients (l_nmod) hepatotoxicity_7\NN\1740|of
D000431_D017093 NONE alcohol_12\NN\7881800|of (r_nmod) consumers_10\NNS\10741590|who|were|regular|alcohol|and|developed (l_conj) developed_15\VBD\1753788|who|failure|days|and|stopping (l_dobj) failure_17\NN\66216|liver
D000431_D017093 NONE alcohol_27\NN\7881800| (r_compound) consumption_28\NN\13440063|alcohol (r_dobj) stopping_26\VBG\2452885|consumption|treated (r_conj) developed_15\VBD\1753788|who|failure|days|and|stopping (l_dobj) failure_17\NN\66216|liver
D000431_D017093 NONE alcohol_12\NN\7881800|of (r_nmod) consumption_10\NN\13440063|regular|alcohol (r_nmod) factors_6\NNS\7326557|with|risk|,|e.g.|consumption (r_nmod) patients_3\NNS\9898892|in|factors (r_nmod) possible_17\JJ\1740|patients|,|failure|is|ingested|. (l_nsubj) failure_15\NN\66216|liver
D000082_D017093 CID paracetamol/day_35\NN\1740|with|g (r_nmod) treated_31\VBN\2376958|while|being|paracetamol/day (r_advcl) stopping_26\VBG\2452885|consumption|treated (r_conj) developed_15\VBD\1753788|who|failure|days|and|stopping (l_dobj) failure_17\NN\66216|liver
15278670
C009250_D012640 NONE sevoflurane_3\NN\1740|of (r_nmod) effects_1\NNS\13245626|the|sevoflurane|convulsions|. (l_nmod) convulsions_6\NNS\14081375|on|lidocaine-induced
C009250_D012640 NONE sevoflurane_3\NN\1740|of (r_nmod) influence_1\NN\5190804|the|sevoflurane|convulsions (l_nmod) convulsions_6\NNS\14081375|on|lidocaine-induced
C009250_D012640 NONE sevoflurane_38\NN\1740|of (r_nmod) concentration_36\NN\4916342|the|end-tidal|sevoflurane (r_nsubj) %_41\NN\1740|when|concentration|was|0.8 (r_advcl) increasing_24\VBG\169651|mg.|significantly|mg.|%|. (l_nsubj) mg._12\NN\1740|threshold|was|41.4|l(-1|infusion|, (l_nsubj) threshold_2\NN\15265518|the|convulsive|mean (l_amod) convulsive_1\JJ\1740|
C009250_D012640 NONE sevoflurane_10\NN\1740|between|and|enflurane (r_nmod) difference_4\NN\4723816|no|significant|threshold|sevoflurane (l_nmod) threshold_8\NN\15265518|in|the|convulsive (l_amod) convulsive_7\JJ\1740|
C009250_D012640 NONE sevoflurane_12\NN\1740|of|or|enflurane (r_nmod) concentrations_10\NNS\4916342|higher|sevoflurane (r_nsubjpass) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|sevoflurane|enflurane|. (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
C009250_D012640 NONE sevoflurane_28\NN\1740|in|%|,|and|% (r_nmod) decreased_23\VBD\169651|pressure|significantly|sevoflurane|enflurane|. (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
C009250_D012640 NONE sevoflurane_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\34213|the|convulsive|toxicity (l_amod) convulsive_7\JJ\1740|
D008012_D012640 CID lidocaine-induced_5\JJ\1740| (r_amod) convulsions_6\NNS\14081375|on|lidocaine-induced
D008012_D012640 CID lidocaine-induced_5\JJ\1740| (r_amod) convulsions_6\NNS\14081375|on|lidocaine-induced
D008012_D012640 CID lidocaine_16\NN\3681148| (r_compound) infusion_17\NN\14589223|with|lidocaine|mg.kg(-1).min(-1|) (r_nmod) mg._12\NN\1740|threshold|was|41.4|l(-1|infusion|, (l_nsubj) threshold_2\NN\15265518|the|convulsive|mean (l_amod) convulsive_1\JJ\1740|
D008012_D012640 CID lidocaine_10\NN\3681148| (r_compound) toxicity_11\NN\13576101|of|lidocaine (r_nmod) effect_8\NN\34213|the|convulsive|toxicity (l_amod) convulsive_7\JJ\1740|
D004737_D012640 NONE enflurane_12\NN\3299929| (r_conj) sevoflurane_10\NN\1740|between|and|enflurane (r_nmod) difference_4\NN\4723816|no|significant|threshold|sevoflurane (l_nmod) threshold_8\NN\15265518|in|the|convulsive (l_amod) convulsive_7\JJ\1740|
D004737_D012640 NONE enflurane_14\NN\3299929| (r_conj) sevoflurane_12\NN\1740|of|or|enflurane (r_nmod) concentrations_10\NNS\4916342|higher|sevoflurane (r_nsubjpass) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|sevoflurane|enflurane|. (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
D004737_D012640 NONE enflurane_37\NN\3299929| (r_dobj) decreased_23\VBD\169651|pressure|significantly|sevoflurane|enflurane|. (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
D001030_D012640 NONE apamin_0\NN\1740|ng (r_nsubj) had_5\VBD\2108377|apamin|tendency|but|significant (l_dobj) tendency_7\NN\6193203|a|decrease (l_acl) decrease_9\VB\169651|to|threshold|l(-1|) (l_dobj) threshold_12\NN\15265518|the|convulsive (l_amod) convulsive_11\JJ\1740|
C009250_D064420 NONE sevoflurane_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\34213|the|convulsive|toxicity (l_nmod) toxicity_11\NN\13576101|of|lidocaine
C009250_D003866 NONE sevoflurane_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\1850315|risk|depression (l_nmod) depression_19\NN\14373582|due|circulatory
D008012_D064420 NONE lidocaine_10\NN\3681148| (r_compound) toxicity_11\NN\13576101|of|lidocaine
D008012_D003866 NONE lidocaine_10\NN\3681148| (r_compound) toxicity_11\NN\13576101|of|lidocaine (r_nmod) effect_8\NN\34213|the|convulsive|toxicity (r_dobj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\1850315|risk|depression (l_nmod) depression_19\NN\14373582|due|circulatory
11569530
D016593_D016171 CID terfenadine_17\NN\1740|(|e.g.|and|terodiline|) (r_dep) withdrawal_8\NN\7206096|to|drugs|market|terfenadine (r_nmod) led_6\VBN\1752884|that|has|withdrawal (r_acl:relcl) side-effect_3\NN\1740|tdp|is|a|led|. (l_nsubj) tdp_0\NN\1740|
D016593_D016171 CID terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|compounds|were|:|terfenadine|. (l_nsubjpass) compounds_1\NNS\5869584|four|known (l_acl) known_2\VBN\2110220|increase (l_xcomp) increase_4\VB\169651|to|interval|and|cause (l_conj) cause_8\VB\1617192|tdp (l_dobj) tdp_9\NN\1740|
D016593_D016171 CID terfenadine_10\NN\1740|(|,|terodiline|,|cisapride|) (r_dep) compounds_1\NNS\5869584|for|shown|terfenadine (l_acl:relcl) shown_4\VBN\2137132|that|have|tdp|clinic (l_dobj) tdp_5\NN\1740|
C010637_D016171 CID terodiline_19\NN\1740| (r_conj) terfenadine_17\NN\1740|(|e.g.|and|terodiline|) (r_dep) withdrawal_8\NN\7206096|to|drugs|market|terfenadine (r_nmod) led_6\VBN\1752884|that|has|withdrawal (r_acl:relcl) side-effect_3\NN\1740|tdp|is|a|led|. (l_nsubj) tdp_0\NN\1740|
C010637_D016171 CID terodiline_15\NN\1740| (r_conj) terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|compounds|were|:|terfenadine|. (l_nsubjpass) compounds_1\NNS\5869584|four|known (l_acl) known_2\VBN\2110220|increase (l_xcomp) increase_4\VB\169651|to|interval|and|cause (l_conj) cause_8\VB\1617192|tdp (l_dobj) tdp_9\NN\1740|
C010637_D016171 CID terodiline_12\NN\1740| (r_appos) terfenadine_10\NN\1740|(|,|terodiline|,|cisapride|) (r_dep) compounds_1\NNS\5869584|for|shown|terfenadine (l_acl:relcl) shown_4\VBN\2137132|that|have|tdp|clinic (l_dobj) tdp_5\NN\1740|
D020117_D016171 CID cisapride_17\NN\1740| (r_conj) terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|compounds|were|:|terfenadine|. (l_nsubjpass) compounds_1\NNS\5869584|four|known (l_acl) known_2\VBN\2110220|increase (l_xcomp) increase_4\VB\169651|to|interval|and|cause (l_conj) cause_8\VB\1617192|tdp (l_dobj) tdp_9\NN\1740|
D020117_D016171 CID cisapride_14\NN\1740| (r_appos) terfenadine_10\NN\1740|(|,|terodiline|,|cisapride|) (r_dep) compounds_1\NNS\5869584|for|shown|terfenadine (l_acl:relcl) shown_4\VBN\2137132|that|have|tdp|clinic (l_dobj) tdp_5\NN\1740|
C063968_D016171 NONE e4031_19\NN\1740| (r_conj) terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|compounds|were|:|terfenadine|. (l_nsubjpass) compounds_1\NNS\5869584|four|known (l_acl) known_2\VBN\2110220|increase (l_xcomp) increase_4\VB\169651|to|interval|and|cause (l_conj) cause_8\VB\1617192|tdp (l_dobj) tdp_9\NN\1740|
17612891
D003024_D009205 CID clozapine_4\NN\3713736|with (r_nmod) associated_2\VBN\628491|clozapine (r_acl) myocarditis_1\NN\14338942|acute|associated|.
D003024_D009205 CID clozapine_12\NN\3713736|of (r_nmod) commencement_10\NN\15180528|with|the|clozapine (r_nmod) associated_7\VBN\628491|commencement (r_acl) myocarditis_6\NN\14338942|of|acute|associated
D003024_D009205 CID clozapine_16\NN\3713736|of (r_nmod) commencement_14\NN\15180528|after|clozapine (r_nmod) developed_7\VBD\1753788|male|onset|commencement|. (l_dobj) onset_10\NN\7325190|a|sudden|myocarditis (l_nmod) myocarditis_12\NN\14338942|of
D003024_D009205 CID clozapine_13\NN\3713736|of (r_nmod) use_11\NN\407535|with|the|clozapine (r_nmod) associated_8\VBN\628491|use (r_acl) complication_7\NN\1073995|myocarditis|is|an|recognized|associated (l_nsubj) myocarditis_2\NN\14338942|
D003024_D012559 NONE clozapine_16\NN\3713736|of (r_nmod) commencement_14\NN\15180528|after|clozapine (r_nmod) developed_7\VBD\1753788|male|onset|commencement|. (l_nsubj) male_4\NN\15388|a|20-year-old|schizophrenia (l_nmod) schizophrenia_6\NN\14398067|with
D003024_D011618 NONE clozapine_2\NN\3713736| (r_nsubj) remains_3\VBZ\2604760|that|clozapine|standard (l_attr) standard_6\NN\13577171|the|gold|treatment (l_nmod) treatment_8\NN\654885|in|psychosis (l_nmod) psychosis_11\NN\14380140|of|resistant
2632720
D007654_D006973 CID ketoconazole_7\NN\1740| (r_compound) treatment_8\NN\654885|of|prolonged|ketoconazole (r_nmod) complication_4\NN\1073995|as|a|treatment (r_nmod) hypertension_1\NN\14057371|arterial|complication|.
D007654_D006973 CID ketoconazole_14\NN\1740|with (r_nmod) treated_8\VBN\2376958|basis|ketoconazole (r_acl) patients_3\NNS\9898892|14|syndrome|treated (r_nsubj) developed_15\VBD\1753788|patients|hypertension|. (l_dobj) hypertension_17\NN\14057371|sustained
D007654_D006973 CID ketoconazole_14\NN\1740| (r_compound) therapy_15\NN\657604|following|ketoconazole (r_nmod) achieved_12\VBN\2524171|cases|levels|had|been|therapy|,|yet|demonstrated (l_conj) demonstrated_22\VBD\2137132|monitoring|hypertension|treatment|. (l_dobj) hypertension_23\NN\14057371|31|patient|and|weeks
D007654_D006973 CID ketoconazole_10\NN\1740|of (r_nmod) doses_8\NNS\3740161|with|high|ketoconazole (r_nmod) treatment_5\NN\654885|long-term|doses (r_nsubj) induce_12\VB\1627355|that|treatment|may|blockade (l_dobj) blockade_14\NN\952963|enzyme|leading (l_acl) leading_15\VBG\1752884|hypertension (l_nmod) hypertension_18\NN\14057371|to|mineralocorticoid-related
D007654_D003480 NONE ketoconazole_14\NN\1740|with (r_nmod) treated_8\VBN\2376958|basis|ketoconazole (r_acl) patients_3\NNS\9898892|14|syndrome|treated (l_nmod) syndrome_7\NN\5870365|with|cushing|'s
D006854_D006973 NONE cortisol_8\NN\14751417|free (r_conj) plasma_4\NN\5398023|normal|and|cortisol (r_compound) levels_9\NNS\4916342|plasma (r_nsubjpass) achieved_12\VBN\2524171|cases|levels|had|been|therapy|,|yet|demonstrated (l_conj) demonstrated_22\VBD\2137132|monitoring|hypertension|treatment|. (l_dobj) hypertension_23\NN\14057371|31|patient|and|weeks
15515654
D003676_D006311 NONE dfo_6\NN\1740|than (r_nmod) other_4\JJ\1740|dfo (r_amod) factor_2\NN\7326557|no|ototoxic|,|other|, (l_amod) ototoxic_1\JJ\1740|
D003676_D006319 CID dfo_6\NN\1740| (r_compound) reduction_7\NN\351485|to|dfo|or|withdrawal (r_nmod) submitted_4\VBN\1952898|subjects|were|reduction|. (l_nsubjpass) subjects_0\NNS\6598915|snhl (l_nmod) snhl_2\NN\1740|with
D003676_D034381 NONE dfo_7\NNP\1740|'s (r_nmod:poss) role_10\NN\719494|of|dfo|contributing|development (l_nmod) development_13\NN\248977|in|the|impairment (l_nmod) impairment_16\NN\7296428|of|hearing
1967484
D013469_D004421 CID sulpiride-induced_0\NN\1740| (r_compound) dystonia_2\NN\1740|sulpiride-induced|tardive|.
D013469_D004421 CID sulpiride_15\NN\1740| (r_compound) therapy_16\NN\657604|sulpiride (r_dobj) starting_14\VBG\2009433|after|therapy (r_advcl) months_12\NNS\15113229|within|2|starting (r_nmod) developed_6\VBD\1753788|who|dystonia|months (l_dobj) dystonia_9\NN\1740|persistent|segmental
D013469_D004421 CID sulpiride-induced_8\JJ\1740| (r_amod) dystonia_10\NN\1740|of|sulpiride-induced|tardive
D013469_D004409 NONE sulpiride-induced_11\JJ\1740| (r_amod) dyskinesia_13\NN\14084880|sulpiride-induced|tardive|and|parkinsonism
D013469_D010302 NONE sulpiride-induced_11\JJ\1740| (r_amod) dyskinesia_13\NN\14084880|sulpiride-induced|tardive|and|parkinsonism (l_conj) parkinsonism_15\NN\14085708|
2425813
D011239_D006529 CID prednisolone_14\NN\2721538|of (r_nmod) administration_12\NN\1133281|following|the|subcutaneous|prednisolone (r_nmod) occurred_5\VBD\2623529|enlargement|rats|administration|. (l_nsubj) enlargement_1\NN\363260|liver|and|wastage
D011239_D009133 CID prednisolone_14\NN\2721538|of (r_nmod) administration_12\NN\1133281|following|the|subcutaneous|prednisolone (r_nmod) occurred_5\VBD\2623529|enlargement|rats|administration|. (l_nsubj) enlargement_1\NN\363260|liver|and|wastage (l_conj) wastage_4\NN\13458571|muscle
18752389
C492458_D017093 NONE simvastatin-ezetimibe-induced_0\JJ\1740| (r_amod) failure_2\NN\66216|simvastatin-ezetimibe-induced|hepatic|necessitating|.
C492458_D017093 NONE simvastatin-ezetimibe-induced_11\JJ\1740| (r_amod) failure_13\NN\66216|of|simvastatin-ezetimibe-induced|liver|resulted
C108606_D056486 NONE ezetimibe_10\NN\1740|with|or|simvastatin-ezetimibe (r_nmod) published_8\VBN\1621555|however|,|events|have|not|been|widely|ezetimibe|. (l_nsubjpass) events_3\NNS\23100|hepatotoxic (l_amod) hepatotoxic_2\JJ\1740|
C108606_D056486 NONE ezetimibe_0\NN\1740| (r_nsubj) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN\2510337|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\2633881|exposure (l_nmod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
C108606_D056486 NONE ezetimibe_15\NN\1740| (r_compound) inhibition_16\NN\1068773|by|ezetimibe|enzymes (r_nmod) exposure_13\NN\5042871|that|mechanism|is|the|increased|simvastatin|inhibition (l_nsubj) mechanism_4\NN\13446390|the|hepatotoxicity (l_nmod) hepatotoxicity_8\NN\1740|of|the|simvastatinezetimibe-induced
C492458_D056486 CID simvastatin-ezetimibe_15\NN\1740|agent (r_conj) ezetimibe_10\NN\1740|with|or|simvastatin-ezetimibe (r_nmod) published_8\VBN\1621555|however|,|events|have|not|been|widely|ezetimibe|. (l_nsubjpass) events_3\NNS\23100|hepatotoxic (l_amod) hepatotoxic_2\JJ\1740|
C492458_D056486 CID simvastatinezetimibe_0\NN\1740|and|escitalopram (r_nsubjpass) discontinued_12\VBN\2609764|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\471711|causes|were|. (l_nsubjpass) causes_17\NNS\7323922|other|potential|hepatotoxicity (l_nmod) hepatotoxicity_19\NN\1740|of
C492458_D056486 CID simvastatinezetimibe-induced_7\JJ\1740| (r_amod) hepatotoxicity_8\NN\1740|of|the|simvastatinezetimibe-induced
C492458_D056486 CID simvastatin-ezetimibe_8\NN\1740|with (r_nmod) hepatotoxicity_6\NN\1740|of|potential|simvastatin-ezetimibe|patients
D019821_D017114 NONE simvastatin_19\NN\3676175|from|mg/day (r_nmod) conversion_17\NN\7359599|simvastatin|simvastatin (r_dobj) developed_7\VBD\1753788|who|failure|after|conversion (l_dobj) failure_10\NN\66216|fulminant|hepatic|necessitating
C492458_D017114 CID mg/day_27\NN\1740|40 (r_appos) simvastatin_23\NN\3676175|to|mg-ezetimibe|mg/day (r_nmod) conversion_17\NN\7359599|simvastatin|simvastatin (r_dobj) developed_7\VBD\1753788|who|failure|after|conversion (l_dobj) failure_10\NN\66216|fulminant|hepatic|necessitating
D019821_D056486 NONE simvastatin_9\NN\3676175|with (r_nmod) maintained_7\VBN\2202928|panel|had|been|simvastatin|months|conversion|evidence|. (l_nmod) evidence_17\NN\5816287|without|hepatotoxicity (l_nmod) hepatotoxicity_19\NN\1740|of
D019821_D056486 NONE simvastatin_30\NN\3676175| (r_compound) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
D019821_D056486 NONE simvastatin_12\NN\3676175| (r_compound) exposure_13\NN\5042871|that|mechanism|is|the|increased|simvastatin|inhibition (l_nsubj) mechanism_4\NN\13446390|the|hepatotoxicity (l_nmod) hepatotoxicity_8\NN\1740|of|the|simvastatinezetimibe-induced
C492458_D003866 NONE simvastatinezetimibe_0\NN\1740|and|escitalopram (l_conj) escitalopram_2\NN\1740|(|taking|) (l_acl:relcl) taking_7\VBG\2367363|which|she|was|depression (l_nmod) depression_9\NN\14373582|for
D015283_D003866 NONE escitalopram_2\NN\1740|(|taking|) (l_acl:relcl) taking_7\VBG\2367363|which|she|was|depression (l_nmod) depression_9\NN\14373582|for
D015283_D056486 NONE escitalopram_2\NN\1740|(|taking|) (r_conj) simvastatinezetimibe_0\NN\1740|and|escitalopram (r_nsubjpass) discontinued_12\VBN\2609764|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\471711|causes|were|. (l_nsubjpass) causes_17\NNS\7323922|other|potential|hepatotoxicity (l_nmod) hepatotoxicity_19\NN\1740|of
D014530_D056486 NONE diphosphate_6\NN\1740| (r_compound) glucoronosyltransferases_7\NNS\1740|by|uridine|diphosphate|ugt|intestine (r_nmod) glucuronidation_3\NN\1740|extensive|glucoronosyltransferases (r_dobj) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN\2510337|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\2633881|exposure (l_nmod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
C532833_D056486 NONE acid_25\NN\14818238|of|simvastatin|hydroxy (r_nmod) glucuronidation_21\NN\1740|the|acid (r_dobj) inhibited_19\VBN\2510337|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\2633881|exposure (l_nmod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
17532790
D007980_D004409 CID l-dopa-induced_10\JJ\1740| (r_amod) dyskinesia_11\NN\14084880|of|l-dopa-induced
D007980_D004409 CID l-dopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid
D007980_D004409 CID l-dopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid (l_appos) lid_3\NN\5313679|(|)
D007980_D004409 CID l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (r_acl:relcl) complications_9\NNS\1073995|among|the|motor|arise|. (l_case) among_6\IN\1740|dyskinesia|is (l_nsubj) dyskinesia_1\NN\14084880|l-dopa-induced|lid
D007980_D004409 CID l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (r_acl:relcl) complications_9\NNS\1073995|among|the|motor|arise|. (l_case) among_6\IN\1740|dyskinesia|is (l_nsubj) dyskinesia_1\NN\14084880|l-dopa-induced|lid (l_appos) lid_3\NN\5313679|(|)
D007980_D004409 CID l-dopa_3\NN\14604959|with (r_nmod) treated_1\VBN\2376958|l-dopa (r_acl) rats_0\NNS\2329401|treated (r_nsubjpass) allocated_5\VBN\2228698|rats|were|groups|presence|. (l_nmod) presence_12\NN\13954253|based|on|the|or|absence|lid (l_nmod) lid_16\NN\5313679|of
D007980_D010300 NONE l-dopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid (r_nsubj) among_6\IN\1740|dyskinesia|is (r_case) complications_9\NNS\1073995|among|the|motor|arise|. (l_acl:relcl) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd
D007980_D010300 NONE l-dopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid (r_nsubj) among_6\IN\1740|dyskinesia|is (r_case) complications_9\NNS\1073995|among|the|motor|arise|. (l_acl:relcl) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd (l_appos) pd_17\NN\14625458|(|)
D007980_D010300 NONE l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd
D007980_D010300 NONE l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd (l_appos) pd_17\NN\14625458|(|)
D007980_D010300 NONE l-dopa_30\NN\14604959| (r_conj) saline_28\NN\14849367|with|,|l-dopa|or|bromocriptine (r_nmod) treated_26\VBN\2376958|saline (r_acl) model_23\NN\5888929|from|the|unilaterally|6-hydroxydopamine-lesion|rat|pd|treated (l_nmod) pd_25\NN\14625458|of
D016627_D010300 NONE 6-hydroxydopamine-lesion_21\JJ\1740| (r_amod) model_23\NN\5888929|from|the|unilaterally|6-hydroxydopamine-lesion|rat|pd|treated (l_nmod) pd_25\NN\14625458|of
D001971_D010300 NONE bromocriptine_32\NN\1740| (r_conj) saline_28\NN\14849367|with|,|l-dopa|or|bromocriptine (r_nmod) treated_26\VBN\2376958|saline (r_acl) model_23\NN\5888929|from|the|unilaterally|6-hydroxydopamine-lesion|rat|pd|treated (l_nmod) pd_25\NN\14625458|of
11752354
D003276_D009203 CID contraceptives_1\NNS\3183080|oral|and|risk (l_conj) risk_4\NN\14541044|the|infarction|. (l_nmod) infarction_7\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_9\NNS\3183080|of|oral (r_nmod) use_6\NN\407535|between|the|contraceptives|and|risk (l_conj) risk_12\NN\14541044|the|infarction (l_nmod) infarction_15\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_29\NNS\3183080|oral (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_dobj) women_60\NNS\9605289|248|years|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction|1990 (l_dobj) infarction_73\NN\14204950|a|first|myocardial
D003276_D009203 CID contraceptives_29\NNS\3183080|oral (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_conj) women_81\NNS\9605289|925|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D003276_D009203 CID contraceptive_39\NN\3183080|of|combined|oral (r_nmod) type_35\NN\5839024|any|contraceptive (r_dobj) used_33\VBD\1156834|who|type (r_acl:relcl) women_31\NNS\9605289|among|used|, (r_nmod) infarction_29\NN\14204950|for|myocardial|women
D003276_D009203 CID contraceptives_5\NNS\3183080|oral (r_dobj) used_3\VBD\1156834|who|contraceptives (r_acl:relcl) women_1\NNS\9605289|among|used (r_nmod) 2.1_11\CD\1740|women|,|ratio|was|interval|and|1.9|:|increased (l_parataxis) increased_53\VBN\169651|risk|was|women|. (l_nsubjpass) risk_48\NN\14541044|the|infarction (l_nmod) infarction_51\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_60\NNS\3183080|second-generation|oral (r_dobj) used_57\VBD\1156834|who|contraceptives (r_acl:relcl) women_55\NNS\9605289|among|used (r_nmod) increased_53\VBN\169651|risk|was|women|. (l_nsubjpass) risk_48\NN\14541044|the|infarction (l_nmod) infarction_51\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_12\NNS\3183080|oral (r_dobj) used_10\VBD\1156834|who|contraceptives|had (r_acl:relcl) women_8\NNS\9605289|among|used (r_nmod) similar_6\JJ\1740|risk|was|women|. (l_nsubj) risk_1\NN\14541044|the|infarction (l_nmod) infarction_4\NN\14204950|of|myocardial
D011372_D009203 NONE progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_dobj) women_60\NNS\9605289|248|years|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction|1990 (l_dobj) infarction_73\NN\14204950|a|first|myocardial
D011372_D009203 NONE progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_conj) women_81\NNS\9605289|925|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D017135_D009203 NONE desogestrel_17\NN\1740|in|third-generation|(|i.e.|,|or|gestodene|)|and|second-generation (r_nmod) included_11\VBN\690614|desogestrel (r_acl) progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_dobj) women_60\NNS\9605289|248|years|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction|1990 (l_dobj) infarction_73\NN\14204950|a|first|myocardial
D017135_D009203 NONE desogestrel_17\NN\1740|in|third-generation|(|i.e.|,|or|gestodene|)|and|second-generation (r_nmod) included_11\VBN\690614|desogestrel (r_acl) progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_conj) women_81\NNS\9605289|925|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
C033273_D009203 NONE gestodene_19\NN\1740| (r_conj) desogestrel_17\NN\1740|in|third-generation|(|i.e.|,|or|gestodene|)|and|second-generation (r_nmod) included_11\VBN\690614|desogestrel (r_acl) progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_dobj) women_60\NNS\9605289|248|years|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction|1990 (l_dobj) infarction_73\NN\14204950|a|first|myocardial
C033273_D009203 NONE gestodene_19\NN\1740| (r_conj) desogestrel_17\NN\1740|in|third-generation|(|i.e.|,|or|gestodene|)|and|second-generation (r_nmod) included_11\VBN\690614|desogestrel (r_acl) progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_conj) women_81\NNS\9605289|925|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D016912_D009203 NONE levonorgestrel_26\NN\1740|(|i.e.|,|) (r_dep) second-generation_22\JJ\1740|levonorgestrel (r_conj) desogestrel_17\NN\1740|in|third-generation|(|i.e.|,|or|gestodene|)|and|second-generation (r_nmod) included_11\VBN\690614|desogestrel (r_acl) progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_dobj) women_60\NNS\9605289|248|years|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction|1990 (l_dobj) infarction_73\NN\14204950|a|first|myocardial
D016912_D009203 NONE levonorgestrel_26\NN\1740|(|i.e.|,|) (r_dep) second-generation_22\JJ\1740|levonorgestrel (r_conj) desogestrel_17\NN\1740|in|third-generation|(|i.e.|,|or|gestodene|)|and|second-generation (r_nmod) included_11\VBN\690614|desogestrel (r_acl) progestagen_10\NN\1740|of|included (r_nmod) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_conj) women_81\NNS\9605289|925|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D004967_D009203 NONE estrogen_34\NN\14745635|of (r_nmod) dose_32\NN\3740161|the|estrogen (r_conj) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_dobj) women_60\NNS\9605289|248|years|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction|1990 (l_dobj) infarction_73\NN\14204950|a|first|myocardial
D004967_D009203 NONE estrogen_34\NN\14745635|of (r_nmod) dose_32\NN\3740161|the|estrogen (r_conj) type_8\NN\5839024|according|the|progestagen|contraceptives|,|dose|,|and|presence|:|identified (l_acl:relcl) identified_56\VBD\699815|study|,|we|and|enrolled|women|and|women (l_conj) women_81\NNS\9605289|925|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
9522143
D011318_D034381 CID prilocaine_2\NN\1740| (r_dobj) given_1\VBN\2327200|prilocaine (r_acl) patients_0\NNS\9898892|given (r_nsubj) likely_5\JJ\1740|patients|were|more|develop|. (l_xcomp) develop_7\VB\1753788|to|loss|those (l_dobj) loss_9\NN\13252973|hearing|22
D011318_D034381 CID prilocaine_12\NN\1740|after (r_nmod) db_10\NN\14622893|loss|was|10|prilocaine|and|db|. (l_nsubj) loss_3\NN\13252973|the|average|hearing|frequencies
D002045_D034381 CID bupivacaine_19\NN\1740| (r_dobj) given_18\VBN\2327200|bupivacaine (r_acl) those_17\DT\1740|than|given|22|p (r_nmod) develop_7\VB\1753788|to|loss|those (l_dobj) loss_9\NN\13252973|hearing|22
D002045_D034381 CID bupivacaine_17\NN\1740|after (r_nmod) db_15\NN\14622893|15|bupivacaine (r_conj) db_10\NN\14622893|loss|was|10|prilocaine|and|db|. (l_nsubj) loss_3\NN\13252973|the|average|hearing|frequencies
10739826
D003276_D054556 CID contraceptives_5\NNS\3183080|of|newer|oral (r_nmod) use_1\NN\407535|recurrent|contraceptives|and|risk (l_conj) risk_8\NN\14541044|the|thromboembolism|. (l_nmod) thromboembolism_11\NN\14100769|of|venous
D003276_D054556 CID contraceptives_17\NNS\3183080|with|newer|oral|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 CID contraceptives_17\NNS\3183080|with|newer|oral|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D003276_D054556 CID oc_19\NN\1740|(|) (r_appos) contraceptives_17\NNS\3183080|with|newer|oral|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 CID oc_19\NN\1740|(|) (r_appos) contraceptives_17\NNS\3183080|with|newer|oral|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D003276_D054556 CID oc_27\NN\1740| (r_compound) use_28\NN\407535|of|oc (r_nmod) patterns_25\NNS\5726345|between|use|,|users (r_nmod) distinguish_23\VB\618878|studies|did|not|patterns|. (l_nsubj) studies_2\NNS\635850|the|epidemiological|assessed (l_acl:relcl) assessed_4\VBD\670261|that|risk (l_dobj) risk_6\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 CID oc_27\NN\1740| (r_compound) use_28\NN\407535|of|oc (r_nmod) patterns_25\NNS\5726345|between|use|,|users (r_nmod) distinguish_23\VB\618878|studies|did|not|patterns|. (l_nsubj) studies_2\NNS\635850|the|epidemiological|assessed (l_acl:relcl) assessed_4\VBD\670261|that|risk (l_dobj) risk_6\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D003276_D054556 CID oc_12\NN\1740|of|generation (r_nmod) users_8\NNS\7846|for|repeat|oc (r_nmod) ratio_3\NN\13815152|the|adjusted|rate|vte|users (l_nmod) vte_5\NN\1740|of
8690168
D006497_D003928 NONE sulphate-associated_3\JJ\1740|heparan (r_amod) sites_5\NNS\8673395|of|sulphate-associated|anionic (r_nmod) reduction_0\NN\351485|sites|membrane|. (l_nmod) membrane_10\NN\4188643|in|the|glomerular|basement|rats (l_nmod) rats_12\NNS\2329401|of|nephropathy (l_nmod) nephropathy_16\NN\14573196|with|streptozotocin-induced|diabetic
D013311_D003928 CID streptozotocin-induced_14\JJ\1740| (r_amod) nephropathy_16\NN\14573196|with|streptozotocin-induced|diabetic
D006497_D003920 NONE sulphate-associated_1\JJ\1740|heparan (r_amod) sites_3\NNS\8673395|sulphate-associated|anionic|membrane (r_nsubjpass) studied_10\VBN\630380|sites|were|rats|,|employing|. (l_nmod) rats_12\NNS\2329401|in|induction (l_nmod) induction_16\NN\7450842|after|diabetes|streptozotocin|and|rats (l_nmod) diabetes_18\NN\14075199|of
D006497_D003920 NONE sulphate_16\NN\15010703| (r_compound) barrier/density_18\NN\1740|a|reduced|heparan|sulphate|charge (r_nsubjpass) found_20\VBN\2426171|that|rats|,|barrier/density|is|externa (l_nmod) rats_5\NNS\2329401|in|streptozotocin-diabetic|excretion (l_amod) streptozotocin-diabetic_4\JJ\1740|
D013311_D003920 NONE streptozotocin_20\NN\1740|by (r_nmod) induction_16\NN\7450842|after|diabetes|streptozotocin|and|rats (l_nmod) diabetes_18\NN\14075199|of
D013311_D003920 NONE streptozotocin-diabetic_4\JJ\1740|
C015445_D003920 NONE blue_34\NN\4959672|cuprolinic (r_appos) dye_32\NN\14984973|the|cationic|blue (r_dobj) employing_29\VBG\1740|dye (r_advcl) studied_10\VBN\630380|sites|were|rats|,|employing|. (l_nmod) rats_12\NNS\2329401|in|induction (l_nmod) induction_16\NN\7450842|after|diabetes|streptozotocin|and|rats (l_nmod) diabetes_18\NN\14075199|of
6666578
D010396_D001018 CID d-penicillamine-induced_0\JJ\1740| (r_amod) angiopathy_1\NN\14204950|d-penicillamine-induced|rats|.
12536034
D002220_D004832 CID carbamazepine_13\NN\1740|of|and|vigabatrin (r_nmod) administration_11\NN\1133281|after|carbamazepine (r_nmod) present_2\VBP\2137132|authors|patients|administration|. (l_dobj) patients_4\NNS\9898892|three|epilepsy (l_nmod) epilepsy_9\NN\14085708|with|de|absence
D020888_D004832 CID vigabatrin_15\NN\1740| (r_conj) carbamazepine_13\NN\1740|of|and|vigabatrin (r_nmod) administration_11\NN\1133281|after|carbamazepine (r_nmod) present_2\VBP\2137132|authors|patients|administration|. (l_dobj) patients_4\NNS\9898892|three|epilepsy (l_nmod) epilepsy_9\NN\14085708|with|de|absence
D005680_D004832 NONE acid-transmitted_2\JJ\1740|gamma-aminobutyric (r_amod) circuitry_4\NN\3278248|the|acid-transmitted|thalamocortical (r_nsubj) accounts_5\VBZ\2604760|circuitry|part|. (l_nmod) part_9\NN\31921|for|a|major|neurophysiology (l_nmod) neurophysiology_13\NN\6081833|of|the|underlying|epilepsy (l_nmod) epilepsy_17\NN\14085708|of|the|absence
2266990
D008454_D020388 NONE mazindol_5\NNP\1740|of (r_nmod) trial_3\NN\786195|randomized|,|double-blind|mazindol|dystrophy|. (l_nmod) dystrophy_8\NN\14151139|in|duchenne
D008454_D020388 NONE mazindol_7\NN\1740|of|,|inhibitor|, (r_nmod) trial_5\NN\786195|a|12-month|controlled|mazindol|boys (l_nmod) boys_18\NNS\9624168|in|83|dystrophy (l_nmod) dystrophy_21\NN\14151139|with|duchenne
D008454_D020388 NONE mazindol_0\NN\1740| (r_compound) doses_1\NNS\3740161|mazindol (r_nsubj) slow_3\VB\151689|doses|not|progression|. (l_dobj) progression_5\NN\8457976|the|weakness (l_nmod) weakness_7\NN\14462666|of|dystrophy (l_nmod) dystrophy_10\NN\14151139|in|duchenne
D008454_D001068 CID mazindol_4\NN\1740|to (r_nmod) attributable_2\JJ\1740|mazindol (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBD\690614|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth
D008454_D001068 CID mazindol_35\NN\1740| (r_compound) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|included|;|dosage|was|%|. (l_ccomp) included_5\VBD\690614|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth
D008454_D014987 CID mazindol_4\NN\1740|to (r_nmod) attributable_2\JJ\1740|mazindol (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBD\690614|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth (l_conj) mouth_14\NN\5610008|dry|%|,|change
D008454_D014987 CID mazindol_35\NN\1740| (r_compound) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|included|;|dosage|was|%|. (l_ccomp) included_5\VBD\690614|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth (l_conj) mouth_14\NN\5610008|dry|%|,|change
D008454_D012817 CID mazindol_4\NN\1740|to (r_nmod) attributable_2\JJ\1740|mazindol (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBD\690614|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth (l_conj) mouth_14\NN\5610008|dry|%|,|change (l_conj) change_21\NN\7283608|behavioral|%|,|and|symptoms (l_conj) symptoms_29\NNS\5823932|gastrointestinal|%
D008454_D012817 CID mazindol_35\NN\1740| (r_compound) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|included|;|dosage|was|%|. (l_ccomp) included_5\VBD\690614|effects|appetite (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth (l_conj) mouth_14\NN\5610008|dry|%|,|change (l_conj) change_21\NN\7283608|behavioral|%|,|and|symptoms (l_conj) symptoms_29\NNS\5823932|gastrointestinal|%
D008454_D018908 NONE mazindol_0\NN\1740| (r_compound) doses_1\NNS\3740161|mazindol (r_nsubj) slow_3\VB\151689|doses|not|progression|. (l_dobj) progression_5\NN\8457976|the|weakness (l_nmod) weakness_7\NN\14462666|of|dystrophy
7453952
D008094_D003919 CID lithium-induced_3\JJ\1740| (r_amod) syndrome_5\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D008094_D003919 CID lithium-induced_9\JJ\1740| (r_amod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D008094_D003919 CID lithium_24\NN\14625458| (r_compound) concentration_25\NN\4916342|between|the|lithium|medulla|and|levels (r_nmod) ratio_21\NN\13815152|of|the|concentration (r_nmod) reduction_18\NN\351485|by|a|ratio|and|elevation (r_nmod) accompanied_15\VBN\1835496|experiments|,|attenuation|was|reduction|. (l_nsubjpass) attenuation_6\NN\7427337|the|syndrome|amiloride (l_nmod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D000584_D003919 NONE amiloride_7\NN\1740|by (r_nmod) attenuation_0\NN\7427337|syndrome|amiloride|rats|. (l_nmod) syndrome_5\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D000584_D003919 NONE amiloride_13\NN\1740|by (r_nmod) attenuation_6\NN\7427337|the|syndrome|amiloride (l_nmod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D000584_D059606 NONE amiloride_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|amiloride|polydipsia (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration
D000584_D059606 NONE amiloride_5\NN\1740| (r_compound) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria
D000584_D059606 NONE amiloride_21\NN\1740| (r_compound) supplementation_22\NN\5108947|prolonged|amiloride (r_nsubj) result_24\VB\2633881|supplementation|would|levels|and|hazardous (r_conj) relieve_16\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria
D000584_D011141 NONE amiloride_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|amiloride|polydipsia (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration (l_conj) polyuria_8\NN\14113228|
D000584_D011141 NONE amiloride_5\NN\1740| (r_compound) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria (l_conj) polyuria_14\NN\14113228|
D000584_D011141 NONE amiloride_21\NN\1740| (r_compound) supplementation_22\NN\5108947|prolonged|amiloride (r_nsubj) result_24\VB\2633881|supplementation|would|levels|and|hazardous (r_conj) relieve_16\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria (l_conj) polyuria_14\NN\14113228|
D008094_D059606 NONE lithium-induced_5\JJ\1740| (r_amod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration
D008094_D059606 NONE lithium_12\NN\14625458| (r_compound) concentration_13\NN\4916342|on|the|lithium|plasma (r_conj) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration
D008094_D059606 NONE lithium-treated_8\JJ\1740| (r_amod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria
D008094_D059606 NONE lithium_27\NN\14625458| (r_compound) levels_28\NNS\4916342|in|elevated|lithium (r_nmod) result_24\VB\2633881|supplementation|would|levels|and|hazardous (r_conj) relieve_16\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria
D008094_D011141 NONE lithium-induced_5\JJ\1740| (r_amod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration (l_conj) polyuria_8\NN\14113228|
D008094_D011141 NONE lithium_12\NN\14625458| (r_compound) concentration_13\NN\4916342|on|the|lithium|plasma (r_conj) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration (l_conj) polyuria_8\NN\14113228|
D008094_D011141 NONE lithium-treated_8\JJ\1740| (r_amod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria (l_conj) polyuria_14\NN\14113228|
D008094_D011141 NONE lithium_27\NN\14625458| (r_compound) levels_28\NNS\4916342|in|elevated|lithium (r_nmod) result_24\VB\2633881|supplementation|would|levels|and|hazardous (r_conj) relieve_16\VB\205885|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia (l_nmod) polydipsia_12\NN\14040660|from|and|polyuria (l_conj) polyuria_14\NN\14113228|
D018021_D059606 NONE licl_35\NN\1740|with (r_nmod) treated_33\VBN\2376958|chronically|licl (r_acl) rats_30\NNS\2329401|in|,|treated (r_nmod) investigated_28\VBN\644583|effect|was|rats|. (l_nsubjpass) effect_1\NN\34213|the|amiloride|polydipsia (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration
D018021_D011141 NONE licl_35\NN\1740|with (r_nmod) treated_33\VBN\2376958|chronically|licl (r_acl) rats_30\NNS\2329401|in|,|treated (r_nmod) investigated_28\VBN\644583|effect|was|rats|. (l_nsubjpass) effect_1\NN\34213|the|amiloride|polydipsia (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria|and|concentration (l_conj) polyuria_8\NN\14113228|
D011188_D003919 NONE potassium_42\NN\14625458| (r_compound) level_43\NN\4916342|in|the|plasma|potassium (r_nmod) elevation_38\NN\7445480|an|level (r_conj) reduction_18\NN\351485|by|a|ratio|and|elevation (r_nmod) accompanied_15\VBN\1835496|experiments|,|attenuation|was|reduction|. (l_nsubjpass) attenuation_6\NN\7427337|the|syndrome|amiloride (l_nmod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
2096243
C017367_D019965 CID carmofur-induced_0\NNP\1740| (r_compound) disorders_3\NNS\14034177|carmofur-induced|organic|mental|.
C017367_D019965 CID carmofur-induced_17\JJ\1740| (r_amod) leukoencephalopathy_18\NN\1740|of|carmofur-induced (r_nmod) onset_15\NN\7325190|after|the|leukoencephalopathy (r_nmod) period_12\NN\13575869|in|the|prognostic|onset (r_nmod) observed_4\VBN\2163746|disorder|was|female|period|. (l_nsubjpass) disorder_2\NN\14034177|organic|mental
C017367_D056784 CID carmofur-induced_17\JJ\1740| (r_amod) leukoencephalopathy_18\NN\1740|of|carmofur-induced
C017367_D056784 CID carmofur-induced_2\JJ\1740| (r_amod) leukoencephalopathy_3\NN\1740|carmofur-induced
C017367_D010554 NONE carmofur-induced_2\JJ\1740| (r_amod) leukoencephalopathy_3\NN\1740|carmofur-induced (r_nsubj) result_6\VB\2633881|consequently|,|leukoencephalopathy|may|uncommonly|syndrome|. (l_nmod) syndrome_10\NN\5870365|in|organic|personality|state
2870085
C047847_D013610 NONE flestolol_0\NN\1740| (r_nsubj) produced_1\VBD\1617192|flestolol|attenuation|. (l_dobj) attenuation_4\NN\7427337|a|dose-dependent|tachycardia (l_nmod) tachycardia_7\NN\14110674|of|isoproterenol-induced
D007545_D013610 CID isoproterenol-induced_6\JJ\1740| (r_amod) tachycardia_7\NN\14110674|of|isoproterenol-induced
C047847_D013617 NONE flestolol_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|flestolol|effectively|rate|. (l_dobj) rate_4\NN\13815152|heart|patients (l_nmod) patients_6\NNS\9898892|in|tachyarrhythmia (l_nmod) tachyarrhythmia_9\NN\1740|with|supraventricular
C047847_D000789 NONE flestolol_6\NN\1740| (r_compound) infusion_7\NN\14589223|flestolol (r_nsubjpass) found_9\VBN\2426171|patients|,|infusion|was|safe|. (l_nmod) patients_1\NNS\9898892|in|angina (l_nmod) angina_4\NN\14171682|with|unstable
C047847_D002637 NONE flestolol_6\NN\1740| (r_compound) infusion_7\NN\14589223|flestolol (r_nsubjpass) found_9\VBN\2426171|patients|,|infusion|was|safe|. (l_xcomp) safe_12\JJ\1740|to|be|and|effective|controlling (l_advcl) controlling_16\VBG\2422663|in|pain (l_dobj) pain_18\NN\14299637|chest
8421099
D015282_D042882 CID octreotide_10\NN\1740|(|) (r_appos) analog_8\NN\4743605|of|somatostatin|octreotide (r_nmod) effects_5\NNS\13245626|of|the|long-term|analog|function (l_nmod) function_14\NN\13783581|on|gallbladder|and|formation|patients (l_conj) formation_17\NN\7938773|gallstone (l_compound) gallstone_16\NN\9230768|
D015282_D042882 CID octreotide_3\NN\1740|with (r_nmod) treatment_1\NN\654885|during|octreotide (r_nmod) developed_7\VBD\1753788|treatment|,|patients|sludge|,|had (l_conj) had_11\VBD\2108377|10|gallstones|,|and|developed (l_dobj) gallstones_12\NNS\9230768|
D015282_D042882 CID octreotide_3\NN\1740|of (r_nmod) withdrawal_1\NN\7206096|after|octreotide|patients (l_nmod) patients_6\NNS\9898892|in|10|gallstones (l_nmod) gallstones_8\NNS\9230768|without
D015282_D042882 CID octreotide_25\NN\1740| (r_compound) therapy_26\NN\657604|during|octreotide|patients (r_nmod) formation_15\NN\7938773|of|the|successive|sludge|therapy (l_nmod) sludge_18\NN\14591635|of|bile|,|gallstones|,|and|cholecystitis (l_conj) gallstones_20\NNS\9230768|
D015282_D000172 NONE octreotide_10\NN\1740|(|) (r_appos) analog_8\NN\4743605|of|somatostatin|octreotide (r_nmod) effects_5\NNS\13245626|of|the|long-term|analog|function (l_nmod) function_14\NN\13783581|on|gallbladder|and|formation|patients (l_nmod) patients_21\NNS\9898892|in|chinese|acromegalic (l_amod) acromegalic_20\JJ\1740|
D015282_D000172 NONE octreotide_26\NN\1740|analog (r_nmod) injection_21\NN\320852|with|sc|octreotide|dosages|mean (r_nmod) treated_18\VBN\2376958|injection (r_acl) patients_14\NNS\9898892|in|20|chinese|acromegaly|treated (l_nmod) acromegaly_17\NN\14366759|with|active
D015282_D000172 NONE octreotide_25\NN\1740| (r_compound) therapy_26\NN\657604|during|octreotide|patients (l_nmod) patients_30\NNS\9898892|in|chinese|acromegalic (l_amod) acromegalic_29\JJ\1740|
D015282_D000172 NONE octreotide_14\NN\1740| (r_compound) therapy_15\NN\657604|during|long-term|octreotide|patients (l_nmod) patients_18\NNS\9898892|of|acromegalic (l_amod) acromegalic_17\JJ\1740|
D015282_D041881 CID octreotide_3\NN\1740|with (r_nmod) treatment_1\NN\654885|during|octreotide (r_nmod) developed_7\VBD\1753788|treatment|,|patients|sludge|,|had (l_conj) had_11\VBD\2108377|10|gallstones|,|and|developed (l_conj) developed_16\VBD\1753788|1|cholecystitis|. (l_dobj) cholecystitis_18\NN\14336539|acute|requiring
D015282_D002764 NONE octreotide_25\NN\1740| (r_compound) therapy_26\NN\657604|during|octreotide|patients (r_nmod) formation_15\NN\7938773|of|the|successive|sludge|therapy (l_nmod) sludge_18\NN\14591635|of|bile|,|gallstones|,|and|cholecystitis (l_conj) cholecystitis_23\NN\14336539|
11334364
D000082_D009336 CID acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity (r_nmod) protection_2\NN\407535|in|deaths|nephrotoxicity|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
D000082_D009336 CID aap_9\NN\1740|such|,|ami|and|dox (r_nmod) drugs_4\NNS\14778436|all|the|,|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|necrosis|. (l_dobj) necrosis_20\NN\11444117|addition|to|organs|blocked
D000082_D007674 CID acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity
D000082_D007674 CID acetaminophen_16\NN\2707683|(aap)-induced (r_compound) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
D000082_D007674 CID (aap)-induced_17\NN\1740| (r_dep) acetaminophen_16\NN\2707683|(aap)-induced (r_compound) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
D000082_D008171 NONE acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity (l_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity
D000082_D008171 NONE acetaminophen_16\NN\2707683|(aap)-induced (r_compound) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) toxicity_23\NN\13576101|amiodarone|lung
D000082_D008171 NONE (aap)-induced_17\NN\1740| (r_dep) acetaminophen_16\NN\2707683|(aap)-induced (r_compound) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) toxicity_23\NN\13576101|amiodarone|lung
D000082_D066126 NONE acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity (l_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract
D000082_D066126 NONE acetaminophen_16\NN\2707683|(aap)-induced (r_compound) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) cardiotoxicity_28\NN\1740|(dox)-induced|mice
D000082_D066126 NONE (aap)-induced_17\NN\1740| (r_dep) acetaminophen_16\NN\2707683|(aap)-induced (r_compound) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) cardiotoxicity_28\NN\1740|(dox)-induced|mice
D000638_D009336 CID amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity (r_nmod) protection_2\NN\407535|in|deaths|nephrotoxicity|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
D000638_D009336 CID ami_11\NN\1740| (r_conj) aap_9\NN\1740|such|,|ami|and|dox (r_nmod) drugs_4\NNS\14778436|all|the|,|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|necrosis|. (l_dobj) necrosis_20\NN\11444117|addition|to|organs|blocked
D000638_D007674 NONE amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity
D000638_D007674 NONE amiodarone_20\NN\2715941|(ami)-induced (r_compound) toxicity_23\NN\13576101|amiodarone|lung (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
D000638_D007674 NONE (ami)-induced_21\JJ\1740| (r_dep) amiodarone_20\NN\2715941|(ami)-induced (r_compound) toxicity_23\NN\13576101|amiodarone|lung (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
D000638_D008171 CID amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity
D000638_D008171 CID amiodarone_20\NN\2715941|(ami)-induced (r_compound) toxicity_23\NN\13576101|amiodarone|lung
D000638_D008171 CID (ami)-induced_21\JJ\1740| (r_dep) amiodarone_20\NN\2715941|(ami)-induced (r_compound) toxicity_23\NN\13576101|amiodarone|lung
D000638_D066126 NONE amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract
D000638_D066126 NONE amiodarone_20\NN\2715941|(ami)-induced (r_compound) toxicity_23\NN\13576101|amiodarone|lung (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) cardiotoxicity_28\NN\1740|(dox)-induced|mice
D000638_D066126 NONE (ami)-induced_21\JJ\1740| (r_dep) amiodarone_20\NN\2715941|(ami)-induced (r_compound) toxicity_23\NN\13576101|amiodarone|lung (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) cardiotoxicity_28\NN\1740|(dox)-induced|mice
D004317_D009336 CID doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract (r_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity (r_nmod) protection_2\NN\407535|in|deaths|nephrotoxicity|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
D004317_D009336 CID dox_13\NN\1740| (r_conj) aap_9\NN\1740|such|,|ami|and|dox (r_nmod) drugs_4\NNS\14778436|all|the|,|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|necrosis|. (l_dobj) necrosis_20\NN\11444117|addition|to|organs|blocked
D004317_D007674 NONE doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract (r_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity
D004317_D007674 NONE doxorubicin_26\NN\2716866| (r_compound) (dox)-induced_27\JJ\1740|doxorubicin (r_nummod) cardiotoxicity_28\NN\1740|(dox)-induced|mice (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
D004317_D007674 NONE (dox)-induced_27\JJ\1740|doxorubicin (r_nummod) cardiotoxicity_28\NN\1740|(dox)-induced|mice (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
D004317_D008171 NONE doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract (r_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity
D004317_D008171 NONE doxorubicin_26\NN\2716866| (r_compound) (dox)-induced_27\JJ\1740|doxorubicin (r_nummod) cardiotoxicity_28\NN\1740|(dox)-induced|mice (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) toxicity_23\NN\13576101|amiodarone|lung
D004317_D008171 NONE (dox)-induced_27\JJ\1740|doxorubicin (r_nummod) cardiotoxicity_28\NN\1740|(dox)-induced|mice (r_conj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) toxicity_23\NN\13576101|amiodarone|lung
D004317_D066126 CID doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract
D004317_D066126 CID doxorubicin_26\NN\2716866| (r_compound) (dox)-induced_27\JJ\1740|doxorubicin (r_nummod) cardiotoxicity_28\NN\1740|(dox)-induced|mice
D004317_D066126 CID (dox)-induced_27\JJ\1740|doxorubicin (r_nummod) cardiotoxicity_28\NN\1740|(dox)-induced|mice
C511402_D009336 NONE extract_29\NN\14589223|by|a|novel|ih636|grape|seed|proanthocyanidin (r_nmod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract (r_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity (r_nmod) protection_2\NN\407535|in|deaths|nephrotoxicity|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
C511402_D009336 NONE gspe_31\NN\1740|by (r_nmod) blocked_29\VBN\1476483|which|was|effectively|gspe (r_acl:relcl) necrosis_20\NN\11444117|addition|to|organs|blocked
C511402_D007674 NONE extract_29\NN\14589223|by|a|novel|ih636|grape|seed|proanthocyanidin (r_nmod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract (r_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity
C511402_D007674 NONE extract_10\NN\14589223|of|ih636|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
C511402_D007674 NONE gspe_12\NN\1740|(|) (r_appos) extract_10\NN\14589223|of|ih636|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity
C511402_D008171 NONE extract_29\NN\14589223|by|a|novel|ih636|grape|seed|proanthocyanidin (r_nmod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract (r_conj) toxicity_18\NN\13576101|amiodarone-induced|lung|and|cardiotoxicity
C511402_D008171 NONE extract_10\NN\14589223|of|ih636|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) toxicity_23\NN\13576101|amiodarone|lung
C511402_D008171 NONE gspe_12\NN\1740|(|) (r_appos) extract_10\NN\14589223|of|ih636|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) toxicity_23\NN\13576101|amiodarone|lung
C511402_D066126 NONE extract_29\NN\14589223|by|a|novel|ih636|grape|seed|proanthocyanidin (r_nmod) cardiotoxicity_21\NN\1740|doxorubicin-induced|extract
C511402_D066126 NONE extract_10\NN\14589223|of|ih636|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) cardiotoxicity_28\NN\1740|(dox)-induced|mice
C511402_D066126 NONE gspe_12\NN\1740|(|) (r_appos) extract_10\NN\14589223|of|ih636|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|acetaminophen|,|toxicity|,|and|cardiotoxicity (l_conj) cardiotoxicity_28\NN\1740|(dox)-induced|mice
C511402_D017695 NONE gspe_30\NN\1740| (r_compound) preexposure_31\NN\1740|of|gspe (r_nmod) absence_28\NN\14449405|in|the|preexposure (r_nmod) revealed_9\VBD\2137132|examination|damage|absence|than|presence|. (l_dobj) damage_14\NN\7296428|moderate|tissue|variety
2440413
D001556_D012640 NONE gamma-hexachlorocyclohexane_3\NN\1740|of|lindane (r_nmod) effects_1\NNS\13245626|differential|gamma-hexachlorocyclohexane|seizures|. (l_nmod) seizures_9\NNS\14081375|on|pharmacologically-induced
D001556_D012640 NONE lindane_5\NN\14919948|(|) (r_appos) gamma-hexachlorocyclohexane_3\NN\1740|of|lindane (r_nmod) effects_1\NNS\13245626|differential|gamma-hexachlorocyclohexane|seizures|. (l_nmod) seizures_9\NNS\14081375|on|pharmacologically-induced
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\NN\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\NN\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_conj) increase_33\VB\169651|conversely|threshold|h|exposure (l_dobj) threshold_34\NN\15265518|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_2\NN\1740|(|) (r_appos) gamma-hexachlorocyclohexane_0\NN\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D001556_D012640 NONE gamma-hch_2\NN\1740|(|) (r_appos) gamma-hexachlorocyclohexane_0\NN\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_conj) increase_33\VB\169651|conversely|threshold|h|exposure (l_dobj) threshold_34\NN\15265518|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE lindane_11\NN\14919948|of|the|insecticide (r_nmod) ingredient_7\NN\3081021|the|active|lindane (r_appos) gamma-hexachlorocyclohexane_0\NN\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D001556_D012640 NONE lindane_11\NN\14919948|of|the|insecticide (r_nmod) ingredient_7\NN\3081021|the|active|lindane (r_appos) gamma-hexachlorocyclohexane_0\NN\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_conj) increase_33\VB\169651|conversely|threshold|h|exposure (l_dobj) threshold_34\NN\15265518|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_30\NN\1740|to (r_nmod) exposure_28\NN\5042871|h|gamma-hch (r_dobj) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D001556_D012640 NONE gamma-hch_30\NN\1740|to (r_nmod) exposure_28\NN\5042871|h|gamma-hch (r_dobj) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_conj) increase_33\VB\169651|conversely|threshold|h|exposure (l_dobj) threshold_34\NN\15265518|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_43\NN\1740|to (r_nmod) exposure_41\NN\5042871|gamma-hch (r_dobj) increase_33\VB\169651|conversely|threshold|h|exposure (r_conj) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D001556_D012640 NONE gamma-hch_43\NN\1740|to (r_nmod) exposure_41\NN\5042871|gamma-hch (r_dobj) increase_33\VB\169651|conversely|threshold|h|exposure (l_dobj) threshold_34\NN\15265518|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_26\NN\1740|of|mg/kg (r_nmod) administration_22\NN\1133281|after|intraperitoneal|gamma-hch (r_nmod) tested_13\VBN\670261|study|,|severity|was|mice|administration|. (l_nsubjpass) severity_5\NN\5036394|the|response (l_nmod) response_7\NN\11410625|of|agents (l_nmod) agents_11\NNS\7347|to|other|seizure-inducing (l_amod) seizure-inducing_10\JJ\1740|
D001556_D012640 NONE gamma-hch_6\NN\1740|of (r_nmod) administration_4\NN\1133281|after|the|gamma-hch (r_nmod) increased_14\VBN\169651|administration|,|activity|was|,|regardless|,|observed|. (l_nsubjpass) activity_9\NN\30358|the|agents (l_nmod) agents_12\NNS\7347|of|seizure-inducing (l_amod) seizure-inducing_11\JJ\1740|
D001556_D012640 NONE gamma-hch_25\NN\1740|after (r_nmod) h_23\NN\14622893|24|gamma-hch (r_nsubj) observed_30\VBN\2163746|while|h|response|was (r_advcl) increased_14\VBN\169651|administration|,|activity|was|,|regardless|,|observed|. (l_nsubjpass) activity_9\NN\30358|the|agents (l_nmod) agents_12\NNS\7347|of|seizure-inducing (l_amod) seizure-inducing_11\JJ\1740|
D001556_D012640 NONE gamma-hch_20\NN\1740|h (r_dobj) occur_8\VB\2623529|that|tolerance|may|activity|gamma-hch|,|decreased (l_nmod) activity_11\NN\30358|to|seizure|induced (l_compound) seizure_10\NN\14081375|
D001556_D012640 NONE gamma-hch_20\NN\1740|h (r_dobj) occur_8\VB\2623529|that|tolerance|may|activity|gamma-hch|,|decreased (l_advcl) decreased_32\VBN\169651|since|response|is (l_nsubjpass) response_24\NN\11410625|the|agents (l_nmod) agents_30\NNS\7347|to|only|these|two|seizure-inducing (l_amod) seizure-inducing_29\JJ\1740|
D001556_D012640 NONE gamma-hch_18\NN\1740| (r_dep) responsible_8\JJ\1740|decrease|h|gamma-hch (l_nmod) decrease_11\NN\7296428|for|the|activity (l_nmod) activity_14\NN\30358|in|seizure (l_compound) seizure_13\NN\14081375|
D010433_D012640 CID ptz_23\NN\1740|(|) (r_appos) pentylenetrazol_21\NN\1740|to|ptz (r_nmod) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D010433_D012640 CID ptz_23\NN\1740|(|) (r_appos) pentylenetrazol_21\NN\1740|to|ptz (r_nmod) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_conj) increase_33\VB\169651|conversely|threshold|h|exposure (l_dobj) threshold_34\NN\15265518|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D010433_D012640 CID ptz-induced_36\JJ\1740| (r_amod) seizures_37\NNS\14081375|to|ptz-induced (r_nmod) threshold_34\NN\15265518|seizures (r_dobj) increase_33\VB\169651|conversely|threshold|h|exposure (r_conj) decrease_17\VB\169651|to|threshold|pentylenetrazol|exposure|and|increase (l_dobj) threshold_19\NN\15265518|seizure (l_compound) seizure_18\NN\14081375|
D010433_D012640 CID ptz-induced_36\JJ\1740| (r_amod) seizures_37\NNS\14081375|to|ptz-induced
D010433_D012640 CID ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D010433_D012640 CID ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_parataxis) different_44\JJ\1740|,|activity|was|not|control|. (l_nsubj) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D010433_D012640 CID ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz (r_acl) activity_11\NN\30358|to|seizure|induced (l_compound) seizure_10\NN\14081375|
D010433_D012640 CID ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz (r_acl) activity_11\NN\30358|to|seizure|induced (r_nmod) occur_8\VB\2623529|that|tolerance|may|activity|gamma-hch|,|decreased (l_advcl) decreased_32\VBN\169651|since|response|is (l_nsubjpass) response_24\NN\11410625|the|agents (l_nmod) agents_30\NNS\7347|to|only|these|two|seizure-inducing (l_amod) seizure-inducing_29\JJ\1740|
D010852_D012640 CID picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D010852_D012640 CID picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_parataxis) different_44\JJ\1740|,|activity|was|not|control|. (l_nsubj) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D010852_D012640 CID ptx_8\NN\1740|(|) (r_appos) picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D010852_D012640 CID ptx_8\NN\1740|(|) (r_appos) picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_parataxis) different_44\JJ\1740|,|activity|was|not|control|. (l_nsubj) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D010852_D012640 CID ptx_16\NN\1740| (r_conj) ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz (r_acl) activity_11\NN\30358|to|seizure|induced (l_compound) seizure_10\NN\14081375|
D010852_D012640 CID ptx_16\NN\1740| (r_conj) ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz (r_acl) activity_11\NN\30358|to|seizure|induced (r_nmod) occur_8\VB\2623529|that|tolerance|may|activity|gamma-hch|,|decreased (l_advcl) decreased_32\VBN\169651|since|response|is (l_nsubjpass) response_24\NN\11410625|the|agents (l_nmod) agents_30\NNS\7347|to|only|these|two|seizure-inducing (l_amod) seizure-inducing_29\JJ\1740|
D015097_D012640 CID acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D015097_D012640 CID acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D015097_D012640 CID mpa_23\NN\1740|(|) (r_appos) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D015097_D012640 CID mpa_23\NN\1740|(|) (r_appos) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D001640_D012640 CID bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D001640_D012640 CID bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D001640_D012640 CID bcc_28\NN\1740|(|) (r_appos) bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D001640_D012640 CID bcc_28\NN\1740|(|) (r_appos) bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
C034818_D012640 CID 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
C034818_D012640 CID 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
C034818_D012640 CID dmcm_34\NN\1740|(|) (r_appos) 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
C034818_D012640 CID dmcm_34\NN\1740|(|) (r_appos) 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D013331_D012640 CID strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D013331_D012640 CID strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D013331_D012640 CID str_40\NN\1740|(|) (r_appos) strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_nsubj) different_44\JJ\1740|,|activity|was|not|control|. (r_parataxis) decreased_12\VBN\169651|activity|was|significantly|;|however|different (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D013331_D012640 CID str_40\NN\1740|(|) (r_appos) strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_compound) seizure_16\NN\14081375|
D005680_D012640 NONE gaba-a_22\NN\1740| (r_nmod:npmod) receptor-linked_23\JJ\1740|gaba-a (r_amod) channel_25\NN\6251781|that|site|may|be|the|receptor-linked|chloride (l_nsubj) site_7\NN\8673395|the|responsible (l_amod) responsible_8\JJ\1740|decrease|h|gamma-hch (l_nmod) decrease_11\NN\7296428|for|the|activity (l_nmod) activity_14\NN\30358|in|seizure (l_compound) seizure_13\NN\14081375|
18182964
D003000_D001289 NONE clonidine_0\NN\2721160|disorder|:|changes (l_nmod) disorder_3\NN\14034177|for|attention-deficit/hyperactivity
D003000_D001289 NONE clonidine_9\NN\2721160|of|used (l_acl) used_10\VBN\1156834|methylphenidate (l_nmod) methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd
D003000_D001289 NONE clonidine_9\NN\2721160|of|used (l_acl) used_10\VBN\1156834|methylphenidate (l_nmod) methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd (l_appos) adhd_21\NN\14304060|(|)
D003000_D001289 NONE clonidine_18\NN\2721160|to|=|,|methylphenidate|,|clonidine|=|,|or|placebo (r_nmod) assigned_16\VBN\2475922|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D003000_D001289 NONE clonidine_32\NN\2721160|and|methylphenidate (r_conj) clonidine_18\NN\2721160|to|=|,|methylphenidate|,|clonidine|=|,|or|placebo (r_nmod) assigned_16\VBN\2475922|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D003000_D001289 NONE clonidine_2\NN\2721160|,|used|, (r_nsubj) appears_10\VBZ\2604760|conclusions|clonidine|safe|. (l_xcomp) safe_11\JJ\1740|and|tolerated|adhd (l_nmod) adhd_17\NN\14304060|in|childhood
D008774_D001289 NONE methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd
D008774_D001289 NONE methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd (l_appos) adhd_21\NN\14304060|(|)
D008774_D001289 NONE methylphenidate_25\NN\4320126|= (r_conj) clonidine_18\NN\2721160|to|=|,|methylphenidate|,|clonidine|=|,|or|placebo (r_nmod) assigned_16\VBN\2475922|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D008774_D001289 NONE methylphenidate_34\NN\4320126| (r_conj) clonidine_32\NN\2721160|and|methylphenidate (r_conj) clonidine_18\NN\2721160|to|=|,|methylphenidate|,|clonidine|=|,|or|placebo (r_nmod) assigned_16\VBN\2475922|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D008774_D001289 NONE methylphenidate_8\NN\4320126|with (r_nmod) used_4\VBN\1156834|methylphenidate (r_acl) clonidine_2\NN\2721160|,|used|, (r_nsubj) appears_10\VBZ\2604760|conclusions|clonidine|safe|. (l_xcomp) safe_11\JJ\1740|and|tolerated|adhd (l_nmod) adhd_17\NN\14304060|in|childhood
D003000_D001919 CID clonidine_12\NN\2721160|with (r_nmod) treated_10\VBN\2376958|clonidine (r_acl) subjects_9\NNS\6598915|in|treated (r_nmod) incidents_5\NNS\7283608|more|bradycardia|subjects|those (l_nmod) bradycardia_7\NN\14110674|of
D003000_D001919 CID clonidine_19\NN\2721160|with (r_nmod) treated_17\VBN\2376958|not|clonidine (r_acl) those_15\DT\1740|compared|with|treated|% (r_nmod) incidents_5\NNS\7283608|more|bradycardia|subjects|those (l_nmod) bradycardia_7\NN\14110674|of
D003000_D001919 CID clonidine_2\NN\2721160| (r_dobj) prescribing_1\VBG\748282|clonidine (r_acl) physicians_0\NNS\10305802|prescribing (r_nsubj) monitor_4\VB\2169352|physicians|should|bradycardia|and|advise|. (l_nmod) bradycardia_6\NN\14110674|for
D003000_D006970 NONE clonidine_4\NN\2721160|on (r_nmod) common_2\JJ\1740|drowsiness|was|clonidine|,|but|resolved|. (l_nsubj) drowsiness_0\NN\14015731|
D003000_D006970 NONE clonidine_2\NN\2721160| (r_dobj) prescribing_1\VBG\748282|clonidine (r_acl) physicians_0\NNS\10305802|prescribing (r_nsubj) monitor_4\VB\2169352|physicians|should|bradycardia|and|advise|. (l_conj) advise_8\VB\813978|patients|likelihood (l_nmod) likelihood_13\NN\4756172|about|the|high|drowsiness (l_nmod) drowsiness_16\NN\14015731|of|initial
8423889
D005473_D009069 CID fluoxetine_5\NN\4169152| (r_compound) medication_6\NN\3247620|after|fluoxetine (r_nmod) increase_0\NN\13576355|disability|medication|. (l_nmod) disability_3\NN\14547369|of|parkinson
D005473_D009069 CID fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|patients|exposure (l_nmod) disability_7\NN\14547369|of|motor
D000928_D009069 NONE antidepressant_20\JJ\1740| (r_amod) fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|patients|exposure (l_nmod) disability_7\NN\14547369|of|motor
D000928_D010300 NONE antidepressant_20\JJ\1740| (r_amod) fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|patients|exposure (l_nmod) patients_10\NNS\9898892|in|four|disease (l_nmod) disease_15\NN\14061805|with|parkinson|'s
D005473_D010300 NONE fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|patients|exposure (l_nmod) patients_10\NNS\9898892|in|four|disease (l_nmod) disease_15\NN\14061805|with|parkinson|'s
D005473_D010300 NONE fluoxetine_9\NN\4169152|of (r_nmod) capacity_7\NN\5202497|of|a|relevant|dopamine-antagonistic|fluoxetine|patients (l_nmod) patients_14\NNS\9898892|in|disease (l_compound) disease_13\NN\14061805|parkinson
D004298_D010300 NONE dopamine-antagonistic_6\JJ\1740| (r_amod) capacity_7\NN\5202497|of|a|relevant|dopamine-antagonistic|fluoxetine|patients (l_nmod) patients_14\NNS\9898892|in|disease (l_compound) disease_13\NN\14061805|parkinson
84204
D002927_D003221 CID cimetidine-associated_7\NN\1740| (r_compound) confusion_9\NN\13972797|with|cimetidine-associated|mental
D002927_D003221 CID cimetidine-associated_3\NN\1740| (r_amod) confusion_5\NN\13972797|of|cimetidine-associated|mental
D002927_D051437 NONE cimetidine_19\NN\14778019| (r_compound) trough-concentrations_20\NNS\1740|cimetidine|microgram/ml (r_conj) dysfunction_8\NN\14204950|renal|p|,|as|trough-concentrations
D002927_D008107 NONE cimetidine_19\NN\14778019| (r_compound) trough-concentrations_20\NNS\1740|cimetidine|microgram/ml (r_conj) dysfunction_8\NN\14204950|renal|p|,|as|trough-concentrations
14976857
D011405_-1 NONE propafenone_5\NN\1740| (r_compound) overdose_6\NN\1740|by|propafenone (r_nmod) induced_3\VBN\1627355|overdose|woman (r_acl) syndrome_2\NN\5870365|transient|platypnea-orthodeoxia-like|induced|.
D011405_D062787 NONE propafenone_5\NN\1740| (r_compound) overdose_6\NN\1740|by|propafenone
D011405_D062787 NONE propafenone_26\NN\1740| (r_compound) overdose_27\NN\1740|by|a|propafenone
D011405_D004437 NONE propafenone_5\NN\1740| (r_compound) overdose_6\NN\1740|by|propafenone (r_nmod) induced_3\VBN\1627355|overdose|woman (l_nmod) woman_10\NN\9605289|in|a|young|anomaly (l_nmod) anomaly_14\NN\14501726|with|ebstein
D011405_D054092 NONE propafenone_26\NN\1740| (r_compound) overdose_27\NN\1740|by|a|propafenone (r_nmod) precipitated_23\VBN\1642924|was|probably|overdose (r_conj) occurred_9\VBD\2623529|shunt|pressure|,|and|precipitated|. (l_nsubj) shunt_1\NN\5248181|this|blood|ovale (l_nmod) ovale_8\NN\1740|via|a|patent|foramen
15009014
D002211_D006940 CID capsaicin_0\NN\15032661|mm|applied (r_nsubj) induced_13\VBD\1627355|capsaicin|increases|and|provoked|. (l_dobj) increases_14\NNS\13576355|flow (l_nmod) flow_20\NN\7311115|in|dural|blood
D001285_D006940 NONE atropine_14\NN\14712692|of|mm|and|tyr6]-vip|, (r_nmod) pre-administration_12\NN\1740|by|topical|atropine (r_nmod) abolished_9\VBN\1740|increases|were|also|pre-administration|mater|. (l_nsubjpass) increases_2\NNS\13576355|the|evoked|flow (l_nmod) flow_6\NN\7311115|in|dural|blood
9698967
D008619_D006973 CID mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_nmod) pressure_4\NN\11419404|in|blood
D008619_D001281 CID mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation
D008619_D011595 NONE mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts
D008619_D019954 NONE mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss
D008619_D014474 NONE mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss (l_conj) loss_16\NN\13252973|consciousness (l_nmod) consciousness_18\NN\5669934|of
D008619_D004387 NONE mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nmod) correction_52\NN\248977|for|contracture (l_nmod) contracture_56\NN\369802|of|dupuytren
D004837_D006973 CID adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_nmod) pressure_4\NN\11419404|in|blood
D004837_D001281 CID adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation
D004837_D011595 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts
D004837_D019954 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss
D004837_D014474 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss (l_conj) loss_16\NN\13252973|consciousness (l_nmod) consciousness_18\NN\5669934|of
D004837_D004387 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mepivacaine_43\NN\1740|with|mg|containing (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) observed_21\VBN\2163746|increase|was|male|,|performance|,|correction|. (l_nmod) correction_52\NN\248977|for|contracture (l_nmod) contracture_56\NN\369802|of|dupuytren
2071257
D005997_D000647 NONE l-alpha-glyceryl-phosphorylcholine_2\NN\1740|of (r_nmod) effect_0\NN\34213|l-alpha-glyceryl-phosphorylcholine|amnesia|. (l_nmod) amnesia_4\NN\5669934|on|caused
D012601_D000647 NONE scopolamine_7\NN\14712692|by (r_nmod) caused_5\VBN\1617192|scopolamine (r_acl) amnesia_4\NN\5669934|on|caused
D005997_D008569 NONE l-alpha-glycerylphosphorylcholine_11\NN\1740|of|l-alpha-gfc (r_nmod) effects_9\NNS\13245626|the|l-alpha-glycerylphosphorylcholine|impairment (l_nmod) impairment_17\NN\7296428|on|memory|induced
D005997_D008569 NONE l-alpha-gfc_13\NN\1740|(|) (r_appos) l-alpha-glycerylphosphorylcholine_11\NN\1740|of|l-alpha-gfc (r_nmod) effects_9\NNS\13245626|the|l-alpha-glycerylphosphorylcholine|impairment (l_nmod) impairment_17\NN\7296428|on|memory|induced
D012601_D008569 CID scopolamine_20\NN\14712692|by|man (r_nmod) induced_18\VBN\1627355|scopolamine (r_acl) impairment_17\NN\7296428|on|memory|induced
D012601_D008569 CID scopolamine_20\NN\14712692|by (r_nmod) induced_18\VBN\1627355|scopolamine (r_acl) impairment_13\NN\7296428|attention|induced (l_nmod) attention_15\NN\5701944|of|and|memory (l_conj) memory_17\NN\5926676|
3719553
D005472_D004342 NONE 5-fluorouracil_3\NN\1740| (r_compound) infusion_4\NN\14589223|to|5-fluorouracil (r_nmod) reaction_1\NN\13446390|allergic|infusion|.
D005472_D004342 NONE 5-fluorouracil_11\NN\1740|to|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting
D005472_D000799 CID 5-fluorouracil_11\NN\1740|to|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary
D005472_D009062 NONE 5-fluorouracil_11\NN\1740|to|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting (r_nsubj) occurred_12\VBD\2623529|reaction|patient|. (l_nmod) patient_15\NN\9898892|in|a|carcinoma (l_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity|,|cirrhosis (l_nmod) cavity_22\NN\9304750|of|the|oral
D005472_D005355 NONE 5-fluorouracil_11\NN\1740|to|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting (r_nsubj) occurred_12\VBD\2623529|reaction|patient|. (l_nmod) patient_15\NN\9898892|in|a|carcinoma (l_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity|,|cirrhosis (l_conj) cirrhosis_24\NN\14116321|,|and|function
D005472_D007674 NONE 5-fluorouracil_11\NN\1740|to|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting (r_nsubj) occurred_12\VBD\2623529|reaction|patient|. (l_nmod) patient_15\NN\9898892|in|a|carcinoma (l_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity|,|cirrhosis (l_conj) cirrhosis_24\NN\14116321|,|and|function (l_conj) function_30\NN\13783581|cisplatin-induced|impaired|renal
D002945_D004342 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function (r_conj) carcinoma_18\NN\14239918|with|recurrent|cavity|,|cirrhosis (r_nmod) patient_15\NN\9898892|in|a|carcinoma (r_nmod) occurred_12\VBD\2623529|reaction|patient|. (l_nsubj) reaction_2\NN\13446390|an|allergic|consisting
D002945_D000799 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function (r_conj) carcinoma_18\NN\14239918|with|recurrent|cavity|,|cirrhosis (r_nmod) patient_15\NN\9898892|in|a|carcinoma (r_nmod) occurred_12\VBD\2623529|reaction|patient|. (l_nsubj) reaction_2\NN\13446390|an|allergic|consisting (l_acl) consisting_3\VBG\2603699|edema (l_nmod) edema_6\NN\14315192|of|angioneurotic|secondary
D002945_D009062 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function (r_conj) carcinoma_18\NN\14239918|with|recurrent|cavity|,|cirrhosis (l_nmod) cavity_22\NN\9304750|of|the|oral
D002945_D005355 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cirrhosis_24\NN\14116321|,|and|function
D002945_D007674 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal
D004155_D004342 NONE diphenhydramine_1\NN\2720725|oral|and|prednisone (r_nsubj) ineffective_5\JJ\1740|diphenhydramine|were|preventing|. (l_advcl) preventing_7\VBG\1740|in|recurrence (l_dobj) recurrence_9\NN\7342049|the|reaction (l_nmod) reaction_13\NN\13446390|of|the|allergic
D011241_D004342 NONE prednisone_3\NN\2721538| (r_conj) diphenhydramine_1\NN\2720725|oral|and|prednisone (r_nsubj) ineffective_5\JJ\1740|diphenhydramine|were|preventing|. (l_advcl) preventing_7\VBG\1740|in|recurrence (l_dobj) recurrence_9\NN\7342049|the|reaction (l_nmod) reaction_13\NN\13446390|of|the|allergic
8739323
D008466_D007674 NONE nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D008466_D007674 NONE ng_10\NN\13717155|(|) (r_appos) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE methotrexate_13\NN\2722166|mtx (r_conj) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE mtx_15\NN\1740|(|) (r_appos) methotrexate_13\NN\2722166|mtx (r_conj) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE mtx_33\NN\1740|[|+|5-fu|] (r_dep) combination_31\NN\7951464|in|mtx (r_conj) administered_27\VBN\2436349|or|combination (r_acl) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE mtx_6\NN\1740|of|+|5-fu|administered (r_nmod) nephrotoxicity_4\NN\1740|mtx
D005472_D007674 NONE 5-fluorouracil_18\NN\1740|5-fu (r_conj) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D005472_D007674 NONE 5-fu_20\NN\1740|(|) (r_appos) 5-fluorouracil_18\NN\1740|5-fu (r_conj) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D005472_D007674 NONE 5-fu_35\NN\1740|+|cy (r_conj) mtx_33\NN\1740|[|+|5-fu|] (r_dep) combination_31\NN\7951464|in|mtx (r_conj) administered_27\VBN\2436349|or|combination (r_acl) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D005472_D007674 NONE 5-fu_8\NN\1740|+|cy (r_conj) mtx_6\NN\1740|of|+|5-fu|administered (r_nmod) nephrotoxicity_4\NN\1740|mtx
D003520_D007674 NONE cyclophosphamide_23\NN\1740|cy (r_conj) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D003520_D007674 NONE cy_25\NN\1740|(|) (r_appos) cyclophosphamide_23\NN\1740|cy (r_conj) nitrogranulogen_8\NN\1740|such|ng|,|methotrexate|,|5-fluorouracil|and|cyclophosphamide (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D003520_D007674 NONE cy_37\NN\1740|cmf (r_conj) 5-fu_35\NN\1740|+|cy (r_conj) mtx_33\NN\1740|[|+|5-fu|] (r_dep) combination_31\NN\7951464|in|mtx (r_conj) administered_27\VBN\2436349|or|combination (r_acl) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen|administered (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs (l_amod) nephrotoxic_1\JJ\1740|
D003520_D007674 NONE cy_10\NN\1740| (r_conj) 5-fu_8\NN\1740|+|cy (r_conj) mtx_6\NN\1740|of|+|5-fu|administered (r_nmod) nephrotoxicity_4\NN\1740|mtx
D003520_D006470 CID cy_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D003520_D003556 CID cy_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D005472_D006470 NONE 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D005472_D003556 NONE 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D008727_D006470 NONE mtx_22\NN\1740| (r_conj) 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D008727_D003556 NONE mtx_22\NN\1740| (r_conj) 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined|. (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause (l_dobj) cystitis_3\NN\14566129|hemorrhagic
20196116
D000995_D017114 CID antituberculosis_0\NN\1740| (r_nmod:npmod) therapy-induced_1\JJ\1740|antituberculosis (r_amod) failure_4\NN\66216|therapy-induced|acute|liver|:|magnitude
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) therapy_1\NN\657604|antituberculosis (r_compound) (att)-associated_2\NN\1740|therapy (r_nummod) failure_5\NN\66216|(att)-associated|acute|liver|att-alf
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) therapy_1\NN\657604|antituberculosis (r_compound) (att)-associated_2\NN\1740|therapy (r_nummod) failure_5\NN\66216|(att)-associated|acute|liver|att-alf (l_appos) att-alf_7\NN\1740|(|)
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) therapy_1\NN\657604|antituberculosis (r_compound) (att)-associated_2\NN\1740|therapy (r_nummod) failure_5\NN\66216|(att)-associated|acute|liver|att-alf (r_nsubj) alf_13\NN\1740|failure|is|the|commonest|drug-induced|asia|.
D001663_D001927 NONE bilirubin_11\NN\14756039|serum|mg/dl|)|,|prolongation|,|and|encephalopathy (l_conj) encephalopathy_33\NN\14084880|grade|iii/iv|presentation
15863244
C106876_D064420 NONE dfu_15\NN\1740|and|piroxicam (r_dep) comparison_0\NN\635850|toxicity|rats|dfu|study|. (l_nmod) toxicity_3\NN\13576101|of|developmental|inhibitors
C106876_D064420 NONE dfu_20\NN\1740|(|;|inhibitors (r_dep) selective_18\JJ\1740|dfu (r_conj) non-selective_13\JJ\1740|of|the|piroxicam|and|selective (r_nmod) toxicity_10\NN\13576101|the|developmental|non-selective
C106876_D064420 NONE phenyl-2(5h)-furanon_24\NN\1740|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl|)|) (r_compound) inhibitors_27\NNS\20090|phenyl-2(5h)-furanon|cox-2 (r_appos) dfu_20\NN\1740|(|;|inhibitors (r_dep) selective_18\JJ\1740|dfu (r_conj) non-selective_13\JJ\1740|of|the|piroxicam|and|selective (r_nmod) toxicity_10\NN\13576101|the|developmental|non-selective
C106876_D064420 NONE dfu_10\NN\1740| (r_compound) toxicity_12\NN\13576101|of|the|dfu|developmental|observed
D010894_D064420 NONE piroxicam_17\NN\3828465| (r_conj) dfu_15\NN\1740|and|piroxicam (r_dep) comparison_0\NN\635850|toxicity|rats|dfu|study|. (l_nmod) toxicity_3\NN\13576101|of|developmental|inhibitors
D010894_D064420 NONE piroxicam_15\NN\3828465|(|) (r_dep) non-selective_13\JJ\1740|of|the|piroxicam|and|selective (r_nmod) toxicity_10\NN\13576101|the|developmental|non-selective
D010894_D064420 NONE piroxicam_26\NN\3828465|of (r_nmod) dose_24\NN\3740161|with|the|highest|piroxicam (r_nmod) treated_20\VBN\2376958|dose (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) found_17\VBN\2426171|toxicity|were|rats|. (l_nsubjpass) toxicity_3\NN\13576101|maternal|,|retardation|,|and|increase
D010894_D006345 NONE piroxicam_23\NN\3828465|to|,|inhibitor (r_nmod) exposed_21\VBN\2110927|piroxicam|data (r_acl) fetuses_20\NNS\1471682|for|rat|exposed (r_nmod) performed_17\VBN\2367363|analysis|was|fetuses|. (l_nsubjpass) analysis_3\NN\633864|the|pooled|statistical|septal (l_nmod) septal_6\JJ\1740|for|ventricular|vsd|and|midline|defects (l_dep) defects_15\NNS\14462666|
D010894_D009436 NONE piroxicam_23\NN\3828465|to|,|inhibitor (r_nmod) exposed_21\VBN\2110927|piroxicam|data (r_acl) fetuses_20\NNS\1471682|for|rat|exposed (r_nmod) performed_17\VBN\2367363|analysis|was|fetuses|. (l_nsubjpass) analysis_3\NN\633864|the|pooled|statistical|septal (l_nmod) septal_6\JJ\1740|for|ventricular|vsd|and|midline|defects (l_dep) defects_15\NNS\14462666|
D010894_D005317 CID piroxicam_26\NN\3828465|of (r_nmod) dose_24\NN\3740161|with|the|highest|piroxicam (r_nmod) treated_20\VBN\2376958|dose (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) found_17\VBN\2426171|toxicity|were|rats|. (l_nsubjpass) toxicity_3\NN\13576101|maternal|,|retardation|,|and|increase (l_conj) retardation_7\NN\7296428|intrauterine|growth
D010894_D009139 CID piroxicam_26\NN\3828465|of (r_nmod) dose_24\NN\3740161|with|the|highest|piroxicam (r_nmod) treated_20\VBN\2376958|dose (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) found_17\VBN\2426171|toxicity|were|rats|. (l_nsubjpass) toxicity_3\NN\13576101|maternal|,|retardation|,|and|increase (l_conj) increase_10\NN\13576355|variations (l_nmod) variations_15\NNS\7296428|of|external
20698227
D012254_D000743 NONE ribavirin_8\NN\2725367| (r_nmod:npmod) associated_9\JJ\1740|ribavirin (r_amod) anemia_11\NN\14189204|for|associated|hemolytic
D012254_D006461 NONE ribavirin_3\NN\2725367| (r_nsubjpass) found_6\VBN\2426171|background/aims|:|recently|ribavirin|has|been|inhibit|and|found (l_conj) found_23\VBN\2426171|number|have|been|cause|. (l_xcomp) cause_25\VB\1617192|to|hemolysis (l_dobj) hemolysis_27\NN\13509528|acute
C473478_D006461 CID sunitinib_18\NN\1740|such|and|sorafenib (r_nmod) inhibitors_15\NNS\20090|of|angiogenesis|sunitinib (r_nmod) number_12\NN\5107765|a|inhibitors (r_nsubjpass) found_23\VBN\2426171|number|have|been|cause|. (l_xcomp) cause_25\VB\1617192|to|hemolysis (l_dobj) hemolysis_27\NN\13509528|acute
C471405_D006461 CID sorafenib_20\NN\1740| (r_conj) sunitinib_18\NN\1740|such|and|sorafenib (r_nmod) inhibitors_15\NNS\20090|of|angiogenesis|sunitinib (r_nmod) number_12\NN\5107765|a|inhibitors (r_nsubjpass) found_23\VBN\2426171|number|have|been|cause|. (l_xcomp) cause_25\VB\1617192|to|hemolysis (l_dobj) hemolysis_27\NN\13509528|acute
C100416_D019698 NONE 2a_16\NN\1740|by|alpha|and|ribavirin (r_nmod) treated_11\VBN\2376958|methods|patients|were|2a|. (l_nsubjpass) patients_3\NNS\9898892|fourteen|infected (l_acl) infected_5\VBN\2316868|chronically|virus (l_nmod) virus_9\NN\9312843|with|hepatitis|c
D012254_D019698 NONE ribavirin_18\NN\2725367| (r_conj) 2a_16\NN\1740|by|alpha|and|ribavirin (r_nmod) treated_11\VBN\2376958|methods|patients|were|2a|. (l_nsubjpass) patients_3\NNS\9898892|fourteen|infected (l_acl) infected_5\VBN\2316868|chronically|virus (l_nmod) virus_9\NN\9312843|with|hepatitis|c
D012254_D019698 NONE ribavirin_18\NN\2725367| (r_nmod:npmod) induced_19\JJ\1740|ribavirin (r_amod) anemia_20\NN\14189204|induced|patients (l_nmod) patients_22\NNS\9898892|in|c (l_nmod) c_25\NN\13714184|with|hepatitis
D012254_D000740 NONE ribavirin_18\NN\2725367| (r_nmod:npmod) induced_19\JJ\1740|ribavirin (r_amod) anemia_20\NN\14189204|induced|patients
3985451
D014859_D006470 NONE warfarin-induced_0\JJ\1740| (r_nummod) hemorrhage_2\NN\14285662|warfarin-induced|iliopsoas|palsy|.
D014859_D020428 CID warfarin-induced_0\JJ\1740| (r_nummod) hemorrhage_2\NN\14285662|warfarin-induced|iliopsoas|palsy|. (l_nmod) palsy_7\NN\14557898|with|subsequent|nerve
D014859_D020428 CID warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (l_nsubj) palsy_3\NN\14557898|anticoagulant-induced|nerve
D014859_D009135 CID warfarin_10\NN\2718259| (r_compound) therapy_11\NN\657604|on|chronic|warfarin (r_nmod) man_7\NN\9605289|of|a|28-year-old|therapy|sustained (l_acl:relcl) sustained_13\VBD\2679899|who|tear|and|developed (l_dobj) tear_17\NN\13771404|a|minor|muscle
D014859_D010146 NONE warfarin_10\NN\2718259| (r_compound) therapy_11\NN\657604|on|chronic|warfarin (r_nmod) man_7\NN\9605289|of|a|28-year-old|therapy|sustained (l_acl:relcl) sustained_13\VBD\2679899|who|tear|and|developed (l_conj) developed_19\VBD\1753788|pain (l_dobj) pain_21\NN\14299637|increasing|and|contracture
D014859_D010146 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (r_ccomp) characterized_16\VBN\609683|represents|;|it|is|pain|. (l_nmod) pain_19\NN\14299637|by|severe|region|,|degrees|,|and|contracture
D014859_D003286 NONE warfarin_10\NN\2718259| (r_compound) therapy_11\NN\657604|on|chronic|warfarin (r_nmod) man_7\NN\9605289|of|a|28-year-old|therapy|sustained (l_acl:relcl) sustained_13\VBD\2679899|who|tear|and|developed (l_conj) developed_19\VBD\1753788|pain (l_dobj) pain_21\NN\14299637|increasing|and|contracture (l_conj) contracture_25\NN\369802|a|flexure|hip
D014859_D003286 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (r_ccomp) characterized_16\VBN\609683|represents|;|it|is|pain|. (l_nmod) pain_19\NN\14299637|by|severe|region|,|degrees|,|and|contracture (l_conj) contracture_35\NN\369802|flexure|extremity
D014859_D010523 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral
D014859_D015417 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (r_ccomp) characterized_16\VBN\609683|represents|;|it|is|pain|. (l_nmod) pain_19\NN\14299637|by|severe|region|,|degrees|,|and|contracture (l_conj) degrees_26\NNS\4916342|varying|impairment (l_nmod) impairment_31\NN\7296428|of|motor
8092427
D000658_D004342 CID amoxicillin_4\NN\3910033|to (r_nmod) reactions_2\NNS\13446390|immediate|allergic|amoxicillin|.
D000658_D004342 CID amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|amoxicillin (r_dobj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_nsubj) patients_26\NNS\9898892|allergic (l_amod) allergic_27\JJ\1740|antibiotics
D000658_D004342 CID amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|amoxicillin (l_amod) immediate_33\JJ\1740|allergic (l_dep) allergic_34\JJ\1740|
D000658_D004342 CID ax_39\NN\3265032|(|) (r_appos) amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|amoxicillin (r_dobj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_nsubj) patients_26\NNS\9898892|allergic (l_amod) allergic_27\JJ\1740|antibiotics
D000658_D004342 CID ax_39\NN\3265032|(|) (r_appos) amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|amoxicillin (l_amod) immediate_33\JJ\1740|allergic (l_dep) allergic_34\JJ\1740|
D000658_D004342 CID ax_11\NN\3265032| (r_compound) allergy_12\NN\14533203|of|immediate|ax
D000658_D004342 CID ax_3\NN\3265032|with (r_nmod) tests_1\NNS\5798043|challenge|ax (r_nsubjpass) performed_5\VBN\2367363|tests|were|subjects|establish|,|and|cases (l_advcl) establish_14\VB\2426171|to|diagnosis (l_dobj) diagnosis_16\NN\152018|the|reaction (l_nmod) reaction_20\NN\13446390|of|immediate|allergic|ax
D000658_D004342 CID ax_22\NN\3265032|to (r_nmod) reaction_20\NN\13446390|of|immediate|allergic|ax
D000658_D004342 CID ax_38\NN\3265032|for (r_nmod) rast_36\NN\1740|ax (r_conj) test_34\NN\5798043|both|skin|and|rast (r_nsubj) negative_40\JJ\1740|test|were|. (r_acl:relcl) cases_27\NNS\7283608|in|15|(|%|)|negative (r_nmod) performed_5\VBN\2367363|tests|were|subjects|establish|,|and|cases (l_advcl) establish_14\VB\2426171|to|diagnosis (l_dobj) diagnosis_16\NN\152018|the|reaction (l_nmod) reaction_20\NN\13446390|of|immediate|allergic|ax
D000658_D004342 CID ax-allergic_6\JJ\1740|
D047090_D004342 NONE beta-lactam_10\NN\1740| (r_compound) antibiotics_11\NNS\2716205|to|beta-lactam (r_nmod) reactions_8\NNS\13446390|with|suspected|allergic|antibiotics
D047090_D004342 NONE beta-lactam_29\NN\1740| (r_compound) antibiotics_30\NNS\2716205|to|beta-lactam (r_nmod) allergic_27\JJ\1740|antibiotics
D047090_D004342 NONE beta-lactam_29\NN\1740| (r_compound) antibiotics_30\NNS\2716205|to|beta-lactam (r_nmod) allergic_27\JJ\1740|antibiotics (r_amod) patients_26\NNS\9898892|allergic (r_nsubj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_dobj) responses_35\NNS\11410625|selective|immediate|amoxicillin (l_amod) immediate_33\JJ\1740|allergic (l_dep) allergic_34\JJ\1740|
D047090_D004342 NONE beta-lactam_10\NN\1740| (r_compound) antibiotics_11\NNS\2716205|to|beta-lactam (r_nmod) allergic_8\JJ\1740|antibiotics
D010406_D004342 NONE penicillin_46\NN\2716866| (r_compound) derivatives_47\NNS\5802185|with|other|penicillin (r_nmod) cross-reacting_43\VBG\1740|were|derivatives (r_conj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_nsubj) patients_26\NNS\9898892|allergic (l_amod) allergic_27\JJ\1740|antibiotics
D010406_D004342 NONE penicillin_46\NN\2716866| (r_compound) derivatives_47\NNS\5802185|with|other|penicillin (r_nmod) cross-reacting_43\VBG\1740|were|derivatives (r_conj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_dobj) responses_35\NNS\11410625|selective|immediate|amoxicillin (l_amod) immediate_33\JJ\1740|allergic (l_dep) allergic_34\JJ\1740|
D010400_D004342 NONE pg_17\NN\1740|of (r_nmod) tolerance_15\NN\5032565|with|good|pg (r_nmod) cases_8\NNS\7283608|the|%|allergy|tolerance (l_nmod) allergy_12\NN\14533203|of|immediate|ax
D010400_D004342 NONE pg_11\NN\1740| (r_dobj) tolerated_10\VBN\802318|who|have|pg|reported (r_acl:relcl) patients_7\NNS\9898892|of|ax-allergic|tolerated (l_amod) ax-allergic_6\JJ\1740|
-1_D007645 NONE bpo_8\NN\1740|to (r_nmod) negative_6\JJ\1740|patients|were|test|bpo|;|negative (l_parataxis) negative_19\JJ\1740|51|were|also|mdm|,|and|46|pg|. (l_nmod) mdm_21\NN\1740|to
D010400_D007645 NONE pg_32\NN\1740|to (r_nmod) negative_19\JJ\1740|51|were|also|mdm|,|and|46|pg|. (l_nmod) mdm_21\NN\1740|to
2054792
D004317_D005334 NONE adriamycin_2\NN\1740|of|combined (l_acl) combined_3\VBN\2630189|hyperthermia (l_nmod) hyperthermia_7\NN\14034177|with|body
D004317_D005334 NONE adriamycin-mediated_3\JJ\1740| (r_amod) activity_5\NN\30358|of|adriamycin-mediated|antitumor (r_nmod) enhancement_1\NN\248977|thermal|activity|and|toxicities|hyperthermia (l_nmod) hyperthermia_13\NN\14034177|by|body
D004317_D005334 NONE adriamycin-mediated_13\JJ\1740| (r_amod) activity_15\NN\30358|both|adriamycin-mediated|antitumor|and|effects (r_dobj) enhanced_11\VBD\227165|hyperthermia|activity|. (l_nsubj) hyperthermia_2\NN\14034177|body|min
D004317_D005334 NONE adriamycin-mediated_7\JJ\1740| (r_amod) effect_9\NN\34213|adriamycin-mediated|antitumor (r_dobj) enhances_6\VBZ\227165|while|hyperthermia|effect (l_nsubj) hyperthermia_5\NN\14034177|body
D004317_D009369 NONE adriamycin_2\NN\1740|of|combined (r_nmod) effect_0\NN\34213|adriamycin|tumor|. (l_nmod) tumor_9\NN\14234074|on|and|tissues
D004317_D064420 NONE adriamycin-mediated_3\JJ\1740| (r_amod) activity_5\NN\30358|of|adriamycin-mediated|antitumor (r_nmod) enhancement_1\NN\248977|thermal|activity|and|toxicities|hyperthermia (l_conj) toxicities_9\NNS\13576101|normal|tissue
D004317_D064420 NONE adriamycin-mediated_7\JJ\1740| (r_amod) effect_9\NN\34213|adriamycin-mediated|antitumor (r_dobj) enhances_6\VBZ\227165|while|hyperthermia|effect (r_advcl) increased_16\VBN\169651|thus|,|enhances|,|toxicity|is|also|,|and|eroded (l_nsubjpass) toxicity_13\NN\13576101|normal|tissue
16787750
D014635_D001927 CID acid_1\NN\14818238|valproic (r_nmod:npmod) induced_2\JJ\1740|acid (r_amod) encephalopathy--19_3\:\1740|induced
D014635_D001927 CID vpa-therapy_18\NN\1740|to (r_nmod:npmod) only_20\RB\1740|vpa-therapy|not (r_advmod) associated_16\VBN\628491|only|children (r_acl) effect_15\NN\34213|-a|side|associated (r_appos) cases_5\NNS\7283608|encephalopathy--19|new|germany|1994|-|effect|. (l_nummod) encephalopathy--19_3\:\1740|induced
D014635_D001927 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|and|encephalopathy (l_conj) encephalopathy_21\NN\14084880|vpa-induced
D014635_D001927 CID vpa-induced_20\JJ\1740| (r_amod) encephalopathy_21\NN\14084880|vpa-induced
D014635_D001927 CID vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced
D014635_D001927 CID vpa_9\NN\1740|of (r_nmod) effect_7\NN\34213|of|causative|vpa|patients|,|but|association (l_nmod) patients_11\NNS\9898892|in|encephalopathy (l_nmod) encephalopathy_13\NN\14084880|with
D014635_D001927 CID vpa-associated_5\JJ\1740| (r_amod) encephalopathy_6\NN\14084880|with|vpa-associated
D014635_D010195 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|and|encephalopathy
D014635_D010195 CID vpa-induced_20\JJ\1740| (r_amod) encephalopathy_21\NN\14084880|vpa-induced (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|and|encephalopathy
D014635_D001855 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|and|encephalopathy (l_conj) suppression_15\NN\13489037|bone|marrow
D014635_D001855 CID vpa-induced_20\JJ\1740| (r_amod) encephalopathy_21\NN\14084880|vpa-induced (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|and|encephalopathy (l_conj) suppression_15\NN\13489037|bone|marrow
D014635_D056486 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced
D014635_D056486 CID vpa-induced_20\JJ\1740| (r_amod) encephalopathy_21\NN\14084880|vpa-induced (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|and|encephalopathy (l_conj) hepatotoxicity_18\NN\1740|vpa-induced
D014635_D003244 CID vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced (r_nmod) signs_2\NNS\6643763|the|typical|encephalopathy (r_nsubj) consciousness_8\NN\5669934|signs|are|impaired|,|slowing|,|frequency|,|with|hyperammonemia|.
D014635_D012640 NONE vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced (r_nmod) signs_2\NNS\6643763|the|typical|encephalopathy (r_nsubj) consciousness_8\NN\5669934|signs|are|impaired|,|slowing|,|frequency|,|with|hyperammonemia|. (l_appos) frequency_18\NN\15286249|increased|seizure (l_compound) seizure_17\NN\14081375|
D014635_D022124 NONE vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced (r_nmod) signs_2\NNS\6643763|the|typical|encephalopathy (r_nsubj) consciousness_8\NN\5669934|signs|are|impaired|,|slowing|,|frequency|,|with|hyperammonemia|. (l_appos) hyperammonemia_23\NN\1740|
6203452
D002945_D002277 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_nsubj) patients_1\NNS\9898892|five|carcinoma (l_nmod) carcinoma_3\NN\14239918|with
D002945_D057049 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized
D002945_D051437 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia
D002945_D051437 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (r_nmod) ascribed_28\VBN\670261|because|failure|may|be|nephrotoxicity (l_nsubjpass) failure_25\NN\66216|renal
D002945_D000743 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia
D002945_D013921 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\NN\14189204|usually
D002945_D013921 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (l_conj) anemia_34\NN\14189204|the|and|thrombocytopenia|suppression (l_conj) thrombocytopenia_36\NN\14189204|
D001761_D002277 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_nsubj) patients_1\NNS\9898892|five|carcinoma (l_nmod) carcinoma_3\NN\14239918|with
D001761_D057049 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized
D001761_D051437 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia
D001761_D000743 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia
D001761_D013921 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\NN\14189204|usually
D014748_D002277 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_nsubj) patients_1\NNS\9898892|five|carcinoma (l_nmod) carcinoma_3\NN\14239918|with
D014748_D057049 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized
D014748_D051437 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia
D014748_D000743 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia
D014748_D013921 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_acl) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\NN\14189204|usually
D002945_D007674 CID cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia
D002945_D000740 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (l_conj) anemia_34\NN\14189204|the|and|thrombocytopenia|suppression
D002945_D001855 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (l_conj) anemia_34\NN\14189204|the|and|thrombocytopenia|suppression (l_nmod) suppression_41\NN\13489037|to|drug-induced|bone|marrow
6747681
D002330_D005910 NONE bcnu_1\NN\1740| (r_compound) chemotherapy_2\NN\661091|intra-arterial|bcnu|treatment|. (l_nmod) treatment_4\NN\654885|for|gliomas (l_nmod) gliomas_7\NNS\14236743|of|malignant|system
D002330_D005910 NONE bcnu_7\NN\1740|of|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_nmod) clearance_5\NN\5089947|because|the|systemic|bcnu (r_nmod) provide_15\VB\2199590|clearance|,|administration|should|advantage|. (l_dobj) advantage_18\NN\5154517|a|substantial|administration (l_nmod) administration_21\NN\1133281|over|intravenous|treatment (l_nmod) treatment_24\NN\654885|for|the|gliomas (l_nmod) gliomas_27\NNS\14236743|of|malignant
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\1740|(|) (r_appos) bcnu_7\NN\1740|of|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_nmod) clearance_5\NN\5089947|because|the|systemic|bcnu (r_nmod) provide_15\VB\2199590|clearance|,|administration|should|advantage|. (l_dobj) advantage_18\NN\5154517|a|substantial|administration (l_nmod) administration_21\NN\1133281|over|intravenous|treatment (l_nmod) treatment_24\NN\654885|for|the|gliomas (l_nmod) gliomas_27\NNS\14236743|of|malignant
D002330_D001254 NONE bcnu_25\NN\1740| (r_compound) therapy_26\NN\657604|of|intra-arterial|bcnu (r_nmod) courses_22\NNS\883297|eight|therapy (r_dobj) received_18\VBD\2210855|patients|courses|. (l_nsubj) patients_1\NNS\9898892|twenty-four|astrocytomas|, (l_nmod) astrocytomas_8\NNS\1740|with|recurrent|grade|,|failed
D000431_D014786 NONE ethanol_11\NN\14708720| (r_compound) diluent_12\NN\14778436|of|the|ethanol (r_nmod) concentration_8\NN\4916342|the|diluent (r_nsubjpass) lowered_14\VBN\1850315|after|concentration|was (r_advcl) decreased_5\VBD\169651|frequency|lowered|. (l_nsubj) frequency_1\NN\15286249|the|loss (l_nmod) loss_4\NN\13252973|of|visual
18261172
D020123_D011507 CID sirolimus-based_6\NN\1740| (r_compound) immunosuppression_7\NN\13973990|to|sirolimus-based (r_nmod) switch_4\NN\3096960|after|immunosuppression|patients (r_nmod) development_0\NN\248977|proteinuria|switch|. (l_nmod) proteinuria_2\NN\14299637|of
D020123_D011507 CID sirolmus_7\NN\1740|srl (r_dep) drug_6\NN\14778436|the|novel|immunosuppressive|)|sirolmus (r_nsubj) lacks_11\VBZ\1740|drug|effects|;|reported (l_parataxis) reported_23\VBN\831651|however|,|proteinuria|has|been|transplantation|. (l_nsubjpass) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_9\NN\1740|(|) (r_appos) sirolmus_7\NN\1740|srl (r_dep) drug_6\NN\14778436|the|novel|immunosuppressive|)|sirolmus (r_nsubj) lacks_11\VBZ\1740|drug|effects|;|reported (l_parataxis) reported_23\VBN\831651|however|,|proteinuria|has|been|transplantation|. (l_nsubjpass) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_20\NN\1740|with (r_nmod) associated_18\VBN\628491|srl (r_acl) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_10\NN\1740|with (r_nmod) associated_8\VBN\628491|srl (r_acl) proteinuria_7\NN\14299637|of|associated
D020123_D011507 CID srl_12\NN\1740|to (r_nmod) switch_10\NN\3096960|after|srl|,|have (r_nmod) develop_4\VB\1753788|thus|,|proteinuria|may|patients|switch|. (l_nsubj) proteinuria_2\NN\14299637|
D020123_D011507 CID srl_0\NN\1740| (r_nsubjpass) used_3\VBN\1156834|srl|should|be|therapy|and|monitored (l_conj) monitored_9\VBN\2169352|patients|proteinuria|. (l_nmod) proteinuria_11\NN\14299637|for|and|dysfunction
D020123_D007674 NONE sirolmus_7\NN\1740|srl (r_dep) drug_6\NN\14778436|the|novel|immunosuppressive|)|sirolmus (r_nsubj) lacks_11\VBZ\1740|drug|effects|;|reported (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\1740|
D020123_D007674 NONE srl_9\NN\1740|(|) (r_appos) sirolmus_7\NN\1740|srl (r_dep) drug_6\NN\14778436|the|novel|immunosuppressive|)|sirolmus (r_nsubj) lacks_11\VBZ\1740|drug|effects|;|reported (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\1740|
D020123_D007674 NONE srl_20\NN\1740|with (r_nmod) associated_18\VBN\628491|srl (r_acl) proteinuria_17\NN\14299637|associated (r_nsubjpass) reported_23\VBN\831651|however|,|proteinuria|has|been|transplantation|. (r_parataxis) lacks_11\VBZ\1740|drug|effects|;|reported (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\1740|
D020123_D007674 NONE srl_0\NN\1740| (r_nsubjpass) used_3\VBN\1156834|srl|should|be|therapy|and|monitored (l_conj) monitored_9\VBN\2169352|patients|proteinuria|. (l_nmod) proteinuria_11\NN\14299637|for|and|dysfunction (l_conj) dysfunction_15\NN\14204950|increased|renal
D000806_D011507 NONE inhibitor_1\NN\20090|ace|and|blocker (r_compound) therapy_8\NN\657604|inhibitor (r_nsubj) reduced_9\VBD\441445|therapy|development|. (l_dobj) development_11\NN\248977|proteinuria (l_compound) proteinuria_10\NN\14299637|
D000806_D011507 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb (r_nmod) used_3\VBN\1156834|srl|should|be|therapy|and|monitored (l_conj) monitored_9\VBN\2169352|patients|proteinuria|. (l_nmod) proteinuria_11\NN\14299637|for|and|dysfunction
D057911_D011507 NONE blocker_4\NN\10101634|angiotensin-releasing|arb (r_conj) inhibitor_1\NN\20090|ace|and|blocker (r_compound) therapy_8\NN\657604|inhibitor (r_nsubj) reduced_9\VBD\441445|therapy|development|. (l_dobj) development_11\NN\248977|proteinuria (l_compound) proteinuria_10\NN\14299637|
D057911_D011507 NONE arb_6\NN\9882007|(|) (r_appos) blocker_4\NN\10101634|angiotensin-releasing|arb (r_conj) inhibitor_1\NN\20090|ace|and|blocker (r_compound) therapy_8\NN\657604|inhibitor (r_nsubj) reduced_9\VBD\441445|therapy|development|. (l_dobj) development_11\NN\248977|proteinuria (l_compound) proteinuria_10\NN\14299637|
D057911_D011507 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb (r_nmod) used_3\VBN\1156834|srl|should|be|therapy|and|monitored (l_conj) monitored_9\VBN\2169352|patients|proteinuria|. (l_nmod) proteinuria_11\NN\14299637|for|and|dysfunction
D000806_D007674 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb (r_nmod) used_3\VBN\1156834|srl|should|be|therapy|and|monitored (l_conj) monitored_9\VBN\2169352|patients|proteinuria|. (l_nmod) proteinuria_11\NN\14299637|for|and|dysfunction (l_conj) dysfunction_15\NN\14204950|increased|renal
D057911_D007674 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb (r_nmod) used_3\VBN\1156834|srl|should|be|therapy|and|monitored (l_conj) monitored_9\VBN\2169352|patients|proteinuria|. (l_nmod) proteinuria_11\NN\14299637|for|and|dysfunction (l_conj) dysfunction_15\NN\14204950|increased|renal
7088431
D004054_D018262 CID des-exposed_6\JJ\1740| (r_amod) offspring_7\NN\10235549|in|des-exposed (r_nmod) development_0\NN\248977|adenocarcinoma|offspring|observation|. (l_nmod) adenocarcinoma_4\NN\14242337|of|clear|cell
D004054_D018262 CID diethylstilbestrol_19\NN\14749794|to (r_nmod) exposed_15\VBN\2110927|utero|diethylstilbestrol (r_acl) women_14\NNS\9605289|in|young|exposed (r_nmod) detected_9\VBN\2163746|follow-up|women (r_acl) cases_1\NNS\7283608|two|adenocarcinoma|detected (l_nmod) adenocarcinoma_5\NN\14242337|of|clear|cell|vagina (l_nmod) vagina_8\NN\5250659|of|the
D004054_D014625 CID diethylstilbestrol_19\NN\14749794|to (r_nmod) exposed_15\VBN\2110927|utero|diethylstilbestrol (r_acl) women_14\NNS\9605289|in|young|exposed (r_nmod) detected_9\VBN\2163746|follow-up|women (r_acl) cases_1\NNS\7283608|two|adenocarcinoma|detected (l_nmod) adenocarcinoma_5\NN\14242337|of|clear|cell|vagina (l_nmod) vagina_8\NN\5250659|of|the
10365197
D003042_D019964 CID cocaine-induced_0\JJ\1740| (r_amod) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|.
D003042_D019964 CID cocaine-dependent_12\JJ\1740| (r_amod) sample_13\NN\5820620|in|an|outpatient|cocaine-dependent (r_nmod) rates_5\NNS\13308999|prevalence|and|symptoms|sample (r_appos) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|.
D003042_D019964 CID cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder
D003042_D019964 CID cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorders_13\NNS\14034177|other|mood
D003042_D019964 CID cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorder_18\NN\14034177|no|mood
D003042_D019964 CID cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder
D003042_D019964 CID cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorders_13\NNS\14034177|other|mood
D003042_D019964 CID cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorder_18\NN\14034177|no|mood
D003042_D001523 NONE cocaine-induced_0\JJ\1740| (r_amod) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|. (l_appos) rates_5\NNS\13308999|prevalence|and|symptoms|sample (l_conj) symptoms_8\NNS\5823932|psychiatric (l_amod) psychiatric_7\JJ\1740|
D003042_D001523 NONE cocaine-dependent_12\JJ\1740| (r_amod) sample_13\NN\5820620|in|an|outpatient|cocaine-dependent (r_nmod) rates_5\NNS\13308999|prevalence|and|symptoms|sample (l_conj) symptoms_8\NNS\5823932|psychiatric (l_amod) psychiatric_7\JJ\1740|
D003042_D001523 NONE cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (r_nsubjpass) compared_20\VBN\644583|outpatients|were|measures|. (l_nmod) measures_22\NNS\168237|on|symptoms (l_nmod) symptoms_25\NNS\5823932|of|psychiatric (l_amod) psychiatric_24\JJ\1740|
D003042_D001523 NONE cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (r_nmod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (r_nsubjpass) compared_20\VBN\644583|outpatients|were|measures|. (l_nmod) measures_22\NNS\168237|on|symptoms (l_nmod) symptoms_25\NNS\5823932|of|psychiatric (l_amod) psychiatric_24\JJ\1740|
D003042_D019970 NONE cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_appos) cimd_8\NN\1740|(|)
D003042_D019970 NONE cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_appos) cimd_8\NN\1740|(|)
3173180
D008795_D006463 CID metronidazole_5\NN\2723292|with (r_nmod) treatment_3\NN\654885|after|metronidazole (r_nmod) syndrome_1\NN\5870365|haemolytic-uraemic|treatment|.
D008795_D006463 CID metronidazole_17\NN\2723292|with (r_nmod) treatment_15\NN\654885|after|metronidazole (r_nmod) developed_10\VBD\1753788|who|syndrome|treatment (l_dobj) syndrome_13\NN\5870365|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_4\NN\2723292|of (r_nmod) involvement_2\NN\1080366|the|metronidazole|aetiology (l_nmod) aetiology_7\NN\7326557|in|the|syndrome (l_nmod) syndrome_11\NN\5870365|of|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_4\NN\2723292|of (r_nmod) involvement_2\NN\1080366|the|metronidazole|aetiology (r_nsubjpass) established_14\VBN\2426171|while|involvement|is|not|firmly (r_advcl) suggest_39\VBP\1010118|established|,|action|link|. (l_nsubj) action_18\NN\30358|the|drug|tissues|injury|and|evidence (l_conj) evidence_31\NN\5816287|the|reported|changes (l_nmod) changes_34\NNS\7283608|of|oxidation|syndrome (l_nmod) syndrome_38\NN\5870365|in|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_4\NN\2723292|of (r_nmod) involvement_2\NN\1080366|the|metronidazole|aetiology (r_nsubjpass) established_14\VBN\2426171|while|involvement|is|not|firmly (r_advcl) suggest_39\VBP\1010118|established|,|action|link|. (l_dobj) link_42\NN\13792579|a|possible|treatment (l_nmod) treatment_45\NN\654885|between|metronidazole|and|cases (l_conj) cases_48\NNS\7283608|some|syndrome (l_nmod) syndrome_52\NN\5870365|of|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_44\NN\2723292| (r_compound) treatment_45\NN\654885|between|metronidazole|and|cases (r_nmod) link_42\NN\13792579|a|possible|treatment (r_dobj) suggest_39\VBP\1010118|established|,|action|link|. (l_advcl) established_14\VBN\2426171|while|involvement|is|not|firmly (l_nsubjpass) involvement_2\NN\1080366|the|metronidazole|aetiology (l_nmod) aetiology_7\NN\7326557|in|the|syndrome (l_nmod) syndrome_11\NN\5870365|of|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_44\NN\2723292| (r_compound) treatment_45\NN\654885|between|metronidazole|and|cases (r_nmod) link_42\NN\13792579|a|possible|treatment (r_dobj) suggest_39\VBP\1010118|established|,|action|link|. (l_nsubj) action_18\NN\30358|the|drug|tissues|injury|and|evidence (l_conj) evidence_31\NN\5816287|the|reported|changes (l_nmod) changes_34\NNS\7283608|of|oxidation|syndrome (l_nmod) syndrome_38\NN\5870365|in|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_44\NN\2723292| (r_compound) treatment_45\NN\654885|between|metronidazole|and|cases (l_conj) cases_48\NNS\7283608|some|syndrome (l_nmod) syndrome_52\NN\5870365|of|the|haemolytic-uraemic
19356053
D020123_D011507 CID sirolimus_7\NN\1740|of (r_nmod) administration_5\NN\1133281|following|the|sirolimus|recipients (r_nmod) proteinuria_2\NN\14299637|significant|administration|.
D020123_D011507 CID sirolimus_16\NN\1740|of (r_nmod) use_14\NN\407535|with|the|sirolimus (r_nmod) linked_11\VBN\628491|use (r_acl) proteinuria_10\NN\14299637|of|significant|linked
D020123_D011507 CID sirolimus_11\NN\1740| (r_compound) use_12\NN\407535|with|sirolimus (r_nmod) associated_9\VBN\628491|use (r_acl) proteinuria_8\NN\14299637|substantial|associated
D020123_D011507 CID sirolimus_12\NN\1740| (r_compound) therapy_13\NN\657604|of|sirolimus (r_nmod) commencement_10\NN\15180528|between|the|therapy|and|proteinuria (l_conj) proteinuria_15\NN\14299637|
D020123_D011507 CID sirolimus_12\NN\1740| (r_compound) therapy_13\NN\657604|of|sirolimus (r_nmod) commencement_10\NN\15180528|between|the|therapy|and|proteinuria (r_nmod) association_7\NN\8008335|the|close|temporal|commencement (r_nsubj) implicated_16\VBD\2677097|patient|,|association|sirolimus|etiology|. (l_nmod) etiology_22\NN\7326557|as|the|likely|proteinuria (l_nmod) proteinuria_25\NN\14299637|of|the
D020123_D011507 CID sirolimus_17\NN\1740| (r_dobj) implicated_16\VBD\2677097|patient|,|association|sirolimus|etiology|. (l_nsubj) association_7\NN\8008335|the|close|temporal|commencement (l_nmod) commencement_10\NN\15180528|between|the|therapy|and|proteinuria (l_conj) proteinuria_15\NN\14299637|
D020123_D011507 CID sirolimus_17\NN\1740| (r_dobj) implicated_16\VBD\2677097|patient|,|association|sirolimus|etiology|. (l_nmod) etiology_22\NN\7326557|as|the|likely|proteinuria (l_nmod) proteinuria_25\NN\14299637|of|the
D020123_D011507 CID sirolimus_16\NN\1740|of (r_nmod) initiation_14\NN\7450842|between|the|sirolimus|and|development (l_conj) development_19\NN\248977|the|proteinuria (l_nmod) proteinuria_22\NN\14299637|of|nephrotic-range
D020123_D011507 CID sirolimus_5\NN\1740| (r_compound) therapy_6\NN\657604|with|sirolimus (r_nmod) correlated_1\VBD\2657219|proteinuria|strongly|therapy|compared|. (l_nsubj) proteinuria_0\NN\14299637|
D020123_D011507 CID sirolimus_6\NN\1740|of (r_nmod) discontinuation_4\NN\209943|sirolimus (r_nsubj) resulted_7\VBD\2633881|patients|,|discontinuation|decrease|. (l_nmod) decrease_10\NN\7296428|in|a|,|not|resolution|,|proteinuria (l_nmod) proteinuria_17\NN\14299637|of
D020123_D011507 CID sirolimus_2\NN\1740| (r_nsubj) induces_3\VBZ\1627355|sirolimus|or|aggravates|proteinuria|subset (l_dobj) proteinuria_7\NN\14299637|pre-existing
D020123_D011507 CID sirolimus_10\NN\1740| (r_nsubjpass) withdrawn_12\VBN\1835496|when|sirolimus|is (r_advcl) resolve_7\VB\352826|does|not|,|withdrawn (r_conj) improve_2\VB\126264|proteinuria|may|,|but|resolve|. (l_nsubj) proteinuria_0\NN\14299637|
D020123_D007674 NONE sirolimus_2\NN\1740| (r_nsubj) agent_7\NN\7347|:|sirolimus|is|the|latest|immunosuppressive|used|,|and|have (l_conj) have_15\VB\2108377|may|nephrotoxicity (l_dobj) nephrotoxicity_17\NN\1740|less|regimens
D003404_D011507 NONE creatinine_22\NN\1740|protein|: (r_compound) ratios_23\NNS\13815152|random|urine|creatinine|,|estimate (r_conj) measurement_16\NN\407535|by|turbidometric|or|ratios (r_nmod) assessed_9\VBN\670261|patients|,|magnitude|was|samples|measurement|. (l_nsubjpass) magnitude_5\NN\4916342|the|proteinuria (l_nmod) proteinuria_7\NN\14299637|of
D003404_D011507 NONE creatinine_22\NN\1740|protein|: (r_compound) ratios_23\NNS\13815152|random|urine|creatinine|,|estimate (l_appos) estimate_26\NN\5802185|an|grams (l_nmod) grams_28\NNS\13717155|of|proteinuria/day (l_nmod) proteinuria/day_30\NN\1740|of
D020123_D009404 NONE sirolimus_16\NN\1740|of (r_nmod) initiation_14\NN\7450842|between|the|sirolimus|and|development (l_conj) development_19\NN\248977|the|proteinuria (l_nmod) proteinuria_22\NN\14299637|of|nephrotic-range (l_amod) nephrotic-range_21\JJ\1740|
7930386
D002997_D012893 CID clomipramine-induced_0\JJ\1740| (r_amod) disturbance_2\NN\407535|clomipramine-induced|sleep
D002997_D012893 CID clomipramine_15\NN\4482543| (r_compound) administration_16\NN\1133281|by|clomipramine (r_nmod) induced_13\VBN\1627355|administration (r_acl) disturbance_11\NN\407535|of|sleep|,|induced
19473225
D018698_D010523 NONE glutamate_1\NN\15010703| (r_compound) supplementation_2\NN\5108947|long-term|glutamate (r_nsubj) failed_3\VBD\1798936|supplementation|protect|. (l_xcomp) protect_5\VB\1127795|to|neurotoxicity (l_nmod) neurotoxicity_8\NN\1740|against|peripheral|paclitaxel
D018698_D010523 NONE glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D018698_D010523 NONE glutamine_25\NN\14601829|its|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D018698_D010523 NONE glutamate_9\NN\15010703| (r_compound) supplementation_10\NN\5108947|of|glutamate (r_nmod) role_7\NN\719494|the|supplementation|preventing (l_advcl) preventing_12\VBG\1740|for|neuropathy (l_dobj) neuropathy_15\NN\14204950|pac-induced|peripheral
D018698_D010523 NONE glutamate_8\NN\15010703| (r_compound) supplementation_9\NN\5108947|glutamate|regimen (r_nsubj) fails_14\VBZ\1798936|that|supplementation|protect (l_xcomp) protect_16\VB\1127795|to|neurotoxicity (l_nmod) neurotoxicity_19\NN\1740|against|peripheral|pac
D017239_D010523 CID paclitaxel_10\NN\1740|of (r_nmod) neurotoxicity_8\NN\1740|against|peripheral|paclitaxel
D017239_D010523 CID paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_14\NN\8324514|(|) (r_appos) paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_30\NN\8324514| (r_compound) neurotoxicity_31\NN\1740|pac (r_dobj) ameliorate_29\VB\126264|to|neurotoxicity (r_xcomp) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac-induced_13\JJ\1740| (r_amod) neuropathy_15\NN\14204950|pac-induced|peripheral
D017239_D010523 CID pac_21\NN\8324514|of (r_nmod) neurotoxicity_19\NN\1740|against|peripheral|pac
D017239_D020258 NONE paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_advcl) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D017239_D020258 NONE pac_14\NN\8324514|(|) (r_appos) paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_advcl) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D017239_D020258 NONE pac_30\NN\8324514| (r_compound) neurotoxicity_31\NN\1740|pac
D018698_D020258 NONE glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D018698_D020258 NONE glutamine_25\NN\14601829|its|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D000596_D010523 NONE acid_24\NN\14818238|related|amino (r_compound) glutamine_25\NN\14601829|its|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D000596_D020258 NONE acid_24\NN\14818238|related|amino (r_compound) glutamine_25\NN\14601829|its|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D017239_D010051 NONE pac-containing_14\JJ\1740| (r_amod) regimen_15\NN\5898568|of|the|same|pac-containing (r_nmod) cycles_10\NNS\15269513|following|six|regimen (r_nmod) analysis_7\NN\633864|for|cycles (r_nmod) available_5\JJ\1740|patients|were|analysis|:|supplemented (l_nsubj) patients_3\NNS\9898892|forty-three|ovarian|cancer (l_compound) cancer_2\NN\14239425|
D018698_D010051 NONE glutamate_22\NN\15010703|by (r_nmod) supplemented_20\VBN\182406|23|had|been|glutamate|period|,|dose|,|and|received (r_parataxis) available_5\JJ\1740|patients|were|analysis|:|supplemented (l_nsubj) patients_3\NNS\9898892|forty-three|ovarian|cancer (l_compound) cancer_2\NN\14239425|
3970039
D000477_D015470 CID agents_4\NNS\7347|with|alkylating (r_nmod) treated_1\VBN\2376958|agents (r_acl) patients_0\NNS\9898892|treated (r_nsubj) have_5\VBP\2108377|patients|risk|,|and|associated (l_dobj) risk_8\NN\14541044|an|increased|development (l_nmod) development_10\NN\248977|of|leukemia (l_nmod) leukemia_14\NN\14239918|of|acute|nonlymphocytic
D000477_D015470 CID agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development|. (r_conj) have_5\VBP\2108377|patients|risk|,|and|associated (l_dobj) risk_8\NN\14541044|an|increased|development (l_nmod) development_10\NN\248977|of|leukemia (l_nmod) leukemia_14\NN\14239918|of|acute|nonlymphocytic
D000477_D008228 CID agents_4\NNS\7347|with|alkylating (r_nmod) treated_1\VBN\2376958|agents (r_acl) patients_0\NNS\9898892|treated (r_nsubj) have_5\VBP\2108377|patients|risk|,|and|associated (l_conj) associated_23\VBN\628491|agents|are|development|. (l_nmod) development_26\NN\248977|with|the|lymphoma (l_nmod) lymphoma_30\NN\14239918|of|non-hodgkin
D000477_D008228 CID agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development|. (l_nmod) development_26\NN\248977|with|the|lymphoma (l_nmod) lymphoma_30\NN\14239918|of|non-hodgkin
D001379_D015470 NONE azathioprine_21\NN\3740161| (r_conj) agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development|. (r_conj) have_5\VBP\2108377|patients|risk|,|and|associated (l_dobj) risk_8\NN\14541044|an|increased|development (l_nmod) development_10\NN\248977|of|leukemia (l_nmod) leukemia_14\NN\14239918|of|acute|nonlymphocytic
D001379_D008228 CID azathioprine_21\NN\3740161| (r_conj) agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development|. (l_nmod) development_26\NN\248977|with|the|lymphoma (l_nmod) lymphoma_30\NN\14239918|of|non-hodgkin
D003520_D001749 CID cyclophosphamide_0\NN\1740| (r_compound) therapy_1\NN\657604|cyclophosphamide (r_nsubj) increases_2\VBZ\169651|therapy|risk|. (l_dobj) risk_4\NN\14541044|the|carcinoma (l_nmod) carcinoma_6\NN\14239918|of|bladder (l_nmod) bladder_9\NN\5515670|of|the
D003520_D002277 CID cyclophosphamide_0\NN\1740| (r_compound) therapy_1\NN\657604|cyclophosphamide (r_nsubj) increases_2\VBZ\169651|therapy|risk|. (l_dobj) risk_4\NN\14541044|the|carcinoma (l_nmod) carcinoma_6\NN\14239918|of|bladder (l_nmod) bladder_9\NN\5515670|of|the
D001379_D001172 NONE azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (l_nmod) arthritis_10\NN\14171682|with|rheumatoid
D001379_D009369 NONE azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (r_nmod) studies_5\NNS\635850|several|long-term|patients (r_attr) been_2\VBN\836236|there|have|studies|and|increased (l_conj) increased_27\VBN\169651|incidence|is|not|. (l_nsubjpass) incidence_18\NN\13821570|the|most (l_nmod) most_20\JJS\1740|of|cancers (l_nmod) cancers_24\NNS\14239425|of|the|common
D003520_D001172 NONE cyclophosphamide_15\NN\1740| (r_conj) azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (l_nmod) arthritis_10\NN\14171682|with|rheumatoid
D003520_D009369 NONE cyclophosphamide_15\NN\1740| (r_conj) azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (r_nmod) studies_5\NNS\635850|several|long-term|patients (r_attr) been_2\VBN\836236|there|have|studies|and|increased (l_conj) increased_27\VBN\169651|incidence|is|not|. (l_nsubjpass) incidence_18\NN\13821570|the|most (l_nmod) most_20\JJS\1740|of|cancers (l_nmod) cancers_24\NNS\14239425|of|the|common
D000477_D009369 NONE agents_31\NNS\7347|particularly|alkylating (r_appos) drugs_27\NNS\14778436|of|immunosuppressive|,|agents|, (r_nmod) use_24\NN\407535|the|drugs|treatment (r_nsubjpass) reserved_41\VBN\2213690|available|,|use|should|be|patients|. (r_conj) collected_14\VBN\2281093|data|are|still|being|,|and|reserved (l_nsubjpass) data_0\NNS\7951464|risk (l_nmod) risk_5\NN\14541044|on|the|possible|increased|malignancy (l_nmod) malignancy_7\NN\14070360|of|arthritis
D000477_D001172 NONE agents_31\NNS\7347|particularly|alkylating (r_appos) drugs_27\NNS\14778436|of|immunosuppressive|,|agents|, (r_nmod) use_24\NN\407535|the|drugs|treatment (r_nsubjpass) reserved_41\VBN\2213690|available|,|use|should|be|patients|. (r_conj) collected_14\VBN\2281093|data|are|still|being|,|and|reserved (l_nsubjpass) data_0\NNS\7951464|risk (l_nmod) risk_5\NN\14541044|on|the|possible|increased|malignancy (l_nmod) malignancy_7\NN\14070360|of|arthritis (l_nmod) arthritis_10\NN\14171682|in|rheumatoid
D000477_D001172 NONE agents_31\NNS\7347|particularly|alkylating (r_appos) drugs_27\NNS\14778436|of|immunosuppressive|,|agents|, (r_nmod) use_24\NN\407535|the|drugs|treatment (l_nmod) treatment_35\NN\654885|in|the|arthritis (l_nmod) arthritis_38\NN\14171682|of|rheumatoid
18081909
C026098_D001927 CID levetiracetam_3\NN\1740|by|added (r_nmod) induced_1\VBN\1627355|levetiracetam (r_acl) encephalopathy_0\NN\14084880|induced|.
C026098_D001927 CID levetiracetam_9\NN\1740|(lev)-induced (r_compound) encephalopathy_11\NN\14084880|of|a|levetiracetam
C026098_D001927 CID (lev)-induced_10\NN\1740| (r_dep) levetiracetam_9\NN\1740|(lev)-induced (r_compound) encephalopathy_11\NN\14084880|of|a|levetiracetam
D014635_D001927 CID valproate_6\NN\1740|to (r_nmod) added_4\VBN\156601|valproate (r_acl) levetiracetam_3\NN\1740|by|added (r_nmod) induced_1\VBN\1627355|levetiracetam (r_acl) encephalopathy_0\NN\14084880|induced|.
C026098_C562694 NONE lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev|. (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy (l_nmod) epilepsy_8\NN\14085708|from|idiopathic|seizures
C026098_D012640 NONE lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev|. (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy (l_nmod) epilepsy_8\NN\14085708|from|idiopathic|seizures (l_nmod) seizures_11\NNS\14081375|with|generalized
C026098_D012640 NONE lev_5\NN\13685678|of (r_nmod) discontinuation_3\NN\209943|following|lev (r_nmod) improved_11\VBD\126264|discontinuation|,|findings|and|decreased (l_conj) decreased_15\VBD\169651|frequency|. (l_nsubj) frequency_14\NN\15286249|seizure (l_compound) seizure_13\NN\14081375|
D014635_C562694 NONE valproate_22\NN\1740|to|vpa (r_nmod) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev|. (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy (l_nmod) epilepsy_8\NN\14085708|from|idiopathic|seizures
D014635_C562694 NONE vpa_24\NN\1740|(|)|mg (r_appos) valproate_22\NN\1740|to|vpa (r_nmod) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev|. (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy (l_nmod) epilepsy_8\NN\14085708|from|idiopathic|seizures
D014635_D012640 NONE valproate_22\NN\1740|to|vpa (r_nmod) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev|. (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy (l_nmod) epilepsy_8\NN\14085708|from|idiopathic|seizures (l_nmod) seizures_11\NNS\14081375|with|generalized
D014635_D012640 NONE vpa_24\NN\1740|(|)|mg (r_appos) valproate_22\NN\1740|to|vpa (r_nmod) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev|. (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy (l_nmod) epilepsy_8\NN\14085708|from|idiopathic|seizures (l_nmod) seizures_11\NNS\14081375|with|generalized
18162529
D012313_D006966 NONE acid_5\NN\14818238|ribonucleic (r_compound) levels_6\NNS\4916342|hypothalamic|prolactin|receptor|messenger|acid|,|signaling (l_conj) signaling_9\NN\33020|prolactin|,|and|inhibition (l_conj) inhibition_13\NN\1068773|hyperprolactinemic|secretion (l_amod) hyperprolactinemic_12\JJ\1740|
D004958_D006966 NONE estradiol_22\NN\14749794|on (r_nmod) dependent_20\JJ\1740|levels|are|estradiol|. (l_nsubj) levels_6\NNS\4916342|hypothalamic|prolactin|receptor|messenger|acid|,|signaling (l_conj) signaling_9\NN\33020|prolactin|,|and|inhibition (l_conj) inhibition_13\NN\1068773|hyperprolactinemic|secretion (l_amod) hyperprolactinemic_12\JJ\1740|
D004958_D006966 NONE estradiol_30\NN\14749794|of (r_nmod) levels_28\NNS\4916342|of|chronic|low|estradiol (r_nmod) presence_24\NN\13954253|only|in|the|levels (r_nmod) caused_8\VBD\1617192|hyperprolactinemia|frequency|rats|,|but|presence|. (l_nsubj) hyperprolactinemia_1\NN\1740|chronic|induced
D004967_D006966 NONE estrogen-induced_20\JJ\1740| (r_amod) surge_22\NN\7405893|the|estrogen-induced|lh (r_conj) secretion_17\NN\13526110|pulsatile|lh|and|surge (r_dep) parameters_9\NNS\5858936|two|neuroendocrine|necessary|:|secretion (r_dobj) inhibited_6\VBD\2510337|whether|hyperprolactinemia|parameters (l_nsubj) hyperprolactinemia_5\NN\1740|chronic
D004298_D006966 NONE dopamine_5\NN\14807737| (r_compound) sulpiride_7\NN\1740|by|the|dopamine|antagonist (r_nmod) induced_2\VBN\1627355|sulpiride (r_acl) hyperprolactinemia_1\NN\1740|chronic|induced
D013469_D006966 CID sulpiride_7\NN\1740|by|the|dopamine|antagonist (r_nmod) induced_2\VBN\1627355|sulpiride (r_acl) hyperprolactinemia_1\NN\1740|chronic|induced
D013256_D006966 NONE steroid-dependent_14\JJ\1740| (r_amod) manner_15\NN\4916342|in|a|steroid-dependent (r_nmod) inhibited_8\VBN\2510337|that|frequency|is|hyperprolactinemia|manner (l_nmod) hyperprolactinemia_11\NN\1740|by|chronic
3503576
D003676_D006311 NONE deferoxamine_8\NN\1740| (r_compound) therapy_9\NN\657604|deferoxamine (r_dobj) receiving_7\VBG\2210855|therapy (r_acl) patients_6\NNS\9898892|in|receiving (r_nmod) neurotoxicity_4\NN\1740|of|auditory|patients
D003676_D006311 NONE deferoxamine_24\NN\1740|with|daily|subcutaneous (r_nmod) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual
D003676_D006311 NONE deferoxamine_9\NN\1740| (r_compound) doses_10\NNS\3740161|deferoxamine (r_dobj) receiving_8\VBG\2210855|since|18|were|initially|doses|excess (r_advcl) restarted_24\VBN\1857717|receiving|,|therapy|was|doses|,|and|exception|demonstrated (l_nmod) doses_27\NNS\3740161|with|lower|,|mg/kg|less|degree (l_nmod) degree_39\NN\4916342|depending|on|the|abnormality (l_nmod) abnormality_42\NN\14034177|of|auditory
D003676_D006311 NONE deferoxamine_14\NN\1740| (r_dobj) receiving_13\VBG\2210855|not|deferoxamine (r_conj) receiving_10\VBG\2210855|and|receiving|,|respectively (r_acl) patients_9\NNS\9898892|in|individual|receiving (r_nmod) demonstrated_5\VBN\2137132|serially|patients (r_acl) deterioration_1\NN\14560612|auditory|and|improvement|,|demonstrated (r_nsubj) provided_18\VBD\2199590|deterioration|,|evidence|. (l_dobj) evidence_20\NN\5816287|convincing|relation (l_nmod) relation_24\NN\2137|for|a|cause-and-effect|administration (l_nmod) administration_27\NN\1133281|between|deferoxamine|and|ototoxicity (l_conj) ototoxicity_29\NN\1740|
D003676_D006311 NONE deferoxamine_26\NN\1740| (r_compound) administration_27\NN\1133281|between|deferoxamine|and|ototoxicity (l_conj) ototoxicity_29\NN\1740|
D007501_D014786 NONE iron_18\NN\14625458| (r_compound) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual
D007501_D006311 NONE iron_18\NN\14625458| (r_compound) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual
D007501_D000740 NONE iron_18\NN\14625458| (r_compound) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (l_nmod) anemia_14\NN\14189204|with|transfusion-dependent
D003676_D014786 NONE deferoxamine_24\NN\1740|with|daily|subcutaneous (r_nmod) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual
D003676_D000740 NONE deferoxamine_24\NN\1740|with|daily|subcutaneous (r_nmod) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (l_nmod) anemia_14\NN\14189204|with|transfusion-dependent
D003676_D064420 NONE deferoxamine_9\NN\1740| (r_compound) doses_10\NNS\3740161|deferoxamine (r_dobj) receiving_8\VBG\2210855|since|18|were|initially|doses|excess (r_advcl) restarted_24\VBN\1857717|receiving|,|therapy|was|doses|,|and|exception|demonstrated (l_dep) demonstrated_55\VBN\2137132|toxicity|was|. (l_nsubjpass) toxicity_53\NN\13576101|no|further
10406016
C007789_D002543 NONE fucoidan_2\NN\1740| (r_compound) treatment_3\NN\654885|of|fucoidan (r_nmod) effect_0\NN\34213|treatment|hemorrhage|. (l_nmod) hemorrhage_7\NN\14285662|on|collagenase-induced|intracerebral|rats
C007789_D002543 NONE fucoidan_5\NN\1740|the|sulfated|polysaccharide|,|reported|, (r_dobj) tested_1\VBD\670261|we|fucoidan|model|. (l_nmod) model_20\NN\5888929|in|a|rat|hemorrhage (l_nmod) hemorrhage_23\NN\14285662|of|intracerebral|induced
C007789_D001925 NONE fucoidan_5\NN\1740|the|sulfated|polysaccharide|,|reported|, (l_acl:relcl) reported_10\VBN\831651|which|has|been|reduce (l_xcomp) reduce_12\VB\441445|to|damage (l_dobj) damage_15\NN\7296428|inflammatory|brain
C007789_D020141 CID fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_dobj) evidence_3\NN\5816287|clotting (l_nmod) clotting_7\NN\13518963|of|impaired|blood|and|hemodilution
C007789_D020141 CID fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_dobj) evidence_3\NN\5816287|clotting (l_nmod) clotting_7\NN\13518963|of|impaired|blood|and|hemodilution (l_conj) hemodilution_9\NN\1740|
C007789_D006406 NONE fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_conj) had_11\VBD\2108377|hematomas|,|and|tended (l_dobj) hematomas_13\NNS\14317720|larger
C007789_D006406 NONE fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_conj) had_11\VBD\2108377|hematomas|,|and|tended (l_conj) tended_16\VBD\2604760|have (l_xcomp) have_18\VB\2108377|to|inflammation|vicinity|days (l_nmod) vicinity_23\NN\8648322|in|the|hematoma (l_nmod) hematoma_26\NN\14317720|of|the
C007789_D007249 NONE fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_conj) had_11\VBD\2108377|hematomas|,|and|tended (l_conj) tended_16\VBD\2604760|have (l_xcomp) have_18\VB\2108377|to|inflammation|vicinity|days (l_dobj) inflammation_20\NN\14299637|less
12716030
D006493_D002543 NONE heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|induction|,|heparin|volume|that|and|bleeding|. (l_nmod) induction_2\NN\7450842|in|ich|using (l_compound) ich_1\NN\1740|
D006493_D002543 NONE heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|induction|,|heparin|volume|that|and|bleeding|. (l_nmod) that_14\DT\1740|over|seen (l_acl) seen_15\VBN\2106506|animals (l_nmod) animals_19\NNS\4475|in|control|ich (l_compound) ich_18\NN\1740|
D006493_D006406 CID heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|induction|,|heparin|volume|that|and|bleeding|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold (l_compound) hematoma_10\NN\14317720|
D006493_D006470 NONE heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|induction|,|heparin|volume|that|and|bleeding|. (l_conj) bleeding_22\NN\14285662|the|7.6-fold
7977601
7858459
D005472_D003221 CID 5-fluorouracil_8\NN\1740|of|and|acid (r_nmod) infusion_6\NN\14589223|by|a|high-dose|5-fluorouracil (r_nmod) induced_2\VBN\1627355|infusion (r_acl) confusion_1\NN\13972797|acute|induced|.
D005472_D003221 CID 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation
D005472_D003221 CID 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability
D002955_D003221 CID acid_11\NN\14818238|folinic (r_conj) 5-fluorouracil_8\NN\1740|of|and|acid (r_nmod) infusion_6\NN\14589223|by|a|high-dose|5-fluorouracil (r_nmod) induced_2\VBN\1627355|infusion (r_acl) confusion_1\NN\13972797|acute|induced|.
D002955_D003221 CID acid_38\NN\14818238|folinic (r_conj) 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation
D002955_D003221 CID acid_38\NN\14818238|folinic (r_conj) 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability
D002945_D013274 NONE cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil (r_dobj) incorporating_8\VBG\1461328|cisplatinum|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D005047_D013274 NONE etoposide_11\NN\1740| (r_conj) cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil (r_dobj) incorporating_8\VBG\1461328|cisplatinum|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D005472_D013274 NONE 5-fluorouracil_14\NN\1740|high-dose|hours|)|and|acid (r_conj) cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil (r_dobj) incorporating_8\VBG\1461328|cisplatinum|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D002955_D013274 NONE acid_22\NN\14818238|folinic (r_conj) 5-fluorouracil_14\NN\1740|high-dose|hours|)|and|acid (r_conj) cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil (r_dobj) incorporating_8\VBG\1461328|cisplatinum|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D005472_D001523 NONE 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability (l_conj) irritability_11\NN\7552087|
D005472_D003128 CID 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (l_nmod) coma_19\NN\5678932|into|a|deep
D002955_D001523 NONE acid_38\NN\14818238|folinic (r_conj) 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability (l_conj) irritability_11\NN\7552087|
D002955_D003128 CID acid_38\NN\14818238|folinic (r_conj) 5-fluorouracil_35\NN\1740|and|acid (r_compound) infusion_39\NN\14589223|of|5-fluorouracil (r_nmod) dose_29\NN\3740161|during|the|first|day|infusion (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBD\124442|then|coma|,|lasting (l_nmod) coma_19\NN\5678932|into|a|deep
D002955_D020258 NONE acid_2\NN\14818238|folinic (r_nsubj) unlikely_4\JJ\1740|because|acid|was|associated (r_advcl) suspected_19\VBN\916909|unlikely|,|neurotoxicity|was|highly|. (l_nsubjpass) neurotoxicity_12\NN\1740|5-fluorouracil
D005472_D020258 NONE 5-fluorouracil_16\NN\1740|due|high-dose (r_nmod) neurotoxicity_12\NN\1740|5-fluorouracil
D005472_D020258 NONE 5-fluorouracil_3\NN\1740| (r_compound) neurotoxicity_4\NN\1740|of|5-fluorouracil
D005463_D020258 NONE fluoroacetate_14\NN\1740|by|and|fluorocitrate (r_nmod) blockade_12\NN\952963|pathogenesis|due|a|krebs|cycle|fluoroacetate|,|deficiency|. (l_nsubj) pathogenesis_1\NN\13533470|the|neurotoxicity (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
C007744_D020258 NONE fluorocitrate_16\NN\1740| (r_conj) fluoroacetate_14\NN\1740|by|and|fluorocitrate (r_nmod) blockade_12\NN\952963|pathogenesis|due|a|krebs|cycle|fluoroacetate|,|deficiency|. (l_nsubj) pathogenesis_1\NN\13533470|the|neurotoxicity (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
D013831_D020258 NONE thiamine_18\NN\15090742| (r_compound) deficiency_19\NN\14449126|thiamine|,|or|deficiency (r_conj) blockade_12\NN\952963|pathogenesis|due|a|krebs|cycle|fluoroacetate|,|deficiency|. (l_nsubj) pathogenesis_1\NN\13533470|the|neurotoxicity (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
C007419_D020258 NONE dihydrouracil_22\NN\1740| (r_compound) dehydrogenase_23\NN\1740|dihydrouracil (r_compound) deficiency_24\NN\14449126|dehydrogenase (r_conj) deficiency_19\NN\14449126|thiamine|,|or|deficiency (r_conj) blockade_12\NN\952963|pathogenesis|due|a|krebs|cycle|fluoroacetate|,|deficiency|. (l_nsubj) pathogenesis_1\NN\13533470|the|neurotoxicity (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
D005472_D009369 NONE 5-fluorouracil/folinic_1\JJ\1740| (r_compound) acid_2\NN\14818238|5-fluorouracil/folinic (r_compound) infusion_3\NN\14589223|acid (r_compound) therapy_4\NN\657604|high-dose|infusion (r_nsubj) become_7\VBN\146138|therapy|has|recently|regimen|. (l_attr) regimen_10\NN\5898568|a|popular|cancers (l_nmod) cancers_13\NNS\14239425|for|various
D002955_D009369 NONE acid_2\NN\14818238|5-fluorouracil/folinic (r_compound) infusion_3\NN\14589223|acid (r_compound) therapy_4\NN\657604|high-dose|infusion (r_nsubj) become_7\VBN\146138|therapy|has|recently|regimen|. (l_attr) regimen_10\NN\5898568|a|popular|cancers (l_nmod) cancers_13\NNS\14239425|for|various
11897407
C067171_D009203 NONE 99mtc-glucarate_0\NN\1740|detection|. (l_nmod) detection_2\NN\5708432|for|infarction (l_nmod) infarction_6\NN\14204950|of|isoproterenol-induced|myocardial|rats
C067171_D009203 NONE 99mtc-glucarate_0\NN\1740| (r_nsubj) easy_2\JJ\1740|99mtc-glucarate|was|prepare|,|stable|and|used|. (l_conj) used_12\VBN\1156834|was|study (l_xcomp) study_14\VB\630380|to|biodistribution (l_dobj) biodistribution_16\NN\1740|its|rats (l_nmod) rats_18\NNS\2329401|in|infarction (l_nmod) infarction_23\NN\14204950|with|isoproterenol-induced|acute|myocardial
D007545_D009203 CID isoproterenol-induced_4\JJ\1740| (r_amod) infarction_6\NN\14204950|of|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_20\JJ\1740| (r_amod) infarction_23\NN\14204950|with|isoproterenol-induced|acute|myocardial
D007545_D007238 NONE isoproterenol_18\NN\3740161|with (r_nmod) obtained_16\VBN\2210855|induction|can|be|easily|isoproterenol|. (r_conj) implies_7\VBZ\943837|model|ligation|but|obtained (l_nsubj) model_2\NN\5888929|the|animal|used (l_acl) used_3\VBN\1156834|produce (l_xcomp) produce_5\VB\1617192|to|infarction (l_dobj) infarction_6\NN\14204950|
D007545_D007238 NONE isoproterenol_12\NN\3740161| (r_compound) administration_13\NN\1133281|h|isoproterenol (r_dobj) developed_6\VBD\1753788|that|rats|infarct|administration (l_dobj) infarct_8\NN\14204950|an
D005937_D007238 NONE acid_7\NN\14818238|on|glucaric (r_nmod) based_4\VBN\2694933|acid (r_acl) radiopharmaceutical_3\NN\3920989|a|new|based (l_amod) new_1\JJ\1740|infarct-avid (l_dep) infarct-avid_2\JJ\1740|
8829025
D016559_D006973 CID tacrolimus_5\NN\1740| (r_dobj) receiving_4\VBG\2210855|tacrolimus (r_acl) patients_3\NNS\9898892|of|receiving (r_nmod) groups_1\NNS\2137|two|patients (r_nsubjpass) compared_7\VBN\644583|groups|were|period|,|group|. (l_dep) group_16\NN\2137|one|comprising|,|and|other (l_acl) comprising_17\VBG\2604760|patients (l_dobj) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\1740|
D016559_D006973 CID tacrolimus_12\NN\1740|with (r_nmod) associated_10\VBN\628491|tacrolimus|recipients (r_acl) nephrotoxicity_9\NN\1740|the|associated (r_dobj) reducing_7\VBG\441445|on|nephrotoxicity (r_advcl) impact_3\NN\7339329|the|observed|positive|nifedipine|reducing (r_nsubj) factor_21\NN\7326557|impact|should|be|an|important|selecting|. (l_advcl) selecting_23\VBG\697589|in|agent (l_dobj) agent_25\NN\7347|an|treat (l_acl:relcl) treat_27\VB\2376958|to|hypertension (l_dobj) hypertension_28\NN\14057371|population
D009543_D006973 NONE nifedipine_23\NN\2938514| (r_dobj) receiving_22\VBG\2210855|who|were|nifedipine (r_acl:relcl) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\1740|
D009543_D006973 NONE nifedipine_33\NN\2938514| (r_dobj) receiving_32\VBG\2210855|not|nifedipine (r_acl) patients_30\NNS\9898892|nonhypertensive|receiving (r_dobj) comprising_28\VBG\2604760|patients (r_acl) other_27\JJ\1740|the|comprising (r_conj) group_16\NN\2137|one|comprising|,|and|other (l_acl) comprising_17\VBG\2604760|patients (l_dobj) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\1740|
D009543_D006973 NONE nifedipine_5\NN\2938514|of (r_nmod) impact_3\NN\7339329|the|observed|positive|nifedipine|reducing (r_nsubj) factor_21\NN\7326557|impact|should|be|an|important|selecting|. (l_advcl) selecting_23\VBG\697589|in|agent (l_dobj) agent_25\NN\7347|an|treat (l_acl:relcl) treat_27\VB\2376958|to|hypertension (l_dobj) hypertension_28\NN\14057371|population
D009543_D007674 NONE nifedipine_5\NN\2938514|of (r_nmod) impact_3\NN\7339329|the|observed|positive|nifedipine|reducing (l_advcl) reducing_7\VBG\441445|on|nephrotoxicity (l_dobj) nephrotoxicity_9\NN\1740|the|associated
D016559_D007674 NONE tacrolimus_12\NN\1740|with (r_nmod) associated_10\VBN\628491|tacrolimus|recipients (r_acl) nephrotoxicity_9\NN\1740|the|associated
14698717
D010672_D011605 NONE phenytoin_6\NN\3550533|with (r_nmod) treatment_4\NN\654885|due|phenytoin|patient (r_nmod) psychosis_1\NN\14380140|acute|treatment|.
D010672_D011605 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|neuralgia (r_nmod) developed_7\VBD\1753788|who|psychosis|treatment (l_dobj) psychosis_8\NN\14380140|
D010672_D011605 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|patients (r_nmod) occur_8\VBP\2623529|that|treatment (r_acl:relcl) symptoms_6\NNS\5823932|the|psychotic|occur
D010672_D014277 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|neuralgia (l_nmod) neuralgia_14\NN\14322699|for|trigeminal
D010672_D004827 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|patients (l_nmod) patients_15\NNS\9898892|in|some|epileptic (l_amod) epileptic_14\JJ\1740|
D010672_D012640 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|patients (r_nmod) occur_8\VBP\2623529|that|treatment (r_acl:relcl) symptoms_6\NNS\5823932|the|psychotic|occur (r_nsubj) result_20\NN\34213|that|symptoms|may|be|the|direct|medication (l_nmod) medication_22\NN\3247620|of|,|unrelated (l_amod) unrelated_24\JJ\1740|seizures (l_nmod) seizures_26\NNS\14081375|to
2304736
D011224_D014550 CID prazosin-induced_0\NN\1740| (r_compound) incontinence_2\NN\13473097|prazosin-induced|stress|.
D011224_D014550 CID prazosin_8\NN\2698769|due|to|,|drug|, (r_nmod) incontinence_5\NN\13473097|of|genuine|stress|prazosin
D011224_D014550 CID prazosin_8\NN\2698769| (r_dobj) taking_7\VBG\2367363|while|prazosin (r_advcl) present_2\VBP\2137132|who|incontinence|taking (l_nmod) incontinence_5\NN\13473097|with|stress
D011224_D014549 NONE prazosin_8\NN\2698769| (r_dobj) taking_7\VBG\2367363|while|prazosin (r_advcl) present_2\VBP\2137132|who|incontinence|taking (r_acl:relcl) patients_0\NNS\9898892|present (r_nsubj) change_10\VB\46534|patients|should|medication|considering|,|resolve|. (l_advcl) resolve_22\VB\352826|because|incontinence|may|spontaneously|change (l_nsubj) incontinence_20\NN\13473097|their
19581773
C417083_D009157 CID interferon_6\NN\2725367|pegylated|and|ribavirin (r_compound) treatment_9\NN\654885|during|interferon|c. (r_nmod) development_0\NN\248977|myasthenia|treatment (l_nmod) myasthenia_3\NN\14187378|of|ocular
C417083_D009157 CID alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (r_nmod) associated_3\VBN\628491|therapy (r_acl) myasthenia_2\NN\14187378|the|ocular|associated
C417083_D009157 CID ifn_35\NN\1740| (r_compound) therapy_36\NN\657604|of|ifn (r_nmod) complications_33\NNS\1073995|of|the|various|eye|therapy (r_nmod) review_28\NN\5733583|with|a|complications (r_nmod) present_23\VBP\2137132|reported|;|therefore|,|we|case|review|. (l_ccomp) reported_18\VBN\831651|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN\14187378|the|ocular|associated
C417083_D019698 NONE interferon_6\NN\2725367|pegylated|and|ribavirin (r_compound) treatment_9\NN\654885|during|interferon|c. (l_nmod) c._13\NN\1740|for|chronic|hepatitis
C417083_D019698 NONE alpha-2b_17\NN\1740|of|pegylated|interferon|(|ifn|)|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc
C417083_D019698 NONE alpha-2b_17\NN\1740|of|pegylated|interferon|(|ifn|)|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc (l_appos) chc_25\NN\1740|(|)
C417083_D019698 NONE alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (l_nmod) chc_14\NN\1740|for
C417083_D019698 NONE ifn_35\NN\1740| (r_compound) therapy_36\NN\657604|of|ifn (r_nmod) complications_33\NNS\1073995|of|the|various|eye|therapy (r_nmod) review_28\NN\5733583|with|a|complications (r_nmod) present_23\VBP\2137132|reported|;|therefore|,|we|case|review|. (l_ccomp) reported_18\VBN\831651|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN\14187378|the|ocular|associated (l_acl) associated_3\VBN\628491|therapy (l_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (l_nmod) chc_14\NN\1740|for
D012254_D009157 CID ribavirin_8\NN\2725367| (r_conj) interferon_6\NN\2725367|pegylated|and|ribavirin (r_compound) treatment_9\NN\654885|during|interferon|c. (r_nmod) development_0\NN\248977|myasthenia|treatment (l_nmod) myasthenia_3\NN\14187378|of|ocular
D012254_D009157 CID ribavirin_12\NN\2725367| (r_conj) alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (r_nmod) associated_3\VBN\628491|therapy (r_acl) myasthenia_2\NN\14187378|the|ocular|associated
D012254_D019698 NONE ribavirin_8\NN\2725367| (r_conj) interferon_6\NN\2725367|pegylated|and|ribavirin (r_compound) treatment_9\NN\654885|during|interferon|c. (l_nmod) c._13\NN\1740|for|chronic|hepatitis
D012254_D019698 NONE ribavirin_19\NN\2725367| (r_conj) alpha-2b_17\NN\1740|of|pegylated|interferon|(|ifn|)|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc
D012254_D019698 NONE ribavirin_19\NN\2725367| (r_conj) alpha-2b_17\NN\1740|of|pegylated|interferon|(|ifn|)|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc (l_appos) chc_25\NN\1740|(|)
D012254_D019698 NONE ribavirin_12\NN\2725367| (r_conj) alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (l_nmod) chc_14\NN\1740|for
C417083_D004172 NONE alpha-2b_17\NN\1740|of|pegylated|interferon|(|ifn|)|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b|c (r_nmod) weeks_8\NNS\15113229|after|9|administration (r_nmod) experienced_3\VBD\2108377|male|diplopia|weeks|. (l_dobj) diplopia_5\NN\14552802|sudden
D012254_D004172 NONE ribavirin_19\NN\2725367| (r_conj) alpha-2b_17\NN\1740|of|pegylated|interferon|(|ifn|)|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b|c (r_nmod) weeks_8\NNS\15113229|after|9|administration (r_nmod) experienced_3\VBD\2108377|male|diplopia|weeks|. (l_dobj) diplopia_5\NN\14552802|sudden
10091617
D012642_D007024 CID selegiline-induced_0\JJ\1740| (r_amod) hypotension_2\NN\14057371|selegiline-induced|postural|disease|:|study
D012642_D007024 CID selegiline_7\NN\1740|with|and|l-dopa (r_nmod) therapy_5\NN\657604|selegiline (r_nsubjpass) associated_11\VBN\628491|that|therapy|was|hypotension (l_nmod) hypotension_16\NN\14057371|with|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_23\NN\1740|of (r_nmod) withdrawal_21\NN\7206096|by|selegiline (r_nmod) abolished_19\VBN\1740|which|was|withdrawal (r_acl:relcl) hypotension_16\NN\14057371|with|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_29\NN\1740| (r_dobj) stopping_28\VBG\2452885|of|selegiline (r_advcl) consequences_26\NNS\34213|of|the|cardiovascular|stopping (r_nmod) course_22\NN\883297|the|time|consequences (r_dobj) determine_19\VB\1645601|to|course|expectation (l_nmod) expectation_32\NN\5941423|in|the|shed (l_acl) shed_36\VB\173338|that|this|might|light|mechanisms (l_nmod) mechanisms_40\NNS\13446390|on|the|causes (l_acl:relcl) causes_45\VBZ\1617192|which|drug|hypotension (l_dobj) hypotension_47\NN\14057371|orthostatic
D012642_D007024 CID selegiline_18\NN\1740|on (r_nmod) patients_16\NNS\9898892|six|20|pd|selegiline|,|lost (r_dobj) marked_10\JJ\1740|which|was|patients (r_acl:relcl) hypotension_7\NN\14057371|systolic|orthostatic|marked
D012642_D007024 CID selegiline_9\NN\1740|of (r_nmod) withdrawal_7\NN\7206096|days|selegiline (r_dobj) ameliorated_3\VBN\126264|hypotension|was|withdrawal|and|abolished|. (l_nsubjpass) hypotension_1\NN\14057371|orthostatic
D012642_D007024 CID selegiline_1\NN\1740| (r_dobj) stopping_0\VBG\2452885|selegiline (r_csubj) reduced_4\VBD\441445|stopping|also|significantly|pressures|. (l_dobj) pressures_11\NNS\11419404|the|supine|systolic|blood|consistent
D012642_D007024 CID selegiline_9\NN\1740|combination (r_nsubjpass) associated_15\VBN\628491|that|selegiline|is|hypotension (l_nmod) hypotension_19\NN\14057371|with|selective|orthostatic
D012642_D010300 NONE selegiline-induced_0\JJ\1740| (r_amod) hypotension_2\NN\14057371|selegiline-induced|postural|disease|:|study (l_nmod) disease_6\NN\14061805|in|parkinson|'s
D012642_D010300 NONE selegiline_32\NN\1740|mg|day|and|l-dopa (r_dobj) receive_29\VB\2210855|to|selegiline (r_xcomp) randomized_27\VBN\278117|receive (r_acl) patients_19\NNS\9898892|in|disease|randomized (r_nmod) mortality_17\NN\5054863|an|increased|patients (r_dobj) found_14\VBD\2426171|objectives|trial|mortality (l_nsubj) objectives_0\NNS\5980875|:|group (l_appos) group_9\NNP\2137|the|kingdom|disease|research|ukpdrg (l_compound) disease_7\NNP\14061805|parkinson
D012642_D010300 NONE selegiline_32\NN\1740|mg|day|and|l-dopa (r_dobj) receive_29\VB\2210855|to|selegiline (r_xcomp) randomized_27\VBN\278117|receive (r_acl) patients_19\NNS\9898892|in|disease|randomized (l_nmod) disease_23\NN\14061805|with|parkinson|pd
D012642_D010300 NONE selegiline_32\NN\1740|mg|day|and|l-dopa (r_dobj) receive_29\VB\2210855|to|selegiline (r_xcomp) randomized_27\VBN\278117|receive (r_acl) patients_19\NNS\9898892|in|disease|randomized (l_nmod) disease_23\NN\14061805|with|parkinson|pd (l_appos) pd_25\NN\14625458|(|)
D012642_D010300 NONE selegiline_17\NN\1740| (r_dobj) receiving_16\VBG\2210855|selegiline (r_acl) patients_15\NNS\9898892|in|pd|receiving|and|withdrawn (l_compound) pd_14\NN\14625458|
D012642_D010300 NONE selegiline_18\NN\1740|on (r_nmod) patients_16\NNS\9898892|six|20|pd|selegiline|,|lost (l_compound) pd_15\NN\14625458|
D007980_D010300 NONE l-dopa_36\NN\14604959| (r_conj) selegiline_32\NN\1740|mg|day|and|l-dopa (r_dobj) receive_29\VB\2210855|to|selegiline (r_xcomp) randomized_27\VBN\278117|receive (r_acl) patients_19\NNS\9898892|in|disease|randomized (r_nmod) mortality_17\NN\5054863|an|increased|patients (r_dobj) found_14\VBD\2426171|objectives|trial|mortality (l_nsubj) objectives_0\NNS\5980875|:|group (l_appos) group_9\NNP\2137|the|kingdom|disease|research|ukpdrg (l_compound) disease_7\NNP\14061805|parkinson
D007980_D010300 NONE l-dopa_36\NN\14604959| (r_conj) selegiline_32\NN\1740|mg|day|and|l-dopa (r_dobj) receive_29\VB\2210855|to|selegiline (r_xcomp) randomized_27\VBN\278117|receive (r_acl) patients_19\NNS\9898892|in|disease|randomized (l_nmod) disease_23\NN\14061805|with|parkinson|pd
D007980_D010300 NONE l-dopa_36\NN\14604959| (r_conj) selegiline_32\NN\1740|mg|day|and|l-dopa (r_dobj) receive_29\VB\2210855|to|selegiline (r_xcomp) randomized_27\VBN\278117|receive (r_acl) patients_19\NNS\9898892|in|disease|randomized (l_nmod) disease_23\NN\14061805|with|parkinson|pd (l_appos) pd_25\NN\14625458|(|)
D007980_D007024 NONE l-dopa_9\NN\14604959| (r_conj) selegiline_7\NN\1740|with|and|l-dopa (r_nmod) therapy_5\NN\657604|selegiline (r_nsubjpass) associated_11\VBN\628491|that|therapy|was|hypotension (l_nmod) hypotension_16\NN\14057371|with|selective|systolic|orthostatic|abolished
D007980_D007024 NONE l-dopa_13\NN\14604959|with (r_nmod) combination_11\NN\7951464|in|l-dopa (r_nmod) selegiline_9\NN\1740|combination (r_nsubjpass) associated_15\VBN\628491|that|selegiline|is|hypotension (l_nmod) hypotension_19\NN\14057371|with|selective|orthostatic
4008111
D000638_D012848 CID amiodarone-induced_0\NN\1740| (r_compound) block_2\NN\21939|amiodarone-induced|sinoatrial|.
D000638_D012848 CID amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|due|chronic|amiodarone (r_nmod) block_3\NN\21939|sinoatrial|administration
D000638_D012848 CID amiodarone_5\NN\2715941|of (r_nmod) dosage_3\NN\13576355|in|the|amiodarone (r_nmod) reduction_0\NN\351485|dosage (r_nsubj) resulted_6\VBD\2633881|reduction|disappearance|. (l_nmod) disappearance_9\NN\42757|in|the|block|and|persistence (l_nmod) block_13\NN\21939|of|the|sinoatrial
D000638_D009202 NONE amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|due|chronic|amiodarone (r_nmod) block_3\NN\21939|sinoatrial|administration (r_dobj) observed_1\VBD\2163746|we|block|boy|. (l_nmod) boy_12\NN\9624168|in|a|5-year-old|cardiomyopathy (l_nmod) cardiomyopathy_15\NN\14103288|with|primary|,|syndrome
D000638_D014927 NONE amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|due|chronic|amiodarone (r_nmod) block_3\NN\21939|sinoatrial|administration (r_dobj) observed_1\VBD\2163746|we|block|boy|. (l_nmod) boy_12\NN\9624168|in|a|5-year-old|cardiomyopathy (l_nmod) cardiomyopathy_15\NN\14103288|with|primary|,|syndrome (l_conj) syndrome_18\NN\5870365|wolff-parkinson-white|and|tachycardia
D000638_D013617 NONE amiodarone_7\NN\2715941| (r_compound) administration_8\NN\1133281|due|chronic|amiodarone (r_nmod) block_3\NN\21939|sinoatrial|administration (r_dobj) observed_1\VBD\2163746|we|block|boy|. (l_nmod) boy_12\NN\9624168|in|a|5-year-old|cardiomyopathy (l_nmod) cardiomyopathy_15\NN\14103288|with|primary|,|syndrome (l_conj) syndrome_18\NN\5870365|wolff-parkinson-white|and|tachycardia (l_conj) tachycardia_21\NN\14110674|supraventricular
D000638_D012804 NONE amiodarone_5\NN\2715941|of (r_nmod) dosage_3\NN\13576355|in|the|amiodarone (r_nmod) reduction_0\NN\351485|dosage (r_nsubj) resulted_6\VBD\2633881|reduction|disappearance|. (l_nmod) disappearance_9\NN\42757|in|the|block|and|persistence (l_conj) persistence_16\NN\5053688|the|bradycardia (l_nmod) bradycardia_20\NN\14110674|of|asymptomatic|sinus
18619688
D004317_D003643 NONE adriamycin-induced_0\JJ\1740| (r_amod) death_3\NN\7296428|adriamycin-induced|autophagic|cardiomyocyte
D004317_D003643 NONE adriamycin_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|adriamycin (r_acl) rats_16\NNS\2329401|in|induced (r_nmod) failure_14\NN\66216|of|heart|rats (r_nmod) pathogenesis_11\NN\13533470|in|the|failure (r_nmod) plays_5\VBZ\1072262|:|death|role|pathogenesis|. (l_nsubj) death_4\NN\7296428|autophagic|cardiomyocyte
D004317_D006333 CID adriamycin-induced_0\JJ\1740| (r_amod) death_3\NN\7296428|adriamycin-induced|autophagic|cardiomyocyte (r_nsubj) plays_4\VBZ\1072262|death|role|model|. (l_nmod) model_11\NN\5888929|in|a|rat|failure (l_nmod) failure_14\NN\66216|of|heart
D004317_D006333 CID adriamycin_9\NN\1740|by (r_nmod) induced_7\VBN\1627355|adriamycin (r_acl) failure_6\NN\66216|heart|induced
D004317_D006333 CID adriamycin_20\NN\1740|by (r_nmod) induced_18\VBN\1627355|adriamycin (r_acl) failure_17\NN\66216|of|heart|induced
D004317_D006333 CID adriamycin_20\NN\1740|by (r_nmod) induced_18\VBN\1627355|adriamycin (r_acl) failure_17\NN\66216|of|heart|induced (r_nmod) progression_14\NN\8457976|in|the|failure (r_nmod) involved_11\VBN\2676054|whether|autophagy|was|progression (r_ccomp) investigate_7\VB\644583|to|involved|,|develop (l_advcl) develop_26\VB\1753788|so|that|we|can|strategy (l_dobj) strategy_30\NN\5902545|a|novel|treatment|failure (l_nmod) failure_33\NN\66216|for|heart
D004317_D006333 CID adriamycin_23\NN\1740|by (r_nmod) induced_21\VBN\1627355|adriamycin (r_acl) model_18\NN\5888929|in|a|heart|failure|rats|induced (l_compound) failure_17\NN\66216|
D004317_D006333 CID adriamycin_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|adriamycin (r_acl) rats_16\NNS\2329401|in|induced (r_nmod) failure_14\NN\66216|of|heart|rats
D004317_D006333 CID adriamycin_13\NN\1740|by (r_nmod) caused_11\VBN\1617192|adriamycin (r_acl) failure_10\NN\66216|of|heart|caused
C025946_D006333 NONE 3-methyladenine_2\NN\1740|3ma|,|inhibitor (r_nsubjpass) used_13\VBN\1156834|3-methyladenine|was|model|. (l_nmod) model_18\NN\5888929|in|a|heart|failure|rats|induced (l_compound) failure_17\NN\66216|
C025946_D006333 NONE 3ma_4\NN\1740|(|) (r_appos) 3-methyladenine_2\NN\1740|3ma|,|inhibitor (r_nsubjpass) used_13\VBN\1156834|3-methyladenine|was|model|. (l_nmod) model_18\NN\5888929|in|a|heart|failure|rats|induced (l_compound) failure_17\NN\66216|
3076126
D008148_D009135 NONE lovastatin_23\NN\3676175|with (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|,
D008148_D009212 CID lovastatin_23\NN\3676175|with (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NN\14299637|with
D008148_D051437 CID lovastatin_23\NN\3676175|with (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
D016572_D009135 CID cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|,
D016572_D009212 NONE cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NN\14299637|with
D016572_D051437 NONE cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
D015248_D009135 CID gemfibrozil_33\NN\3740161| (r_conj) cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|,
D015248_D009212 NONE gemfibrozil_33\NN\3740161| (r_conj) cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NN\14299637|with
D015248_D051437 NONE gemfibrozil_33\NN\3740161| (r_conj) cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
D009525_D009135 CID niacin_35\NN\15090742| (r_conj) cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|,
D009525_D009212 NONE niacin_35\NN\15090742| (r_conj) cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NN\14299637|with
D009525_D051437 NONE niacin_35\NN\15090742| (r_conj) cyclosporin_31\NN\1740|with|,|gemfibrozil|or|niacin (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|in|treated (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|,|patients|. (l_nsubjpass) myopathy_0\NN\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
12615818
D017373_D054556 CID acetate_9\NN\15010703|cyproterone (r_dobj) prescribed_7\VBN\748282|acetate|combination (r_acl) women_6\NNS\9605289|in|prescribed (r_nmod) thromboembolism_4\NN\14100769|of|venous|women
D017373_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D017373_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D017373_D054556 CID cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated
D017373_D054556 CID cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (r_nmod) associated_10\VBN\628491|use (r_acl) risk_7\NN\14541044|an|increased|vte|associated (l_nmod) vte_9\NN\1740|of
D004997_D054556 CID estradiol_14\NN\14749794|with|ethinyl (r_nmod) combination_11\NN\7951464|in|estradiol (r_nmod) prescribed_7\VBN\748282|acetate|combination (r_acl) women_6\NNS\9605289|in|prescribed (r_nmod) thromboembolism_4\NN\14100769|of|venous|women
D004997_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D004997_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D004997_D054556 CID cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated
D004997_D054556 CID cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (r_nmod) associated_10\VBN\628491|use (r_acl) risk_7\NN\14541044|an|increased|vte|associated (l_nmod) vte_9\NN\1740|of
D017373_D000152 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D017373_D000152 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D017373_D000152 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|we|analysis|estimate (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested (l_acl) nested_16\VBN\2649830|population (l_nmod) population_19\NN\7942152|within|a|women (l_nmod) women_21\NNS\9605289|of|aged (l_amod) aged_22\JJ\1740|years|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism|or|pcos
D017373_D000152 NONE cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism|or|pcos
D017373_D006628 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D017373_D006628 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D017373_D006628 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|we|analysis|estimate (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested (l_acl) nested_16\VBN\2649830|population (l_nmod) population_19\NN\7942152|within|a|women (l_nmod) women_21\NNS\9605289|of|aged (l_amod) aged_22\JJ\1740|years|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism|or|pcos (l_conj) hirsutism_31\NN\4683453|
D017373_D006628 NONE cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism|or|pcos (l_conj) hirsutism_21\NN\4683453|
D017373_D011085 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D017373_D011085 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D017373_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D017373_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D017373_D011085 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|we|analysis|estimate (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested (l_acl) nested_16\VBN\2649830|population (l_nmod) population_19\NN\7942152|within|a|women (l_nmod) women_21\NNS\9605289|of|aged (l_amod) aged_22\JJ\1740|years|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism|or|pcos (l_conj) pcos_33\NN\1740|
D017373_D011085 NONE cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism|or|pcos (l_conj) pcos_23\NN\1740|
D004997_D000152 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D004997_D000152 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D004997_D000152 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|we|analysis|estimate (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested (l_acl) nested_16\VBN\2649830|population (l_nmod) population_19\NN\7942152|within|a|women (l_nmod) women_21\NNS\9605289|of|aged (l_amod) aged_22\JJ\1740|years|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism|or|pcos
D004997_D000152 NONE cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism|or|pcos
D004997_D006628 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D004997_D006628 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D004997_D006628 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|we|analysis|estimate (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested (l_acl) nested_16\VBN\2649830|population (l_nmod) population_19\NN\7942152|within|a|women (l_nmod) women_21\NNS\9605289|of|aged (l_amod) aged_22\JJ\1740|years|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism|or|pcos (l_conj) hirsutism_31\NN\4683453|
D004997_D006628 NONE cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism|or|pcos (l_conj) hirsutism_21\NN\4683453|
D004997_D011085 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D004997_D011085 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D004997_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D004997_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\JJ\1740|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D004997_D011085 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|we|analysis|estimate (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested (l_acl) nested_16\VBN\2649830|population (l_nmod) population_19\NN\7942152|within|a|women (l_nmod) women_21\NNS\9605289|of|aged (l_amod) aged_22\JJ\1740|years|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism|or|pcos (l_conj) pcos_33\NN\1740|
D004997_D011085 NONE cpa/ee_15\NN\1740|of (r_nmod) use_13\NN\407535|with|the|cpa/ee|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism|or|pcos (l_conj) pcos_23\NN\1740|
D003276_D054556 NONE contraceptives_21\NNS\3183080|compared|with|conventional|combined|oral|cocs (r_nmod) risk_6\NN\14541044|an|increased|thromboembolism|contraceptives (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 NONE contraceptives_21\NNS\3183080|compared|with|conventional|combined|oral|cocs (r_nmod) risk_6\NN\14541044|an|increased|thromboembolism|contraceptives (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
11706060
D019344_D009202 NONE lactate_8\NN\14850483|plasma (r_dobj) elevates_6\VBZ\2391803|lactate|mice (r_conj) causes_3\VBZ\1617192|therapy|cardiomyopathy|and|elevates|. (l_dobj) cardiomyopathy_4\NN\14103288|
D019344_D009202 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\NN\14103288|in|cm|and|lactate
D019344_D009202 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\NN\14103288|in|cm|and|lactate (l_appos) cm_12\NN\13649268|(|)
D019344_D009202 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\NN\14103288|in|cm|and|lactate
D019344_D009202 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\NN\14103288|in|cm|and|lactate (l_appos) cm_12\NN\13649268|(|)
D019344_D009202 NONE la_41\NN\14625458|of|plasma (r_nmod) determination_38\NN\43195|la (r_conj) mrna_20\NN\14832193|(|ventricular|encoding|,|and|determination (r_dep) quantitation_10\NN\1740|abundance|mrna (l_nmod) abundance_12\NN\5108740|of|markers (l_nmod) markers_15\NNS\21939|of|molecular|cm (l_nmod) cm_17\NN\13649268|of
D019344_D009202 NONE la_10\NN\14625458|with|elevated (r_nmod) cm_7\NN\13649268|mitochondrial|la|mice
D019344_D000163 NONE lactate_8\NN\14850483|plasma (r_dobj) elevates_6\VBZ\2391803|lactate|mice (l_nmod) mice_12\NNS\2329401|in|transgenic|aids (l_compound) aids_11\NN\13974317|
D019344_D000163 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (l_nmod) aids_23\NNP\13974317|in
D019344_D000163 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (l_nmod) aids_23\NNP\13974317|in
D019344_D000163 NONE la_10\NN\14625458|with|elevated (r_nmod) cm_7\NN\13649268|mitochondrial|la|mice (l_nmod) mice_14\NNS\2329401|in|aids|transgenic (l_compound) aids_12\NN\13974317|
D019344_D028361 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\NN\14103288|in|cm|and|lactate (r_nmod) implicated_8\VBN\2677097|therapy|is|cardiomyopathy|mechanisms|. (l_nmod) mechanisms_25\NNS\13446390|through|dysfunction (l_nmod) dysfunction_28\NN\14204950|of|mitochondrial
D019344_D028361 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\NN\14103288|in|cm|and|lactate (r_nmod) implicated_8\VBN\2677097|therapy|is|cardiomyopathy|mechanisms|. (l_nmod) mechanisms_25\NNS\13446390|through|dysfunction (l_nmod) dysfunction_28\NN\14204950|of|mitochondrial
D015215_D000163 NONE zidovudine_33\NN\3834836|of|,|lamivudine|,|and|indinavir|or|control (r_nmod) combination_31\NN\7951464|with|the|haart|zidovudine (r_nmod) treated_27\VBN\2376958|determine|,|mice|were|combination|days|. (l_nsubjpass) mice_13\NNS\2329401|8-week-old|hemizygous|transgenic|aids|gag/pol (l_compound) aids_12\NN\13974317|
D019259_D000163 NONE lamivudine_35\NN\3834836| (r_conj) zidovudine_33\NN\3834836|of|,|lamivudine|,|and|indinavir|or|control (r_nmod) combination_31\NN\7951464|with|the|haart|zidovudine (r_nmod) treated_27\VBN\2376958|determine|,|mice|were|combination|days|. (l_nsubjpass) mice_13\NNS\2329401|8-week-old|hemizygous|transgenic|aids|gag/pol (l_compound) aids_12\NN\13974317|
D019469_D000163 NONE indinavir_38\NN\4013993| (r_conj) zidovudine_33\NN\3834836|of|,|lamivudine|,|and|indinavir|or|control (r_nmod) combination_31\NN\7951464|with|the|haart|zidovudine (r_nmod) treated_27\VBN\2376958|determine|,|mice|were|combination|days|. (l_nsubjpass) mice_13\NNS\2329401|8-week-old|hemizygous|transgenic|aids|gag/pol (l_compound) aids_12\NN\13974317|
D002118_D009202 NONE calcium_30\NN\14625458| (r_compound) atpase_31\NN\1740|sarcoplasmic|calcium|serca2|) (r_conj) factor_24\NN\7326557|atrial|natriuretic|anf|and|atpase (r_dobj) encoding_21\VBG\115157|factor (r_acl) mrna_20\NN\14832193|(|ventricular|encoding|,|and|determination (r_dep) quantitation_10\NN\1740|abundance|mrna (l_nmod) abundance_12\NN\5108740|of|markers (l_nmod) markers_15\NNS\21939|of|molecular|cm (l_nmod) cm_17\NN\13649268|of
19037603
D019259_D012216 NONE lamivudine_3\NN\3834836|of (r_nmod) use_1\NN\407535|prophylactic|lamivudine|therapy|. (l_nmod) therapy_7\NN\657604|with|chronic|immunosuppressive|disorders (l_nmod) disorders_10\NNS\14034177|for|rheumatologic
D019259_D012216 NONE lamivudine_18\NN\3834836|of (r_nmod) administration_16\NN\1133281|of|the|prophylactic|lamivudine|patients (l_nmod) patients_30\NNS\9898892|in|positive|disease (l_nmod) disease_33\NN\14061805|with|rheumatologic
D019259_D012216 NONE lamivudine_23\NN\3834836| (r_compound) therapies_24\NNS\657604|lamivudine (r_dep) immunosuppressive_20\JJ\1740|on|both|and|prophylactic|therapies (r_nmod) patients_11\NNS\9898892|11|positive|diseases|,|immunosuppressive|, (l_nmod) diseases_14\NNS\14061805|with|rheumatologic
D006514_D012216 NONE antigen_24\NN\20090|hepatitis|b|virus|surface|ag (r_nmod:npmod) positive_29\JJ\1740|antigen (r_amod) patients_30\NNS\9898892|in|positive|disease (l_nmod) disease_33\NN\14061805|with|rheumatologic
D006514_D012216 NONE ag_27\NN\14821043|(|hbs|) (r_appos) antigen_24\NN\20090|hepatitis|b|virus|surface|ag (r_nmod:npmod) positive_29\JJ\1740|antigen (r_amod) patients_30\NNS\9898892|in|positive|disease (l_nmod) disease_33\NN\14061805|with|rheumatologic
D006514_D012216 NONE ag_9\NN\14821043|hbs (r_nmod:npmod) positive_10\JJ\1740|ag (r_amod) patients_11\NNS\9898892|11|positive|diseases|,|immunosuppressive|, (l_nmod) diseases_14\NNS\14061805|with|rheumatologic
1468485
D010100_D006470 NONE oxygen_1\NN\14622893| (r_compound) therapy_2\NN\657604|hyperbaric|oxygen|control|. (l_nmod) control_4\NN\5190804|for|cystitis (l_nmod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D010100_D003556 NONE oxygen_1\NN\14622893| (r_compound) therapy_2\NN\657604|hyperbaric|oxygen|control|. (l_nmod) control_4\NN\5190804|for|cystitis (l_nmod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D003520_D006470 CID cyclophosphamide-induced_7\JJ\1740| (r_amod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_10\NN\1740| (r_compound) therapy_11\NN\657604|due|cyclophosphamide|granulomatosis (r_nmod) cystitis_7\NN\14566129|of|intractable|hemorrhagic|therapy
D003520_D006470 CID cyclophosphamide-induced_16\JJ\1740| (r_amod) cystitis_18\NN\14566129|of|cyclophosphamide-induced|hemorrhagic
D003520_D003556 CID cyclophosphamide-induced_7\JJ\1740| (r_amod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_10\NN\1740| (r_compound) therapy_11\NN\657604|due|cyclophosphamide|granulomatosis (r_nmod) cystitis_7\NN\14566129|of|intractable|hemorrhagic|therapy
D003520_D003556 CID cyclophosphamide-induced_16\JJ\1740| (r_amod) cystitis_18\NN\14566129|of|cyclophosphamide-induced|hemorrhagic
D003520_D014890 NONE cyclophosphamide_10\NN\1740| (r_compound) therapy_11\NN\657604|due|cyclophosphamide|granulomatosis (l_nmod) granulomatosis_15\NN\1740|for|wegener
D015237_D006470 NONE alpha_14\NN\6828818|of|prostaglandin|f2 (r_nmod) instillation_10\NN\320852|alpha (r_conj) irrigation_5\NN\1057200|including|bladder|saline|and|instillation (r_nmod) treatment_1\NN\654885|conservative|,|irrigation|, (r_nsubj) failed_16\VBD\1798936|treatment|control|. (l_xcomp) control_19\VB\2422663|to|totally|hemorrhage (l_dobj) hemorrhage_20\NN\14285662|
17400887
D013726_D020078 NONE terbutaline_6\NN\1740| (r_compound) treatment_7\NN\654885|after|neonatal|terbutaline|rats (r_nmod) neuroinflammation_0\NN\1740|and|abnormalities|treatment|:|implications
D013726_D001523 NONE terbutaline_6\NN\1740| (r_compound) treatment_7\NN\654885|after|neonatal|terbutaline|rats (r_nmod) neuroinflammation_0\NN\1740|and|abnormalities|treatment|:|implications (l_conj) abnormalities_3\NNS\14034177|behavioral
D013726_D001321 CID terbutaline_6\NN\1740| (r_compound) treatment_7\NN\654885|after|neonatal|terbutaline|rats (r_nmod) neuroinflammation_0\NN\1740|and|abnormalities|treatment|:|implications (l_dep) implications_11\NNS\5774614|autism|. (l_nmod) autism_13\NN\14304060|for
D013726_D001321 CID terbutaline_0\NN\1740|,|agonist|, (r_nsubjpass) associated_13\VBN\628491|terbutaline|has|been|concordance|. (l_nmod) concordance_16\NN\13968547|with|increased|autism|twins (l_nmod) autism_18\NN\14304060|for
D013726_D007752 NONE terbutaline_0\NN\1740|,|agonist|, (l_appos) agonist_4\NN\9613191|a|beta2-adrenoceptor|used (l_acl) used_5\VBN\1156834|arrest (l_xcomp) arrest_7\VB\1212572|to|labor (l_dobj) labor_9\NN\7974025|preterm
8649546
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) dyskinesia_3\NN\14084880|of|levodopa-induced
D007980_D004409 CID levodopa-induced_12\JJ\1740| (r_amod) dyskinesia_16\NNS\14084880|levodopa-induced|ballistic|pd
D007980_D010300 NONE levodopa-induced_2\JJ\1740| (r_amod) dyskinesia_3\NN\14084880|of|levodopa-induced (r_nmod) improvement_0\NN\7359599|dyskinesia|propranolol|disease|. (l_nmod) disease_9\NN\14061805|in|parkinson
D007980_D010300 NONE levodopa-induced_12\JJ\1740| (r_amod) dyskinesia_16\NNS\14084880|levodopa-induced|ballistic|pd (l_nmod) pd_18\NNP\14625458|in
D011433_D004409 NONE propranolol_5\NN\1740|by (r_nmod) improvement_0\NN\7359599|dyskinesia|propranolol|disease|. (l_nmod) dyskinesia_3\NN\14084880|of|levodopa-induced
D011433_D004409 NONE propranolol_16\NN\1740|low-dose (r_dobj) received_14\VBD\2210855|patients|propranolol|adjunct|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\2110220|disease (l_nmod) disease_6\NN\14061805|from|parkinson|pd|dyskinesia (l_nmod) dyskinesia_13\NNS\14084880|with|disabling
D011433_D010300 NONE propranolol_5\NN\1740|by (r_nmod) improvement_0\NN\7359599|dyskinesia|propranolol|disease|. (l_nmod) disease_9\NN\14061805|in|parkinson
D011433_D010300 NONE propranolol_16\NN\1740|low-dose (r_dobj) received_14\VBD\2210855|patients|propranolol|adjunct|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\2110220|disease (l_nmod) disease_6\NN\14061805|from|parkinson|pd|dyskinesia
D011433_D010300 NONE propranolol_16\NN\1740|low-dose (r_dobj) received_14\VBD\2210855|patients|propranolol|adjunct|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\2110220|disease (l_nmod) disease_6\NN\14061805|from|parkinson|pd|dyskinesia (l_appos) pd_8\NN\14625458|(|)
8682684
D000082_D007022 CID acetaminophen-induced_0\NN\1740| (r_compound) hypotension_1\NN\14057371|acetaminophen-induced|.
D000082_D007022 CID acetaminophen_2\NN\2707683| (r_nsubjpass) demonstrated_5\VBN\2137132|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\1617192|to|symptoms|individuals (l_dobj) symptoms_8\NNS\5823932|anaphylaxis|hypotension|, (l_nmod) hypotension_13\NN\14057371|including
D000082_D007022 CID acetaminophen_18\NN\2707683|of (r_nmod) administration_16\NN\1133281|after|acetaminophen (r_nmod) developed_14\VBD\1753788|whom|episodes|reproducibly|administration (l_nsubj) episodes_10\NNS\7283608|transient|hypotension (l_nmod) hypotension_12\NN\14057371|of
D000082_D007022 CID acetaminophen_9\NN\2707683| (r_dobj) consider_8\VB\689344|for|clinicians|to|acetaminophen|patients (l_nmod) patients_11\NNS\9898892|in|hypotension (l_nmod) hypotension_13\NN\14057371|with|origin
D000082_D002318 NONE acetaminophen_3\NN\2707683| (r_nsubj) produce_5\VB\1617192|for|acetaminophen|to|toxicities (l_dobj) toxicities_7\NNS\13576101|cardiovascular
D000082_D000707 NONE acetaminophen_2\NN\2707683| (r_nsubjpass) demonstrated_5\VBN\2137132|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\1617192|to|symptoms|individuals (l_dobj) symptoms_8\NNS\5823932|anaphylaxis|hypotension|, (l_nmod) anaphylaxis_10\NN\14533203|of|,
D000082_D016638 NONE acetaminophen_18\NN\2707683|of (r_nmod) administration_16\NN\1133281|after|acetaminophen (r_nmod) developed_14\VBD\1753788|whom|episodes|reproducibly|administration (r_acl:relcl) patients_6\NNS\9898892|two|ill|developed (l_amod) ill_5\JJ\1740|critically
9523805
D011318_D009422 CID prilocaine_11\NN\1740|with|and|bupivacaine (r_nmod) incidence_9\NN\13821570|a|lower|prilocaine|than (r_dep) symptoms_2\NNS\5823932|transient|neurologic|anesthesia|:|incidence|.
D011318_D009422 CID prilocaine_9\NN\1740|lidocaine (r_dobj) compares_8\VBZ\644583|accordingly|,|study|prilocaine|respect|. (l_nmod) respect_15\NN\5817845|with|duration (l_nmod) duration_17\NN\15113229|to|action|and|risk (l_conj) risk_22\NN\14541044|relative|tnss (l_nmod) tnss_24\NN\1740|of
D011318_D009422 CID prilocaine_16\NN\1740| (r_dobj) receiving_15\VBG\2210855|prilocaine (r_acl) patients_14\NNS\9898892|30|receiving|= (r_nsubj) had_22\VBD\2108377|patients|them|,|and|had (r_conj) experienced_8\VBD\2108377|patients|tnss|,|had (l_dobj) tnss_9\NNS\1740|
D011318_D009422 CID prilocaine_16\NN\1740| (r_dobj) receiving_15\VBG\2210855|prilocaine (r_acl) patients_14\NNS\9898892|30|receiving|= (r_nsubj) had_22\VBD\2108377|patients|them|,|and|had (l_conj) had_32\VBD\2108377|none|tnss|. (l_dobj) tnss_33\NNS\1740|
D011318_D009422 CID prilocaine_2\NN\1740| (r_nsubj) preferable_5\JJ\1740|:|prilocaine|may|be|lidocaine|procedures|has (l_advcl) has_14\VBZ\2108377|because|it|duration (l_dobj) duration_17\NN\15113229|a|similar|action|but|incidence (l_conj) incidence_23\NN\13821570|a|lower|tnss (l_nmod) tnss_25\NNS\1740|of
D002045_D009422 NONE bupivacaine_13\NN\1740| (r_conj) prilocaine_11\NN\1740|with|and|bupivacaine (r_nmod) incidence_9\NN\13821570|a|lower|prilocaine|than (r_dep) symptoms_2\NNS\5823932|transient|neurologic|anesthesia|:|incidence|.
D002045_D009422 NONE bupivacaine_21\NN\1740|with (r_nmod) infrequent_19\JJ\1740|are|bupivacaine (r_conj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss
D002045_D009422 NONE bupivacaine_21\NN\1740|with (r_nmod) infrequent_19\JJ\1740|are|bupivacaine (r_conj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss (l_appos) tnss_10\NNS\1740|(|)
D002045_D009422 NONE bupivacaine_13\NN\1740| (r_conj) lidocaine_11\NN\3681148|with|and|bupivacaine (r_nmod) prilocaine_9\NN\1740|lidocaine (r_dobj) compares_8\VBZ\644583|accordingly|,|study|prilocaine|respect|. (l_nmod) respect_15\NN\5817845|with|duration (l_nmod) duration_17\NN\15113229|to|action|and|risk (l_conj) risk_22\NN\14541044|relative|tnss (l_nmod) tnss_24\NN\1740|of
D002045_D009422 NONE bupivacaine_31\NN\1740| (r_dobj) receiving_30\VBG\2210855|bupivacaine (r_acl) patients_29\NNS\9898892|of|30|receiving (r_nmod) none_26\NN\15228378|patients (r_nsubj) had_32\VBD\2108377|none|tnss|. (r_conj) had_22\VBD\2108377|patients|them|,|and|had (r_conj) experienced_8\VBD\2108377|patients|tnss|,|had (l_dobj) tnss_9\NNS\1740|
D002045_D009422 NONE bupivacaine_31\NN\1740| (r_dobj) receiving_30\VBG\2210855|bupivacaine (r_acl) patients_29\NNS\9898892|of|30|receiving (r_nmod) none_26\NN\15228378|patients (r_nsubj) had_32\VBD\2108377|none|tnss|. (l_dobj) tnss_33\NNS\1740|
D008012_D009422 CID lidocaine_16\NN\3681148|with (r_nmod) than_14\IN\1740|lidocaine (r_prep) incidence_9\NN\13821570|a|lower|prilocaine|than (r_dep) symptoms_2\NNS\5823932|transient|neurologic|anesthesia|:|incidence|.
D008012_D009422 CID lidocaine_14\NN\3681148| (r_compound) anesthesia_16\NN\14034177|lidocaine|spinal (r_dobj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss
D008012_D009422 CID lidocaine_14\NN\3681148| (r_compound) anesthesia_16\NN\14034177|lidocaine|spinal (r_dobj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss (l_appos) tnss_10\NNS\1740|(|)
D008012_D009422 CID lidocaine_11\NN\3681148|with|and|bupivacaine (r_nmod) prilocaine_9\NN\1740|lidocaine (r_dobj) compares_8\VBZ\644583|accordingly|,|study|prilocaine|respect|. (l_nmod) respect_15\NN\5817845|with|duration (l_nmod) duration_17\NN\15113229|to|action|and|risk (l_conj) risk_22\NN\14541044|relative|tnss (l_nmod) tnss_24\NN\1740|of
D008012_D009422 CID lidocaine_7\NN\3681148| (r_dobj) receiving_6\VBG\2210855|lidocaine (r_acl) patients_5\NNS\9898892|30|receiving (r_nsubj) experienced_8\VBD\2108377|patients|tnss|,|had (l_dobj) tnss_9\NNS\1740|
D008012_D009422 CID lidocaine_7\NN\3681148| (r_dobj) receiving_6\VBG\2210855|lidocaine (r_acl) patients_5\NNS\9898892|30|receiving (r_nsubj) experienced_8\VBD\2108377|patients|tnss|,|had (l_conj) had_22\VBD\2108377|patients|them|,|and|had (l_conj) had_32\VBD\2108377|none|tnss|. (l_dobj) tnss_33\NNS\1740|
D008012_D009422 CID lidocaine_7\NN\3681148|to (r_nmod) preferable_5\JJ\1740|:|prilocaine|may|be|lidocaine|procedures|has (l_advcl) has_14\VBZ\2108377|because|it|duration (l_dobj) duration_17\NN\15113229|a|similar|action|but|incidence (l_conj) incidence_23\NN\13821570|a|lower|tnss (l_nmod) tnss_25\NNS\1740|of
17854040
D019259_D006509 NONE lamivudine-resistance_3\NN\1740|with (r_nmod) associated_1\VBN\628491|lamivudine-resistance|patients (l_nmod) patients_14\NNS\9898892|in|therapy-na|ve|infected|with|co-infection (l_amod) infected_13\JJ\1740|virus
D019259_D006509 NONE lamivudine-resistance_3\NN\1740|with (r_nmod) associated_1\VBN\628491|lamivudine-resistance|patients (r_acl) mutations_0\NNS\4475|associated|:|implications|. (l_dep) implications_21\NNS\5774614|therapy (l_nmod) therapy_24\NN\657604|for|antiretroviral|patients (l_nmod) patients_32\NNS\9898892|in|hbv|hiv|co-infected|african (l_amod) co-infected_29\JJ\1740|
D019259_D006509 NONE lamivudine-resistant_7\JJ\1740| (r_amod) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (l_compound) b_9\NN\1355326|
D019259_D006509 NONE lamivudine-na_17\JJ\1740| (r_amod) carriers_20\NNS\9629752|in|selected|lamivudine-na|ve|hbv|co-infection (r_nmod) strains_14\NNS\7358060|virus|carriers (l_compound) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (l_compound) b_9\NN\1355326|
D019259_D006509 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (l_amod) infected_4\JJ\1740|hbv
D019259_D006509 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_amod) mono-infected_17\JJ\1740|
D019259_D006509 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\JJ\1740|
D019259_D006509 NONE lamivudine-resistant_1\JJ\1740| (r_amod) strains_2\NNS\7358060|hbv|lamivudine-resistant (r_nsubjpass) detected_4\VBN\2163746|strains|were|patients|. (l_nmod) patients_13\NNS\9898892|in|15|mono-infected|chronic|b|and|patients (l_compound) b_12\NN\1355326|hepatitis
D019259_D006509 NONE lamivudine-resistant_1\JJ\1740| (r_amod) strains_2\NNS\7358060|hbv|lamivudine-resistant (r_nsubjpass) detected_4\VBN\2163746|strains|were|patients|. (l_nmod) patients_13\NNS\9898892|in|15|mono-infected|chronic|b|and|patients (l_conj) patients_20\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_19\JJ\1740|
D019259_D006509 NONE lamivudine-resistant_14\JJ\1740| (r_amod) strains_15\NNS\7358060|of|hbv|lamivudine-resistant|patients (l_nmod) patients_21\NNS\9898892|in|therapy-na|ve|hbv-hiv|co-infected (l_amod) co-infected_20\JJ\1740|
D019259_D006509 NONE lamivudine-containing_20\JJ\1740| (r_amod) treatment_27\NN\654885|lamivudine-containing|active|antiretroviral|arv|haart (r_compound) regimens_31\NNS\5898568|treatment (r_nsubj) become_32\VBP\146138|when|regimens|applied|,|likely (l_advcl) likely_42\JJ\1740|as|this|is|have (l_xcomp) have_44\VB\2108377|to|implications|management (l_nmod) management_49\NN\1123598|in|the|patients (l_nmod) patients_53\NNS\9898892|of|hbv-hiv|co-infected (l_amod) co-infected_52\JJ\1740|
D019259_D015658 NONE lamivudine-resistance_3\NN\1740|with (r_nmod) associated_1\VBN\628491|lamivudine-resistance|patients (l_nmod) patients_14\NNS\9898892|in|therapy-na|ve|infected|with|co-infection (l_acl:relcl) co-infection_19\NN\1740|hiv
D019259_D015658 NONE lamivudine-resistance_3\NN\1740|with (r_nmod) associated_1\VBN\628491|lamivudine-resistance|patients (r_acl) mutations_0\NNS\4475|associated|:|implications|. (l_dep) implications_21\NNS\5774614|therapy (l_nmod) therapy_24\NN\657604|for|antiretroviral|patients (l_nmod) patients_32\NNS\9898892|in|hbv|hiv|co-infected|african (l_amod) co-infected_29\JJ\1740|
D019259_D015658 NONE lamivudine-resistant_7\JJ\1740| (r_amod) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (r_compound) strains_14\NNS\7358060|virus|carriers (l_nmod) carriers_20\NNS\9629752|in|selected|lamivudine-na|ve|hbv|co-infection (l_nmod) co-infection_30\NN\1740|with|virus|patients
D019259_D015658 NONE lamivudine-na_17\JJ\1740| (r_amod) carriers_20\NNS\9629752|in|selected|lamivudine-na|ve|hbv|co-infection (l_nmod) co-infection_30\NN\1740|with|virus|patients
D019259_D015658 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (l_appos) co-infection_10\NN\1740|with|hiv
D019259_D015658 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\JJ\1740|
D019259_D015658 NONE lamivudine-resistant_1\JJ\1740| (r_amod) strains_2\NNS\7358060|hbv|lamivudine-resistant (r_nsubjpass) detected_4\VBN\2163746|strains|were|patients|. (l_nmod) patients_13\NNS\9898892|in|15|mono-infected|chronic|b|and|patients (l_conj) patients_20\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_19\JJ\1740|
D019259_D015658 NONE lamivudine-resistant_14\JJ\1740| (r_amod) strains_15\NNS\7358060|of|hbv|lamivudine-resistant|patients (l_nmod) patients_21\NNS\9898892|in|therapy-na|ve|hbv-hiv|co-infected (l_amod) co-infected_20\JJ\1740|
D019259_D015658 NONE lamivudine-containing_20\JJ\1740| (r_amod) treatment_27\NN\654885|lamivudine-containing|active|antiretroviral|arv|haart (r_compound) regimens_31\NNS\5898568|treatment (r_nsubj) become_32\VBP\146138|when|regimens|applied|,|likely (l_advcl) likely_42\JJ\1740|as|this|is|have (l_xcomp) have_44\VB\2108377|to|implications|management (l_nmod) management_49\NN\1123598|in|the|patients (l_nmod) patients_53\NNS\9898892|of|hbv-hiv|co-infected (l_amod) co-infected_52\JJ\1740|
D012964_D006509 NONE therapy-na_5\NN\1740| (r_amod) patients_14\NNS\9898892|in|therapy-na|ve|infected|with|co-infection (l_amod) infected_13\JJ\1740|virus
D012964_D006509 NONE therapy-na_5\NN\1740| (r_amod) patients_14\NNS\9898892|in|therapy-na|ve|infected|with|co-infection (r_nmod) associated_1\VBN\628491|lamivudine-resistance|patients (r_acl) mutations_0\NNS\4475|associated|:|implications|. (l_dep) implications_21\NNS\5774614|therapy (l_nmod) therapy_24\NN\657604|for|antiretroviral|patients (l_nmod) patients_32\NNS\9898892|in|hbv|hiv|co-infected|african (l_amod) co-infected_29\JJ\1740|
D012964_D006509 NONE lamivudine-na_17\JJ\1740| (r_amod) carriers_20\NNS\9629752|in|selected|lamivudine-na|ve|hbv|co-infection (r_nmod) strains_14\NNS\7358060|virus|carriers (l_compound) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (l_compound) b_9\NN\1355326|
D012964_D006509 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (l_amod) infected_4\JJ\1740|hbv
D012964_D006509 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_amod) mono-infected_17\JJ\1740|
D012964_D006509 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\JJ\1740|
D012964_D006509 NONE therapy-na_17\NN\1740| (r_amod) patients_21\NNS\9898892|in|therapy-na|ve|hbv-hiv|co-infected (l_amod) co-infected_20\JJ\1740|
D012964_D015658 NONE therapy-na_5\NN\1740| (r_amod) patients_14\NNS\9898892|in|therapy-na|ve|infected|with|co-infection (l_acl:relcl) co-infection_19\NN\1740|hiv
D012964_D015658 NONE therapy-na_5\NN\1740| (r_amod) patients_14\NNS\9898892|in|therapy-na|ve|infected|with|co-infection (r_nmod) associated_1\VBN\628491|lamivudine-resistance|patients (r_acl) mutations_0\NNS\4475|associated|:|implications|. (l_dep) implications_21\NNS\5774614|therapy (l_nmod) therapy_24\NN\657604|for|antiretroviral|patients (l_nmod) patients_32\NNS\9898892|in|hbv|hiv|co-infected|african (l_amod) co-infected_29\JJ\1740|
D012964_D015658 NONE lamivudine-na_17\JJ\1740| (r_amod) carriers_20\NNS\9629752|in|selected|lamivudine-na|ve|hbv|co-infection (l_nmod) co-infection_30\NN\1740|with|virus|patients
D012964_D015658 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (l_appos) co-infection_10\NN\1740|with|hiv
D012964_D015658 NONE lamivudine-na_1\NN\1740| (r_compound) patients_5\NNS\9898892|thirty-five|lamivudine-na|ve|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\JJ\1740|
D012964_D015658 NONE therapy-na_17\NN\1740| (r_amod) patients_21\NNS\9898892|in|therapy-na|ve|hbv-hiv|co-infected (l_amod) co-infected_20\JJ\1740|
1436384
D000661_D020258 CID amphetamine-induced_2\JJ\1740| (r_amod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
D000661_D020258 CID amphetamine_10\NN\3248958|of|and|compounds (r_nmod) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
D004298_D020258 NONE dopamine_6\NN\14807737| (r_compound) neurons_7\NNS\5430628|toward|striatal|dopamine|rodents (r_nmod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
D004298_D020258 NONE dopamine_16\NN\14807737| (r_compound) neurons_17\NNS\5430628|toward|nigrostriatal|dopamine (r_nmod) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
C070935_D020258 NONE ly274614_11\NN\1740|by|,|antagonist (r_nmod) protection_0\NN\407535|neurotoxicity|ly274614|. (l_nmod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
C070935_D020258 NONE ly274614_23\NN\1740| (r_nsubj) antagonist_28\NN\7846|that|ly274614|is|an|nmda|receptor|effects (r_conj) involves_18\VBZ\2676054|that|effect|receptors|and|antagonist (l_nsubj) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
D000596_D020258 NONE acid_16\NN\14818238| (r_compound) antagonist_17\NN\7846|an|excitatory|amino|acid (r_appos) ly274614_11\NN\1740|by|,|antagonist (r_nmod) protection_0\NN\407535|neurotoxicity|ly274614|. (l_nmod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
D016202_D020258 NONE nmda_19\NN\1740| (r_compound) receptors_20\NNS\5225602|nmda (r_dobj) involves_18\VBZ\2676054|that|effect|receptors|and|antagonist (l_nsubj) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
D016202_D020258 NONE nmda_26\NN\1740| (r_compound) antagonist_28\NN\7846|that|ly274614|is|an|nmda|receptor|effects (r_conj) involves_18\VBZ\2676054|that|effect|receptors|and|antagonist (l_nsubj) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
3629586
D015790_D006402 NONE cefonicid_4\NN\1740|of|and|cefazedone (r_nmod) effects_2\NNS\13245626|the|hematologic|cefonicid|dog|:|model (l_dep) model_13\NN\5888929|a|potential|hematotoxicity|. (l_nmod) hematotoxicity_16\NN\1740|of|cephalosporin|man
D015790_D006402 NONE cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|of|receiving (r_nmod) %_15\NN\1740|in|50|dogs (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\JJ\1740|anemia|was|the|most|cytopenias|and|occurred|. (l_nmod) cytopenias_9\NNS\14189204|of|the
D015790_D006402 NONE cefonicid_16\NN\1740|(|not|cefazedone)-treated (r_compound) dogs_21\NNS\2083346|cefonicid (r_nsubj) showed_22\VBD\2137132|reproduced|;|dogs|period|that|. (l_ccomp) reproduced_10\VBN\1621555|rechallenge|,|syndrome|was|dogs (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
D015790_D006402 NONE cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses|dogs (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\1740|similar
D015790_D006402 NONE cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses|dogs (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\1740|similar (l_amod) similar_17\JJ\1740|dyscrasias (l_nmod) dyscrasias_22\NNS\14052046|to|the|cephalosporin-induced|blood|described
C021341_D006402 NONE cefazedone_6\NN\1740| (r_conj) cefonicid_4\NN\1740|of|and|cefazedone (r_nmod) effects_2\NNS\13245626|the|hematologic|cefonicid|dog|:|model (l_dep) model_13\NN\5888929|a|potential|hematotoxicity|. (l_nmod) hematotoxicity_16\NN\1740|of|cephalosporin|man
C021341_D006402 NONE cefazedone_29\NN\1740|840|mg/kg (r_conj) cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|of|receiving (r_nmod) %_15\NN\1740|in|50|dogs (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\JJ\1740|anemia|was|the|most|cytopenias|and|occurred|. (l_nmod) cytopenias_9\NNS\14189204|of|the
C021341_D006402 NONE cefazedone)-treated_20\NN\1740| (r_conj) cefonicid_16\NN\1740|(|not|cefazedone)-treated (r_compound) dogs_21\NNS\2083346|cefonicid (r_nsubj) showed_22\VBD\2137132|reproduced|;|dogs|period|that|. (l_ccomp) reproduced_10\VBN\1621555|rechallenge|,|syndrome|was|dogs (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
C021341_D006402 NONE cefazedone_11\NN\1740| (r_conj) cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses|dogs (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\1740|similar
C021341_D006402 NONE cefazedone_11\NN\1740| (r_conj) cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses|dogs (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\1740|similar (l_amod) similar_17\JJ\1740|dyscrasias (l_nmod) dyscrasias_22\NNS\14052046|to|the|cephalosporin-induced|blood|described
D002511_D006402 NONE cephalosporin_15\NN\2716866| (r_compound) hematotoxicity_16\NN\1740|of|cephalosporin|man
D002511_D006402 NONE cephalosporin_0\NN\2716866| (r_compound) antibiotics_1\NNS\2716205|cephalosporin (r_nsubj) cause_2\VBP\1617192|antibiotics|variety|remain|. (l_dobj) variety_4\NN\7951464|a|disturbances (l_nmod) disturbances_7\NNS\407535|of|hematologic|man|,
D002511_D006402 NONE cephalosporin_4\NN\2716866|with|either (r_nmod) rechallenge_1\NN\1740|upon|cephalosporin (r_nmod) reproduced_10\VBN\1621555|rechallenge|,|syndrome|was|dogs (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
D002511_D006402 NONE cephalosporin-induced_20\JJ\1740| (r_amod) dyscrasias_22\NNS\14052046|to|the|cephalosporin-induced|blood|described (r_nmod) similar_17\JJ\1740|dyscrasias (r_amod) hematotoxicity_16\NN\1740|similar
D002511_D006402 NONE cephalosporin-induced_20\JJ\1740| (r_amod) dyscrasias_22\NNS\14052046|to|the|cephalosporin-induced|blood|described
D015790_D064420 NONE cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_nmod) studies_4\NNS\635850|in|four|subacute|toxicity (l_compound) toxicity_3\NN\13576101|
D015790_D000740 CID cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia
D015790_D000740 CID cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|of|receiving (r_nmod) %_15\NN\1740|in|50|dogs (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\JJ\1740|anemia|was|the|most|cytopenias|and|occurred|. (l_nsubj) anemia_2\NN\14189204|a|nonregenerative
D015790_D009503 CID cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) neutropenia_23\NN\14196405|
D015790_D013921 CID cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) thrombocytopenia_26\NN\14189204|
C021341_D064420 NONE cefazedone_12\NN\1740| (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_nmod) studies_4\NNS\635850|in|four|subacute|toxicity (l_compound) toxicity_3\NN\13576101|
C021341_D000740 CID cefazedone_12\NN\1740| (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia
C021341_D000740 CID cefazedone_29\NN\1740|840|mg/kg (r_conj) cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) dogs_17\NNS\2083346|of|receiving (r_nmod) %_15\NN\1740|in|50|dogs (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\JJ\1740|anemia|was|the|most|cytopenias|and|occurred|. (l_nsubj) anemia_2\NN\14189204|a|nonregenerative
C021341_D009503 CID cefazedone_12\NN\1740| (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) neutropenia_23\NN\14196405|
C021341_D013921 CID cefazedone_12\NN\1740| (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid|dogs (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) thrombocytopenia_26\NN\14189204|
21029050
D013390_D001049 CID succinylcholine_9\NN\3800001|after (r_nmod) apnea_7\NN\14299637|with|prolonged|succinylcholine
D013390_D001049 CID succinylcholine_13\NN\3800001|of (r_nmod) action_11\NN\30358|of|succinylcholine (r_nmod) duration_9\NN\15113229|with|a|prolonged|action (r_nmod) patients_5\NNS\9898892|13|duration (r_nsubj) had_14\VBD\2108377|patients|mutations|,|indicating (l_advcl) indicating_19\VBG\952524|reason (l_ccomp) reason_25\NN\9178821|that|this|is|the|possible|period (l_nmod) period_29\NN\13575869|for|a|prolonged|apnea (l_nmod) apnea_31\NN\14299637|of
12707296
D001120_D006973 NONE l-arginine_0\NN\1740| (r_compound) transport_1\NN\3575240|l-arginine|humans|. (l_nmod) humans_3\NNS\31264|in|hypertension (l_nmod) hypertension_6\NN\14057371|with|cortisol-induced
D001120_D006973 NONE l-arginine-nitric_2\JJ\1740| (r_amod) system_4\NN\3575240|a|deficient|l-arginine-nitric|oxide (r_nsubjpass) implicated_6\VBN\2677097|system|is|hypertension|. (l_nmod) hypertension_9\NN\14057371|in|cortisol-induced
D001120_D006973 NONE l-arginine_15\NN\1740| (r_compound) system_17\NN\3575240|in|the|l-arginine|transport (r_nmod) abnormalities_12\NNS\14034177|with|system (r_nmod) associated_10\VBN\628491|that|increases|are|not|abnormalities (l_nsubjpass) increases_4\NNS\13576355|cortisol-induced|pressure (l_nmod) pressure_7\NN\11419404|in|blood
D006854_D006973 NONE cortisol-induced_5\JJ\1740| (r_amod) hypertension_6\NN\14057371|with|cortisol-induced
D006854_D006973 NONE cortisol-induced_8\JJ\1740| (r_amod) hypertension_9\NN\14057371|in|cortisol-induced
D006854_D006973 NONE cortisol-induced_3\JJ\1740| (r_amod) increases_4\NNS\13576355|cortisol-induced|pressure (l_nmod) pressure_7\NN\11419404|in|blood
D009569_D006973 NONE oxide_3\NN\14818238| (r_compound) system_4\NN\3575240|a|deficient|l-arginine-nitric|oxide (r_nsubjpass) implicated_6\VBN\2677097|system|is|hypertension|. (l_nmod) hypertension_9\NN\14057371|in|cortisol-induced
3750012
D010396_D009157 CID penicillamine_4\NN\3740161|by|and|therapy|arthritis (r_nmod) caused_2\VBN\1617192|penicillamine (r_acl) gravis_1\NN\1740|myasthenia|caused|.
D010396_D009157 CID penicillamine_14\NN\3740161|and|chloroquine (r_compound) therapy_17\NN\657604|after|penicillamine|arthritis (r_nmod) had_7\VBD\2108377|who|gravis|therapy (l_dobj) gravis_12\NN\1740|reversible|myasthenia
D010396_D001172 NONE penicillamine_4\NN\3740161|by|and|therapy|arthritis (l_nmod) arthritis_10\NN\14171682|for|rheumatoid
D010396_D001172 NONE penicillamine_14\NN\3740161|and|chloroquine (r_compound) therapy_17\NN\657604|after|penicillamine|arthritis (l_nmod) arthritis_20\NN\14171682|for|rheumatoid
D002738_D009157 CID chloroquine_6\NN\2721948| (r_compound) therapy_7\NN\657604|chloroquine (r_conj) penicillamine_4\NN\3740161|by|and|therapy|arthritis (r_nmod) caused_2\VBN\1617192|penicillamine (r_acl) gravis_1\NN\1740|myasthenia|caused|.
D002738_D009157 CID chloroquine_16\NN\2721948| (r_conj) penicillamine_14\NN\3740161|and|chloroquine (r_compound) therapy_17\NN\657604|after|penicillamine|arthritis (r_nmod) had_7\VBD\2108377|who|gravis|therapy (l_dobj) gravis_12\NN\1740|reversible|myasthenia
D002738_D001172 NONE chloroquine_6\NN\2721948| (r_compound) therapy_7\NN\657604|chloroquine (r_conj) penicillamine_4\NN\3740161|by|and|therapy|arthritis (l_nmod) arthritis_10\NN\14171682|for|rheumatoid
D002738_D001172 NONE chloroquine_16\NN\2721948| (r_conj) penicillamine_14\NN\3740161|and|chloroquine (r_compound) therapy_17\NN\657604|after|penicillamine|arthritis (l_nmod) arthritis_20\NN\14171682|for|rheumatoid
6308277
D002110_D064420 NONE caffeine_2\NN\14712692| (r_compound) toxicity_3\NN\13576101|in|caffeine
D002110_D064420 NONE caffeine_11\NN\14712692|of (r_nmod) effects_9\NNS\13245626|the|stimulatory|caffeine|cns (r_dobj) augment_6\VB\153263|to|effects (r_xcomp) reported_4\VBN\831651|because|salicylates|have|been|augment (r_advcl) focused_18\VBN\628491|reported|,|attention|was|possibility|. (l_nmod) possibility_21\NN\5944958|on|the|reduced (l_acl) reduced_31\VBD\441445|that|presence|toxicity (l_dobj) toxicity_34\NN\13576101|the|cns|caffeine
D002110_D064420 NONE caffeine_36\NN\14712692|of (r_nmod) toxicity_34\NN\13576101|the|cns|caffeine
D000082_D064420 NONE acetaminophen_5\NN\2707683|by (r_nmod) reduction_0\NN\351485|toxicity|acetaminophen|. (l_nmod) toxicity_3\NN\13576101|in|caffeine
D000082_D064420 NONE acetaminophen_26\NN\2707683|of|micrograms/ml (r_nmod) presence_24\NN\13954253|the|acetaminophen (r_nsubj) reduced_31\VBD\441445|that|presence|toxicity (l_dobj) toxicity_34\NN\13576101|the|cns|caffeine
D000082_D012640 NONE acetaminophen_11\NN\2707683|with|mg/kg (r_nmod) pretreatment_9\NN\1740|acetaminophen (r_nsubj) increased_16\VBD\169651|that|:|1|pretreatment|interval|;|and|reduced (l_dobj) interval_18\NN\33615|the|administration (l_nmod) administration_21\NN\1133281|between|the|caffeine|mg/kg|and|onset|factor (l_conj) onset_33\NN\7325190|the|convulsions (l_nmod) convulsions_36\NNS\14081375|of|fatal
D000082_D012640 NONE acetaminophen_11\NN\2707683|with|mg/kg (r_nmod) pretreatment_9\NN\1740|acetaminophen (r_nsubj) increased_16\VBD\169651|that|:|1|pretreatment|interval|;|and|reduced (l_conj) reduced_54\VBD\441445|2|pretreatment|incidence (l_dobj) incidence_56\NN\13821570|the|seizures (l_nmod) seizures_59\NNS\14081375|of|audiogenic|produced
D000082_D012640 NONE acetaminophen_49\NN\2707683|with|mg/kg (r_nmod) pretreatment_47\NN\1740|acetaminophen (r_nsubj) reduced_54\VBD\441445|2|pretreatment|incidence (r_conj) increased_16\VBD\169651|that|:|1|pretreatment|interval|;|and|reduced (l_dobj) interval_18\NN\33615|the|administration (l_nmod) administration_21\NN\1133281|between|the|caffeine|mg/kg|and|onset|factor (l_conj) onset_33\NN\7325190|the|convulsions (l_nmod) convulsions_36\NNS\14081375|of|fatal
D000082_D012640 NONE acetaminophen_49\NN\2707683|with|mg/kg (r_nmod) pretreatment_47\NN\1740|acetaminophen (r_nsubj) reduced_54\VBD\441445|2|pretreatment|incidence (l_dobj) incidence_56\NN\13821570|the|seizures (l_nmod) seizures_59\NNS\14081375|of|audiogenic|produced
D000082_D012640 NONE acetaminophen_19\NN\2707683|by (r_nmod) reduced_12\VBN\441445|frequency|was|%|acetaminophen|. (l_nsubjpass) frequency_1\NN\15286249|the|seizures|caffeine (l_nmod) seizures_4\NNS\14081375|of|sound-induced
D000082_D012640 NONE acetaminophen_6\NN\2707683|mg/kg (r_nsubj) modify_15\VB\109660|absence|,|acetaminophen|did|not|seizures|and|alter|tests|. (l_dobj) seizures_17\NNS\14081375|the|induced
D002110_D012640 CID caffeine_23\NN\14712692|of (r_nmod) administration_21\NN\1133281|between|the|caffeine|mg/kg|and|onset|factor (l_conj) onset_33\NN\7325190|the|convulsions (l_nmod) convulsions_36\NNS\14081375|of|fatal
D002110_D012640 CID caffeine_23\NN\14712692|of (r_nmod) administration_21\NN\1133281|between|the|caffeine|mg/kg|and|onset|factor (r_nmod) interval_18\NN\33615|the|administration (r_dobj) increased_16\VBD\169651|that|:|1|pretreatment|interval|;|and|reduced (l_conj) reduced_54\VBD\441445|2|pretreatment|incidence (l_dobj) incidence_56\NN\13821570|the|seizures (l_nmod) seizures_59\NNS\14081375|of|audiogenic|produced
D002110_D012640 CID caffeine_65\NN\14712692|presence|of|mg/kg (r_dobj) produced_60\VBN\1617192|caffeine (r_acl) seizures_59\NNS\14081375|of|audiogenic|produced (r_nmod) incidence_56\NN\13821570|the|seizures (r_dobj) reduced_54\VBD\441445|2|pretreatment|incidence (r_conj) increased_16\VBD\169651|that|:|1|pretreatment|interval|;|and|reduced (l_dobj) interval_18\NN\33615|the|administration (l_nmod) administration_21\NN\1133281|between|the|caffeine|mg/kg|and|onset|factor (l_conj) onset_33\NN\7325190|the|convulsions (l_nmod) convulsions_36\NNS\14081375|of|fatal
D002110_D012640 CID caffeine_65\NN\14712692|presence|of|mg/kg (r_dobj) produced_60\VBN\1617192|caffeine (r_acl) seizures_59\NNS\14081375|of|audiogenic|produced
D002110_D012640 CID caffeine_10\NN\14712692|after|mg/kg (r_nmod) frequency_1\NN\15286249|the|seizures|caffeine (l_nmod) seizures_4\NNS\14081375|of|sound-induced
D002110_D012640 CID caffeine_4\NN\14712692|of (r_nmod) absence_2\NN\14449405|in|the|caffeine (r_nmod) modify_15\VB\109660|absence|,|acetaminophen|did|not|seizures|and|alter|tests|. (l_dobj) seizures_17\NNS\14081375|the|induced
D010433_D012640 CID pentylenetetrezol_30\NN\1740|of (r_nmod) dose_28\NN\3740161|the|convulsant|pentylenetetrezol|mice (r_dobj) alter_25\VB\126264|did|not|dose (r_conj) modify_15\VB\109660|absence|,|acetaminophen|did|not|seizures|and|alter|tests|. (l_dobj) seizures_17\NNS\14081375|the|induced
2515254
D005996_D008881 CID nitroglycerin_11\NN\15015501|of|patients|or|ointment (r_nmod) application_9\NN\947128|a|sided|frontotemporal|nitroglycerin (r_dobj) received_4\VBD\2210855|patients|application|study|. (l_nsubj) patients_3\NNS\9898892|twenty|common|migraine (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_7\NN\15015501|by (r_nmod) induced_5\VBN\1627355|attacks|were|nitroglycerin|patients|patient|. (l_nsubjpass) attacks_3\NNS\955060|onset|migraine (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_13\NN\15015501|with|frontotemporal (r_nmod) attack_10\NN\955060|an|early|onset|nitroglycerin (r_dobj) developed_6\VBD\1753788|who|attack (r_acl:relcl) patients_3\NNS\9898892|20|migraine|,|developed|, (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_5\NN\15015501|of (r_nmod) effect_3\NN\34213|the|migraine-inducing|nitroglycerin (l_amod) migraine-inducing_2\JJ\1740|
D005996_D008881 CID nitroglycerin_5\NN\15015501|of (r_nmod) effect_3\NN\34213|the|migraine-inducing|nitroglycerin (r_nsubj) seems_6\VBZ\2604760|thus|effect|depend|,|suggesting|. (l_advcl) suggesting_19\VBG\1010118|importance (l_ccomp) importance_27\NN\5138488|that|region|is|of|crucial|development (l_nmod) development_30\NN\248977|in|the|crisis (l_nmod) crisis_34\NN\14411243|of|a|migraine (l_compound) migraine_33\NN\14326607|
D005996_D010146 NONE nitroglycerin_5\NN\15015501|of (r_nmod) effect_3\NN\34213|the|migraine-inducing|nitroglycerin (r_nsubj) seems_6\VBZ\2604760|thus|effect|depend|,|suggesting|. (l_xcomp) depend_8\VB\2604760|to|stimulation (l_nmod) stimulation_11\NN\242808|on|direct|site (l_nmod) site_15\NN\8673395|of|the|habitual|pain (l_nmod) pain_17\NN\14299637|of
2355241
D007980_D002543 NONE levodopa_23\NN\14604959|of (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage (l_nmod) haemorrhage_5\NN\14285662|of|cerebral|cause
D007980_D003643 NONE levodopa_23\NN\14604959|of (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage (l_nmod) haemorrhage_5\NN\14285662|of|cerebral|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) death_10\NN\7296428|of
D007980_D010300 NONE levodopa_23\NN\14604959|of (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage (l_nmod) haemorrhage_5\NN\14285662|of|cerebral|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) patients_12\NNS\9898892|in|disease (l_nmod) disease_16\NN\14061805|with|parkinson|'s
D007980_D010300 NONE levodopa_23\NN\14604959|of (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (l_conj) mechanism_27\NN\13446390|a|hypotensive|levels (l_nmod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (l_nmod) brain_36\NN\5462674|in|the|parkinsonian (l_amod) parkinsonian_35\JJ\1740|
D007980_D007022 CID levodopa_23\NN\14604959|of (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (l_amod) hypotensive_20\JJ\1740|
D007980_D007022 CID levodopa_23\NN\14604959|of (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (l_conj) mechanism_27\NN\13446390|a|hypotensive|levels (l_amod) hypotensive_26\JJ\1740|
D009638_D002543 NONE noradrenaline_31\NN\14807929| (r_compound) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage (l_nmod) haemorrhage_5\NN\14285662|of|cerebral|cause
D009638_D003643 NONE noradrenaline_31\NN\14807929| (r_compound) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage (l_nmod) haemorrhage_5\NN\14285662|of|cerebral|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) death_10\NN\7296428|of
D009638_D010300 NONE noradrenaline_31\NN\14807929| (r_compound) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage (l_nmod) haemorrhage_5\NN\14285662|of|cerebral|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) patients_12\NNS\9898892|in|disease (l_nmod) disease_16\NN\14061805|with|parkinson|'s
D009638_D010300 NONE noradrenaline_31\NN\14807929| (r_compound) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (l_nmod) brain_36\NN\5462674|in|the|parkinsonian (l_amod) parkinsonian_35\JJ\1740|
D009638_D007022 NONE noradrenaline_31\NN\14807929| (r_compound) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|and|mechanism (l_amod) hypotensive_20\JJ\1740|
D009638_D007022 NONE noradrenaline_31\NN\14807929| (r_compound) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (l_amod) hypotensive_26\JJ\1740|
20588063
D011692_D009401 CID aminonucleoside_17\NN\1740| (r_compound) nephrosis_18\NN\14304060|in|early|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_2\NN\1740| (r_compound) nephrosis_3\NN\14304060|puromycin|aminonucleoside|pan
1867351
D015767_D008288 NONE mefloquine_10\NN\2721948|with (r_nmod) treatment_8\NN\654885|mefloquine (r_conj) prophylaxis_6\NN\1077350|for|malaria|and|treatment (l_compound) malaria_5\NN\14178913|
9199746
D000583_D064420 NONE amikacin_4\NN\1740|after|intravitreal (r_nmod) toxicity_1\NN\13576101|macula|amikacin|.
D000617_D009877 NONE aminoglycosides_4\NNS\1740|intravitreal (r_nsubj) improved_7\VBN\126264|although|aminoglycosides|have|substantially|prognosis (l_dobj) prognosis_9\NN\6748969|visual|endophthalmitis (l_nmod) endophthalmitis_11\NN\1740|in
D000617_D007238 NONE aminoglycosides_4\NNS\1740|intravitreal (r_nsubj) improved_7\VBN\126264|although|aminoglycosides|have|substantially|prognosis (r_advcl) impair_16\VB\258857|improved|,|infarction|may|recovery (l_nsubj) infarction_14\NN\14204950|macular
D000583_D012164 CID amikacin_8\NN\1740| (r_compound) toxicity_10\NN\13576101|of|presumed|amikacin|retinal|treatment
D000583_D012164 CID amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (r_nmod) toxicity_10\NN\13576101|of|presumed|amikacin|retinal|treatment
D000583_D013290 NONE amikacin_8\NN\1740| (r_compound) toxicity_10\NN\13576101|of|presumed|amikacin|retinal|treatment (l_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (l_nmod) endophthalmitis_20\NN\1740|for|alpha-haemolytic|streptococcal
D000583_D013290 NONE amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (l_nmod) endophthalmitis_20\NN\1740|for|alpha-haemolytic|streptococcal
D014640_D012164 NONE vancomycin_16\NN\2716866| (r_conj) amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (r_nmod) toxicity_10\NN\13576101|of|presumed|amikacin|retinal|treatment
D014640_D013290 NONE vancomycin_16\NN\2716866| (r_conj) amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (l_nmod) endophthalmitis_20\NN\1740|for|alpha-haemolytic|streptococcal
D019793_D013684 NONE fluorescein_1\NN\14598383| (r_compound) angiography_2\NN\904623|fundus|fluorescein (r_nsubj) confirmed_3\VBD\1011725|angiography|closure|. (l_dobj) closure_6\NN\280853|macular|capillary|and|telangiectasis (l_conj) telangiectasis_8\NN\1740|
19211690
D013739_D006973 NONE testosterone-dependent_0\JJ\1740| (r_amod) hypertension_1\NN\14057371|testosterone-dependent|and|upregulation|.
D013739_D006973 NONE testosterone_0\NN\14747587| (r_nsubj) contributes_1\VBZ\126264|testosterone|development|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats|diet
D017673_D006973 NONE salt-sensitive_9\JJ\1740| (r_amod) rats_10\NNS\2329401|in|dahl|salt-sensitive (r_nmod) upregulation_3\NN\1740|angiotensinogen|rats (r_conj) hypertension_1\NN\14057371|testosterone-dependent|and|upregulation|.
D013739_D007674 NONE testosterone_22\NN\14747587|by|causes (l_acl:relcl) causes_25\VBZ\1617192|that|also|increases (l_dobj) increases_26\NNS\13576355|bp|and|injury (l_conj) injury_31\NN\14052046|renal
D013739_D007674 NONE testosterone_0\NN\14747587| (r_compound) replacement_1\NN\196485|testosterone|rats (r_nsubj) increased_6\VBD\169651|replacement|bp|. (l_dobj) bp_7\NN\1740|,|injury|,|and|upregulation (l_conj) injury_10\NN\14052046|renal
D013739_D007674 NONE testosterone_0\NN\14747587| (r_nsubj) contributes_1\VBZ\126264|testosterone|development|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats|diet (l_conj) injury_9\NN\14052046|renal
D000809_D006973 NONE renin-angiotensin_23\JJ\1740| (r_amod) system_24\NN\3575240|of|the|intrarenal|renin-angiotensin (r_nmod) upregulation_19\NN\1740|possibly|through|system (r_nmod) contributes_1\VBZ\126264|testosterone|development|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats|diet
D000809_D007674 NONE renin-angiotensin_23\JJ\1740| (r_amod) system_24\NN\3575240|of|the|intrarenal|renin-angiotensin (r_nmod) upregulation_19\NN\1740|possibly|through|system (r_nmod) contributes_1\VBZ\126264|testosterone|development|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats|diet (l_conj) injury_9\NN\14052046|renal
12198388
D000109_D012640 NONE acetylcholine_4\NN\14807558| (r_compound) release_5\NN\3748886|between|hippocampal|acetylcholine|and|sensitivity (r_nmod) relationship_1\NN\31921|the|release|lines|. (l_nmod) lines_18\NNS\8426461|in|withdrawal|selected|mouse (l_compound) withdrawal_11\NN\7206096|seizure-prone (l_amod) seizure-prone_12\JJ\1740|and|seizure-resistant
D000109_D012640 NONE acetylcholine_4\NN\14807558| (r_compound) release_5\NN\3748886|between|hippocampal|acetylcholine|and|sensitivity (r_nmod) relationship_1\NN\31921|the|release|lines|. (l_nmod) lines_18\NNS\8426461|in|withdrawal|selected|mouse (l_compound) withdrawal_11\NN\7206096|seizure-prone (l_amod) seizure-prone_12\JJ\1740|and|seizure-resistant (l_conj) seizure-resistant_15\JJ\1740|withdrawal
D000109_D012640 NONE ach_1\NN\1740|hippocampal (r_nsubjpass) measured_4\VBN\697589|ach|also|was|testing|. (l_nmod) testing_6\VBG\670261|during|convulsions (l_nmod) convulsions_9\NNS\14081375|for|handling-induced
D000109_D012640 NONE ach_2\NN\1740|hippocampal (r_nsubjpass) measured_4\VBN\697589|when|ach|was|testing (l_nmod) testing_6\VBG\670261|during|convulsions (l_nmod) convulsions_9\NNS\14081375|for|handling-induced
D000109_D012640 NONE ach_12\NN\1740|extracellular (r_nsubj) elevated_15\JJ\1740|measured|,|ach|was|significantly|%|mice|,|but|elevated|. (l_advcl) measured_4\VBN\697589|when|ach|was|testing (l_nmod) testing_6\VBG\670261|during|convulsions (l_nmod) convulsions_9\NNS\14081375|for|handling-induced
D000431_D012640 NONE alcohol-na_8\JJ\1740| (r_amod) withdrawal_10\NN\7206096|alcohol-na|ve|seizure-prone (l_amod) seizure-prone_11\JJ\1740|wsp|and-resistant|wsr
D000431_D012640 NONE ethanol_20\NN\14708720| (r_compound) severity_22\NN\5036394|with|ethanol|withdrawal (r_nmod) associated_18\VBN\628491|that|differences|may|be|severity (l_nsubjpass) differences_6\NNS\4723816|activity (l_nmod) activity_9\NN\30358|in|cholinergic|and|sensitivity (l_conj) sensitivity_12\NN\5651971|postsynaptic|convulsants (l_nmod) convulsants_15\NNS\1740|to|cholinergic
D000431_D012640 NONE alcohol_28\NN\7881800| (r_compound) withdrawal_29\NN\7206096|in|alcohol (r_nmod) implicate_24\VBP\2677097|mechanisms|withdrawal (r_conj) suggest_4\VBP\1010118|conclusions|:|results|associated|and|implicate|. (l_ccomp) associated_18\VBN\628491|that|differences|may|be|severity (l_nsubjpass) differences_6\NNS\4723816|activity (l_nmod) activity_9\NN\30358|in|cholinergic|and|sensitivity (l_conj) sensitivity_12\NN\5651971|postsynaptic|convulsants (l_nmod) convulsants_15\NNS\1740|to|cholinergic
D009538_D014202 NONE nicotine_3\NN\14712692|,|carbachol|,|or|neostigmine (r_dobj) administered_2\VBN\2436349|animals|were|nicotine|infusion|,|and|recorded (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_nmod) onset_19\NN\7325190|to|tremor (l_nmod) tremor_21\NN\345926|of|and|clonus
D002217_D014202 NONE carbachol_5\NN\1740| (r_conj) nicotine_3\NN\14712692|,|carbachol|,|or|neostigmine (r_dobj) administered_2\VBN\2436349|animals|were|nicotine|infusion|,|and|recorded (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_nmod) onset_19\NN\7325190|to|tremor (l_nmod) tremor_21\NN\345926|of|and|clonus
D009388_D014202 NONE neostigmine_8\NN\2718084| (r_conj) nicotine_3\NN\14712692|,|carbachol|,|or|neostigmine (r_dobj) administered_2\VBN\2436349|animals|were|nicotine|infusion|,|and|recorded (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_nmod) onset_19\NN\7325190|to|tremor (l_nmod) tremor_21\NN\345926|of|and|clonus
D009538_D012640 CID nicotine_9\NN\14712692|by|,|carbachol|,|and|neostigmine (r_nmod) induced_7\VBN\1627355|nicotine (r_acl) endpoints_6\NNS\8566028|to|several|convulsion|induced (l_compound) convulsion_5\NN\14081375|
D002217_D012640 CID carbachol_11\NN\1740| (r_conj) nicotine_9\NN\14712692|by|,|carbachol|,|and|neostigmine (r_nmod) induced_7\VBN\1627355|nicotine (r_acl) endpoints_6\NNS\8566028|to|several|convulsion|induced (l_compound) convulsion_5\NN\14081375|
D009388_D012640 CID neostigmine_14\NN\2718084| (r_conj) nicotine_9\NN\14712692|by|,|carbachol|,|and|neostigmine (r_nmod) induced_7\VBN\1627355|nicotine (r_acl) endpoints_6\NNS\8566028|to|several|convulsion|induced (l_compound) convulsion_5\NN\14081375|
2670794
D000809_D011665 NONE angiotensin_5\NN\4522421| (r_compound) enzyme_7\NN\14723628|of|angiotensin|converting|captopril (r_nmod) inhibitor_3\NN\20090|of|an|enzyme (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary|coagulation
D000809_D011665 NONE angiotensin_11\NN\4522421| (r_compound) enzyme_13\NN\14723628|of|angiotensin|converting|ace (r_nmod) inhibitor_9\NN\20090|an|enzyme (r_appos) captopril_2\NN\2673637|of|mg/kg|,|inhibitor|, (r_nmod) injection_0\NN\320852|captopril (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|model|. (l_dobj) insufficiency_23\NN\14462946|pulmonary
D000809_D051437 NONE angiotensin_5\NN\4522421| (r_compound) enzyme_7\NN\14723628|of|angiotensin|converting|captopril (r_nmod) inhibitor_3\NN\20090|of|an|enzyme (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary|coagulation
D000809_D051437 NONE angiotensin_11\NN\4522421| (r_compound) enzyme_13\NN\14723628|of|angiotensin|converting|ace (r_nmod) inhibitor_9\NN\20090|an|enzyme (r_appos) captopril_2\NN\2673637|of|mg/kg|,|inhibitor|, (r_nmod) injection_0\NN\320852|captopril (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|model|. (l_dobj) insufficiency_23\NN\14462946|pulmonary
D000809_D004211 NONE angiotensin_5\NN\4522421| (r_compound) enzyme_7\NN\14723628|of|angiotensin|converting|captopril (r_nmod) inhibitor_3\NN\20090|of|an|enzyme (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary|coagulation (l_nmod) coagulation_19\NN\13518963|due|intravascular|rat
D002216_D011665 NONE captopril_9\NN\2673637|(|) (r_appos) enzyme_7\NN\14723628|of|angiotensin|converting|captopril (r_nmod) inhibitor_3\NN\20090|of|an|enzyme (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary|coagulation
D002216_D011665 NONE captopril_2\NN\2673637|of|mg/kg|,|inhibitor|, (r_nmod) injection_0\NN\320852|captopril (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|model|. (l_dobj) insufficiency_23\NN\14462946|pulmonary
D002216_D051437 NONE captopril_9\NN\2673637|(|) (r_appos) enzyme_7\NN\14723628|of|angiotensin|converting|captopril (r_nmod) inhibitor_3\NN\20090|of|an|enzyme (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary|coagulation
D002216_D051437 NONE captopril_2\NN\2673637|of|mg/kg|,|inhibitor|, (r_nmod) injection_0\NN\320852|captopril (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|model|. (l_dobj) insufficiency_23\NN\14462946|pulmonary
D002216_D004211 NONE captopril_9\NN\2673637|(|) (r_appos) enzyme_7\NN\14723628|of|angiotensin|converting|captopril (r_nmod) inhibitor_3\NN\20090|of|an|enzyme (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary|coagulation (l_nmod) coagulation_19\NN\13518963|due|intravascular|rat
D014148_D004211 CID acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (l_nmod) coagulation_3\NN\13518963|of|intravascular
D014148_D004211 CID amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (l_nmod) coagulation_3\NN\13518963|of|intravascular
D014148_D011665 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling
D014148_D011665 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling
D014148_D051437 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling
D014148_D051437 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling
D014148_D014947 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling (l_acl) resembling_28\VBG\2657219|that (l_dobj) that_29\DT\1740|occurring (l_acl) occurring_30\VBG\2623529|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man
D014148_D014947 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling (l_acl) resembling_28\VBG\2657219|that (l_dobj) that_29\DT\1740|occurring (l_acl) occurring_30\VBG\2623529|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man
D014148_D018805 NONE acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling (l_acl) resembling_28\VBG\2657219|that (l_dobj) that_29\DT\1740|occurring (l_acl) occurring_30\VBG\2623529|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man (l_conj) sepsis_34\NN\14174549|
D014148_D018805 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|tranexamic|amca (r_conj) thrombin_11\NN\14735953|of|and|acid (r_nmod) injection_9\NN\320852|by|thrombin|rat (r_nmod) induction_0\NN\7450842|coagulation|and|inhibition|injection (r_nsubj) gives_21\VBZ\2327200|induction|rise|insufficiency|. (l_nmod) insufficiency_27\NN\14462946|to|pulmonary|resembling (l_acl) resembling_28\VBG\2657219|that (l_dobj) that_29\DT\1740|occurring (l_acl) occurring_30\VBG\2623529|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man (l_conj) sepsis_34\NN\14174549|
D014508_D007674 NONE urea_9\NN\14727670|in|serum|and|weight (r_nmod) increase_6\NN\13576355|by|an|urea (r_nmod) reflected_3\VBN\923793|as|increase (r_acl) damage_1\NN\7296428|renal|reflected
D002216_D007674 NONE captopril_17\NN\2673637|by (r_nmod) prevented_15\VBN\1740|damage|was|captopril|. (l_nsubjpass) damage_1\NN\7296428|renal|reflected
D002216_D007674 NONE captopril_0\NN\2673637| (r_nsubj) reduce_8\VB\441445|captopril|may|,|mechanism|,|increase|,|diminishing|. (l_advcl) diminishing_26\VBG\169651|thereby|aggregation|,|result (l_nmod) result_38\NN\34213|with|the|deposited (l_acl) deposited_44\VBN\1340439|that|fibrin|will|be|and|produced (l_conj) produced_52\VBN\1617192|damage|will|be (l_nsubjpass) damage_49\NN\7296428|thus|less|kidney
6287825
D013831_D010523 CID thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency
D013831_D010523 CID thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency (r_nsubj) common_11\JJ\1740|neuropathy|was|%|and|presented|. (l_conj) presented_17\VBD\2137132|neuropathy (l_nmod) neuropathy_23\NN\14204950|mainly|as|sensory
D013831_D044342 NONE thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|nutritional|thiamine
D012256_D010523 CID riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency
D012256_D010523 CID riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency (r_nsubj) common_11\JJ\1740|neuropathy|was|%|and|presented|. (l_conj) presented_17\VBD\2137132|neuropathy (l_nmod) neuropathy_23\NN\14204950|mainly|as|sensory
D012256_D044342 NONE riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|nutritional|thiamine
D007538_D009422 NONE isoniazid_0\NN\2716205| (r_nsubj) agent_5\NN\7347|isoniazid|was|the|frequent|neuropathy|. (l_nmod) neuropathy_8\NN\14204950|in|drug-induced
3192036
2894766
D012460_D008180 CID sulfasalazine-induced_0\NN\1740| (r_amod) erythematosus_2\NN\1740|sulfasalazine-induced|lupus|.
D012460_D008180 CID sulfasalazine-induced_7\JJ\1740| (r_amod) lupus_8\NN\14219661|sulfasalazine-induced|,|manifested
D012460_D008180 CID sulfasalazine_3\NN\1740| (r_dobj) use_2\VBP\1156834|who|sulfasalazine|treat (r_acl:relcl) physicians_0\NNS\10305802|use (r_nsubj) aware_13\JJ\1740|physicians|should|be|signs|. (l_nmod) signs_16\NNS\6643763|of|the|syndrome (l_nmod) syndrome_20\NN\5870365|of|sulfasalazine-induced|lupus
D012460_D008180 CID sulfasalazine-induced_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|sulfasalazine-induced|lupus
D012460_D011014 CID sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (r_dobj) receiving_23\VBG\2210855|who|was|therapy (r_acl:relcl) man_19\NN\9605289|in|a|43-year-old|,|receiving (r_nmod) developed_15\VBD\1753788|pneumonitis|man|. (l_nsubj) pneumonitis_0\NN\14336539|,|effusions|,|evidence|,|and|autoantibodies
D012460_D010996 CID sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (r_dobj) receiving_23\VBG\2210855|who|was|therapy (r_acl:relcl) man_19\NN\9605289|in|a|43-year-old|,|receiving (r_nmod) developed_15\VBD\1753788|pneumonitis|man|. (l_nsubj) pneumonitis_0\NN\14336539|,|effusions|,|evidence|,|and|autoantibodies (l_conj) effusions_4\NNS\6880249|bilateral|pleural
D012460_D002305 CID sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (r_dobj) receiving_23\VBG\2210855|who|was|therapy (r_acl:relcl) man_19\NN\9605289|in|a|43-year-old|,|receiving (r_nmod) developed_15\VBD\1753788|pneumonitis|man|. (l_nsubj) pneumonitis_0\NN\14336539|,|effusions|,|evidence|,|and|autoantibodies (l_conj) evidence_7\NN\5816287|echocardiographic|tamponade (l_nmod) tamponade_10\NN\14507951|of|cardiac
D012460_D003093 NONE sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (l_nmod) colitis_30\NN\14336539|for|chronic|ulcerative
D012460_D012700 NONE sulfasalazine-induced_7\JJ\1740| (r_amod) lupus_8\NN\14219661|sulfasalazine-induced|,|manifested (l_acl:relcl) manifested_11\VBD\1015244|which|serositis|absence (l_nmod) serositis_13\NN\1740|with|and|involvement
D012460_D015212 NONE sulfasalazine_3\NN\1740| (r_dobj) use_2\VBP\1156834|who|sulfasalazine|treat (l_xcomp) treat_5\VB\2376958|to|patients (l_dobj) patients_6\NNS\9898892|disease (l_nmod) disease_10\NN\14061805|with|inflammatory|bowel
D012460_D015212 NONE sulfasalazine-induced_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|sulfasalazine-induced|lupus (r_nmod) signs_16\NNS\6643763|of|the|syndrome (r_nmod) aware_13\JJ\1740|physicians|should|be|signs|. (l_nsubj) physicians_0\NNS\10305802|use (l_acl:relcl) use_2\VBP\1156834|who|sulfasalazine|treat (l_xcomp) treat_5\VB\2376958|to|patients (l_dobj) patients_6\NNS\9898892|disease (l_nmod) disease_10\NN\14061805|with|inflammatory|bowel
9855119
D016559_D005922 NONE fk506_55\NN\1740| (r_compound) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|= (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|=|,|nephropathy|,|and|nephropathy|. (l_conj) nephropathy_38\NN\14573196|recurrent|iga|=
D016559_D005922 NONE fk506_65\NN\1740| (r_compound) nephropathy_66\NN\14573196|mild-type|fk506|= (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|=|,|nephropathy|,|and|nephropathy|. (l_conj) nephropathy_38\NN\14573196|recurrent|iga|=
D016559_D007674 NONE fk506_55\NN\1740| (r_compound) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|=
D016559_D007674 NONE fk506_55\NN\1740| (r_compound) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|= (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|=|,|nephropathy|,|and|nephropathy|. (l_conj) nephropathy_66\NN\14573196|mild-type|fk506|=
D016559_D007674 NONE fk506_65\NN\1740| (r_compound) nephropathy_66\NN\14573196|mild-type|fk506|= (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|=|,|nephropathy|,|and|nephropathy|. (l_conj) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|=
D016559_D007674 NONE fk506_65\NN\1740| (r_compound) nephropathy_66\NN\14573196|mild-type|fk506|=
D016559_D007674 NONE fk506_14\NN\1740| (r_compound) nephropathy_15\NN\14573196|minimal-type|chronic|fk506
D016559_D007674 NONE fk506_1\NN\1740| (r_compound) nephropathy_2\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_10\NN\1740| (r_compound) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy|,|included (l_compound) nephropathy_11\NN\14573196|
D016559_D007674 NONE fk506_10\NN\1740| (r_compound) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy|,|included (r_nmod) patients_5\NNS\9898892|of|group (r_nmod) levels_3\NNS\4916342|the|serum|creatinine|patients|, (r_nsubj) higher_22\JJR\1740|levels|were|statistically|those|p|. (l_nmod) those_24\DT\1740|than|group (l_nmod) group_30\NN\2137|in|the|minimum-type|chronic|fk506-nephropathy (l_compound) fk506-nephropathy_29\NN\1740|
D016559_D007674 NONE fk506-nephropathy_29\NN\1740| (r_compound) group_30\NN\2137|in|the|minimum-type|chronic|fk506-nephropathy (r_nmod) those_24\DT\1740|than|group (r_nmod) higher_22\JJR\1740|levels|were|statistically|those|p|. (l_nsubj) levels_3\NNS\4916342|the|serum|creatinine|patients|, (l_nmod) patients_5\NNS\9898892|of|group (l_nmod) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy|,|included (l_compound) nephropathy_11\NN\14573196|
D016559_D007674 NONE fk506-nephropathy_29\NN\1740|
D016559_D007674 NONE fk506_7\NN\1740| (r_compound) nephropathy_8\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_7\NN\1740| (r_compound) nephropathy_8\NN\14573196|chronic|fk506 (r_nsubj) consists_9\VBZ\2603699|that|nephropathy|primarily|arteriolopathy (r_ccomp) demonstrates_4\VBZ\2137132|study|consists|,|and|suggests (l_conj) suggests_23\VBZ\1010118|condition (l_ccomp) condition_31\NN\24720|that|nephropathy|is|a|lead (l_nsubj) nephropathy_28\NN\14573196|mild-type|chronic|fk506
D016559_D007674 NONE fk506_27\NN\1740| (r_compound) nephropathy_28\NN\14573196|mild-type|chronic|fk506 (r_nsubj) condition_31\NN\24720|that|nephropathy|is|a|lead (r_ccomp) suggests_23\VBZ\1010118|condition (r_conj) demonstrates_4\VBZ\2137132|study|consists|,|and|suggests (l_ccomp) consists_9\VBZ\2603699|that|nephropathy|primarily|arteriolopathy (l_nsubj) nephropathy_8\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_27\NN\1740| (r_compound) nephropathy_28\NN\14573196|mild-type|chronic|fk506
D016559_D005923 CID fk506_1\NN\1740| (r_compound) nephropathy_2\NN\14573196|chronic|fk506 (r_nsubj) consisted_3\VBD\2603699|nephropathy|vacuolization|. (l_nmod) vacuolization_9\NN\13920835|of|rough|tubular|biopsies|,|arteriolopathy|and|form (l_conj) arteriolopathy_15\NN\1740|angiodegeneration|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN\1740|focal|segmental|biopsies
D016559_D005355 NONE fk506_1\NN\1740| (r_compound) nephropathy_2\NN\14573196|chronic|fk506 (r_nsubj) consisted_3\VBD\2603699|nephropathy|vacuolization|. (l_nmod) vacuolization_9\NN\13920835|of|rough|tubular|biopsies|,|arteriolopathy|and|form (l_conj) form_37\NN\6286395|the|striped|fibrosis|biopsies (l_nmod) fibrosis_40\NN\14204950|of|interstitial
D003404_D007674 NONE creatinine_2\NN\1740| (r_compound) levels_3\NNS\4916342|the|serum|creatinine|patients|, (l_nmod) patients_5\NNS\9898892|of|group (l_nmod) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy|,|included (l_compound) nephropathy_11\NN\14573196|
D003404_D007674 NONE creatinine_2\NN\1740| (r_compound) levels_3\NNS\4916342|the|serum|creatinine|patients|, (r_nsubj) higher_22\JJR\1740|levels|were|statistically|those|p|. (l_nmod) those_24\DT\1740|than|group (l_nmod) group_30\NN\2137|in|the|minimum-type|chronic|fk506-nephropathy (l_compound) fk506-nephropathy_29\NN\1740|
18544179
D005283_D009325 NONE fentanyl_1\NN\2707683| (r_dobj) omitting_0\VBG\471711|fentanyl (r_csubj) reduces_2\VBZ\441445|omitting|nausea|,|increasing|. (l_dobj) nausea_3\NN\14299637|and|vomiting
D005283_D009325 NONE fentanyl_4\NN\2707683|of (r_nmod) omission_2\NN\70965|fentanyl (r_nsubj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_conj) reduce_19\VB\441445|did|incidence|% (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (l_conj) nausea_28\NN\14299637|moderate
D005283_D009325 NONE fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (l_conj) nausea_28\NN\14299637|moderate
D005283_D009325 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (l_conj) nausea_28\NN\14299637|moderate
D005283_D009325 NONE fentanyl_3\NN\2707683| (r_compound) groups_4\NNS\2137|the|two|fentanyl (r_dobj) combining_0\VBG\2630189|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|,|decreased|. (l_dobj) benefits_8\NNS\13278375|further|significant|avoidance|,|reducing|,|respectively (l_acl) reducing_15\VBG\441445|nausea|%|%|= (l_dobj) nausea_17\NN\14299637|postoperative|and|vomiting|and|nausea (l_conj) nausea_21\NN\14299637|prior
D005283_D009325 NONE fentanyl_3\NN\2707683| (r_compound) groups_4\NNS\2137|the|two|fentanyl (r_dobj) combining_0\VBG\2630189|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|,|decreased|. (l_advcl) decreased_57\VBN\169651|while|nausea|was|%|%|= (l_nsubjpass) nausea_50\NN\14299637|h
D005283_D014839 NONE fentanyl_1\NN\2707683| (r_dobj) omitting_0\VBG\471711|fentanyl (r_csubj) reduces_2\VBZ\441445|omitting|nausea|,|increasing|. (l_dobj) nausea_3\NN\14299637|and|vomiting (l_conj) vomiting_5\NN\116687|
D005283_D014839 NONE fentanyl_4\NN\2707683|of (r_nmod) omission_2\NN\70965|fentanyl (r_nsubj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_conj) reduce_19\VB\441445|did|incidence|% (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|,
D005283_D014839 NONE fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|,
D005283_D014839 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|,
D005283_D010146 NONE fentanyl_1\NN\2707683| (r_dobj) omitting_0\VBG\471711|fentanyl (r_csubj) reduces_2\VBZ\441445|omitting|nausea|,|increasing|. (l_advcl) increasing_8\VBG\169651|without|pain|,|sevoflurane (l_dobj) pain_9\NN\14299637|
D005283_D010146 NONE fentanyl_11\NN\2707683|of (r_nmod) omission_9\NN\70965|by|the|fentanyl (r_nmod) unaffected_6\JJ\1740|severity|were|omission|. (l_nsubj) severity_1\NN\5036394|pain|and|requirements (l_compound) pain_0\NN\14299637|
C009250_D009325 NONE sevoflurane_12\NN\1740|after|surgery (r_nmod) increasing_8\VBG\169651|without|pain|,|sevoflurane (r_advcl) reduces_2\VBZ\441445|omitting|nausea|,|increasing|. (l_dobj) nausea_3\NN\14299637|and|vomiting
C009250_D014839 NONE sevoflurane_12\NN\1740|after|surgery (r_nmod) increasing_8\VBG\169651|without|pain|,|sevoflurane (r_advcl) reduces_2\VBZ\441445|omitting|nausea|,|increasing|. (l_dobj) nausea_3\NN\14299637|and|vomiting (l_conj) vomiting_5\NN\116687|
C009250_D010146 NONE sevoflurane_12\NN\1740|after|surgery (r_nmod) increasing_8\VBG\169651|without|pain|,|sevoflurane (l_dobj) pain_9\NN\14299637|
C009250_D010146 NONE sevoflurane_23\NN\1740| (r_compound) anaesthesia_24\NN\14034177|after|sevoflurane (r_nmod) h_21\NN\14622893|in|the|first|24|anaesthesia (r_nmod) nausea_12\NN\14299637|of|postoperative|and|vomiting|h (l_conj) vomiting_14\NN\116687|and|pain (l_conj) pain_16\NN\14299637|
C009250_D020250 NONE sevoflurane_13\NN\1740|with (r_nmod) induction_7\NN\7450842|of|and|maintenance|sevoflurane (r_nmod) advantages_5\NNS\5154517|despite|induction (r_nmod) occurs_19\VBZ\2623529|advantages|,|nausea|frequently|. (l_nsubj) nausea_16\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_18\NN\116687|
C009250_D020250 NONE sevoflurane_23\NN\1740| (r_compound) anaesthesia_24\NN\14034177|after|sevoflurane (r_nmod) h_21\NN\14622893|in|the|first|24|anaesthesia (r_nmod) nausea_12\NN\14299637|of|postoperative|and|vomiting|h (l_conj) vomiting_14\NN\116687|and|pain
C009250_D020250 NONE sevoflurane_33\NN\1740|to (r_nmod) supplement_31\NN\6365467|to|be|an|unnecessary|sevoflurane|surgery (r_xcomp) appears_23\VBZ\2604760|conclusion|exacerbated|,|it|supplement|. (l_advcl) exacerbated_4\VBD\126264|as|fentanyl|nausea|improvement|and|had (l_dobj) nausea_6\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_8\NN\116687|
D005283_D020250 CID fentanyl_4\NN\2707683|of (r_nmod) omission_2\NN\70965|fentanyl (r_nsubj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D005283_D020250 CID fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (r_nmod) incidence_21\NN\13821570|the|vomiting (r_dobj) reduce_19\VB\441445|did|incidence|% (r_conj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D005283_D020250 CID fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (r_nmod) incidence_21\NN\13821570|the|vomiting (r_dobj) reduce_19\VB\441445|did|incidence|% (r_conj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D005283_D020250 CID fentanyl_3\NN\2707683| (r_compound) groups_4\NNS\2137|the|two|fentanyl (r_dobj) combining_0\VBG\2630189|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|,|decreased|. (l_dobj) benefits_8\NNS\13278375|further|significant|avoidance|,|reducing|,|respectively (l_acl) reducing_15\VBG\441445|nausea|%|%|= (l_dobj) nausea_17\NN\14299637|postoperative|and|vomiting|and|nausea (l_conj) vomiting_19\NN\116687|
D005283_D020250 CID fentanyl_3\NN\2707683| (r_nsubj) exacerbated_4\VBD\126264|as|fentanyl|nausea|improvement|and|had (l_dobj) nausea_6\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_8\NN\116687|
D003907_D020250 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (r_nmod) incidence_21\NN\13821570|the|vomiting (r_dobj) reduce_19\VB\441445|did|incidence|% (r_conj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D003907_D020250 NONE dexamethasone_0\NN\2721538| (r_nsubj) had_1\VBD\2108377|dexamethasone|effect|incidence|. (l_nmod) incidence_7\NN\13821570|on|the|or|severity|nausea (l_nmod) nausea_12\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_14\NN\116687|
D003907_D014839 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|,
D003907_D009325 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone (r_nmod) vomiting_23\NN\116687|of|and/or|nausea|prior|%|fentanyl|,|respectively|, (l_conj) nausea_28\NN\14299637|moderate
D005283_D012131 CID fentanyl_0\NN\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\2108377|effect|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension
D005283_D007022 CID fentanyl_0\NN\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\2108377|effect|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_16\NN\14057371|and|bradycardia
D005283_D001919 CID fentanyl_0\NN\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\2108377|effect|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_16\NN\14057371|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
C009250_D012131 NONE sevoflurane-sparing_9\NN\1740| (r_amod) effect_10\NN\34213|no|sevoflurane-sparing (r_dobj) had_7\VBD\2108377|effect|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension
C009250_D007022 NONE sevoflurane-sparing_9\NN\1740| (r_amod) effect_10\NN\34213|no|sevoflurane-sparing (r_dobj) had_7\VBD\2108377|effect|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_16\NN\14057371|and|bradycardia
C009250_D001919 NONE sevoflurane-sparing_9\NN\1740| (r_amod) effect_10\NN\34213|no|sevoflurane-sparing (r_dobj) had_7\VBD\2108377|effect|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_conj) hypotension_16\NN\14057371|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
D005283_D010149 NONE fentanyl_3\NN\2707683| (r_nsubj) exacerbated_4\VBD\126264|as|fentanyl|nausea|improvement|and|had (l_nmod) improvement_11\NN\7359599|without|an|pain (l_nmod) pain_14\NN\14299637|in|postoperative
C009250_D010149 NONE sevoflurane_33\NN\1740|to (r_nmod) supplement_31\NN\6365467|to|be|an|unnecessary|sevoflurane|surgery (r_xcomp) appears_23\VBZ\2604760|conclusion|exacerbated|,|it|supplement|. (l_advcl) exacerbated_4\VBD\126264|as|fentanyl|nausea|improvement|and|had (l_nmod) improvement_11\NN\7359599|without|an|pain (l_nmod) pain_14\NN\14299637|in|postoperative
15188772
D004837_D018487 NONE epinephrine_12\NN\14807929| (r_compound) overdose_13\NN\1740|due|accidental|iatrogenic|epinephrine (r_nmod) dysfunction_7\NN\14204950|severe|reversible|systolic|overdose|.
D004837_D018487 NONE epinephrine_13\NN\14807929|of (r_nmod) mg_11\NN\13717155|with|8|epinephrine (r_nmod) injected_8\VBN\81072|uteri|was|inadvertently|mg (r_acl:relcl) woman_2\NN\9605289|a|35-year-old|injected (r_nsubj) developed_14\VBD\1753788|woman|stunning|. (l_dobj) stunning_16\NN\1740|myocardial|characterized (l_acl:relcl) characterized_19\VBN\609683|that|was|compromise (l_nmod) compromise_23\NN\1202904|by|severe|hemodynamic|,|dysfunction|,|and|markers (l_conj) dysfunction_35\NN\14204950|profound
D004837_D062787 NONE epinephrine_12\NN\14807929| (r_compound) overdose_13\NN\1740|due|accidental|iatrogenic|epinephrine
D002395_D009202 NONE catecholamine-induced_0\JJ\1740| (r_amod) cardiomyopathy_1\NN\14103288|catecholamine-induced|excess
D002395_D009202 NONE catecholamines_8\NNS\5407119|of|endogenous (r_nmod) excess_5\NN\5119367|due|chronic|catecholamines (r_nmod) cardiomyopathy_1\NN\14103288|catecholamine-induced|excess
D004837_D017682 CID epinephrine_13\NN\14807929|of (r_nmod) mg_11\NN\13717155|with|8|epinephrine (r_nmod) injected_8\VBN\81072|uteri|was|inadvertently|mg (r_acl:relcl) woman_2\NN\9605289|a|35-year-old|injected (r_nsubj) developed_14\VBD\1753788|woman|stunning|. (l_dobj) stunning_16\NN\1740|myocardial|characterized
D004837_D009202 NONE epinephrine_13\NN\14807929|of (r_nmod) mg_11\NN\13717155|with|8|epinephrine (r_nmod) injected_8\VBN\81072|uteri|was|inadvertently|mg (r_acl:relcl) woman_2\NN\9605289|a|35-year-old|injected (r_nsubj) developed_14\VBD\1753788|woman|stunning|. (l_dobj) stunning_16\NN\1740|myocardial|characterized (l_acl:relcl) characterized_19\VBN\609683|that|was|compromise (l_nmod) compromise_23\NN\1202904|by|severe|hemodynamic|,|dysfunction|,|and|markers (l_conj) markers_42\NNS\21939|modestly|elevated|biochemical|necrosis (l_nmod) necrosis_45\NN\11444117|of|myocardial
8669433
D000082_D007676 NONE acetaminophen_3\NN\2707683|of (r_nmod) use_1\NN\407535|habitual|acetaminophen|factor|:|comparison|. (l_nmod) factor_7\NN\7326557|as|a|risk|failure (l_nmod) failure_11\NN\66216|for|chronic|renal
D000082_D007676 NONE acetaminophen_27\NN\2707683|of (r_nmod) use_25\NN\407535|habitual|acetaminophen (r_nsubjpass) associated_30\VBN\628491|that|use|is|also|failure|,|risk (l_nmod) failure_34\NN\66216|with|chronic|renal|and|esrd
D000082_D007676 NONE acetaminophen_27\NN\2707683|of (r_nmod) use_25\NN\407535|habitual|acetaminophen (r_nsubjpass) associated_30\VBN\628491|that|use|is|also|failure|,|risk (l_nmod) failure_34\NN\66216|with|chronic|renal|and|esrd (l_conj) esrd_36\NN\1740|
D000082_D007676 NONE acetaminophen_7\NN\2707683| (r_conj) phenacetin_5\NN\2707683|both|and|acetaminophen (r_nsubj) contribute_9\VB\126264|that|phenacetin|may|burden|,|less (l_nmod) burden_12\NN\5832264|to|the|esrd (l_nmod) esrd_14\NN\1740|of
D000082_D007676 NONE acetaminophen_6\NN\2707683|of (r_nmod) use_4\NN\407535|habitual|acetaminophen|alone (r_nsubj) increases_8\VBZ\169651|that|use|risk (l_dobj) risk_10\NN\14541044|the|esrd (l_nmod) esrd_12\NN\1740|of
D010615_D007676 CID phenacetin_16\NN\2707683|with (r_nmod) comparison_14\NN\635850|a|phenacetin (r_appos) use_1\NN\407535|habitual|acetaminophen|factor|:|comparison|. (l_nmod) factor_7\NN\7326557|as|a|risk|failure (l_nmod) failure_11\NN\66216|for|chronic|renal
D010615_D007676 CID phenacetin_14\NN\2707683|of (r_nmod) use_12\NN\407535|habitual|phenacetin (r_nsubjpass) associated_16\VBN\628491|that|use|is|development|,|risk (l_nmod) development_19\NN\248977|with|the|failure (l_nmod) failure_23\NN\66216|of|chronic|renal|and|disease
D010615_D007676 CID phenacetin_14\NN\2707683|of (r_nmod) use_12\NN\407535|habitual|phenacetin (r_nsubjpass) associated_16\VBN\628491|that|use|is|development|,|risk (l_nmod) development_19\NN\248977|with|the|failure (l_nmod) failure_23\NN\66216|of|chronic|renal|and|disease (l_conj) disease_27\NN\14061805|end-stage|renal|esrd
D010615_D007676 CID phenacetin_14\NN\2707683|of (r_nmod) use_12\NN\407535|habitual|phenacetin (r_nsubjpass) associated_16\VBN\628491|that|use|is|development|,|risk (l_nmod) development_19\NN\248977|with|the|failure (l_nmod) failure_23\NN\66216|of|chronic|renal|and|disease (l_conj) disease_27\NN\14061805|end-stage|renal|esrd (l_appos) esrd_29\NN\1740|(|)
D010615_D007676 CID phenacetin_5\NN\2707683|both|and|acetaminophen (r_nsubj) contribute_9\VB\126264|that|phenacetin|may|burden|,|less (l_nmod) burden_12\NN\5832264|to|the|esrd (l_nmod) esrd_14\NN\1740|of
2549018
D005473_D017109 CID fluoxetine-induced_0\JJ\1740| (r_amod) akathisia_1\NN\1740|fluoxetine-induced|:|implications|.
D005473_D017109 CID fluoxetine_3\NN\4169152| (r_dobj) receiving_2\VBG\2210855|fluoxetine|treatment (r_acl) patients_1\NNS\9898892|five|receiving (r_nsubj) developed_14\VBD\1753788|patients|akathisia|. (l_dobj) akathisia_15\NN\1740|
D005473_D017109 CID fluoxetine-induced_2\JJ\1740| (r_amod) symptoms_3\NNS\5823932|the|typical|fluoxetine-induced|restlessness (r_nsubj) indistinguishable_22\JJ\1740|symptoms|were|those|. (l_nmod) those_24\DT\1740|from|akathisia (l_nmod) akathisia_27\NN\1740|of|neuroleptic-induced
D005473_D017109 CID fluoxetine-induced_15\JJ\1740| (r_amod) akathisia_16\NN\1740|of|fluoxetine-induced (r_nmod) symptoms_13\NNS\5823932|the|akathisia (r_nsubj) identical_18\JJ\1740|that|symptoms|were|,|milder (r_ccomp) reported_10\VBD\831651|patients|identical|. (l_nsubj) patients_1\NNS\9898892|three|experienced (l_acl:relcl) experienced_4\VBN\2108377|who|had|akathisia|past (l_dobj) akathisia_6\NN\1740|neuroleptic-induced
D005473_D017109 CID fluoxetine-induced_15\JJ\1740| (r_amod) akathisia_16\NN\1740|of|fluoxetine-induced
D005473_D017109 CID fluoxetine_9\NN\4169152|of (r_nmod) effect_7\NN\34213|to|be|a|common|side|fluoxetine (r_xcomp) appeared_1\VBD\2604760|akathisia|effect|and|responded|. (l_nsubj) akathisia_0\NN\1740|
D005473_D017109 CID fluoxetine-induced_4\JJ\1740| (r_amod) akathisia_5\NN\1740|fluoxetine-induced
D005473_D017109 CID fluoxetine-induced_4\JJ\1740| (r_amod) akathisia_5\NN\1740|fluoxetine-induced (r_nsubjpass) caused_8\VBN\1617192|that|akathisia|may|be|inhibition|and|identical (l_conj) identical_31\JJ\1740|that|pathophysiology|may|be (l_nsubj) pathophysiology_19\NN\1740|the|akathisia (l_nmod) akathisia_22\NN\1740|of|fluoxetine-induced|and|jitteriness
D005473_D017109 CID fluoxetine-induced_21\JJ\1740| (r_amod) akathisia_22\NN\1740|of|fluoxetine-induced|and|jitteriness (r_nmod) pathophysiology_19\NN\1740|the|akathisia (r_nsubj) identical_31\JJ\1740|that|pathophysiology|may|be (r_conj) caused_8\VBN\1617192|that|akathisia|may|be|inhibition|and|identical (l_nsubjpass) akathisia_5\NN\1740|fluoxetine-induced
D005473_D017109 CID fluoxetine-induced_21\JJ\1740| (r_amod) akathisia_22\NN\1740|of|fluoxetine-induced|and|jitteriness
D005473_D009771 NONE fluoxetine_3\NN\4169152| (r_dobj) receiving_2\VBG\2210855|fluoxetine|treatment (l_nmod) treatment_6\NN\654885|for|the|disorder (l_nmod) disorder_10\NN\14034177|of|obsessive|compulsive|or|depression
D005473_D003865 NONE fluoxetine_3\NN\4169152| (r_dobj) receiving_2\VBG\2210855|fluoxetine|treatment (l_nmod) treatment_6\NN\654885|for|the|disorder (l_nmod) disorder_10\NN\14034177|of|obsessive|compulsive|or|depression (l_conj) depression_13\NN\14373582|major
D005473_D001008 NONE fluoxetine-induced_2\JJ\1740| (r_amod) symptoms_3\NNS\5823932|the|typical|fluoxetine-induced|restlessness (l_nmod) restlessness_5\NN\4773351|of|,|pacing (l_conj) pacing_8\NN\15122011|constant|,|movements|,|and|anxiety (l_conj) anxiety_20\NN\14373582|marked
D011433_D017109 NONE propranolol_20\NN\1740|with|the|antagonist|,|reduction (r_nmod) treatment_15\NN\654885|to|propranolol (r_nmod) responded_12\VBD\2367363|generally|well|treatment (r_conj) appeared_1\VBD\2604760|akathisia|effect|and|responded|. (l_nsubj) akathisia_0\NN\1740|
D000928_D017109 NONE antidepressant-induced_25\JJ\1740|tricyclic (r_amod) jitteriness_27\NN\7523905|antidepressant-induced|"|" (r_conj) akathisia_22\NN\1740|of|fluoxetine-induced|and|jitteriness (r_nmod) pathophysiology_19\NN\1740|the|akathisia (r_nsubj) identical_31\JJ\1740|that|pathophysiology|may|be (r_conj) caused_8\VBN\1617192|that|akathisia|may|be|inhibition|and|identical (l_nsubjpass) akathisia_5\NN\1740|fluoxetine-induced
D000928_D017109 NONE antidepressant-induced_25\JJ\1740|tricyclic (r_amod) jitteriness_27\NN\7523905|antidepressant-induced|"|" (r_conj) akathisia_22\NN\1740|of|fluoxetine-induced|and|jitteriness
16330293
20003049
C031942_D013921 NONE argatroban_4\NN\1740|of|plasma (r_nmod) elevation_1\NN\7445480|prolonged|argatroban|patient|. (l_nmod) patient_9\NN\9898892|in|a|transplant|history (l_nmod) history_13\NN\15120823|with|a|suspected|thrombocytopenia (l_nmod) thrombocytopenia_16\NN\14189204|of|heparin-induced|thrombosis
C031942_D013921 NONE argatroban_18\NN\1740| (r_dobj) administered_17\VBN\2436349|report|,|patient|was|argatroban|anticoagulation|. (l_nsubjpass) patient_9\NN\9898892|a|65-year-old|ill|history (l_nmod) history_13\NN\15120823|with|a|suspected|hitt (l_nmod) hitt_15\NN\1740|of
C031942_D013927 NONE argatroban_4\NN\1740|of|plasma (r_nmod) elevation_1\NN\7445480|prolonged|argatroban|patient|. (l_nmod) patient_9\NN\9898892|in|a|transplant|history (l_nmod) history_13\NN\15120823|with|a|suspected|thrombocytopenia (l_nmod) thrombocytopenia_16\NN\14189204|of|heparin-induced|thrombosis (l_nmod) thrombosis_18\NN\14100769|with
C031942_D013927 NONE argatroban_18\NN\1740| (r_dobj) administered_17\VBN\2436349|report|,|patient|was|argatroban|anticoagulation|. (l_nsubjpass) patient_9\NN\9898892|a|65-year-old|ill|history (l_nmod) history_13\NN\15120823|with|a|suspected|hitt (l_nmod) hitt_15\NN\1740|of
D006493_D013921 NONE heparin-induced_15\JJ\1740| (r_amod) thrombocytopenia_16\NN\14189204|of|heparin-induced|thrombosis
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_appos) hit_23\NN\36762|(|)
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis|hitt
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis|hitt (l_appos) hitt_30\NN\1740|(|)
D006493_D013927 NONE heparin-induced_15\JJ\1740| (r_amod) thrombocytopenia_16\NN\14189204|of|heparin-induced|thrombosis (l_nmod) thrombosis_18\NN\14100769|with
D006493_D013927 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis|hitt (l_nmod) thrombosis_28\NN\14100769|with
D006493_D013927 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis|hitt (l_appos) hitt_30\NN\1740|(|)
C031942_D016638 NONE argatroban_18\NN\1740| (r_dobj) administered_17\VBN\2436349|report|,|patient|was|argatroban|anticoagulation|. (l_nsubjpass) patient_9\NN\9898892|a|65-year-old|ill|history (l_amod) ill_8\JJ\1740|critically
C031942_D008107 NONE argatroban_6\NN\1740|of (r_nmod) concentrations_4\NNS\4916342|high|argatroban (r_nsubjpass) measured_8\VBN\697589|concentrations|were|samples|range|,|and|observed (l_conj) observed_36\VBN\2163746|life|was|minutes|. (l_dep) minutes_46\NNS\6502378|(|t(1/2|is|51|[|<|minutes|]|) (l_dep) minutes_52\NNS\6502378|181|impairment (l_nmod) impairment_55\NN\7296428|with|hepatic
C031942_D008107 NONE argatroban_25\NN\1740| (r_compound) life_27\NN\13954253|a|prolonged|plasma|argatroban|half|t(1/2|)|minutes (r_nsubjpass) observed_36\VBN\2163746|life|was|minutes|. (l_dep) minutes_46\NNS\6502378|(|t(1/2|is|51|[|<|minutes|]|) (l_dep) minutes_52\NNS\6502378|181|impairment (l_nmod) impairment_55\NN\7296428|with|hepatic
C031942_D001778 NONE argatroban_5\NN\1740| (r_compound) concentration_6\NN\4916342|of|plasma|argatroban (r_nmod) correlation_2\NN\13841213|concentration|variables|and|course (r_nsubj) suggest_16\VBP\1010118|conclusions|correlation|contributed|. (l_ccomp) contributed_26\VBN\126264|that|levels|may|have|coagulopathy (l_nmod) coagulopathy_32\NN\1740|to|patient|extended
C031942_D001778 NONE argatroban_23\NN\1740|of|plasma (r_nmod) levels_20\NNS\4916342|prolonged|elevated|argatroban (r_nsubj) contributed_26\VBN\126264|that|levels|may|have|coagulopathy (l_nmod) coagulopathy_32\NN\1740|to|patient|extended
C031942_D001778 NONE argatroban_8\NN\1740| (r_compound) concentration_9\NN\4916342|plasma|argatroban (r_dobj) measure_6\VB\697589|to|concentration|context (l_nmod) context_12\NN\6284777|in|the|cpb (l_nmod) cpb_14\NN\1740|of|and|coagulopathy (l_conj) coagulopathy_17\NN\1740|extended
15649445
D012110_D004409 CID reserpine_1\NN\2721160|acute|and|haloperidol (r_compound) treatments_5\NNS\654885|reserpine (r_nsubj) change_6\VBP\46534|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\1617192|dyskinesia|rats (l_dobj) dyskinesia_14\NN\14084880|orofacial
D012110_D004409 CID reserpine-_0\NN\1740|and|haloperidol-induced (r_compound) dyskinesia_4\NN\14084880|reserpine-|orofacial
D012110_D004409 CID reserpine-_0\NN\1740|and|haloperidol-induced (r_compound) dyskinesia_4\NN\14084880|reserpine-|orofacial (r_nsubj) models_8\NNS\5888929|dyskinesia|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related
D012110_D004409 CID reserpine-_0\NN\1740|and|haloperidol-induced (r_compound) dyskinesia_4\NN\14084880|reserpine-|orofacial (r_nsubj) models_8\NNS\5888929|dyskinesia|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related (l_appos) td_13\NN\1740|(|)
D012110_D004409 CID reserpine_12\NN\2721160|and|haloperidol (r_compound) administration_16\NN\1133281|by|acute|reserpine|rats (r_nmod) induced_7\VBD\1627355|study|,|authors|dyskinesia|administration|. (l_dobj) dyskinesia_9\NN\14084880|orofacial
D006220_D004409 CID haloperidol_4\NN\3713736|subchronic (r_conj) reserpine_1\NN\2721160|acute|and|haloperidol (r_compound) treatments_5\NNS\654885|reserpine (r_nsubj) change_6\VBP\46534|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\1617192|dyskinesia|rats (l_dobj) dyskinesia_14\NN\14084880|orofacial
D006220_D004409 CID haloperidol-induced_2\JJ\1740| (r_conj) reserpine-_0\NN\1740|and|haloperidol-induced (r_compound) dyskinesia_4\NN\14084880|reserpine-|orofacial
D006220_D004409 CID haloperidol-induced_2\JJ\1740| (r_conj) reserpine-_0\NN\1740|and|haloperidol-induced (r_compound) dyskinesia_4\NN\14084880|reserpine-|orofacial (r_nsubj) models_8\NNS\5888929|dyskinesia|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related
D006220_D004409 CID haloperidol-induced_2\JJ\1740| (r_conj) reserpine-_0\NN\1740|and|haloperidol-induced (r_compound) dyskinesia_4\NN\14084880|reserpine-|orofacial (r_nsubj) models_8\NNS\5888929|dyskinesia|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related (l_appos) td_13\NN\1740|(|)
D006220_D004409 CID haloperidol_15\NN\3713736|subchronic (r_conj) reserpine_12\NN\2721160|and|haloperidol (r_compound) administration_16\NN\1133281|by|acute|reserpine|rats (r_nmod) induced_7\VBD\1627355|study|,|authors|dyskinesia|administration|. (l_dobj) dyskinesia_9\NN\14084880|orofacial
D018698_D004409 NONE glutamate_9\NN\15010703| (r_compound) uptake_10\NN\13440063|synaptosomal|brain|glutamate (r_dobj) change_6\VBP\46534|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\1617192|dyskinesia|rats (l_dobj) dyskinesia_14\NN\14084880|orofacial
D018698_D004409 NONE glutamate_5\NN\15010703| (r_compound) uptake_6\NN\13440063|in|glutamate (r_nmod) decrease_3\NN\7296428|a|uptake (r_nsubj) correlates_7\VBZ\2657219|importantly|,|decrease|negatively|increase|. (l_nmod) increase_11\NN\13576355|with|an|incidence (l_nmod) incidence_14\NN\13821570|in|the|diskinesia (l_nmod) diskinesia_17\NN\1740|of|orofacial
8919272
D014635_D001927 CID valproate_11\NN\1740|of|the|drug (r_nmod) administration_6\NN\1133281|after|chronic|valproate|rats (r_nmod) encephalopathy_3\NN\14084880|of|administration
D014635_D001927 CID valproate_8\NN\1740|sodium (r_dep) drug_6\NN\14778436|of|the|antiepileptic|valproate|polfa (r_nmod) application_2\NN\947128|long-term|intragastric|drug|dose|daily|rats|1|months (r_nsubj) revealed_39\VBD\2137132|application|disorders|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating (l_acl) indicating_42\VBG\952524|damage (l_dobj) damage_44\NN\7296428|cerebellum|encephalopathy (l_appos) encephalopathy_48\NN\14084880|(|"|valproate|"|)
D014635_D001927 CID valproate_47\NN\1740| (r_compound) encephalopathy_48\NN\14084880|(|"|valproate|"|)
D014635_D001927 CID valproate_15\NN\1740| (r_compound) encephalopathy_16\NN\14084880|of|valproate
D014635_D009422 NONE valproate_8\NN\1740|sodium (r_dep) drug_6\NN\14778436|of|the|antiepileptic|valproate|polfa (r_nmod) application_2\NN\947128|long-term|intragastric|drug|dose|daily|rats|1|months (r_nsubj) revealed_39\VBD\2137132|application|disorders|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating
D014635_D009422 NONE valproate_47\NN\1740| (r_compound) encephalopathy_48\NN\14084880|(|"|valproate|"|) (r_appos) damage_44\NN\7296428|cerebellum|encephalopathy (r_dobj) indicating_42\VBG\952524|damage (r_acl) disorders_41\NNS\14034177|neurological|indicating
D014635_D002526 NONE valproate_8\NN\1740|sodium (r_dep) drug_6\NN\14778436|of|the|antiepileptic|valproate|polfa (r_nmod) application_2\NN\947128|long-term|intragastric|drug|dose|daily|rats|1|months (r_nsubj) revealed_39\VBD\2137132|application|disorders|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating (l_acl) indicating_42\VBG\952524|damage (l_dobj) damage_44\NN\7296428|cerebellum|encephalopathy
D014635_D002526 NONE valproate_47\NN\1740| (r_compound) encephalopathy_48\NN\14084880|(|"|valproate|"|) (r_appos) damage_44\NN\7296428|cerebellum|encephalopathy
D014635_D056486 NONE valproate_15\NN\1740| (r_compound) encephalopathy_16\NN\14084880|of|valproate (r_nmod) development_13\NN\248977|upon|the|encephalopathy (r_nmod) influence_2\NN\5190804|the|possible|damage|development (l_nmod) damage_6\NN\7296428|of|the|hepatic|,|hyperammonemia|,
D014635_D022124 NONE valproate_15\NN\1740| (r_compound) encephalopathy_16\NN\14084880|of|valproate (r_nmod) development_13\NN\248977|upon|the|encephalopathy (r_nmod) influence_2\NN\5190804|the|possible|damage|development (l_nmod) damage_6\NN\7296428|of|the|hepatic|,|hyperammonemia|, (l_appos) hyperammonemia_9\NN\1740|mainly
6503301
D003606_D006504 CID dacarbazine_4\NN\1740| (r_compound) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (r_nmod) disease_2\NN\14061805|veno-occlusive|liver|therapy|.
D003606_D006504 CID dtic_7\NN\8337324|(|) (r_appos) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (r_nmod) disease_2\NN\14061805|veno-occlusive|liver|therapy|.
D003606_D006504 CID dacarbazine_12\NN\1740|dtic (r_compound) therapy_16\NN\657604|after|dacarbazine|melanoma (r_nmod) outcome_10\NN\7291312|with|fatal|therapy (r_nmod) disease_4\NN\14061805|of|veno-occlusive|liver|outcome (l_nmod) liver_7\NN\5298729|of|the
D003606_D006504 CID dtic_14\NN\8337324|(|) (r_appos) dacarbazine_12\NN\1740|dtic (r_compound) therapy_16\NN\657604|after|dacarbazine|melanoma (r_nmod) outcome_10\NN\7291312|with|fatal|therapy (r_nmod) disease_4\NN\14061805|of|veno-occlusive|liver|outcome (l_nmod) liver_7\NN\5298729|of|the
D003606_D008545 NONE dacarbazine_4\NN\1740| (r_compound) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (l_nmod) melanoma_10\NN\14252320|for
D003606_D008545 NONE dtic_7\NN\8337324|(|) (r_appos) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (l_nmod) melanoma_10\NN\14252320|for
D003606_D008545 NONE dacarbazine_12\NN\1740|dtic (r_compound) therapy_16\NN\657604|after|dacarbazine|melanoma (l_nmod) melanoma_18\NN\14252320|for
D003606_D008545 NONE dtic_14\NN\8337324|(|) (r_appos) dacarbazine_12\NN\1740|dtic (r_compound) therapy_16\NN\657604|after|dacarbazine|melanoma (l_nmod) melanoma_18\NN\14252320|for
10342929
D000806_D000799 CID inhibitors_4\NNS\20090|due|ace (r_nmod) angioedema_0\NN\14316714|inhibitors|:|common|.
D000806_D000799 CID inhibitor_11\NN\20090|enzyme (r_compound) treatment_12\NN\654885|during|inhibitor (r_nmod) incidence_2\NN\13821570|the|estimated|angioedema|treatment (l_nmod) angioedema_4\NN\14316714|of
1720453
D007069_D007674 CID ifosfamide_3\NN\1740| (r_compound) toxicity_5\NN\13576101|of|ifosfamide|renal|children
D007069_C535700 NONE ifosfamide_3\NN\1740| (r_compound) toxicity_5\NN\13576101|of|ifosfamide|renal|children (l_nmod) children_7\NNS\9622049|in|treated (l_acl) treated_8\VBN\2376958|tumors (l_nmod) tumors_12\NNS\14234074|for|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\NN\1740| (r_compound) protocol_21\NN\6652242|the|same|ifosfamide|chemotherapy|study (r_dobj) received_16\VBN\2210855|who|have|protocol (r_conj) children_5\NNS\9622049|of|74|tumors|and|received (l_nmod) tumors_9\NNS\14234074|with|malignant|mesenchymal|remission
D007069_C535700 NONE ifosfamide_19\NN\1740| (r_compound) protocol_21\NN\6652242|the|same|ifosfamide|chemotherapy|study (l_appos) study_31\NNP\635850|(|international|society|tumor|84|[|mmt|]|) (l_compound) tumor_30\NNP\14234074|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_18\NN\1740|of (r_nmod) efficacy_16\NN\5199286|to|the|ifosfamide|treatment (l_nmod) treatment_21\NN\654885|in|the|tumors (l_nmod) tumors_24\NNS\14234074|of|mesenchymal|children
D003404_D006030 NONE creatinine_22\NN\1740| (r_compound) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) electrolytes_9\NNS\14589223|urinary|,|glucosuria|,|ph|,|osmolarity|,|clearance|,|microglobulinuria (l_conj) glucosuria_11\NN\14267841|,|proteinuria|,|aminoaciduria
D003404_D011507 NONE creatinine_22\NN\1740| (r_compound) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) electrolytes_9\NNS\14589223|urinary|,|glucosuria|,|ph|,|osmolarity|,|clearance|,|microglobulinuria (l_conj) glucosuria_11\NN\14267841|,|proteinuria|,|aminoaciduria (l_conj) proteinuria_13\NN\14299637|
D003404_D000608 NONE creatinine_22\NN\1740| (r_compound) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) electrolytes_9\NNS\14589223|urinary|,|glucosuria|,|ph|,|osmolarity|,|clearance|,|microglobulinuria (l_conj) glucosuria_11\NN\14267841|,|proteinuria|,|aminoaciduria (l_conj) aminoaciduria_15\NN\14299637|
D010710_D006030 NONE phosphate_25\NN\15010703| (r_compound) reabsorption_27\NN\13526110|phosphate|tubular (r_conj) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) electrolytes_9\NNS\14589223|urinary|,|glucosuria|,|ph|,|osmolarity|,|clearance|,|microglobulinuria (l_conj) glucosuria_11\NN\14267841|,|proteinuria|,|aminoaciduria
D010710_D011507 NONE phosphate_25\NN\15010703| (r_compound) reabsorption_27\NN\13526110|phosphate|tubular (r_conj) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) electrolytes_9\NNS\14589223|urinary|,|glucosuria|,|ph|,|osmolarity|,|clearance|,|microglobulinuria (l_conj) glucosuria_11\NN\14267841|,|proteinuria|,|aminoaciduria (l_conj) proteinuria_13\NN\14299637|
D010710_D000608 NONE phosphate_25\NN\15010703| (r_compound) reabsorption_27\NN\13526110|phosphate|tubular (r_conj) clearance_23\NN\5089947|creatinine|,|reabsorption (r_conj) electrolytes_9\NNS\14589223|urinary|,|glucosuria|,|ph|,|osmolarity|,|clearance|,|microglobulinuria (l_conj) glucosuria_11\NN\14267841|,|proteinuria|,|aminoaciduria (l_conj) aminoaciduria_15\NN\14299637|
D010710_D064420 NONE phosphate_51\NN\15010703| (r_compound) reabsorption_52\NN\13526110|low|phosphate (r_conj) microglobulinuria_48\NN\1740|with|elevated|beta|2|and|reabsorption (r_nmod) patients_43\NNS\9898892|five|microglobulinuria (r_dobj) included_41\VBD\690614|group|patients (r_conj) included_13\VBD\690614|first|patients|;|and|included|. (l_dobj) patients_15\NNS\9898892|four|(|%|developed (l_acl:relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting
D010710_D005198 NONE phosphate_51\NN\15010703| (r_compound) reabsorption_52\NN\13526110|low|phosphate (r_conj) microglobulinuria_48\NN\1740|with|elevated|beta|2|and|reabsorption (r_nmod) patients_43\NNS\9898892|five|microglobulinuria (r_dobj) included_41\VBD\690614|group|patients (r_conj) included_13\VBD\690614|first|patients|;|and|included|. (l_dobj) patients_15\NNS\9898892|four|(|%|developed (l_acl:relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting (l_acl) resulting_28\VBG\2633881|syndrome (l_nmod) syndrome_32\NN\5870365|in|fanconi|'s|tdfs
D010710_D005198 NONE phosphate_51\NN\15010703| (r_compound) reabsorption_52\NN\13526110|low|phosphate (r_conj) microglobulinuria_48\NN\1740|with|elevated|beta|2|and|reabsorption (r_nmod) patients_43\NNS\9898892|five|microglobulinuria (r_dobj) included_41\VBD\690614|group|patients (r_conj) included_13\VBD\690614|first|patients|;|and|included|. (l_dobj) patients_15\NNS\9898892|four|(|%|developed (l_acl:relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting (l_acl) resulting_28\VBG\2633881|syndrome (l_nmod) syndrome_32\NN\5870365|in|fanconi|'s|tdfs (l_appos) tdfs_34\NN\1740|(|)
D007069_D064420 NONE ifosfamide_13\NN\1740|of (r_nmod) g/m2_11\NN\1740|of|60|ifosfamide (r_nmod) dose_8\NN\3740161|with|the|higher|cumulative|g/m2|,|age (r_nmod) correlated_3\VBN\2657219|toxicity|was|dose|. (l_nsubjpass) toxicity_1\NN\13576101|severe
D007069_D009369 NONE ifosfamide_13\NN\1740|of (r_nmod) g/m2_11\NN\1740|of|60|ifosfamide (r_nmod) dose_8\NN\3740161|with|the|higher|cumulative|g/m2|,|age (l_conj) age_17\NN\4916342|a|younger|old|,|and|predominance (l_conj) predominance_29\NN\14441825|a|involvement (l_nmod) involvement_33\NN\1080366|of|vesicoprostatic|tumor (l_compound) tumor_32\NN\14234074|
20619828
D002997_D001008 CID clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|results|exposure|changes|. (l_dobj) changes_12\NNS\7283608|significant|behavioral|include (l_acl:relcl) include_14\VBP\690614|that|anxiety (l_dobj) anxiety_16\NN\14373582|enhanced|maze|,|inflexibility
D002997_-1 NONE clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|results|exposure|changes|. (l_dobj) changes_12\NNS\7283608|significant|behavioral|include (l_acl:relcl) include_14\VBP\690614|that|anxiety (l_dobj) anxiety_16\NN\14373582|enhanced|maze|,|inflexibility (l_conj) inflexibility_27\NN\5023741|behavioral|perseveration
D002997_-1 NONE clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|results|exposure|changes|. (l_dobj) changes_12\NNS\7283608|significant|behavioral|include (l_acl:relcl) include_14\VBP\690614|that|anxiety (l_dobj) anxiety_16\NN\14373582|enhanced|maze|,|inflexibility (l_conj) inflexibility_27\NN\5023741|behavioral|perseveration (l_dep) perseveration_29\NN\6196584|(|task|and|learning|)|,|impairment|,|hoarding|,|and|dysfunction (l_conj) dysfunction_55\NN\14204950|corticostriatal
D002997_D008569 CID clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|results|exposure|changes|. (l_dobj) changes_12\NNS\7283608|significant|behavioral|include (l_acl:relcl) include_14\VBP\690614|that|anxiety (l_dobj) anxiety_16\NN\14373582|enhanced|maze|,|inflexibility (l_conj) inflexibility_27\NN\5023741|behavioral|perseveration (l_dep) perseveration_29\NN\6196584|(|task|and|learning|)|,|impairment|,|hoarding|,|and|dysfunction (l_conj) impairment_43\NN\7296428|memory|paradigm
D002997_D060845 CID clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|results|exposure|changes|. (l_dobj) changes_12\NNS\7283608|significant|behavioral|include (l_acl:relcl) include_14\VBP\690614|that|anxiety (l_dobj) anxiety_16\NN\14373582|enhanced|maze|,|inflexibility (l_conj) inflexibility_27\NN\5023741|behavioral|perseveration (l_dep) perseveration_29\NN\6196584|(|task|and|learning|)|,|impairment|,|hoarding|,|and|dysfunction (l_conj) hoarding_51\NN\4217882|
19820426
C558899_D066126 NONE lopinavir/ritonavir_8\NN\1740| (r_compound) therapy_9\NN\657604|to|lopinavir/ritonavir (r_nmod) related_6\JJ\1740|therapy (r_amod) toxicity_5\NN\13576101|with|cardiac|related
C558899_D006327 CID lopinavir/ritonavir_13\NN\1740| (r_compound) therapy_14\NN\657604|to|lopinavir/ritonavir|,|agent (r_nmod) related_11\JJ\1740|therapy (r_amod) cardiomyopathy_10\NN\14103288|dilated|related (r_conj) block_7\NN\21939|complete|heart|and|cardiomyopathy
C558899_D002311 CID lopinavir/ritonavir_13\NN\1740| (r_compound) therapy_14\NN\657604|to|lopinavir/ritonavir|,|agent (r_nmod) related_11\JJ\1740|therapy (r_amod) cardiomyopathy_10\NN\14103288|dilated|related
C558899_D001919 CID lopinavir/ritonavir_13\NN\1740| (r_compound) therapy_14\NN\657604|to|lopinavir/ritonavir|,|agent (r_nmod) related_11\JJ\1740|therapy (r_amod) cardiomyopathy_10\NN\14103288|dilated|related (r_conj) block_7\NN\21939|complete|heart|and|cardiomyopathy (r_dobj) developed_4\VBD\1753788|one|block|,|developed|. (l_advcl) developed_25\VBD\1753788|while|twin|bradycardia (l_dobj) bradycardia_27\NN\14110674|mild
18023325
D004221_D014826 CID disulfiram_6\NN\3740161| (r_compound) intoxication_7\NN\14034177|after|acute|disulfiram (r_nmod) palsy_3\NN\14557898|acute|fold|intoxication|.
D004221_D014826 CID disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\1740|by|a|disulfiram (r_nmod) caused_3\VBN\1617192|overdose (r_acl) neuropathy_2\NN\14204950|acute|peripheral|caused (r_nsubj) rare_10\JJ\1740|neuropathy|is|very|and|is (l_conj) is_13\VBZ\836236|there|report (l_attr) report_15\NN\6470073|no|it (l_nmod) it_17\PRP\6125041|of|leading (l_acl) leading_18\VBG\1752884|palsy|. (l_nmod) palsy_22\NN\14557898|to|fold
D004221_D010523 CID disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\1740|by|a|disulfiram (r_nmod) caused_3\VBN\1617192|overdose (r_acl) neuropathy_2\NN\14204950|acute|peripheral|caused
D004221_D062787 NONE disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\1740|by|a|disulfiram
D004221_D010243 NONE disulfiram_22\NN\3740161| (r_compound) intoxication_23\NN\14034177|by|high-dose|disulfiram (r_nmod) caused_19\VBN\1617192|intoxication (r_acl) polyneuropathy_18\NN\1740|superimposed|severe|acute|sensorimotor|axonal|caused (r_conj) palsy_6\NN\14557898|of|acute|nerve|and|polyneuropathy
D004221_D011115 NONE disulfiram_22\NN\3740161| (r_compound) intoxication_23\NN\14034177|by|high-dose|disulfiram (r_nmod) caused_19\VBN\1617192|intoxication (r_acl) polyneuropathy_18\NN\1740|superimposed|severe|acute|sensorimotor|axonal|caused
18631865
D020123_D051436 NONE rapamycin_16\NN\1740| (r_compound) mtor_18\NN\1740|of|rapamycin|(|) (r_compound) inhibitors_20\NNS\20090|to|target|mtor|,|sirolimus|, (r_nmod) conversion_8\NN\7359599|after|inhibitors|inhibitors (r_nmod) observed_6\VBN\2163746|excretion|has|been|conversion|recipients|. (l_nmod) recipients_28\NNS\9764201|in|renal|transplant|nephropathy (l_nmod) nephropathy_32\NN\14573196|with|chronic|allograft
D020123_D051436 NONE sirolimus_23\NN\1740|especially (r_appos) inhibitors_20\NNS\20090|to|target|mtor|,|sirolimus|, (r_nmod) conversion_8\NN\7359599|after|inhibitors|inhibitors (r_nmod) observed_6\VBN\2163746|excretion|has|been|conversion|recipients|. (l_nmod) recipients_28\NNS\9764201|in|renal|transplant|nephropathy (l_nmod) nephropathy_32\NN\14573196|with|chronic|allograft
D020123_D011507 CID sirolimus_5\NN\1740| (r_dobj) due_3\JJ\1740|whether|proteinuria|was|to|sirolimus|or|consequence (l_nsubj) proteinuria_1\NN\14299637|
D020123_D011507 CID sirolimus_5\NN\1740| (r_dobj) due_3\JJ\1740|whether|proteinuria|was|to|sirolimus|or|consequence (r_advcl) remained_14\VBD\2604760|due|unsolved|observed|. (l_advcl) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (l_nsubjpass) proteinuria_19\NN\14299637|range
D020123_D011507 CID sirolimus_24\NN\1740| (r_compound) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (r_advcl) remained_14\VBD\2604760|due|unsolved|observed|. (l_advcl) due_3\JJ\1740|whether|proteinuria|was|to|sirolimus|or|consequence (l_nsubj) proteinuria_1\NN\14299637|
D020123_D011507 CID sirolimus_24\NN\1740| (r_compound) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (l_nsubjpass) proteinuria_19\NN\14299637|range
D020123_D011507 CID sirolimus_34\NN\1740| (r_dobj) received_33\VBD\2210855|who|sirolimus|novo (r_acl:relcl) patients_31\NNS\9898892|in|received (r_conj) transplantation_28\NN\671351|in|islet|and|patients (r_nmod) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (r_advcl) remained_14\VBD\2604760|due|unsolved|observed|. (l_advcl) due_3\JJ\1740|whether|proteinuria|was|to|sirolimus|or|consequence (l_nsubj) proteinuria_1\NN\14299637|
D020123_D011507 CID sirolimus_34\NN\1740| (r_dobj) received_33\VBD\2210855|who|sirolimus|novo (r_acl:relcl) patients_31\NNS\9898892|in|received (r_conj) transplantation_28\NN\671351|in|islet|and|patients (r_nmod) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (l_nsubjpass) proteinuria_19\NN\14299637|range
6773726
D005996_D007022 CID nitroglycerin_5\NN\15015501|by (r_nmod) provocation_0\NN\1221611|hypotension|nitroglycerin|neuropathy|? (l_nmod) hypotension_3\NN\14057371|of|postural
D005996_D003929 NONE nitroglycerin_5\NN\15015501|by (r_nmod) provocation_0\NN\1221611|hypotension|nitroglycerin|neuropathy|? (l_nmod) neuropathy_9\NN\14204950|in|diabetic|autonomic
D005996_D003920 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|. (l_nmod) subjects_16\NNS\6598915|in|5|normal|,|subjects (l_conj) subjects_20\NNS\6598915|12|diabetic|neuropathy|,|and|subjects (l_amod) diabetic_19\JJ\1740|
D005996_D003920 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|. (l_nmod) subjects_16\NNS\6598915|in|5|normal|,|subjects (l_conj) subjects_20\NNS\6598915|12|diabetic|neuropathy|,|and|subjects (l_conj) subjects_28\NNS\6598915|5|diabetic|neuropathy (l_amod) diabetic_27\JJ\1740|
D005996_D003920 NONE nitroglycerin_19\NN\15015501|after (r_nmod) decrease_13\NN\7296428|the|pressure|nitroglycerin (r_conj) increase_7\NN\13576355|of|the|rate|and|decrease (r_nmod) magnitude_1\NN\4916342|the|and|course|increase (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|,|whereas|occurred (l_nmod) subjects_27\NNS\6598915|in|the|normal|neuropathy (l_amod) normal_24\JJ\1740|and|diabetic (l_conj) diabetic_26\JJ\1740|
D005996_D003920 NONE nitroglycerin_19\NN\15015501|after (r_nmod) decrease_13\NN\7296428|the|pressure|nitroglycerin (r_conj) increase_7\NN\13576355|of|the|rate|and|decrease (r_nmod) magnitude_1\NN\4916342|the|and|course|increase (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|,|whereas|occurred (l_parataxis) occurred_47\VBD\2623529|increase|subjects|. (l_nmod) subjects_51\NNS\6598915|in|the|diabetic|neuropathy (l_amod) diabetic_50\JJ\1740|
D005996_D009422 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|. (l_nmod) subjects_16\NNS\6598915|in|5|normal|,|subjects (l_conj) subjects_20\NNS\6598915|12|diabetic|neuropathy|,|and|subjects (l_nmod) neuropathy_23\NN\14204950|without|autonomic
D005996_D009422 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|. (l_nmod) subjects_16\NNS\6598915|in|5|normal|,|subjects (l_conj) subjects_20\NNS\6598915|12|diabetic|neuropathy|,|and|subjects (l_conj) subjects_28\NNS\6598915|5|diabetic|neuropathy (l_nmod) neuropathy_31\NN\14204950|with|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\15015501|after (r_nmod) decrease_13\NN\7296428|the|pressure|nitroglycerin (r_conj) increase_7\NN\13576355|of|the|rate|and|decrease (r_nmod) magnitude_1\NN\4916342|the|and|course|increase (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|,|whereas|occurred (l_nmod) subjects_27\NNS\6598915|in|the|normal|neuropathy (l_nmod) neuropathy_30\NN\14204950|without|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\15015501|after (r_nmod) decrease_13\NN\7296428|the|pressure|nitroglycerin (r_conj) increase_7\NN\13576355|of|the|rate|and|decrease (r_nmod) magnitude_1\NN\4916342|the|and|course|increase (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|,|whereas|occurred (l_parataxis) occurred_47\VBD\2623529|increase|subjects|. (l_nmod) subjects_51\NNS\6598915|in|the|diabetic|neuropathy (l_nmod) neuropathy_54\NN\14204950|with|autonomic
227508
D003000_D006973 NONE clonidine_17\NN\2721160|by|intravenous|,|micrograms/kg|, (r_nmod) produced_14\VBN\1617192|clonidine (r_acl) decrease_7\NN\7296428|the|pressure|produced (r_nsubjpass) inhibited_25\VBN\2510337|rats|decrease|was|or|reversed|. (l_nmod) rats_5\NNS\2329401|in|unanesthetized|,|hypertensive (l_amod) hypertensive_4\JJ\1740|spontaneously
D003000_D006973 NONE clonidine_7\NN\2721160|,|10(-5|m|, (r_nsubj) influence_18\VB\137313|membranes|clonidine|did|not|binding|,|and|influence (l_nmod) membranes_2\NNS\4188643|in|brain|rats (l_nmod) rats_6\NNS\2329401|from|hypertensive (l_amod) hypertensive_5\JJ\1740|spontaneously
D003000_D006973 NONE clonidine-suppressible_41\JJ\1740| (r_amod) binding_42\NN\4688246|clonidine-suppressible|[3h]-dihydroergocryptine (r_dobj) influence_40\VB\137313|naloxone|did|not|binding|. (r_conj) influence_18\VB\137313|membranes|clonidine|did|not|binding|,|and|influence (l_nmod) membranes_2\NNS\4188643|in|brain|rats (l_nmod) rats_6\NNS\2329401|from|hypertensive (l_amod) hypertensive_5\JJ\1740|spontaneously
-1_D006973 NONE nalozone_29\NN\1740|by|,|mg/kg (r_nmod) reversed_27\VBN\109660|nalozone (r_conj) inhibited_25\VBN\2510337|rats|decrease|was|or|reversed|. (l_nmod) rats_5\NNS\2329401|in|unanesthetized|,|hypertensive (l_amod) hypertensive_4\JJ\1740|spontaneously
-1_D006973 NONE [3h]-naloxone_22\NN\1740|of|nm (r_nmod) binding_20\NN\4688246|stereoselective|[3h]-naloxone (r_dobj) influence_18\VB\137313|membranes|clonidine|did|not|binding|,|and|influence (l_nmod) membranes_2\NNS\4188643|in|brain|rats (l_nmod) rats_6\NNS\2329401|from|hypertensive (l_amod) hypertensive_5\JJ\1740|spontaneously
-1_D006973 NONE [3h]-dihydroergocryptine_44\NN\1740|of|nm (r_nmod) binding_42\NN\4688246|clonidine-suppressible|[3h]-dihydroergocryptine (r_dobj) influence_40\VB\137313|naloxone|did|not|binding|. (r_conj) influence_18\VB\137313|membranes|clonidine|did|not|binding|,|and|influence (l_nmod) membranes_2\NNS\4188643|in|brain|rats (l_nmod) rats_6\NNS\2329401|from|hypertensive (l_amod) hypertensive_5\JJ\1740|spontaneously
D008750_D007022 CID alpha-methyldopa_6\NN\1740|of|mg/kg (r_nmod) effect_2\NN\34213|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_1\JJ\1740|
D009270_D007022 NONE naloxone_12\NN\3808977|by (r_nmod) reversed_10\VBN\109660|effect|was|also|partially|naloxone|. (l_nsubjpass) effect_2\NN\34213|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_1\JJ\1740|
D009270_D006973 NONE naloxone_29\NN\3808977|,|m|, (r_nsubj) influence_40\VB\137313|naloxone|did|not|binding|. (r_conj) influence_18\VB\137313|membranes|clonidine|did|not|binding|,|and|influence (l_nmod) membranes_2\NNS\4188643|in|brain|rats (l_nmod) rats_6\NNS\2329401|from|hypertensive (l_amod) hypertensive_5\JJ\1740|spontaneously
1378968
D008094_D007676 CID lithium-induced_8\JJ\1740| (r_amod) failure_11\NN\66216|on|lithium-induced|chronic|renal|rats
D008094_D007674 NONE lithium-induced_2\JJ\1740| (r_amod) nephropathy_3\NN\14573196|with|lithium-induced
D008094_D007674 NONE li-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|li-induced|,|reduced
D008094_D051437 NONE lithium-induced_2\JJ\1740| (r_amod) nephropathy_3\NN\14573196|with|lithium-induced (r_nmod) rats_0\NNS\2329401|nephropathy (r_nsubjpass) subjected_5\VBN\137313|rats|were|feeding|,|attempt|. (l_nmod) attempt_26\NN\407535|in|an|induce (l_acl) induce_28\VB\1627355|to|hyperfiltration (l_dobj) hyperfiltration_30\NN\1740|glomerular|and|progression (l_conj) progression_33\NN\8457976|further|failure (l_nmod) failure_36\NN\66216|of|renal
D008094_D051437 NONE lithium_21\NN\14625458| (r_nmod:npmod) pretreated_22\JJ\1740|lithium (r_amod) rats_23\NNS\2329401|in|pretreated (r_nmod) levels_19\NNS\4916342|plasma|creatinine|rats (r_dobj) decrease_16\VB\169651|levels (r_conj) increase_13\VB\169651|to|gfr|and|decrease (r_xcomp) tended_11\VBD\2604760|fact|increase (r_conj) accentuante_3\VB\1740|to|progression|and|tended (l_dobj) progression_4\NN\8457976|failure (l_nmod) failure_7\NN\66216|of|renal
D008094_D011507 CID lithium_0\NN\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|absence|. (l_dobj) proteinuria_3\NN\14299637|and|hypertension
D008094_D011507 CID li-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|li-induced|,|reduced (r_nsubjpass) associated_17\VBN\628491|that|nephropathy|,|is|proteinuria (l_nmod) proteinuria_19\NN\14299637|with|and|hypertension
D008094_D006973 CID lithium_0\NN\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|absence|. (l_dobj) proteinuria_3\NN\14299637|and|hypertension (l_conj) hypertension_6\NN\14057371|systolic
D008094_D006973 CID li-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|li-induced|,|reduced (r_nsubjpass) associated_17\VBN\628491|that|nephropathy|,|is|proteinuria (l_nmod) proteinuria_19\NN\14299637|with|and|hypertension (l_conj) hypertension_23\NN\14057371|arterial|systolic
D008094_D005921 NONE lithium_0\NN\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|absence|. (l_nmod) absence_8\NN\14449405|in|glomerulosclerosis (l_nmod) glomerulosclerosis_10\NN\1740|of
D003404_D051437 NONE creatinine_18\NN\1740| (r_compound) levels_19\NNS\4916342|plasma|creatinine|rats (r_dobj) decrease_16\VB\169651|levels (r_conj) increase_13\VB\169651|to|gfr|and|decrease (r_xcomp) tended_11\VBD\2604760|fact|increase (r_conj) accentuante_3\VB\1740|to|progression|and|tended (l_dobj) progression_4\NN\8457976|failure (l_nmod) failure_7\NN\66216|of|renal
11198499
C023754_D007022 CID tizanidine_5\NN\1740|of (r_nmod) initiation_3\NN\7450842|following|the|tizanidine|patient (r_nmod) hypotension_0\NN\14057371|initiation|.
C023754_D007022 CID tizanidine_27\NN\1740|of|,|agonist|, (r_nmod) addition_25\NN\3081021|following|the|tizanidine|treatment (r_nmod) developed_21\VBD\1753788|who|hypotension|addition (l_dobj) hypotension_22\NN\14057371|
C023754_D006973 NONE tizanidine_5\NN\1740|of (r_nmod) initiation_3\NN\7450842|following|the|tizanidine|patient (l_nmod) patient_8\NN\9898892|in|a|treated (l_acl) treated_9\VBN\2376958|inhibitor (l_nmod) inhibitor_15\NN\20090|with|an|angiotensin|converting|enzyme|hypertension (l_nmod) hypertension_18\NN\14057371|for|chronic
C023754_D006973 NONE tizanidine_27\NN\1740|of|,|agonist|, (r_nmod) addition_25\NN\3081021|following|the|tizanidine|treatment (r_nmod) developed_21\VBD\1753788|who|hypotension|addition (r_acl:relcl) hypertension_19\NN\14057371|developed
C023754_D006973 NONE tizanidine_4\NN\1740|of|and|agents (r_nmod) interaction_2\NN\37396|the|possible|tizanidine (r_nsubjpass) kept_11\VBN\2367363|interaction|should|be|mind|prescribing|. (l_advcl) prescribing_15\VBG\748282|when|therapy (l_dobj) therapy_16\NN\657604|treat (l_acl) treat_18\VB\2376958|to|hypertension (l_dobj) hypertension_20\NN\14057371|either|or|spasticity|patients
D000809_D007022 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|with|an|angiotensin|converting|enzyme|hypertension (r_nmod) treated_9\VBN\2376958|inhibitor (r_acl) patient_8\NN\9898892|in|a|treated (r_nmod) initiation_3\NN\7450842|following|the|tizanidine|patient (r_nmod) hypotension_0\NN\14057371|initiation|.
D000809_D007022 NONE angiotensin_4\NN\4522421| (r_compound) inhibitors_7\NNS\20090|with|angiotensin|converting|enzyme (r_nmod) treated_2\VBN\2376958|chronically|inhibitors (r_acl) adults_0\NNS\7846|treated (r_nsubj) have_9\VB\2108377|adults|may|ability|blocked|. (l_dobj) ability_12\NN\4723816|a|limited|respond (l_acl) respond_14\VB\2367363|to|hypotension (l_nmod) hypotension_16\NN\14057371|to
D000809_D007022 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|an|angiotensin|converting|enzyme (r_appos) lisinopril_9\NN\2673637|with|,|inhibitor|, (r_nmod) treated_7\VBN\2376958|chronically|lisinopril|control (l_advcl) control_18\VB\2422663|to|hypertension (l_dobj) hypertension_19\NN\14057371|developed (l_acl:relcl) developed_21\VBD\1753788|who|hypotension|addition (l_dobj) hypotension_22\NN\14057371|
D000809_D006973 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|with|an|angiotensin|converting|enzyme|hypertension (l_nmod) hypertension_18\NN\14057371|for|chronic
D000809_D006973 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|an|angiotensin|converting|enzyme (r_appos) lisinopril_9\NN\2673637|with|,|inhibitor|, (r_nmod) treated_7\VBN\2376958|chronically|lisinopril|control (l_advcl) control_18\VB\2422663|to|hypertension (l_dobj) hypertension_19\NN\14057371|developed
D017706_D006973 NONE lisinopril_9\NN\2673637|with|,|inhibitor|, (r_nmod) treated_7\VBN\2376958|chronically|lisinopril|control (l_advcl) control_18\VB\2422663|to|hypertension (l_dobj) hypertension_19\NN\14057371|developed
D017706_D007022 CID lisinopril_9\NN\2673637|with|,|inhibitor|, (r_nmod) treated_7\VBN\2376958|chronically|lisinopril|control (l_advcl) control_18\VB\2422663|to|hypertension (l_dobj) hypertension_19\NN\14057371|developed (l_acl:relcl) developed_21\VBD\1753788|who|hypotension|addition (l_dobj) hypotension_22\NN\14057371|
D017706_D009128 NONE lisinopril_9\NN\2673637|with|,|inhibitor|, (r_nmod) treated_7\VBN\2376958|chronically|lisinopril|control (l_advcl) control_18\VB\2422663|to|hypertension (l_dobj) hypertension_19\NN\14057371|developed (l_acl:relcl) developed_21\VBD\1753788|who|hypotension|addition (l_nmod) addition_25\NN\3081021|following|the|tizanidine|treatment (l_nmod) treatment_35\NN\654885|for|the|spasticity (l_nmod) spasticity_37\NN\4770535|of
D000809_D009128 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|an|angiotensin|converting|enzyme (r_appos) lisinopril_9\NN\2673637|with|,|inhibitor|, (r_nmod) treated_7\VBN\2376958|chronically|lisinopril|control (l_advcl) control_18\VB\2422663|to|hypertension (l_dobj) hypertension_19\NN\14057371|developed (l_acl:relcl) developed_21\VBD\1753788|who|hypotension|addition (l_nmod) addition_25\NN\3081021|following|the|tizanidine|treatment (l_nmod) treatment_35\NN\654885|for|the|spasticity (l_nmod) spasticity_37\NN\4770535|of
C023754_D009128 NONE tizanidine_27\NN\1740|of|,|agonist|, (r_nmod) addition_25\NN\3081021|following|the|tizanidine|treatment (l_nmod) treatment_35\NN\654885|for|the|spasticity (l_nmod) spasticity_37\NN\4770535|of
C023754_D009128 NONE tizanidine_4\NN\1740|of|and|agents (r_nmod) interaction_2\NN\37396|the|possible|tizanidine (r_nsubjpass) kept_11\VBN\2367363|interaction|should|be|mind|prescribing|. (l_advcl) prescribing_15\VBG\748282|when|therapy (l_dobj) therapy_16\NN\657604|treat (l_acl) treat_18\VB\2376958|to|hypertension (l_dobj) hypertension_20\NN\14057371|either|or|spasticity|patients (l_conj) spasticity_22\NN\4770535|
16740173
2611118
D004008_D006521 NONE sodium_6\NN\14625458|diclofenac (r_compound) therapy_7\NN\657604|with|sodium (r_nmod) associated_3\VBN\628491|therapy (r_acl) hepatitis_2\NN\14127211|chronic|active|associated|.
D004008_D006521 NONE sodium_13\NN\14625458|with|diclofenac (r_nmod) therapy_10\NN\657604|after|months|sodium|progressed (r_nmod) developed_3\VBD\1753788|patient|hepatitis|therapy|,|finding|. (l_dobj) hepatitis_6\NN\14127211|chronic|active
D004008_D056486 CID diclofenac_21\NN\1740|by (r_nmod) induced_19\VBN\1627355|diclofenac (r_acl) hepatitis_18\NN\14127211|commonly|,|severe|induced (r_conj) recorded_11\VBN\2225492|although|well-tolerated|,|abnormalities|have|been|and|,|hepatitis|. (l_nsubjpass) abnormalities_5\NNS\14034177|asymptomatic|function (l_nmod) function_8\NN\13783581|of|liver
D004008_D056486 CID diclofenac_21\NN\1740|by (r_nmod) induced_19\VBN\1627355|diclofenac (r_acl) hepatitis_18\NN\14127211|commonly|,|severe|induced
12589964
D004317_D009202 CID doxorubicin-induced_14\JJ\1740| (r_amod) rats_16\NNS\2329401|in|doxorubicin-induced|cardiomyopathy (r_nmod) markers_9\NNS\21939|as|damage|rats (l_nmod) damage_12\NN\7296428|of|myocardial
D004317_D009202 CID doxorubicin-induced_14\JJ\1740| (r_amod) rats_16\NNS\2329401|in|doxorubicin-induced|cardiomyopathy (l_compound) cardiomyopathy_15\NN\14103288|
D004317_D009202 CID doxorubicin_20\NN\2716866|(dox)-induced (r_compound) cardiomyopathy_22\NN\14103288|of|doxorubicin (r_nmod) model_18\NN\5888929|in|a|rat|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (l_nmod) damage_14\NN\7296428|of|myocardial
D004317_D009202 CID doxorubicin_20\NN\2716866|(dox)-induced (r_compound) cardiomyopathy_22\NN\14103288|of|doxorubicin
D004317_D009202 CID (dox)-induced_21\NN\1740| (r_dep) doxorubicin_20\NN\2716866|(dox)-induced (r_compound) cardiomyopathy_22\NN\14103288|of|doxorubicin (r_nmod) model_18\NN\5888929|in|a|rat|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (l_nmod) damage_14\NN\7296428|of|myocardial
D004317_D009202 CID (dox)-induced_21\NN\1740| (r_dep) doxorubicin_20\NN\2716866|(dox)-induced (r_compound) cardiomyopathy_22\NN\14103288|of|doxorubicin
D004317_D009202 CID dox_8\NN\1740|after|rats (r_nmod) injury_6\NN\14052046|of|ischemic|dox (r_nmod) markers_3\NNS\21939|among|injury (r_nmod) conclusions_0\NNS\5837957|:|markers (r_nsubj) showed_13\VBD\2137132|conclusions|,|ctnt|ability|. (l_dobj) ability_16\NN\4723816|the|greatest|detect (l_acl) detect_18\VB\2163746|to|damage (l_dobj) damage_20\NN\7296428|myocardial|assessed
D004317_D006331 NONE doxorubicin_20\NN\2716866|(dox)-induced (r_compound) cardiomyopathy_22\NN\14103288|of|doxorubicin (r_nmod) model_18\NN\5888929|in|a|rat|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (r_nmod) value_4\NN\5856066|the|diagnostic|ctni|diagnosis (r_dobj) investigated_1\VBD\644583|we|value|,|and|examined (l_conj) examined_26\VBD\789138|we|relationship|. (l_dobj) relationship_28\NN\31921|the|ctni|development (l_nmod) development_36\NN\248977|with|the|disorders (l_nmod) disorders_39\NNS\14034177|of|cardiac|monitored
D004317_D006331 NONE (dox)-induced_21\NN\1740| (r_dep) doxorubicin_20\NN\2716866|(dox)-induced (r_compound) cardiomyopathy_22\NN\14103288|of|doxorubicin (r_nmod) model_18\NN\5888929|in|a|rat|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (r_nmod) value_4\NN\5856066|the|diagnostic|ctni|diagnosis (r_dobj) investigated_1\VBD\644583|we|value|,|and|examined (l_conj) examined_26\VBD\789138|we|relationship|. (l_dobj) relationship_28\NN\31921|the|ctni|development (l_nmod) development_36\NN\248977|with|the|disorders (l_nmod) disorders_39\NNS\14034177|of|cardiac|monitored
D004317_D064420 NONE dox_5\NN\1740| (r_compound) rats_6\NNS\2329401|of|the|dox (r_nmod) eighteen_2\CD\13745420|rats (r_nsubj) died_7\VBD\146138|eighteen|prematurely|toxicity|period|. (l_nmod) toxicity_11\NN\13576101|of|general
D004317_D005355 NONE dox_8\NN\1740| (r_dobj) given_7\VBN\2327200|dox (r_acl) rats_6\NNS\2329401|from|all|given (r_nmod) hearts_3\NNS\496167|of|rats (r_nmod) evaluation_1\NN\874067|histological|hearts (r_nsubj) revealed_9\VBD\2137132|evaluation|degrees|. (l_dobj) degrees_12\NNS\4916342|significant|slight|fibrosis (l_nmod) fibrosis_17\NN\14204950|of|perivascular
D004317_D017202 NONE dox_8\NN\1740|after|rats (r_nmod) injury_6\NN\14052046|of|ischemic|dox
D004317_D066126 NONE dox_13\NN\1740|after (r_nmod) amount_7\NN\13329641|between|the|ctni|dox (r_nmod) discrepancy_4\NN\4748836|a|amount|, (r_attr) was_2\VBD\836236|although|there|discrepancy|heterogeneity (r_advcl) likely_32\JJ\1740|was|,|it|is|indicates|. (l_ccomp) indicates_39\VBZ\952524|that|ctnt|damage|and|marker (l_conj) marker_56\NN\21939|that|ctnt|should|be|a|useful|prediction (l_nmod) prediction_59\NN\5772356|for|the|cardiotoxicity|and|experiments (l_nmod) cardiotoxicity_63\NN\1740|of|induced
D004317_D066126 NONE dox_38\NN\1740|after (r_nmod) ctnt_34\NN\1740|rats|dox (r_nsubj) indicates_39\VBZ\952524|that|ctnt|damage|and|marker (l_conj) marker_56\NN\21939|that|ctnt|should|be|a|useful|prediction (l_nmod) prediction_59\NN\5772356|for|the|cardiotoxicity|and|experiments (l_nmod) cardiotoxicity_63\NN\1740|of|induced
2887062
D004967_D015175 CID estrogen-induced_8\JJ\1740| (r_amod) prolactinomas_10\NNS\1740|of|estrogen-induced|rat|treatment
D004967_D015175 CID estrogen-induced_21\JJ\1740| (r_amod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma (r_nmod) applied_19\VBN\2676054|clarify|,|analyses|were|cells|injection|. (l_advcl) clarify_1\VB\939277|to|effects (l_dobj) effects_3\NNS\13245626|the|bromocriptine|cells|vivo (l_nmod) cells_8\NNS\3080309|on|prolactinoma (l_compound) prolactinoma_7\NN\1740|
D004967_D015175 CID estrogen-induced_21\JJ\1740| (r_amod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma (l_compound) prolactinoma_23\NN\1740|
D001971_D015175 NONE bromocriptine_12\NN\1740| (r_compound) treatment_13\NN\654885|after|bromocriptine (r_nmod) prolactinomas_10\NNS\1740|of|estrogen-induced|rat|treatment
D001971_D015175 NONE bromocriptine_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|the|bromocriptine|cells|vivo (l_nmod) cells_8\NNS\3080309|on|prolactinoma (l_compound) prolactinoma_7\NN\1740|
D001971_D015175 NONE bromocriptine_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|the|bromocriptine|cells|vivo (r_dobj) clarify_1\VB\939277|to|effects (r_advcl) applied_19\VBN\2676054|clarify|,|analyses|were|cells|injection|. (l_nmod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma (l_compound) prolactinoma_23\NN\1740|
D001971_D015175 NONE bromocriptine_33\NN\1740|of|mg/kg (r_nmod) injection_31\NN\320852|h|bromocriptine (r_dep) applied_19\VBN\2676054|clarify|,|analyses|were|cells|injection|. (l_advcl) clarify_1\VB\939277|to|effects (l_dobj) effects_3\NNS\13245626|the|bromocriptine|cells|vivo (l_nmod) cells_8\NNS\3080309|on|prolactinoma (l_compound) prolactinoma_7\NN\1740|
D001971_D015175 NONE bromocriptine_33\NN\1740|of|mg/kg (r_nmod) injection_31\NN\320852|h|bromocriptine (r_dep) applied_19\VBN\2676054|clarify|,|analyses|were|cells|injection|. (l_nmod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma (l_compound) prolactinoma_23\NN\1740|
D001971_D000236 NONE bromocriptine_15\NN\1740| (r_compound) treatment_16\NN\654885|after|bromocriptine|cells (l_nmod) cells_20\NNS\3080309|of|the|adenoma (l_compound) adenoma_19\NN\14236226|
3409645
D008727_D007172 CID methotrexate_21\NN\2722166|of (r_nmod) taking_19\NN\37396|the|methotrexate (r_conj) co-morbidity_16\NN\1740|with|and|taking (r_nmod) associated_14\VBN\628491|to|be|co-morbidity (r_xcomp) found_11\VBN\2426171|was|associated (r_conj) common_3\JJ\1740|impotence|was|more|patients|controls|and|found|. (l_nsubj) impotence_0\NN\4723816|
9721172
D007052_D001649 NONE ibuprofen_28\NN\3828465| (r_compound) use_29\NN\407535|with|ibuprofen (r_nmod) associated_26\VBN\628491|child|;|this|was|temporally|use|. (l_nsubjpass) child_3\NN\9622049|a|healthy|developed (l_acl:relcl) developed_5\VBD\1753788|who|syndrome|described (l_dobj) syndrome_15\NN\5870365|acute|,|severe|,|progressive|vanishing|duct
D007052_D013262 CID ibuprofen_28\NN\3828465| (r_compound) use_29\NN\407535|with|ibuprofen (r_nmod) associated_26\VBN\628491|child|;|this|was|temporally|use|. (l_nsubjpass) child_3\NN\9622049|a|healthy|developed (l_acl:relcl) developed_5\VBD\1753788|who|syndrome|described (l_advcl) described_21\VBN\1001294|shortly|after|syndrome|is (l_nsubjpass) syndrome_19\NN\5870365|stevens-johnson
D014580_D002779 NONE acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\JJ\1740|therapy|,|disease|was|,|shown|. (l_nsubj) disease_14\NN\14061805|her|cholestatic
D014580_D005355 NONE acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\JJ\1740|therapy|,|disease|was|,|shown|. (l_advcl) shown_20\VBN\2137132|with|cirrhosis|biopsy|presentation (l_nsubj) cirrhosis_19\NN\14116321|
D011241_D002779 NONE prednisone_6\NN\2721538|,|and|tacrolimus (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\JJ\1740|therapy|,|disease|was|,|shown|. (l_nsubj) disease_14\NN\14061805|her|cholestatic
D011241_D005355 NONE prednisone_6\NN\2721538|,|and|tacrolimus (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\JJ\1740|therapy|,|disease|was|,|shown|. (l_advcl) shown_20\VBN\2137132|with|cirrhosis|biopsy|presentation (l_nsubj) cirrhosis_19\NN\14116321|
D016559_D002779 NONE tacrolimus_10\NN\1740|then (r_conj) prednisone_6\NN\2721538|,|and|tacrolimus (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\JJ\1740|therapy|,|disease|was|,|shown|. (l_nsubj) disease_14\NN\14061805|her|cholestatic
D016559_D005355 NONE tacrolimus_10\NN\1740|then (r_conj) prednisone_6\NN\2721538|,|and|tacrolimus (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\JJ\1740|therapy|,|disease|was|,|shown|. (l_advcl) shown_20\VBN\2137132|with|cirrhosis|biopsy|presentation (l_nsubj) cirrhosis_19\NN\14116321|
15338796
D000420_D014202 CID salbutamol_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|tremor|side|salbutamol|,|quantified|. (l_compound) tremor_0\NN\345926|
D000420_D014202 CID salbutamol_8\NN\1740|of (r_nmod) effects_6\NNS\13245626|tremor|side|salbutamol (l_compound) tremor_4\NN\345926|
D000420_D014202 CID salbutamol_19\NN\1740|of (r_nmod) doses_17\NNS\3740161|of|cumulative|salbutamol (r_nmod) administration_14\NN\1133281|after|doses (r_nmod) assessed_4\VBD\670261|determine|we|tremor|administration|. (l_dobj) tremor_5\NN\345926|patients
D000420_D014202 CID salbutamol_2\NN\1740| (r_nsubj) increased_4\VBD\169651|results|:|salbutamol|significantly|severity|way|. (l_dobj) severity_6\NN\5036394|tremor|patients (l_compound) tremor_5\NN\345926|
D000420_D008173 NONE salbutamol_19\NN\1740|of (r_nmod) doses_17\NNS\3740161|of|cumulative|salbutamol (r_nmod) administration_14\NN\1133281|after|doses (r_nmod) assessed_4\VBD\670261|determine|we|tremor|administration|. (l_dobj) tremor_5\NN\345926|patients (l_nmod) patients_8\NNS\9898892|in|44|disease (l_nmod) disease_12\NN\14061805|with|obstructive|lung
1549199
D007980_D064420 NONE levodopa_9\NN\14604959| (r_compound) therapy_10\NN\657604|for|levodopa (r_nmod) dose_7\NN\3740161|no|single|correct|starting|therapy (r_attr) is_2\VBZ\836236|while|there|dose (r_advcl) started_16\VBN\2009433|is|,|individuals|can|be|formula|,|following|. (l_advcl) following_25\VBG\1835496|rule (l_dobj) rule_28\NN\5835747|the|general|attempt (l_acl) attempt_31\VB\2367363|not|to|titrate (l_xcomp) titrate_33\VB\489837|to|carbidopa-levodopa|point (l_nmod) point_37\NN\5868954|to|the|normality (l_nmod) normality_40\NN\13920835|of|"|,|"|lead (l_acl:relcl) lead_45\VB\1752884|which|can|toxicity (l_nmod) toxicity_47\NN\13576101|to
D007980_D064420 NONE carbidopa-levodopa_34\NN\1740| (r_dobj) titrate_33\VB\489837|to|carbidopa-levodopa|point (l_nmod) point_37\NN\5868954|to|the|normality (l_nmod) normality_40\NN\13920835|of|"|,|"|lead (l_acl:relcl) lead_45\VB\1752884|which|can|toxicity (l_nmod) toxicity_47\NN\13576101|to
D002230_D064420 NONE carbidopa-levodopa_34\NN\1740| (r_dobj) titrate_33\VB\489837|to|carbidopa-levodopa|point (l_nmod) point_37\NN\5868954|to|the|normality (l_nmod) normality_40\NN\13920835|of|"|,|"|lead (l_acl:relcl) lead_45\VB\1752884|which|can|toxicity (l_nmod) toxicity_47\NN\13576101|to
D007980_D005767 CID levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced|,|disturbances (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis (r_conj) disorders_8\NNS\14034177|such|gastrointestinal|,|hypotension|,|or|interactions
D007980_D007024 CID levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced|,|disturbances (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis
D007980_D011618 NONE levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced|,|disturbances
D007980_D012893 NONE levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced|,|disturbances (l_conj) disturbances_17\NNS\407535|sleep|or|parasomnias
D007980_D020447 CID levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced|,|disturbances (l_conj) disturbances_17\NNS\407535|sleep|or|parasomnias (l_conj) parasomnias_19\NNS\1740|
15458908
D020849_D010024 NONE raloxifene_6\NN\1740| (r_compound) evaluation_7\NN\874067|of|raloxifene (r_nmod) outcomes_4\NNS\7291312|the|multiple|evaluation|,|trial|, (r_nsubj) enrolled_17\VBD\2471690|methods|outcomes|women|. (l_dobj) women_20\NNS\9605289|7,705|postmenopausal|osteoporosis (l_nmod) osteoporosis_22\NN\14204950|with
D020849_D054556 CID raloxifene_10\NN\1740| (r_nsubjpass) associated_12\VBN\628491|results|,|raloxifene|was|risk|risk|. (l_nmod) risk_16\NN\14541044|with|an|increased|thromboembolism (l_nmod) thromboembolism_19\NN\14100769|for|venous
D020849_D054556 CID raloxifene_2\NN\1740| (r_nsubjpass) associated_4\VBN\628491|:|raloxifene|was|risk|,|but|was|. (l_nmod) risk_8\NN\14541044|with|an|increased|thromboembolism (l_nmod) thromboembolism_11\NN\14100769|for|venous
D020849_D002386 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|cataracts|. (l_nmod) cataracts_6\NNS\14252864|for|rr
D020849_D002386 NONE raloxifene_2\NN\1740| (r_nsubjpass) associated_4\VBN\628491|:|raloxifene|was|risk|,|but|was|. (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease
D020849_D005705 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|cataracts|. (l_nmod) cataracts_6\NNS\14252864|for|rr (l_dep) rr_8\NN\1740|(|0.9|;|ci|1.1|)|,|disease (l_conj) disease_20\NN\14061805|gallbladder|rr
D020849_D005705 NONE raloxifene_2\NN\1740| (r_nsubjpass) associated_4\VBN\628491|:|raloxifene|was|risk|,|but|was|. (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease (l_conj) disease_23\NN\14061805|gallbladder|,|hyperplasia
D020849_D004714 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|cataracts|. (l_nmod) cataracts_6\NNS\14252864|for|rr (l_dep) rr_8\NN\1740|(|0.9|;|ci|1.1|)|,|disease (l_conj) disease_20\NN\14061805|gallbladder|rr (l_dep) rr_22\NN\1740|(|1.0|;|ci|)|,|hyperplasia|,|or|cancer (l_conj) hyperplasia_34\NN\14365950|endometrial|rr
D020849_D004714 NONE raloxifene_2\NN\1740| (r_nsubjpass) associated_4\VBN\628491|:|raloxifene|was|risk|,|but|was|. (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease (l_conj) disease_23\NN\14061805|gallbladder|,|hyperplasia (l_conj) hyperplasia_26\NN\14365950|endometrial|,|or|cancer
D020849_D016889 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|cataracts|. (l_nmod) cataracts_6\NNS\14252864|for|rr (l_dep) rr_8\NN\1740|(|0.9|;|ci|1.1|)|,|disease (l_conj) disease_20\NN\14061805|gallbladder|rr (l_dep) rr_22\NN\1740|(|1.0|;|ci|)|,|hyperplasia|,|or|cancer (l_conj) cancer_49\NN\14239425|endometrial|rr
D020849_D016889 NONE raloxifene_2\NN\1740| (r_nsubjpass) associated_4\VBN\628491|:|raloxifene|was|risk|,|but|was|. (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease (l_conj) disease_23\NN\14061805|gallbladder|,|hyperplasia (l_conj) hyperplasia_26\NN\14365950|endometrial|,|or|cancer (l_conj) cancer_30\NN\14239425|endometrial
18343374
D002996_D012170 CID clomiphene-induced_6\JJ\1740| (r_amod) ovulation_7\NN\13526110|with|clomiphene-induced (r_nmod) associated_4\VBN\628491|ovulation (r_acl) occlusion_3\NN\14081375|vein|associated|.
D002996_D012170 CID citrate_14\NN\14850483|with|clomiphene|cc (r_nmod) associated_11\VBN\628491|citrate (r_acl) occlusion_10\NN\14081375|of|vein|associated
D002996_D012170 CID cc_16\NN\13616054|(|) (r_appos) citrate_14\NN\14850483|with|clomiphene|cc (r_nmod) associated_11\VBN\628491|citrate (r_acl) occlusion_10\NN\14081375|of|vein|associated
D002996_D012170 CID cc_12\NN\13616054|with (r_nmod) induction_10\NN\7450842|after|ovulation|cc (r_nmod) occlusion_7\NN\14081375|measure(s|central|vein|induction|.
D002996_D012170 CID cc_15\NN\13616054|of (r_nmod) courses_13\NNS\883297|after|eight|cc (r_nmod) developed_6\VBD\1753788|result(s|):|woman|occlusion|courses|. (l_dobj) occlusion_10\NN\14081375|central|retinal|vein
D002996_D012170 CID cc_16\NN\13616054|with (r_nmod) treatment_14\NN\654885|after|cc (r_nmod) occlusion_12\NN\14081375|of|vein|treatment
D002996_D013923 NONE cc_10\NN\13616054|of (r_nmod) complications_8\NNS\1073995|on|the|thromboembolic|cc (l_amod) thromboembolic_7\JJ\1740|
D002996_D013923 NONE cc_24\NN\13616054| (r_compound) intake_25\NN\13440063|after|cc (r_nmod) disturbance_22\NN\407535|mild|visual|intake (r_nsubj) uncommon_28\JJ\1740|although|disturbance|is|not (r_advcl) include_13\VB\690614|search|does|not|complication|,|uncommon|. (l_nsubj) search_1\NN\407535|a|literature (l_nmod) literature_4\NN\6362953|of|the|complications (l_nmod) complications_8\NNS\1073995|on|the|thromboembolic|cc (l_amod) thromboembolic_7\JJ\1740|
D002996_D014786 CID cc_10\NN\13616054|of (r_nmod) complications_8\NNS\1073995|on|the|thromboembolic|cc (r_nmod) literature_4\NN\6362953|of|the|complications (r_nmod) search_1\NN\407535|a|literature (r_nsubj) include_13\VB\690614|search|does|not|complication|,|uncommon|. (l_advcl) uncommon_28\JJ\1740|although|disturbance|is|not (l_nsubj) disturbance_22\NN\407535|mild|visual|intake
D002996_D014786 CID cc_24\NN\13616054| (r_compound) intake_25\NN\13440063|after|cc (r_nmod) disturbance_22\NN\407535|mild|visual|intake
D002996_D007247 NONE cc_9\NN\13616054|with (r_nmod) patients_7\NNS\9898892|infertility|cc (l_compound) infertility_6\NN\14034177|
10743446
D007649_D006930 NONE ketamine_5\NN\3054098|of|administered|and|lidocaine (r_nmod) effects_1\NNS\13245626|differential|ketamine|hyperalgesia|. (l_nmod) hyperalgesia_12\NN\1740|on|dynamic|induced
D007649_D006930 NONE ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|(|dynamic|)|and|hyperalgesia (l_conj) hyperalgesia_23\NN\1740|punctate-evoked|(|static|)|induced
D007649_D006930 NONE ketamine_0\NN\3054098| (r_nsubj) reduced_1\VBD\441445|ketamine|area|significantly|and|tended (l_dobj) area_4\NN\8630985|both|the|hyperalgesia (l_nmod) hyperalgesia_9\NN\1740|of|brush-evoked
D007649_D006930 NONE ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|hyperalgesia (l_nmod) hyperalgesia_11\NN\1740|on|static
D007649_D006930 NONE ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|hyperalgesia (r_nsubj) suggest_12\VBP\1010118|effects|mediated|. (l_ccomp) mediated_20\VBN\761713|that|types|are|mechanisms|and|have (l_nsubjpass) types_16\NNS\5839024|the|two|hyperalgesia (l_nmod) hyperalgesia_18\NN\1740|of
D008012_D006930 NONE lidocaine_7\NN\3681148| (r_conj) ketamine_5\NN\3054098|of|administered|and|lidocaine (r_nmod) effects_1\NNS\13245626|differential|ketamine|hyperalgesia|. (l_nmod) hyperalgesia_12\NN\1740|on|dynamic|induced
D008012_D006930 NONE lidocaine_11\NN\3681148| (r_conj) ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|(|dynamic|)|and|hyperalgesia (l_conj) hyperalgesia_23\NN\1740|punctate-evoked|(|static|)|induced
D008012_D006930 NONE lidocaine_0\NN\3681148| (r_nsubj) reduced_1\VBD\441445|lidocaine|area|significantly|. (l_dobj) area_3\NN\8630985|the|hyperalgesia (l_nmod) hyperalgesia_6\NN\1740|of|punctate-evoked
D008012_D006930 NONE lidocaine_6\NN\3681148| (r_conj) ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|hyperalgesia (l_nmod) hyperalgesia_11\NN\1740|on|static
D008012_D006930 NONE lidocaine_6\NN\3681148| (r_conj) ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|hyperalgesia (r_nsubj) suggest_12\VBP\1010118|effects|mediated|. (l_ccomp) mediated_20\VBN\761713|that|types|are|mechanisms|and|have (l_nsubjpass) types_16\NNS\5839024|the|two|hyperalgesia (l_nmod) hyperalgesia_18\NN\1740|of
D002211_D006930 CID capsaicin_16\NN\15032661|by|intradermal|humans (r_nmod) induced_13\VBN\1627355|capsaicin (r_acl) hyperalgesia_12\NN\1740|on|dynamic|induced
D002211_D006930 CID capsaicin_26\NN\15032661|by (r_nmod) induced_24\VBN\1627355|capsaicin (r_acl) hyperalgesia_23\NN\1740|punctate-evoked|(|static|)|induced
D007649_D010146 NONE ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|(|dynamic|)|and|hyperalgesia
D007649_D010146 NONE ketamine_0\NN\3054098| (r_nsubj) reduced_1\VBD\441445|ketamine|area|significantly|and|tended (l_conj) tended_13\VBD\2604760|it|reduce|. (l_xcomp) reduce_15\VB\441445|to|pain (l_dobj) pain_17\NN\14299637|brush-evoked
D008012_D010146 NONE lidocaine_11\NN\3681148| (r_conj) ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|(|dynamic|)|and|hyperalgesia
D002211_D010146 CID capsaicin_26\NN\15032661|by (r_nmod) induced_24\VBN\1627355|capsaicin (r_acl) hyperalgesia_23\NN\1740|punctate-evoked|(|static|)|induced (r_conj) pain_17\NN\14299637|on|brush-evoked|(|dynamic|)|and|hyperalgesia
3412544
D000082_D014523 NONE paracetamol_1\NN\1740| (r_nsubj) cause_2\VB\1617192|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\14239425|urothelial|or|necrosis
D000082_D007681 NONE paracetamol_1\NN\1740| (r_nsubj) cause_2\VB\1617192|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\14239425|urothelial|or|necrosis (l_conj) necrosis_8\NN\11444117|renal|papillary
D000082_D007681 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated
D000082_D007681 NONE paracetamol_12\NN\1740| (r_compound) consumption_13\NN\13440063|from|paracetamol (r_nmod) risk_10\NN\14541044|an|increased|consumption|necrosis (l_nmod) necrosis_17\NN\11444117|for|renal|papillary|or|any
D010615_D007681 CID phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated
D010615_D007681 CID phenacetin_13\NN\2707683|of|,|increased (r_nmod) consumption_11\NN\13440063|by|phenacetin (r_nmod) increased_7\VBN\169651|risk|was|20-fold|consumption|. (l_nsubjpass) risk_1\NN\14541044|the|necrosis (l_nmod) necrosis_5\NN\11444117|of|renal|papillary
D010615_D007680 CID phenacetin_13\NN\2707683|of|,|increased (l_acl:relcl) increased_17\VBD\169651|which|also|risk (l_dobj) risk_19\NN\14541044|the|cancer (l_nmod) cancer_21\NN\14239425|for|pelvis|but|cancer (l_nmod) pelvis_25\NN\5578911|of|the|renal|and|bladder (l_conj) bladder_27\NN\5515670|
D010615_D007680 NONE phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated (l_conj) cancer_8\NN\14239425|pelvis (l_nmod) pelvis_12\NN\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D010615_D014516 NONE phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated (l_conj) cancer_8\NN\14239425|pelvis (l_nmod) pelvis_12\NN\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D010615_D014516 NONE phenacetin_13\NN\2707683|of|,|increased (l_acl:relcl) increased_17\VBD\169651|which|also|risk (l_dobj) risk_19\NN\14541044|the|cancer (l_nmod) cancer_21\NN\14239425|for|pelvis|but|cancer (l_conj) cancer_32\NN\14239425|not|for|ureteric
D010615_D001749 CID phenacetin_13\NN\2707683|of|,|increased (l_acl:relcl) increased_17\VBD\169651|which|also|risk (l_dobj) risk_19\NN\14541044|the|cancer (l_nmod) cancer_21\NN\14239425|for|pelvis|but|cancer (l_nmod) pelvis_25\NN\5578911|of|the|renal|and|bladder (l_conj) bladder_27\NN\5515670|
D010615_D001749 NONE phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated (l_conj) cancer_8\NN\14239425|pelvis (l_nmod) pelvis_12\NN\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D007680 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated (l_conj) cancer_8\NN\14239425|pelvis (l_nmod) pelvis_12\NN\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D014516 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated (l_conj) cancer_8\NN\14239425|pelvis (l_nmod) pelvis_12\NN\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D014516 NONE paracetamol_12\NN\1740| (r_compound) consumption_13\NN\13440063|from|paracetamol (r_nmod) risk_10\NN\14541044|an|increased|consumption|necrosis (r_dobj) substantiate_7\VB\2604760|to|risk (r_xcomp) unable_5\JJ\1740|contrast|,|we|were|substantiate|was|. (l_advcl) was_25\VBD\836236|although|there|suggestion (l_attr) suggestion_27\NN\5833840|a|association (l_nmod) association_30\NN\8008335|of|an|cancer (l_nmod) cancer_32\NN\14239425|with|ureter (l_nmod) ureter_35\NN\5250659|of|the
D000082_D001749 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) necrosis_6\NN\11444117|renal|papillary|or|cancer|associated (l_conj) cancer_8\NN\14239425|pelvis (l_nmod) pelvis_12\NN\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D009369 NONE paracetamol_12\NN\1740| (r_compound) consumption_13\NN\13440063|from|paracetamol (r_nmod) risk_10\NN\14541044|an|increased|consumption|necrosis (l_nmod) necrosis_17\NN\11444117|for|renal|papillary|or|any (l_conj) any_19\DT\1740|cancers (l_nmod) cancers_22\NNS\14239425|of|these
17242861
D010862_D012640 NONE pilocarpine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|to|pilocarpine-induced
D010862_D012640 NONE pilocarpine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|to|pilocarpine-induced (r_nmod) susceptibility_2\NN\13920835|for|seizures|,|model (r_nmod) qtls_0\NNS\1740|susceptibility|, (r_nsubjpass) reported_17\VBN\831651|qtls|have|not|been|,|and|used (l_conj) used_25\VBN\1156834|css|have|not|previously|been|localize|. (l_xcomp) localize_27\VB\2694933|to|genes (l_dobj) genes_30\NNS\8459252|seizure|susceptibility (l_compound) seizure_28\NN\14081375|
D010862_D012640 NONE pilocarpine-induced_24\JJ\1740| (r_amod) seizures_25\NNS\14081375|to|pilocarpine-induced
D010862_D012640 NONE pilocarpine-induced_19\JJ\1740| (r_amod) seizures_20\NNS\14081375|to|pilocarpine-induced
D010862_D004833 CID pilocarpine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|to|pilocarpine-induced (r_nmod) susceptibility_2\NN\13920835|for|seizures|,|model (l_appos) model_8\NN\5888929|a|epilepsy (l_nmod) epilepsy_12\NN\14085708|of|lobe
17879945
D019438_D050197 CID ritonavir_5\NN\4013993| (r_compound) treatment_6\NN\654885|ritonavir (r_nsubj) increases_7\VBZ\169651|that|treatment|formation|extent|than (l_dobj) formation_10\NN\7938773|atherosclerotic|lesion|mice (l_compound) lesion_9\NN\14204950|
11391224
D003042_D006974 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) glomerulonephritis_18\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_15\NN\14113228|henoch-schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\14113228|lupus|,|nephritis (r_conj) microangiopathy_9\NN\1740|thrombotic|,|nephritis (r_conj) hypertension_6\NN\14057371|of|malignant|,|microangiopathy
D003042_D057049 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) glomerulonephritis_18\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_15\NN\14113228|henoch-schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\14113228|lupus|,|nephritis (r_conj) microangiopathy_9\NN\1740|thrombotic|,|nephritis
D003042_D008181 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) glomerulonephritis_18\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_15\NN\14113228|henoch-schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\14113228|lupus|,|nephritis
D003042_D011695 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) glomerulonephritis_18\NN\14113798|crescentic|,|and|failure (r_conj) nephritis_15\NN\14113228|henoch-schonlein|,|glomerulonephritis
D003042_D005921 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) glomerulonephritis_18\NN\14113798|crescentic|,|and|failure
D003042_D058186 CID cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal
20880751
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|patients|:
D007980_D004409 CID levodopa-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|levodopa-induced
D007980_D004409 CID levodopa-induced_39\JJ\1740| (r_amod) dyskinesias_40\NNS\14084880|of|levodopa-induced
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|patients|: (l_nmod) patients_3\NNS\9898892|in|disease (l_nmod) disease_7\NN\14061805|with|parkinson|'s
D007980_D010300 NONE levodopa_0\NN\14604959| (r_nsubj) drug_5\NN\14778436|levodopa|is|the|effective|treatment|. (l_nmod) treatment_8\NN\654885|for|the|disease (l_nmod) disease_12\NN\14061805|of|parkinson
D004298_D004409 NONE dopamine_7\NN\14807737| (r_compound) precursor_8\NN\14580897|of|this|dopamine (r_nmod) use_4\NN\407535|the|long-term|precursor (r_nsubjpass) complicated_10\VBN\126264|however|,|use|is|fluctuations|. (l_nmod) fluctuations_14\NNS\7345593|by|disabling|and|dyskinesias (l_conj) dyskinesias_16\NNS\14084880|
D004298_D004409 NONE dopamine_21\NN\14807737| (r_compound) subtypes_23\NNS\1740|dopamine|receptor|,|receptors (r_conj) mechanisms_19\NNS\13446390|of|presynaptic|,|subtypes|,|and|systems (r_nmod) role_14\NN\719494|on|the|differential|mechanisms|pathophysiology (l_nmod) pathophysiology_37\NN\1740|in|the|dyskinesias (l_nmod) dyskinesias_40\NNS\14084880|of|levodopa-induced
D018698_D004409 NONE glutamate_28\NN\15010703| (r_compound) receptors_29\NNS\5225602|ionotropic|glutamate (r_conj) subtypes_23\NNS\1740|dopamine|receptor|,|receptors (r_conj) mechanisms_19\NNS\13446390|of|presynaptic|,|subtypes|,|and|systems (r_nmod) role_14\NN\719494|on|the|differential|mechanisms|pathophysiology (l_nmod) pathophysiology_37\NN\1740|in|the|dyskinesias (l_nmod) dyskinesias_40\NNS\14084880|of|levodopa-induced
9754849
D008691_D002819 CID methadone_7\NN\3808564|to (r_nmod) adjustment_5\NN\7357388|with|rapid|methadone (r_nmod) associated_2\VBN\628491|adjustment (r_acl) movements_1\NNS\191142|choreoathetoid|associated|.
D008691_D002819 CID methadone_22\NN\3808564|to|the|agonist (r_nmod) adjustment_15\NN\7357388|by|rapid|methadone|inpatient (r_nmod) induced_12\VBN\1627355|both|transiently|adjustment (r_acl) euphoria_6\NN\7527656|of|and|movements|induced (l_conj) movements_9\NNS\191142|choreoathetoid
D003042_D002819 CID cocaine_12\NN\3492717|with|not|opiates (r_nmod) intoxications_10\NNS\14034177|during|cocaine (r_nmod) abnormalities_8\NNS\14034177|to|be|occasional|movement|intoxications (r_xcomp) known_3\VBN\2110220|hyperkinesias|are|abnormalities|. (l_nsubjpass) hyperkinesias_1\NNS\1740|choreatiform
D003042_D002819 CID cocaine_30\NN\3492717| (r_conj) heroine_28\NN\5929008|and|cocaine (r_dobj) abusing_27\VBG\2514187|previously|heroine (r_acl) inpatient_25\NN\10405694|in|an|abusing (r_nmod) adjustment_15\NN\7357388|by|rapid|methadone|inpatient (r_nmod) induced_12\VBN\1627355|both|transiently|adjustment (r_acl) euphoria_6\NN\7527656|of|and|movements|induced (l_conj) movements_9\NNS\191142|choreoathetoid
D003042_D006948 CID cocaine_12\NN\3492717|with|not|opiates (r_nmod) intoxications_10\NNS\14034177|during|cocaine (r_nmod) abnormalities_8\NNS\14034177|to|be|occasional|movement|intoxications (r_xcomp) known_3\VBN\2110220|hyperkinesias|are|abnormalities|. (l_nsubjpass) hyperkinesias_1\NNS\1740|choreatiform
D003042_D020820 NONE cocaine_12\NN\3492717|with|not|opiates (r_nmod) intoxications_10\NNS\14034177|during|cocaine (r_nmod) abnormalities_8\NNS\14034177|to|be|occasional|movement|intoxications
D003932_D002819 NONE heroine_28\NN\5929008|and|cocaine (r_dobj) abusing_27\VBG\2514187|previously|heroine (r_acl) inpatient_25\NN\10405694|in|an|abusing (r_nmod) adjustment_15\NN\7357388|by|rapid|methadone|inpatient (r_nmod) induced_12\VBN\1627355|both|transiently|adjustment (r_acl) euphoria_6\NN\7527656|of|and|movements|induced (l_conj) movements_9\NNS\191142|choreoathetoid
11587867
D014750_D001927 NONE vincristin_6\NN\1740| (r_compound) administration_7\NN\1133281|due|accidental|intrathecal|vincristin (r_nmod) myeloencephalopathy_1\NN\1740|fatal|administration|:|report
D014750_D054198 NONE vincristine_9\NN\3917455| (r_compound) instillation_10\NN\320852|of|accidental|intrathecal|vincristine|girl (l_nmod) girl_15\NN\10787470|in|a|old|leucemia|and|man (l_nmod) leucemia_20\NN\1740|with|recurrent|acute|lymphoblastic
D014750_D054198 NONE vincristine_9\NN\3917455| (r_compound) instillation_10\NN\320852|of|accidental|intrathecal|vincristine|girl (l_nmod) girl_15\NN\10787470|in|a|old|leucemia|and|man (l_conj) man_25\NN\9605289|a|old|lymphoma (l_nmod) lymphoma_28\NN\14239918|with|lymphoblastic
D014750_D003711 CID vincristine_26\NN\3917455|to (r_nmod) exposed_24\VBN\2110927|vincristine (r_acl) areas_23\NNS\8630985|in|exposed (r_nmod) transformation_21\NN\7296428|pseudocystic|areas (r_conj) degeneration_12\NN\29677|myelin|as|transformation|,|accompanied (l_nmod) myelin_14\JJ\1740|of|and|axons (l_conj) axons_16\NNS\5464104|
D014750_D009410 CID vincristine_26\NN\3917455|to (r_nmod) exposed_24\VBN\2110927|vincristine (r_acl) areas_23\NNS\8630985|in|exposed (r_nmod) transformation_21\NN\7296428|pseudocystic|areas (r_conj) degeneration_12\NN\29677|myelin|as|transformation|,|accompanied (l_nmod) myelin_14\JJ\1740|of|and|axons (l_conj) axons_16\NNS\5464104|
D014750_-1 NONE vincristine_26\NN\3917455|to (r_nmod) exposed_24\VBN\2110927|vincristine (r_acl) areas_23\NNS\8630985|in|exposed (r_nmod) transformation_21\NN\7296428|pseudocystic|areas
230316
D006912_D020258 NONE hydroxyquinolines_3\NNS\1740|of|halogenated (r_nmod) neurotoxicity_0\NN\1740|hydroxyquinolines|analysis
D006912_D020258 NONE hydroxyquinolines_13\NNS\1740|to|halogenated (r_nmod) reactions_10\NNS\13446390|of|possible|neurotoxic|hydroxyquinolines|reported (l_amod) neurotoxic_9\JJ\1740|
D007464_D009422 NONE clioquinol_25\NN\2720201|of (r_nmod) dose_23\NN\3740161|of|a|high|clioquinol (r_nmod) ingestion_19\NN\13440063|to|the|dose|period (r_nmod) related_16\JJ\1740|usually|ingestion (r_amod) encephalopathy_14\NN\14084880|of|an|acute|reversible|related (r_nmod) consisted_9\VBD\2603699|six|disturbance|encephalopathy|. (l_nsubj) disturbance_8\NN\407535|the|neurological
D007464_D001927 CID clioquinol_25\NN\2720201|of (r_nmod) dose_23\NN\3740161|of|a|high|clioquinol (r_nmod) ingestion_19\NN\13440063|to|the|dose|period (r_nmod) related_16\JJ\1740|usually|ingestion (r_amod) encephalopathy_14\NN\14084880|of|an|acute|reversible|related
D007464_C538178 NONE clioquinol_13\NN\2720201| (r_dobj) received_12\VBN\2210855|many|had|clioquinol|treatment (l_nmod) treatment_15\NN\654885|as|enteropathica (l_nmod) enteropathica_18\NN\1740|for|acrodermatitis
14765563
D011803_D020922 NONE quinine_23\NN\2721948| (r_nsubj) available_26\JJ\1740|banned|,|quinine|is|widely|beverages|. (l_advcl) banned_8\VBD\2480923|although|administration|use|lack (l_dobj) use_10\NN\407535|its|cramps (l_nmod) cramps_14\NNS\14299637|for|nocturnal|leg
D011803_D002493 NONE quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications (l_dobj) complications_11\NNS\1073995|neurological|,|confusion
D011803_D003221 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications (l_dobj) complications_11\NNS\1073995|neurological|,|confusion (l_nmod) confusion_14\NN\13972797|including|,|status|,|women
D011803_D012640 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications (l_dobj) complications_11\NNS\1073995|neurological|,|confusion (l_nmod) confusion_14\NN\13972797|including|,|status|,|women (l_conj) status_18\NN\24720|altered|mental|,|seizures (l_conj) seizures_20\NNS\14081375|,|and|coma
D011803_D003128 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications (l_dobj) complications_11\NNS\1073995|neurological|,|confusion (l_nmod) confusion_14\NN\13972797|including|,|status|,|women (l_conj) status_18\NN\24720|altered|mental|,|seizures (l_conj) seizures_20\NNS\14081375|,|and|coma (l_conj) coma_23\NN\5678932|
9293063
D003613_D001650 CID danazol_10\NN\1740|with (r_nmod) treatment_8\NN\654885|with|long-term|danazol (r_nmod) association_5\NN\8008335|in|treatment (r_nmod) occurring_3\VBG\2623529|association (r_acl) hamartoma_2\NN\14234074|duct|occurring|.
D003613_D001650 CID danazol_18\NN\1740| (r_compound) treatment_19\NN\654885|on|long-term|danazol (r_nsubj) had_14\VBD\2108377|who|been|treatment (r_parataxis) report_1\VBP\831651|we|case|had|. (l_dobj) case_3\NN\7283608|a|hamartoma (l_nmod) hamartoma_7\NN\14234074|of|duct|developed
D003613_D006222 CID danazol_10\NN\1740|with (r_nmod) treatment_8\NN\654885|with|long-term|danazol (r_nmod) association_5\NN\8008335|in|treatment (r_nmod) occurring_3\VBG\2623529|association (r_acl) hamartoma_2\NN\14234074|duct|occurring|.
D003613_D006222 CID danazol_18\NN\1740| (r_compound) treatment_19\NN\654885|on|long-term|danazol (r_nsubj) had_14\VBD\2108377|who|been|treatment (r_parataxis) report_1\VBP\831651|we|case|had|. (l_dobj) case_3\NN\7283608|a|hamartoma (l_nmod) hamartoma_7\NN\14234074|of|duct|developed
2385256
D008274_D009157 CID magnesium_6\NN\14625458| (r_compound) administration_7\NN\1133281|after|magnesium (r_nmod) presenting_2\VBG\2137132|weakness|administration (r_acl) gravis_1\NN\1740|myasthenia|presenting|.
D008274_D009157 CID magnesium_3\NN\14625458| (r_compound) administration_4\NN\1133281|after|magnesium (r_nmod) paralysis_1\NN\14557898|administration (r_nsubjpass) described_7\VBN\1001294|although|paralysis|has|been|patients (l_nmod) patients_9\NNS\9898892|in|gravis (l_nmod) gravis_13\NN\1740|with|known|myasthenia
D008274_D009468 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|after|parenteral|magnesium|preeclampsia (r_nmod) became_12\VBD\146138|who|quadriplegic|administration (r_acl:relcl) patient_3\NN\9898892|a|history|became (l_nmod) history_7\NN\15120823|with|no|prior|disease (l_nmod) disease_10\NN\14061805|of|neuromuscular
D008274_D011782 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|after|parenteral|magnesium|preeclampsia (r_nmod) became_12\VBD\146138|who|quadriplegic|administration (l_acomp) quadriplegic_14\JJ\1740|virtually
D008274_D011225 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|after|parenteral|magnesium|preeclampsia (l_nmod) preeclampsia_20\NN\14191037|for
D008274_D010243 NONE magnesium_3\NN\14625458| (r_compound) administration_4\NN\1133281|after|magnesium (r_nmod) paralysis_1\NN\14557898|administration
D008274_D020511 NONE magnesium_10\NN\14625458|of (r_nmod) effects_8\NNS\13245626|to|the|neuromuscular|magnesium (r_nmod) sensitive_4\JJ\1740|who|are|unusually|effects (r_acl:relcl) patients_0\NNS\9898892|sensitive (r_nsubjpass) suspected_13\VBN\916909|patients|should|be|having|. (l_advcl) having_15\VBG\2108377|of|disorder (l_dobj) disorder_18\NN\14034177|an|underlying|transmission (l_nmod) transmission_21\NN\121166|of|neuromuscular
6103707
D005445_D010146 CID flunitrazepam_7\NN\1740|of (r_nmod) injection_5\NN\320852|on|i.m.|flunitrazepam (r_nmod) pain_2\NN\14299637|injection
7053303
D002927_D003704 CID cimetidine_10\NN\14778019|possibly|due|(|level|dose (r_nmod) case_4\NN\7283608|one|dementia|cimetidine|) (l_nmod) dementia_6\NN\14395018|of
D002927_D003704 CID cimetidine_38\NN\14778019| (r_compound) levels_39\NNS\4916342|cimetidine|microgram/ml (r_dobj) had_37\VBD\2108377|who|levels (r_acl:relcl) patients_30\NNS\9898892|of|13|disease|had (r_nmod) group_27\NN\2137|in|a|patients (r_nmod) was_1\VBD\836236|there|case|group|. (l_attr) case_4\NN\7283608|one|dementia|cimetidine|) (l_nmod) dementia_6\NN\14395018|of
D002927_D003704 CID cimetidine_3\NN\14778019| (r_compound) levels_4\NNS\4916342|high|cimetidine|alone (r_nsubj) induce_9\VB\1627355|thus|,|levels|do|not|always|dementia|. (l_dobj) dementia_10\NN\14395018|
D002927_D008107 NONE cimetidine_10\NN\14778019|possibly|due|(|level|dose (r_nmod) case_4\NN\7283608|one|dementia|cimetidine|) (r_attr) was_1\VBD\836236|there|case|group|. (l_nmod) group_27\NN\2137|in|a|patients (l_nmod) patients_30\NNS\9898892|of|13|disease|had (l_nmod) disease_35\NN\14061805|without|liver
D002927_D008107 NONE cimetidine_38\NN\14778019| (r_compound) levels_39\NNS\4916342|cimetidine|microgram/ml (r_dobj) had_37\VBD\2108377|who|levels (r_acl:relcl) patients_30\NNS\9898892|of|13|disease|had (l_nmod) disease_35\NN\14061805|without|liver
D002927_D007674 NONE cimetidine_10\NN\14778019|possibly|due|(|level|dose (r_nmod) case_4\NN\7283608|one|dementia|cimetidine|) (r_attr) was_1\VBD\836236|there|case|group|. (l_nmod) group_27\NN\2137|in|a|patients (l_nmod) patients_30\NNS\9898892|of|13|disease|had (l_nmod) disease_35\NN\14061805|without|liver
D002927_D007674 NONE cimetidine_38\NN\14778019| (r_compound) levels_39\NNS\4916342|cimetidine|microgram/ml (r_dobj) had_37\VBD\2108377|who|levels (r_acl:relcl) patients_30\NNS\9898892|of|13|disease|had (l_nmod) disease_35\NN\14061805|without|liver
18329269
D006220_D002375 CID haloperidol-induced_36\JJ\1740| (r_amod) model_38\NN\5888929|in|the|rat|haloperidol-induced|catalepsy|disease (l_compound) catalepsy_37\NN\14023236|
D006220_D010300 NONE haloperidol-induced_36\JJ\1740| (r_amod) model_38\NN\5888929|in|the|rat|haloperidol-induced|catalepsy|disease (l_nmod) disease_42\NN\14061805|for|parkinson|'s
19657887
D000431_D005483 CID alcohol_9\NN\7881800|of (r_nmod) ingestion_7\NN\13440063|after|the|alcohol (r_nmod) hour_4\NN\15154774|in|1|ingestion (r_nmod) developed_12\VBD\1753788|hour|,|he|malaise|flushing|. (l_nmod) flushing_15\NN\1740|with|face|,|tachycardia (l_nmod) face_18\NN\5225090|of|the
D000431_D013610 CID alcohol_9\NN\7881800|of (r_nmod) ingestion_7\NN\13440063|after|the|alcohol (r_nmod) hour_4\NN\15154774|in|1|ingestion (r_nmod) developed_12\VBD\1753788|hour|,|he|malaise|flushing|. (l_nmod) flushing_15\NN\1740|with|face|,|tachycardia (l_conj) tachycardia_20\NN\14110674|,|and|dyspnea
D000431_D004417 CID alcohol_9\NN\7881800|of (r_nmod) ingestion_7\NN\13440063|after|the|alcohol (r_nmod) hour_4\NN\15154774|in|1|ingestion (r_nmod) developed_12\VBD\1753788|hour|,|he|malaise|flushing|. (l_nmod) flushing_15\NN\1740|with|face|,|tachycardia (l_conj) tachycardia_20\NN\14110674|,|and|dyspnea (l_conj) dyspnea_23\NN\14299637|
D004221_D005483 NONE disulfiram-like_7\JJ\1740| (r_amod) syndrome_8\NN\5870365|disulfiram-like|flushing (l_nmod) flushing_10\NN\1740|with|,|tachycardia
D004221_D013610 NONE disulfiram-like_7\JJ\1740| (r_amod) syndrome_8\NN\5870365|disulfiram-like|flushing (l_nmod) flushing_10\NN\1740|with|,|tachycardia (l_conj) tachycardia_12\NN\14110674|,|and|hypotension
D004221_D007022 NONE disulfiram-like_7\JJ\1740| (r_amod) syndrome_8\NN\5870365|disulfiram-like|flushing (l_nmod) flushing_10\NN\1740|with|,|tachycardia (l_conj) tachycardia_12\NN\14110674|,|and|hypotension (l_conj) hypotension_16\NN\14057371|arterial
9249847
D014700_D013611 CID verapamil_7\NN\2938514|after|and|ablation (r_nmod) tachycardia_5\NN\14110674|induced|intractable|atrioventricular|reentrant|verapamil|patient|.
D014700_D013611 CID verapamil_10\NN\2938514|after (r_nmod) beats_8\NNS\8289449|by|junctional|escape|verapamil|or|block (r_nmod) caused_4\VBN\1617192|beats (r_acl) qrs_0\NN\1740|preexcitation|,|caused|, (r_nsubj) established_22\VBD\2426171|qrs|attack|. (l_dobj) attack_25\NN\955060|frequent|avrt (l_compound) avrt_24\NN\1740|
D014700_D014927 NONE verapamil_7\NN\2938514|after|and|ablation (r_nmod) tachycardia_5\NN\14110674|induced|intractable|atrioventricular|reentrant|verapamil|patient|. (l_nmod) patient_13\NN\9898892|in|a|syndrome (l_nmod) syndrome_16\NN\5870365|with|wolff-parkinson-white|and|cardiomyopathy
D014700_D002311 NONE verapamil_7\NN\2938514|after|and|ablation (r_nmod) tachycardia_5\NN\14110674|induced|intractable|atrioventricular|reentrant|verapamil|patient|. (l_nmod) patient_13\NN\9898892|in|a|syndrome (l_nmod) syndrome_16\NN\5870365|with|wolff-parkinson-white|and|cardiomyopathy (l_conj) cardiomyopathy_20\NN\14103288|idiopathic|dilated
2312209
D007548_D009203 CID dinitrate_7\NN\1740|of|isosorbide (r_nmod) administration_4\NN\1133281|following|sublingual|dinitrate (r_nmod) infarction_1\NN\14204950|myocardial|administration|.
D007548_D009203 CID dinitrate_20\NN\1740|of|isosorbide|mg (r_nmod) administration_17\NN\1133281|following|the|dinitrate|sublingually (r_nmod) suffered_6\VBD\2110220|a|78-year-old|infarction|administration|. (l_dobj) infarction_10\NN\14204950|a|recurrent|myocardial|wall
D007548_D009336 NONE dinitrate_20\NN\1740|of|isosorbide|mg (r_nmod) administration_17\NN\1133281|following|the|dinitrate|sublingually (r_nmod) suffered_6\VBD\2110220|a|78-year-old|infarction|administration|. (l_nsubj) 78-year-old_1\JJ\1740|necrosis (l_nmod) necrosis_5\NN\11444117|with|healed|septal
8386779
D017693_D004414 NONE bicarbonate_1\NN\14798450|sodium (r_nsubj) alleviates_2\VBZ\205885|bicarbonate|pain|. (l_dobj) pain_4\NN\14299637|penile|induced
D017693_D004414 NONE bicarbonate_43\NN\14798450|of|sodium (r_nmod) addition_40\NN\3081021|with|the|bicarbonate (r_dep) injections_35\NNS\320852|following|intracorporeal|addition (r_nmod) incidence_29\NN\13821570|the|pain|injections (r_dobj) comparing_27\VBG\644583|incidence|medications.|total (r_acl) study_26\NN\635850|a|randomized|comparing (r_dobj) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|acidity (l_nmod) acidity_17\NN\4992163|due|the|medication (l_case) due_14\JJ\1740|whether|pain|could|be|to (l_nsubj) pain_7\NN\14299637|penile|associated
D017693_D004414 NONE bicarbonate_43\NN\14798450|of|sodium (r_nmod) addition_40\NN\3081021|with|the|bicarbonate (r_dep) injections_35\NNS\320852|following|intracorporeal|addition (r_nmod) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_100\NN\14798450|of|sodium|meq. (r_nmod) addition_97\NN\3081021|the|bicarbonate (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|acidity (l_nmod) acidity_17\NN\4992163|due|the|medication (l_case) due_14\JJ\1740|whether|pain|could|be|to (l_nsubj) pain_7\NN\14299637|penile|associated
D017693_D004414 NONE bicarbonate_100\NN\14798450|of|sodium|meq. (r_nmod) addition_97\NN\3081021|the|bicarbonate (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_6\NN\14798450|without|sodium|added (r_nmod) patients_3\NNS\9898892|of|the|19|bicarbonate (r_nmod) complained_16\VBD\843959|patients|11|pain|,|complained|. (l_nmod) pain_19\NN\14299637|of|penile|medication
D017693_D004414 NONE bicarbonate_6\NN\14798450|without|sodium|added (r_nmod) patients_3\NNS\9898892|of|the|19|bicarbonate (r_nmod) complained_16\VBD\843959|patients|11|pain|,|complained|. (l_advcl) complained_40\VBD\843959|while|1|pain (l_nmod) pain_43\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_39\NN\14798450|sodium (r_dobj) received_37\VBD\2210855|who|bicarbonate (r_acl:relcl) men_31\NNS\8208016|of|the|19|%|received (r_nmod) 1_27\CD\13741022|only|men (r_nsubj) complained_40\VBD\843959|while|1|pain (r_advcl) complained_16\VBD\843959|patients|11|pain|,|complained|. (l_nmod) pain_19\NN\14299637|of|penile|medication
D017693_D004414 NONE bicarbonate_39\NN\14798450|sodium (r_dobj) received_37\VBD\2210855|who|bicarbonate (r_acl:relcl) men_31\NNS\8208016|of|the|19|%|received (r_nmod) 1_27\CD\13741022|only|men (r_nsubj) complained_40\VBD\843959|while|1|pain (l_nmod) pain_43\NN\14299637|of|penile
D017693_D007172 NONE bicarbonate_1\NN\14798450|sodium (r_nsubj) alleviates_2\VBZ\205885|bicarbonate|pain|. (l_dobj) pain_4\NN\14299637|penile|induced (l_acl) induced_5\VBN\1627355|injections (l_nmod) injections_8\NNS\320852|by|intracavernous|dysfunction (l_nmod) dysfunction_11\NN\14204950|for|erectile
D017693_D007172 NONE bicarbonate_43\NN\14798450|of|sodium (r_nmod) addition_40\NN\3081021|with|the|bicarbonate (r_dep) injections_35\NNS\320852|following|intracorporeal|addition (r_nmod) incidence_29\NN\13821570|the|pain|injections (r_dobj) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) total_49\NN\3553|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
D017693_D007172 NONE bicarbonate_100\NN\14798450|of|sodium|meq. (r_nmod) addition_97\NN\3081021|the|bicarbonate (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) total_49\NN\3553|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
D010208_D004414 NONE papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|acidity (l_nmod) acidity_17\NN\4992163|due|the|medication (l_case) due_14\JJ\1740|whether|pain|could|be|to (l_nsubj) pain_7\NN\14299637|penile|associated
D010208_D004414 NONE papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D010208_D007172 NONE papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) total_49\NN\3553|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
D010646_D004414 CID phentolamine_78\NN\4537602| (r_conj) papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|acidity (l_nmod) acidity_17\NN\4992163|due|the|medication (l_case) due_14\JJ\1740|whether|pain|could|be|to (l_nsubj) pain_7\NN\14299637|penile|associated
D010646_D004414 CID phentolamine_78\NN\4537602| (r_conj) papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D010646_D007172 NONE phentolamine_78\NN\4537602| (r_conj) papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) total_49\NN\3553|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
D000527_D004414 CID e1_84\NN\1740|prostaglandin (r_appos) micrograms_81\NNS\13717155|10|.|e1|with|ph|or|without|ph (r_conj) papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|acidity (l_nmod) acidity_17\NN\4992163|due|the|medication (l_case) due_14\JJ\1740|whether|pain|could|be|to (l_nsubj) pain_7\NN\14299637|penile|associated
D000527_D004414 CID e1_84\NN\1740|prostaglandin (r_appos) micrograms_81\NNS\13717155|10|.|e1|with|ph|or|without|ph (r_conj) papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D000527_D007172 NONE e1_84\NN\1740|prostaglandin (r_appos) micrograms_81\NNS\13717155|10|.|e1|with|ph|or|without|ph (r_conj) papaverine_73\NN\3800001|mg.|,|micrograms|phentolamine|and|micrograms (r_dobj) received_61\VBD\2210855|ml.|combination|papaverine|addition (r_parataxis) performed_23\VBD\2367363|attempt|,|we|study|received|. (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence|medications.|total (l_dobj) total_49\NN\3553|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
11007689
D016572_D057049 CID cyclosporine_0\NN\1740|and|microangiopathy|. (l_conj) microangiopathy_4\NN\1740|tacrolimus-associated|thrombotic
D016572_D057049 CID cyclosporine_13\NN\1740|of (r_nmod) use_11\NN\407535|with|the|cyclosporine (r_nmod) associated_8\VBN\628491|use (r_acl) microangiopathy_4\NN\1740|of|thrombotic|tma|associated
D016572_D057049 CID cyclosporine_13\NN\1740|of (r_nmod) use_11\NN\407535|with|the|cyclosporine (r_nmod) associated_8\VBN\628491|use (r_acl) microangiopathy_4\NN\1740|of|thrombotic|tma|associated (l_appos) tma_6\NN\1740|(|)
D016572_D057049 CID cyclosporine-induced_20\JJ\1740| (r_amod) tma_21\NN\1740|of|cyclosporine-induced
D016572_D057049 CID cyclosporine_16\NN\1740|to|and|tacrolimus (r_nmod) exposed_13\VBN\2110927|sequentially|cyclosporine (r_acl) patients_12\NNS\9898892|in|exposed (r_nmod) recurrence_8\NN\7342049|of|the|tma|patients (l_nmod) tma_10\NN\1740|of
D016572_D057049 CID cyclosporine-induced_13\JJ\1740| (r_amod) tma_14\NN\1740|cyclosporine-induced|responded
D016572_D057049 CID cyclosporine_21\NN\1740|of (r_nmod) withdrawal_19\NN\7206096|to|the|cyclosporine|conjunction (r_nmod) responded_16\VBD\2367363|that|withdrawal (r_acl:relcl) tma_14\NN\1740|cyclosporine-induced|responded
D016572_D057049 CID cyclosporine_5\NN\1740|from (r_nmod) switched_3\VBN\138508|who|are|cyclosporine|tacrolimus|or|versa (r_acl:relcl) patients_0\NNS\9898892|switched (r_nsubjpass) monitored_14\VBN\2169352|patients|should|be|closely|signs|. (l_nmod) signs_17\NNS\6643763|for|the|and|symptoms|tma (l_nmod) tma_22\NN\1740|of|recurrent
D016559_D057049 CID tacrolimus-associated_2\JJ\1740| (r_amod) microangiopathy_4\NN\1740|tacrolimus-associated|thrombotic
D016559_D057049 CID tacrolimus_6\NN\1740|to (r_nmod) switching_4\VBG\138508|tacrolimus (r_nsubjpass) reported_9\VBN\831651|result|,|switching|has|been|option|. (l_xcomp) option_15\NN\6480506|to|be|a|viable|therapeutic|setting (l_nmod) setting_18\NN\8567235|in|the|tma (l_nmod) tma_21\NN\1740|of|cyclosporine-induced
D016559_D057049 CID tacrolimus_6\NN\1740|of (r_nmod) application_4\NN\947128|with|the|widespread|tacrolimus|transplantation (r_nmod) recognized_16\VBN\686447|application|,|tma|has|also|been|. (l_nsubjpass) tma_12\NN\1740|tacrolimus-associated
D016559_D057049 CID tacrolimus-associated_11\JJ\1740| (r_amod) tma_12\NN\1740|tacrolimus-associated
D016559_D057049 CID tacrolimus_18\NN\1740| (r_conj) cyclosporine_16\NN\1740|to|and|tacrolimus (r_nmod) exposed_13\VBN\2110927|sequentially|cyclosporine (r_acl) patients_12\NNS\9898892|in|exposed (r_nmod) recurrence_8\NN\7342049|of|the|tma|patients (l_nmod) tma_10\NN\1740|of
D016559_D057049 CID tacrolimus_2\NN\1740|of (r_nmod) introduction_0\NN\235435|tacrolimus|agent (r_nsubj) resulted_8\VBD\2633881|introduction|recurrence|. (l_nmod) recurrence_11\NN\7342049|in|the|tma|and|loss (l_nmod) tma_13\NN\1740|of
D016559_D057049 CID tacrolimus_7\NN\1740|to (r_nmod) switched_3\VBN\138508|who|are|cyclosporine|tacrolimus|or|versa (r_acl:relcl) patients_0\NNS\9898892|switched (r_nsubjpass) monitored_14\VBN\2169352|patients|should|be|closely|signs|. (l_nmod) signs_17\NNS\6643763|for|the|and|symptoms|tma (l_nmod) tma_22\NN\1740|of|recurrent
10704919
D013629_D006461 CID tamoxifen_6\NN\2714883|by (r_nmod) induced_4\VBN\1627355|tamoxifen (r_acl) hemolysis_0\NN\13509528|erythrocytes|induced
D013629_D006461 CID tam_0\NNP\2954340| (r_nsubj) induces_1\VBZ\1627355|tam|hemolysis|function|. (l_dobj) hemolysis_2\NN\13509528|erythrocytes
D013629_D006461 CID tam_13\NN\2954340|microm (r_nsubj) induces_14\VBZ\1627355|tam|hemolysis|. (r_conj) variable_5\JJ\1740|extension|is|samples|,|but|induces (l_nsubj) extension_1\NN\15272029|the|hemolysis (l_nmod) hemolysis_3\NN\13509528|of
D013629_D006461 CID tam_13\NN\2954340|microm (r_nsubj) induces_14\VBZ\1627355|tam|hemolysis|. (l_dobj) hemolysis_16\NN\13509528|total|suspensions
D013629_D006461 CID tam_4\NN\2954340|of (r_nmod) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D013629_D006461 CID tam_4\NN\2954340|of (r_nmod) effect_2\NN\34213|the|hemolytic|tam (r_nsubjpass) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_advcl) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D013629_D006461 CID tam-induced_28\JJ\1740| (r_amod) hemolysis_29\NN\13509528|tam-induced (r_nsubj) related_32\JJ\1740|that|hemolysis|is|not|damage (r_ccomp) indicating_26\VBG\952524|related (r_advcl) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D013629_D006461 CID tam-induced_28\JJ\1740| (r_amod) hemolysis_29\NN\13509528|tam-induced
D013629_D006461 CID tam-induced_17\JJ\1740| (r_amod) hemolysis_18\NN\13509528|with|tam-induced
D013629_D006461 CID tam_3\NN\2954340|by (r_nmod) caused_1\VBN\1617192|tam (r_acl) hemolysis_0\NN\13509528|caused
D013629_D006461 CID tam_3\NN\2954340|by (r_nmod) caused_1\VBN\1617192|tam (r_acl) hemolysis_0\NN\13509528|caused (r_nsubjpass) preceded_6\VBN\2690708|hemolysis|was|not|leakage|,|excluding|. (l_advcl) excluding_18\VBG\471711|also|mechanism|,|effects (l_dobj) mechanism_22\NN\13446390|a|colloid-osmotic|type|hemolysis (l_nmod) hemolysis_24\NN\13509528|of
D013629_D006461 CID tam_15\NN\2954340| (r_compound) incorporation_16\NN\1237415|to|a|decreased|tam|membranes (r_nmod) related_11\JJ\1740|that|protection|is|incorporation|and|avoided (l_nsubj) protection_5\NN\407535|the|hemolysis|tocopherols (l_nmod) hemolysis_7\NN\13509528|from
D013629_D006461 CID tam-induced_2\JJ\1740| (r_amod) hemolysis_3\NN\13509528|tam-induced
D013629_D001943 NONE tamoxifen_0\NN\2714883|tam|,|drug|, (l_appos) drug_7\NN\14778436|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\748282|widely|chemotherapy (l_nmod) chemotherapy_13\NN\661091|in|the|cancer (l_nmod) cancer_16\NN\14239425|of|breast
D013629_D001943 NONE tam_2\NN\2954340|(|) (r_appos) tamoxifen_0\NN\2714883|tam|,|drug|, (l_appos) drug_7\NN\14778436|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\748282|widely|chemotherapy (l_nmod) chemotherapy_13\NN\661091|in|the|cancer (l_nmod) cancer_16\NN\14239425|of|breast
D013629_D000743 CID tamoxifen_0\NN\2714883|tam|,|drug|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|changes|. (l_dobj) changes_19\NNS\7283608|shape (l_nmod) shape_23\NN\5062748|in|normal|discoid|erythrocytes|and|anemia (l_conj) anemia_28\NN\14189204|hemolytic
D013629_D000743 CID tam_2\NN\2954340|(|) (r_appos) tamoxifen_0\NN\2714883|tam|,|drug|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|changes|. (l_dobj) changes_19\NNS\7283608|shape (l_nmod) shape_23\NN\5062748|in|normal|discoid|erythrocytes|and|anemia (l_conj) anemia_28\NN\14189204|hemolytic
D013629_D000743 CID tam_6\NN\2954340|of (r_nmod) effects_4\NNS\13245626|the|tam|erythrocytes (r_dobj) evaluates_2\VBZ\670261|work|effects|,|attempting|. (l_advcl) attempting_12\VBG\2367363|identify (l_xcomp) identify_14\VB\699815|to|mechanisms (l_dobj) mechanisms_17\NNS\13446390|the|underlying|anemia|and|involvement (l_nmod) anemia_21\NN\14189204|on|tam-induced|hemolytic
D013629_D000743 CID tam-induced_19\JJ\1740| (r_amod) anemia_21\NN\14189204|on|tam-induced|hemolytic
D013629_D000743 CID tam_13\NNP\2954340|by (r_nmod) promoted_11\VBN\2556126|tam (r_acl) shape_6\NN\5062748|the|abnormal|erythrocyte|and|stability|promoted|,|resulting (l_acl) resulting_15\VBG\2633881|anemia (l_nmod) anemia_18\NN\14189204|in|hemolytic
D024502_D006461 NONE alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_advcl) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D024502_D006461 NONE alpha-t_13\NN\1740|(|) (r_appos) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE alpha-t_13\NN\1740|(|) (r_appos) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_advcl) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D024502_D006461 NONE acetate_17\NN\15010703|alpha-tocopherol|alpha-tac|hydroxyl (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE acetate_17\NN\15010703|alpha-tocopherol|alpha-tac|hydroxyl (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_advcl) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D024502_D006461 NONE alpha-tac_19\NN\1740|(|) (r_appos) acetate_17\NN\15010703|alpha-tocopherol|alpha-tac|hydroxyl (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE alpha-tac_19\NN\1740|(|) (r_appos) acetate_17\NN\15010703|alpha-tocopherol|alpha-tac|hydroxyl (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_advcl) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D017665_D006461 NONE hydroxyl_24\NN\14621446|(|inactivated|functional|) (r_appos) acetate_17\NN\15010703|alpha-tocopherol|alpha-tac|hydroxyl (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D017665_D006461 NONE hydroxyl_24\NN\14621446|(|inactivated|functional|) (r_appos) acetate_17\NN\15010703|alpha-tocopherol|alpha-tac|hydroxyl (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_advcl) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D010100_D006461 NONE oxygen_7\NN\14622893| (r_compound) consumption_8\NN\13440063|of|oxygen|and|oxidation|both (l_dep) both_12\DT\1740|determined (l_acl) determined_13\VBN\1645601|parallel (l_nmod) parallel_15\NN\4743605|in|hemolysis (l_nmod) hemolysis_18\NN\13509528|with|tam-induced
D011188_D006461 NONE k(+_11\NN\1740|of|) (r_nmod) leakage_9\NN\7407777|by|the|k(+|cells (r_nmod) preceded_6\VBN\2690708|hemolysis|was|not|leakage|,|excluding|. (l_nsubjpass) hemolysis_0\NN\13509528|caused
D011188_D006461 NONE k(+_11\NN\1740|of|) (r_nmod) leakage_9\NN\7407777|by|the|k(+|cells (r_nmod) preceded_6\VBN\2690708|hemolysis|was|not|leakage|,|excluding|. (l_advcl) excluding_18\VBG\471711|also|mechanism|,|effects (l_dobj) mechanism_22\NN\13446390|a|colloid-osmotic|type|hemolysis (l_nmod) hemolysis_24\NN\13509528|of
D024505_D006461 NONE tocopherols_9\NNS\14724645|by (r_nmod) protection_5\NN\407535|the|hemolysis|tocopherols (l_nmod) hemolysis_7\NN\13509528|from
17600377
C524754_D003072 NONE p-coumarate_5\NN\1740|maltolyl (r_appos) compound_2\NN\5869584|a|novel|,|p-coumarate|, (r_nsubj) attenuates_7\VBZ\224901|compound|deficits|and|shows|. (l_dobj) deficits_9\NNS\5113133|cognitive
C524754_D003072 NONE p-coumarate_9\NN\1740|maltolyl (r_nsubj) improve_11\VB\126264|whether|p-coumarate|could|decline (l_dobj) decline_13\NN\13458571|cognitive|rats
C524754_D003072 NONE p-coumarate_1\NN\1740|maltolyl (r_nsubjpass) found_3\VBN\2426171|p-coumarate|was|attenuate|. (l_xcomp) attenuate_5\VB\224901|to|deficits|models|and|reduce (l_dobj) deficits_7\NNS\5113133|cognitive
C524754_D003072 NONE p-coumarate_15\NN\1740|maltolyl (r_nsubj) candidate_20\NN\10450303|that|p-coumarate|is|a|effective|disease (l_nmod) disease_24\NN\14061805|against|alzheimer|'s|characterized (l_acl:relcl) characterized_27\VBN\609683|that|is|death (l_nmod) death_32\NN\7296428|by|spread|neuronal|and|decline (l_conj) decline_35\NN\13458571|progressive|function (l_nmod) function_38\NN\13783581|of|cognitive
C524754_D003704 NONE p-coumarate_5\NN\1740|maltolyl (r_appos) compound_2\NN\5869584|a|novel|,|p-coumarate|, (r_nsubj) attenuates_7\VBZ\224901|compound|deficits|and|shows|. (l_conj) shows_11\VBZ\2137132|effects|models (l_dobj) models_20\NNS\5888929|vitro|dementia (l_compound) dementia_19\NN\14395018|
D012601_D003072 CID scopolamine-injected_15\JJ\1740| (r_amod) rats_16\NNS\2329401|in|scopolamine-injected|and|rats (r_nmod) decline_13\NN\13458571|cognitive|rats
C544092_D003072 NONE 42)-infused_23\JJ\1740|peptide(1 (r_nummod) rats_24\NNS\2329401|in|42)-infused (r_conj) rats_16\NNS\2329401|in|scopolamine-injected|and|rats (r_nmod) decline_13\NN\13458571|cognitive|rats
C544092_D003072 NONE 42)-infused_32\NN\1740|amyloid|peptide(1|- (r_nummod) rats_33\NNS\2329401|of|the|42)-infused (r_nmod) hippocampus_25\NN\5462674|in|the|rats (r_nmod) observed_22\VBN\2163746|hippocampus (r_acl) death_21\NN\7296428|apoptotic|cell|observed (r_dobj) reduce_18\VB\441445|to|death (r_conj) attenuate_5\VB\224901|to|deficits|models|and|reduce (l_dobj) deficits_7\NNS\5113133|cognitive
C524754_D000544 NONE p-coumarate_15\NN\1740|maltolyl (r_nsubj) candidate_20\NN\10450303|that|p-coumarate|is|a|effective|disease (l_nmod) disease_24\NN\14061805|against|alzheimer|'s|characterized
C524754_D009410 NONE p-coumarate_15\NN\1740|maltolyl (r_nsubj) candidate_20\NN\10450303|that|p-coumarate|is|a|effective|disease (l_nmod) disease_24\NN\14061805|against|alzheimer|'s|characterized (l_acl:relcl) characterized_27\VBN\609683|that|is|death (l_nmod) death_32\NN\7296428|by|spread|neuronal|and|decline
17175308
D020123_D011507 CID sirolimus_4\NN\1740|to (r_nmod) conversion_2\NN\7359599|after|sirolimus|recipients (r_nmod) proteinuria_0\NN\14299637|conversion|.
D020123_D011507 CID sirolimus_11\NN\1740| (r_compound) therapy_12\NN\657604|of|sirolimus (r_nmod) consequence_9\NN\34213|as|a|therapy (r_nmod) reported_6\VBN\831651|recently|,|proteinuria|has|been|consequence|,|remained|. (l_nsubjpass) proteinuria_3\NN\14299637|
D020123_D011507 CID srl_18\NN\1740| (r_compound) conversion_19\NN\7359599|after|srl (r_nmod) displayed_14\VBD\2137132|proteinuria|conversion (l_dobj) proteinuria_16\NN\14299637|increased
D020123_D011507 CID srl_8\NN\1740|of (r_nmod) use_6\NN\407535|after|the|srl|therapy (r_nmod) common_3\JJ\1740|proteinuria|was|use|. (l_nsubj) proteinuria_1\NN\14299637|heavy
D020123_D051436 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma
D020123_D007674 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_appos) can_24\NN\3094503|(|)
D020123_D007674 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_dep) sarcoma_39\NN\14239918|kaposi|,|cancers|,|tumors|,|carsinom|)|or|nephropathy (l_conj) nephropathy_57\NN\14573196|bk|virus|=
D020123_D009369 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_dep) neoplasia_31\NN\13533470|=|;
D020123_D012514 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_dep) sarcoma_39\NN\14239918|kaposi|,|cancers|,|tumors|,|carsinom|)|or|nephropathy
D020123_D012878 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_dep) sarcoma_39\NN\14239918|kaposi|,|cancers|,|tumors|,|carsinom|)|or|nephropathy (l_appos) cancers_43\NNS\14239425|four|skin
D020123_D007414 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_dep) sarcoma_39\NN\14239918|kaposi|,|cancers|,|tumors|,|carsinom|)|or|nephropathy (l_appos) tumors_47\NNS\14234074|one|intestinal
D020123_D002292 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|=|neoplasia|sarcoma (l_dep) sarcoma_39\NN\14239918|kaposi|,|cancers|,|tumors|,|carsinom|)|or|nephropathy (l_appos) carsinom_52\NN\1740|one|renal|cell
11773892
D016572_D007674 CID cyclosporine_5\NN\1740|and|tacrolimus (r_dep) inhibitors_4\NNS\20090|the|calcineurin|cyclosporine (r_nsubjpass) known_10\VBN\2110220|inhibitors|are|both|nephrotoxic (l_xcomp) nephrotoxic_13\JJ\1740|to|be
D016559_D007674 CID tacrolimus_7\NN\1740| (r_conj) cyclosporine_5\NN\1740|and|tacrolimus (r_dep) inhibitors_4\NNS\20090|the|calcineurin|cyclosporine (r_nsubjpass) known_10\VBN\2110220|inhibitors|are|both|nephrotoxic (l_xcomp) nephrotoxic_13\JJ\1740|to|be
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum|mg/dl (r_appos) crf_16\NN\1740|,|creatinine|,|n=41|;|and|esrd (r_conj) controls_7\NNS\5190804|,|crf|,|n=748|;|crf (l_appos) crf_10\NN\1740|no|or|esrd
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum|mg/dl (r_appos) crf_16\NN\1740|,|creatinine|,|n=41|;|and|esrd (r_conj) controls_7\NNS\5190804|,|crf|,|n=748|;|crf (l_appos) crf_10\NN\1740|no|or|esrd (l_conj) esrd_12\NN\1740|
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum|mg/dl (r_appos) crf_16\NN\1740|,|creatinine|,|n=41|;|and|esrd
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum|mg/dl (r_appos) crf_16\NN\1740|,|creatinine|,|n=41|;|and|esrd (l_conj) esrd_28\NN\1740|,|n=45
D003404_D007676 NONE creatinine_13\NN\1740| (r_compound) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (r_dobj) had_9\VBD\2108377|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf (l_compound) crf_5\NN\1740|and|esrd
D003404_D007676 NONE creatinine_13\NN\1740| (r_compound) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (r_dobj) had_9\VBD\2108377|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf (l_compound) crf_5\NN\1740|and|esrd (l_conj) esrd_7\NN\1740|
D003404_D007676 NONE creatinine_42\NN\1740|a|higher|1-year|serum (r_conj) percentage_18\NN\13815742|a|greater|patients|,|requirement|,|and|creatinine (r_conj) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (r_dobj) had_9\VBD\2108377|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf (l_compound) crf_5\NN\1740|and|esrd
D003404_D007676 NONE creatinine_42\NN\1740|a|higher|1-year|serum (r_conj) percentage_18\NN\13815742|a|greater|patients|,|requirement|,|and|creatinine (r_conj) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (r_dobj) had_9\VBD\2108377|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\9898892|crf (l_compound) crf_5\NN\1740|and|esrd (l_conj) esrd_7\NN\1740|
D003404_D007676 NONE creatinine_16\NN\1740|of|serum (r_nmod) increase_13\NN\13576355|an|creatinine|compared (r_nsubj) factors_34\NNS\7326557|that|increase|were|independent|risk|development|ratios (l_nmod) development_37\NN\248977|for|the|crf (l_nmod) crf_39\NN\1740|of|or|esrd
D003404_D007676 NONE creatinine_16\NN\1740|of|serum (r_nmod) increase_13\NN\13576355|an|creatinine|compared (r_nsubj) factors_34\NNS\7326557|that|increase|were|independent|risk|development|ratios (l_nmod) development_37\NN\248977|for|the|crf (l_nmod) crf_39\NN\1740|of|or|esrd (l_conj) esrd_41\NN\1740|
D003404_D007676 NONE creatinine_11\NN\1740|a|preoperative|serum (r_dobj) have_4\VBP\2108377|patients|creatinine|and|likely|. (l_nsubj) patients_0\NNS\9898892|develop (l_acl:relcl) develop_2\VBP\1753788|who|esrd (l_dobj) esrd_3\NN\1740|
D003404_D007676 NONE creatinine_6\NN\1740|of|serum (r_nmod) increase_3\NN\13576355|an|creatinine|times (r_nsubj) predictive_13\JJ\1740|however|,|increase|is|more|development|. (l_nmod) development_16\NN\248977|of|the|crf (l_nmod) crf_18\NN\1740|of|or|esrd
D003404_D007676 NONE creatinine_6\NN\1740|of|serum (r_nmod) increase_3\NN\13576355|an|creatinine|times (r_nsubj) predictive_13\JJ\1740|however|,|increase|is|more|development|. (l_nmod) development_16\NN\248977|of|the|crf (l_nmod) crf_18\NN\1740|of|or|esrd (l_conj) esrd_20\NN\1740|
D003404_D006530 NONE creatinine_13\NN\1740| (r_compound) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (l_conj) percentage_18\NN\13815742|a|greater|patients|,|requirement|,|and|creatinine (l_nmod) patients_20\NNS\9898892|of|syndrome (l_nmod) syndrome_23\NN\5870365|with|hepatorenal
D003404_D006530 NONE creatinine_42\NN\1740|a|higher|1-year|serum (r_conj) percentage_18\NN\13815742|a|greater|patients|,|requirement|,|and|creatinine (l_nmod) patients_20\NNS\9898892|of|syndrome (l_nmod) syndrome_23\NN\5870365|with|hepatorenal
D003404_D006530 NONE creatinine_11\NN\1740|a|preoperative|serum (r_dobj) have_4\VBP\2108377|patients|creatinine|and|likely|. (l_conj) likely_15\JJ\1740|are|more|have (l_xcomp) have_17\VB\2108377|to|syndrome (l_dobj) syndrome_19\NN\5870365|hepatorenal
18308784
C035054_D007859 NONE rg1_1\NN\1740|ginsenoside (r_nsubj) restores_2\VBZ\1631072|rg1|impairment|. (l_dobj) impairment_4\NN\7296428|the|learning (l_nmod) learning_6\NN\5701944|of|induced
C035054_D007859 NONE rg1_0\NN\1740|,|ginsenoside|, (r_nsubj) ameliorate_11\VB\126264|rg1|could|impairment|. (l_dobj) impairment_14\NN\7296428|learning
C035054_D007859 NONE rg1_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|rg1|impairment|and|mechanism (l_nmod) impairment_14\NN\7296428|on|learning|administration
D009020_D007859 CID morphine_10\NN\2707683| (r_compound) administration_11\NN\1133281|by|chronic|morphine|rats (r_nmod) induced_7\VBN\1627355|administration (r_acl) learning_6\NN\5701944|of|induced
D009020_D007859 CID morphine_17\NN\2707683| (r_compound) administration_18\NN\1133281|by|chronic|morphine (r_nmod) impairment_14\NN\7296428|on|learning|administration
D036145_D007859 NONE ginsenoside_4\NN\1740|as|a|extracted (r_nmod) rg1_0\NN\1740|,|ginsenoside|, (r_nsubj) ameliorate_11\VB\126264|rg1|could|impairment|. (l_dobj) impairment_14\NN\7296428|learning
7468724
D013726_D002318 CID terbutaline_4\NN\1740| (r_compound) treatment_5\NN\654885|with|terbutaline|labor (r_nmod) associated_2\VBN\628491|treatment (r_acl) complications_1\NNS\1073995|cardiovascular|associated|.
D013726_D002318 CID terbutaline_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|terbutaline|labor (r_acl) patients_8\NNS\9898892|eight|160|treated (r_dobj) occurred_3\VBD\2623529|complications|patients|. (l_nsubj) complications_2\NNS\1073995|severe|cardiovascular
D013726_D007752 NONE terbutaline_4\NN\1740| (r_compound) treatment_5\NN\654885|with|terbutaline|labor (l_nmod) labor_8\NN\7974025|for|preterm
D013726_D007752 NONE terbutaline_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|terbutaline|labor (l_nmod) labor_14\NN\7974025|for|preterm
6209318
D008801_D001145 NONE mexiletine_1\NN\2715941|and|placebo (r_compound) trial_6\NNP\786195|international|mexiletine|antiarrhythmic|coronary|:|i. (r_nsubj) report_9\VB\831651|trial|arrhythmia|. (l_nmod) arrhythmia_11\NN\14103288|on|and|findings
D008801_D009203 NONE mexiletine_9\NN\2715941|of|mexitil-perlongets (r_nmod) form_7\NN\6286395|of|the|release|mexiletine (r_nmod) effects_2\NNS\13245626|the|antiarrhythmic|form (r_nsubjpass) evaluated_14\VBN\670261|effects|were|trial|. (l_nmod) trial_19\NN\786195|in|a|double-blind|placebo|patients (l_nmod) patients_22\NNS\9898892|in|630|infarction (l_nmod) infarction_27\NN\14204950|with|recent|documented|myocardial
D008801_D009203 NONE mexitil-perlongets_11\NN\1740|(|) (r_appos) mexiletine_9\NN\2715941|of|mexitil-perlongets (r_nmod) form_7\NN\6286395|of|the|release|mexiletine (r_nmod) effects_2\NNS\13245626|the|antiarrhythmic|form (r_nsubjpass) evaluated_14\VBN\670261|effects|were|trial|. (l_nmod) trial_19\NN\786195|in|a|double-blind|placebo|patients (l_nmod) patients_22\NNS\9898892|in|630|infarction (l_nmod) infarction_27\NN\14204950|with|recent|documented|myocardial
D008801_D003643 NONE mexiletine_6\NN\2715941| (r_compound) group_7\NN\2137|in|the|mexiletine (r_nmod) were_1\VBD\836236|there|deaths|group|%|than (l_attr) deaths_3\NNS\7296428|more
D008801_D014202 CID mexiletine_16\NN\2715941| (r_compound) group_17\NN\2137|in|the|mexiletine (r_nmod) frequent_13\JJ\1740|effects|were|more|group|than|. (l_nsubj) effects_3\NNS\13245626|recognized|side|,|tremor|, (l_appos) tremor_6\NN\345926|particularly|and|problems
D008801_D012817 CID mexiletine_16\NN\2715941| (r_compound) group_17\NN\2137|in|the|mexiletine (r_nmod) frequent_13\JJ\1740|effects|were|more|group|than|. (l_nsubj) effects_3\NNS\13245626|recognized|side|,|tremor|, (l_appos) tremor_6\NN\345926|particularly|and|problems (l_conj) problems_9\NNS\14408086|gastrointestinal
10807237
D003042_D000783 NONE cocaine-related_14\JJ\1740| (r_amod) aneurysms_15\NNS\14057371|with|cocaine-related
D003042_D000783 NONE cocaine-related_25\JJ\1740| (r_amod) aneurysms_26\NNS\14057371|with|cocaine-related
D003042_D000783 NONE cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine (r_nsubj) predisposed_4\VBD\680841|conclusion|:|use|rupture|age|. (l_nmod) age_11\NN\4916342|at|a|earlier|and|aneurysms (l_conj) aneurysms_16\NNS\14057371|in|smaller
D003042_D017542 CID cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine (r_nsubj) predisposed_4\VBD\680841|conclusion|:|use|rupture|age|. (l_dobj) rupture_6\NN\14285662|aneurysmal
8741744
D009538_D009069 NONE nicotine_25\NN\14712692|by|kg(-1|, (r_nmod) caused_23\VBN\1617192|nicotine (r_acl) hypoactivity_22\NN\1740|the|early|free-field|locomotor|caused|i.m.|)
D009538_D009069 NONE nicotine-induced_44\JJ\1740| (r_amod) hyperactivity_45\NN\14052403|the|later|min|nicotine-induced (r_dobj) enhanced_35\VBD\227165|hyperactivity|,|and|raised (r_conj) blunted_12\VBD\224901|controls|,|lesions|significantly|hypoactivity|,|enhanced|. (l_dobj) hypoactivity_22\NN\1740|the|early|free-field|locomotor|caused|i.m.|)
D009538_D006948 CID nicotine_25\NN\14712692|by|kg(-1|, (r_nmod) caused_23\VBN\1617192|nicotine (r_acl) hypoactivity_22\NN\1740|the|early|free-field|locomotor|caused|i.m.|) (r_dobj) blunted_12\VBD\224901|controls|,|lesions|significantly|hypoactivity|,|enhanced|. (l_conj) enhanced_35\VBD\227165|hyperactivity|,|and|raised (l_dobj) hyperactivity_45\NN\14052403|the|later|min|nicotine-induced
D009538_D006948 CID nicotine-induced_44\JJ\1740| (r_amod) hyperactivity_45\NN\14052403|the|later|min|nicotine-induced
1616457
D010424_D000647 CID pentobarbital_7\NN\2792049|by (r_nmod) caused_5\VBN\1617192|pentobarbital (r_acl) amnesia_4\NN\5669934|under|caused
D010424_D000647 CID pentobarbital_15\NN\2792049|by|mg/kg (r_nmod) produced_13\VBN\1617192|pentobarbital (r_acl) amnesia_12\NN\5669934|of|produced
15130900
D003520_D001749 CID cyclophosphamide_12\NN\1740|to (r_nmod) relation_10\NN\2137|cyclophosphamide (r_conj) risks_8\NNS\14541044|and|relation|. (r_conj) cancer_2\NN\14239425|bladder|granulomatosis|:|risks
D003520_D001749 CID cyclophosphamide_16\NN\1740|to (r_nmod) relation_14\NN\2137|its|cyclophosphamide|,|patients (r_conj) risk_7\NN\14541044|the|cancer|and|relation (l_nmod) cancer_10\NN\14239425|of|bladder|,
D003520_D001749 CID cyclophosphamide_16\NN\1740|between|and|cancer (l_conj) cancer_19\NN\14239425|bladder
D003520_D001749 CID cyclophosphamide_12\NN\1740|in (r_nmod) increment_10\NN\29677|for|every|g|cyclophosphamide (r_nmod) doubled_5\VBD\247390|risk|increment|or|. (l_nsubj) risk_1\NN\14541044|the|cancer (l_nmod) cancer_4\NN\14239425|of|bladder
D003520_D001749 CID cyclophosphamide_9\NN\1740|between|and|risk (l_conj) risk_12\NN\14541044|the|cancer|,|risks|also (l_nmod) cancer_15\NN\14239425|of|bladder
D003520_D014890 NONE cyclophosphamide_12\NN\1740|to (r_nmod) relation_10\NN\2137|cyclophosphamide (r_conj) risks_8\NNS\14541044|and|relation|. (r_conj) cancer_2\NN\14239425|bladder|granulomatosis|:|risks (l_nmod) granulomatosis_6\NN\1740|in|wegener
D003520_D014890 NONE cyclophosphamide_16\NN\1740|to (r_nmod) relation_14\NN\2137|its|cyclophosphamide|,|patients (l_nmod) patients_19\NNS\9898892|in|granulomatosis (l_nmod) granulomatosis_23\NN\1740|with|wegener
D003520_D014890 NONE cyclophosphamide_9\NN\1740|between|and|risk (r_nmod) relationship_7\NN\31921|a|dose-response|cyclophosphamide (r_dobj) indicate_4\VBP\952524|conclusion|:|results|relationship|possibility|. (l_dobj) possibility_28\NN\5944958|the|operating (l_advcl) operating_32\VBG\2439501|of|factors|granulomatosis (l_nmod) granulomatosis_37\NN\1740|before|wegener
12653683
D012964_D009404 NONE sodium_1\NN\14625458| (r_compound) channel_2\NN\6251781|epithelial|sodium|enac (r_compound) mrna_7\NN\14832193|channel|subunit|and|expression|rats|. (l_nmod) rats_12\NNS\2329401|in|syndrome (l_nmod) syndrome_17\NN\5870365|with|puromycin|aminonucleoside-induced|nephrotic
D012964_D009404 NONE sodium_6\NN\14625458| (r_compound) excretion_7\NN\13466586|urinary|sodium (r_nsubjpass) decreased_9\VBN\169651|syndrome|,|excretion|is|phase|. (l_nmod) syndrome_3\NN\5870365|in|experimental|nephrotic
D011692_D009404 CID aminonucleoside-induced_15\JJ\1740| (r_amod) syndrome_17\NN\5870365|with|puromycin|aminonucleoside-induced|nephrotic
D011692_D009404 CID aminonucleoside_12\NN\1740|puromycin (r_compound) (pan)-induced_13\JJ\1740|aminonucleoside (r_nummod) syndrome_15\NN\5870365|in|(pan)-induced|nephrotic
D011692_D009404 CID (pan)-induced_13\JJ\1740|aminonucleoside (r_nummod) syndrome_15\NN\5870365|in|(pan)-induced|nephrotic
D011692_D009404 CID pan-induced_22\JJ\1740| (r_amod) syndrome_24\NN\5870365|of|pan-induced|nephrotic|rats
D012964_D011507 NONE sodium_5\NN\14625458| (r_compound) excretion_6\NN\13466586|of|urinary|sodium|,|concentration|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D012964_D011507 NONE sodium_4\NN\14625458| (r_compound) excretion_5\NN\13466586|of|urinary|sodium (r_nmod) kinetics_1\NNS\6100236|the|excretion|and|appearance (l_conj) appearance_8\NN\4723816|the|proteinuria (l_nmod) proteinuria_10\NN\14299637|of
D000450_D011507 NONE aldosterone_9\NN\14751863| (r_compound) concentration_10\NN\4916342|plasma|aldosterone (r_conj) excretion_6\NN\13466586|of|urinary|sodium|,|concentration|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D011692_D011507 CID pan_26\NN\3101986|of|either|or|vehicle (r_nmod) dose_23\NN\3740161|with|a|single|pan (r_nmod) treated_19\VBN\2376958|dose (r_acl) rats_18\NNS\2329401|in|male|sprague-dawley|treated (r_nmod) studied_14\VBN\630380|courses|were|rats|. (l_nsubjpass) courses_2\NNS\883297|the|time|excretion (l_nmod) excretion_6\NN\13466586|of|urinary|sodium|,|concentration|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D000450_D009404 NONE aldosterone_36\NN\14751863|by (r_nmod) regulation_34\NN\6652242|from|the|aldosterone (r_nmod) escape_31\VB\2075462|to|regulation|day (r_xcomp) appears_29\VBZ\2604760|escape (r_conj) increased_11\VBN\169651|conclusion|,|expression|is|phase|,|but|appears|. (l_nmod) phase_16\NN\15113229|in|the|early|model (l_nmod) model_20\NN\5888929|of|the|experimental|syndrome (l_nmod) syndrome_24\NN\5870365|of|pan-induced|nephrotic|rats
10737864
D003000_D001919 CID clonidine_14\NN\2721160| (r_nsubj) induces_15\VBZ\1627355|given|that|clonidine|withdrawal (l_dobj) withdrawal_17\NN\7206096|sympathetic|and|bradycardia (l_conj) bradycardia_19\NN\14110674|
D003000_D001919 CID clonidine_24\NN\2721160|'s (r_nmod:poss) effects_27\NNS\13245626|clonidine|developmental|rate (r_nsubj) mirror_35\VB\2136271|that|effects|would|other (r_ccomp) hypothesized_22\VBD\719734|exhibits|,|we|mirror|. (l_advcl) exhibits_5\VBZ\2632167|given|that|dominance|pattern|,|and|induces (l_conj) induces_15\VBZ\1627355|given|that|clonidine|withdrawal (l_dobj) withdrawal_17\NN\7206096|sympathetic|and|bradycardia (l_conj) bradycardia_19\NN\14110674|
D003000_D001919 CID clonidine-induced_17\JJ\1740| (r_amod) bradycardia_18\NN\14110674|clonidine-induced
18186898
D019259_D006509 NONE lamivudine_0\NN\3834836| (r_nsubjpass) added_2\VBN\156601|lamivudine|was|infection|. (l_nmod) infection_9\NN\14052046|because|nova|b|follow-up
D016559_D000138 NONE tacrolimus_1\NN\1740| (r_nsubjpass) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (l_xcomp) cause_7\NN\7323922|to|be|the|acidosis (l_nmod) acidosis_12\NN\14204950|of|late|post-transplant|renal
D016559_D000138 NONE tacrolimus_1\NN\1740| (r_nsubjpass) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (r_advcl) got_24\VBD\146138|suspected|,|acidosis|worse|. (l_nsubj) acidosis_19\NN\14204950|,|and|imbalance
D020123_D000138 NONE sirolimus_17\NN\1740|by (r_nmod) replaced_15\VBN\1631072|was|sirolimus (r_conj) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (l_xcomp) cause_7\NN\7323922|to|be|the|acidosis (l_nmod) acidosis_12\NN\14204950|of|late|post-transplant|renal
D020123_D000138 NONE sirolimus_17\NN\1740|by (r_nmod) replaced_15\VBN\1631072|was|sirolimus (r_conj) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (r_advcl) got_24\VBD\146138|suspected|,|acidosis|worse|. (l_nsubj) acidosis_19\NN\14204950|,|and|imbalance
D016559_D005198 CID tacrolimus_20\NN\1740|by (r_nmod) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|that|dysfunction|may|have|dysfunction (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy
D016559_D009135 CID tacrolimus_20\NN\1740|by (r_nmod) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|that|dysfunction|may|have|dysfunction (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy (l_conj) myopathy_9\NN\14204950|
D016559_D028361 NONE tacrolimus_20\NN\1740|by (r_nmod) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered
D019259_D005198 CID lamivudine_24\NN\3834836|by (r_nmod) augmented_22\VBN\153263|lamivudine (r_conj) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|that|dysfunction|may|have|dysfunction (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy
D019259_D009135 CID lamivudine_24\NN\3834836|by (r_nmod) augmented_22\VBN\153263|lamivudine (r_conj) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|that|dysfunction|may|have|dysfunction (l_nsubj) dysfunction_7\NN\14204950|patient|tubular|and|myopathy (l_conj) myopathy_9\NN\14204950|
D019259_D028361 NONE lamivudine_24\NN\3834836|by (r_nmod) augmented_22\VBN\153263|lamivudine (r_conj) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered
10683478
D001058_D007035 CID apomorphine_0\NN\3786417|,|agonist|, (r_nsubjpass) selected_8\VBN\697589|apomorphine|was|effects|. (l_nmod) effects_14\NNS\13245626|due|its|biphasic|behavioral|,|ability (l_conj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\14034177|
D001058_D007035 CID apomorphine_11\NN\3786417|to (r_nmod) responses_9\NNS\11410625|upon|other|physiological|apomorphine|hypothermia (l_nmod) hypothermia_15\NN\14034177|such|drug-induced
D018491_D007035 NONE agonist_5\NN\9613191|a|nonselective|dopamine (r_appos) apomorphine_0\NN\3786417|,|agonist|, (r_nsubjpass) selected_8\VBN\697589|apomorphine|was|effects|. (l_nmod) effects_14\NNS\13245626|due|its|biphasic|behavioral|,|ability (l_conj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\14034177|
D004298_D007035 NONE dopamine_28\NN\14807737| (r_compound) turnover_29\NN\13819207|to|dopamine|brain (r_nmod) changes_26\NNS\7283608|distinct|turnover (r_dobj) produce_24\VB\1617192|to|changes (r_conj) induce_19\VB\1627355|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\14034177|
D001058_D006948 CID apomorphine-induced_5\JJ\1740| (r_amod) hyperactivity_6\NN\14052403|of|apomorphine-induced
10669626
D014859_D061205 CID warfarin-induced_0\JJ\1740| (r_amod) calcification_2\NN\13446390|warfarin-induced|artery
D014859_D061205 CID warfarin_22\NN\2718259|of (r_nmod) doses_20\NNS\3740161|sufficient|warfarin (r_dobj) given_18\VBN\2327200|doses|inhibit (r_acl) rats_17\NNS\2329401|in|given (r_nmod) extent_12\NN\13939892|the|calcification|rats (l_nmod) calcification_15\NN\13446390|of|artery
D014859_D061205 CID warfarin-treated_17\JJ\1740| (r_amod) rats_18\NNS\2329401|in|warfarin-treated (r_nmod) calcification_15\NN\13446390|on|artery|rats
D014859_D061205 CID warfarin_5\NN\2718259|with (r_nmod) treatment_0\NN\654885|weeks|warfarin (r_nsubj) caused_6\VBD\1617192|treatment|calcification|. (l_dobj) calcification_9\NN\13446390|massive|focal|media|rats|and|calcification (l_nmod) media_13\NNS\3575240|of|the|artery (l_compound) artery_12\NN\5417975|
D014859_D061205 CID warfarin_18\NN\2718259| (r_compound) treatment_19\NN\654885|of|warfarin (r_nmod) weeks_16\NNS\15113229|after|4|treatment (r_nmod) detected_8\VBN\2163746|contrast|,|calcification|could|be|rats|weeks|. (l_nsubjpass) calcification_5\NN\13446390|no|artery
D014859_D061205 CID warfarin-induced_8\JJ\1740| (r_amod) calcification_10\NN\13446390|to|warfarin-induced|artery|animals
D014859_D061205 CID warfarin_7\NN\2718259|with (r_nmod) treatment_1\NN\654885|concurrent|groups|warfarin (r_nsubj) produced_8\VBD\1617192|treatment|calcification|. (l_dobj) calcification_11\NN\13446390|massive|focal|media|rats|but|calcification (l_nmod) media_15\NNS\3575240|of|the|artery (l_compound) artery_14\NN\5417975|
D014859_D061205 CID warfarin_7\NN\2718259|with (r_nmod) treatment_1\NN\654885|concurrent|groups|warfarin (r_nsubj) produced_8\VBD\1617192|treatment|calcification|. (l_dobj) calcification_11\NN\13446390|massive|focal|media|rats|but|calcification (l_conj) calcification_25\NN\13446390|no|detectable|artery|group
D014859_D061205 CID warfarin-induced_59\JJ\1740| (r_amod) calcification_61\NN\13446390|to|warfarin-induced|artery (r_nmod) resistant_57\JJ\1740|that|was|calcification|,|ie|rats (r_acl:relcl) groups_54\NNS\2137|of|the|resistant (r_nmod) either_51\DT\1740|compared|with|groups (r_nmod) levels_39\NNS\4916342|with|higher|phosphate|rats|either (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|. (l_advcl) determined_15\VBN\1645601|although|explanation|can|not|be|study (l_nsubjpass) explanation_2\NN\6722453|the|association (l_nmod) association_5\NN\8008335|for|the|calcification (l_nmod) calcification_8\NN\13446390|between|artery|and|status
D014859_D061205 CID warfarin-induced_59\JJ\1740| (r_amod) calcification_61\NN\13446390|to|warfarin-induced|artery (r_nmod) resistant_57\JJ\1740|that|was|calcification|,|ie|rats (r_acl:relcl) groups_54\NNS\2137|of|the|resistant (r_nmod) either_51\DT\1740|compared|with|groups (r_nmod) levels_39\NNS\4916342|with|higher|phosphate|rats|either (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (l_nmod) phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|calcification (l_nmod) calcification_33\NN\13446390|to|artery
D014859_D061205 CID warfarin-induced_59\JJ\1740| (r_amod) calcification_61\NN\13446390|to|warfarin-induced|artery
D014859_D061205 CID warfarin-induced_7\JJ\1740| (r_amod) calcification_9\NN\13446390|to|warfarin-induced|artery
D014859_D061205 CID warfarin_13\NN\2718259| (r_conj) d_11\NN\15089472|between|vitamin|and|warfarin (r_nmod) synergy_8\NN\13518963|the|possible|d|calcification (l_nmod) calcification_16\NN\13446390|in|artery
D014859_D061205 CID warfarin_7\NN\2718259|of|the|vitamin|k|antagonist (r_nmod) doses_1\NNS\3740161|high|warfarin (r_nsubjpass) known_10\VBN\2110220|doses|are|also|cause|,|but|times|. (l_xcomp) cause_12\VB\1617192|to|calcification (l_dobj) calcification_13\NN\13446390|media (l_nmod) media_17\NNS\3575240|of|the|artery (l_compound) artery_16\NN\5417975|
D014859_D061205 CID warfarin_20\NN\2718259| (r_conj) d_18\NN\15089472|with|vitamin|plus|warfarin (r_nmod) treated_15\VBN\2376958|d (r_acl) rats_14\NNS\2329401|in|treated (r_nmod) sites_9\NNS\8673395|at|calcification|rats (l_nmod) calcification_12\NN\13446390|of|artery
D014807_D061205 NONE d._9\NN\1740|vitamin (r_conj) growth_6\NN\13526110|by|and|d. (r_nmod) accelerated_4\VBN\226566|calcification|is|growth (l_nsubjpass) calcification_2\NN\13446390|warfarin-induced|artery
D014807_D061205 NONE d_8\NN\15089472|vitamin (r_compound) treatment_9\NN\654885|d (r_conj) growth_5\NN\13526110|and|treatment (r_nsubj) enhance_10\VBP\227165|that|growth|extent (l_dobj) extent_12\NN\13939892|the|calcification|rats (l_nmod) calcification_15\NN\13446390|of|artery
D014807_D061205 NONE d_11\NN\15089472|between|vitamin|and|warfarin (r_nmod) synergy_8\NN\13518963|the|possible|d|calcification (l_nmod) calcification_16\NN\13446390|in|artery
D014807_D061205 NONE d_4\NN\15089472|of|vitamin (r_nmod) doses_1\NNS\3740161|high|d (r_nsubjpass) known_6\VBN\2110220|doses|are|cause|. (l_xcomp) cause_8\VB\1617192|to|calcification|days (l_dobj) calcification_9\NN\13446390|media (l_nmod) media_13\NN\3575240|of|the|artery (l_compound) artery_12\NN\5417975|
D014807_D061205 NONE d_10\NN\15089472| (r_compound) dose_11\NN\3740161|of|vitamin|d (r_nmod) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_nmod) calcification_14\NN\13446390|on|artery
D014807_D061205 NONE d_10\NN\15089472| (r_compound) dose_11\NN\3740161|of|vitamin|d (r_nmod) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_acl:relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_20\NN\15089472| (r_compound) dose_21\NN\3740161|of|vitamin|d (r_nmod) effect_17\NN\34213|the|dose|elevation|, (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_nmod) calcification_14\NN\13446390|on|artery
D014807_D061205 NONE d_20\NN\15089472| (r_compound) dose_21\NN\3740161|of|vitamin|d (r_nmod) effect_17\NN\34213|the|dose|elevation|, (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_acl:relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_33\NN\15089472|vitamin (r_nsubj) induce_35\VB\1627355|that|d|may|calcification|effect (r_ccomp) suggests_30\VBZ\1010118|which|induce (r_acl:relcl) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_nmod) calcification_14\NN\13446390|on|artery
D014807_D061205 NONE d_33\NN\15089472|vitamin (r_nsubj) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_18\NN\15089472|with|vitamin|plus|warfarin (r_nmod) treated_15\VBN\2376958|d (r_acl) rats_14\NNS\2329401|in|treated (r_nmod) sites_9\NNS\8673395|at|calcification|rats (l_nmod) calcification_12\NN\13446390|of|artery
D014807_D002114 NONE d_8\NN\15089472|vitamin (r_compound) treatment_9\NN\654885|d (r_conj) growth_5\NN\13526110|and|treatment (r_nsubj) enhance_10\VBP\227165|that|growth|extent (l_dobj) extent_12\NN\13939892|the|calcification|rats (l_nmod) rats_17\NNS\2329401|in|given (l_acl) given_18\VBN\2327200|doses|inhibit (l_xcomp) inhibit_24\VB\2510337|to|gamma-carboxylation (l_dobj) gamma-carboxylation_25\NN\1740|protein (l_nmod) protein_29\NN\14944888|of|matrix|gla|,|inhibitor (l_appos) inhibitor_33\NN\20090|a|calcification|known (l_compound) calcification_32\NN\13446390|
D014807_D002114 NONE d-treated_30\JJ\1740| (r_amod) rats_31\NNS\2329401|of|vitamin|d-treated (r_nmod) media_27\NNS\3575240|in|the|rats (r_nmod) calcification_24\NN\13446390|of|media
D014807_D002114 NONE d_15\NN\15089472|by|vitamin (r_nmod) produced_12\VBN\1617192|d (r_acl) elevation_8\NN\7445480|on|the|calcium|produced (r_nmod) effect_5\NN\34213|no|elevation (r_dobj) had_3\VBD\2108377|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|,|synergy|is|probably|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity (l_dobj) activity_35\NN\30358|the|protein|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014807_D002114 NONE d_23\NN\15089472|vitamin (r_conj) warfarin_20\NN\2718259|between|and|d (r_nmod) synergy_18\NN\13518963|the|warfarin (r_nsubjpass) explained_27\VBN\831651|had|,|synergy|is|probably|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity (l_dobj) activity_35\NN\30358|the|protein|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_22\NN\2718259|of (r_nmod) doses_20\NNS\3740161|sufficient|warfarin (r_dobj) given_18\VBN\2327200|doses|inhibit (l_xcomp) inhibit_24\VB\2510337|to|gamma-carboxylation (l_dobj) gamma-carboxylation_25\NN\1740|protein (l_nmod) protein_29\NN\14944888|of|matrix|gla|,|inhibitor (l_appos) inhibitor_33\NN\20090|a|calcification|known (l_compound) calcification_32\NN\13446390|
D014859_D002114 NONE warfarin_5\NN\2718259|with (r_nmod) treatment_0\NN\654885|weeks|warfarin (r_nsubj) caused_6\VBD\1617192|treatment|calcification|. (l_dobj) calcification_9\NN\13446390|massive|focal|media|rats|and|calcification (l_conj) calcification_21\NN\13446390|less|extensive|focal|rats
D014859_D002114 NONE warfarin_17\NN\2718259| (r_compound) administration_18\NN\1133281|concurrent|warfarin (r_nsubj) increased_20\VBD\169651|that|administration|dramatically|extent|days (l_dobj) extent_22\NN\13939892|the|calcification (l_nmod) calcification_24\NN\13446390|of|media
D014859_D002114 NONE warfarin_1\NN\2718259| (r_compound) treatment_2\NN\654885|warfarin (r_nsubj) had_3\VBD\2108377|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|,|synergy|is|probably|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity (l_dobj) activity_35\NN\30358|the|protein|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_20\NN\2718259|between|and|d (r_nmod) synergy_18\NN\13518963|the|warfarin (r_nsubjpass) explained_27\VBN\831651|had|,|synergy|is|probably|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity (l_dobj) activity_35\NN\30358|the|protein|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_32\NN\2718259| (r_nsubj) inhibits_33\VBZ\2510337|that|warfarin|activity (l_dobj) activity_35\NN\30358|the|protein|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D010710_D061205 NONE phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|. (l_advcl) determined_15\VBN\1645601|although|explanation|can|not|be|study (l_nsubjpass) explanation_2\NN\6722453|the|association (l_nmod) association_5\NN\8008335|for|the|calcification (l_nmod) calcification_8\NN\13446390|between|artery|and|status
D010710_D061205 NONE phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|calcification (l_nmod) calcification_33\NN\13446390|to|artery
D010710_D061205 NONE phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (l_nmod) levels_39\NNS\4916342|with|higher|phosphate|rats|either (l_nmod) either_51\DT\1740|compared|with|groups (l_nmod) groups_54\NNS\2137|of|the|resistant (l_acl:relcl) resistant_57\JJ\1740|that|was|calcification|,|ie|rats (l_nmod) calcification_61\NN\13446390|to|warfarin-induced|artery
D010710_D061205 NONE phosphate_42\NN\15010703|of|serum (r_nmod) levels_39\NNS\4916342|with|higher|phosphate|rats|either (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|. (l_advcl) determined_15\VBN\1645601|although|explanation|can|not|be|study (l_nsubjpass) explanation_2\NN\6722453|the|association (l_nmod) association_5\NN\8008335|for|the|calcification (l_nmod) calcification_8\NN\13446390|between|artery|and|status
D010710_D061205 NONE phosphate_42\NN\15010703|of|serum (r_nmod) levels_39\NNS\4916342|with|higher|phosphate|rats|either (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (l_nmod) phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|calcification (l_nmod) calcification_33\NN\13446390|to|artery
D010710_D061205 NONE phosphate_42\NN\15010703|of|serum (r_nmod) levels_39\NNS\4916342|with|higher|phosphate|rats|either (l_nmod) either_51\DT\1740|compared|with|groups (l_nmod) groups_54\NNS\2137|of|the|resistant (l_acl:relcl) resistant_57\JJ\1740|that|was|calcification|,|ie|rats (l_nmod) calcification_61\NN\13446390|to|warfarin-induced|artery
D010710_D061205 NONE phosphate_16\NN\15010703| (r_compound) levels_17\NNS\4916342|to|higher|serum|phosphate (r_nmod) related_12\JJ\1740|that|susceptibility|could|be|levels (l_nsubj) susceptibility_5\NN\13920835|increased|calcification (l_nmod) calcification_9\NN\13446390|to|warfarin-induced|artery
D014812_D061205 NONE k_5\NN\13608598| (r_compound) warfarin_7\NN\2718259|of|the|vitamin|k|antagonist (r_nmod) doses_1\NNS\3740161|high|warfarin (r_nsubjpass) known_10\VBN\2110220|doses|are|also|cause|,|but|times|. (l_xcomp) cause_12\VB\1617192|to|calcification (l_dobj) calcification_13\NN\13446390|media (l_nmod) media_17\NNS\3575240|of|the|artery (l_compound) artery_16\NN\5417975|
D002118_D061205 NONE calcium_27\NN\14625458|of|serum (r_nmod) elevation_24\NN\7445480|on|the|calcium (r_nmod) effect_17\NN\34213|the|dose|elevation|, (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_nmod) calcification_14\NN\13446390|on|artery
D002118_D061205 NONE calcium_27\NN\14625458|of|serum (r_nmod) elevation_24\NN\7445480|on|the|calcium (r_nmod) effect_17\NN\34213|the|dose|elevation|, (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_acl:relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D002118_D061205 NONE calcium_43\NN\14625458|on|serum (r_nmod) effect_40\NN\34213|through|its|calcium (r_nmod) induce_35\VB\1627355|that|d|may|calcification|effect (r_ccomp) suggests_30\VBZ\1010118|which|induce (r_acl:relcl) effect_7\NN\34213|between|the|dose|calcification|and|effect|suggests (l_nmod) calcification_14\NN\13446390|on|artery
D002118_D061205 NONE calcium_43\NN\14625458|on|serum (r_nmod) effect_40\NN\34213|through|its|calcium (r_nmod) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D002118_D002114 NONE calcium_11\NN\14625458|in|serum (r_nmod) elevation_8\NN\7445480|on|the|calcium|produced (r_nmod) effect_5\NN\34213|no|elevation (r_dobj) had_3\VBD\2108377|because|treatment|effect (r_advcl) explained_27\VBN\831651|had|,|synergy|is|probably|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity (l_dobj) activity_35\NN\30358|the|protein|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D015055_D061205 NONE gamma-carboxylated_34\JJ\1740|that|protein|was|indeed|not|. (r_ccomp) showed_25\VBD\2137132|analysis|gamma-carboxylated (r_conj) found_7\VBN\2426171|levels|are|sites|,|and|showed (l_nmod) sites_9\NNS\8673395|at|calcification|rats (l_nmod) calcification_12\NN\13446390|of|artery
D015055_D002114 NONE gamma-carboxyglutamate_6\NN\1740| (r_compound) residues_7\NNS\20827|the|gamma-carboxyglutamate|protein (r_nsubjpass) required_14\VBN\754942|although|residues|are|apparently|function (l_nmod) function_17\NN\13783581|for|its|inhibitor (l_nmod) inhibitor_21\NN\20090|as|a|calcification (l_compound) calcification_20\NN\13446390|
D015055_D002114 NONE gamma-carboxyglutamate_6\NN\1740| (r_compound) residues_7\NNS\20827|the|gamma-carboxyglutamate|protein (r_nsubjpass) required_14\VBN\754942|although|residues|are|apparently|function (r_advcl) required_26\VBN\754942|that|required|,|they|are|not|accumulation (l_nmod) accumulation_29\NN\13497135|for|its|sites (l_nmod) sites_32\NNS\8673395|at|calcification (l_compound) calcification_31\NN\13446390|
10791295
D001058_D010554 CID apomorphine-induced_2\JJ\1740| (r_amod) behavior_4\NN\407535|of|apomorphine-induced|aggressive
D001058_D010554 CID apomorphine-induced_3\JJ\1740| (r_amod) s.c._7\NN\1740|of|apomorphine-induced|mg/kg (r_nmod) development_1\NN\248977|the|s.c.|daily|)|behavior (l_nmod) behavior_12\NN\407535|aggressive|rats
D001058_D010554 CID apomorphine_5\NN\3786417| (r_compound) treatment_6\NN\654885|repeated|apomorphine (r_nsubj) induced_7\VBD\1627355|animals|,|treatment|development|evidenced|. (l_dobj) development_10\NN\248977|a|gradual|behavior (l_nmod) behavior_13\NN\407535|of|aggressive
D001058_D010554 CID apomorphine_5\NN\3786417| (r_compound) treatment_6\NN\654885|repeated|apomorphine (r_nsubj) induced_7\VBD\1627355|animals|,|treatment|development|evidenced|. (l_advcl) evidenced_15\VBN\1015244|as|intensity (l_nmod) intensity_19\NN\5090441|by|the|increased|aggressiveness|and|latency (l_nmod) aggressiveness_21\NN\4835724|of
D001058_D010554 CID apomorphine-induced_14\JJ\1740| (r_amod) behavior_16\NN\407535|of|the|apomorphine-induced|aggressive
18503483
D016559_D020968 CID tacrolimus-associated_2\JJ\1740| (r_amod) neuritis_4\NN\14336539|of|tacrolimus-associated|brachial
C107135_D020968 NONE everolimus_8\NN\1740|to (r_nmod) conversion_6\NN\7359599|after|everolimus|recipient|-- (r_nmod) recovery_0\NN\7357388|neuritis|conversion|report (l_nmod) neuritis_4\NN\14336539|of|tacrolimus-associated|brachial
3015567
D009599_D007022 CID nitroprusside-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|nitroprusside-induced
D009599_D007022 CID nitroprusside-induced_7\JJ\1740| (r_amod) hypotension_8\NN\14057371|to|nitroprusside-induced
D003345_D007022 NONE corticosterone_16\NN\14752057| (r_compound) level_17\NN\4916342|at|a|plasma|corticosterone|micrograms/dl (r_nmod) occurs_12\VBZ\2623529|level (r_conj) observed_10\VBN\2163746|suppression|is|and|occurs|. (l_nsubjpass) suppression_0\NN\13489037|secretion|response (l_nmod) response_5\NN\11410625|in|hypotension (l_nmod) hypotension_8\NN\14057371|to|nitroprusside-induced
17241784
D019821_D009135 CID statin_8\NN\3740161| (r_compound) therapy_9\NN\657604|with|statin (r_nmod) associated_6\VBN\628491|therapy (r_acl) myopathy_1\NN\14204950|progressive|up-regulation|associated|.
D019821_D009135 CID statins_0\NNS\3740161| (r_nsubj) cause_2\VB\1617192|statins|can|myopathy|. (l_dobj) myopathy_5\NN\14204950|a|necrotizing|and|hyperckaemia|reversible
D019821_D009135 CID statins_9\NNS\3740161| (r_nsubj) induce_11\VB\1627355|whereby|statins|may|myopathy (l_dobj) myopathy_13\NN\14204950|a|,|persists
D019821_D009135 CID statins_4\NNS\3740161| (r_nsubj) initiate_6\VB\1617192|that|statins|may|myopathy (l_dobj) myopathy_9\NN\14204950|an|immune-mediated|persists
D019821_D009135 CID statins_13\NNS\3740161|by (r_nmod) induction_11\NN\7450842|the|statins|response|up-regulation (r_dobj) involve_9\VB\2676054|may|induction (r_conj) uncertain_6\JJ\1740|mechanism|is|but|involve|. (l_nsubj) mechanism_1\NN\13446390|the|myopathy (l_nmod) myopathy_4\NN\14204950|of|this
D019821_-1 NONE statins_0\NNS\3740161| (r_nsubj) cause_2\VB\1617192|statins|can|myopathy|. (l_dobj) myopathy_5\NN\14204950|a|necrotizing|and|hyperckaemia|reversible (l_conj) hyperckaemia_7\NN\1740|
9245658
D009538_D002318 CID nicotine_3\NN\14712692|of (r_nmod) role_1\NN\719494|the|nicotine|disease|. (l_nmod) disease_7\NN\14061805|in|smoking-related|cardiovascular
D009538_D002318 CID nicotine_0\NN\14712692| (r_nsubj) activates_1\VBZ\1641914|nicotine|system|and|contribute|. (l_conj) contribute_11\VB\126264|way|could|disease (l_nmod) disease_14\NN\14061805|to|cardiovascular
D009538_D050197 CID nicotine_7\NN\14712692| (r_nsubj) play_9\VB\1072262|that|nicotine|could|role|accelerating (l_advcl) accelerating_13\VBG\226566|in|atherosclerosis (l_dobj) atherosclerosis_14\NN\14108324|
D009538_D013927 NONE nicotine_0\NN\14712692| (r_nsubj) appear_3\VB\2604760|nicotine|does|not|enhance|. (l_xcomp) enhance_5\VB\227165|to|thrombosis (l_dobj) thrombosis_6\NN\14100769|humans
2578334
D001374_D011230 CID 5-azacytidine_0\NN\1740| (r_nsubj) potentiates_1\VBZ\229605|5-azacytidine|initiation|. (l_dobj) initiation_2\NN\7450842|induced (l_acl) induced_3\VBN\1627355|carcinogens (l_nmod) carcinogens_5\NNS\20090|by|liver
D001374_D011230 CID 5-azacytidine_22\NN\1740|5-azc|,|inhibitor|, (r_nsubjpass) given_38\VBN\2327200|test|,|5-azacytidine|was|rats|phase|. (l_advcl) test_1\VB\670261|to|validity (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_acl) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic
D001374_D011230 CID 5-azc_24\NN\1740|(|)|mg/kg (r_appos) 5-azacytidine_22\NN\1740|5-azc|,|inhibitor|, (r_nsubjpass) given_38\VBN\2327200|test|,|5-azacytidine|was|rats|phase|. (l_advcl) test_1\VB\670261|to|validity (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_acl) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic
D001564_D011230 CID benzo[a]-pyrene_53\NN\1740|mg/kg|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_appos) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) given_38\VBN\2327200|test|,|5-azacytidine|was|rats|phase|. (l_advcl) test_1\VB\670261|to|validity (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_acl) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic
D008770_D011230 CID n-methyl-n-nitrosourea_59\NN\1740|mg/kg (r_conj) benzo[a]-pyrene_53\NN\1740|mg/kg|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_appos) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) given_38\VBN\2327200|test|,|5-azacytidine|was|rats|phase|. (l_advcl) test_1\VB\670261|to|validity (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_acl) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic
D019813_D011230 CID 1,2-dimethylhydrazine_65\NN\1740|1,2-dmh|mg/kg (r_conj) benzo[a]-pyrene_53\NN\1740|mg/kg|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_appos) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) given_38\VBN\2327200|test|,|5-azacytidine|was|rats|phase|. (l_advcl) test_1\VB\670261|to|validity (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_acl) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic
D019813_D011230 CID 1,2-dmh_67\NN\1740|(|) (r_appos) 1,2-dimethylhydrazine_65\NN\1740|1,2-dmh|mg/kg (r_conj) benzo[a]-pyrene_53\NN\1740|mg/kg|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_appos) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) given_38\VBN\2327200|test|,|5-azacytidine|was|rats|phase|. (l_advcl) test_1\VB\670261|to|validity (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_acl) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic
15899738
D003401_D001281 CID creatine_5\NN\14601829| (r_compound) monohydrate_6\NN\14910440|creatine (r_compound) supplementation_7\NN\5108947|with|monohydrate (r_nmod) associated_3\VBN\628491|supplementation (r_acl) fibrillation_2\NN\14361664|lone|atrial|associated|.
D003401_D001145 NONE creatine_5\NN\14601829| (r_dobj) linked_4\VBN\628491|reports|have|creatine|development|. (l_nmod) development_8\NN\248977|to|the|arrhythmia (l_nmod) arrhythmia_10\NN\14103288|of
12907309
C121465_D020258 NONE mpep_3\NN\1740|of|,|antagonist|, (r_nmod) action_1\NN\30358|neuroprotective|mpep|neurotoxicity (l_nmod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic
C121465_D005334 NONE mpep_3\NN\1740|of|,|antagonist|, (r_nmod) action_1\NN\30358|neuroprotective|mpep|neurotoxicity (r_nsubjpass) associated_15\VBN\628491|action|is|decrease|. (l_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (l_conj) inhibition_23\NN\1068773|hyperthermia|rats (l_nmod) hyperthermia_25\NN\14034177|of
C121465_D005334 NONE mpep_3\NN\1740|by (r_nmod) rendered_1\VBN\120316|mpep (r_acl) neuroprotection_0\NN\1740|rendered (r_nsubjpass) associated_6\VBN\628491|neuroprotection|may|be|reduction|. (l_nmod) reduction_9\NN\351485|with|the|efflux|blockade|,|and|decrease (l_conj) decrease_29\NN\7296428|with|a|hyperthermia (l_nmod) hyperthermia_31\NN\14034177|in
D008694_D020258 NONE methamphetamine-induced_11\JJ\1740| (r_amod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic
D008694_D005334 CID methamphetamine-induced_11\JJ\1740| (r_amod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic (r_nmod) action_1\NN\30358|neuroprotective|mpep|neurotoxicity (r_nsubjpass) associated_15\VBN\628491|action|is|decrease|. (l_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (l_conj) inhibition_23\NN\1068773|hyperthermia|rats (l_nmod) hyperthermia_25\NN\14034177|of
D008694_D005334 CID methamphetamine_6\NN\2704153|sc)-induced (r_compound) hyperthermia_11\NN\14034177|the|methamphetamine
D008694_D005334 CID methamphetamine-induced_12\JJ\1740| (r_amod) efflux_14\NN\13482330|of|the|methamphetamine-induced|dopamine|striatum (r_nmod) reduction_9\NN\351485|with|the|efflux|blockade|,|and|decrease (l_conj) decrease_29\NN\7296428|with|a|hyperthermia (l_nmod) hyperthermia_31\NN\14034177|in
D004298_D020258 NONE dopamine_20\NN\14807737| (r_compound) outflow_21\NN\7407777|in|dopamine (r_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (r_nmod) associated_15\VBN\628491|action|is|decrease|. (l_nsubjpass) action_1\NN\30358|neuroprotective|mpep|neurotoxicity (l_nmod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic
D004298_D005334 NONE dopamine_20\NN\14807737| (r_compound) outflow_21\NN\7407777|in|dopamine (r_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (l_conj) inhibition_23\NN\1068773|hyperthermia|rats (l_nmod) hyperthermia_25\NN\14034177|of
D004298_D005334 NONE dopamine_13\NN\14807737| (r_compound) efflux_14\NN\13482330|of|the|methamphetamine-induced|dopamine|striatum (r_nmod) reduction_9\NN\351485|with|the|efflux|blockade|,|and|decrease (l_conj) decrease_29\NN\7296428|with|a|hyperthermia (l_nmod) hyperthermia_31\NN\14034177|in
C121465_D064420 NONE mpep_12\NN\1740|by (r_nmod) blockade_8\NN\952963|the|mglur5|mpep (r_nsubj) protect_14\VB\1127795|that|blockade|may|neurones|toxicity (l_nmod) toxicity_19\NN\13576101|against|methamphetamine-induced
D008694_D064420 NONE methamphetamine-induced_18\JJ\1740| (r_amod) toxicity_19\NN\13576101|against|methamphetamine-induced
15632880
D013148_D051437 CID spironolactone-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|spironolactone-induced|renal|and|hyperkalemia|patients|.
D013148_D051437 CID spironolactone_11\NN\2721160|of (r_nmod) use_9\NN\407535|the|spironolactone|patients (r_dobj) evaluating_7\VBG\670261|use (r_acl) trial_6\NN\786195|a|previous|randomized|controlled|evaluating (r_nsubj) reported_16\VBD\831651|trial|risk (l_dobj) risk_19\NN\14541044|a|low|hyperkalemia (l_nmod) hyperkalemia_21\NN\14299637|of|%|and|insufficiency (l_conj) insufficiency_28\NN\14462946|renal|%
D013148_D051437 CID spironolactone_21\NN\2721160|with (r_nmod) treated_19\VBN\2376958|spironolactone (r_acl) patients_18\NNS\9898892|in|heart|failure|treated (r_nmod) prevalence_6\NN\4764412|the|and|associations|hyperkalemia|patients (l_nmod) hyperkalemia_11\NN\14299637|of|and|insufficiency (l_conj) insufficiency_14\NN\14462946|renal
D013148_D051437 CID spironolactone_13\NN\2721160|of (r_nmod) discontinuation_11\NN\209943|spironolactone (r_dobj) required_10\VBD\754942|sixty-seven|discontinuation|hyperkalemia|. (l_nmod) hyperkalemia_16\NN\14299637|due|=|or|failure (l_conj) failure_24\NN\66216|renal|=
D013148_D051437 CID spironolactone-induced_2\JJ\1740| (r_amod) hyperkalemia_3\NN\14299637|spironolactone-induced|and|insufficiency (l_conj) insufficiency_6\NN\14462946|renal
D013148_D006947 CID spironolactone-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|spironolactone-induced|renal|and|hyperkalemia|patients|. (l_conj) hyperkalemia_4\NN\14299637|
D013148_D006947 CID spironolactone_11\NN\2721160|of (r_nmod) use_9\NN\407535|the|spironolactone|patients (r_dobj) evaluating_7\VBG\670261|use (r_acl) trial_6\NN\786195|a|previous|randomized|controlled|evaluating (r_nsubj) reported_16\VBD\831651|trial|risk (l_dobj) risk_19\NN\14541044|a|low|hyperkalemia (l_nmod) hyperkalemia_21\NN\14299637|of|%|and|insufficiency
D013148_D006947 CID spironolactone_21\NN\2721160|with (r_nmod) treated_19\VBN\2376958|spironolactone (r_acl) patients_18\NNS\9898892|in|heart|failure|treated (r_nmod) prevalence_6\NN\4764412|the|and|associations|hyperkalemia|patients (l_nmod) hyperkalemia_11\NN\14299637|of|and|insufficiency
D013148_D006947 CID spironolactone_13\NN\2721160|of (r_nmod) discontinuation_11\NN\209943|spironolactone (r_dobj) required_10\VBD\754942|sixty-seven|discontinuation|hyperkalemia|. (l_nmod) hyperkalemia_16\NN\14299637|due|=|or|failure
D013148_D006947 CID spironolactone-induced_2\JJ\1740| (r_amod) hyperkalemia_3\NN\14299637|spironolactone-induced|and|insufficiency
D013148_D006333 NONE spironolactone-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|spironolactone-induced|renal|and|hyperkalemia|patients|. (l_nmod) patients_6\NNS\9898892|in|failure (l_nmod) failure_9\NN\66216|with|heart
D013148_D006333 NONE spironolactone_11\NN\2721160|of (r_nmod) use_9\NN\407535|the|spironolactone|patients (l_nmod) patients_15\NNS\9898892|in|heart|failure (l_compound) failure_14\NN\66216|
D013148_D006333 NONE spironolactone_11\NN\2721160|of (r_nmod) benefits_9\NNS\13278375|the|spironolactone (r_nsubjpass) reported_13\VBN\831651|since|benefits|were (r_advcl) changed_6\VBN\46534|because|treatments|have|reported (l_nsubj) treatments_1\NNS\654885|failure (l_nmod) failure_4\NN\66216|for|heart
D013148_D006333 NONE spironolactone_21\NN\2721160|with (r_nmod) treated_19\VBN\2376958|spironolactone (r_acl) patients_18\NNS\9898892|in|heart|failure|treated (l_compound) failure_17\NN\66216|
D013148_D006333 NONE spironolactone_14\NN\2721160|with (r_nmod) treated_12\VBN\2376958|spironolactone|practice (r_acl) patients_11\NNS\9898892|of|failure|treated (l_compound) failure_10\NN\66216|heart
D011188_D006947 NONE k(+_7\NN\1740|(|)|meq/l|) (r_appos) hyperkalemia_5\NN\14299637|k(+|or|insufficiency
D011188_D006947 NONE potassium_17\NN\14625458| (r_compound) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\14299637|
D011188_D006947 NONE potassium_22\NN\14625458| (r_compound) doses_24\NNS\3740161|lower|baseline|potassium|supplement (r_conj) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\14299637|
D011188_D051437 NONE k(+_7\NN\1740|(|)|meq/l|) (r_appos) hyperkalemia_5\NN\14299637|k(+|or|insufficiency (l_conj) insufficiency_15\NN\14462946|renal|cr
D002857_D006947 NONE cr_17\NN\14625458|(|>|mg/dl|) (r_dep) insufficiency_15\NN\14462946|renal|cr (r_conj) hyperkalemia_5\NN\14299637|k(+|or|insufficiency
D002857_D051437 NONE cr_17\NN\14625458|(|>|mg/dl|) (r_dep) insufficiency_15\NN\14462946|renal|cr
D011188_D003920 NONE potassium_17\NN\14625458| (r_compound) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_conj) likely_8\JJ\1740|more|have (l_xcomp) have_10\VB\2108377|to|diabetes (l_dobj) diabetes_11\NN\14075199|
D011188_D003920 NONE potassium_22\NN\14625458| (r_compound) doses_24\NNS\3740161|lower|baseline|potassium|supplement (r_conj) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_conj) likely_8\JJ\1740|more|have (l_xcomp) have_10\VB\2108377|to|diabetes (l_dobj) diabetes_11\NN\14075199|
D003404_D051437 NONE creatinine_14\NN\1740|higher|baseline|serum (r_conj) weight_9\NN\5009170|lower|baseline|body|and|creatinine (r_dobj) had_5\VBD\2108377|patients|weight|,|required|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|insufficiency (l_dobj) insufficiency_4\NN\14462946|renal
D049971_D051437 NONE thiazide_31\NN\3214670| (r_compound) diuretics_32\NNS\3247620|with|thiazide (r_nmod) treated_29\VBN\2376958|to|be|diuretics|controls (r_xcomp) likely_26\JJ\1740|were|more|treated (r_conj) required_16\VBD\754942|doses|,|and|likely (r_conj) had_5\VBD\2108377|patients|weight|,|required|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|insufficiency (l_dobj) insufficiency_4\NN\14462946|renal
8437969
D002927_D054138 CID cimetidine_5\NN\14778019|with|continuous-infusion (r_nmod) associated_2\VBN\628491|cimetidine (r_acl) arrest_1\NN\88481|sinus|associated|.
D002927_D054138 CID cimetidine_23\NN\14778019|continuous-infusion|mg/hour (r_dobj) receiving_21\VBG\2210855|while|cimetidine (r_advcl) developed_11\VBD\1753788|man|episodes|receiving|. (l_dobj) episodes_15\NNS\7283608|recurrent|,|brief|arrest (l_nmod) arrest_19\NN\88481|of|apparent|sinus
D002927_D054138 CID cimetidine_12\NN\14778019|with|continuous-infusion (r_nmod) associated_9\VBN\628491|cimetidine (r_acl) arrest_8\NN\88481|of|sinus|associated
D002927_D001919 CID cimetidine_7\NN\14778019|of (r_nmod) infusions_5\NNS\14589223|of|intermittent|intravenous|cimetidine (r_nmod) administration_1\NN\1133281|the|infusions (r_nsubjpass) associated_10\VBN\628491|administration|is|infrequently|development|. (l_nmod) development_13\NN\248977|with|the|bradyarrhythmias (l_nmod) bradyarrhythmias_15\NNS\1740|of
D002927_D007938 NONE cimetidine_23\NN\14778019|continuous-infusion|mg/hour (r_dobj) receiving_21\VBG\2210855|while|cimetidine (r_advcl) developed_11\VBD\1753788|man|episodes|receiving|. (l_nsubj) man_2\NN\9605289|a|40-year-old|leukemia|and|history (l_nmod) leukemia_4\NN\14239918|with
D002927_D006331 NONE cimetidine_23\NN\14778019|continuous-infusion|mg/hour (r_dobj) receiving_21\VBG\2210855|while|cimetidine (r_advcl) developed_11\VBD\1753788|man|episodes|receiving|. (l_nsubj) man_2\NN\9605289|a|40-year-old|leukemia|and|history (l_conj) history_7\NN\15120823|no|disease (l_nmod) disease_10\NN\14061805|of|cardiac
D002927_D001145 NONE cimetidine_6\NN\14778019| (r_compound) administration_7\NN\1133281|to|cimetidine (r_nmod) related_4\JJ\1740|arrhythmias|were|temporally|administration|,|disappeared|. (l_nsubj) arrhythmias_1\NNS\14103288|the
D011899_D001145 NONE ranitidine_18\NN\14778019| (r_compound) treatment_19\NN\654885|during|ranitidine (r_nmod) recur_16\VB\339934|did|not|treatment (r_conj) disappeared_9\VBD\2609764|dechallenge|,|and|recur (r_conj) related_4\JJ\1740|arrhythmias|were|temporally|administration|,|disappeared|. (l_nsubj) arrhythmias_1\NNS\14103288|the
3827439
D000666_D058186 CID amphotericin_6\NN\2716866|from (r_nmod) failure_4\NN\66216|recurrent|reversible|acute|renal|amphotericin|.
D000666_D058186 CID b_18\NN\1355326|of|amphotericin (r_nmod) administration_15\NN\1133281|immediately|following|the|b|occasions (r_nmod) developed_8\VBD\1753788|patient|failure|administration|. (l_dobj) failure_11\NN\66216|acute|renal
D000666_D058186 CID amphotericin_3\NN\2716866|, (r_nsubj) activate_15\VB\1641914|that|amphotericin|setting|,|may|feedback|,|contributing (l_advcl) contributing_20\VBG\126264|thereby|failure (l_nmod) failure_24\NN\66216|to|acute|renal
D000666_D005355 NONE b_18\NN\1355326|of|amphotericin (r_nmod) administration_15\NN\1133281|immediately|following|the|b|occasions (r_nmod) developed_8\VBD\1753788|patient|failure|administration|. (l_nsubj) patient_1\NN\9898892|a|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|with|cryptogenic|and|sporotrichosis
D000666_D013174 NONE b_18\NN\1355326|of|amphotericin (r_nmod) administration_15\NN\1133281|immediately|following|the|b|occasions (r_nmod) developed_8\VBD\1753788|patient|failure|administration|. (l_nsubj) patient_1\NN\9898892|a|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|with|cryptogenic|and|sporotrichosis (l_conj) sporotrichosis_7\NN\14176895|disseminated
17042910
C065179_D006973 NONE atorvastatin_3\NN\3676175|of (r_nmod) effects_1\NNS\13245626|anti-oxidant|atorvastatin|hypertension|. (l_nmod) hypertension_6\NN\14057371|in|dexamethasone-induced|rat
C065179_D006973 NONE atorvastatin_0\NN\3676175|ato (r_nsubj) possesses_4\VBZ\2630189|atorvastatin|properties|. (l_dobj) properties_6\NNS\32613|pleiotropic|reported (l_acl:relcl) reported_10\VBN\831651|that|have|been|improve (l_xcomp) improve_12\VB\126264|to|function|availability (l_nmod) availability_17\NN\4718563|through|increased|no|and|o2-|production (l_dep) production_23\NN\30358|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
C065179_D006973 NONE ato_2\NN\1740|(|) (r_appos) atorvastatin_0\NN\3676175|ato (r_nsubj) possesses_4\VBZ\2630189|atorvastatin|properties|. (l_dobj) properties_6\NNS\32613|pleiotropic|reported (l_acl:relcl) reported_10\VBN\831651|that|have|been|improve (l_xcomp) improve_12\VB\126264|to|function|availability (l_nmod) availability_17\NN\4718563|through|increased|no|and|o2-|production (l_dep) production_23\NN\30358|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
D003907_D006973 CID dexamethasone-induced_5\JJ\1740| (r_amod) hypertension_6\NN\14057371|in|dexamethasone-induced|rat
D003907_D006973 CID dexamethasone_2\NN\2721538| (r_compound) (dex)-induced_3\NN\1740|dexamethasone (r_compound) hypertension_4\NN\14057371|(dex)-induced
D003907_D006973 CID (dex)-induced_3\NN\1740|dexamethasone (r_compound) hypertension_4\NN\14057371|(dex)-induced
D009569_D006973 NONE oxide_13\NN\14818238|nitric|no (r_compound) deficiency_17\NN\14449126|with|oxide|and|production (r_nmod) associated_10\VBN\628491|deficiency (r_acl) dysfunction_9\NN\14204950|by|endothelial|associated (r_nmod) characterized_6\VBN\609683|1|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D009569_D006973 NONE no_15\NN\7204911|(|) (r_appos) oxide_13\NN\14818238|nitric|no (r_compound) deficiency_17\NN\14449126|with|oxide|and|production (r_nmod) associated_10\VBN\628491|deficiency (r_acl) dysfunction_9\NN\14204950|by|endothelial|associated (r_nmod) characterized_6\VBN\609683|1|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D009569_D006973 NONE no_19\NN\7204911|of (r_nmod) availability_17\NN\4718563|through|increased|no|and|o2-|production (l_dep) production_23\NN\30358|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
D013481_D006973 NONE superoxide_20\NN\14971519|o2- (r_compound) production_24\NN\30358|increased|superoxide (r_conj) deficiency_17\NN\14449126|with|oxide|and|production (r_nmod) associated_10\VBN\628491|deficiency (r_acl) dysfunction_9\NN\14204950|by|endothelial|associated (r_nmod) characterized_6\VBN\609683|1|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D013481_D006973 NONE o2-_22\NN\1740|(|) (r_appos) superoxide_20\NN\14971519|o2- (r_compound) production_24\NN\30358|increased|superoxide (r_conj) deficiency_17\NN\14449126|with|oxide|and|production (r_nmod) associated_10\VBN\628491|deficiency (r_acl) dysfunction_9\NN\14204950|by|endothelial|associated (r_nmod) characterized_6\VBN\609683|1|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D013481_D006973 NONE o2-_22\NN\1740|reduced (r_conj) availability_17\NN\4718563|through|increased|no|and|o2-|production (l_dep) production_23\NN\30358|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
354896
D008012_D006323 CID lidocaine-induced_0\JJ\1740| (r_nummod) asystole_2\NN\14204950|lidocaine-induced|cardiac|.
D008012_D003866 NONE lidocaine_8\NN\3681148|of (r_nmod) bolus_6\NN\13899404|of|a|single|50-mg|lidocaine (r_nmod) administration_1\NN\1133281|intravenous|bolus|man (r_nsubj) resulted_13\VBD\2633881|administration|depression|. (l_nmod) depression_16\NN\14373582|in|profound|activity
D008012_D001919 NONE lidocaine_29\NN\3681148|to (r_nmod) idiosyncrasy_27\NN\4763925|a|true|lidocaine (r_dobj) represented_24\VBD\2664769|,|this|probably|idiosyncrasy|. (r_conj) had_2\VBD\2108377|patient|conditions|;|and|,|thus|represented (l_dobj) conditions_6\NNS\14512817|no|apparent|associated|predisposed (l_acl:relcl) predisposed_10\VBN\680841|which|might|have|him|development (l_nmod) development_14\NN\248977|to|the|bradyarrhythmias (l_nmod) bradyarrhythmias_16\NNS\1740|of
10520387
D004809_D007022 NONE ephedrine_11\NN\14712692|of (r_nmod) doses_9\NNS\3740161|different|ephedrine (r_dobj) adding_7\VBG\156601|of|doses|propofol|obtund (l_advcl) obtund_17\VB\192051|order|to|response (l_dobj) response_20\NN\11410625|the|hypotensive (l_amod) hypotensive_19\JJ\1740|
D004809_D007022 NONE ephedrine_3\NN\14712692|of (r_nmod) addition_1\NN\3081021|the|ephedrine|propofol (r_nsubj) appears_6\VBZ\2604760|addition|method|. (l_xcomp) method_11\NN\5616786|to|be|an|effective|obtunding (l_advcl) obtunding_13\VBG\192051|of|response|doses (l_dobj) response_16\NN\11410625|the|hypotensive|propofol (l_amod) hypotensive_15\JJ\1740|
D015742_D007022 CID propofol_13\NN\1740|to (r_nmod) adding_7\VBG\156601|of|doses|propofol|obtund (l_advcl) obtund_17\VB\192051|order|to|response (l_dobj) response_20\NN\11410625|the|hypotensive (l_amod) hypotensive_19\JJ\1740|
D015742_D007022 CID propofol_5\NN\1740|to (r_nmod) addition_1\NN\3081021|the|ephedrine|propofol (r_nsubj) appears_6\VBZ\2604760|addition|method|. (l_xcomp) method_11\NN\5616786|to|be|an|effective|obtunding (l_advcl) obtunding_13\VBG\192051|of|response|doses (l_dobj) response_16\NN\11410625|the|hypotensive|propofol (l_amod) hypotensive_15\JJ\1740|
D015742_D007022 CID propofol_18\NN\1740|to (r_nmod) response_16\NN\11410625|the|hypotensive|propofol (l_amod) hypotensive_15\JJ\1740|
D004809_D013610 CID ephedrine_9\NN\14712692|of (r_nmod) use_7\NN\407535|with|the|ephedrine|combination (r_nmod) associated_4\VBN\628491|use (r_acl) tachycardia_3\NN\14110674|marked|associated
D004809_D013610 CID ephedrine/propofol/mixtures_24\NN\1740|the (r_nsubj) studied_25\VBN\630380|of|ephedrine/propofol/mixtures (r_advcl) any_21\DT\1740|of|studied (r_nmod) use_16\NN\407535|the|patients|any (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|inducing (l_acl) inducing_7\VBG\1627355|of|tachycardia|ischemia (l_nsubj) tachycardia_6\NN\14110674|this
D015742_D013610 CID propofol_13\NN\1740|with (r_nmod) combination_11\NN\7951464|in|propofol (r_nmod) use_7\NN\407535|with|the|ephedrine|combination (r_nmod) associated_4\VBN\628491|use (r_acl) tachycardia_3\NN\14110674|marked|associated
D015742_D013610 CID ephedrine/propofol/mixtures_24\NN\1740|the (r_nsubj) studied_25\VBN\630380|of|ephedrine/propofol/mixtures (r_advcl) any_21\DT\1740|of|studied (r_nmod) use_16\NN\407535|the|patients|any (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|inducing (l_acl) inducing_7\VBG\1627355|of|tachycardia|ischemia (l_nsubj) tachycardia_6\NN\14110674|this
D004809_D017202 NONE ephedrine/propofol/mixtures_24\NN\1740|the (r_nsubj) studied_25\VBN\630380|of|ephedrine/propofol/mixtures (r_advcl) any_21\DT\1740|of|studied (r_nmod) use_16\NN\407535|the|patients|any (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|inducing (l_acl) inducing_7\VBG\1627355|of|tachycardia|ischemia (l_dobj) ischemia_9\NN\14195315|myocardial
D015742_D017202 NONE ephedrine/propofol/mixtures_24\NN\1740|the (r_nsubj) studied_25\VBN\630380|of|ephedrine/propofol/mixtures (r_advcl) any_21\DT\1740|of|studied (r_nmod) use_16\NN\407535|the|patients|any (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|inducing (l_acl) inducing_7\VBG\1627355|of|tachycardia|ischemia (l_dobj) ischemia_9\NN\14195315|myocardial
7265370
D014223_D053040 CID triamterene_0\NN\1740| (r_compound) nephrolithiasis_1\NN\14115914|triamterene|complicating|.
D014223_D053040 CID triamterene_3\NN\1740| (r_compound) nephrolithiasis_4\NN\14115914|of|triamterene
D014223_D053040 CID triamterene_2\NN\1740| (r_compound) nephrolithiasis_3\NN\14115914|triamterene
C020743_D053040 NONE dyazide_3\NN\1740| (r_compound) therapy_4\NN\657604|dyazide (r_dobj) complicating_2\VBG\126264|therapy (r_acl) nephrolithiasis_1\NN\14115914|triamterene|complicating|.
C020743_D053040 NONE hydrochlorothiazide-triamterene_14\NN\1740| (r_compound) therapy_15\NN\657604|of|hydrochlorothiazide-triamterene|hypertension (r_nmod) years_12\NNS\15144371|after|4|therapy (r_nmod) man_9\NN\9605289|in|a|years (r_nmod) reported_6\VBN\831651|case|is|man|. (l_nsubjpass) case_1\NN\7283608|a|nephrolithiasis (l_nmod) nephrolithiasis_4\NN\14115914|of|triamterene
D014223_D006973 NONE triamterene_3\NN\1740| (r_compound) nephrolithiasis_4\NN\14115914|of|triamterene (r_nmod) case_1\NN\7283608|a|nephrolithiasis (r_nsubjpass) reported_6\VBN\831651|case|is|man|. (l_nmod) man_9\NN\9605289|in|a|years (l_nmod) years_12\NNS\15144371|after|4|therapy (l_nmod) therapy_15\NN\657604|of|hydrochlorothiazide-triamterene|hypertension (l_nmod) hypertension_17\NN\14057371|for
C020743_D006973 NONE hydrochlorothiazide-triamterene_14\NN\1740| (r_compound) therapy_15\NN\657604|of|hydrochlorothiazide-triamterene|hypertension (l_nmod) hypertension_17\NN\14057371|for
18208574
D006493_D013927 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|with|heparin-induced (r_nmod) patients_10\NNS\9898892|in|thrombocytopenia (r_nmod) thrombosis_8\NN\14100769|patients
D006493_D013927 CID heparin-induced_12\JJ\1740| (r_amod) assay_18\NN\5733583|of|a|two-step|heparin-induced|thrombocytopenia|hit|antigen (r_nmod) density_5\NN\4941325|optical|and|inhibition|assay (r_dobj) correlate_3\VB\2657219|to|density|thrombosis|;|utilizes (l_nmod) thrombosis_20\NN\14100769|with
D006493_D013927 CID heparin_31\NN\2718259| (r_compound) concentration_32\NN\4916342|of|a|high|heparin (r_nmod) characteristics_27\NNS\5849040|reaction|inhibition|concentration (r_dobj) utilizes_24\VBZ\161225|assay|characteristics (r_parataxis) correlate_3\VB\2657219|to|density|thrombosis|;|utilizes (l_nmod) thrombosis_20\NN\14100769|with
D006493_D013921 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|with|heparin-induced
D006493_D013921 CID heparin-induced_12\JJ\1740| (r_amod) assay_18\NN\5733583|of|a|two-step|heparin-induced|thrombocytopenia|hit|antigen (l_compound) thrombocytopenia_13\NN\14189204|
D006493_D013921 CID heparin-induced_12\JJ\1740| (r_amod) assay_18\NN\5733583|of|a|two-step|heparin-induced|thrombocytopenia|hit|antigen (l_compound) hit_15\NN\36762|(|)
D006493_D013921 CID heparin_31\NN\2718259| (r_compound) concentration_32\NN\4916342|of|a|high|heparin (r_nmod) characteristics_27\NNS\5849040|reaction|inhibition|concentration (r_dobj) utilizes_24\VBZ\161225|assay|characteristics (r_parataxis) correlate_3\VB\2657219|to|density|thrombosis|;|utilizes (l_dobj) density_5\NN\4941325|optical|and|inhibition|assay (l_nmod) assay_18\NN\5733583|of|a|two-step|heparin-induced|thrombocytopenia|hit|antigen (l_compound) thrombocytopenia_13\NN\14189204|
D006493_D013921 CID heparin_31\NN\2718259| (r_compound) concentration_32\NN\4916342|of|a|high|heparin (r_nmod) characteristics_27\NNS\5849040|reaction|inhibition|concentration (r_dobj) utilizes_24\VBZ\161225|assay|characteristics (r_parataxis) correlate_3\VB\2657219|to|density|thrombosis|;|utilizes (l_dobj) density_5\NN\4941325|optical|and|inhibition|assay (l_nmod) assay_18\NN\5733583|of|a|two-step|heparin-induced|thrombocytopenia|hit|antigen (l_compound) hit_15\NN\36762|(|)
D006493_D013921 CID heparin_25\NN\2718259|to (r_nmod) exposure_23\NN\5042871|after|heparin (r_nmod) patients_4\NNS\9898892|decrease|exposure|,|had (l_nmod) decrease_10\NN\7296428|with|%|count|or|thrombocytopenia (l_conj) thrombocytopenia_15\NN\14189204|150
D006493_D013921 CID heparin_50\NN\2718259|of (r_nmod) concentration_48\NN\4916342|with|high|heparin (r_nmod) inhibition_45\NN\1068773|50|concentration (r_conj) density_36\NN\4941325|optical|od|0.4|and|inhibition|] (r_nsubjpass) included_53\VBN\690614|patients|density|were|study|. (l_nsubjpass) patients_4\NNS\9898892|decrease|exposure|,|had (l_nmod) decrease_10\NN\7296428|with|%|count|or|thrombocytopenia (l_conj) thrombocytopenia_15\NN\14189204|150
1987816
D008094_D011141 CID lithium-induced_0\JJ\1740| (r_amod) polyuria_1\NN\14113228|lithium-induced
11379838
D000928_D001714 CID antidepressant-induced_0\JJ\1740| (r_amod) mania_1\NN\9180259|antidepressant-induced|patients|:|identification
D000928_D001714 CID antidepressant-induced_0\JJ\1740| (r_amod) mania_1\NN\9180259|antidepressant-induced|patients|:|identification (l_nmod) patients_4\NNS\9898892|in|bipolar (l_amod) bipolar_3\JJ\1740|
D000928_D001714 CID antidepressants_12\NNS\3740161|with (r_nmod) associated_10\VBN\628491|antidepressants (r_acl) mania_9\NN\9180259|to|associated
D000928_D001714 CID antidepressants_12\NNS\3740161|with (r_nmod) associated_10\VBN\628491|antidepressants (r_acl) mania_9\NN\9180259|to|associated (r_nmod) switching_7\VBG\138508|of|mania (r_acl) risks_5\NNS\14541044|about|possible|switching (r_nmod) concerns_2\NNS\5682950|risks (r_nsubj) continue_13\VBP\2367363|concerns|interfere|. (l_xcomp) interfere_15\VB\2451370|to|establishment (l_nmod) establishment_18\NN\235435|with|the|paradigm (l_nmod) paradigm_23\NN\13803782|of|an|optimal|treatment|depression (l_nmod) depression_26\NN\14373582|for|bipolar
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant|used (r_nmod) type_39\NN\5839024|therapy (r_conj) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant|used (r_nmod) type_39\NN\5839024|therapy (r_conj) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant|used (r_nmod) type_39\NN\5839024|therapy (r_conj) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_nummod) i_27\CD\14622893|
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant|used (r_nmod) type_39\NN\5839024|therapy (r_conj) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) bipolar_29\NNP\1740|ii|) (l_nummod) ii_30\CD\13741022|
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant|used (r_nmod) type_39\NN\5839024|therapy (r_conj) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic (l_amod) manic_36\JJ\1740|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_nummod) i_27\CD\14622893|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) bipolar_29\NNP\1740|ii|) (l_nummod) ii_30\CD\13741022|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic (l_amod) manic_36\JJ\1740|
D017367_D001714 CID inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D017367_D001714 CID inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D017367_D001714 CID inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_nummod) i_27\CD\14622893|
D017367_D001714 CID inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) bipolar_29\NNP\1740|ii|) (l_nummod) ii_30\CD\13741022|
D017367_D001714 CID inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic (l_amod) manic_36\JJ\1740|
D017367_D001714 CID ssris_60\NNS\2718811|[|] (r_appos) inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D017367_D001714 CID ssris_60\NNS\2718811|[|] (r_appos) inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (r_dep) diagnosis_23\NN\152018|bipolar (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D017367_D001714 CID ssris_60\NNS\2718811|[|] (r_appos) inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_nummod) i_27\CD\14622893|
D017367_D001714 CID ssris_60\NNS\2718811|[|] (r_appos) inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) bipolar_29\NNP\1740|ii|) (l_nummod) ii_30\CD\13741022|
D017367_D001714 CID ssris_60\NNS\2718811|[|] (r_appos) inhibitors_58\NNS\20090|selective|serotonin|reuptake|ssris (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|particularly|,|inhibitors|) (r_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic (l_amod) manic_36\JJ\1740|
D017367_D001714 CID ssris_31\NNS\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients|[|8/33|) (r_nmod) %_23\NN\1740|in|24|subgroup (r_conj) occurred_7\VBD\2623529|switches|%|(|and|%|;|experienced|. (l_nsubj) switches_2\NNS\3096960|hypomania (l_nmod) hypomania_4\NN\1740|to|or|mania
D017367_D001714 CID ssris_31\NNS\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients|[|8/33|) (r_nmod) %_23\NN\1740|in|24|subgroup (r_conj) occurred_7\VBD\2623529|switches|%|(|and|%|;|experienced|. (l_nsubj) switches_2\NNS\3096960|hypomania (l_nmod) hypomania_4\NN\1740|to|or|mania (l_conj) mania_6\NN\9180259|
D017367_D001714 CID ssris_31\NNS\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients|[|8/33|) (r_nmod) %_23\NN\1740|in|24|subgroup (r_conj) occurred_7\VBD\2623529|switches|%|(|and|%|;|experienced|. (l_conj) experienced_44\VBD\2108377|%|episodes|,|and|experienced (l_dobj) episodes_46\NNS\7283608|manic (l_amod) manic_45\JJ\1740|
D017367_D001714 CID ssris_31\NNS\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients|[|8/33|) (r_nmod) %_23\NN\1740|in|24|subgroup (r_conj) occurred_7\VBD\2623529|switches|%|(|and|%|;|experienced|. (l_conj) experienced_44\VBD\2108377|%|episodes|,|and|experienced (l_conj) experienced_56\VBD\2108377|%|episodes (l_dobj) episodes_58\NNS\7283608|hypomanic (l_amod) hypomanic_57\JJ\1740|
D008094_D001714 NONE lithium_71\NN\14625458|(|vs.|anticonvulsants|) (r_dep) use_64\NN\407535|and|type|stabilizers|lithium (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D008094_D001714 NONE lithium_71\NN\14625458|(|vs.|anticonvulsants|) (r_dep) use_64\NN\407535|and|type|stabilizers|lithium (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (r_nmod) variables_17\NNS\2452|on|several|age (r_nmod) compared_9\VBN\644583|patients|were|those|variables|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D008094_D001714 NONE lithium_71\NN\14625458|(|vs.|anticonvulsants|) (r_dep) use_64\NN\407535|and|type|stabilizers|lithium (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (l_conj) diagnosis_23\NN\152018|bipolar (l_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_nummod) i_27\CD\14622893|
D008094_D001714 NONE lithium_71\NN\14625458|(|vs.|anticonvulsants|) (r_dep) use_64\NN\407535|and|type|stabilizers|lithium (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (l_conj) diagnosis_23\NN\152018|bipolar (l_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) bipolar_29\NNP\1740|ii|) (l_nummod) ii_30\CD\13741022|
D008094_D001714 NONE lithium_71\NN\14625458|(|vs.|anticonvulsants|) (r_dep) use_64\NN\407535|and|type|stabilizers|lithium (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|use|,|and|temperament (l_conj) diagnosis_23\NN\152018|bipolar (l_dep) bipolar_26\JJ\1740|(|dsm-iv|i|vs.|bipolar|,|number|,|type|therapy (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic (l_amod) manic_36\JJ\1740|
19889778
2696505
D007741_D007022 CID labetalol_4\NN\2721160|of|and|nitroprusside (r_nmod) comparison_2\NN\635850|a|randomized|labetalol|hypotension|. (l_nmod) hypotension_9\NN\14057371|for|induced
D007741_D007022 CID labetalol-induced_5\JJ\1740| (r_amod) hypotension_6\NN\14057371|labetalol-induced|and|hypotension
D007741_D007022 CID labetalol-induced_5\JJ\1740| (r_amod) hypotension_6\NN\14057371|labetalol-induced|and|hypotension (l_conj) hypotension_9\NN\14057371|nitroprusside-induced
D009599_D007022 CID nitroprusside_6\NN\1740| (r_conj) labetalol_4\NN\2721160|of|and|nitroprusside (r_nmod) comparison_2\NN\635850|a|randomized|labetalol|hypotension|. (l_nmod) hypotension_9\NN\14057371|for|induced
D009599_D007022 CID nitroprusside-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|nitroprusside-induced (r_conj) hypotension_6\NN\14057371|labetalol-induced|and|hypotension
D009599_D007022 CID nitroprusside-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|nitroprusside-induced
D009599_D016534 CID nitroprusside_31\NN\1740|of (r_nmod) discontinuation_29\NN\209943|after|nitroprusside (r_nmod) observed_24\VBN\2163746|associated|;|hypertension|was|patients|discontinuation|. (l_ccomp) associated_3\VBN\628491|infusion|was|increase (l_nmod) increase_13\NN\13576355|with|a|significant|rate (l_nmod) rate_16\NN\13815152|in|heart|and|output (l_conj) output_19\NN\4007894|cardiac
D009599_D006973 NONE nitroprusside_31\NN\1740|of (r_nmod) discontinuation_29\NN\209943|after|nitroprusside (r_nmod) observed_24\VBN\2163746|associated|;|hypertension|was|patients|discontinuation|. (l_nsubjpass) hypertension_22\NN\14057371|rebound
11961407
D014443_D009401 NONE tyrosine_2\NN\14601829| (r_compound) phosphatase_3\NN\14732946|glepp1|receptor|tyrosine|ptpro|nephrosis|. (l_nmod) nephrosis_10\NN\14304060|in|rat|pan
D011692_D009401 CID pan_9\NN\3101986| (r_compound) nephrosis_10\NN\14304060|in|rat|pan
D011692_D009401 CID aminonucleoside_1\NN\1740| (r_compound) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_11\NN\1740|of|puromycin|pan (r_nmod) injection_8\NN\320852|by|single|intraperitoneal|aminonucleoside (r_nmod) induced_4\VBN\1627355|nephrosis|was|injection|. (l_nsubjpass) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID pan_13\NN\3101986|(|,|bw|) (r_appos) aminonucleoside_11\NN\1740|of|puromycin|pan (r_nmod) injection_8\NN\320852|by|single|intraperitoneal|aminonucleoside (r_nmod) induced_4\VBN\1627355|nephrosis|was|injection|. (l_nsubjpass) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D011507 CID pan_21\NN\3101986| (r_compound) injection_22\NN\320852|after|pan (r_nmod) 0_4\CD\13741022|at|,|5|days|injection (r_nmod) analyzed_2\VBN\78760|tissues|were|0|include|. (l_advcl) include_26\VB\690614|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|proteinuria|associated|days|and|phase (l_nmod) proteinuria_32\NN\14299637|of
D011692_D011507 CID pan_21\NN\3101986| (r_compound) injection_22\NN\320852|after|pan (r_nmod) 0_4\CD\13741022|at|,|5|days|injection (r_nmod) analyzed_2\VBN\78760|tissues|were|0|include|. (l_advcl) include_26\VB\690614|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|proteinuria|associated|days|and|phase (l_conj) phase_47\NN\15113229|the|chronic|proteinuria|days (l_nmod) proteinuria_49\NN\14299637|of|associated
D011692_D005921 NONE pan_21\NN\3101986| (r_compound) injection_22\NN\320852|after|pan (r_nmod) 0_4\CD\13741022|at|,|5|days|injection (r_nmod) analyzed_2\VBN\78760|tissues|were|0|include|. (l_advcl) include_26\VB\690614|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|proteinuria|associated|days|and|phase (l_conj) phase_47\NN\15113229|the|chronic|proteinuria|days (l_nmod) proteinuria_49\NN\14299637|of|associated (l_acl) associated_50\VBN\628491|glomerulosclerosis (l_nmod) glomerulosclerosis_52\NN\1740|with
18020536
D001569_D004244 CID bzds/rds_4\NNS\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability|and|tiredness|and|symptoms
D001569_D007319 CID bzds/rds_4\NNS\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability|and|tiredness|and|symptoms (l_conj) inability_10\NN\23271|sleep (l_acl) sleep_12\VB\14405|to|awaking
D001569_D005221 CID bzds/rds_4\NNS\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability|and|tiredness|and|symptoms (l_conj) tiredness_18\NN\14015731|mornings|week
D001569_D003866 CID bzds/rds_4\NNS\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability|and|tiredness|and|symptoms (l_conj) symptoms_32\NNS\5823932|with|stronger|depressive|measured
3828020
D010665_D002544 CID phenylpropanolamine_8\NN\2682038|of (r_nmod) dose_6\NN\3740161|with|a|single|oral|phenylpropanolamine (r_nmod) infarction_1\NN\14204950|cerebral|dose|.
D010665_D002544 CID ppa_20\NN\1740|of (r_nmod) dose_18\NN\3740161|a|single|oral|ppa (r_dobj) taking_14\VBG\2367363|after|dose (r_advcl) suffered_9\VBD\2110220|who|infarction|taking (l_dobj) infarction_12\NN\14204950|a|cerebral
12084448
D007069_D001927 CID ifosfamide_0\NN\1740| (r_compound) encephalopathy_1\NN\14084880|ifosfamide|presenting|.
D007069_D020820 NONE ifosfamide_0\NN\1740| (r_compound) encephalopathy_1\NN\14084880|ifosfamide|presenting|. (l_acl) presenting_2\VBG\2137132|asterixis (l_nmod) asterixis_4\NN\1740|with
D007069_D020820 NONE ifosfamide_3\NN\1740|of (r_nmod) administration_1\NN\1133281|the|ifosfamide (r_nsubjpass) discontinued_5\VBN\2609764|administration|was|and|resolved (l_conj) resolved_12\VBD\352826|h|asterixis|completely|. (l_nsubj) asterixis_11\NN\1740|the
D007069_D020820 NONE ifosfamide_12\NN\1740|of (r_nmod) infusion_10\NN\14589223|during|ifosfamide (r_nmod) presence_6\NN\13954253|the|asterixis|infusion|,|findings|and|resolution (l_nmod) asterixis_8\NN\1740|of
D007069_D020820 NONE ifx_41\NN\1740|of (r_nmod) use_39\NN\407535|with|the|ifx (r_nmod) associated_36\VBN\628491|that|myoclonus|is|use (r_ccomp) suggest_31\VBP\1010118|patient|,|presence|associated|. (l_nsubj) presence_6\NN\13954253|the|asterixis|infusion|,|findings|and|resolution (l_nmod) asterixis_8\NN\1740|of
D007069_D009207 CID ifosfamide_25\NN\1740|of (r_nmod) infusion_23\NN\14589223|after|the|ifosfamide|plasmacytoma (r_nmod) developed_9\VBD\1753788|who|myoclonus|infusion (l_dobj) myoclonus_14\NN\14360459|severe|,|disabling|negative|extremities
D007069_D009207 CID ifosfamide_12\NN\1740|of (r_nmod) infusion_10\NN\14589223|during|ifosfamide (r_nmod) presence_6\NN\13954253|the|asterixis|infusion|,|findings|and|resolution (r_nsubj) suggest_31\VBP\1010118|patient|,|presence|associated|. (l_ccomp) associated_36\VBN\628491|that|myoclonus|is|use (l_nsubjpass) myoclonus_34\NN\14360459|negative
D007069_D009207 CID ifx_41\NN\1740|of (r_nmod) use_39\NN\407535|with|the|ifx (r_nmod) associated_36\VBN\628491|that|myoclonus|is|use (l_nsubjpass) myoclonus_34\NN\14360459|negative
D007069_D010954 NONE ifosfamide_25\NN\1740|of (r_nmod) infusion_23\NN\14589223|after|the|ifosfamide|plasmacytoma (l_nmod) plasmacytoma_27\NN\14235200|for
1639466
D002118_D009400 NONE calcium_4\NN\14625458| (r_compound) blocker_6\NN\10101634|the|calcium|channel (r_compound) nitrendipine_7\NN\1740|of|blocker (r_nmod) effect_1\NN\34213|adverse|nitrendipine|nephrosclerosis|. (l_nmod) nephrosclerosis_9\NN\14113228|on|rats
D002118_D006978 NONE calcium_4\NN\14625458| (r_compound) blocker_6\NN\10101634|the|calcium|channel (r_compound) nitrendipine_7\NN\1740|of|blocker (r_nmod) effect_1\NN\34213|adverse|nitrendipine|nephrosclerosis|. (l_nmod) nephrosclerosis_9\NN\14113228|on|rats (l_nmod) rats_11\NNS\2329401|in|hypertension (l_nmod) hypertension_14\NN\14057371|with|renovascular
D002118_D006978 NONE calcium_8\NN\14625458| (r_compound) nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|. (l_nmod) rats_37\NNS\2329401|in|hypertension (l_nmod) hypertension_44\NN\14057371|with|two-kidney|,|clip|renovascular
D009568_D009400 CID nitrendipine_7\NN\1740|of|blocker (r_nmod) effect_1\NN\34213|adverse|nitrendipine|nephrosclerosis|. (l_nmod) nephrosclerosis_9\NN\14113228|on|rats
D009568_D006978 NONE nitrendipine_7\NN\1740|of|blocker (r_nmod) effect_1\NN\34213|adverse|nitrendipine|nephrosclerosis|. (l_nmod) nephrosclerosis_9\NN\14113228|on|rats (l_nmod) rats_11\NNS\2329401|in|hypertension (l_nmod) hypertension_14\NN\14057371|with|renovascular
D009568_D006978 NONE nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|. (l_nmod) rats_37\NNS\2329401|in|hypertension (l_nmod) hypertension_44\NN\14057371|with|two-kidney|,|clip|renovascular
D002118_D000419 NONE calcium_8\NN\14625458| (r_compound) nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|,|and|morphology (l_conj) albuminuria_23\NN\14299637|
D009568_D000419 CID nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|,|and|morphology (l_conj) albuminuria_23\NN\14299637|
D009568_D000419 CID nitrendipine-treated_5\JJ\1740| (r_amod) group_6\NN\2137|in|the|nitrendipine-treated (r_nmod) increased_8\VBD\169651|contrast|,|group|albuminuria|12.8|progressively|163|compared|hr|. (l_nsubj) albuminuria_7\NN\14299637|
D000809_D000419 NONE angiotensin_14\NN\4522421| (r_compound) enalapril_18\NN\2673637|the|angiotensin|converting|enzyme|inhibitor (r_conj) nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|,|and|morphology (l_conj) albuminuria_23\NN\14299637|
D000809_D006978 NONE angiotensin_14\NN\4522421| (r_compound) enalapril_18\NN\2673637|the|angiotensin|converting|enzyme|inhibitor (r_conj) nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|. (l_nmod) rats_37\NNS\2329401|in|hypertension (l_nmod) hypertension_44\NN\14057371|with|two-kidney|,|clip|renovascular
D004656_D000419 NONE enalapril_18\NN\2673637|the|angiotensin|converting|enzyme|inhibitor (r_conj) nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|,|and|morphology (l_conj) albuminuria_23\NN\14299637|
D004656_D006978 NONE enalapril_18\NN\2673637|the|angiotensin|converting|enzyme|inhibitor (r_conj) nitrendipine_11\NN\1740|with|the|calcium|channel|blocker|or|enalapril (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|pressure (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|. (l_nmod) rats_37\NNS\2329401|in|hypertension (l_nmod) hypertension_44\NN\14057371|with|two-kidney|,|clip|renovascular
D004656_D006973 NONE enalapril-treated_33\JJ\1740|=|,|or|nitrendipine-treated (r_conj) controls_27\NNS\5190804|untreated|hypertensive|=|,|enalapril-treated (r_dep) groups_23\NNS\2137|to|three|:|controls (r_nmod) assigned_20\VBN\2475922|clipping|,|rats|were|randomly|groups|. (l_nsubjpass) rats_10\NNS\2329401|hypertensive|hg (l_amod) hypertensive_9\JJ\1740|
D004656_D006973 NONE enalapril-treated_33\JJ\1740|=|,|or|nitrendipine-treated (r_conj) controls_27\NNS\5190804|untreated|hypertensive|=|,|enalapril-treated (l_amod) hypertensive_26\JJ\1740|
D004656_D006973 NONE enalapril-treated_23\JJ\1740| (r_amod) group_24\NN\2137|in|the|enalapril-treated (r_nmod) lower_20\JJR\1740|group|mm2 (r_conj) higher_6\JJR\1740|addition|,|size|was|group|mm2|but|lower|controls|. (l_advcl) controls_37\NNS\5190804|compared|with|the|hypertensive|mm2 (l_amod) hypertensive_36\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_40\JJ\1740|= (r_conj) enalapril-treated_33\JJ\1740|=|,|or|nitrendipine-treated (r_conj) controls_27\NNS\5190804|untreated|hypertensive|=|,|enalapril-treated (r_dep) groups_23\NNS\2137|to|three|:|controls (r_nmod) assigned_20\VBN\2475922|clipping|,|rats|were|randomly|groups|. (l_nsubjpass) rats_10\NNS\2329401|hypertensive|hg (l_amod) hypertensive_9\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_40\JJ\1740|= (r_conj) enalapril-treated_33\JJ\1740|=|,|or|nitrendipine-treated (r_conj) controls_27\NNS\5190804|untreated|hypertensive|=|,|enalapril-treated (l_amod) hypertensive_26\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_5\JJ\1740| (r_amod) group_6\NN\2137|in|the|nitrendipine-treated (r_nmod) increased_8\VBD\169651|contrast|,|group|albuminuria|12.8|progressively|163|compared|hr|. (l_nmod) hr_24\NN\15154774|with|19.2|mg/24|controls (l_nmod) controls_28\NNS\5190804|in|the|hypertensive (l_amod) hypertensive_27\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|nitrendipine-treated (r_nmod) increased_6\VBN\169651|furthermore|,|index|was|significantly|group|controls|0.38|. (l_advcl) controls_15\NNS\5190804|compared|with|the|hypertensive (l_amod) hypertensive_14\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|nitrendipine-treated (r_nmod) higher_6\JJR\1740|addition|,|size|was|group|mm2|but|lower|controls|. (l_advcl) controls_37\NNS\5190804|compared|with|the|hypertensive|mm2 (l_amod) hypertensive_36\JJ\1740|
D004656_D005921 NONE enalapril_14\NN\2673637| (r_compound) treatment_15\NN\654885|after|enalapril (r_nmod) change_12\VB\46534|excretion|did|not|treatment|. (l_nsubj) excretion_7\NN\13466586|albumin|and|glomerulosclerosis (l_conj) glomerulosclerosis_9\NN\1740|
D009568_D005921 NONE nitrendipine-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|nitrendipine-treated (r_nmod) increased_6\VBN\169651|furthermore|,|index|was|significantly|group|controls|0.38|. (l_nsubjpass) index_3\NN\13850304|glomerulosclerosis (l_compound) glomerulosclerosis_2\NN\1740|
1664218
D000677_D002289 NONE amsacrine_5\NN\1740| (r_compound) analogue_6\NN\4743605|the|amsacrine (r_compound) ci-921_7\NN\1740|of|analogue|nsc (r_nmod) study_2\NN\635850|phase|ii|ci-921|cancer|. (l_nmod) cancer_16\NN\14239425|in|non-small|cell|lung
C042315_D002289 NONE ci-921_7\NN\1740|of|analogue|nsc (r_nmod) study_2\NN\635850|phase|ii|ci-921|cancer|. (l_nmod) cancer_16\NN\14239425|in|non-small|cell|lung
C042315_D002289 NONE 343499_10\CD\1740| (r_nummod) nsc_9\NNP\8123696|(|343499|) (r_appos) ci-921_7\NN\1740|of|analogue|nsc (r_nmod) study_2\NN\635850|phase|ii|ci-921|cancer|. (l_nmod) cancer_16\NN\14239425|in|non-small|cell|lung
11532387
D018967_D013375 CID risperidone_7\NN\1740|of (r_nmod) reduction_5\NN\351485|during|dose|risperidone (r_nmod) syndrome_2\NN\5870365|withdrawal-emergent|rabbit|reduction|.
D018967_D013375 CID risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D018967_D001480 CID risperidone_7\NN\1740|of (r_nmod) reduction_5\NN\351485|during|dose|risperidone (r_nmod) syndrome_2\NN\5870365|withdrawal-emergent|rabbit|reduction|.
D018967_D001480 CID risperidone_8\NN\1740|of (r_nmod) reduction_6\NN\351485|during|dose|risperidone (r_nmod) developed_2\VBD\1753788|patient|rs|reduction|. (l_dobj) rs_3\NNP\13635336|
D018967_D001480 CID risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D018967_D001480 CID risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|influence (l_dobj) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NNS\13635336|of
D012701_D013375 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D012701_D013375 NONE serotonin_31\NN\14807737| (r_compound) system_32\NN\3575240|of|the|serotonin (r_nmod) influence_28\NN\5190804|the|pathophysiologic|system|development (r_dobj) suggesting_25\VBG\1010118|influence (r_advcl) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D012701_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D012701_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|influence (l_dobj) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NNS\13635336|of
D012701_D001480 NONE serotonin_31\NN\14807737| (r_compound) system_32\NN\3575240|of|the|serotonin (r_nmod) influence_28\NN\5190804|the|pathophysiologic|system|development (r_dobj) suggesting_25\VBG\1010118|influence (r_advcl) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D012701_D001480 NONE serotonin_31\NN\14807737| (r_compound) system_32\NN\3575240|of|the|serotonin (r_nmod) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NNS\13635336|of
D004298_D013375 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D004298_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs (l_nmod) rs_5\NNS\13635336|of|withdrawal-emergent|case
D004298_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|influence (l_dobj) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NNS\13635336|of
9812111
D006220_D011618 NONE haloperidol_7\NN\3713736|of (r_nmod) trial_5\NN\786195|a|randomized|,|placebo-controlled|dose-comparison|haloperidol|psychosis|. (l_nmod) psychosis_9\NN\14380140|for|and|behaviors|disease
D006220_D011618 NONE haloperidol_19\NN\3713736|of|and|placebo (r_nmod) doses_17\NNS\3740161|of|two|haloperidol (r_nmod) efficacy_11\NN\5199286|the|and|effects|doses|treatment (l_nmod) treatment_24\NN\654885|in|the|psychosis (l_nmod) psychosis_26\NN\14380140|of|and|behaviors|patients
D006220_D011618 NONE haloperidol_12\NN\3713736|standard-dose (r_nsubj) efficacious_14\JJ\1740|patients|,|haloperidol|was|and|superior|scores|. (l_nmod) scores_24\NNS\13757724|for|factor|and|agitation (l_nmod) factor_32\NN\7326557|on|the|scale|psychosis (l_compound) psychosis_31\NN\14380140|
D006220_D011618 NONE haloperidol_20\NN\3713736|to|both|low-dose|and|placebo (r_nmod) superior_16\JJ\1740|haloperidol (r_conj) efficacious_14\JJ\1740|patients|,|haloperidol|was|and|superior|scores|. (l_nmod) scores_24\NNS\13757724|for|factor|and|agitation (l_nmod) factor_32\NN\7326557|on|the|scale|psychosis (l_compound) psychosis_31\NN\14380140|
D006220_D011618 NONE haloperidol_6\NN\3713736|with (r_nmod) observed_4\VBN\2163746|haloperidol (r_acl) window_3\NN\3391770|the|narrow|therapeutic|observed (r_nsubj) apply_9\VB\2676054|window|may|also|neuroleptics|. (l_nmod) neuroleptics_12\NNS\4470232|to|other|used (l_acl) used_13\VBN\1156834|patients (l_nmod) patients_18\NNS\9898892|in|alzheimer|'s|disease|psychosis (l_nmod) psychosis_20\NN\14380140|with|and|behaviors
D006220_D019958 NONE haloperidol_7\NN\3713736|of (r_nmod) trial_5\NN\786195|a|randomized|,|placebo-controlled|dose-comparison|haloperidol|psychosis|. (l_nmod) psychosis_9\NN\14380140|for|and|behaviors|disease (l_conj) behaviors_12\NNS\407535|disruptive
D006220_D019958 NONE haloperidol_19\NN\3713736|of|and|placebo (r_nmod) doses_17\NNS\3740161|of|two|haloperidol (r_nmod) efficacy_11\NN\5199286|the|and|effects|doses|treatment (l_nmod) treatment_24\NN\654885|in|the|psychosis (l_nmod) psychosis_26\NN\14380140|of|and|behaviors|patients (l_conj) behaviors_29\NNS\407535|disruptive
D006220_D019958 NONE haloperidol_6\NN\3713736|with (r_nmod) observed_4\VBN\2163746|haloperidol (r_acl) window_3\NN\3391770|the|narrow|therapeutic|observed (r_nsubj) apply_9\VB\2676054|window|may|also|neuroleptics|. (l_nmod) neuroleptics_12\NNS\4470232|to|other|used (l_acl) used_13\VBN\1156834|patients (l_nmod) patients_18\NNS\9898892|in|alzheimer|'s|disease|psychosis (l_nmod) psychosis_20\NN\14380140|with|and|behaviors (l_conj) behaviors_23\NNS\407535|disruptive
D006220_D000544 NONE haloperidol_7\NN\3713736|of (r_nmod) trial_5\NN\786195|a|randomized|,|placebo-controlled|dose-comparison|haloperidol|psychosis|. (l_nmod) psychosis_9\NN\14380140|for|and|behaviors|disease (l_nmod) disease_16\NN\14061805|in|alzheimer|'s
D006220_D000544 NONE haloperidol_19\NN\3713736|of|and|placebo (r_nmod) doses_17\NNS\3740161|of|two|haloperidol (r_nmod) efficacy_11\NN\5199286|the|and|effects|doses|treatment (l_nmod) treatment_24\NN\654885|in|the|psychosis (l_nmod) psychosis_26\NN\14380140|of|and|behaviors|patients (l_nmod) patients_31\NNS\9898892|in|disease (l_nmod) disease_35\NN\14061805|with|alzheimer|'s
D006220_D000544 NONE haloperidol_16\NN\3713736|,|mg/day|,|and|haloperidol (r_nsubjpass) compared_40\VBN\644583|,|haloperidol|were|outpatients|. (l_nmod) outpatients_43\NNS\10405694|in|71|disease (l_nmod) disease_47\NN\14061805|with|alzheimer|'s
D006220_D000544 NONE haloperidol_28\NN\3713736|,|mg/day|, (r_conj) haloperidol_16\NN\3713736|,|mg/day|,|and|haloperidol (r_nsubjpass) compared_40\VBN\644583|,|haloperidol|were|outpatients|. (l_nmod) outpatients_43\NNS\10405694|in|71|disease (l_nmod) disease_47\NN\14061805|with|alzheimer|'s
D006220_D000544 NONE haloperidol_6\NN\3713736|with (r_nmod) observed_4\VBN\2163746|haloperidol (r_acl) window_3\NN\3391770|the|narrow|therapeutic|observed (r_nsubj) apply_9\VB\2676054|window|may|also|neuroleptics|. (l_nmod) neuroleptics_12\NNS\4470232|to|other|used (l_acl) used_13\VBN\1156834|patients (l_nmod) patients_18\NNS\9898892|in|alzheimer|'s|disease|psychosis (l_compound) disease_17\NN\14061805|
D006220_D011595 NONE haloperidol_12\NN\3713736|standard-dose (r_nsubj) efficacious_14\JJ\1740|patients|,|haloperidol|was|and|superior|scores|. (l_nmod) scores_24\NNS\13757724|for|factor|and|agitation (l_conj) agitation_36\NN\14373582|on|psychomotor
D006220_D011595 NONE haloperidol_20\NN\3713736|to|both|low-dose|and|placebo (r_nmod) superior_16\JJ\1740|haloperidol (r_conj) efficacious_14\JJ\1740|patients|,|haloperidol|was|and|superior|scores|. (l_nmod) scores_24\NNS\13757724|for|factor|and|agitation (l_conj) agitation_36\NN\14373582|on|psychomotor
D006220_D001480 CID haloperidol_10\NN\3713736|for (r_nmod) profile_8\NN\6999802|a|favorable|therapeutic|haloperidol|doses (r_dobj) indicated_4\VBD\952524|results|profile|,|developed|. (l_advcl) developed_22\VBD\1753788|although|subgroup|signs (l_dobj) signs_27\NNS\6643763|severe|extrapyramidal
12443032
D003042_D002637 CID cocaine_0\NN\3492717| (r_nmod:npmod) related_1\JJ\1740|cocaine (r_amod) pain_3\NN\14299637|related|chest|seeing
D003042_D002637 CID cocaine_6\NN\3492717|of (r_nmod) tendency_4\NN\6193203|the|cocaine|produce (l_acl) produce_8\VB\1617192|to|pain (l_dobj) pain_10\NN\14299637|chest
D003042_D002637 CID cocaine_6\NN\3492717|of (r_nmod) tendency_4\NN\6193203|the|cocaine|produce (r_nsubj) ought_11\MD\1740|in|,|tendency|to|. (l_xcomp) to_12\TO\1740|be|mind|faced (l_advcl) faced_22\VBN\2439281|when|victim (l_nmod) victim_26\NN\9630641|with|a|young|pain|otherwise (l_nmod) pain_29\NN\14299637|of|chest
D003042_D002637 CID cocaine_7\NN\3492717| (r_compound) use_8\NN\407535|to|cocaine (r_nmod) related_5\JJ\1740|use (r_acl) pain_4\NN\14299637|of|chest|related
3997294
D000638_D010996 CID amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|during|amiodarone (r_nmod) neuropathy_7\NN\14204950|therapy (r_conj) pneumonitis_0\NN\14336539|effusion|and|neuropathy|. (l_nmod) effusion_5\NN\6880249|with|pleural
D000638_D010490 CID amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|during|amiodarone (r_nmod) neuropathy_7\NN\14204950|therapy (r_conj) pneumonitis_0\NN\14336539|effusion|and|neuropathy|. (l_nmod) effusion_5\NN\6880249|with|pleural
D000638_D009422 NONE amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|during|amiodarone (r_nmod) neuropathy_7\NN\14204950|therapy
D000638_D002318 NONE amiodarone_11\NN\2715941|with|dose (r_nmod) treated_9\VBN\2376958|patient|was|amiodarone|months|,|control|. (l_nsubjpass) patient_1\NN\9898892|a|disease (l_nmod) disease_4\NN\14061805|with|sinuatrial|and|pacemaker
D000638_D013617 NONE amiodarone_11\NN\2715941|with|dose (r_nmod) treated_9\VBN\2376958|patient|was|amiodarone|months|,|control|. (l_nmod) control_29\NN\5190804|for|tachyarrhythmias (l_nmod) tachyarrhythmias_32\NNS\1740|of|supraventricular
D000638_D011014 CID amiodarone_14\NN\2715941| (r_compound) pneumonitis_15\NN\14336539|of|amiodarone
D000638_D011014 CID amiodarone_20\NN\2715941|of (r_nmod) withdrawal_18\NN\7206096|immediate|amiodarone|,|and|therapy (r_conj) diagnosis_12\NN\152018|for|early|pneumonitis|,|withdrawal (l_nmod) pneumonitis_15\NN\14336539|of|amiodarone
D013256_D011014 NONE steroid_26\NN\14727670| (r_compound) therapy_27\NN\657604|prompt|steroid|ensure (r_conj) withdrawal_18\NN\7206096|immediate|amiodarone|,|and|therapy (r_conj) diagnosis_12\NN\152018|for|early|pneumonitis|,|withdrawal (l_nmod) pneumonitis_15\NN\14336539|of|amiodarone
16160878
D014579_D006973 NONE u-ii_6\NN\1740|of (r_nmod) injection_4\NN\320852|intracerebroventricular|u-ii (r_nsubj) causes_7\VBZ\1617192|injection|hypertension|and|stimulates|. (l_dobj) hypertension_8\NN\14057371|and|bradycardia
D014579_D001919 NONE u-ii_6\NN\1740|of (r_nmod) injection_4\NN\320852|intracerebroventricular|u-ii (r_nsubj) causes_7\VBZ\1617192|injection|hypertension|and|stimulates|. (l_dobj) hypertension_8\NN\14057371|and|bradycardia (l_conj) bradycardia_10\NN\14110674|
D014579_D010409 NONE u-ii_9\NN\1740|of (r_nmod) administration_7\NN\1133281|the|central|u-ii (r_nsubj) had_10\VBD\2108377|dose|,|administration|effect|. (l_dobj) effect_12\NN\34213|no|temperature (l_nmod) temperature_15\NN\13575869|on|body|,|nociception|,|erection|,|and|level (l_conj) erection_21\NN\14037619|apomorphine-induced|penile|and|behavior
D001058_D010409 CID apomorphine-induced_19\JJ\1740| (r_amod) erection_21\NN\14037619|apomorphine-induced|penile|and|behavior
D003345_D010409 NONE corticosterone_29\NN\14752057| (r_compound) level_30\NN\4916342|stress-induced|plasma|corticosterone (r_conj) temperature_15\NN\13575869|on|body|,|nociception|,|erection|,|and|level (l_conj) erection_21\NN\14037619|apomorphine-induced|penile|and|behavior
D014579_D001523 NONE u-ii_4\NN\1740| (r_nsubjpass) involved_7\VBN\2676054|that|u-ii|may|be|aspects (l_nmod) aspects_10\NNS\5849789|in|some|disorders (l_nmod) disorders_13\NNS\14034177|of|psychiatric
1147734
D011441_D008107 NONE propylthiouracil_4\NN\14727670|by (r_nmod) caused_2\VBN\1617192|propylthiouracil (r_acl) disease_1\NN\14061805|liver|caused|.
D011441_D006521 CID propylthiouracil_29\NN\14727670|of (r_nmod) administration_27\NN\1133281|by|the|propylthiouracil (r_nmod) caused_24\VBN\1617192|administration (r_acl) hepatitis_23\NN\14127211|with|chronic|active|(|aggressive|)|caused
7802851
D000525_D016584 NONE alprazolam_3\NN\2830852|of|and|placebo (r_nmod) efficacy_1\NN\5199286|the|alprazolam|disorder|,|and|profiles (l_nmod) disorder_8\NN\14034177|in|panic|agoraphobia
D000525_D016584 NONE alprazolam_20\NN\2830852|to|or|placebo (r_nmod) randomised_18\VBN\278117|patients|were|alprazolam|. (l_nsubjpass) patients_7\NNS\9898892|154|met (l_acl:relcl) met_9\VBD\1182709|who|criteria (l_dobj) criteria_11\NNS\13577171|dsm-iii|disorder (l_nmod) disorder_14\NN\14034177|for|panic|agoraphobia
D000525_D000379 NONE alprazolam_3\NN\2830852|of|and|placebo (r_nmod) efficacy_1\NN\5199286|the|alprazolam|disorder|,|and|profiles (l_nmod) disorder_8\NN\14034177|in|panic|agoraphobia (l_nmod) agoraphobia_10\NN\14381416|with
D000525_D000379 NONE alprazolam_20\NN\2830852|to|or|placebo (r_nmod) randomised_18\VBN\278117|patients|were|alprazolam|. (l_nsubjpass) patients_7\NNS\9898892|154|met (l_acl:relcl) met_9\VBD\1182709|who|criteria (l_dobj) criteria_11\NNS\13577171|dsm-iii|disorder (l_nmod) disorder_14\NN\14034177|for|panic|agoraphobia (l_nmod) agoraphobia_16\NN\14381416|with
D000525_D003866 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects
D000525_D004775 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects (l_conj) enuresis_21\NN\13496972|,|disinhibition
D000525_D001523 NONE alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects (l_conj) aggression_25\NN\4657876|
D000525_D001523 NONE alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects (l_conj) side-effects_29\NNS\1740|more|,|sedation (l_appos) sedation_32\NN\14034177|particularly|,|irritability|,|memory|,|loss|and|ataxia (l_conj) irritability_34\NN\7552087|
D000525_D008569 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects (l_conj) side-effects_29\NNS\1740|more|,|sedation (l_appos) sedation_32\NN\14034177|particularly|,|irritability|,|memory|,|loss|and|ataxia (l_conj) memory_37\NN\5926676|impaired
D000525_D015431 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects (l_conj) side-effects_29\NNS\1740|more|,|sedation (l_appos) sedation_32\NN\14034177|particularly|,|irritability|,|memory|,|loss|and|ataxia (l_conj) loss_40\NN\13252973|weight
D000525_D001259 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|. (l_dobj) reactions_10\NNS\13446390|more|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|and|aggression|;|and|side-effects (l_conj) side-effects_29\NNS\1740|more|,|sedation (l_appos) sedation_32\NN\14034177|particularly|,|irritability|,|memory|,|loss|and|ataxia (l_conj) ataxia_42\NN\14084880|
1728522
D019980_D006099 CID acid_9\NN\14818238|clavulanic (r_conj) amoxicillin_6\NN\3910033|of|and|acid (r_nmod) combination_4\NN\7951464|due|amoxicillin (r_nmod) hepatitis_1\NN\14127211|granulomatous|combination|.
D019980_D006099 CID acid-induced_9\JJ\1740|amoxicillin-clavulanic (r_amod) hepatitis_10\NN\14127211|with|acid-induced|granulomas (l_nmod) granulomas_14\NNS\14235200|with|histologic|multiple
D019980_D056486 CID acid_9\NN\14818238|clavulanic (r_conj) amoxicillin_6\NN\3910033|of|and|acid (r_nmod) combination_4\NN\7951464|due|amoxicillin (r_nmod) hepatitis_1\NN\14127211|granulomatous|combination|.
D019980_D056486 CID acid-induced_9\JJ\1740|amoxicillin-clavulanic (r_amod) hepatitis_10\NN\14127211|with|acid-induced|granulomas
6534871
D007545_D009203 CID isoproterenol-induced_8\JJ\1740| (r_amod) infarction_10\NN\14204950|of|isoproterenol-induced|myocardial
983936
D001241_D009202 NONE acid_3\NN\14818238|of|acetylsalicylic|,|dipyridamole|and|hydrocortisone (r_nmod) effects_0\NNS\13245626|acid|injury|. (l_nmod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D004176_D009202 NONE dipyridamole_5\NN\1740|, (r_conj) acid_3\NN\14818238|of|acetylsalicylic|,|dipyridamole|and|hydrocortisone (r_nmod) effects_0\NNS\13245626|acid|injury|. (l_nmod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D006854_D009202 NONE hydrocortisone_8\NN\14751417| (r_conj) acid_3\NN\14818238|of|acetylsalicylic|,|dipyridamole|and|hydrocortisone (r_nmod) effects_0\NNS\13245626|acid|injury|. (l_nmod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D004837_D009202 CID epinephrine-induced_10\JJ\1740| (r_amod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D004837_D009202 CID epinephrine_9\NN\14807929| (r_compound) infusion_10\NN\14589223|(|epinephrine|) (r_appos) model_2\NN\5888929|a|reproducible|producing|infusion (l_acl) producing_4\VBG\1617192|for|injury (l_dobj) injury_7\NN\14052046|diffuse|myocardial
D004837_D009203 NONE epinephrine_9\NN\14807929| (r_compound) infusion_10\NN\14589223|(|epinephrine|) (r_appos) model_2\NN\5888929|a|reproducible|producing|infusion (r_nsubjpass) developed_14\VBN\1753788|model|has|been|study|. (l_xcomp) study_16\VB\630380|to|effects (l_dobj) effects_19\NNS\13245626|the|cardioprotective|agents (l_nmod) agents_21\NNS\7347|of|or|maneuvers|alter (l_acl:relcl) alter_26\VB\126264|which|might|evolution (l_dobj) evolution_28\NN\29677|the|infarction (l_nmod) infarction_32\NN\14204950|of|acute|myocardial
347884
D006220_D019967 NONE haloperidol_6\NN\3713736|with (r_nmod) study_4\NN\635850|in|the|blind|haloperidol (r_nmod) found_11\VBN\2426171|study|,|substances|were|effective|. (l_xcomp) effective_15\JJ\1740|to|be|highly|treatment (l_nmod) treatment_18\NN\654885|in|the|syndromes (l_nmod) syndromes_21\NNS\5870365|of|psychotic|belonging (l_acl) belonging_22\VBG\2604760|predominantly|group (l_nmod) group_27\NN\2137|to|the|schizophrenia
603022
D005702_D062787 NONE hydrobromide_1\NN\1740|galanthamine|,|drug|, (r_nsubjpass) used_14\VBN\1156834|hydrobromide|was|patient|. (l_nmod) patient_17\NN\9898892|in|a|demonstrating (l_acl) demonstrating_18\VBG\2137132|effects (l_dobj) effects_20\NNS\13245626|central|overdosage (l_nmod) overdosage_26\NN\1740|of|scopolamine
D012601_D062787 CID scopolamine_22\NN\14712692|hyoscine (r_compound) overdosage_26\NN\1740|of|scopolamine
D012601_D062787 CID hyoscine_24\NN\14712692|(|) (r_appos) scopolamine_22\NN\14712692|hyoscine (r_compound) overdosage_26\NN\1740|of|scopolamine
12464714
C093622_D008881 NONE rizatriptan_7\NN\1740|for|mg (r_nmod) efficacy_3\NN\5199286|of|and|preference|rizatriptan|versus|ergotamine/caffeine|migraine (l_nmod) migraine_13\NN\14326607|in
C093622_D008881 NONE rizatriptan_0\NN\1740| (r_nsubj) agonist_7\NN\9613191|rizatriptan|is|a|selective|5-ht(1b/1d|)|receptor|absorption|. (l_nmod) absorption_11\NN\13558490|with|rapid|oral|and|onset|treatment (l_nmod) treatment_20\NN\654885|in|the|acute|migraine (l_nmod) migraine_22\NN\14326607|of
C093622_D008881 NONE rizatriptan_12\NN\1740| (r_compound) tablet_15\NN\4233405|for|1|rizatriptan|mg|tablets (r_nmod) preference_9\NN\7497473|the|tablet|patients (l_nmod) patients_26\NNS\9898892|in|439|treating (l_acl) treating_27\VBG\2376958|attack|therapy (l_dobj) attack_31\NN\955060|a|single|migraine (l_compound) migraine_30\NN\14326607|
D004878_D008881 NONE ergotamine/caffeine_11\NN\1740| (r_conj) efficacy_3\NN\5199286|of|and|preference|rizatriptan|versus|ergotamine/caffeine|migraine (l_nmod) migraine_13\NN\14326607|in
D004878_D008881 NONE ergotamine_18\NN\14712692| (r_compound) tablets_23\NNS\4233405|to|2|ergotamine|mg (r_nmod) tablet_15\NN\4233405|for|1|rizatriptan|mg|tablets (r_nmod) preference_9\NN\7497473|the|tablet|patients (l_nmod) patients_26\NNS\9898892|in|439|treating (l_acl) treating_27\VBG\2376958|attack|therapy (l_dobj) attack_31\NN\955060|a|single|migraine (l_compound) migraine_30\NN\14326607|
D002110_D008881 NONE ergotamine/caffeine_11\NN\1740| (r_conj) efficacy_3\NN\5199286|of|and|preference|rizatriptan|versus|ergotamine/caffeine|migraine (l_nmod) migraine_13\NN\14326607|in
D002110_D008881 NONE mg/caffeine_20\NN\1740|1 (r_quantmod) mg_22\NN\13717155|mg/caffeine|100 (r_compound) tablets_23\NNS\4233405|to|2|ergotamine|mg (r_nmod) tablet_15\NN\4233405|for|1|rizatriptan|mg|tablets (r_nmod) preference_9\NN\7497473|the|tablet|patients (l_nmod) patients_26\NNS\9898892|in|439|treating (l_acl) treating_27\VBG\2376958|attack|therapy (l_dobj) attack_31\NN\955060|a|single|migraine (l_compound) migraine_30\NN\14326607|
D012701_D008881 NONE 5-ht(1b/1d_4\NN\1740| (r_compound) agonist_7\NN\9613191|rizatriptan|is|a|selective|5-ht(1b/1d|)|receptor|absorption|. (l_nmod) absorption_11\NN\13558490|with|rapid|oral|and|onset|treatment (l_nmod) treatment_20\NN\654885|in|the|acute|migraine (l_nmod) migraine_22\NN\14326607|of
C093622_D006261 NONE rizatriptan_19\NN\1740| (r_dobj) preferring_18\VBG\1777210|rizatriptan (r_acl) patients_17\NNS\9898892|of|preferring (r_nmod) %_15\NN\1740|by|67.3|patients|and|% (r_nmod) cited_12\VBN\730052|% (r_acl) reason_8\NN\9178821|relief|was|the|important|preference|,|cited|. (l_nsubj) relief_1\NN\7492516|faster|headache (l_nmod) headache_3\NN\5829480|of
C093622_D006261 NONE rizatriptan_9\NN\1740|for (r_nmod) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NN\5829480|
C093622_D006261 NONE rizatriptan_24\NN\1740| (r_nsubj) superior_26\JJ\1740|with|rizatriptan|being|ergotamine/caffeine|min (r_advcl) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NN\5829480|
D004878_D006261 NONE ergotamine/caffeine_27\NN\1740| (r_dobj) preferred_26\VBD\1777210|who|ergotamine/caffeine (r_acl:relcl) patients_24\NNS\9898892|of|preferred (r_nmod) %_22\NN\1740|54.2|patients (r_conj) %_15\NN\1740|by|67.3|patients|and|% (r_nmod) cited_12\VBN\730052|% (r_acl) reason_8\NN\9178821|relief|was|the|important|preference|,|cited|. (l_nsubj) relief_1\NN\7492516|faster|headache (l_nmod) headache_3\NN\5829480|of
D004878_D006261 NONE ergotamine/caffeine_14\NN\1740|for (r_nmod) %_12\NN\1740|47.3|ergotamine/caffeine|p (r_conj) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NN\5829480|
D004878_D006261 NONE ergotamine/caffeine_28\NN\1740|to (r_nmod) superior_26\JJ\1740|with|rizatriptan|being|ergotamine/caffeine|min (r_advcl) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NN\5829480|
D002110_D006261 NONE ergotamine/caffeine_27\NN\1740| (r_dobj) preferred_26\VBD\1777210|who|ergotamine/caffeine (r_acl:relcl) patients_24\NNS\9898892|of|preferred (r_nmod) %_22\NN\1740|54.2|patients (r_conj) %_15\NN\1740|by|67.3|patients|and|% (r_nmod) cited_12\VBN\730052|% (r_acl) reason_8\NN\9178821|relief|was|the|important|preference|,|cited|. (l_nsubj) relief_1\NN\7492516|faster|headache (l_nmod) headache_3\NN\5829480|of
D002110_D006261 NONE ergotamine/caffeine_14\NN\1740|for (r_nmod) %_12\NN\1740|47.3|ergotamine/caffeine|p (r_conj) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NN\5829480|
D002110_D006261 NONE ergotamine/caffeine_28\NN\1740|to (r_nmod) superior_26\JJ\1740|with|rizatriptan|being|ergotamine/caffeine|min (r_advcl) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NN\5829480|
C093622_D010146 NONE rizatriptan_15\NN\1740|of (r_nmod) favor_13\NN\34574|in|rizatriptan (r_nmod) also_11\RB\1740|endpoint|was|favor|. (l_nsubj) endpoint_2\NN\8566028|the|co-primary|being (l_advcl) being_4\VBG\836236|of|free|h (l_acomp) free_6\JJ\1740|pain (l_nmod:npmod) pain_5\NN\14299637|
C093622_D010146 NONE rizatriptan_10\NN\1740|h (r_dobj) free_6\JJ\1740|percent|were|pain|rizatriptan|,|compared|superior (l_nmod:npmod) pain_5\NN\14299637|
C093622_D010146 NONE rizatriptan_27\NN\1740| (r_nsubj) superior_29\JJ\1740|,|rizatriptan|being|h|. (r_dep) free_6\JJ\1740|percent|were|pain|rizatriptan|,|compared|superior (l_nmod:npmod) pain_5\NN\14299637|
C093622_D010146 NONE rizatriptan_6\NN\1740| (r_dobj) taking_5\VBG\2367363|rizatriptan (r_acl) patients_4\NNS\9898892|of|taking (r_nmod) %_2\NN\1740|36|patients (r_nsubj) free_9\JJ\1740|%|were|pain|h|and|had|,|compared|. (l_nmod:npmod) pain_8\NN\14299637|
D004878_D010146 NONE ergotamine/caffeine_18\NN\1740|with (r_nmod) treated_16\VBN\2376958|ergotamine/caffeine (r_acl) %_15\NN\1740|with|24.3|treated|p (r_nmod) compared_12\VBN\644583|% (r_prep) free_6\JJ\1740|percent|were|pain|rizatriptan|,|compared|superior (l_nmod:npmod) pain_5\NN\14299637|
D004878_D010146 NONE ergotamine/caffeine_33\NN\1740|on (r_nmod) patients_31\NNS\9898892|of|ergotamine/caffeine (r_nmod) %_29\NN\1740|to|20|patients|p (r_nmod) compared_26\VBN\644583|% (r_prep) free_9\JJ\1740|%|were|pain|h|and|had|,|compared|. (l_nmod:npmod) pain_8\NN\14299637|
D002110_D010146 NONE ergotamine/caffeine_18\NN\1740|with (r_nmod) treated_16\VBN\2376958|ergotamine/caffeine (r_acl) %_15\NN\1740|with|24.3|treated|p (r_nmod) compared_12\VBN\644583|% (r_prep) free_6\JJ\1740|percent|were|pain|rizatriptan|,|compared|superior (l_nmod:npmod) pain_5\NN\14299637|
D002110_D010146 NONE ergotamine/caffeine_33\NN\1740|on (r_nmod) patients_31\NNS\9898892|of|ergotamine/caffeine (r_nmod) %_29\NN\1740|to|20|patients|p (r_nmod) compared_26\VBN\644583|% (r_prep) free_9\JJ\1740|%|were|pain|h|and|had|,|compared|. (l_nmod:npmod) pain_8\NN\14299637|
C093622_D009325 CID rizatriptan_0\NN\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia
C093622_D009325 CID rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|. (l_conj) nausea_32\NN\14299637|%|and|somnolence
C093622_D014839 NONE rizatriptan_0\NN\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) vomiting_15\NN\116687|
C093622_D012001 NONE rizatriptan_0\NN\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) phonophobia_17\NN\14382238|
C093622_D020795 NONE rizatriptan_0\NN\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) photophobia_19\NN\14382238|
D004878_D009325 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia
D004878_D009325 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|. (l_conj) nausea_32\NN\14299637|%|and|somnolence
D004878_D014839 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) vomiting_15\NN\116687|
D004878_D012001 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) phonophobia_17\NN\14382238|
D004878_D020795 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) photophobia_19\NN\14382238|
D002110_D009325 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia
D002110_D009325 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|. (l_conj) nausea_32\NN\14299637|%|and|somnolence
D002110_D014839 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) vomiting_15\NN\116687|
D002110_D012001 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) phonophobia_17\NN\14382238|
D002110_D020795 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|. (l_nmod) proportions_8\NNS\13824815|in|the|patients (l_nmod) patients_10\NNS\9898892|of|nausea|and|patients (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting|,|phonophobia|or|photophobia (l_conj) photophobia_19\NN\14382238|
C093622_D004244 CID rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|.
C093622_D006970 NONE rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|. (l_conj) nausea_32\NN\14299637|%|and|somnolence (l_conj) somnolence_40\NN\14015731|%
D004878_D004244 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|.
D004878_D006970 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|. (l_conj) nausea_32\NN\14299637|%|and|somnolence (l_conj) somnolence_40\NN\14015731|%
D002110_D004244 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|.
D002110_D006970 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\NN\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan (r_nsubj) dizziness_24\NN\14299637|events|,|respectively|,|were|%|,|nausea|. (l_conj) nausea_32\NN\14299637|%|and|somnolence (l_conj) somnolence_40\NN\14015731|%
6634932
C002616_D017180 NONE um-272_0\NN\1740|n-dimethylpropranolol|,|agent|, (r_nsubjpass) administered_13\VBN\2436349|um-272|was|sublingually|dogs|. (l_nmod) dogs_16\NNS\2083346|to|tachycardias (l_nmod) tachycardias_20\NNS\14110674|with|ouabain-induced|ventricular
C002616_D017180 NONE n-dimethylpropranolol_4\NN\1740|(|n|,|) (r_appos) um-272_0\NN\1740|n-dimethylpropranolol|,|agent|, (r_nsubjpass) administered_13\VBN\2436349|um-272|was|sublingually|dogs|. (l_nmod) dogs_16\NNS\2083346|to|tachycardias (l_nmod) tachycardias_20\NNS\14110674|with|ouabain-induced|ventricular
C002616_D017180 NONE um-272_1\NNP\1740|sublingual (r_nsubj) converted_2\VBD\126264|um-272|tachycardia|rhythm|dogs|. (l_dobj) tachycardia_4\NN\14110674|ventricular
D010042_D017180 CID ouabain-induced_18\JJ\1740| (r_amod) tachycardias_20\NNS\14110674|with|ouabain-induced|ventricular
3865016
D005047_D054218 NONE etoposide_4\NN\1740|of|and|a (r_nmod) effect_2\NN\34213|a|synergistic|etoposide (r_nsubjpass) observed_9\VBN\2163746|effect|was|patient|. (l_nmod) patient_12\NN\9898892|in|a|leukemia (l_nmod) leukemia_16\NN\14239918|with|acute|t-lymphocytic|relapse
D016572_D054218 NONE a_7\NN\13649268|cyclosporin (r_conj) etoposide_4\NN\1740|of|and|a (r_nmod) effect_2\NN\34213|a|synergistic|etoposide (r_nsubjpass) observed_9\VBN\2163746|effect|was|patient|. (l_nmod) patient_12\NN\9898892|in|a|leukemia (l_nmod) leukemia_16\NN\14239918|with|acute|t-lymphocytic|relapse
D005047_D017254 NONE etoposide_4\NN\1740|of|and|a (r_nmod) administration_2\NN\1133281|the|concomitant|etoposide (r_nsubj) resulted_8\VBD\2633881|administration|eradication|. (l_nmod) eradication_10\NN\7334490|in|infiltration (l_nmod) infiltration_15\NN\975452|of|hitherto|refractory|leukemic|marrow
D016572_D017254 NONE a_7\NN\13649268|cyclosporin (r_conj) etoposide_4\NN\1740|of|and|a (r_nmod) administration_2\NN\1133281|the|concomitant|etoposide (r_nsubj) resulted_8\VBD\2633881|administration|eradication|. (l_nmod) eradication_10\NN\7334490|in|infiltration (l_nmod) infiltration_15\NN\975452|of|hitherto|refractory|leukemic|marrow
19445921
C066201_D009203 NONE a_5\NN\13649268|of|salvianolic|acid (r_nmod) effect_1\NN\34213|cardioprotective|a|infarction|. (l_nmod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
C066201_D009203 NONE a_13\NN\13649268|of|salvianolic|acid (r_nmod) potential_9\NN\14481929|the|cardioprotective|a|infarction (l_nmod) infarction_17\NN\14204950|on|isoproterenol-induced|myocardial|rats
C066201_D009203 NONE a_9\NN\13649268|salvianolic|acid|possessing (r_nsubj) has_13\VBZ\2108377|that|a|effect (l_dobj) effect_17\NN\34213|a|significant|protective|infarction (l_nmod) infarction_21\NN\14204950|against|isoproterenol-induced|myocardial
D007545_D009203 CID isoproterenol-induced_7\JJ\1740| (r_amod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_15\JJ\1740| (r_amod) infarction_17\NN\14204950|on|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_19\JJ\1740| (r_amod) infarction_21\NN\14204950|against|isoproterenol-induced|myocardial
D000244_D012131 NONE adp/o_13\NN\1740| (r_conj) ratio_11\NN\13815152|by|decreased|respiratory|control|and|adp/o (r_nmod) characterized_6\VBN\609683|ratio (r_acl) dysfunction_5\NN\14204950|mitochondrial|respiratory|characterized
D007545_D012131 NONE isoproterenol-treated_17\JJ\1740| (r_amod) rats_18\NNS\2329401|in|isoproterenol-treated (r_nmod) observed_15\VBN\2163746|addition|,|dysfunction|was|rats|. (l_nsubjpass) dysfunction_5\NN\14204950|mitochondrial|respiratory|characterized
C066201_D006331 NONE a_4\NN\13649268|of|salvianolic|acid (r_nmod) administration_0\NN\1133281|a|period (r_nsubj) attenuated_12\VBD\224901|administration|significantly|dysfunction|and|improved|. (l_dobj) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury
C066201_D009202 NONE a_4\NN\13649268|of|salvianolic|acid (r_nmod) administration_0\NN\1133281|a|period (r_nsubj) attenuated_12\VBD\224901|administration|significantly|dysfunction|and|improved|. (l_dobj) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury (l_conj) injury_18\NN\14052046|myocardial
C066201_D009202 NONE a_6\NN\13649268|of|salvianolic|acid (r_nmod) role_2\NN\719494|the|protective|a|damage (l_nmod) damage_10\NN\7296428|against|isoproterenol-induced|myocardial
D007545_D006331 NONE isoproterenol-induced_13\JJ\1740| (r_amod) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury
D007545_D009202 NONE isoproterenol-induced_13\JJ\1740| (r_amod) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury (l_conj) injury_18\NN\14052046|myocardial
D007545_D009202 NONE isoproterenol-induced_8\JJ\1740| (r_amod) damage_10\NN\7296428|against|isoproterenol-induced|myocardial
1527456
D008012_D014012 NONE lignocaine_7\NN\1740|of|lidocaine (r_nmod) instillation_5\NN\320852|by|intratympanic|lignocaine|tubes (r_nmod) treatment_0\NN\654885|tinnitus|instillation|. (l_nmod) tinnitus_2\NN\14299637|of
D008012_D014012 NONE lidocaine_9\NN\3681148|(|)|cent (r_appos) lignocaine_7\NN\1740|of|lidocaine (r_nmod) instillation_5\NN\320852|by|intratympanic|lignocaine|tubes (r_nmod) treatment_0\NN\654885|tinnitus|instillation|. (l_nmod) tinnitus_2\NN\14299637|of
D008012_D014012 NONE lignocaine_12\NN\1740|of|lidocaine (r_nmod) instillation_10\NN\320852|by|intratympanic|lignocaine|grommet (r_nmod) treating_6\VBG\2376958|of|ist|instillation|,|courses (l_dobj) ist_7\NNP\1740|
D008012_D014012 NONE lidocaine_14\NN\3681148|(|)|cent (r_appos) lignocaine_12\NN\1740|of|lidocaine (r_nmod) instillation_10\NN\320852|by|intratympanic|lignocaine|grommet (r_nmod) treating_6\VBG\2376958|of|ist|instillation|,|courses (l_dobj) ist_7\NNP\1740|
17244258
D003520_D003556 CID cyclophosphamide-induced_9\JJ\1740| (r_amod) cystitis_10\NN\14566129|in|cyclophosphamide-induced|rat
D003520_D003556 CID cyclophosphamide-induced_1\JJ\1740| (r_amod) cystitis_2\NN\14566129|in|cyclophosphamide-induced|rat
3856631
D008727_D008577 NONE methotrexate_8\NN\2722166|with|high-dose|intravenous (r_nmod) induction_1\NN\7450842|remission|leukemia|methotrexate|. (l_nmod) leukemia_4\NN\14239918|of|meningeal
D008727_D054198 NONE methotrexate_16\NN\2722166|intravenous (r_compound) regimen_17\NN\5898568|with|a|high-dose|methotrexate|designed (r_nmod) treated_11\VBN\2376958|children|were|regimen|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_nmod) leukemia_5\NN\14239918|with|acute|lymphoblastic
D008727_D054198 NONE methotrexate_26\NN\2722166| (r_compound) concentrations_27\NNS\4916342|csf|methotrexate|mol/l (r_dobj) achieve_22\VB\2524171|to|and|maintain|concentrations|need (r_xcomp) designed_20\VBN\1631534|that|was|achieve (r_acl:relcl) regimen_17\NN\5898568|with|a|high-dose|methotrexate|designed (r_nmod) treated_11\VBN\2376958|children|were|regimen|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_nmod) leukemia_5\NN\14239918|with|acute|lymphoblastic
D008727_D054198 NONE methotrexate_2\NN\2722166|high-dose|intravenous (r_nsubj) treatment_6\NN\654885|methotrexate|is|an|effective|induction|. (l_nmod) induction_9\NN\7450842|for|the|remission|relapse (l_nmod) relapse_14\NN\66636|after|meningeal|leukemia (l_nmod) leukemia_18\NN\14239918|in|acute|lymphoblastic
D008727_D002493 NONE methotrexate_16\NN\2722166|intravenous (r_compound) regimen_17\NN\5898568|with|a|high-dose|methotrexate|designed (r_nmod) treated_11\VBN\2376958|children|were|regimen|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_acl:relcl) developed_7\VBD\1753788|who|disease (l_dobj) disease_9\NN\14061805|meningeal
D008727_D002493 NONE methotrexate_26\NN\2722166| (r_compound) concentrations_27\NNS\4916342|csf|methotrexate|mol/l (r_dobj) achieve_22\VB\2524171|to|and|maintain|concentrations|need (r_xcomp) designed_20\VBN\1631534|that|was|achieve (r_acl:relcl) regimen_17\NN\5898568|with|a|high-dose|methotrexate|designed (r_nmod) treated_11\VBN\2376958|children|were|regimen|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_acl:relcl) developed_7\VBD\1753788|who|disease (l_dobj) disease_9\NN\14061805|meningeal
D001663_D064420 NONE bilirubin_10\NN\14756039| (r_conj) transaminase_8\NN\15077571|transient|serum|and|bilirubin (r_compound) elevations_11\NNS\7445480|toxicities|were|transaminase|,|neutropenia|. (l_nsubj) toxicities_3\NNS\13576101|the|common|encountered
D001663_D009503 NONE bilirubin_10\NN\14756039| (r_conj) transaminase_8\NN\15077571|transient|serum|and|bilirubin (r_compound) elevations_11\NNS\7445480|toxicities|were|transaminase|,|neutropenia|. (l_conj) neutropenia_13\NN\14196405|,|and|mucositis
D001663_D052016 NONE bilirubin_10\NN\14756039| (r_conj) transaminase_8\NN\15077571|transient|serum|and|bilirubin (r_compound) elevations_11\NNS\7445480|toxicities|were|transaminase|,|neutropenia|. (l_conj) neutropenia_13\NN\14196405|,|and|mucositis (l_conj) mucositis_16\NN\1740|
7862923
D002220_D012559 NONE carbamazepine_0\NN\1740| (r_nsubjpass) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic
D002220_D019965 NONE carbamazepine_0\NN\1740| (r_nsubjpass) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic (l_conj) psychotic_14\JJ\1740|organic
C036006_D012559 NONE oxcarbazepine_7\NN\1740|to|its|10-keto|analogue (r_nmod) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic
C036006_D019965 NONE oxcarbazepine_7\NN\1740|to|its|10-keto|analogue (r_nmod) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic (l_conj) psychotic_14\JJ\1740|organic
D006220_D012559 NONE haloperidol_18\NN\3713736|concomitantly|,|chlorpromazine|or|clozapine (r_dobj) using_16\VBG\1156834|haloperidol (r_advcl) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic
D006220_D019965 NONE haloperidol_18\NN\3713736|concomitantly|,|chlorpromazine|or|clozapine (r_dobj) using_16\VBG\1156834|haloperidol (r_advcl) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic (l_conj) psychotic_14\JJ\1740|organic
D002746_D012559 NONE chlorpromazine_20\NN\3713736| (r_conj) haloperidol_18\NN\3713736|concomitantly|,|chlorpromazine|or|clozapine (r_dobj) using_16\VBG\1156834|haloperidol (r_advcl) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic
D002746_D019965 NONE chlorpromazine_20\NN\3713736| (r_conj) haloperidol_18\NN\3713736|concomitantly|,|chlorpromazine|or|clozapine (r_dobj) using_16\VBG\1156834|haloperidol (r_advcl) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic (l_conj) psychotic_14\JJ\1740|organic
D003024_D012559 NONE clozapine_22\NN\3713736| (r_conj) haloperidol_18\NN\3713736|concomitantly|,|chlorpromazine|or|clozapine (r_dobj) using_16\VBG\1156834|haloperidol (r_advcl) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic
D003024_D019965 NONE clozapine_22\NN\3713736| (r_conj) haloperidol_18\NN\3713736|concomitantly|,|chlorpromazine|or|clozapine (r_dobj) using_16\VBG\1156834|haloperidol (r_advcl) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|patients|using|. (l_nmod) patients_15\NNS\9898892|among|six|difficult-to-treat|schizophrenic (l_amod) schizophrenic_11\JJ\1740|or|psychotic (l_conj) psychotic_14\JJ\1740|organic
3425586
D003622_D000743 CID dapsone-associated_0\NN\1740| (r_compound) anemia_4\NN\14189204|dapsone-associated|heinz|body|hemolytic|woman|.
D003622_D000743 CID dapsone_23\NN\2716205|of|mg/day|associated (r_nmod) dose_21\NN\3740161|a|dapsone (r_dobj) taking_19\VBG\2367363|while|dose (r_advcl) developed_12\VBD\1753788|woman|anemia|taking|. (l_dobj) anemia_17\NN\14189204|a|heinz|body|hemolytic
D003622_D000743 CID dapsone_21\NN\2716205| (r_nsubj) cause_24\VB\1617192|since|dapsone|does|not|anemia|dose (l_dobj) anemia_26\NN\14189204|hemolytic
D003622_D007918 NONE dapsone_23\NN\2716205|of|mg/day|associated (r_nmod) dose_21\NN\3740161|a|dapsone (r_dobj) taking_19\VBG\2367363|while|dose (r_advcl) developed_12\VBD\1753788|woman|anemia|taking|. (l_nsubj) woman_2\NN\9605289|a|cambodian|trait (l_nmod) trait_6\NN\24264|with|hemoglobin|e|ae|and|leprosy (l_conj) leprosy_11\NN\14127211|
D003622_D006461 NONE dapsone_23\NN\2716205|of|mg/day|associated (l_acl) associated_30\VBN\628491|not|usually|hemolysis (l_nmod) hemolysis_33\NN\13509528|with|clinical
18821488
C080436_D064420 NONE 8-aminoquinoline_8\NN\1740|the (r_compound) 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740|of|8-aminoquinoline|8-[(4-amino-l-methylbutyl)amino]-|wr242511 (r_nmod) administration_5\NN\1133281|following|5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) toxicity_0\NN\13576101|monkeys|administration|.
C068820_D064420 NONE 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740|of|8-aminoquinoline|8-[(4-amino-l-methylbutyl)amino]-|wr242511 (r_nmod) administration_5\NN\1133281|following|5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) toxicity_0\NN\13576101|monkeys|administration|.
C068820_D064420 NONE wr242511_12\NN\1740|(|) (r_appos) 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740|of|8-aminoquinoline|8-[(4-amino-l-methylbutyl)amino]-|wr242511 (r_nmod) administration_5\NN\1133281|following|5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) toxicity_0\NN\13576101|monkeys|administration|.
C068820_D064420 NONE wr242511_4\NN\1740| (r_nsubjpass) pursued_8\VBN\2367363|that|wr242511|should|not|be|pretreatment|dissociated (l_advcl) dissociated_25\VBN\2431320|unless|characteristics|can|be|successfully|those (l_nmod) those_27\DT\1740|from|producing (l_acl) producing_28\VBG\1617192|toxicity (l_dobj) toxicity_30\NN\13576101|undesirable
C068820_D008708 NONE wr242511_6\NN\1740|of (r_nmod) doses_4\NNS\3740161|the|selected|wr242511|,|produced|, (l_acl:relcl) produced_9\VBD\1617192|which|methemoglobinemia|studies (l_dobj) methemoglobinemia_11\NN\1740|significant|dogs
C068820_D006456 CID wr242511_11\NN\1740|of|mg/kg (r_nmod) postinjection_9\NN\1740|minutes|wr242511 (r_advmod) noted_5\VBN\1009240|furthermore|,|hemoglobinuria|was|postinjection|,|and|occurred (l_nsubjpass) hemoglobinuria_3\NN\14299637|transient
C068820_D011041 NONE wr242511_4\NN\1740| (r_nsubjpass) pursued_8\VBN\2367363|that|wr242511|should|not|be|pretreatment|dissociated (l_nmod) pretreatment_11\NN\1740|as|a|poisoning (l_nmod) poisoning_14\NN\14034177|for|cn
1732369
D004280_D009369 NONE dobutamine_0\NN\1740| (r_compound) echocardiography_2\NN\177127|dobutamine|stress|:|indicator|. (l_appos) indicator_6\NN\6636259|a|sensitive|function (l_nmod) function_10\NN\13783581|of|diminished|myocardial|survivors (l_nmod) survivors_15\NNS\9630641|in|asymptomatic|doxorubicin-treated|long-term|cancer (l_nmod) cancer_18\NN\14239425|of|childhood
D004280_D009369 NONE dobutamine_21\NN\1740| (r_compound) infusion_22\NN\14589223|dobutamine (r_dobj) using_20\VBG\1156834|infusion|differentiate (l_advcl) differentiate_24\VB\618878|to|survivors|subjects (l_dobj) survivors_27\NNS\9630641|asymptomatic|long-term|cancer (l_nmod) cancer_30\NN\14239425|of|childhood|treated
D004317_D009369 NONE doxorubicin-treated_13\JJ\1740| (r_amod) survivors_15\NNS\9630641|in|asymptomatic|doxorubicin-treated|long-term|cancer (l_nmod) cancer_18\NN\14239425|of|childhood
D004317_D009369 NONE doxorubicin_13\NN\2716866|due (r_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin (r_nmod) test_7\NN\5798043|a|sensitive|echocardiographic|screening|damage (r_dobj) develop_1\VB\1753788|to|test (r_advcl) performed_19\VBN\2367363|develop|,|study|was|using|. (l_xcomp) using_20\VBG\1156834|infusion|differentiate (l_advcl) differentiate_24\VB\618878|to|survivors|subjects (l_dobj) survivors_27\NNS\9630641|asymptomatic|long-term|cancer (l_nmod) cancer_30\NN\14239425|of|childhood|treated
D004317_D009369 NONE doxorubicin_33\NN\2716866|with (r_nmod) treated_31\VBN\2376958|doxorubicin (r_acl) cancer_30\NN\14239425|of|childhood|treated
D004317_D009202 CID doxorubicin_0\NN\2716866| (r_nsubj) agent_6\NN\7347|doxorubicin|is|an|effective|anticancer|chemotherapeutic|known|. (l_acl) known_7\VBN\2110220|cause (l_xcomp) cause_9\VB\1617192|to|cardiomyopathy (l_dobj) cardiomyopathy_13\NN\14103288|acute
D004317_D006331 NONE doxorubicin_13\NN\2716866|due (r_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin
D004317_D006331 NONE doxorubicin_33\NN\2716866|with (r_nmod) treated_31\VBN\2376958|doxorubicin (r_acl) cancer_30\NN\14239425|of|childhood|treated (r_nmod) survivors_27\NNS\9630641|asymptomatic|long-term|cancer (r_dobj) differentiate_24\VB\618878|to|survivors|subjects (r_advcl) using_20\VBG\1156834|infusion|differentiate (r_xcomp) performed_19\VBN\2367363|develop|,|study|was|using|. (l_advcl) develop_1\VB\1753788|to|test (l_dobj) test_7\NN\5798043|a|sensitive|echocardiographic|screening|damage (l_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin
D004280_D006331 NONE dobutamine_21\NN\1740| (r_compound) infusion_22\NN\14589223|dobutamine (r_dobj) using_20\VBG\1156834|infusion|differentiate (r_xcomp) performed_19\VBN\2367363|develop|,|study|was|using|. (l_advcl) develop_1\VB\1753788|to|test (l_dobj) test_7\NN\5798043|a|sensitive|echocardiographic|screening|damage (l_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NN\1740|of|intravenous|bolus|pirarubicin (r_nmod) study_3\NN\635850|a|phase|i|4'-0-tetrahydropyranyladriamycin (r_nsubjpass) done_15\VBN\1640855|study|was|patients|. (l_nmod) patients_18\NNS\9898892|in|55|status (l_nmod) status_22\NN\24720|in|good|performance|tumors (l_nmod) tumors_25\NNS\14234074|with|refractory
C027260_D009369 NONE pirarubicin_12\NN\1740|(|) (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NN\1740|of|intravenous|bolus|pirarubicin (r_nmod) study_3\NN\635850|a|phase|i|4'-0-tetrahydropyranyladriamycin (r_nsubjpass) done_15\VBN\1640855|study|was|patients|. (l_nmod) patients_18\NNS\9898892|in|55|status (l_nmod) status_22\NN\24720|in|good|performance|tumors (l_nmod) tumors_25\NNS\14234074|with|refractory
9727773
D001067_D006976 CID suppressants_9\NNS\3247620|with|appetite (r_nmod) associated_6\VBN\628491|suppressants|belgium (r_acl) hypertension_5\NN\14057371|of|primary|pulmonary|associated
D001067_D006976 CID suppressant_21\NN\3247620| (r_compound) drugs_22\NNS\14778436|of|appetite|suppressant (r_nmod) intake_18\NN\13440063|with|the|drugs (r_nmod) associated_15\VBN\628491|which|has|been|intake (r_acl:relcl) disease_10\NN\14061805|hypertension|is|a|rare|,|associated|. (l_nsubj) hypertension_2\NN\14057371|primary|pulmonary
D001067_D006976 CID suppressants_18\NNS\3247620|appetite (r_dobj) taken_16\VBN\2367363|uncertain|,|5|had|suppressants|. (l_ccomp) uncertain_10\JJ\1740|patients|diagnosis|was (l_nsubj) diagnosis_4\NN\152018|the|hypertension (l_nmod) hypertension_8\NN\14057371|of|primary|pulmonary
D001067_D006976 CID suppressants_7\NNS\3247620|of|appetite (r_nmod) prescription_4\NN\6786629|of|unrestricted|suppressants (r_nmod) policy_1\NN\5902545|a|prescription (r_nsubj) lead_9\VB\1752884|policy|may|incidence|. (l_nmod) incidence_13\NN\13821570|to|a|high|hypertension (l_nmod) hypertension_18\NN\14057371|of|associated|primary|pulmonary
20067456
D016642_D012735 NONE bupropion_5\NN\1740|of|the|adjunctive (r_nmod) effects_1\NNS\13245626|the|bupropion|dysfunction|:|study|. (l_nmod) dysfunction_9\NN\14204950|on|male|sexual|induced
D016642_D012735 NONE bupropion_10\NN\1740|adjunctive (r_compound) sustained-release_11\JJ\1740|of|bupropion|sr (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D016642_D012735 NONE bupropion_10\NN\1740|adjunctive (r_compound) sustained-release_11\JJ\1740|of|bupropion|sr (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D016642_D012735 NONE bupropion_10\NN\1740|adjunctive (r_compound) sustained-release_11\JJ\1740|of|bupropion|sr (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (r_dobj) determine_3\VB\1645601|to|safety|,|side-effect (l_advcl) side-effect_38\NN\1740|as|sd|is|a|common|ssris|and|have (l_nsubj) sd_34\NN\1740|
D016642_D012735 NONE bupropion_2\NN\1740| (r_nsubj) treatment_6\NN\654885|:|bupropion|is|an|effective|sd (l_nmod) sd_9\NN\1740|for|male|induced
D017367_D012735 NONE inhibitor_16\NN\20090|by|a|selective|serotonin|reuptake (r_nmod) induced_10\VBN\1627355|inhibitor (r_acl) dysfunction_9\NN\14204950|on|male|sexual|induced
D017367_D012735 NONE inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D017367_D012735 NONE inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D017367_D012735 NONE inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (r_dobj) determine_3\VB\1645601|to|safety|,|side-effect (l_advcl) side-effect_38\NN\1740|as|sd|is|a|common|ssris|and|have (l_nsubj) sd_34\NN\1740|
D017367_D012735 NONE ssri_30\NN\2718811|(|) (r_appos) inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D017367_D012735 NONE ssri_30\NN\2718811|(|) (r_appos) inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D017367_D012735 NONE ssri_30\NN\2718811|(|) (r_appos) inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (r_dobj) determine_3\VB\1645601|to|safety|,|side-effect (l_advcl) side-effect_38\NN\1740|as|sd|is|a|common|ssris|and|have (l_nsubj) sd_34\NN\1740|
D017367_D012735 NONE ssris_40\NNS\2718811|of (r_nmod) side-effect_38\NN\1740|as|sd|is|a|common|ssris|and|have (r_advcl) determine_3\VB\1645601|to|safety|,|side-effect (l_dobj) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D017367_D012735 NONE ssris_40\NNS\2718811|of (r_nmod) side-effect_38\NN\1740|as|sd|is|a|common|ssris|and|have (r_advcl) determine_3\VB\1645601|to|safety|,|side-effect (l_dobj) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D017367_D012735 NONE ssris_40\NNS\2718811|of (r_nmod) side-effect_38\NN\1740|as|sd|is|a|common|ssris|and|have (l_nsubj) sd_34\NN\1740|
D017367_D012735 NONE ssri_19\NN\2718811|of (r_nmod) type_17\NN\5839024|ssri|used (r_conj) duration_13\NN\15113229|by|the|sd|,|type|and|age (l_nmod) sd_15\NN\1740|of
D017367_D012735 NONE ssris_12\NNS\2718811|by (r_nmod) induced_10\VBN\1627355|ssris (r_acl) sd_9\NN\1740|for|male|induced
2924746
D002220_D064420 NONE carbamazepine_1\NN\1740| (r_compound) treatment_2\NN\654885|chronic|carbamazepine|rat|:|efficacy (l_dep) efficacy_7\NN\5199286|,|toxicity|,|and|effect|. (l_conj) toxicity_9\NN\13576101|
D005492_D064420 NONE folate_17\NN\15090742| (r_compound) concentrations_18\NNS\4916342|on|plasma|folate (r_nmod) effect_12\NN\34213|concentrations (r_conj) efficacy_7\NN\5199286|,|toxicity|,|and|effect|. (l_conj) toxicity_9\NN\13576101|
D019946_D012640 NONE glycol_13\NN\14766364|propylene|, (r_appos) vehicle_10\NN\3100490|a|common|,|glycol (r_nsubjpass) found_22\VBN\2426171|course|,|vehicle|itself|doses|,|was|exhibit|. (l_xcomp) exhibit_24\VB\2632167|to|properties|and|inhibited (l_dobj) properties_26\NNS\32613|protective|seizures (l_nmod) seizures_29\NNS\14081375|against|induced
D019946_D015430 NONE glycol_13\NN\14766364|propylene|, (r_appos) vehicle_10\NN\3100490|a|common|,|glycol (r_nsubjpass) found_22\VBN\2426171|course|,|vehicle|itself|doses|,|was|exhibit|. (l_xcomp) exhibit_24\VB\2632167|to|properties|and|inhibited (l_conj) inhibited_31\VBD\2510337|gain (l_dobj) gain_33\NN\13576355|weight
D005481_D012640 CID ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNS\14081375|induced
D005481_D012640 CID ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNS\14081375|induced (r_nsubjpass) found_10\VBN\2426171|seizures|were|also|measure|. (l_xcomp) measure_16\NN\168237|to|be|a|sensitive|protection|seizures (l_nmod) seizures_22\NNS\14081375|than|induced
D005481_D012640 CID hfde_6\NN\1740|(|) (r_appos) ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNS\14081375|induced
D005481_D012640 CID hfde_6\NN\1740|(|) (r_appos) ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNS\14081375|induced (r_nsubjpass) found_10\VBN\2426171|seizures|were|also|measure|. (l_xcomp) measure_16\NN\168237|to|be|a|sensitive|protection|seizures (l_nmod) seizures_22\NNS\14081375|than|induced
D005481_D012640 CID hfde-induced_21\JJ\1740| (r_amod) seizures_22\NNS\14081375|against|hfde-induced
D002220_D012640 NONE cbz_20\NN\1740|by (r_nmod) protection_18\NN\407535|of|cbz (r_nmod) measure_16\NN\168237|to|be|a|sensitive|protection|seizures (r_xcomp) found_10\VBN\2426171|seizures|were|also|measure|. (l_nsubjpass) seizures_0\NNS\14081375|induced
D002220_D012640 NONE cbz_20\NN\1740|by (r_nmod) protection_18\NN\407535|of|cbz (r_nmod) measure_16\NN\168237|to|be|a|sensitive|protection|seizures (l_nmod) seizures_22\NNS\14081375|than|induced
D002220_D012640 NONE cbz_3\NN\1740|of (r_nmod) administration_1\NN\1133281|oral|cbz|suspension|h|dose (r_nsubj) protective_19\JJ\1740|administration|was|continuously|seizures|and|toxic|. (l_nmod) seizures_22\NNS\14081375|against|hfde-induced
D002220_D015430 NONE cbz_3\NN\1740|of (r_nmod) administration_1\NN\1133281|oral|cbz|suspension|h|dose (r_nsubj) protective_19\JJ\1740|administration|was|continuously|seizures|and|toxic|. (l_conj) toxic_26\JJ\1740|was|minimally|measured (l_advcl) measured_28\VBN\697589|as|gain (l_nmod) gain_31\NN\13576355|by|weight|weeks
D005481_D015430 NONE hfde-induced_21\JJ\1740| (r_amod) seizures_22\NNS\14081375|against|hfde-induced (r_nmod) protective_19\JJ\1740|administration|was|continuously|seizures|and|toxic|. (l_conj) toxic_26\JJ\1740|was|minimally|measured (l_advcl) measured_28\VBN\697589|as|gain (l_nmod) gain_31\NN\13576355|by|weight|weeks
9660111
D014299_D007035 NONE tri_4\NNP\1740|(|given|i.p.|) (r_nsubj) antagonize_11\VB\1787955|experiment|tri|does|not|hypothermia|and|potentiate|. (l_dobj) hypothermia_14\NN\14034177|the|reserpine|mice
D012110_D007035 CID reserpine_13\NN\2721160| (r_compound) hypothermia_14\NN\14034177|the|reserpine|mice
D006916_D007035 NONE 5-hydroxytryptophan_22\NN\1740| (r_compound) twitches_24\NNS\14360459|the|5-hydroxytryptophan|head|rats (r_dobj) potentiate_20\VB\229605|does|not|twitches (r_conj) antagonize_11\VB\1787955|experiment|tri|does|not|hypothermia|and|potentiate|. (l_dobj) hypothermia_14\NN\14034177|the|reserpine|mice
D014299_D006948 CID tri_0\NN\1740|given (r_nsubj) increases_5\VBZ\169651|tri|hyperactivity|. (l_dobj) hyperactivity_8\NN\14052403|the|locomotor|induced
D003913_D006948 CID d-amphetamine_11\NN\1740|by|,|quinpirole|and|(+)-7-hydroxy-dipropyloaminotetralin|effects (r_nmod) induced_9\VBN\1627355|d-amphetamine (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D019257_D006948 CID quinpirole_13\NN\1740| (r_conj) d-amphetamine_11\NN\1740|by|,|quinpirole|and|(+)-7-hydroxy-dipropyloaminotetralin|effects (r_nmod) induced_9\VBN\1627355|d-amphetamine (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D004298_D006948 NONE dopamine_17\NN\14807737| (r_compound) d2_18\NN\1740|dopamine|and|d3 (r_compound) effects_21\NNS\13245626|(|d2|) (r_appos) d-amphetamine_11\NN\1740|by|,|quinpirole|and|(+)-7-hydroxy-dipropyloaminotetralin|effects (r_nmod) induced_9\VBN\1627355|d-amphetamine (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D010656_D010554 NONE phenylephrine_7\NN\2682038|by|given (r_nmod) evoked_5\VBN\1617192|phenylephrine|rats (r_acl) stimulation_4\NN\242808|the|behaviour|evoked|,|evaluated|as|aggressiveness|,|mediated (l_conj) aggressiveness_25\NN\4835724|the|evoked
D003000_D010554 NONE clonidine_28\NN\2721160|by|mice (r_nmod) evoked_26\VBN\1617192|clonidine (r_acl) aggressiveness_25\NN\4835724|the|evoked
9401499
D013988_D000741 CID ticlopidine-induced_0\JJ\1740| (r_amod) anemia_2\NN\14189204|ticlopidine-induced|aplastic|:|report
D013988_D000741 CID ticlopidine-induced_8\JJ\1740| (r_amod) anemia_10\NN\14189204|with|ticlopidine-induced|aplastic
D013988_D000741 CID ticlopidine-induced_2\JJ\1740| (r_amod) anemia_4\NN\14189204|for|ticlopidine-induced|aplastic
D013988_D000380 CID ticlopidine_9\NN\1740|of (r_nmod) initiation_7\NN\7450842|after|ticlopidine (r_nmod) occurred_1\VBD\2623529|agranulocytosis|initiation|,|so|recommended (l_nsubj) agranulocytosis_0\NN\14189204|
9351491
D018967_D011618 NONE risperidone_6\NN\1740|'s (r_nmod:poss) profile_9\NN\6999802|risperidone|pharmacologic (r_nsubj) produce_11\VB\1617192|that|profile|may|efficacy|features (l_dobj) efficacy_13\NN\5199286|improved|symptoms|and|propensity|; (l_nmod) symptoms_17\NNS\5823932|for|negative|psychotic
D018967_D010302 CID risperidone_8\NN\1740|with|%|and|haloperidol (r_nmod) treated_6\VBN\2376958|risperidone (r_acl) subjects_5\NNS\6598915|in|treated (r_nmod) observed_3\VBN\2163746|parkinsonism|was|subjects|and|observed|. (l_nsubjpass) parkinsonism_1\NN\14085708|drug-induced
D006220_D010302 CID haloperidol_14\NN\3713736|% (r_conj) risperidone_8\NN\1740|with|%|and|haloperidol (r_nmod) treated_6\VBN\2376958|risperidone (r_acl) subjects_5\NNS\6598915|in|treated (r_nmod) observed_3\VBN\2163746|parkinsonism|was|subjects|and|observed|. (l_nsubjpass) parkinsonism_1\NN\14085708|drug-induced
7234705
D011342_D017180 CID procainamide-induced_0\JJ\1740| (r_amod) tachycardia_3\NN\14110674|procainamide-induced|polymorphous|ventricular|.
D011342_D017180 CID procainamide-induced_3\JJ\1740| (r_amod) tachycardia_6\NN\14110674|of|procainamide-induced|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\1740|of (r_nmod) mg_15\NN\13717155|of|400|procainamide (r_nmod) administration_10\NN\1133281|after|intravenous|mg|treatment (r_nmod) appeared_7\VBD\2604760|patients|,|tachycardia|administration|. (l_nsubj) tachycardia_6\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\1740|of (r_nmod) mg_15\NN\13717155|of|400|procainamide (r_nmod) administration_10\NN\1133281|after|intravenous|mg|treatment (l_nmod) treatment_20\NN\654885|for|the|tachycardia (l_nmod) tachycardia_24\NN\14110674|of|sustained|ventricular
D011342_D017180 CID procainamide_16\NN\1740| (r_compound) therapy_17\NN\657604|of|procainamide (r_nmod) continuation_14\NN\407535|despite|therapy (r_nmod) reoccur_24\VB\1740|continuation|,|tachycardia|did|not|. (l_nsubj) tachycardia_21\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_5\NN\1740| (r_nsubj) produce_7\VB\1617192|that|procainamide|can|syndrome (l_dobj) syndrome_12\NN\5870365|an|acquired|prolonged|q-t|tachycardia (l_nmod) tachycardia_16\NN\14110674|with|polymorphous|ventricular
D011342_D018879 NONE procainamide_6\NN\1740| (r_nsubjpass) administered_8\VBN\2436349|patients|,|procainamide|was|orally|treatment|. (l_nmod) treatment_11\NN\654885|for|contractions (l_nmod) contractions_16\NNS\358931|of|chronic|premature|ventricular|or|flutter
D011342_D001282 NONE procainamide_6\NN\1740| (r_nsubjpass) administered_8\VBN\2436349|patients|,|procainamide|was|orally|treatment|. (l_nmod) treatment_11\NN\654885|for|contractions (l_nmod) contractions_16\NNS\358931|of|chronic|premature|ventricular|or|flutter (l_conj) flutter_19\NN\331950|atrial
D011342_D008133 NONE procainamide_5\NN\1740| (r_nsubj) produce_7\VB\1617192|that|procainamide|can|syndrome (l_dobj) syndrome_12\NN\5870365|an|acquired|prolonged|q-t|tachycardia
8955532
D001920_D006973 NONE bradykinin_4\NN\1740| (r_compound) receptors_6\NNS\5225602|of|bradykinin|b2 (r_nmod) activation_2\NN\13561719|of|receptors (r_nmod) role_0\NN\719494|activation|disruption|. (l_nmod) disruption_8\NN\1066163|in|barrier|hypertension (l_nmod) hypertension_15\NN\14057371|during|acute
D001920_D006973 NONE bradykinin_13\NN\1740|of (r_nmod) synthesis/release_11\NN\1740|of|bradykinin (r_nmod) role_9\NN\719494|the|synthesis/release|activate (l_acl) activate_15\VB\1641914|to|receptors|disruption (l_nmod) disruption_19\NN\1066163|in|barrier|hypertension (l_nmod) hypertension_26\NN\14057371|during|acute
D001920_D006973 NONE bradykinin_19\NN\1740|of (r_nmod) synthesis/release_17\NN\1740|to|the|bradykinin|activate (r_nmod) related_14\JJ\1740|that|disruption|is|not|synthesis/release (l_nsubj) disruption_4\NN\1066163|barrier|hypertension (l_nmod) hypertension_11\NN\14057371|during|acute
D003911_D006973 NONE dextran_11\NN\1740|of|fluorescent-labeled (r_nmod) clearance_8\NN\5089947|by|dextran|before|hypertension (l_nmod) hypertension_17\NN\14057371|phenylephrine-induced|acute|rats
D010656_D006973 CID phenylephrine-induced_15\JJ\1740| (r_amod) hypertension_17\NN\14057371|phenylephrine-induced|acute|rats
C065679_D006973 NONE hoe-140_24\NN\1740|microm (r_conj) vehicle_22\NN\3100490|with|and|hoe-140 (r_nmod) treated_20\VBN\2376958|vehicle (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) hypertension_17\NN\14057371|phenylephrine-induced|acute|rats
20080983
C048833_D012893 NONE modafinil_15\NN\1740|of|morning-dosed (r_nmod) effect_12\NN\34213|the|modafinil|sleep (l_nmod) sleep_17\NN\14034177|on|and|sleepiness|users (l_conj) sleepiness_20\NN\14015731|daytime
C048833_D012893 NONE modafinil_0\NN\1740| (r_nsubjpass) associated_2\VBN\628491|modafinil|was|latency|. (l_nmod) latency_7\NN\15269513|with|increased|daytime|sleep|,|measured|,|and|decrease (l_conj) decrease_22\NN\7296428|a|significant|sleepiness (l_nmod) sleepiness_26\NN\14015731|in|subjective|daytime
C048833_D012893 NONE modafinil_3\NN\1740|morning-dosed (r_nsubj) promotes_4\VBZ\2556126|modafinil|sleep|,|normalizes|. (l_conj) normalizes_8\VBZ\109660|architecture|,|and|decreases (l_conj) decreases_13\VBZ\169651|sleepiness|users (l_dobj) sleepiness_15\NN\14015731|daytime
D003042_D012893 CID cocaine_23\NN\3492717| (r_compound) users_24\NNS\7846|in|chronic|cocaine (r_nmod) sleep_17\NN\14034177|on|and|sleepiness|users (l_conj) sleepiness_20\NN\14015731|daytime
D003042_D012893 CID cocaine_18\NN\3492717| (r_compound) users_19\NNS\7846|in|abstinent|cocaine (r_nmod) decreases_13\VBZ\169651|sleepiness|users (l_dobj) sleepiness_15\NN\14015731|daytime
8752018
D008094_D003072 CID lithium-associated_0\JJ\1740| (r_amod) deficits_4\NNS\5113133|lithium-associated|cognitive|reduced|:|series
D008094_D003072 CID lithium_15\NN\14625458|of (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (r_nmod) management_7\NN\1123598|about|the|effects (r_nmod) written_4\VBN\1697816|although|much|has|been|management (r_advcl) remain_40\VBP\2604760|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss
D008094_D003072 CID lithium_15\NN\14625458|of (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (r_nmod) management_7\NN\1123598|about|the|effects (r_nmod) written_4\VBN\1697816|although|much|has|been|management (r_advcl) remain_40\VBP\2604760|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss (l_conj) loss_33\NN\13252973|creativity|,|and|impairments (l_nmod) creativity_35\NN\5616246|of
D008094_D003072 CID lithium_15\NN\14625458|of (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (r_nmod) management_7\NN\1123598|about|the|effects (r_nmod) written_4\VBN\1697816|although|much|has|been|management (r_advcl) remain_40\VBP\2604760|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss (l_conj) loss_33\NN\13252973|creativity|,|and|impairments (l_conj) impairments_39\NNS\7296428|functional
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss (l_conj) loss_33\NN\13252973|creativity|,|and|impairments (l_nmod) creativity_35\NN\5616246|of
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss (l_conj) loss_33\NN\13252973|creativity|,|and|impairments (l_conj) impairments_39\NNS\7296428|functional
D008094_D003072 CID lithium_10\NN\14625458|from (r_nmod) switching_6\VBG\138508|in|patients|lithium|sodium|alleviate (l_advcl) alleviate_15\VB\205885|to|impairments (l_dobj) impairments_20\NNS\7296428|such|cognitive
D008094_D003072 CID lithium_9\NN\14625458|of|, (r_nmod) substitution_7\NN\7337390|lithium|fully|,|sodium (r_nsubj) helpful_21\JJ\1740|where|substitution|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|deficits (l_dobj) deficits_31\NNS\5113133|the|cognitive|attributed
D008094_D003072 CID lithium_34\NN\14625458|to (r_nmod) attributed_32\VBN\670261|lithium|patients (r_acl) deficits_31\NNS\5113133|the|cognitive|attributed
D008094_D003072 CID lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss
D008094_D003072 CID lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss (l_conj) loss_22\NN\13252973|creativity|,|and|impairments (l_nmod) creativity_24\NN\5616246|of
D008094_D003072 CID lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss (l_conj) loss_22\NN\13252973|creativity|,|and|impairments (l_conj) impairments_28\NNS\7296428|functional
D014635_D003072 NONE sodium_11\NN\14625458|to|divalproex (r_nmod) switch_8\NN\3096960|by|a|sodium (r_nmod) reduced_5\VBN\441445|switch (r_acl) deficits_4\NNS\5113133|lithium-associated|cognitive|reduced|:|series
D014635_D003072 NONE sodium_13\NN\14625458|to|divalproex (r_nmod) switching_6\VBG\138508|in|patients|lithium|sodium|alleviate (l_advcl) alleviate_15\VB\205885|to|impairments (l_dobj) impairments_20\NNS\7296428|such|cognitive
D014635_D003072 NONE sodium_18\NN\14625458|with|divalproex (r_nmod) substitution_7\NN\7337390|lithium|fully|,|sodium (r_nsubj) helpful_21\JJ\1740|where|substitution|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|deficits (l_dobj) deficits_31\NNS\5113133|the|cognitive|attributed
D014635_D003072 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss
D014635_D003072 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss (l_conj) loss_22\NN\13252973|creativity|,|and|impairments (l_nmod) creativity_24\NN\5616246|of
D014635_D003072 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss (l_conj) loss_22\NN\13252973|creativity|,|and|impairments (l_conj) impairments_28\NNS\7296428|functional
D008094_D001714 NONE lithium_2\NN\14625458| (r_nsubj) remains_3\VBZ\2604760|background|:|lithium|treatment|. (l_attr) treatment_6\NN\654885|a|first-line|treatment (l_nmod) treatment_12\NN\654885|for|the|acute|disorder (l_nmod) disorder_15\NN\14034177|of|bipolar
D008094_D001714 NONE lithium_10\NN\14625458|from (r_nmod) switching_6\VBG\138508|in|patients|lithium|sodium|alleviate (l_dobj) patients_8\NNS\9898892|bipolar (l_amod) bipolar_7\JJ\1740|
D008094_D001714 NONE lithium_9\NN\14625458|of|, (r_nmod) substitution_7\NN\7337390|lithium|fully|,|sodium (r_nsubj) helpful_21\JJ\1740|where|substitution|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|deficits (l_dobj) deficits_31\NNS\5113133|the|cognitive|attributed (l_acl) attributed_32\VBN\670261|lithium|patients (l_nmod) patients_38\NNS\9898892|in|our|bipolar (l_amod) bipolar_37\JJ\1740|
D008094_D001714 NONE lithium_34\NN\14625458|to (r_nmod) attributed_32\VBN\670261|lithium|patients (l_nmod) patients_38\NNS\9898892|in|our|bipolar (l_amod) bipolar_37\JJ\1740|
D008094_D001714 NONE lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_amod) bipolar_16\JJ\1740|
D008094_D011141 NONE lithium_15\NN\14625458|of (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor
D008094_D011141 NONE lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (r_nsubj) remain_40\VBP\2604760|written|,|effects|understudied|. (l_advcl) written_4\VBN\1697816|although|much|has|been|management (l_nmod) management_7\NN\1123598|about|the|effects (l_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor
D008094_D014202 NONE lithium_15\NN\14625458|of (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor (l_conj) tremor_21\NN\345926|
D008094_D014202 NONE lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (r_nsubj) remain_40\VBP\2604760|written|,|effects|understudied|. (l_advcl) written_4\VBN\1697816|although|much|has|been|management (l_nmod) management_7\NN\1123598|about|the|effects (l_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|,|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor (l_conj) tremor_21\NN\345926|
D014635_D001714 NONE sodium_13\NN\14625458|to|divalproex (r_nmod) switching_6\VBG\138508|in|patients|lithium|sodium|alleviate (l_dobj) patients_8\NNS\9898892|bipolar (l_amod) bipolar_7\JJ\1740|
D014635_D001714 NONE sodium_18\NN\14625458|with|divalproex (r_nmod) substitution_7\NN\7337390|lithium|fully|,|sodium (r_nsubj) helpful_21\JJ\1740|where|substitution|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|deficits (l_dobj) deficits_31\NNS\5113133|the|cognitive|attributed (l_acl) attributed_32\VBN\670261|lithium|patients (l_nmod) patients_38\NNS\9898892|in|our|bipolar (l_amod) bipolar_37\JJ\1740|
D014635_D001714 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|:|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_amod) bipolar_16\JJ\1740|
11875660
D001374_D009436 NONE 5-azacytidine_6\NN\1740|by (r_nmod) induced_4\VBN\1627355|5-azacytidine|day (r_acl) exencephaly_3\NN\1740|the|induced
2445283
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) tolerance_0\NN\5032565|and|effect|ribavirin|patients|. (l_nmod) patients_7\NNS\9898892|in|fever (l_nmod) fever_11\NN\14299637|with|argentine|hemorrhagic
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) tolerance_0\NN\5032565|and|effect|ribavirin (r_nsubjpass) studied_7\VBN\630380|tolerance|was|patients|. (l_nmod) patients_10\NNS\9898892|in|6|fever (l_nmod) fever_14\NN\14299637|with|argentine|hemorrhagic|ahf|days
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) tolerance_0\NN\5032565|and|effect|ribavirin (r_nsubjpass) studied_7\VBN\630380|tolerance|was|patients|. (l_nmod) patients_10\NNS\9898892|in|6|fever (l_nmod) fever_14\NN\14299637|with|argentine|hemorrhagic|ahf|days (l_appos) ahf_16\NN\1740|(|)
D012254_D006478 NONE ribavirin_7\NN\2725367| (r_nsubj) has_8\VBZ\2108377|that|ribavirin|effect|cases|,|and|managed (l_nmod) cases_14\NNS\7283608|in|advanced|ahf (l_nmod) ahf_16\NN\1740|of
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) effect_3\NN\34213|the|possible|beneficial|ribavirin|days (l_nmod) days_9\NNS\15140892|during|the|initial|ahf (l_nmod) ahf_11\NN\1740|of
D012254_D014766 NONE ribavirin_2\NN\2725367|of (r_nmod) administration_0\NN\1133281|ribavirin (r_nsubj) resulted_3\VBD\2633881|administration|neutralization|. (l_nmod) neutralization_6\NN\231567|in|a|viremia|and|drop (l_nmod) viremia_8\NN\14204950|of
D012254_D000740 CID ribavirin_7\NN\2725367| (r_nsubj) has_8\VBZ\2108377|that|ribavirin|effect|cases|,|and|managed (l_conj) managed_31\VBN\2524171|that|anemia|can|be|easily (l_nsubjpass) anemia_20\NN\14189204|,|reaction|,
6386793
D004308_D003866 NONE hydrochloride_10\NN\14817592|of|dothiepin (r_nmod) efficacy_5\NN\5199286|of|the|and|safety|hydrochloride|treatment (l_nmod) treatment_13\NN\654885|in|the|disorder (l_nmod) disorder_17\NN\14034177|of|major|depressive
D004308_D003866 NONE dothiepin_8\NN\1740|and|amitriptyline (r_nsubjpass) compared_12\VBN\644583|study|,|dothiepin|were|placebo|treatment|. (l_nmod) treatment_17\NN\654885|in|the|outpatients (l_nmod) outpatients_21\NNS\10405694|of|33|depressed (l_amod) depressed_20\JJ\1740|
D004308_D003866 NONE dothiepin_0\NN\1740|and|amitriptyline (r_nsubj) effective_5\JJ\1740|dothiepin|were|equally|alleviating|,|and|superior (l_advcl) alleviating_7\VBG\205885|in|symptoms (l_dobj) symptoms_9\NNS\5823932|the|illness (l_nmod) illness_12\NN\14052046|of|depressive
D004308_D003866 NONE dothiepin_0\NN\1740| (r_nsubjpass) found_3\VBN\2426171|dothiepin|thus|was|drug|. (l_xcomp) drug_9\NN\14778436|to|be|an|effective|antidepressant|associated (l_acl) associated_10\VBN\628491|effects|treatment (l_nmod) treatment_19\NN\654885|in|the|outpatients (l_nmod) outpatients_22\NNS\10405694|of|depressed (l_amod) depressed_21\JJ\1740|
D000639_D003866 NONE amitriptyline_10\NN\4482543| (r_conj) dothiepin_8\NN\1740|and|amitriptyline (r_nsubjpass) compared_12\VBN\644583|study|,|dothiepin|were|placebo|treatment|. (l_nmod) treatment_17\NN\654885|in|the|outpatients (l_nmod) outpatients_21\NNS\10405694|of|33|depressed (l_amod) depressed_20\JJ\1740|
D000639_D003866 NONE amitriptyline_2\NN\4482543| (r_conj) dothiepin_0\NN\1740|and|amitriptyline (r_nsubj) effective_5\JJ\1740|dothiepin|were|equally|alleviating|,|and|superior (l_advcl) alleviating_7\VBG\205885|in|symptoms (l_dobj) symptoms_9\NNS\5823932|the|illness (l_nmod) illness_12\NN\14052046|of|depressive
D000639_D003866 NONE amitriptyline_16\NN\4482543|than (r_nmod) effects_14\NNS\13245626|with|fewer|side|amitriptyline (r_nmod) associated_10\VBN\628491|effects|treatment (l_nmod) treatment_19\NN\654885|in|the|outpatients (l_nmod) outpatients_22\NNS\10405694|of|depressed (l_amod) depressed_21\JJ\1740|
D004308_D014786 NONE dothiepin_24\NN\1740|with (r_nmod) less_22\JJR\1740|incidence|were|significantly|dothiepin|than|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth
D004308_D014987 NONE dothiepin_24\NN\1740|with (r_nmod) less_22\JJR\1740|incidence|were|significantly|dothiepin|than|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth (l_conj) mouth_16\NN\5610008|dry|,|and|drowsiness
D000639_D014786 CID amitriptyline_27\NN\4482543|with (r_nmod) than_25\IN\1740|amitriptyline (r_prep) less_22\JJR\1740|incidence|were|significantly|dothiepin|than|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth
D000639_D014987 CID amitriptyline_27\NN\4482543|with (r_nmod) than_25\IN\1740|amitriptyline (r_prep) less_22\JJR\1740|incidence|were|significantly|dothiepin|than|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth (l_conj) mouth_16\NN\5610008|dry|,|and|drowsiness
D000928_D003866 NONE antidepressant_8\JJ\1740| (r_amod) drug_9\NN\14778436|to|be|an|effective|antidepressant|associated (l_acl) associated_10\VBN\628491|effects|treatment (l_nmod) treatment_19\NN\654885|in|the|outpatients (l_nmod) outpatients_22\NNS\10405694|of|depressed (l_amod) depressed_21\JJ\1740|
3403780
D000082_D003128 NONE paracetamol-associated_0\NN\1740| (r_compound) coma_1\NN\5678932|paracetamol-associated|,|acidosis|.
D000082_D000138 CID paracetamol-associated_0\NN\1740| (r_compound) coma_1\NN\5678932|paracetamol-associated|,|acidosis|. (l_conj) acidosis_4\NN\14204950|metabolic|,|failure
D000082_D000138 CID paracetamol_13\NN\1740| (r_compound) ingestion_14\NN\13440063|following|paracetamol (r_nmod) acidosis_4\NN\14204950|of|metabolic|,|failure|and|failure|ingestion
D000082_D058186 CID paracetamol_13\NN\1740| (r_compound) ingestion_14\NN\13440063|following|paracetamol (r_nmod) acidosis_4\NN\14204950|of|metabolic|,|failure|and|failure|ingestion (l_conj) failure_11\NN\66216|hepatic
D000082_D058186 NONE paracetamol-associated_0\NN\1740| (r_compound) coma_1\NN\5678932|paracetamol-associated|,|acidosis|. (l_conj) acidosis_4\NN\14204950|metabolic|,|failure (l_conj) failure_9\NN\66216|renal
D000082_D017093 NONE paracetamol-associated_0\NN\1740| (r_compound) coma_1\NN\5678932|paracetamol-associated|,|acidosis|. (l_conj) acidosis_4\NN\14204950|metabolic|,|failure (l_conj) failure_9\NN\66216|renal
D000082_D017114 CID paracetamol_13\NN\1740| (r_compound) ingestion_14\NN\13440063|following|paracetamol (r_nmod) acidosis_4\NN\14204950|of|metabolic|,|failure|and|failure|ingestion (l_conj) failure_11\NN\66216|hepatic
18560792
D010479_D006349 NONE pergolide_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|pergolide (r_acl) disease_2\NN\14061805|valvular|heart|patients|treated|.
D010479_D006349 NONE pergolide_17\NN\1740|with (r_nmod) treated_15\VBN\2376958|pergolide (r_acl) patients_7\NNS\9898892|in|disease|treated (r_nmod) reported_5\VBN\831651|abnormalities|have|been|patients|. (l_nsubjpass) abnormalities_2\NNS\14034177|valvular|heart
D010479_D006349 NONE pergolide_12\NN\1740|of (r_nmod) role_10\NN\719494|of|the|pergolide (r_nmod) suggestive_7\JJ\1740|role (r_amod) pattern_2\NN\5726345|a|restrictive|regurgitation|,|suggestive|, (l_nmod) regurgitation_5\NN\7406350|of|valvular
D010479_D006349 NONE pergolide_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|pergolide|was|patients|,|resulting|and|returned (l_nmod) patients_5\NNS\9898892|in|10|disease (l_nmod) disease_9\NN\14061805|with|valvular|heart
D010479_D006349 NONE pergolide_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|pergolide (r_acl) patients_12\NNS\9898892|in|pd|treated (r_nmod) regurgitation_9\NN\7406350|of|restrictive|valve|patients
D010479_D010300 NONE pergolide_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|pergolide (r_acl) disease_2\NN\14061805|valvular|heart|patients|treated|. (l_nmod) patients_4\NNS\9898892|in|disease (l_nmod) disease_8\NN\14061805|with|parkinson
D010479_D010300 NONE pergolide_17\NN\1740|with (r_nmod) treated_15\VBN\2376958|pergolide (r_acl) patients_7\NNS\9898892|in|disease|treated (l_nmod) disease_11\NN\14061805|with|parkinson|'s|pd
D010479_D010300 NONE pergolide_17\NN\1740|with (r_nmod) treated_15\VBN\2376958|pergolide (r_acl) patients_7\NNS\9898892|in|disease|treated (l_nmod) disease_11\NN\14061805|with|parkinson|'s|pd (l_appos) pd_13\NN\14625458|(|)
D010479_D010300 NONE pergolide_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|pergolide (r_acl) patients_4\NNS\9898892|all|pd|area|treated (l_compound) pd_3\NN\14625458|
D010479_D010300 NONE pergolide_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|pergolide (r_acl) patients_12\NNS\9898892|in|pd|treated (l_compound) pd_11\NN\14625458|
D010479_D006333 NONE pergolide_12\NN\1740|of (r_nmod) role_10\NN\719494|of|the|pergolide (r_nmod) suggestive_7\JJ\1740|role (r_amod) pattern_2\NN\5726345|a|restrictive|regurgitation|,|suggestive|, (r_nsubjpass) observed_15\VBN\2163746|pattern|was|patients|. (l_nmod) patients_22\NNS\9898892|in|12/30|two (l_nmod) two_24\CD\13741022|including|failure (l_nmod) failure_27\NN\66216|with|heart
D010479_D006333 NONE pergolide_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|pergolide|was|patients|,|resulting|and|returned (l_conj) returned_32\VBD\1835496|patients|examination|. (l_nsubj) patients_28\NNS\9898892|the|two|failure (l_nmod) failure_31\NN\66216|with|heart
D004298_D006349 NONE dopamine_31\NN\14807737| (r_compound) agonists_32\NNS\9613191|to|non-ergot|dopamine (r_nmod) converted_28\VBN\126264|when|treatment|is|agonists (r_advcl) usual_23\JJ\1740|that|improvement|is|converted (r_ccomp) reveals_17\VBZ\2137132|usual (r_conj) supports_2\VBZ\2199590|study|frequency|and|reveals|. (l_dobj) frequency_5\NN\15286249|the|high|regurgitation (l_nmod) regurgitation_9\NN\7406350|of|restrictive|valve|patients
D004298_D010300 NONE dopamine_31\NN\14807737| (r_compound) agonists_32\NNS\9613191|to|non-ergot|dopamine (r_nmod) converted_28\VBN\126264|when|treatment|is|agonists (r_advcl) usual_23\JJ\1740|that|improvement|is|converted (r_ccomp) reveals_17\VBZ\2137132|usual (r_conj) supports_2\VBZ\2199590|study|frequency|and|reveals|. (l_dobj) frequency_5\NN\15286249|the|high|regurgitation (l_nmod) regurgitation_9\NN\7406350|of|restrictive|valve|patients (l_nmod) patients_12\NNS\9898892|in|pd|treated (l_compound) pd_11\NN\14625458|
11027905
D007649_D009369 NONE ketamine_4\NN\3054098|of|intravenous (r_nmod) effect_1\NN\34213|analgesic|ketamine|patients|therapy|:|study (l_nmod) patients_7\NNS\9898892|in|cancer (l_compound) cancer_6\NN\14239425|
D007649_D009369 NONE ketamine_7\NN\3054098|of (r_nmod) doses_5\NNS\3740161|of|subhypnotic|ketamine (r_nmod) bolus_2\NN\13899404|a|slow|doses|mg/kg (r_nsubjpass) given_16\VBN\2327200|bolus|was|patients|study|. (l_nmod) patients_20\NNS\9898892|to|10|cancer|unrelieved (l_compound) cancer_19\NN\14239425|
D009020_D009369 NONE morphine_9\NN\2707683| (r_compound) therapy_10\NN\657604|on|morphine (r_nmod) effect_1\NN\34213|analgesic|ketamine|patients|therapy|:|study (l_nmod) patients_7\NNS\9898892|in|cancer (l_compound) cancer_6\NN\14239425|
D009020_D009369 NONE morphine_26\NN\2707683|by (r_nmod) unrelieved_24\VBN\1740|pain|was|morphine (r_acl:relcl) patients_20\NNS\9898892|to|10|cancer|unrelieved (l_compound) cancer_19\NN\14239425|
D009020_D010146 NONE morphine_4\NN\2707683|to (r_nmod) responsive_2\JJ\1740|not|morphine (r_amod) pain_0\NN\14299637|responsive
D009020_D010146 NONE morphine_26\NN\2707683|by (r_nmod) unrelieved_24\VBN\1740|pain|was|morphine (l_nsubjpass) pain_22\NN\14299637|whose
D009020_D010146 NONE morphine_3\NN\2707683| (r_compound) analgesia_4\NN\14034177|morphine (r_dobj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_7\NN\14299637|
D016202_D010146 NONE n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_26\NN\14299637|
D016202_D010146 NONE nmda_9\NN\1740|(|) (r_appos) n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_26\NN\14299637|
D016202_D009437 NONE n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_32\NN\14299637|such|neuropathic
D016202_D009437 NONE nmda_9\NN\1740|(|) (r_appos) n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_32\NN\14299637|such|neuropathic
D007649_D010146 NONE ketamine_15\NN\3054098|such (r_nmod) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_26\NN\14299637|
D007649_D010146 NONE ketamine_7\NN\3054098|of (r_nmod) doses_5\NNS\3740161|of|subhypnotic|ketamine (r_nmod) bolus_2\NN\13899404|a|slow|doses|mg/kg (r_nsubjpass) given_16\VBN\2327200|bolus|was|patients|study|. (l_nmod) patients_20\NNS\9898892|to|10|cancer|unrelieved (l_acl:relcl) unrelieved_24\VBN\1740|pain|was|morphine (l_nsubjpass) pain_22\NN\14299637|whose
D007649_D010146 NONE ketamine_0\NN\3054098|,|not|solution|, (r_nsubj) reduced_8\VBD\441445|ketamine|significantly|intensity|doses|. (l_dobj) intensity_11\NN\5090441|the|pain|patients (l_compound) pain_10\NN\14299637|
D007649_D010146 NONE ketamine_0\NN\3054098| (r_nsubj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_7\NN\14299637|
D007649_D009437 NONE ketamine_15\NN\3054098|such (r_nmod) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_32\NN\14299637|such|neuropathic
D007649_D009437 NONE ketamine_0\NN\3054098| (r_nsubj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_13\NN\14299637|such|neuropathic
D009020_D009437 NONE morphine_3\NN\2707683| (r_compound) analgesia_4\NN\14034177|morphine (r_dobj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_13\NN\14299637|such|neuropathic
9390208
D008942_D001943 NONE mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
D008942_D001943 NONE mitoxantrone_18\NN\1740|by|,|mg/m2|,|day|and|infusion (r_nmod) treated_8\VBD\2376958|october|,|we|patients|mitoxantrone|h|day|. (l_dobj) patients_10\NNS\9898892|13|cancer (l_nmod) cancer_16\NN\14239425|with|chemotherapy-treated|metastatic|breast
D008942_D064420 NONE mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_dep) benefit_23\NN\13278375|low|palliative|and|toxicity|. (l_conj) toxicity_27\NN\13576101|high|treatment-related
D005472_D001943 NONE 5-fu_15\NN\1740|of|high-dose|and|leucovorin|): (r_nmod) infusion_12\NN\14589223|48-hour|continuous|5-fu (r_conj) mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
D005472_D001943 NONE 5-fu_30\NN\1740|of|,|mg/m2 (r_nmod) infusion_28\NN\14589223|continuous|5-fu|,|leucovorin (r_conj) mitoxantrone_18\NN\1740|by|,|mg/m2|,|day|and|infusion (r_nmod) treated_8\VBD\2376958|october|,|we|patients|mitoxantrone|h|day|. (l_dobj) patients_10\NNS\9898892|13|cancer (l_nmod) cancer_16\NN\14239425|with|chemotherapy-treated|metastatic|breast
D005472_D064420 NONE 5-fu_15\NN\1740|of|high-dose|and|leucovorin|): (r_nmod) infusion_12\NN\14589223|48-hour|continuous|5-fu (r_conj) mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_dep) benefit_23\NN\13278375|low|palliative|and|toxicity|. (l_conj) toxicity_27\NN\13576101|high|treatment-related
D002955_D001943 NONE leucovorin_17\NN\1740|mfl (r_conj) 5-fu_15\NN\1740|of|high-dose|and|leucovorin|): (r_nmod) infusion_12\NN\14589223|48-hour|continuous|5-fu (r_conj) mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
D002955_D001943 NONE leucovorin_37\NN\1740|with|,|mg/m2|, (r_nmod) infusion_28\NN\14589223|continuous|5-fu|,|leucovorin (r_conj) mitoxantrone_18\NN\1740|by|,|mg/m2|,|day|and|infusion (r_nmod) treated_8\VBD\2376958|october|,|we|patients|mitoxantrone|h|day|. (l_dobj) patients_10\NNS\9898892|13|cancer (l_nmod) cancer_16\NN\14239425|with|chemotherapy-treated|metastatic|breast
D002955_D064420 NONE leucovorin_17\NN\1740|mfl (r_conj) 5-fu_15\NN\1740|of|high-dose|and|leucovorin|): (r_nmod) infusion_12\NN\14589223|48-hour|continuous|5-fu (r_conj) mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_dep) benefit_23\NN\13278375|low|palliative|and|toxicity|. (l_conj) toxicity_27\NN\13576101|high|treatment-related
C085788_D001943 NONE mfl_19\NN\1740|( (r_appos) leucovorin_17\NN\1740|mfl (r_conj) 5-fu_15\NN\1740|of|high-dose|and|leucovorin|): (r_nmod) infusion_12\NN\14589223|48-hour|continuous|5-fu (r_conj) mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
C085788_D064420 NONE mfl_19\NN\1740|( (r_appos) leucovorin_17\NN\1740|mfl (r_conj) 5-fu_15\NN\1740|of|high-dose|and|leucovorin|): (r_nmod) infusion_12\NN\14589223|48-hour|continuous|5-fu (r_conj) mitoxantrone_8\NN\1740|by|and|infusion (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|benefit (l_dep) benefit_23\NN\13278375|low|palliative|and|toxicity|. (l_conj) toxicity_27\NN\13576101|high|treatment-related
C085788_D064420 NONE regimen_2\NN\5898568|the|mfl (r_nsubj) achieves_3\VBZ\2524171|regimen|benefit|and|induces|. (l_conj) induces_8\VBZ\1627355|toxicity|rate (l_dobj) toxicity_10\NN\13576101|severe
234669
D000628_D014693 CID aminophylline_2\NN\2905612|of (r_nmod) effects_0\NNS\13245626|aminophylline|threshold|. (l_nmod) threshold_5\NN\15265518|on|the|initiating (l_acl) initiating_7\VBG\1617192|for|fibrillation|failure (l_dobj) fibrillation_9\NN\14361664|ventricular
D000628_D014693 CID aminophylline_3\NN\2905612|of (r_nmod) effects_1\NNS\13245626|the|aminophylline|threshold (l_nmod) threshold_8\NN\15265518|on|the|fibrillation|conditions (l_compound) fibrillation_7\NN\14361664|ventricular
D000628_D014693 CID aminophylline_4\NN\2905612|of (r_nmod) infusion_2\NN\14589223|during|the|aminophylline (r_nmod) reduced_11\VBN\441445|infusion|,|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|fibrillation (l_compound) fibrillation_8\NN\14361664|ventricular
D000628_D014693 CID aminophylline_30\NN\2905612|of (r_nmod) infusion_28\NN\14589223|aminophylline (r_nsubj) resulted_31\VBD\2633881|produced|,|infusion|decrease|. (l_nmod) decrease_36\NN\7296428|in|an|greater|threshold|percent (l_nmod) threshold_40\NN\15265518|in|fibrillation (l_compound) fibrillation_39\NN\14361664|ventricular
D000628_D012131 NONE aminophylline_2\NN\2905612|of (r_nmod) effects_0\NNS\13245626|aminophylline|threshold|. (l_nmod) threshold_5\NN\15265518|on|the|initiating (l_acl) initiating_7\VBG\1617192|for|fibrillation|failure (l_nmod) failure_12\NN\66216|during|respiratory
D000628_D012131 NONE aminophylline_3\NN\2905612|of (r_nmod) effects_1\NNS\13245626|the|aminophylline|threshold (l_nmod) threshold_8\NN\15265518|on|the|fibrillation|conditions (l_nmod) conditions_12\NNS\14512817|during|normal|acid-base|and|failure (l_conj) failure_16\NN\66216|during|respiratory
D000628_D012131 NONE aminophylline_30\NN\2905612|of (r_nmod) infusion_28\NN\14589223|aminophylline (r_nsubj) resulted_31\VBD\2633881|produced|,|infusion|decrease|. (l_advcl) produced_4\VBN\1617192|when|failure|was|hypoventilation (l_nsubjpass) failure_2\NN\66216|respiratory
D000628_D012131 NONE aminophylline_24\NN\2905612|particularly (r_appos) agents_21\NNS\7347|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB\1072262|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB\126264|although|factors|may|incidence (l_nmod) incidence_12\NN\13821570|to|the|increased|arrhythmias (l_nmod) arrhythmias_15\NNS\14103288|of|ventricular|failure (l_nmod) failure_18\NN\66216|in|respiratory
D010100_D014693 NONE oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|partial|oxygen (r_conj) ph_21\NN\5038959|and|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|,|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|fibrillation (l_compound) fibrillation_8\NN\14361664|ventricular
C093415_D014693 NONE po2_28\NN\1740|(|) (r_appos) oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|partial|oxygen (r_conj) ph_21\NN\5038959|and|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|,|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|fibrillation (l_compound) fibrillation_8\NN\14361664|ventricular
D002245_D014693 NONE dioxide_32\NN\14971519|carbon|co2 (r_conj) oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|partial|oxygen (r_conj) ph_21\NN\5038959|and|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|,|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|fibrillation (l_compound) fibrillation_8\NN\14361664|ventricular
D002245_D014693 NONE co2_34\NN\14836127|(|) (r_appos) dioxide_32\NN\14971519|carbon|co2 (r_conj) oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|partial|oxygen (r_conj) ph_21\NN\5038959|and|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|,|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|fibrillation (l_compound) fibrillation_8\NN\14361664|ventricular
D000628_D007040 NONE aminophylline_30\NN\2905612|of (r_nmod) infusion_28\NN\14589223|aminophylline (r_nsubj) resulted_31\VBD\2633881|produced|,|infusion|decrease|. (l_advcl) produced_4\VBN\1617192|when|failure|was|hypoventilation (l_nmod) hypoventilation_6\NN\1740|by|ph
D000628_D001145 NONE aminophylline_24\NN\2905612|particularly (r_appos) agents_21\NNS\7347|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB\1072262|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB\126264|although|factors|may|incidence (l_nmod) incidence_12\NN\13821570|to|the|increased|arrhythmias (l_nmod) arrhythmias_15\NNS\14103288|of|ventricular|failure
19884587
D013449_D000757 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|. (l_nmod) anencephaly_4\NN\14465048|with|=
D013449_D018636 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|. (l_nmod) anencephaly_4\NN\14465048|with|= (l_dep) =_11\JJ\1740|(|or|aor|]|3.4|;|interval|,|syndrome (l_conj) syndrome_30\NN\5870365|hypoplastic|left|heart|=|,|coarctation
D013449_D001017 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|. (l_nmod) anencephaly_4\NN\14465048|with|= (l_dep) =_11\JJ\1740|(|or|aor|]|3.4|;|interval|,|syndrome (l_conj) syndrome_30\NN\5870365|hypoplastic|left|heart|=|,|coarctation (l_conj) coarctation_45\NN\7313241|aorta|=|,|atresia (l_nmod) aorta_48\NN\5333777|of|the
D013449_D002754 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|. (l_nmod) anencephaly_4\NN\14465048|with|= (l_dep) =_11\JJ\1740|(|or|aor|]|3.4|;|interval|,|syndrome (l_conj) syndrome_30\NN\5870365|hypoplastic|left|heart|=|,|coarctation (l_conj) coarctation_45\NN\7313241|aorta|=|,|atresia (l_conj) atresia_64\NN\14501726|choanal|=|,|deficiency
D013449_D017880 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|. (l_nmod) anencephaly_4\NN\14465048|with|= (l_dep) =_11\JJ\1740|(|or|aor|]|3.4|;|interval|,|syndrome (l_conj) syndrome_30\NN\5870365|hypoplastic|left|heart|=|,|coarctation (l_conj) coarctation_45\NN\7313241|aorta|=|,|atresia (l_conj) atresia_64\NN\14501726|choanal|=|,|deficiency (l_conj) deficiency_81\NN\14449126|transverse|limb|=|,|and|hernia
D013449_D006548 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|. (l_nmod) anencephaly_4\NN\14465048|with|= (l_dep) =_11\JJ\1740|(|or|aor|]|3.4|;|interval|,|syndrome (l_conj) syndrome_30\NN\5870365|hypoplastic|left|heart|=|,|coarctation (l_conj) coarctation_45\NN\7313241|aorta|=|,|atresia (l_conj) atresia_64\NN\14501726|choanal|=|,|deficiency (l_conj) deficiency_81\NN\14449126|transverse|limb|=|,|and|hernia (l_conj) hernia_98\NN\14295248|diaphragmatic|=
D009582_D000853 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|=|,|syndrome
D009582_D008850 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|=|,|syndrome (l_conj) microphthalmos_6\NNS\1740|
D009582_D018636 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|=|,|syndrome (l_conj) syndrome_24\NN\5870365|hypoplastic|left|heart|=|,|defects
D009582_D006344 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|=|,|syndrome (l_conj) syndrome_24\NN\5870365|hypoplastic|left|heart|=|,|defects (l_conj) defects_41\NNS\14462666|atrial|septal|=|,|and|lip
D009582_D002971 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|=|,|syndrome (l_conj) syndrome_24\NN\5870365|hypoplastic|left|heart|=|,|defects (l_conj) defects_41\NNS\14462666|atrial|septal|=|,|and|lip (l_conj) lip_58\NN\5301392|cleft|palate|=
D009582_D002972 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|=|,|syndrome (l_conj) syndrome_24\NN\5870365|hypoplastic|left|heart|=|,|defects (l_conj) defects_41\NNS\14462666|atrial|septal|=|,|and|lip (l_conj) lip_58\NN\5301392|cleft|palate|= (l_nmod) palate_61\NN\8660339|with|cleft
D010406_D000014 NONE penicillins_4\NNS\2716866|,|erythromycins|,|used (r_nsubjpass) associated_20\VBN\628491|conclusions|reassuringly|,|penicillins|,|were|not|defects|. (l_nmod) defects_24\NNS\14462666|with|many|birth
D004917_D000014 NONE erythromycins_6\NNS\2716866|,|and|cephalosporins (r_conj) penicillins_4\NNS\2716866|,|erythromycins|,|used (r_nsubjpass) associated_20\VBN\628491|conclusions|reassuringly|,|penicillins|,|were|not|defects|. (l_nmod) defects_24\NNS\14462666|with|many|birth
D002511_D000014 NONE cephalosporins_9\NNS\2716866| (r_conj) erythromycins_6\NNS\2716866|,|and|cephalosporins (r_conj) penicillins_4\NNS\2716866|,|erythromycins|,|used (r_nsubjpass) associated_20\VBN\628491|conclusions|reassuringly|,|penicillins|,|were|not|defects|. (l_nmod) defects_24\NNS\14462666|with|many|birth
D013449_D000014 CID sulfonamides_0\NNS\2716205|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\628491|sulfonamides|were|defects|,|indicating|. (l_nmod) defects_8\NNS\14462666|with|several|birth
D009582_D000014 CID nitrofurantoins_2\NNS\2716205| (r_conj) sulfonamides_0\NNS\2716205|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\628491|sulfonamides|were|defects|,|indicating|. (l_nmod) defects_8\NNS\14462666|with|several|birth
7504976
D002231_D056486 CID carbimazole_14\NN\1740|between|and|benzylthiouracil (r_nmod) cross-reactivity_12\NN\1740|with|carbimazole (r_nmod) one_10\CD\13741022|including|cross-reactivity (r_nmod) cases_8\NNS\7283608|four|one|. (r_appos) hepatitis_1\NN\14127211|toxic|induced|:|cases
D002231_D056486 CID carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D056486 CID omercazole_11\NN\1740|(|n|) (r_appos) carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D056486 CID carbimazole_12\NN\1740|following (r_nmod) hepatitis_10\NN\14127211|a|mixed|carbimazole
D002231_D056486 CID carbimazole_21\NN\1740| (r_dobj) replaced_20\VBN\1631072|after|benzylthiouracil|had|carbimazole (r_advcl) appeared_12\VBD\2604760|which|replaced (r_acl:relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared
C019269_D056486 NONE benzylthiouracil_16\NN\1740| (r_conj) carbimazole_14\NN\1740|between|and|benzylthiouracil (r_nmod) cross-reactivity_12\NN\1740|with|carbimazole (r_nmod) one_10\CD\13741022|including|cross-reactivity (r_nmod) cases_8\NNS\7283608|four|one|. (r_appos) hepatitis_1\NN\14127211|toxic|induced|:|cases
C019269_D056486 NONE benzylthiouracil_14\NN\1740|ne (r_nsubj) replaced_20\VBN\1631072|after|benzylthiouracil|had|carbimazole (r_advcl) appeared_12\VBD\2604760|which|replaced (r_acl:relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared
C019269_D056486 NONE ne_17\NNP\14622893|(|basd|) (r_appos) benzylthiouracil_14\NN\1740|ne (r_nsubj) replaced_20\VBN\1631072|after|benzylthiouracil|had|carbimazole (r_advcl) appeared_12\VBD\2604760|which|replaced (r_acl:relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared
D002231_D002779 CID carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D002779 CID omercazole_11\NN\1740|(|n|) (r_appos) carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D002779 CID carbimazole_12\NN\1740|following (r_nmod) hepatitis_10\NN\14127211|a|mixed|carbimazole (l_amod) mixed_4\JJ\1740|cholestatic (l_dep) cholestatic_6\JJ\1740|(|and|cytolytic|)
7988234
D008790_D000799 CID metoprolol_6\NN\2832168|of (r_nmod) administration_4\NN\1133281|the|intravenous|metoprolol (r_dobj) following_1\VBG\1835496|administration (r_acl) angioedema_0\NN\14316714|following|.
D008790_D000799 CID metoprolol_12\NN\2832168|intravenous (r_nsubjpass) given_14\VBN\2327200|day|,|metoprolol|was|,|resulting|. (l_advcl) resulting_16\VBG\2633881|angioedema (l_nmod) angioedema_19\NN\14316714|in|severe
D017706_D000799 CID lisinopril_6\NN\2673637| (r_compound) therapy_7\NN\657604|to|lisinopril (r_nmod) secondary_4\JJ\1740|therapy (r_amod) angioedema_3\NN\14316714|of|secondary
D013256_D000799 NONE steroids_7\NNS\14727670|with|intravenous|and|hydrochloride (r_nmod) therapy_4\NN\657604|after|steroids (r_nmod) resolved_2\VBD\352826|angioedema|therapy|. (l_nsubj) angioedema_1\NN\14316714|the
D004155_D000799 NONE diphenhydramine_9\NN\2720725| (r_compound) hydrochloride_10\NN\14817592|diphenhydramine (r_conj) steroids_7\NNS\14727670|with|intravenous|and|hydrochloride (r_nmod) therapy_4\NN\657604|after|steroids (r_nmod) resolved_2\VBD\352826|angioedema|therapy|. (l_nsubj) angioedema_1\NN\14316714|the
12684739
D020888_D019966 NONE gvg_35\NN\1740|of|sub-chronic|dose (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_acl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance
D020888_D005128 CID gvg_35\NN\1740|of|sub-chronic|dose (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D020888_D005128 CID gvg_35\NN\1740|of|sub-chronic|dose (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NNS\1740|(|)
D003042_D019966 NONE cocaine-induced_37\JJ\1740| (r_amod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_acl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance
D003042_D005128 NONE cocaine-induced_37\JJ\1740| (r_amod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D003042_D005128 NONE cocaine-induced_37\JJ\1740| (r_amod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NNS\1740|(|)
D004298_D019966 NONE dopamine_45\NN\14807737|accumbens (r_compound) da_47\NN\10484858|in|dopamine|(|) (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_acl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance
D004298_D019966 NONE da_47\NN\10484858|in|dopamine|(|) (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_acl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance
D004298_D005128 NONE dopamine_45\NN\14807737|accumbens (r_compound) da_47\NN\10484858|in|dopamine|(|) (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D004298_D005128 NONE dopamine_45\NN\14807737|accumbens (r_compound) da_47\NN\10484858|in|dopamine|(|) (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NNS\1740|(|)
D004298_D005128 NONE da_47\NN\10484858|in|dopamine|(|) (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D004298_D005128 NONE da_47\NN\10484858|in|dopamine|(|) (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|da (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_nsubj) objectives_0\NNS\5980875|:|success (l_nmod) success_5\NN\7283608|given|its|preclinical|treating|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NNS\1740|(|)
14657095
D000666_D002311 CID b_6\NN\1355326|amphotericin (r_compound) therapy_7\NN\657604|to|b (r_nmod) related_3\JJ\1740|therapy (r_amod) cardiomyopathy_2\NN\14103288|reversible|dilated|related|.
D000666_D002311 CID b_20\NN\1355326|with|amphotericin|amb|coccidioidomycosis (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|cardiomyopathy|months (l_dobj) cardiomyopathy_7\NN\14103288|dilated|and|failure
D000666_D002311 CID amb_22\NN\1740|(|) (r_appos) b_20\NN\1355326|with|amphotericin|amb|coccidioidomycosis (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|cardiomyopathy|months (l_dobj) cardiomyopathy_7\NN\14103288|dilated|and|failure
D000666_D006333 CID b_20\NN\1355326|with|amphotericin|amb|coccidioidomycosis (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|cardiomyopathy|months (l_dobj) cardiomyopathy_7\NN\14103288|dilated|and|failure (l_conj) failure_12\NN\66216|clinical|congestive|heart
D000666_D006333 CID amb_22\NN\1740|(|) (r_appos) b_20\NN\1355326|with|amphotericin|amb|coccidioidomycosis (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|cardiomyopathy|months (l_dobj) cardiomyopathy_7\NN\14103288|dilated|and|failure (l_conj) failure_12\NN\66216|clinical|congestive|heart
D000666_D006333 CID amb._12\.\1740|for (r_nmod) substituted_10\VBN\126264|after|posaconazole|was|amb. (r_advcl) resolved_6\VBD\352826|abnormalities|substituted (l_nsubj) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure (l_conj) failure_5\NN\66216|heart
D000666_D003047 NONE b_20\NN\1355326|with|amphotericin|amb|coccidioidomycosis (l_nmod) coccidioidomycosis_26\NN\14176895|for|disseminated
D000666_D003047 NONE amb_22\NN\1740|(|) (r_appos) b_20\NN\1355326|with|amphotericin|amb|coccidioidomycosis (l_nmod) coccidioidomycosis_26\NN\14176895|for|disseminated
C101425_D006333 NONE posaconazole_8\NN\1740| (r_nsubjpass) substituted_10\VBN\126264|after|posaconazole|was|amb. (r_advcl) resolved_6\VBD\352826|abnormalities|substituted (l_nsubj) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure (l_conj) failure_5\NN\66216|heart
D000666_D064420 NONE amb._12\.\1740|of (r_nmod) toxicity_10\NN\13576101|the|rare|amb.
20098969
D008694_D001145 NONE methamphetamine_2\NN\2704153| (r_nsubj) stimulant_9\NN\5816287|:|methamphetamine|is|a|addictive|,|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension
D008694_D006973 NONE methamphetamine_2\NN\2704153| (r_nsubj) stimulant_9\NN\5816287|:|methamphetamine|is|a|addictive|,|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension (l_conj) hypertension_26\NN\14057371|,|hallucinations
D008694_D006212 NONE methamphetamine_2\NN\2704153| (r_nsubj) stimulant_9\NN\5816287|:|methamphetamine|is|a|addictive|,|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension (l_conj) hypertension_26\NN\14057371|,|hallucinations (l_conj) hallucinations_28\NNS\14376855|,|and|behavior
D008694_D001523 NONE methamphetamine_2\NN\2704153| (r_nsubj) stimulant_9\NN\5816287|:|methamphetamine|is|a|addictive|,|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension (l_conj) hypertension_26\NN\14057371|,|hallucinations (l_conj) hallucinations_28\NNS\14376855|,|and|behavior (l_conj) behavior_32\NN\407535|violent
D008694_D014987 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries
D008694_D003731 CID methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries (l_conj) caries_14\NN\13456715|rampant|mouth|,|and|wear
D008694_D003731 CID methamphetamine_5\NN\2704153|of (r_nmod) use_3\NN\407535|her|methamphetamine (r_dobj) reported_1\VBD\831651|she|use|years|and|experienced|. (l_conj) experienced_12\VBN\2108377|had|not|episodes|started (l_dobj) episodes_16\NNS\7283608|any|major|carious
D008694_-1 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries (l_conj) caries_14\NN\13456715|rampant|mouth|,|and|wear (l_appos) mouth_18\NN\5610008|(|"|meth|"|)
D008694_-1 NONE methamphetamines_26\NNS\2704153| (r_dobj) abusing_25\VBG\2514187|who|may|be|methamphetamines (r_acl:relcl) patients_21\NNS\9898892|abusing (r_dobj) manage_20\VB\2524171|patients (r_conj) recognize_18\VB\686447|practitioners|and|manage (r_ccomp) help_15\VB\2556126|to|recognize (r_advcl) presented_13\VBN\2137132|case|was|help (l_nsubjpass) case_5\NN\7283608|this|clinical|showing (l_acl) showing_6\VBG\2137132|manifestations (l_dobj) manifestations_8\NNS\7321772|oral|mouth (l_nmod) mouth_11\NN\5610008|of|meth
D008694_D057085 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\14536438|,|caries (l_conj) caries_14\NN\13456715|rampant|mouth|,|and|wear (l_conj) wear_25\NN\14561618|excessive|tooth
16005948
-1_D062787 NONE gnc92h2_6\NN\1740|of|antibody (r_nmod) evaluation_0\NN\874067|gnc92h2|immunotherapy|. (l_nmod) immunotherapy_9\NN\661091|as|an|overdose (l_nmod) overdose_12\NN\1740|for|cocaine
-1_D062787 NONE gnc92h2_7\NN\1740|antibody (r_dobj) potential_2\NN\14481929|the|therapeutic|gnc92h2 (r_nsubjpass) examined_9\VBN\789138|potential|was|using|. (l_xcomp) using_10\VBG\1156834|model (l_dobj) model_12\NN\5888929|a|overdose (l_nmod) overdose_15\NN\1740|of|cocaine
-1_D062787 NONE gnc92h2_7\NN\1740|of (r_nmod) potential_5\NN\14481929|the|important|gnc92h2|tool (l_nmod) tool_11\NN\3563967|as|a|therapeutic|overdose (l_nmod) overdose_14\NN\1740|against|cocaine
D003042_D062787 NONE cocaine_4\NN\3492717|of (r_nmod) use_2\NN\407535|the|illicit|cocaine (r_nsubj) continues_5\VBZ\2367363|use|proportions|and|remains (l_conj) remains_14\VBZ\2604760|treatment|elusive|. (l_nsubj) treatment_10\NN\654885|overdose (l_nmod) overdose_13\NN\1740|for|cocaine
D003042_D064420 NONE cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|of|cocaine
D003042_D012640 CID cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|of|cocaine (r_nmod) blockade_1\NN\952963|significant|toxicity (r_nsubjpass) observed_6\VBN\2163746|blockade|was|dose|. (l_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2|,|reduced (l_acl:relcl) reduced_22\VBN\441445|where|behaviors|were|%|,|seizures|and|death (l_conj) seizures_28\NNS\14081375|%
D003042_D003643 NONE cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|of|cocaine (r_nmod) blockade_1\NN\952963|significant|toxicity (r_nsubjpass) observed_6\VBN\2163746|blockade|was|dose|. (l_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2|,|reduced (l_acl:relcl) reduced_22\VBN\441445|where|behaviors|were|%|,|seizures|and|death (l_conj) death_34\NN\7296428|%
D003042_D003643 NONE post-cocaine_6\JJ\1740|even (r_amod) injection_7\NN\320852|post-cocaine (r_nmod:tmod) prevented_3\VBD\1740|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\7296428|
-1_D064420 NONE gnc92h2_12\NN\1740|of|mg/kg (r_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2|,|reduced (r_nmod) observed_6\VBN\2163746|blockade|was|dose|. (l_nsubjpass) blockade_1\NN\952963|significant|toxicity (l_nmod) toxicity_4\NN\13576101|of|cocaine
-1_D012640 NONE gnc92h2_12\NN\1740|of|mg/kg (r_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2|,|reduced (l_acl:relcl) reduced_22\VBN\441445|where|behaviors|were|%|,|seizures|and|death (l_conj) seizures_28\NNS\14081375|%
-1_D003643 NONE gnc92h2_12\NN\1740|of|mg/kg (r_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2|,|reduced (l_acl:relcl) reduced_22\VBN\441445|where|behaviors|were|%|,|seizures|and|death (l_conj) death_34\NN\7296428|%
-1_D003643 NONE gnc92h2_2\NN\1740| (r_nsubj) prevented_3\VBD\1740|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\7296428|
3560095
D005480_D001171 NONE flurbiprofen_0\NN\3828465|treatment|. (l_nmod) treatment_3\NN\654885|in|the|arthritis (l_nmod) arthritis_7\NN\14171682|of|juvenile|rheumatoid
D005480_D001171 NONE flurbiprofen_11\NN\3828465|with (r_nmod) treated_9\VBN\2376958|who|were|flurbiprofen|dose (r_acl:relcl) patients_1\NNS\9898892|thirty-four|arthritis|,|treated|, (l_nmod) arthritis_5\NN\14171682|with|juvenile|rheumatoid
D005480_D001168 NONE flurbiprofen_11\NN\3828465|with (r_nmod) treated_9\VBN\2376958|who|were|flurbiprofen|dose (r_acl:relcl) patients_1\NNS\9898892|thirty-four|arthritis|,|treated|, (r_nsubj) had_20\VBD\2108377|patients|decreases|weeks|. (l_dobj) decreases_23\NNS\7296428|significant|baseline|indices (l_nmod) indices_29\NNS\13850304|in|6|arthritis (l_compound) arthritis_28\NN\14171682|
1601297
D003042_D009202 NONE cocaine_8\NN\3492717| (r_compound) abusers_9\NNS\9633969|in|hospitalized|cocaine (r_nmod) injury_4\NN\14052046|of|myocardial|abusers
D003042_D009202 NONE cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined
D003042_D012559 NONE cocaine-abusing_7\JJ\1740| (r_amod) patients_8\NNS\9898892|of|99|cocaine-abusing (r_nmod) electrocardiograms_1\NNS\7000195|the|ecg|patients (r_nsubjpass) compared_10\VBN\644583|electrocardiograms|were|ecgs|. (l_nmod) ecgs_13\NNS\7000195|with|the|controls (l_nmod) controls_17\NNS\5190804|of|50|schizophrenic (l_amod) schizophrenic_16\JJ\1740|
D003042_D009203 CID cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|infarction (l_nmod) infarction_20\NN\14204950|as|myocardial|,|ischemia|,|and|block
D003042_D007511 NONE cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|infarction (l_nmod) infarction_20\NN\14204950|as|myocardial|,|ischemia|,|and|block (l_conj) ischemia_22\NN\14195315|
D003042_D002037 CID cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|infarction (l_nmod) infarction_20\NN\14204950|as|myocardial|,|ischemia|,|and|block (l_conj) block_27\NN\21939|bundle|branch
26094
D008750_D003866 CID dopa_13\NN\14601829|methyl (r_nmod:npmod) treated_14\JJ\1740|dopa (r_amod) patients_15\NNS\9898892|in|treated|histories (r_nmod) occurring_10\VBG\2623529|patients (r_acl) depressions_9\NNS\14373582|of|occurring
D008750_D001523 NONE dopa_13\NN\14601829|methyl (r_nmod:npmod) treated_14\JJ\1740|dopa (r_amod) patients_15\NNS\9898892|in|treated|histories (l_nmod) histories_18\NNS\15120823|with|psychiatric (l_amod) psychiatric_17\JJ\1740|
18951540
D007980_D004409 CID levodopa-induced_5\JJ\1740| (r_amod) dyskinesias_6\NNS\14084880|for|levodopa-induced|disease
D007980_D010300 NONE levodopa-induced_5\JJ\1740| (r_amod) dyskinesias_6\NNS\14084880|for|levodopa-induced|disease (l_nmod) disease_10\NN\14061805|in|parkinson|'s
11256525
D019808_D001002 CID losartan_4\NN\1740| (r_compound) administration_5\NN\1133281|following|losartan|patient (r_nmod) anuria_2\NN\14061805|repeated|transient|administration|.
D019808_D001002 CID losartan_25\NN\1740| (r_compound) administration_26\NN\1133281|after|losartan (r_nmod) developed_18\VBD\1753788|who|episodes|administration (l_dobj) episodes_20\NNS\7283608|two|anuria (l_nmod) anuria_23\NN\14061805|of|transient
D019808_D001002 CID losartan_9\NN\1740|of (r_nmod) mg_7\NN\13717155|of|50|losartan (r_nmod) dose_4\NN\3740161|the|first|mg (r_nsubj) resulted_10\VBD\2633881|surprisingly|,|dose|anuria|. (l_nmod) anuria_14\NN\14061805|in|a|sudden|,|lasted
D019808_D001002 CID losartan_7\NN\1740| (r_nsubjpass) prescribed_9\VBN\748282|later|,|mistake|,|losartan|was|again|and|developed (l_conj) developed_22\VBD\1753788|dose|,|patient|episode (l_dobj) episode_25\NN\7283608|a|second|anuria|lasting (l_nmod) anuria_28\NN\14061805|of|transient
D019808_D006973 NONE losartan_25\NN\1740| (r_compound) administration_26\NN\1133281|after|losartan (r_nmod) developed_18\VBD\1753788|who|episodes|administration (r_acl:relcl) man_8\NN\9605289|of|a|70-year-old|hypertensive|kidney|developed (l_amod) hypertensive_7\JJ\1740|
D019808_D051436 NONE losartan_25\NN\1740| (r_compound) administration_26\NN\1133281|after|losartan (r_nmod) developed_18\VBD\1753788|who|episodes|administration (r_acl:relcl) man_8\NN\9605289|of|a|70-year-old|hypertensive|kidney|developed (l_nmod) kidney_12\NN\5333259|with|a|solitary|and|insufficiency (l_conj) insufficiency_16\NN\14462946|chronic|renal
D019808_D006331 NONE losartan_5\NN\1740| (r_nsubjpass) prescribed_7\VBN\748282|dysfunction|losartan|was|. (l_nmod) dysfunction_4\NN\14204950|due|severe|systolic
D005665_D001002 NONE furosemide_22\NN\3214670|high-dose|and|amine (r_compound) infusion_25\NN\14589223|despite|furosemide (r_nmod) lasted_17\VBD\2704349|which|hours|infusion (r_acl:relcl) anuria_14\NN\14061805|in|a|sudden|,|lasted
D000588_D001002 NONE amine_24\NN\14951377| (r_conj) furosemide_22\NN\3214670|high-dose|and|amine (r_compound) infusion_25\NN\14589223|despite|furosemide (r_nmod) lasted_17\VBD\2704349|which|hours|infusion (r_acl:relcl) anuria_14\NN\14061805|in|a|sudden|,|lasted
D000809_D012078 NONE renin-angiotensin_22\JJ\1740| (r_amod) system_23\NN\3575240|of|the|renin-angiotensin|ras (r_nmod) activation_19\NN\13561719|in|a|strong|system (r_nmod) resulted_15\VBD\2633881|patient|,|stenosis|certainly|activation|. (l_nsubj) stenosis_6\NN\14204950|renal|artery|combined
D000809_D006333 NONE renin-angiotensin_22\JJ\1740| (r_amod) system_23\NN\3575240|of|the|renin-angiotensin|ras (r_nmod) activation_19\NN\13561719|in|a|strong|system (r_nmod) resulted_15\VBD\2633881|patient|,|stenosis|certainly|activation|. (l_nsubj) stenosis_6\NN\14204950|renal|artery|combined (l_acl) combined_7\VBN\2630189|failure (l_nmod) failure_10\NN\66216|with|heart|and|therapy
D000804_D014652 NONE ii_9\CD\13741022| (r_nummod) losartan_12\NN\1740|the|angiotensin|ii|receptor|antagonist (r_nsubj) cause_14\VB\1617192|that|losartan|can|complications|patients|and|used (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_22\NN\14061805|with|renovascular
D019808_D014652 NONE losartan_12\NN\1740|the|angiotensin|ii|receptor|antagonist (r_nsubj) cause_14\VB\1617192|that|losartan|can|complications|patients|and|used (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_22\NN\14061805|with|renovascular
15602202
D017963_D009395 CID azithromycin_6\NN\2716205|by (r_nmod) induced_4\VBN\1627355|azithromycin (r_acl) nephritis_3\NN\14113228|recurrent|acute|interstitial|induced|.
D017963_D009395 CID azithromycin-induced_8\JJ\1740| (r_amod) nephritis_12\NN\14113228|with|recurrent|,|azithromycin-induced|,|acute|interstitial
10721819
D007545_D013610 NONE isoproterenol_5\NN\3740161|with (r_nmod) pretreatment_3\NN\1740|of|long-term|isoproterenol (r_nmod) effects_0\NNS\13245626|pretreatment|tachycardia|. (l_nmod) tachycardia_8\NN\14110674|on|bromocriptine-induced|rats
D007545_D013610 NONE isoproterenol_31\NN\3740161| (r_compound) pretreatment_32\NN\1740|by|5-day|isoproterenol (r_nmod) reduced_28\VBN\441445|ii|pretreatment (r_conj) mediated_17\VBN\761713|that|tachycardia|is|i|activation|and|reduced (l_nsubjpass) tachycardia_6\NN\14110674|bromocriptine-induced|,|persisted|,
D007545_D013610 NONE isoproterenol_10\NN\3740161|with (r_nmod) pretreatment_8\NN\1740|prolonged|isoproterenol (r_nsubj) abolish_12\VB\1740|whether|pretreatment|could|tachycardia (l_dobj) tachycardia_14\NN\14110674|bromocriptine-induced|rats
D007545_D013610 NONE isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|by|isoproterenol (r_nmod) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (l_nsubjpass) tachycardia_9\NN\14110674|
D007545_D013610 NONE isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|15-day|isoproterenol (r_nsubj) abolished_9\VBD\1740|that|pretreatment|only|but|reversed|bradycardia|,|effect (l_conj) reversed_11\VBD\109660|tachycardia (l_dobj) tachycardia_13\NN\14110674|bromocriptine-induced
D001971_D013610 CID bromocriptine-induced_7\JJ\1740| (r_amod) tachycardia_8\NN\14110674|on|bromocriptine-induced|rats
D001971_D013610 CID bromocriptine-induced_5\JJ\1740| (r_amod) tachycardia_6\NN\14110674|bromocriptine-induced|,|persisted|,
D001971_D013610 CID bromocriptine-induced_13\JJ\1740| (r_amod) tachycardia_14\NN\14110674|bromocriptine-induced|rats
D001971_D013610 CID bromocriptine_5\NN\1740|intravenous|microg/kg (r_nsubj) induced_10\VBD\1627355|rats|,|bromocriptine|hypotension|. (l_dobj) hypotension_12\NN\14057371|significant|and|tachycardia (l_conj) tachycardia_14\NN\14110674|
D001971_D013610 CID bromocriptine-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|bromocriptine-induced (r_nsubjpass) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (l_nsubjpass) tachycardia_9\NN\14110674|
D001971_D013610 CID bromocriptine-induced_12\JJ\1740| (r_amod) tachycardia_13\NN\14110674|bromocriptine-induced
D001971_D013610 CID bromocriptine_13\NN\1740|of (r_nmod) tachycardia_11\NN\14110674|the|central|bromocriptine
D004298_D013610 NONE dopamine_20\NN\14807737| (r_compound) receptor_22\NN\5225602|central|dopamine|d2 (r_compound) activation_23\NN\13561719|by|receptor (r_nmod) mediated_17\VBN\761713|that|tachycardia|is|i|activation|and|reduced (l_nsubjpass) tachycardia_6\NN\14110674|bromocriptine-induced|,|persisted|,
D004298_D013610 NONE dopamine_27\NN\14807737| (r_compound) receptors_29\NNS\5225602|at|peripheral|dopamine|d2 (r_nmod) mask_19\VB\2158587|to|bradycardia|receptors (r_conj) predominate_16\VB\2696801|to|and|mask (r_xcomp) appears_14\VBZ\2604760|that|,|rats|,|tachycardia|predominate (l_nsubj) tachycardia_11\NN\14110674|the|central|bromocriptine
D007545_D006332 CID isoproterenol_0\NN\3740161| (r_compound) pretreatment_1\NN\1740|isoproterenol|days (r_nsubj) caused_5\VBD\1617192|pretreatment|hypertrophy|affecting|. (l_dobj) hypertrophy_7\NN\14365950|cardiac
D001971_D007022 CID bromocriptine_5\NN\1740|intravenous|microg/kg (r_nsubj) induced_10\VBD\1627355|rats|,|bromocriptine|hypotension|. (l_dobj) hypotension_12\NN\14057371|significant|and|tachycardia
D001971_D007022 CID bromocriptine-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|bromocriptine-induced
D001971_D001919 NONE bromocriptine-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|bromocriptine-induced (r_nsubjpass) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (l_nmod) bradycardia_14\NN\14110674|to|significant
D001971_D001919 NONE bromocriptine-induced_12\JJ\1740| (r_amod) tachycardia_13\NN\14110674|bromocriptine-induced (r_dobj) reversed_11\VBD\109660|tachycardia (r_conj) abolished_9\VBD\1740|that|pretreatment|only|but|reversed|bradycardia|,|effect (l_nmod) bradycardia_15\NN\14110674|to
D001971_D001919 NONE bromocriptine_13\NN\1740|of (r_nmod) tachycardia_11\NN\14110674|the|central|bromocriptine (r_nsubj) appears_14\VBZ\2604760|that|,|rats|,|tachycardia|predominate (l_xcomp) predominate_16\VB\2696801|to|and|mask (l_conj) mask_19\VB\2158587|to|bradycardia|receptors (l_dobj) bradycardia_21\NN\14110674|the|agonist
D007545_D007022 NONE isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|by|isoproterenol (r_nmod) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|. (l_nsubjpass) hypotension_1\NN\14057371|bromocriptine-induced
D007545_D001919 CID isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|by|isoproterenol (r_nmod) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (l_nmod) bradycardia_14\NN\14110674|to|significant
D007545_D001919 CID isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|15-day|isoproterenol (r_nsubj) abolished_9\VBD\1740|that|pretreatment|only|but|reversed|bradycardia|,|effect (l_nmod) bradycardia_15\NN\14110674|to
D004294_D007022 NONE domperidone_24\NN\1740|by|i.v.|mg/kg (r_nmod) reduced_21\VBN\441445|that|was|partly|domperidone (r_acl:relcl) effect_17\NN\34213|an|reduced (r_dobj) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (r_advcl) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|. (l_nsubjpass) hypotension_1\NN\14057371|bromocriptine-induced
D004294_D013610 NONE domperidone_24\NN\1740|by|i.v.|mg/kg (r_nmod) reduced_21\VBN\441445|that|was|partly|domperidone (r_acl:relcl) effect_17\NN\34213|an|reduced (r_dobj) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (l_nsubjpass) tachycardia_9\NN\14110674|
D004294_D001919 CID domperidone_24\NN\1740|by|i.v.|mg/kg (r_nmod) reduced_21\VBN\441445|that|was|partly|domperidone (r_acl:relcl) effect_17\NN\34213|an|reduced (r_dobj) reversed_11\VBN\109660|while|tachycardia|was|bradycardia|,|effect (l_nmod) bradycardia_14\NN\14110674|to|significant
D004298_D001919 NONE dopamine_27\NN\14807737| (r_compound) receptors_29\NNS\5225602|at|peripheral|dopamine|d2 (r_nmod) mask_19\VB\2158587|to|bradycardia|receptors (l_dobj) bradycardia_21\NN\14110674|the|agonist
20621845
D002122_D017545 CID cacl2-induced_14\JJ\1740| (r_amod) aneurysm_17\NN\14057371|cacl2-induced|thoracic|aortic|model
D002122_D017545 CID chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial (r_nmod) model_10\NN\5888929|a|rat|aneurysm|injury (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa
D002122_D017545 CID chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial (r_nmod) model_10\NN\5888929|a|rat|aneurysm|injury (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa (l_appos) taa_16\NN\1740|(|)
D002122_D017545 CID chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial (r_nmod) model_10\NN\5888929|a|rat|aneurysm|injury (r_dobj) establish_7\VB\2426171|to|model|and|explore (l_conj) explore_27\VB\789138|to|role (l_dobj) role_30\NN\719494|the|potential|disintegrin|formation (l_nmod) formation_54\NN\7938773|in|taa (l_compound) taa_53\NN\1740|
D002122_D017545 CID cacl(2))-induced_22\NN\1740|( (r_appos) chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial (r_nmod) model_10\NN\5888929|a|rat|aneurysm|injury (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa
D002122_D017545 CID cacl(2))-induced_22\NN\1740|( (r_appos) chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial (r_nmod) model_10\NN\5888929|a|rat|aneurysm|injury (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa (l_appos) taa_16\NN\1740|(|)
D002122_D017545 CID cacl(2))-induced_22\NN\1740|( (r_appos) chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial (r_nmod) model_10\NN\5888929|a|rat|aneurysm|injury (r_dobj) establish_7\VB\2426171|to|model|and|explore (l_conj) explore_27\VB\789138|to|role (l_dobj) role_30\NN\719494|the|potential|disintegrin|formation (l_nmod) formation_54\NN\7938773|in|taa (l_compound) taa_53\NN\1740|
D002122_D017545 CID )_11\-RRB-\1740| (r_punct) cacl(2_10\NN\1740|periarterial|) (r_nummod) exposure_12\NN\5042871|by|cacl(2|rats (r_nmod) model_7\NN\5888929|a|taa|exposure (l_compound) taa_6\NN\1740|
D002122_D014652 NONE chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial
D002122_D014652 NONE cacl(2))-induced_22\NN\1740|( (r_appos) chloride_20\NN\14818238|calcium|cacl(2))-induced (r_compound) injury_24\NN\14052046|by|chloride|arterial
3615541
D000661_D006948 CID amphetamine-induced_6\JJ\1740| (r_amod) hyperactivity_7\NN\14052403|of|amphetamine-induced|injections
D002116_D006948 NONE calcitonin_10\NN\5413241| (r_compound) injections_11\NNS\320852|by|intracerebral|calcitonin (r_nmod) hyperactivity_7\NN\14052403|of|amphetamine-induced|injections
18410508
D008694_D020258 NONE methamphetamine-induced_0\JJ\1740| (r_amod) neurotoxicity_1\NN\1740|methamphetamine-induced|and|activation
D008694_D020258 NONE meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (l_nmod) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D008694_D020258 NONE meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (r_advcl) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_ccomp) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (l_nmod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
D008694_D020258 NONE meth-induced_32\JJ\1740| (r_amod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation (r_nmod) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (r_ccomp) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_advcl) selective_11\JJ\1740|because|damage|is|highly|system (l_nmod) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D008694_D020258 NONE meth-induced_32\JJ\1740| (r_amod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
D008694_D020258 NONE meth_25\NN\2704153|with (r_nmod) treated_23\VBN\2376958|mice|were|meth|and|examined|. (l_conj) examined_27\VBN\789138|neurotoxicity (l_nmod) neurotoxicity_30\NN\1740|for|striatal
D008694_D020258 NONE meth_11\NN\2704153| (r_compound) neurotoxicity_12\NN\1740|meth|or|activation
D015632_D009422 CID mptp-induced_29\JJ\1740| (r_amod) neurodegeneration_30\NN\1740|of|mptp-induced|neurons
D015632_D009422 CID mptp_8\NN\1740| (r_conj) meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused
D004298_D009422 NONE da_32\NN\10484858| (r_compound) neurons_33\NNS\5430628|of|da (r_nmod) neurodegeneration_30\NN\1740|of|mptp-induced|neurons
D004298_D009422 NONE da_14\NN\10484858| (r_compound) system_16\NN\3575240|for|the|da|neuronal|models (r_nmod) selective_11\JJ\1740|because|damage|is|highly|system (l_nsubj) damage_3\NN\7296428|the|cns|caused
D008694_D009422 CID meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused
D008694_D009422 CID meth-induced_32\JJ\1740| (r_amod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation (r_nmod) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (r_ccomp) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_advcl) selective_11\JJ\1740|because|damage|is|highly|system (l_nsubj) damage_3\NN\7296428|the|cns|caused
D015632_D020258 NONE mptp_8\NN\1740| (r_conj) meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (l_nmod) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D015632_D020258 NONE mptp_8\NN\1740| (r_conj) meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (r_advcl) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_ccomp) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (l_nmod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
D004298_D020258 NONE da_14\NN\10484858| (r_compound) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D004298_D020258 NONE da_14\NN\10484858| (r_compound) system_16\NN\3575240|for|the|da|neuronal|models (r_nmod) selective_11\JJ\1740|because|damage|is|highly|system (r_advcl) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_ccomp) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (l_nmod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
2572625
C084599_D056486 CID clotiazepam-induced_0\NN\1740| (r_compound) hepatitis_2\NN\14127211|clotiazepam-induced|acute|.
C084599_D056486 CID clotiazepam_24\NN\1740|of|,|derivative (r_nmod) administration_22\NN\1133281|of|clotiazepam (r_nmod) onset_20\NN\7325190|after|the|administration (r_nmod) developed_8\VBD\1753788|who|hepatitis|,|onset (l_dobj) hepatitis_10\NN\14127211|acute|necrosis
C084599_D056486 CID clotiazepam_9\NN\1740|to (r_nmod) related_7\JJ\1740|chemically|clotiazepam (r_amod) benzodiazepines_4\NNS\3771443|of|several|,|related|, (r_nmod) administration_1\NN\1133281|the|benzodiazepines (r_nsubj) interfere_13\VB\2451370|administration|did|not|recovery|and|induce|. (l_conj) induce_19\VB\1627355|did|not|relapse (l_dobj) relapse_21\NN\66636|any|hepatitis (l_nmod) hepatitis_23\NN\14127211|of
C084599_D056486 CID clotiazepam_4\NN\1740| (r_nsubj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis (l_dobj) hepatitis_8\NN\14127211|acute
C084599_D056486 CID clotiazepam_4\NN\1740| (r_nsubj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis (r_ccomp) shows_2\VBZ\2137132|observation|induce|and|suggests|. (l_conj) suggests_10\VBZ\1010118|is (l_ccomp) is_13\VBZ\836236|that|there|hepatotoxicity (l_attr) hepatotoxicity_16\NN\1740|no|cross|clotiazepam
C084599_D056486 CID clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam (r_attr) is_13\VBZ\836236|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\1010118|is (r_conj) shows_2\VBZ\2137132|observation|induce|and|suggests|. (l_ccomp) induce_6\VB\1627355|that|clotiazepam|can|hepatitis (l_dobj) hepatitis_8\NN\14127211|acute
C084599_D056486 CID clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam
C084599_D047508 NONE clotiazepam_24\NN\1740|of|,|derivative (r_nmod) administration_22\NN\1133281|of|clotiazepam (r_nmod) onset_20\NN\7325190|after|the|administration (r_nmod) developed_8\VBD\1753788|who|hepatitis|,|onset (l_dobj) hepatitis_10\NN\14127211|acute|necrosis (l_nmod) necrosis_14\NN\11444117|with|extensive|hepatocellular
C013295_D056486 NONE thienodiazepine_27\NN\1740| (r_compound) derivative_28\NN\5802185|a|thienodiazepine (r_appos) clotiazepam_24\NN\1740|of|,|derivative (r_nmod) administration_22\NN\1133281|of|clotiazepam (r_nmod) onset_20\NN\7325190|after|the|administration (r_nmod) developed_8\VBD\1753788|who|hepatitis|,|onset (l_dobj) hepatitis_10\NN\14127211|acute|necrosis
C013295_D047508 NONE thienodiazepine_27\NN\1740| (r_compound) derivative_28\NN\5802185|a|thienodiazepine (r_appos) clotiazepam_24\NN\1740|of|,|derivative (r_nmod) administration_22\NN\1133281|of|clotiazepam (r_nmod) onset_20\NN\7325190|after|the|administration (r_nmod) developed_8\VBD\1753788|who|hepatitis|,|onset (l_dobj) hepatitis_10\NN\14127211|acute|necrosis (l_nmod) necrosis_14\NN\11444117|with|extensive|hepatocellular
D001569_D056486 NONE benzodiazepines_4\NNS\3771443|of|several|,|related|, (r_nmod) administration_1\NN\1133281|the|benzodiazepines (r_nsubj) interfere_13\VB\2451370|administration|did|not|recovery|and|induce|. (l_conj) induce_19\VB\1627355|did|not|relapse (l_dobj) relapse_21\NN\66636|any|hepatitis (l_nmod) hepatitis_23\NN\14127211|of
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|several (r_conj) clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam (r_attr) is_13\VBZ\836236|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\1010118|is (r_conj) shows_2\VBZ\2137132|observation|induce|and|suggests|. (l_ccomp) induce_6\VB\1627355|that|clotiazepam|can|hepatitis (l_dobj) hepatitis_8\NN\14127211|acute
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|several (r_conj) clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam
16938416
D013739_D050197 CID testosterone_1\NN\14747587|high-dose (r_nsubjpass) associated_3\VBN\628491|testosterone|is|atherosclerosis|. (l_nmod) atherosclerosis_5\NN\14108324|with|women
D013739_D050197 CID estrogen-testosterone_26\NN\1740| (r_compound) therapy_27\NN\657604|between|self-reported|administered|high-dose|estrogen-testosterone|estradiol-|and|atherosclerosis (l_conj) atherosclerosis_36\NN\14108324|aortic
D013739_D050197 CID testosterone_7\NN\14747587| (r_compound) therapy_8\NN\657604|high-dose|testosterone (r_nsubj) affect_11\VB\126264|that|therapy|may|adversely|atherosclerosis (l_dobj) atherosclerosis_12\NN\14108324|women
D004967_D050197 NONE estrogen-testosterone_26\NN\1740| (r_compound) therapy_27\NN\657604|between|self-reported|administered|high-dose|estrogen-testosterone|estradiol-|and|atherosclerosis (l_conj) atherosclerosis_36\NN\14108324|aortic
C032109_D050197 NONE esters_32\NNS\14727670|testosterone (r_conj) estradiol-_29\NN\1740|(|and|esters|) (r_dep) therapy_27\NN\657604|between|self-reported|administered|high-dose|estrogen-testosterone|estradiol-|and|atherosclerosis (l_conj) atherosclerosis_36\NN\14108324|aortic
D002784_D003920 NONE cholesterol_9\NN\15058310| (r_compound) level_10\NN\4916342|cholesterol|,|pressure (r_conj) diabetes_7\NN\14075199|for|,|level
D000431_D003920 NONE alcohol_17\NN\7881800| (r_compound) use_18\NN\407535|alcohol (r_conj) pressure_14\NN\11419404|systolic|blood|,|or|use (r_conj) level_10\NN\4916342|cholesterol|,|pressure (r_conj) diabetes_7\NN\14075199|for|,|level
18464113
D019259_D006509 NONE lamivudine_0\NN\3834836|prevention|. (l_nmod) prevention_3\NN\1073995|for|the|reactivation|patients (l_nmod) reactivation_8\NN\1740|of|virus (l_compound) virus_7\NN\9312843|hepatitis|b (l_compound) b_6\NN\1355326|
D019259_D006509 NONE lamivudine_20\NN\3834836|the|agent (r_dobj) received_16\VBD\2210855|study|,|patients|lamivudine|ct|group|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection (l_nmod) infection_15\NN\14052046|with|chronic|hbv
D019259_D006509 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_acl:relcl) group_29\NN\2137|compared|with|historical|control|receive (r_nmod) received_16\VBD\2210855|study|,|patients|lamivudine|ct|group|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection (l_nmod) infection_15\NN\14052046|with|chronic|hbv
D019259_D009369 NONE lamivudine_0\NN\3834836|prevention|. (l_nmod) prevention_3\NN\1073995|for|the|reactivation|patients (l_nmod) patients_18\NNS\9898892|in|antigen|seropositive|cancer|undergoing (l_compound) cancer_17\NN\14239425|
D019259_D009369 NONE lamivudine_20\NN\3834836|the|agent (r_dobj) received_16\VBD\2210855|study|,|patients|lamivudine|ct|group|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_compound) cancer_4\NN\14239425|
D019259_D009369 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_acl:relcl) group_29\NN\2137|compared|with|historical|control|receive (r_nmod) received_16\VBD\2210855|study|,|patients|lamivudine|ct|group|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_compound) cancer_4\NN\14239425|
D019259_D009369 NONE lamivudine_5\NN\3834836|prophylactic (r_nsubj) decreases_7\VBZ\169651|that|lamivudine|significantly|incidence (l_dobj) incidence_9\NN\13821570|the|reactivation|and|morbidity|during|therapy (l_conj) morbidity_15\NN\13826959|overall|patients (l_nmod) patients_18\NNS\9898892|in|cancer (l_compound) cancer_17\NN\14239425|
D006514_D006509 CID antigen_12\NN\20090|hepatitis-b|surface|hbsag (r_compound) patients_18\NNS\9898892|in|antigen|seropositive|cancer|undergoing (r_nmod) prevention_3\NN\1073995|for|the|reactivation|patients (l_nmod) reactivation_8\NN\1740|of|virus (l_compound) virus_7\NN\9312843|hepatitis|b (l_compound) b_6\NN\1355326|
D006514_D006509 CID hbsag_14\NN\1740|(|) (r_appos) antigen_12\NN\20090|hepatitis-b|surface|hbsag (r_compound) patients_18\NNS\9898892|in|antigen|seropositive|cancer|undergoing (r_nmod) prevention_3\NN\1073995|for|the|reactivation|patients (l_nmod) reactivation_8\NN\1740|of|virus (l_compound) virus_7\NN\9312843|hepatitis|b (l_compound) b_6\NN\1355326|
D006514_D009369 NONE antigen_12\NN\20090|hepatitis-b|surface|hbsag (r_compound) patients_18\NNS\9898892|in|antigen|seropositive|cancer|undergoing (l_compound) cancer_17\NN\14239425|
D006514_D009369 NONE hbsag_14\NN\1740|(|) (r_appos) antigen_12\NN\20090|hepatitis-b|surface|hbsag (r_compound) patients_18\NNS\9898892|in|antigen|seropositive|cancer|undergoing (l_compound) cancer_17\NN\14239425|
D019259_D019337 NONE lamivudine_20\NN\3834836|the|agent (r_dobj) received_16\VBD\2210855|study|,|patients|lamivudine|ct|group|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection
D019259_D019337 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_acl:relcl) group_29\NN\2137|compared|with|historical|control|receive (r_nmod) received_16\VBD\2210855|study|,|patients|lamivudine|ct|group|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection
D019259_D056486 NONE lamivudine_3\NN\3834836| (r_compound) group_4\NN\2137|in|the|prophylactic|lamivudine (r_nmod) observed_8\VBN\2163746|group|hepatitis|were|patient|p|. (l_nsubjpass) hepatitis_6\NN\14127211|severe
12483326
D016190_D005128 NONE carboplatin_9\NN\1740|of (r_nmod) injection_7\NN\320852|after|intracarotid|carboplatin|glioblastomas (r_nmod) toxicity_4\NN\13576101|severe|ocular|injection|.
D016190_D005128 NONE carboplatin_2\NN\1740| (r_nsubjpass) said_4\VBN\940384|generally|,|carboplatin|is|have|. (l_xcomp) have_6\VB\2108377|to|effects (l_dobj) effects_9\NNS\13245626|milder|side|cisplatin (l_nmod) cisplatin_11\NN\1740|than|,|known (l_acl:relcl) known_20\VBN\2110220|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D016190_D005128 NONE carboplatin_16\NN\1740|of (r_nmod) injection_14\NN\320852|after|intracarotid|carboplatin|,|reported (r_nmod) toxicity_11\NN\13576101|of|severe|ocular|injection
D016190_D005128 NONE carboplatin_7\NN\1740|of (r_nmod) injection_5\NN\320852|intracarotid|carboplatin (r_dobj) performing_3\VBG\2367363|when|injection (r_advcl) aware_12\JJ\1740|performing|,|we|must|be|toxicity|. (l_nmod) toxicity_18\NN\13576101|of|its|blinding|ocular
D016190_D009916 NONE carboplatin_9\NN\1740|of (r_nmod) injection_7\NN\320852|after|intracarotid|carboplatin|glioblastomas (r_nmod) toxicity_4\NN\13576101|severe|ocular|injection|.
D016190_D009916 NONE carboplatin_2\NN\1740| (r_nsubjpass) said_4\VBN\940384|generally|,|carboplatin|is|have|. (l_xcomp) have_6\VB\2108377|to|effects (l_dobj) effects_9\NNS\13245626|milder|side|cisplatin (l_nmod) cisplatin_11\NN\1740|than|,|known (l_acl:relcl) known_20\VBN\2110220|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D016190_D009916 NONE carboplatin_16\NN\1740|of (r_nmod) injection_14\NN\320852|after|intracarotid|carboplatin|,|reported (r_nmod) toxicity_11\NN\13576101|of|severe|ocular|injection
D016190_D005909 NONE carboplatin_9\NN\1740|of (r_nmod) injection_7\NN\320852|after|intracarotid|carboplatin|glioblastomas (l_nmod) glioblastomas_12\NNS\14236743|for|recurrent
D016190_D005909 NONE carboplatin_10\NN\1740|of (r_nmod) injection_8\NN\320852|an|intracarotid|carboplatin|glioblastomas (l_nmod) glioblastomas_13\NNS\14236743|for|recurrent|lobe
D002945_D005128 NONE cisplatin_11\NN\1740|than|,|known (l_acl:relcl) known_20\VBN\2110220|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D002945_D009916 NONE cisplatin_11\NN\1740|than|,|known (l_acl:relcl) known_20\VBN\2110220|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D016190_D064420 NONE carboplatin_7\NN\1740| (r_compound) toxicity_8\NN\13576101|by|carboplatin
8410052
D019344_D001480 NONE lactate_10\NN\14850483|of (r_nmod) infusion_8\NN\14589223|by|lactate|ph|or|stab (r_nmod) produced_6\VBN\1617192|injury|was|infusion|. (l_nsubjpass) injury_1\NN\14052046|focal|cortex (l_nmod) cortex_4\NN\5462674|in|the
D010862_D002544 CID pilocarpine-induced_10\JJ\1740| (r_amod) epilepticus_12\NN\1740|by|prolonged|pilocarpine-induced|status (r_nmod) evoked_7\VBN\1617192|infarcts|were|epilepticus|. (l_nsubjpass) infarcts_0\NNS\14204950|reticulata (l_nmod) reticulata_5\NN\1740|in|substantia|nigra|pars
D010862_D013226 CID pilocarpine-induced_10\JJ\1740| (r_amod) epilepticus_12\NN\1740|by|prolonged|pilocarpine-induced|status
2265898
C009265_D004827 CID levodopa/carbidopa_4\NN\1740| (r_compound) administration_5\NN\1133281|by|levodopa/carbidopa (r_nmod) caused_2\VBN\1617192|administration|patients (r_acl) epilepsy_1\NN\14085708|serial|caused|.
C009265_D007676 NONE carbidopa/levodopa_34\NN\1740| (r_compound) preparation_35\NN\407535|a|carbidopa/levodopa (r_dobj) receiving_32\VBG\2210855|both|had|been|preparation|;|and|had (r_conj) had_11\VBD\2108377|patients|failure|years|but|begun|;|receiving|. (l_dobj) failure_14\NN\66216|chronic|renal|,|hemodialysis
C009265_D001523 NONE carbidopa/levodopa_34\NN\1740| (r_compound) preparation_35\NN\407535|a|carbidopa/levodopa (r_dobj) receiving_32\VBG\2210855|both|had|been|preparation|;|and|had (l_conj) had_39\VBD\2108377|both|onset (l_dobj) onset_41\NN\7325190|the|hallucinosis (l_nmod) hallucinosis_43\NN\14373582|of|and|seizures|,|refractory
C009265_D012640 NONE carbidopa/levodopa_34\NN\1740| (r_compound) preparation_35\NN\407535|a|carbidopa/levodopa (r_dobj) receiving_32\VBG\2210855|both|had|been|preparation|;|and|had (l_conj) had_39\VBD\2108377|both|onset (l_dobj) onset_41\NN\7325190|the|hallucinosis (l_nmod) hallucinosis_43\NN\14373582|of|and|seizures|,|refractory (l_conj) seizures_46\NNS\14081375|recurrent
9100294
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) blockers_9\NNS\10101634|to|calcium|channel (r_nmod) exposed_5\VBN\2110927|blockers (r_acl) fetuses_4\NNS\1471682|in|rat|exposed (r_nmod) alterations_1\NNS\7283608|cardiovascular|fetuses|.
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) blocker_9\NN\10101634|a|new|calcium|channel|,|ro|, (r_nsubj) induced_16\VBD\1627355|that|blocker|alterations (l_dobj) alterations_18\NNS\7283608|cardiovascular|fetuses
D002118_D018376 NONE calcium_10\NN\14625458| (r_compound) blockers_12\NNS\10101634|calcium|channel|general (r_nsubj) induce_15\VBP\1627355|that|blockers|malformations (l_dobj) malformations_17\NNS\14213199|cardiovascular|indicating
D002118_D018376 NONE calcium_15\NN\14625458| (r_compound) blockers_17\NNS\10101634|of|the|four|calcium|channel (r_nmod) each_11\DT\1740|to|blockers (r_nmod) exposure_9\NN\5042871|after|each (r_nmod) observed_7\VBN\2163746|incidence|was|exposure|,|but|significant (l_nsubjpass) incidence_2\NN\13821570|a|low|malformations (l_nmod) malformations_5\NNS\14213199|of|cardiovascular
D020748_D018376 CID 5967_14\CD\1740| (r_nummod) ro_11\NN\6894544|40|-|5967 (r_appos) blocker_9\NN\10101634|a|new|calcium|channel|,|ro|, (r_nsubj) induced_16\VBD\1627355|that|blocker|alterations (l_dobj) alterations_18\NNS\7283608|cardiovascular|fetuses
D014700_D018376 CID verapamil_27\NN\2938514|only|for|and|nifedipine (r_nmod) significant_24\JJ\1740|incidence|was|statistically|verapamil|. (r_conj) observed_7\VBN\2163746|incidence|was|exposure|,|but|significant (l_nsubjpass) incidence_2\NN\13821570|a|low|malformations (l_nmod) malformations_5\NNS\14213199|of|cardiovascular
D009543_D018376 CID nifedipine_29\NN\2938514| (r_conj) verapamil_27\NN\2938514|only|for|and|nifedipine (r_nmod) significant_24\JJ\1740|incidence|was|statistically|verapamil|. (r_conj) observed_7\VBN\2163746|incidence|was|exposure|,|but|significant (l_nsubjpass) incidence_2\NN\13821570|a|low|malformations (l_nmod) malformations_5\NNS\14213199|of|cardiovascular
15957009
C507242_D008569 NONE ro4368554_5\NN\1740| (r_dep) antagonist_4\NN\7846|the|selective|receptor|ro4368554 (r_nsubj) restores_6\VBZ\1631072|antagonist|performance|. (l_dobj) performance_8\NN\6619065|memory|models (l_nmod) models_13\NNS\5888929|in|cholinergic|deficiency (l_nmod) deficiency_16\NN\14449126|of|memory|rat
C507242_D008569 NONE ro4368554_2\NN\1740|mg/kg|and|metrifonate (r_nsubj) reversed_24\VBD\109660|both|,|ro4368554|deficits|. (l_dobj) deficits_26\NNS\5113133|memory|induced|mg/kg
C507242_D008569 NONE ro4368554_4\NN\1740| (r_nsubj) improve_7\VB\126264|although|ro4368554|did|not|deficit (r_advcl) reversed_14\VBD\109660|conclusion|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_16\JJ\1740|a|and|serotonergic|deficit (l_dep) deficit_21\NN\5113133|memory
C507242_D008569 NONE ro4368554_37\NN\1740|by|and (r_nmod) facilitation_32\NN\13920835|in|the|memory|ro4368554|,|possibly|,|antagonists (r_nmod) involved_29\VBN\2676054|that|mechanisms|may|be|facilitation (r_ccomp) suggesting_23\VBG\1010118|involved (r_advcl) reversed_14\VBD\109660|conclusion|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_16\JJ\1740|a|and|serotonergic|deficit (l_dep) deficit_21\NN\5113133|memory
D014236_D008569 NONE metrifonate_15\NN\1740|mg/kg (r_conj) ro4368554_2\NN\1740|mg/kg|and|metrifonate (r_nsubj) reversed_24\VBD\109660|both|,|ro4368554|deficits|. (l_dobj) deficits_26\NNS\5113133|memory|induced|mg/kg
D012601_D008569 CID scopolamine_29\NN\14712692|and|trp (r_compound) depletion_32\NN\351638|by|scopolamine (r_nmod) induced_27\VBN\1627355|depletion (r_acl) deficits_26\NNS\5113133|memory|induced|mg/kg
D014364_D008569 NONE trp_31\NN\1740| (r_conj) scopolamine_29\NN\14712692|and|trp (r_compound) depletion_32\NN\351638|by|scopolamine (r_nmod) induced_27\VBN\1627355|depletion (r_acl) deficits_26\NNS\5113133|memory|induced|mg/kg
D012701_D008569 NONE 5-ht(6_43\NN\1740| (r_compound) antagonists_46\NNS\7846|other|5-ht(6|)|receptor (r_conj) facilitation_32\NN\13920835|in|the|memory|ro4368554|,|possibly|,|antagonists (r_nmod) involved_29\VBN\2676054|that|mechanisms|may|be|facilitation (r_ccomp) suggesting_23\VBG\1010118|involved (r_advcl) reversed_14\VBD\109660|conclusion|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_16\JJ\1740|a|and|serotonergic|deficit (l_dep) deficit_21\NN\5113133|memory
16428221
D008774_D020293 CID methylphenidate_4\NN\4320126| (r_compound) intake_5\NN\13440063|following|oral|methylphenidate|adult (r_nmod) vasculitis_1\NN\14336539|cerebral|intake|:|report
D008774_D020293 CID methylphenidate_20\NN\4320126| (r_compound) intake_21\NN\13440063|after|methylphenidate|children (r_nmod) reported_18\VBN\831651|cases|stroke|has|been|intake|. (r_conj) documented_8\VBN\1000214|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\14336539|cerebral|associated
D008774_D019969 NONE methylphenidate_20\NN\4320126| (r_compound) intake_21\NN\13440063|after|methylphenidate|children (r_nmod) reported_18\VBN\831651|cases|stroke|has|been|intake|. (r_conj) documented_8\VBN\1000214|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\14336539|cerebral|associated (l_acl) associated_2\VBN\628491|abuse (l_nmod) abuse_5\NN\418025|with|amphetamine
D008774_D002544 NONE methylphenidate_20\NN\4320126| (r_compound) intake_21\NN\13440063|after|methylphenidate|children (r_nmod) reported_18\VBN\831651|cases|stroke|has|been|intake|. (l_nsubjpass) stroke_15\NN\556313|ischaemic
D008774_D002544 NONE methylphenidate_12\NN\4320126|with (r_nmod) treated_10\VBN\2376958|who|was|methylphenidate|hyperactivity|and|suffered (l_conj) suffered_17\VBD\2110220|strokes (l_nmod) strokes_21\NNS\556313|from|multiple|ischaemic
D008774_D006948 NONE methylphenidate_12\NN\4320126|with (r_nmod) treated_10\VBN\2376958|who|was|methylphenidate|hyperactivity|and|suffered (l_nmod) hyperactivity_15\NN\14052403|due
D008774_D014657 NONE methylphenidate_3\NN\4320126| (r_nmod:npmod) mediated_4\JJ\1740|methylphenidate (r_amod) vasculitis_5\NN\14336539|mediated
D008774_D014657 NONE methylphenidate_18\NN\4320126| (r_compound) therapy_19\NN\657604|of|methylphenidate (r_nmod) history_16\NN\15120823|a|therapy (r_conj) symptoms_13\NNS\5823932|with|neurological|and|history (r_nmod) patients_10\NNS\9898892|in|symptoms (r_nmod) considered_8\VBN\689344|that|vasculitis|should|be|patients (l_nsubjpass) vasculitis_5\NN\14336539|mediated
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_acl) data_3\NNS\7951464|based|on|clinical|,|indicating (r_nmod) carried_23\VBN\1850315|data|,|study|was|out|elucidate|. (l_advcl) elucidate_28\VB\939277|in|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D006470 CID caa_9\NN\1740|(|) (r_appos) chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_acl) data_3\NNS\7951464|based|on|clinical|,|indicating (r_nmod) carried_23\VBN\1850315|data|,|study|was|out|elucidate|. (l_advcl) elucidate_28\VB\939277|in|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D006470 CID caa_32\NN\1740|of (r_nmod) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D003556 CID chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_acl) data_3\NNS\7951464|based|on|clinical|,|indicating (r_nmod) carried_23\VBN\1850315|data|,|study|was|out|elucidate|. (l_advcl) elucidate_28\VB\939277|in|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D003556 CID caa_9\NN\1740|(|) (r_appos) chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_acl) data_3\NNS\7951464|based|on|clinical|,|indicating (r_nmod) carried_23\VBN\1850315|data|,|study|was|out|elucidate|. (l_advcl) elucidate_28\VB\939277|in|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D003556 CID caa_32\NN\1740|of (r_nmod) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D001745 NONE caa_4\NN\1740|administration (r_nsubj) contribute_10\VB\126264|that|caa|does|not|damage (l_nmod) damage_13\NN\7296428|to|bladder
424937
D008750_D056486 CID methyldopa_6\NN\2721160|by (r_nmod) induced_4\VBN\1627355|methyldopa (r_acl) injury_3\NN\14052046|of|hepatic|induced
D008750_D056486 CID methyldopa-induced_22\JJ\1740| (r_amod) hepatitis_23\NN\14127211|of|methyldopa-induced
D008750_D056486 CID methyldopa_14\NN\2721160|between|and|dysfunction (r_nmod) relationship_12\NN\31921|the|causal|methyldopa (r_nsubjpass) proved_19\VBN\2604760|patient|,|relationship|was|recurrence|. (l_nmod) recurrence_22\NN\7342049|with|the|hepatitis|weeks (l_nmod) hepatitis_24\NN\14127211|of
D008750_D008107 NONE methyldopa_7\NN\2721160|to (r_nmod) related_5\JJ\1740|methyldopa (r_amod) disease_4\NN\14061805|with|liver|related
D008750_D008107 NONE methyldopa_14\NN\2721160|between|and|dysfunction (l_conj) dysfunction_17\NN\14204950|hepatic
D008750_D017093 NONE methyldopa_17\NN\2721160| (r_dobj) taking_16\VBG\2367363|who|had|been|methyldopa|years (r_acl:relcl) another_11\DT\1740|,|taking|, (r_nsubj) showed_22\VBD\2137132|another|resolution|period|. (r_conj) died_2\VBD\146138|patient|,|presented|,|and|showed (l_advcl) presented_5\VBN\2137132|having|failure (l_nmod) failure_8\NN\66216|in|hepatic
D008750_D017114 NONE methyldopa-induced_22\JJ\1740| (r_amod) hepatitis_23\NN\14127211|of|methyldopa-induced (r_nmod) episode_20\NN\7283608|after|a|prior|hepatitis (r_nmod) recommenced_14\VBN\348746|when|drug|was|accidentally|episode (r_advcl) developed_6\VBD\1753788|patient|hepatitis|recommenced|. (l_dobj) hepatitis_8\NN\14127211|fulminant
2802551
D012964_D007674 NONE sodium_0\NN\14625458| (r_compound) status_1\NN\24720|sodium (r_nsubj) influences_2\VBZ\137313|status|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN\1740|chronic|b|rats
D000666_D007674 CID b_5\NN\1355326|amphotericin (r_compound) nephrotoxicity_6\NN\1740|chronic|b|rats
D000666_D007674 CID b_5\NN\1355326|of|amphotericin|mg/kg (r_nmod) potential_2\NN\14481929|the|nephrotoxic|b (l_amod) nephrotoxic_1\JJ\1740|
8953972
D004837_D013345 CID epinephrine_8\NN\14807929|of (r_nmod) use_6\NN\407535|with|prehospital|epinephrine (r_nmod) associated_3\VBN\628491|use (r_acl) bleeding_2\NN\14285662|fatal|intracranial|associated|.
D004837_D012128 NONE epinephrine_26\NN\14807929|subcutaneous (r_dobj) administer_24\VB\2436349|to|epinephrine (r_xcomp) led_16\VBD\1752884|onset|paramedics|scene|administer|. (l_nsubj) onset_2\NN\7325190|the|sudden|distress (l_nmod) distress_5\NN\7494363|of|respiratory|,|rash|and|history
D004837_D005076 NONE epinephrine_26\NN\14807929|subcutaneous (r_dobj) administer_24\VB\2436349|to|epinephrine (r_xcomp) led_16\VBD\1752884|onset|paramedics|scene|administer|. (l_nsubj) onset_2\NN\7325190|the|sudden|distress (l_nmod) distress_5\NN\7494363|of|respiratory|,|rash|and|history (l_conj) rash_7\NN\14321469|,
D004837_D006323 CID epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\2108377|epinephrine|role|arrest (l_nmod) arrest_7\NN\88481|in|cardiac|care
D004837_D004342 NONE epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\2108377|epinephrine|role|arrest (r_ccomp) viewed_28\VBN\689344|has|;|however|,|use|should|be|caution|. (l_nsubjpass) use_14\NN\407535|paramedics|patients (l_nmod) patients_18\NNS\9898892|in|reaction (l_nmod) reaction_22\NN\13446390|with|suspected|allergic|and|hypertension
D004837_D006973 NONE epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\2108377|epinephrine|role|arrest (r_ccomp) viewed_28\VBN\689344|has|;|however|,|use|should|be|caution|. (l_nsubjpass) use_14\NN\407535|paramedics|patients (l_nmod) patients_18\NNS\9898892|in|reaction (l_nmod) reaction_22\NN\13446390|with|suspected|allergic|and|hypertension (l_conj) hypertension_25\NN\14057371|severe
12627929
C067311_D054556 CID docetaxel_9\NN\1740|of|and|thalidomide (r_nmod) combination_7\NN\7951464|with|the|docetaxel (r_nmod) thromboembolism_4\NN\14100769|of|venous|combination
C067311_D054556 CID docetaxel_24\NN\1740|with|or|combination (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (r_nmod) frequency_6\NN\15286249|the|thromboembolism|patients (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
C067311_D054556 CID docetaxel_24\NN\1740|with|or|combination (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (r_nmod) frequency_6\NN\15286249|the|thromboembolism|patients (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
C067311_D054556 CID docetaxel_11\NN\1740| (r_dobj) received_10\VBD\2210855|who|docetaxel|alone (r_acl:relcl) patients_8\NNS\9898892|of|23|received (r_nmod) none_5\NN\15228378|patients (r_nsubj) developed_13\VBD\1753788|none|vte|, (l_dobj) vte_14\NN\1740|
C067311_D054556 CID docetaxel_11\NN\1740| (r_dobj) received_10\VBD\2210855|who|docetaxel|alone (r_acl:relcl) patients_8\NNS\9898892|of|23|received (r_nmod) none_5\NN\15228378|patients (r_nsubj) developed_13\VBD\1753788|none|vte|, (r_dep) measurements_0\NNS\407535|and|results|:|developed|whereas|developed (l_dep) developed_30\VBD\1753788|patients|vte|p=0.025|. (l_dobj) vte_31\NN\1740|
C067311_D054556 CID docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) patients_20\NNS\9898892|47|%|received (r_nsubj) developed_30\VBD\1753788|patients|vte|p=0.025|. (r_dep) measurements_0\NNS\407535|and|results|:|developed|whereas|developed (l_dep) developed_13\VBD\1753788|none|vte|, (l_dobj) vte_14\NN\1740|
C067311_D054556 CID docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) patients_20\NNS\9898892|47|%|received (r_nsubj) developed_30\VBD\1753788|patients|vte|p=0.025|. (l_dobj) vte_31\NN\1740|
C067311_D054556 CID docetaxel_7\NN\1740|to (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel|treatment (r_nsubj) increases_15\VBZ\169651|addition|significantly|frequency (l_dobj) frequency_17\NN\15286249|the|vte (l_nmod) vte_19\NN\1740|of
C067311_D011471 NONE docetaxel_9\NN\1740|of|and|thalidomide (r_nmod) combination_7\NN\7951464|with|the|docetaxel (r_nmod) thromboembolism_4\NN\14100769|of|venous|combination (r_nmod) frequency_1\NN\15286249|increased|thromboembolism|patients|. (l_nmod) patients_13\NNS\9898892|in|cancer (l_nmod) cancer_18\NN\14239425|with|metastatic|androgen-independent|prostate
C067311_D011471 NONE docetaxel_24\NN\1740|with|or|combination (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (l_nmod) cancer_19\NN\14239425|with|advanced|androgen-independent|prostate
C067311_D011471 NONE docetaxel_7\NN\1740|to (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel|treatment (l_nmod) treatment_10\NN\654885|in|the|cancer (l_nmod) cancer_13\NN\14239425|of|prostate
D013792_D054556 CID thalidomide_11\NN\4166841| (r_conj) docetaxel_9\NN\1740|of|and|thalidomide (r_nmod) combination_7\NN\7951464|with|the|docetaxel (r_nmod) thromboembolism_4\NN\14100769|of|venous|combination
D013792_D054556 CID thalidomide_30\NN\4166841|with (r_nmod) combination_28\NN\7951464|in|thalidomide (r_conj) docetaxel_24\NN\1740|with|or|combination (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (r_nmod) frequency_6\NN\15286249|the|thromboembolism|patients (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D013792_D054556 CID thalidomide_30\NN\4166841|with (r_nmod) combination_28\NN\7951464|in|thalidomide (r_conj) docetaxel_24\NN\1740|with|or|combination (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (r_nmod) frequency_6\NN\15286249|the|thromboembolism|patients (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D013792_D054556 CID thalidomide_29\NN\4166841| (r_conj) docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) patients_20\NNS\9898892|47|%|received (r_nsubj) developed_30\VBD\1753788|patients|vte|p=0.025|. (r_dep) measurements_0\NNS\407535|and|results|:|developed|whereas|developed (l_dep) developed_13\VBD\1753788|none|vte|, (l_dobj) vte_14\NN\1740|
D013792_D054556 CID thalidomide_29\NN\4166841| (r_conj) docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) patients_20\NNS\9898892|47|%|received (r_nsubj) developed_30\VBD\1753788|patients|vte|p=0.025|. (l_dobj) vte_31\NN\1740|
D013792_D054556 CID thalidomide_5\NN\4166841|of (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel|treatment (r_nsubj) increases_15\VBZ\169651|addition|significantly|frequency (l_dobj) frequency_17\NN\15286249|the|vte (l_nmod) vte_19\NN\1740|of
D013792_D011471 NONE thalidomide_11\NN\4166841| (r_conj) docetaxel_9\NN\1740|of|and|thalidomide (r_nmod) combination_7\NN\7951464|with|the|docetaxel (r_nmod) thromboembolism_4\NN\14100769|of|venous|combination (r_nmod) frequency_1\NN\15286249|increased|thromboembolism|patients|. (l_nmod) patients_13\NNS\9898892|in|cancer (l_nmod) cancer_18\NN\14239425|with|metastatic|androgen-independent|prostate
D013792_D011471 NONE thalidomide_30\NN\4166841|with (r_nmod) combination_28\NN\7951464|in|thalidomide (r_conj) docetaxel_24\NN\1740|with|or|combination (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (l_nmod) cancer_19\NN\14239425|with|advanced|androgen-independent|prostate
D013792_D011471 NONE thalidomide_5\NN\4166841|of (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel|treatment (l_nmod) treatment_10\NN\654885|in|the|cancer (l_nmod) cancer_13\NN\14239425|of|prostate
9334596
D013739_D007172 NONE testosterone_8\NN\14747587|of|serum|and|determination (r_nmod) results_5\NNS\34213|the|testosterone|patients (l_nmod) patients_14\NNS\9898892|in|1,022|referred (l_acl) referred_15\VBN\730052|dysfunction (l_nmod) dysfunction_19\NN\14204950|because|erectile
D013739_D007172 NONE testosterone_5\NN\14747587| (r_compound) levels_6\NNS\4916342|of|the|other|low|testosterone (r_nmod) most_0\JJS\1740|levels (r_nsubj) seemed_7\VBD\2604760|most|result|. (l_xcomp) result_9\VB\2633881|to|dysfunction|hormone|and|have (l_conj) have_24\VB\2108377|to|role|improvement (l_dobj) role_28\NN\719494|only|a|small|dysfunction (l_nmod) dysfunction_31\NN\14204950|in|erectile
D013739_D007172 NONE testosterone_8\NN\14747587|of|low|and|prolactin (r_nmod) prevalences_3\NNS\4764412|low|and|effects|testosterone|dysfunction (l_nmod) dysfunction_14\NN\14204950|in|erectile
D013739_D020018 CID testosterone_5\NN\14747587|for (r_nmod) screened_3\VBN\2533282|patient|was|testosterone|and|screened (l_conj) screened_9\VBN\2533282|451|were|prolactin|desire|. (l_nmod) desire_18\NN\26192|on|basis|of|low|sexual|,|gynecomastia|or|testosterone|ng./ml
D013739_D020018 CID testosterone_22\NN\14747587| (r_conj) desire_18\NN\26192|on|basis|of|low|sexual|,|gynecomastia|or|testosterone|ng./ml
D013739_D020018 CID testosterone_1\NN\14747587| (r_dobj) determining_0\VBG\1645601|testosterone|cases (l_nmod) cases_4\NNS\7283608|in|desire (l_nmod) desire_8\NN\26192|of|low|sexual|or|examination
D013739_D020018 CID testosterone_23\NN\14747587|with|low (r_nmod) cases_20\NNS\7283608|of|the|testosterone (r_nmod) %_17\NN\1740|40|cases|,|% (r_dobj) missed_15\VBN\1825237|determining|would|have|%|. (l_csubj) determining_0\VBG\1645601|testosterone|cases (l_nmod) cases_4\NNS\7283608|in|desire (l_nmod) desire_8\NN\26192|of|low|sexual|or|examination
D013739_D020018 CID testosterone_8\NN\14747587| (r_nsubjpass) determined_10\VBN\1645601|that|age|testosterone|be|cases|but|measured (l_nmod) cases_13\NNS\7283608|in|desire (l_nmod) desire_17\NN\26192|of|low|sexual|and|examination
D013739_D020018 CID testosterone_14\NN\14747587| (r_compound) ng./ml_18\NN\1740|testosterone|4 (r_conj) gynecomastia_12\NN\14501726|and/or|ng./ml (r_conj) desire_10\NN\26192|of|low|sexual|,|gynecomastia
D013739_D006177 NONE testosterone_5\NN\14747587|for (r_nmod) screened_3\VBN\2533282|patient|was|testosterone|and|screened (l_conj) screened_9\VBN\2533282|451|were|prolactin|desire|. (l_nmod) desire_18\NN\26192|on|basis|of|low|sexual|,|gynecomastia|or|testosterone|ng./ml (l_conj) gynecomastia_20\NN\14501726|
D013739_D006177 NONE testosterone_22\NN\14747587| (r_conj) desire_18\NN\26192|on|basis|of|low|sexual|,|gynecomastia|or|testosterone|ng./ml (l_conj) gynecomastia_20\NN\14501726|
D013739_D006177 NONE testosterone_14\NN\14747587| (r_compound) ng./ml_18\NN\1740|testosterone|4 (r_conj) gynecomastia_12\NN\14501726|and/or|ng./ml
C004648_D007006 NONE heptylate_5\NN\1740|of|testosterone|or|gonadotropin|and|bromocriptine (l_conj) gonadotropin_9\NN\5407119|human|chorionic|hypogonadism (l_nmod) hypogonadism_11\NN\14076126|for
C004648_D006966 NONE heptylate_5\NN\1740|of|testosterone|or|gonadotropin|and|bromocriptine (l_conj) bromocriptine_13\NN\1740|hyperprolactinemia (l_nmod) hyperprolactinemia_15\NN\1740|for
D001971_D007006 NONE bromocriptine_13\NN\1740|hyperprolactinemia (r_conj) heptylate_5\NN\1740|of|testosterone|or|gonadotropin|and|bromocriptine (l_conj) gonadotropin_9\NN\5407119|human|chorionic|hypogonadism (l_nmod) hypogonadism_11\NN\14076126|for
D001971_D006966 NONE bromocriptine_13\NN\1740|hyperprolactinemia (l_nmod) hyperprolactinemia_15\NN\1740|for
D013739_D010911 NONE testosterone_6\NN\14747587| (r_compound) determination_7\NN\43195|after|testosterone (r_nmod) discovered_4\VBN\2163746|tumors|were|determination|. (l_nsubjpass) tumors_2\NNS\14234074|two|pituitary
D013739_D007027 NONE testosterone_5\NN\14747587| (r_compound) levels_6\NNS\4916342|of|the|other|low|testosterone (r_nmod) most_0\JJS\1740|levels (r_nsubj) seemed_7\VBD\2604760|most|result|. (l_xcomp) result_9\VB\2633881|to|dysfunction|hormone|and|have (l_nmod) dysfunction_13\NN\14204950|from|nonorganic|hypothalamic
11279304
D018943_D066126 NONE anthracycline-induced_7\JJ\1740| (r_amod) cardiotoxicity_8\NN\1740|of|anthracycline-induced
D018943_D066126 NONE anthracyclines_0\NNS\1740| (r_nsubj) drugs_4\NNS\14778436|anthracyclines|are|effective|antineoplastic|,|but|cause (l_conj) cause_9\VBP\1617192|they|frequently|cardiotoxicity|. (l_dobj) cardiotoxicity_11\NN\1740|dose-related
D018943_D066126 NONE anthracycline_4\NN\1740| (r_compound) therapy_5\NN\657604|of|conventional|anthracycline (r_nmod) cardiotoxicity_1\NN\1740|the|therapy
D018943_D066126 NONE anthracycline-induced_24\JJ\1740| (r_amod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients
D018943_D066126 NONE anthracycline-induced_16\JJ\1740| (r_amod) cardiotoxicity_17\NN\1740|of|anthracycline-induced
D018943_D006331 NONE anthracycline_4\NN\1740| (r_compound) therapy_5\NN\657604|of|conventional|anthracycline (r_nmod) cardiotoxicity_1\NN\1740|the|therapy (r_nsubj) highlights_6\VBZ\514463|cardiotoxicity|need|. (l_dobj) need_8\NN\13920835|a|search (l_acl) search_10\VB\2131279|to|methods (l_nmod) methods_12\NNS\5616786|for|sensitive (l_acl:relcl) sensitive_16\JJ\1740|that|are|highly|and|capable (l_conj) capable_18\JJ\1740|predicting (l_advcl) predicting_20\VBG\916909|of|dysfunction (l_dobj) dysfunction_22\NN\14204950|cardiac
D018943_D015470 NONE anthracycline-induced_24\JJ\1740| (r_amod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients (l_nmod) patients_27\NNS\9898892|in|leukemia|treated (l_nmod) leukemia_30\NN\14239918|with|acute
D003630_D066126 NONE daunorubicin_34\NN\1740| (r_compound) (dnr)-containing_35\NN\1740|daunorubicin (r_compound) regimen_36\NN\5898568|with|a|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) patients_27\NNS\9898892|in|leukemia|treated (r_nmod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients
D003630_D066126 NONE (dnr)-containing_35\NN\1740|daunorubicin (r_compound) regimen_36\NN\5898568|with|a|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) patients_27\NNS\9898892|in|leukemia|treated (r_nmod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients
D003630_D015470 NONE daunorubicin_34\NN\1740| (r_compound) (dnr)-containing_35\NN\1740|daunorubicin (r_compound) regimen_36\NN\5898568|with|a|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) patients_27\NNS\9898892|in|leukemia|treated (l_nmod) leukemia_30\NN\14239918|with|acute
D003630_D015470 NONE (dnr)-containing_35\NN\1740|daunorubicin (r_compound) regimen_36\NN\5898568|with|a|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) patients_27\NNS\9898892|in|leukemia|treated (l_nmod) leukemia_30\NN\14239918|with|acute
D003630_D015470 NONE dnr-containing_9\JJ\1740| (r_amod) regimen_10\NN\5898568|with|a|dnr-containing (r_nmod) treated_6\VBN\2376958|patients|were|regimen|. (l_nsubjpass) patients_1\NNS\9898892|thirteen|leukemia (l_nmod) leukemia_4\NN\14239918|with|acute
D003630_D006333 CID dnr_16\NN\1740| (r_dobj) given_15\VBN\2327200|dnr (r_acl) patients_11\NNS\9898892|in|the|failure|given|,|mg/m(2 (l_nmod) failure_14\NN\66216|without|heart
9931093
D016559_D006973 CID 506-induced_3\JJ\1740|fk (r_amod) hypertension_4\NN\14057371|of|506-induced|rat
D016559_D006973 CID 506_5\CD\1740| (r_nummod) fk_4\NN\1740|of|506 (r_nmod) utility_2\NN\8186047|the|clinical|fk (r_nsubjpass) complicated_7\VBN\126264|utility|is|hypertension|. (l_nmod) hypertension_10\NN\14057371|by|substantial|and|nephrotoxicity
D016559_D006973 CID 506-induced_6\JJ\1740|fk (r_amod) hypertension_7\NN\14057371|of|506-induced
D016559_D006973 CID 506_16\CD\1740| (r_nummod) fk_15\NN\1740|of|506 (r_nmod) effects_13\NNS\13245626|the|chronic|fk|synthesis (r_dobj) studied_10\VBD\630380|clarify|,|we|effects|. (l_advcl) clarify_1\VB\939277|to|mechanisms (l_dobj) mechanisms_3\NNS\13446390|the|hypertension (l_nmod) hypertension_7\NN\14057371|of|506-induced
D016559_D006973 CID 506-induced_17\JJ\1740|fk (r_amod) hypertension_18\NN\14057371|on|506-induced|rats
D016559_D006973 CID 506-induced_14\JJ\1740|fk (r_amod) hypertension_15\NN\14057371|506-induced|rats
D016559_D007674 NONE 506_5\CD\1740| (r_nummod) fk_4\NN\1740|of|506 (r_nmod) utility_2\NN\8186047|the|clinical|fk (r_nsubjpass) complicated_7\VBN\126264|utility|is|hypertension|. (l_nmod) hypertension_10\NN\14057371|by|substantial|and|nephrotoxicity (l_conj) nephrotoxicity_12\NN\1740|
D009569_D006973 NONE oxide_42\NN\14818238| (r_compound) synthase_43\NN\1740|the|endothelial|nitric|oxide|enos (r_compound) activity_47\NN\30358|synthase (r_conj) synthesis_19\NN\13446390|on|the|endothelin-1|,|expression|,|activity|,|and|expression (r_nmod) effects_13\NNS\13245626|the|chronic|fk|synthesis (r_dobj) studied_10\VBD\630380|clarify|,|we|effects|. (l_advcl) clarify_1\VB\939277|to|mechanisms (l_dobj) mechanisms_3\NNS\13446390|the|hypertension (l_nmod) hypertension_7\NN\14057371|of|506-induced
C079574_D006973 NONE 139317_14\CD\1740| (r_nummod) fr_13\NN\14625458|139317 (r_appos) antagonist_12\NN\7846|of|the|specific|endothelin|type|receptor|fr (r_nmod) effect_4\NN\34213|the|antagonist|hypertension (l_nmod) hypertension_18\NN\14057371|on|506-induced|rats
C079574_D006973 NONE 139317_4\CD\1740| (r_nummod) fr_3\NN\14625458|of|139317|(|kg-1|.|d-1|) (r_nmod) administration_1\NN\1133281|the|fr (r_nsubj) prevented_12\VBD\1740|administration|hypertension|. (l_dobj) hypertension_15\NN\14057371|506-induced|rats
6229975
D013999_D009203 NONE timolol_6\NN\2832168| (r_compound) treatment_7\NN\654885|during|long-term|timolol|infarction (l_nmod) infarction_10\NN\14204950|after|myocardial
D013999_D009203 NONE timolol_4\NN\2832168| (r_compound) treatment_5\NN\654885|of|long-term|timolol (r_nmod) effect_1\NN\34213|the|treatment|size (l_nmod) size_8\NN\5090441|on|heart|infarction (l_nmod) infarction_11\NN\14204950|after|myocardial
D013999_D009203 NONE timolol_27\NN\2832168|115 (r_appos) placebo_24\NN\3740161|(|126|,|timolol|) (r_dep) patients_22\NNS\9898892|including|241|placebo (r_nmod) study_19\NN\635850|in|a|double-blind|patients (r_nmod) evaluated_13\VBN\670261|effect|was|x-ray|study|. (l_nsubjpass) effect_1\NN\34213|the|treatment|size (l_nmod) size_8\NN\5090441|on|heart|infarction (l_nmod) infarction_11\NN\14204950|after|myocardial
D013999_D001919 NONE timolol-induced_6\JJ\1740| (r_amod) bradycardia_7\NN\14110674|by|timolol-induced|and|increase
D013999_D007238 NONE timolol_15\NN\2832168| (r_compound) group_16\NN\2137|in|the|timolol (r_nmod) unchanged_12\JJ\1740|group (r_xcomp) remained_11\VBD\2604760|unchanged (r_conj) increased_5\VBD\169651|re-infarction|,|size|group|and|remained|. (l_nmod) re-infarction_1\NN\1740|after
11419773
D002110_D001145 NONE caffeine-induced_0\JJ\1740| (r_nummod) arrhythmia_2\NN\14103288|caffeine-induced|cardiac|:|danger|.
D002110_D008945 NONE caffeine_30\NN\14712692|of (r_nmod) concentration_28\NN\4916342|a|high|caffeine (r_dobj) containing_25\VBG\2632940|concentration (r_acl) drink_24\NN\7578363|a|"|energy|"|guarana|health|containing (r_dobj) consuming_16\VBG\1168468|after|drink (r_advcl) developed_11\VBD\1753788|who|fibrillation|consuming (r_acl:relcl) woman_4\NN\9605289|a|25-year-old|prolapse|developed (l_nmod) prolapse_9\NN\14548343|with|pre-existing|mitral|valve
D002110_D014693 CID caffeine_30\NN\14712692|of (r_nmod) concentration_28\NN\4916342|a|high|caffeine (r_dobj) containing_25\VBG\2632940|concentration (r_acl) drink_24\NN\7578363|a|"|energy|"|guarana|health|containing (r_dobj) consuming_16\VBG\1168468|after|drink (r_advcl) developed_11\VBD\1753788|who|fibrillation|consuming (l_dobj) fibrillation_14\NN\14361664|intractable|ventricular
18809400
D008063_D028361 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) prevents_2\VBZ\1740|acid|damage|. (l_dobj) damage_4\NN\7296428|mitochondrial|and|neurotoxicity|neuropathy
D008063_D028361 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|,|plays (l_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nsubj) damage_15\NN\7296428|mitochondrial
D008063_D028361 NONE acid_31\NN\14818238|of|alpha-lipoic (r_nmod) effects_28\NNS\13245626|neuroprotective|acid (r_nsubj) depend_32\VBP\2604760|if|effects|protection (r_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nsubj) damage_15\NN\7296428|mitochondrial
D008063_D028361 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) exerts_2\VBZ\1158872|acid|effects|neurotoxicity|rescues|. (l_dep) rescues_14\VBZ\2551832|:|it|toxicity|and|induces (l_dobj) toxicity_17\NN\13576101|the|mitochondrial
D008063_D020258 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) prevents_2\VBZ\1740|acid|damage|. (l_dobj) damage_4\NN\7296428|mitochondrial|and|neurotoxicity|neuropathy (l_conj) neurotoxicity_6\NN\1740|
D008063_D020258 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|,|plays (l_nmod) neurotoxicity_11\NN\1740|against|induced
D008063_D020258 NONE acid_31\NN\14818238|of|alpha-lipoic (r_nmod) effects_28\NNS\13245626|neuroprotective|acid (r_nsubj) depend_32\VBP\2604760|if|effects|protection (r_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (r_conj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|,|plays (l_nmod) neurotoxicity_11\NN\1740|against|induced
D008063_D020258 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) exerts_2\VBZ\1158872|acid|effects|neurotoxicity|rescues|. (l_nmod) neurotoxicity_8\NN\1740|against|induced|neurons
D008063_D009422 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) prevents_2\VBZ\1740|acid|damage|. (l_dobj) damage_4\NN\7296428|mitochondrial|and|neurotoxicity|neuropathy (l_nmod) neuropathy_10\NN\14204950|in|experimental|chemotherapy
D008063_D009410 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|,|plays (l_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nmod) cascade_23\NN\9475292|in|toxic|neurodegenerative
D008063_D009410 NONE acid_31\NN\14818238|of|alpha-lipoic (r_nmod) effects_28\NNS\13245626|neuroprotective|acid (r_nsubj) depend_32\VBP\2604760|if|effects|protection (r_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nmod) cascade_23\NN\9475292|in|toxic|neurodegenerative
D017239_D010523 CID paclitaxel_32\NN\1740|to|and|cisplatin|,|drugs (r_nmod) exposing_19\VBG\2110927|by|cultures|paclitaxel (r_advcl) mimic_13\VBP\1742886|that|closely|condition|exposing (r_acl:relcl) model_5\NN\5888929|an|in|neuropathy|mimic (l_nmod) neuropathy_10\NN\14204950|of|induced|peripheral
D002945_D010523 CID cisplatin_34\NN\1740| (r_conj) paclitaxel_32\NN\1740|to|and|cisplatin|,|drugs (r_nmod) exposing_19\VBG\2110927|by|cultures|paclitaxel (r_advcl) mimic_13\VBP\1742886|that|closely|condition|exposing (r_acl:relcl) model_5\NN\5888929|an|in|neuropathy|mimic (l_nmod) neuropathy_10\NN\14204950|of|induced|peripheral
D008063_D001480 NONE acid_8\NN\14818238|of|alpha-lipoic (r_nmod) efficacy_5\NN\5199286|the|acid|preventing|and|function (l_advcl) preventing_10\VBG\1740|in|damage (l_dobj) damage_12\NN\7296428|axonal|and|apoptosis
D008063_D001480 NONE acid_30\NN\14818238|alpha-lipoic (r_conj) agents_27\NNS\7347|to|toxic|and|acid (r_nmod) exposure_24\NN\5042871|after|agents (r_nmod) function_17\NN\13783581|the|and|morphology|mitochondria|exposure (r_conj) efficacy_5\NN\5199286|the|acid|preventing|and|function (l_advcl) preventing_10\VBG\1740|in|damage (l_dobj) damage_12\NN\7296428|axonal|and|apoptosis
D002945_D028361 NONE cisplatin_5\NN\1740|both|and|paclitaxel (r_nsubj) cause_8\VBP\1617192|that|cisplatin|impairment (l_dobj) impairment_11\NN\7296428|early|mitochondrial|loss
D002945_D028361 NONE cisplatin_13\NN\1740| (r_conj) paclitaxel_11\NN\1740|and|cisplatin (r_nmod:npmod) induced_14\JJ\1740|paclitaxel (r_amod) neurotoxicity_15\NN\1740|in|induced (r_nmod) event_8\NN\23100|conclusion|toxicity|is|an|early|common|neurotoxicity|. (l_nsubj) toxicity_3\NN\13576101|mitochondrial
D017239_D028361 NONE paclitaxel_7\NN\1740| (r_conj) cisplatin_5\NN\1740|both|and|paclitaxel (r_nsubj) cause_8\VBP\1617192|that|cisplatin|impairment (l_dobj) impairment_11\NN\7296428|early|mitochondrial|loss
D017239_D028361 NONE paclitaxel_11\NN\1740|and|cisplatin (r_nmod:npmod) induced_14\JJ\1740|paclitaxel (r_amod) neurotoxicity_15\NN\1740|in|induced (r_nmod) event_8\NN\23100|conclusion|toxicity|is|an|early|common|neurotoxicity|. (l_nsubj) toxicity_3\NN\13576101|mitochondrial
D017239_D020258 NONE paclitaxel_11\NN\1740|and|cisplatin (r_nmod:npmod) induced_14\JJ\1740|paclitaxel (r_amod) neurotoxicity_15\NN\1740|in|induced
D002945_D020258 NONE cisplatin_13\NN\1740| (r_conj) paclitaxel_11\NN\1740|and|cisplatin (r_nmod:npmod) induced_14\JJ\1740|paclitaxel (r_amod) neurotoxicity_15\NN\1740|in|induced
D008063_D010523 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) reduce_7\VB\441445|that|acid|might|risk (l_dobj) risk_9\NN\14541044|the|developing (l_advcl) developing_11\VBG\1753788|of|toxicity|patients (l_dobj) toxicity_14\NN\13576101|peripheral|nerve
12369736
D003042_D009069 CID cocaine-induced_14\JJ\1740| (r_amod) hyperactivity_16\NN\14052403|on|the|cocaine-induced|locomotor|rats
D003042_D009069 CID cocaine_34\NN\3492717|by|rats (r_nmod) induced_32\VBN\1627355|cocaine (r_acl) hyperactivity_31\NN\14052403|on|the|locomotor|induced
D003042_D009069 CID cocaine_14\NN\3492717|to (r_nmod) prior_12\RB\1740|cocaine (r_prep) administered_9\VBN\2436349|shell|prior (r_acl) gr_0\NN\1740|55562|,|administered|, (r_nsubj) attenuated_17\VBD\224901|gr|dose-dependently|hyperactivity|. (l_dobj) hyperactivity_21\NN\14052403|the|psychostimulant-induced|locomotor
D003042_D009069 CID cocaine_4\NN\3492717| (r_nmod:npmod) induced_5\JJ\1740|cocaine (r_amod) hyperlocomotion_6\NN\1740|induced
C103477_D009069 NONE 55562_1\CD\1740|microg/side (r_appos) gr_0\NN\1740|55562|,|administered|, (r_nsubj) attenuated_17\VBD\224901|gr|dose-dependently|hyperactivity|. (l_dobj) hyperactivity_21\NN\14052403|the|psychostimulant-induced|locomotor
C103477_D009069 NONE 55562_38\CD\1740| (r_nummod) gr_37\NN\1740|(|55562|) (r_appos) antagonist_35\NN\7846|of|the|receptor|gr|and|agonist|, (r_nmod) effects_30\NNS\13245626|in|inhibitory|antagonist (r_nmod) consisting_25\VBG\2603699|effects|respectively (r_acl) modification_24\NN\191142|this|consisting (r_appos) ligands_12\NNS\20090|by|5-ht1b|receptor|microinjected|,|modification (r_nmod) modified_8\VBN\109660|that|hyperlocomotion|is|ligands (l_nsubjpass) hyperlocomotion_6\NN\1740|induced
C065046_D009069 CID 93129_44\CD\1740| (r_nummod) cp_43\NN\1740|(|93129|) (r_appos) agonist_41\NN\9613191|cp (r_conj) antagonist_35\NN\7846|of|the|receptor|gr|and|agonist|, (r_nmod) effects_30\NNS\13245626|in|inhibitory|antagonist (r_nmod) consisting_25\VBG\2603699|effects|respectively (r_acl) modification_24\NN\191142|this|consisting (r_appos) ligands_12\NNS\20090|by|5-ht1b|receptor|microinjected|,|modification (r_nmod) modified_8\VBN\109660|that|hyperlocomotion|is|ligands (l_nsubjpass) hyperlocomotion_6\NN\1740|induced
17439425
D019820_D006973 NONE xanthine_2\NN\14727670| (r_compound) oxidase_3\NN\14732946|of|xanthine (r_nmod) role_0\NN\719494|oxidase|hypertension|. (l_nmod) hypertension_6\NN\14057371|in|dexamethasone-induced|rats
D019820_D006973 NONE xanthine_7\NN\14727670| (r_compound) oxidase_8\NN\14732946|of|xanthine|xo|,|implicated|,|hypertension (l_nmod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht
D019820_D006973 NONE xanthine_7\NN\14727670| (r_compound) oxidase_8\NN\14732946|of|xanthine|xo|,|implicated|,|hypertension (l_nmod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht (l_appos) dex-ht_28\NN\1740|(|)
D003907_D006973 CID dexamethasone-induced_5\JJ\1740| (r_amod) hypertension_6\NN\14057371|in|dexamethasone-induced|rats
D003907_D006973 CID dexamethasone-induced_25\JJ\1740| (r_amod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht
D003907_D006973 CID dexamethasone-induced_25\JJ\1740| (r_amod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht (l_appos) dex-ht_28\NN\1740|(|)
D003907_D006973 CID dex-ht_28\NN\1740|(|) (r_appos) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht
D003907_D006973 CID dex-ht_28\NN\1740|(|)
D003907_D006973 CID dex_2\NN\1740| (r_nsubj) increased_3\VBD\169651|5|dex|sbp|and|decreased|. (l_dobj) sbp_4\NN\1740|mmhg
D003907_D006973 CID dex-ht_6\NN\1740|
D009569_D006973 NONE oxide-redox_14\NN\1740|nitric (r_compound) imbalance_15\NN\13934274|with|oxide-redox (r_nmod) associated_11\VBN\628491|1|hypertension|is|imbalance|. (l_nsubjpass) hypertension_3\NN\14057371|glucocorticoid-induced|gc-ht|rat
D009569_D006973 NONE oxide-redox_14\NN\1740|nitric (r_compound) imbalance_15\NN\13934274|with|oxide-redox (r_nmod) associated_11\VBN\628491|1|hypertension|is|imbalance|. (l_nsubjpass) hypertension_3\NN\14057371|glucocorticoid-induced|gc-ht|rat (l_appos) gc-ht_5\NN\1740|(|)
D003907_D015431 CID dex_2\NN\1740| (r_nsubj) increased_3\VBD\169651|5|dex|sbp|and|decreased|. (l_conj) decreased_20\VBD\169651|thymus|< (l_dobj) thymus_21\NN\11579418|p|and|bodyweights (l_conj) bodyweights_28\NNS\1740|
D000493_D006973 NONE allopurinol_2\NN\3740161| (r_nsubj) prevent_5\VB\1740|6|allopurinol|did|not|dex-ht|. (l_dobj) dex-ht_6\NN\1740|
D000493_D006973 NONE allopurinol_8\NN\3740161| (r_nsubj) failed_9\VBD\1798936|that|allopurinol|prevent (l_xcomp) prevent_11\VB\1740|to|hypertension (l_dobj) hypertension_15\NN\14057371|induced
D000493_D006973 NONE allopurinol_8\NN\3740161| (r_nsubj) failed_9\VBD\1798936|that|allopurinol|prevent (r_ccomp) findings_6\NNS\7951464|this|together|with|our|previous|failed (r_nsubj) suggests_17\VBZ\1010118|findings|,|determinant|. (l_ccomp) determinant_25\NN\5686481|that|activity|is|not|a|major|gc-ht (l_nmod) gc-ht_27\NN\1740|of|rat
2008831
D008755_D000788 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|direct|intracoronary|methylergonovine (r_nmod) effect_0\NN\34213|administration|patients|. (l_nmod) patients_8\NNS\9898892|in|with|angina (l_nmod) angina_13\NN\14171682|variant
D008755_D000788 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|intracoronary|methylergonovine (r_nmod) effects_1\NNS\13245626|the|administration (r_nsubjpass) studied_8\VBN\630380|effects|were|patients|. (l_nmod) patients_11\NNS\9898892|in|21|angina|and|patients|and|others|group (l_nmod) angina_14\NN\14171682|with|variant
D008755_D000788 NONE methylergonovine_19\NN\1740|of (r_nmod) dose_17\NN\3740161|of|a|low|methylergonovine (r_nmod) injection_12\NN\320852|an|intracoronary|dose (r_dobj) use_9\VBP\1156834|which|injection (r_acl:relcl) tests_6\NNS\5798043|spasm|provocation|,|use|, (r_nsubj) have_21\VBP\2108377|that|tests|sensitivity|and|greater (l_dobj) sensitivity_24\NN\5651971|a|high|angina (l_nmod) angina_27\NN\14171682|in|variant
D008755_D002637 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|intracoronary|methylergonovine (r_nmod) effects_1\NNS\13245626|the|administration (r_nsubjpass) studied_8\VBN\630380|effects|were|patients|. (l_nmod) patients_11\NNS\9898892|in|21|angina|and|patients|and|others|group (l_conj) patients_17\NNS\9898892|22|pain (l_nmod) pain_21\NN\14299637|with|atypical|chest
D008755_D000787 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|intracoronary|methylergonovine (r_nmod) effects_1\NNS\13245626|the|administration (r_nsubjpass) studied_8\VBN\630380|effects|were|patients|. (l_nmod) patients_11\NNS\9898892|in|21|angina|and|patients|and|others|group (l_conj) others_24\NNS\1740|in|pectoris (l_nmod) pectoris_27\NN\1740|without|angina
D008755_D013035 NONE methylergonovine_19\NN\1740|of (r_nmod) dose_17\NN\3740161|of|a|low|methylergonovine (r_nmod) injection_12\NN\320852|an|intracoronary|dose (r_dobj) use_9\VBP\1156834|which|injection (r_acl:relcl) tests_6\NNS\5798043|spasm|provocation|,|use|, (l_compound) spasm_4\NN\14299637|
8558192
C030852_C562729 NONE vinorelbine_4\NN\1740|of (r_nmod) trial_2\NN\786195|phase|ii|vinorelbine|carcinoma|.|group|. (l_nmod) carcinoma_10\NN\14239918|in|metastatic|squamous|cell|esophageal
C030852_C562729 NONE vinorelbine_11\NN\1740|of|vnb|administered (l_acl) administered_15\VBN\2436349|agent|carcinoma (l_nmod) carcinoma_25\NN\14239918|in|metastatic|squamous|cell|esophageal
C030852_C562729 NONE vnb_13\NN\1740|(|) (r_appos) vinorelbine_11\NN\1740|of|vnb|administered (l_acl) administered_15\VBN\2436349|agent|carcinoma (l_nmod) carcinoma_25\NN\14239918|in|metastatic|squamous|cell|esophageal
C030852_C562729 NONE vnb_6\NN\1740| (r_nsubj) agent_10\NN\7347|that|vnb|is|an|active|carcinoma (l_nmod) carcinoma_16\NN\14239918|in|metastatic|esophageal|squamous|cell
C030852_D009369 NONE vinorelbine_4\NN\1740|of (r_nmod) trial_2\NN\786195|phase|ii|vinorelbine|carcinoma|.|group|. (l_appos) group_24\NNP\2137|organization|cancer|cooperative (l_compound) organization_13\NNP\7950920|european|research (l_nmod) research_15\NNP\633864|for|and|treatment|cancer (l_nmod) cancer_19\NNP\14239425|of
C030852_D009369 NONE vinorelbine_4\NN\1740|of (r_nmod) trial_2\NN\786195|phase|ii|vinorelbine|carcinoma|.|group|. (l_appos) group_24\NNP\2137|organization|cancer|cooperative (l_compound) cancer_22\NNP\14239425|treat
D002945_D064420 NONE cisplatin-based_9\JJ\1740| (r_amod) chemotherapy_10\NN\661091|with|cisplatin-based (r_nmod) pretreated_7\VBN\1740|chemotherapy (r_acl) 16_6\CD\13745420|pretreated (r_conj) patients_1\NNS\9898892|thirty|chemotherapy|and|16 (r_nsubj) assessable_12\JJ\1740|patients|were|toxicity|. (l_nmod) toxicity_14\NN\13576101|for|and|response
C030852_D064420 NONE vnb_0\NN\1740| (r_nsubjpass) tolerated_3\VBN\802318|vnb|was|well|and|occurred (l_conj) occurred_13\VBD\2623529|instances|. (l_nsubj) instances_6\NNS\7283608|zero|toxicity (l_nmod) toxicity_12\NN\13576101|of|who|grade|nonhematologic
C030852_D064420 NONE vnb_12\NN\1740|of (r_nmod) evaluation_10\NN\874067|further|vnb|therapy (r_nsubjpass) warranted_17\VBN\1012073|profile|,|evaluation|is|. (l_nmod) profile_4\NN\6999802|given|its|excellent|tolerance|and|toxicity (l_conj) toxicity_7\NN\13576101|low
6888657
D004967_D010911 NONE estrogen-induced_2\JJ\1740| (r_amod) tumors_4\NNS\14234074|of|estrogen-induced|adenohypophyseal|rat
D004054_D010911 CID diethylstilbestrol_12\NN\14749794|with|des|implanted (r_nmod) treatment_10\NN\654885|by|chronic|diethylstilbestrol (r_nmod) induced_3\VBN\1627355|tumors|were|rats|treatment|. (l_nsubjpass) tumors_1\NNS\14234074|pituitary
D004054_D010911 CID des_14\NN\14749794|(|,|mg|) (r_appos) diethylstilbestrol_12\NN\14749794|with|des|implanted (r_nmod) treatment_10\NN\654885|by|chronic|diethylstilbestrol (r_nmod) induced_3\VBN\1627355|tumors|were|rats|treatment|. (l_nsubjpass) tumors_1\NNS\14234074|pituitary
D004054_D009369 NONE des-induced_12\JJ\1740| (r_amod) tumor_13\NN\14234074|the|des-induced
10835440
D009553_D020521 NONE nimodipine_3\NN\1740|of|intravenous (r_nmod) effect_0\NN\34213|nimodipine|pressure|. (l_nmod) pressure_6\NN\11419404|on|blood|and|outcome (l_conj) outcome_8\NN\7291312|stroke (l_nmod) stroke_11\NN\556313|after|acute
D009553_D020521 NONE nimodipine_6\NN\1740|intravenous (r_compound) trial_10\NNP\786195|the|nimodipine|west|european|stroke|inwest (l_compound) stroke_9\NNP\556313|
D009553_D020521 NONE nimodipine_6\NN\1740|intravenous (r_compound) trial_10\NNP\786195|the|nimodipine|west|european|stroke|inwest (r_appos) background_0\NN\4921011|and|purpose|:|trial (r_nsubj) found_14\VBD\2426171|background|correlation|. (l_dobj) correlation_16\NN\13841213|a|reduction (l_nmod) reduction_19\NN\351485|between|nimodipine-induced|pressure|and|outcome (l_conj) outcome_29\NN\7291312|an|unfavorable|stroke (l_nmod) stroke_32\NN\556313|in|acute
D009553_D020521 NONE nimodipine-induced_18\JJ\1740| (r_amod) reduction_19\NN\351485|between|nimodipine-induced|pressure|and|outcome (r_nmod) correlation_16\NN\13841213|a|reduction (r_dobj) found_14\VBD\2426171|background|correlation|. (l_nsubj) background_0\NN\4921011|and|purpose|:|trial (l_appos) trial_10\NNP\786195|the|nimodipine|west|european|stroke|inwest (l_compound) stroke_9\NNP\556313|
D009553_D020521 NONE nimodipine-induced_18\JJ\1740| (r_amod) reduction_19\NN\351485|between|nimodipine-induced|pressure|and|outcome (l_conj) outcome_29\NN\7291312|an|unfavorable|stroke (l_nmod) stroke_32\NN\556313|in|acute
D009553_D020521 NONE nimodipine_20\NN\1740|of|high-dose (r_nmod) administration_17\NN\1133281|after|the|intravenous|nimodipine|stroke (l_nmod) stroke_23\NN\556313|after|acute
D009553_D007022 CID nimodipine_6\NN\1740|intravenous (r_compound) trial_10\NNP\786195|the|nimodipine|west|european|stroke|inwest (r_appos) background_0\NN\4921011|and|purpose|:|trial (r_nsubj) found_14\VBD\2426171|background|correlation|. (l_dobj) correlation_16\NN\13841213|a|reduction (l_nmod) reduction_19\NN\351485|between|nimodipine-induced|pressure|and|outcome (l_nmod) pressure_22\NN\11419404|in|blood|bp
D009553_D007022 CID nimodipine-induced_18\JJ\1740| (r_amod) reduction_19\NN\351485|between|nimodipine-induced|pressure|and|outcome (l_nmod) pressure_22\NN\11419404|in|blood|bp
D009553_D007022 CID nimodipine_0\NN\1740| (r_compound) treatment_1\NN\654885|nimodipine (r_nsubj) resulted_2\VBD\2633881|treatment|reduction|. (l_nmod) reduction_7\NN\351485|in|a|significant|bp|baseline|placebo (l_nmod) bp_10\NN\1740|in|systolic|sbp|and|bp
D009553_D002544 NONE nimodipine_30\NN\1740|mg/h|(|low-dose|)|n=101 (r_conj) placebo_20\NN\3740161|n=100|,|nimodipine|,|or|nimodipine (r_dobj) receive_19\VB\2210855|to|placebo (r_xcomp) allocated_17\VBN\2228698|methods|patients|were|consecutively|receive|. (l_nsubjpass) patients_2\NNS\9898892|diagnosis|hours (l_nmod) diagnosis_6\NN\152018|with|a|clinical|stroke (l_nmod) stroke_9\NN\556313|of|ischemic
D009553_D002544 NONE nimodipine_41\NN\1740|mg/h|(|high-dose|)|n=94 (r_conj) placebo_20\NN\3740161|n=100|,|nimodipine|,|or|nimodipine (r_dobj) receive_19\VB\2210855|to|placebo (r_xcomp) allocated_17\VBN\2228698|methods|patients|were|consecutively|receive|. (l_nsubjpass) patients_2\NNS\9898892|diagnosis|hours (l_nmod) diagnosis_6\NN\152018|with|a|clinical|stroke (l_nmod) stroke_9\NN\556313|of|ischemic
8590259
C016986_D015814 CID apraclonidine-treated_8\JJ\1740| (r_amod) eyes_9\NNS\5945642|for|apraclonidine-treated (r_nmod) significant_6\JJ\1740|effects|were|statistically|eyes|study|and|significant|. (l_nsubj) effects_3\NNS\13245626|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\1740|
C016986_D015814 CID apraclonidine_29\NN\1740|of|% (r_nmod) administration_25\NN\1133281|after|topical|apraclonidine (r_nmod) hours_22\NNS\15118228|from|three|administration (r_nmod) eyes_19\NNS\5945642|for|contralateral|hours (r_nmod) significant_16\JJ\1740|also|statistically|eyes (r_conj) significant_6\JJ\1740|effects|were|statistically|eyes|study|and|significant|. (l_nsubj) effects_3\NNS\13245626|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\1740|
11679859
D011346_D017109 CID prochlorperazine_3\NN\2719750|of (r_nmod) administration_1\NN\1133281|intravenous|prochlorperazine|infusion (r_nsubj) affect_12\VB\126264|administration|does|not|incidence|:|trial|. (l_dobj) incidence_14\NN\13821570|the|akathisia (l_nmod) akathisia_16\NN\1740|of
D011346_D017109 CID prochlorperazine_15\NN\2719750|of|intravenous (r_nmod) administration_12\NN\1133281|after|prochlorperazine|bolus (r_nmod) rate_8\NN\13815152|the|akathisia|administration (l_nmod) akathisia_10\NN\1740|of
D011346_D017109 CID prochlorperazine_12\NN\2719750| (r_nsubjpass) administered_14\VBN\2436349|when|prochlorperazine|was|means (r_acl) reduction_5\NN\351485|a|%|incidence|administered (l_nmod) incidence_8\NN\13821570|in|the|akathisia (l_nmod) akathisia_10\NN\1740|of
D011346_D006261 NONE prochlorperazine_8\NN\2719750|with (r_nmod) treated_6\VBN\2376958|prochlorperazine|headache (l_nmod) headache_10\NN\5829480|for|,|nausea
D011346_D006261 NONE prochlorperazine_3\NN\2719750|of (r_nmod) efficacy_1\NN\5199286|the|prochlorperazine|treatment (l_nmod) treatment_6\NN\654885|in|the|headache (l_nmod) headache_8\NN\5829480|of|and|nausea
D011346_D009325 NONE prochlorperazine_8\NN\2719750|with (r_nmod) treated_6\VBN\2376958|prochlorperazine|headache (l_nmod) headache_10\NN\5829480|for|,|nausea (l_conj) nausea_12\NN\14299637|,|or|vomiting
D011346_D009325 NONE prochlorperazine_3\NN\2719750|of (r_nmod) efficacy_1\NN\5199286|the|prochlorperazine|treatment (l_nmod) treatment_6\NN\654885|in|the|headache (l_nmod) headache_8\NN\5829480|of|and|nausea (l_conj) nausea_10\NN\14299637|
D011346_D014839 NONE prochlorperazine_8\NN\2719750|with (r_nmod) treated_6\VBN\2376958|prochlorperazine|headache (l_nmod) headache_10\NN\5829480|for|,|nausea (l_conj) nausea_12\NN\14299637|,|or|vomiting (l_conj) vomiting_15\NN\116687|
15036754
D010755_D012640 NONE organophosphate-induced_0\JJ\1740| (r_amod) convulsions_1\NNS\14081375|organophosphate-induced|and|prevention
D010755_D004194 NONE organophosphate-induced_0\JJ\1740| (r_amod) convulsions_1\NNS\14081375|organophosphate-induced|and|prevention (l_conj) prevention_3\NN\1073995|damages|. (l_nmod) damages_6\NNS\13282550|of|neuropathological
D010755_D064420 NONE ops_4\NNS\1740|of (r_nmod) toxicity_2\NN\13576101|the|acute|ops
D010755_D064420 NONE op-induced_8\JJ\1740| (r_amod) signs_10\NNS\6643763|severe|typical|op-induced|toxicity (l_compound) toxicity_9\NN\13576101|
D000109_D064420 NONE acetylcholine_25\NN\14807558|ach (r_compound) levels_29\NNS\4916342|acetylcholine (r_dobj) elevates_24\VBZ\2391803|which|levels (r_acl:relcl) system_18\NN\3575240|in|the|central|nervous|cns|,|elevates (r_nmod) aches_13\NNS\14322699|with|system (r_nmod) binding_11\NN\4688246|of|their|irreversible|aches (r_nmod) result_7\NN\34213|toxicity|is|the|binding|. (l_nsubj) toxicity_2\NN\13576101|the|acute|ops
D000109_D064420 NONE ach_27\NN\1740|(|) (r_appos) acetylcholine_25\NN\14807558|ach (r_compound) levels_29\NNS\4916342|acetylcholine (r_dobj) elevates_24\VBZ\2391803|which|levels (r_acl:relcl) system_18\NN\3575240|in|the|central|nervous|cns|,|elevates (r_nmod) aches_13\NNS\14322699|with|system (r_nmod) binding_11\NN\4688246|of|their|irreversible|aches (r_nmod) result_7\NN\34213|toxicity|is|the|binding|. (l_nsubj) toxicity_2\NN\13576101|the|acute|ops
D007531_D064420 NONE dfp-atropine_4\NN\1740|with (r_nmod) treated_2\VBN\2376958|dfp-atropine (r_acl) rats_1\NNS\2329401|the|treated (r_nsubj) showed_5\VBD\2137132|rats|signs|. (l_dobj) signs_10\NNS\6643763|severe|typical|op-induced|toxicity (l_compound) toxicity_9\NN\13576101|
D007531_D064420 NONE dfp_8\NN\1740| (r_compound) toxicity_9\NN\13576101|against|dfp
D007531_D064420 NONE dfp_26\NN\1740|of (r_nmod) toxicity_24\NN\13576101|the|dfp|rat
D001285_D064420 NONE dfp-atropine_4\NN\1740|with (r_nmod) treated_2\VBN\2376958|dfp-atropine (r_acl) rats_1\NNS\2329401|the|treated (r_nsubj) showed_5\VBD\2137132|rats|signs|. (l_dobj) signs_10\NNS\6643763|severe|typical|op-induced|toxicity (l_compound) toxicity_9\NN\13576101|
D001285_D064420 NONE atropine-mk801_0\NN\1740| (r_nsubj) offer_3\VB\2327200|atropine-mk801|did|not|protection|. (l_dobj) protection_6\NN\407535|any|additional|toxicity (l_nmod) toxicity_9\NN\13576101|against|dfp
D001285_D064420 NONE atropine_11\NN\14712692|with (r_nmod) combination_9\NN\7951464|in|atropine (r_nmod) cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
C048599_D011041 NONE cpa_1\NN\9761403|,|diazepam|or|2pam (r_nsubjpass) given_7\VBN\2327200|when|cpa|was|dfp-atropine (r_advcl) prevented_14\VBD\1740|given|,|treatments|,|delayed|occurrence|. (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
C048599_D011041 NONE cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D003975_D011041 NONE diazepam_3\NN\2830852| (r_conj) cpa_1\NN\9761403|,|diazepam|or|2pam (r_nsubjpass) given_7\VBN\2327200|when|cpa|was|dfp-atropine (r_advcl) prevented_14\VBD\1740|given|,|treatments|,|delayed|occurrence|. (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D003975_D011041 NONE diazepam_5\NN\2830852|and|2pam (r_conj) cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D011220_D011041 NONE 2pam_5\NN\1740| (r_conj) cpa_1\NN\9761403|,|diazepam|or|2pam (r_nsubjpass) given_7\VBN\2327200|when|cpa|was|dfp-atropine (r_advcl) prevented_14\VBD\1740|given|,|treatments|,|delayed|occurrence|. (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D011220_D011041 NONE 2pam_7\NN\1740| (r_conj) diazepam_5\NN\2830852|and|2pam (r_conj) cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D007531_D011041 NONE dfp-atropine_10\NN\1740|after (r_nmod) given_7\VBN\2327200|when|cpa|was|dfp-atropine (r_advcl) prevented_14\VBD\1740|given|,|treatments|,|delayed|occurrence|. (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D007531_D011041 NONE dfp_26\NN\1740|of (r_nmod) toxicity_24\NN\13576101|the|dfp|rat (r_dobj) reduced_22\VBD\441445|thus|toxicity (r_conj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D001285_D011041 NONE dfp-atropine_10\NN\1740|after (r_nmod) given_7\VBN\2327200|when|cpa|was|dfp-atropine (r_advcl) prevented_14\VBD\1740|given|,|treatments|,|delayed|occurrence|. (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D001285_D011041 NONE atropine_11\NN\14712692|with (r_nmod) combination_9\NN\7951464|in|atropine (r_nmod) cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D016291_D064420 NONE atropine-mk801_0\NN\1740| (r_nsubj) offer_3\VB\2327200|atropine-mk801|did|not|protection|. (l_dobj) protection_6\NN\407535|any|additional|toxicity (l_nmod) toxicity_9\NN\13576101|against|dfp
C048599_D064420 NONE cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
D003975_D064420 NONE diazepam_5\NN\2830852|and|2pam (r_conj) cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
D011220_D064420 NONE 2pam_7\NN\1740| (r_conj) diazepam_5\NN\2830852|and|2pam (r_conj) cpa_3\NN\9761403|,|diazepam|combination (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
12905102
D003024_D003693 CID clozapine_2\NN\3713736| (r_compound) treatment_3\NN\654885|during|clozapine (r_nmod) delirium_0\NN\14391660|treatment|:|incidence
D003024_D003693 CID clozapine_9\NN\3713736| (r_compound) treatment_10\NN\654885|during|clozapine (r_nmod) incidence_2\NN\13821570|and|factors|delirium|treatment (l_nmod) delirium_7\NN\14391660|for
D003024_D003693 CID clozapine_15\NN\3713736|with (r_nmod) treated_13\VBN\2376958|clozapine (r_acl) inpatients_12\NNS\10405694|all|adult|psychiatric|treated|(|1995 (r_dobj) identify_8\VB\699815|to|inpatients (r_xcomp) used_3\VBD\1156834|methods|we|records|identify|,|reviewed|. (l_conj) reviewed_22\VBD\644583|records|score|,|and|tested (l_xcomp) score_27\VB\1111028|to|incidence (l_dobj) incidence_28\NN\13821570|and|severity|delirium (l_nmod) delirium_32\NN\14391660|of
D003024_D003693 CID clozapine-treated_9\JJ\1740| (r_amod) inpatients_10\NNS\10405694|of|clozapine-treated (r_nmod) %_7\NN\1740|in|10|inpatients (r_nmod) found_4\VBN\2426171|delirium|was|%|,|patients|. (l_nsubjpass) delirium_2\NN\14391660|
D003024_D001523 NONE clozapine_15\NN\3713736|with (r_nmod) treated_13\VBN\2376958|clozapine (r_acl) inpatients_12\NNS\10405694|all|adult|psychiatric|treated|(|1995 (l_amod) psychiatric_11\JJ\1740|
1592014
D003042_D012640 CID cocaine_4\NN\3492717| (r_compound) benzoylecgonine_6\NN\1740|by|the|cocaine|metabolite|rats (r_nmod) induced_1\VBN\1627355|benzoylecgonine (r_acl) seizures_0\NNS\14081375|induced|.
D003042_D012640 CID cocaine_6\NN\3492717|of (r_nmod) half-life_1\NN\15113229|the|t1/2|cocaine (r_nsubj) short_9\JJ\1740|half-life|is|relatively|,|but|occur (l_conj) occur_27\VB\2623529|some|can|exposure|. (l_nsubj) some_12\DT\1740|consequences|,|seizures|, (l_nmod) seizures_22\NNS\14081375|such|and|strokes
D003042_D012640 CID cocaine_9\NN\3492717|of (r_nmod) metabolite_7\NN\20090|of|the|major|cocaine|,|benzoylecgonine|, (r_nmod) potential_3\NN\14481929|the|metabolite|cause (l_acl) cause_17\VB\1617192|to|seizures (l_dobj) seizures_18\NNS\14081375|
D003042_D012640 CID cocaine_17\NN\3492717|of (r_nmod) amounts_15\NNS\13329641|by|equimolar|cocaine (r_nmod) induced_12\VBN\1627355|amounts (r_acl) those_11\DT\1740|than|induced (r_nmod) latencies_9\NNS\15269513|longer|those (r_dobj) had_6\VBD\2108377|latencies (r_conj) occurred_2\VBD\2623529|seizures|frequently|and|had|. (l_nsubj) seizures_1\NNS\14081375|be-induced
D003042_D012640 CID cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced
D003042_D012640 CID cocaine-injected_13\JJ\1740| (r_amod) animals_14\NNS\4475|than|cocaine-injected|seizures (r_nmod) activity_11\NN\30358|more|locomotor|animals (r_dobj) had_7\VBD\2108377|rats|activity|. (l_nsubj) rats_1\NNS\2329401|be-injected|have (l_acl:relcl) have_5\VB\2108377|that|did|not|seizures (l_dobj) seizures_6\NNS\14081375|
D003042_D012640 CID cocaine-injected_13\JJ\1740| (r_amod) animals_14\NNS\4475|than|cocaine-injected|seizures (l_nmod) seizures_16\NNS\14081375|without
D003042_D012640 CID cocaine-_3\NN\1740|and|be-induced (r_compound) seizures_6\NNS\14081375|cocaine-
D003042_D012640 CID cocaine-_3\NN\1740|and|be-induced (r_compound) seizures_6\NNS\14081375|cocaine- (r_nsubj) differ_7\VBP\1740|that|seizures|respects (r_ccomp) finding_1\NN\43195|the|differ (r_nsubj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
D003042_D012640 CID cocaine-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|for|cocaine-induced (r_nmod) mechanism_15\NN\13446390|one|seizures (r_dobj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_ccomp) differ_7\VBP\1740|that|seizures|respects (l_nsubj) seizures_6\NNS\14081375|cocaine-
D003042_D012640 CID cocaine-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|for|cocaine-induced
D003042_D012640 CID cocaine_25\NN\3492717| (r_compound) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_ccomp) differ_7\VBP\1740|that|seizures|respects (l_nsubj) seizures_6\NNS\14081375|cocaine-
D003042_D012640 CID cocaine_25\NN\3492717| (r_compound) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
C005618_D012640 CID benzoylecgonine_6\NN\1740|by|the|cocaine|metabolite|rats (r_nmod) induced_1\VBN\1627355|benzoylecgonine (r_acl) seizures_0\NNS\14081375|induced|.
C005618_D012640 CID benzoylecgonine_11\NN\1740|be (r_appos) metabolite_7\NN\20090|of|the|major|cocaine|,|benzoylecgonine|, (r_nmod) potential_3\NN\14481929|the|metabolite|cause (l_acl) cause_17\VB\1617192|to|seizures (l_dobj) seizures_18\NNS\14081375|
C005618_D012640 CID be_13\NN\14625458|(|) (r_appos) benzoylecgonine_11\NN\1740|be (r_appos) metabolite_7\NN\20090|of|the|major|cocaine|,|benzoylecgonine|, (r_nmod) potential_3\NN\14481929|the|metabolite|cause (l_acl) cause_17\VB\1617192|to|seizures (l_dobj) seizures_18\NNS\14081375|
C005618_D012640 CID be-induced_0\JJ\1740| (r_amod) seizures_1\NNS\14081375|be-induced
C005618_D012640 CID be_21\NN\14625458|by (r_nmod) induced_19\VBN\1627355|be (r_acl) those_18\DT\1740|induced (r_nsubj) prolonged_23\JJ\1740|,|those|were|,|multiple|,|and|resulted|. (r_dep) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted|prolonged (l_nsubjpass) seizures_2\NNS\14081375|cocaine-induced
C005618_D012640 CID be-injected_0\JJ\1740| (r_amod) rats_1\NNS\2329401|be-injected|have (l_acl:relcl) have_5\VB\2108377|that|did|not|seizures (l_dobj) seizures_6\NNS\14081375|
C005618_D012640 CID be-injected_0\JJ\1740| (r_amod) rats_1\NNS\2329401|be-injected|have (r_nsubj) had_7\VBD\2108377|rats|activity|. (l_dobj) activity_11\NN\30358|more|locomotor|animals (l_nmod) animals_14\NNS\4475|than|cocaine-injected|seizures (l_nmod) seizures_16\NNS\14081375|without
C005618_D012640 CID be-induced_5\JJ\1740| (r_conj) cocaine-_3\NN\1740|and|be-induced (r_compound) seizures_6\NNS\14081375|cocaine-
C005618_D012640 CID be-induced_5\JJ\1740| (r_conj) cocaine-_3\NN\1740|and|be-induced (r_compound) seizures_6\NNS\14081375|cocaine- (r_nsubj) differ_7\VBP\1740|that|seizures|respects (r_ccomp) finding_1\NN\43195|the|differ (r_nsubj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
C005618_D012640 CID be_28\NN\14625458| (r_appos) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_ccomp) differ_7\VBP\1740|that|seizures|respects (l_nsubj) seizures_6\NNS\14081375|cocaine-
C005618_D012640 CID be_28\NN\14625458| (r_appos) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
D003042_D020521 NONE cocaine_6\NN\3492717|of (r_nmod) half-life_1\NN\15113229|the|t1/2|cocaine (r_nsubj) short_9\JJ\1740|half-life|is|relatively|,|but|occur (l_conj) occur_27\VB\2623529|some|can|exposure|. (l_nsubj) some_12\DT\1740|consequences|,|seizures|, (l_nmod) seizures_22\NNS\14081375|such|and|strokes (l_conj) strokes_24\NNS\556313|
D003042_D003643 NONE cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced (r_nsubjpass) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted|prolonged (l_conj) resulted_14\VBD\2633881|death (l_nmod) death_16\NN\7296428|in
D003042_D003643 NONE cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced (r_nsubjpass) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted|prolonged (l_dep) prolonged_23\JJ\1740|,|those|were|,|multiple|,|and|resulted|. (l_conj) resulted_34\VBD\2633881|rarely|death (l_nmod) death_36\NN\7296428|in
C005618_D003643 NONE be_21\NN\14625458|by (r_nmod) induced_19\VBN\1627355|be (r_acl) those_18\DT\1740|induced (r_nsubj) prolonged_23\JJ\1740|,|those|were|,|multiple|,|and|resulted|. (r_dep) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted|prolonged (l_conj) resulted_14\VBD\2633881|death (l_nmod) death_16\NN\7296428|in
C005618_D003643 NONE be_21\NN\14625458|by (r_nmod) induced_19\VBN\1627355|be (r_acl) those_18\DT\1740|induced (r_nsubj) prolonged_23\JJ\1740|,|those|were|,|multiple|,|and|resulted|. (l_conj) resulted_34\VBD\2633881|rarely|death (l_nmod) death_36\NN\7296428|in
15120741
D010862_D013226 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\1617192|similar|,|injection|epilepticus|,|but|identified (l_dobj) epilepticus_9\NN\1740|status|se|and|development|mice
D010862_D013226 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\1617192|similar|,|injection|epilepticus|,|but|identified (l_dobj) epilepticus_9\NN\1740|status|se|and|development|mice (l_appos) se_11\NN\14724645|(|)
D010862_D013226 CID pilocarpine-treated_34\JJ\1740| (r_amod) mice_35\NNS\2329401|pilocarpine-treated|experience (l_acl:relcl) experience_39\VB\2108377|that|did|not|se (l_dobj) se_40\NN\14724645|
D010862_D012640 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\1617192|similar|,|injection|epilepticus|,|but|identified (l_dobj) epilepticus_9\NN\1740|status|se|and|development|mice (l_conj) development_16\NN\248977|the|eventual|seizures|c57bl/6 (l_nmod) seizures_19\NNS\14081375|of|spontaneous|and|sprouting
D008274_D013226 NONE mg(2+)-free_1\NN\1740| (r_amod) medium_3\NN\3575240|in|mg(2+)-free|bathing|containing (r_nmod) resulted_21\VBD\2633881|medium|,|stimulation|spike|. (l_nmod) spike_26\NN\7307895|in|a|single|population|cells (l_nmod) cells_29\NNS\3080309|in|granule|mice (l_nmod) mice_32\NNS\2329401|from|control|and|mice (l_conj) mice_35\NNS\2329401|pilocarpine-treated|experience (l_acl:relcl) experience_39\VB\2108377|that|did|not|se (l_dobj) se_40\NN\14724645|
D001640_D013226 NONE bicuculline_5\NN\1740|,|conditions (r_dobj) containing_4\VBG\2632940|bicuculline (r_acl) medium_3\NN\3575240|in|mg(2+)-free|bathing|containing (r_nmod) resulted_21\VBD\2633881|medium|,|stimulation|spike|. (l_nmod) spike_26\NN\7307895|in|a|single|population|cells (l_nmod) cells_29\NNS\3080309|in|granule|mice (l_nmod) mice_32\NNS\2329401|from|control|and|mice (l_conj) mice_35\NNS\2329401|pilocarpine-treated|experience (l_acl:relcl) experience_39\VB\2108377|that|did|not|se (l_dobj) se_40\NN\14724645|
D018698_D013226 NONE glutamate_37\NN\15010703| (r_compound) antagonists_39\NNS\7846|by|ionotropic|glutamate|receptor (r_nmod) blocked_34\VBN\1476483|which|were|antagonists (r_acl:relcl) afterdischarges_24\NNS\1740|repetitive|duration|,|blocked (r_conj) shifts_21\NNS\7446404|by|negative|dc|and|afterdischarges (r_nmod) followed_11\VBN\1835496|,|latency|,|shifts (r_acl) spike_10\NN\7307895|in|a|population|followed (r_nmod) resulted_6\VBD\2633881|survivors|,|stimulation|spike|. (l_nmod) survivors_2\NNS\9630641|in|se (l_compound) se_1\NN\14724645|
D018698_D013226 NONE glutamate_1\NN\15010703| (r_compound) photostimulation_2\NN\1740|focal|glutamate|layer|sites (r_nsubj) resulted_15\VBD\2633881|photostimulation|responses|. (l_nmod) responses_18\NNS\11410625|in|population|duration|slices (l_nmod) slices_26\NNS\13285176|in|survivors|not|groups (l_nmod) survivors_29\NNS\9630641|from|se (l_compound) se_28\NN\14724645|
11581460
D005283_D016055 CID fentanyl_12\NN\2707683|of (r_nmod) infusion_10\NN\14589223|of|continuous|intravenous|fentanyl (r_nmod) result_6\NN\34213|as|a|infusion (r_nmod) retention_1\NN\809465|bladder|urine|result|:|reports (l_nmod) urine_3\NN\14853947|of
D005283_D009127 NONE fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|various|reported|side|administration (r_nsubj) include_7\VBP\690614|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|wall|,|hypotension
D005283_D007022 CID fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|various|reported|side|administration (r_nsubj) include_7\VBP\690614|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|wall|,|hypotension (l_conj) hypotension_12\NN\14057371|,|depression|,|and|bradycardia
D005283_D012131 CID fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|various|reported|side|administration (r_nsubj) include_7\VBP\690614|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|wall|,|hypotension (l_conj) hypotension_12\NN\14057371|,|depression|,|and|bradycardia (l_conj) depression_15\NN\14373582|respiratory
D005283_D001919 CID fentanyl_5\NN\2707683| (r_compound) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|various|reported|side|administration (r_nsubj) include_7\VBP\690614|effects|rigidity|. (l_dobj) rigidity_10\NN\5023233|wall|,|hypotension (l_conj) hypotension_12\NN\14057371|,|depression|,|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
D005283_D001745 CID fentanyl_22\NN\2707683|of (r_nmod) infusion_20\NN\14589223|of|continuous|fentanyl (r_nmod) result_17\NN\34213|as|a|infusion (r_nmod) leading_8\VBG\1752884|dilatation|result (r_acl) retention_7\NN\809465|of|bladder|leading
D005283_D006869 NONE fentanyl_22\NN\2707683|of (r_nmod) infusion_20\NN\14589223|of|continuous|fentanyl (r_nmod) result_17\NN\34213|as|a|infusion (r_nmod) leading_8\VBG\1752884|dilatation|result (l_nmod) dilatation_12\NN\14034177|to|renal|pelvocalyceal|mimicking (l_acl) mimicking_13\VBG\1742886|hydronephrosis (l_dobj) hydronephrosis_14\NN\14204950|
3676049
D007530_D007022 CID isoflurane-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|during|isoflurane-induced|patients
D007530_D007022 CID isoflurane-induced_12\JJ\1740| (r_amod) hypotension_13\NN\14057371|during|isoflurane-induced
D007530_D007022 CID isoflurane_19\NN\3570838|of (r_nmod) dose_17\NN\3740161|the|isoflurane (r_dobj) increasing_15\VBG\169651|by|dose (r_advcl) induced_13\VBN\1627355|hypotension|was|increasing|,|and|maintained|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|map
D007530_D002532 NONE isoflurane-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|during|isoflurane-induced|patients (l_nmod) patients_9\NNS\9898892|in|subjected (l_acl) subjected_10\VBN\137313|surgery (l_nmod) surgery_12\NN\6045562|to|aneurysms (l_nmod) aneurysms_15\NNS\14057371|for|cerebral
D007530_D002532 NONE isoflurane-induced_12\JJ\1740| (r_amod) hypotension_13\NN\14057371|during|isoflurane-induced (r_nmod) measured_10\VBN\697589|flow|were|hypotension|patients|. (l_nmod) patients_16\NNS\9898892|in|10|subjected (l_acl) subjected_17\VBN\137313|craniotomy (l_nmod) craniotomy_19\NN\671351|to|clipping (l_nmod) clipping_21\NN\6400510|for|aneurysm (l_nmod) aneurysm_25\NN\14057371|of|a|cerebral
D010100_D007022 NONE oxygen_8\NN\14622893|for (r_nmod) rate_6\NN\13815152|cerebral|metabolic|oxygen (r_conj) flow_2\NN\7311115|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN\697589|flow|were|hypotension|patients|. (l_nmod) hypotension_13\NN\14057371|during|isoflurane-induced
D010100_D002532 NONE oxygen_8\NN\14622893|for (r_nmod) rate_6\NN\13815152|cerebral|metabolic|oxygen (r_conj) flow_2\NN\7311115|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN\697589|flow|were|hypotension|patients|. (l_nmod) patients_16\NNS\9898892|in|10|subjected (l_acl) subjected_17\VBN\137313|craniotomy (l_nmod) craniotomy_19\NN\671351|to|clipping (l_nmod) clipping_21\NN\6400510|for|aneurysm (l_nmod) aneurysm_25\NN\14057371|of|a|cerebral
D014978_D013345 NONE xenon-133_22\NN\1740| (r_dobj) using_21\VBG\1156834|xenon-133|i.v. (r_acl) modification_15\NN\191142|by|a|technique|using (r_nmod) measured_4\VBN\697589|flow|were|haemorrhage|modification|maintained (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid
D007530_D013345 NONE isoflurane_30\NN\3570838| (r_compound) concentration_31\NN\4916342|with|an|inspired|isoflurane|%|oxide (r_nmod) maintained_26\VBN\2202928|anaesthesia|was|concentration|,|min-1|and|min-1|paco2|mean|. (r_parataxis) measured_4\VBN\697589|flow|were|haemorrhage|modification|maintained (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid
D009609_D013345 NONE oxide_40\NN\14818238|plus|%|nitrous|oxygen|) (r_nmod) concentration_31\NN\4916342|with|an|inspired|isoflurane|%|oxide (r_nmod) maintained_26\VBN\2202928|anaesthesia|was|concentration|,|min-1|and|min-1|paco2|mean|. (r_parataxis) measured_4\VBN\697589|flow|were|haemorrhage|modification|maintained (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid
D010100_D013345 NONE oxygen_42\NN\14622893|in (r_nmod) oxide_40\NN\14818238|plus|%|nitrous|oxygen|) (r_nmod) concentration_31\NN\4916342|with|an|inspired|isoflurane|%|oxide (r_nmod) maintained_26\VBN\2202928|anaesthesia|was|concentration|,|min-1|and|min-1|paco2|mean|. (r_parataxis) measured_4\VBN\697589|flow|were|haemorrhage|modification|maintained (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid
D008628_D007022 NONE hg_11\NN\14625458|of|55|mm (r_nmod) map_5\NN\4076846|to|an|average|hg (r_nmod) hypotension_1\NN\14057371|controlled|map
D007530_D000783 NONE isoflurane_7\NN\3570838| (r_compound) concentration_8\NN\4916342|the|isoflurane (r_nsubjpass) reduced_10\VBN\441445|clipping|concentration|was|%|. (l_nmod) clipping_2\NN\6400510|after|the|aneurysm (l_nmod) aneurysm_5\NN\14057371|of|the
14596845
D000661_D019966 NONE amphetamine_13\NN\3248958|of (r_nmod) dose_11\NN\3740161|to|a|low|amphetamine (r_nmod) cross-sensitization_7\NN\1740|behavioral|dose (r_dobj) causes_5\VBZ\1617192|diet|cross-sensitization|. (l_nsubj) diet_1\NN\7560652|a|promoting (l_acl) promoting_2\VBG\2556126|dependency (l_dobj) dependency_4\NN\24720|sugar
D000661_D006948 CID amphetamine_13\NN\3248958|of (r_nmod) dose_11\NN\3740161|to|a|low|amphetamine (r_nmod) cross-sensitization_7\NN\1740|behavioral|dose
D000661_D006948 CID amphetamine_22\NN\3248958|of (r_nmod) dose_20\NN\3740161|to|a|low|amphetamine (r_nmod) cross-sensitization_16\NN\1740|behavioral|dose
D000661_D006948 CID amphetamine_14\NN\3248958|to (r_nmod) response_12\NN\11410625|in|amphetamine (r_nmod) hyperactive_10\JJ\1740|animals|were|response|compared|.
D000661_D006948 CID amphetamine_30\NN\3248958| (r_compound) injection_31\NN\320852|by|amphetamine (r_nmod) followed_28\VBN\1835496|injection (r_acl) sucrose_25\NN\14836642|(|libitum|%|and|chow|followed|,|chow|) (r_dep) groups_19\NNS\2137|with|four|control|sucrose (r_nmod) compared_15\VBN\644583|groups (r_prep) hyperactive_10\JJ\1740|animals|were|response|compared|.
D000661_D006948 CID amphetamine_37\NN\3248958| (r_compound) injection_38\NN\320852|by|amphetamine (r_nmod) followed_35\VBN\1835496|injection (r_acl) chow_34\NN\7971582|cyclic|followed|,|chow|,|or|sucrose (r_conj) sucrose_25\NN\14836642|(|libitum|%|and|chow|followed|,|chow|) (r_dep) groups_19\NNS\2137|with|four|control|sucrose (r_nmod) compared_15\VBN\644583|groups (r_prep) hyperactive_10\JJ\1740|animals|were|response|compared|.
D000661_D006948 CID amphetamine_44\NN\3248958|with (r_nmod) chow_42\NN\7971582|libitum|amphetamine (r_conj) chow_34\NN\7971582|cyclic|followed|,|chow|,|or|sucrose (r_conj) sucrose_25\NN\14836642|(|libitum|%|and|chow|followed|,|chow|) (r_dep) groups_19\NNS\2137|with|four|control|sucrose (r_nmod) compared_15\VBN\644583|groups (r_prep) hyperactive_10\JJ\1740|animals|were|response|compared|.
D013395_D006948 CID sucrose_6\NN\14836642|cyclic|and|chow (r_dobj) experienced_4\VBN\2108377|that|had|sucrose (r_acl:relcl) animals_1\NNS\4475|the|experienced (r_nsubj) hyperactive_10\JJ\1740|animals|were|response|compared|.
D013395_D006948 CID sucrose_25\NN\14836642|(|libitum|%|and|chow|followed|,|chow|) (r_dep) groups_19\NNS\2137|with|four|control|sucrose (r_nmod) compared_15\VBN\644583|groups (r_prep) hyperactive_10\JJ\1740|animals|were|response|compared|.
D013395_D006948 CID sucrose_50\NN\14836642|cyclic|%|and|chow (r_conj) chow_34\NN\7971582|cyclic|followed|,|chow|,|or|sucrose (r_conj) sucrose_25\NN\14836642|(|libitum|%|and|chow|followed|,|chow|) (r_dep) groups_19\NNS\2137|with|four|control|sucrose (r_nmod) compared_15\VBN\644583|groups (r_prep) hyperactive_10\JJ\1740|animals|were|response|compared|.
12617329
D006170_D007674 NONE arabic_6\NN\6986894|with|gum (r_nmod) treatment_3\NN\654885|of|arabic (r_nmod) effect_1\NN\34213|the|treatment|nephrotoxicity|:|study (l_nmod) nephrotoxicity_9\NN\1740|on|gentamicin|rats
D006170_D007674 NONE arabic_14\NN\6986894|with|gum (r_nmod) treatment_9\NN\654885|of|rats|arabic (r_nmod) effect_7\NN\34213|the|treatment|failure (l_nmod) failure_18\NN\66216|on|acute|renal|induced (l_acl) induced_19\VBN\1627355|nephrotoxicity (l_nmod) nephrotoxicity_25\NN\1740|by|gentamicin
D006170_D007674 NONE arabic_6\JJ\1740|gum (r_amod) treatment_7\NN\654885|arabic (r_nsubj) induced_9\VBN\1627355|that|treatment|has|amelioration (l_dobj) amelioration_12\NN\248977|a|modest|some (l_nmod) some_14\DT\1740|of|indices (l_nmod) indices_20\NNS\13850304|of|the|histological|nephrotoxicity (l_nmod) nephrotoxicity_23\NN\1740|of|gm
D005839_D007674 NONE gentamicin_8\NN\2716866| (r_compound) nephrotoxicity_9\NN\1740|on|gentamicin|rats
D005839_D007674 NONE gentamicin_21\NN\2716866|gm (r_compound) nephrotoxicity_25\NN\1740|by|gentamicin
D005839_D007674 NONE gm_23\NN\13717155|(|) (r_appos) gentamicin_21\NN\2716866|gm (r_compound) nephrotoxicity_25\NN\1740|by|gentamicin
D005839_D007674 NONE gm_22\NN\13717155| (r_compound) nephrotoxicity_23\NN\1740|of|gm
D006170_D058186 CID arabic_14\NN\6986894|with|gum (r_nmod) treatment_9\NN\654885|of|rats|arabic (r_nmod) effect_7\NN\34213|the|treatment|failure (l_nmod) failure_18\NN\66216|on|acute|renal|induced
D005839_D058186 CID gentamicin_21\NN\2716866|gm (r_compound) nephrotoxicity_25\NN\1740|by|gentamicin (r_nmod) induced_19\VBN\1627355|nephrotoxicity (r_acl) failure_18\NN\66216|on|acute|renal|induced
D005839_D058186 CID gm_23\NN\13717155|(|) (r_appos) gentamicin_21\NN\2716866|gm (r_compound) nephrotoxicity_25\NN\1740|by|gentamicin (r_nmod) induced_19\VBN\1627355|nephrotoxicity (r_acl) failure_18\NN\66216|on|acute|renal|induced
D003404_D007674 NONE creatinine_8\NN\1740|of|and|urea (r_nmod) concentrations_6\NNS\4916342|the|creatinine|plasma|and|glutathione (r_dobj) measuring_4\VBG\697589|by|concentrations|,|and|examination (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D014508_D007674 NONE urea_10\NN\14727670| (r_conj) creatinine_8\NN\1740|of|and|urea (r_nmod) concentrations_6\NNS\4916342|the|creatinine|plasma|and|glutathione (r_dobj) measuring_4\VBG\697589|by|concentrations|,|and|examination (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D005978_D007674 NONE glutathione_16\NN\1740|reduced|gsh|cortex (r_conj) concentrations_6\NNS\4916342|the|creatinine|plasma|and|glutathione (r_dobj) measuring_4\VBG\697589|by|concentrations|,|and|examination (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D005978_D007674 NONE gsh_18\NN\1740|(|) (r_appos) glutathione_16\NN\1740|reduced|gsh|cortex (r_conj) concentrations_6\NNS\4916342|the|creatinine|plasma|and|glutathione (r_dobj) measuring_4\VBG\697589|by|concentrations|,|and|examination (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D006170_D007683 NONE arabic_8\NN\6986894|with|gum|and|gm (r_nmod) treatment_5\NN\654885|concomitant|arabic (r_nsubj) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D006170_D007683 NONE arabic_82\NN\6986894|with|gum (r_nmod) given_77\VBN\2327200|gm|together|arabic (r_acl) rats_76\NNS\2329401|in|given (r_nmod) severe_74\JJ\1740|to|be|less|rats (r_xcomp) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm_10\NN\13717155| (r_conj) arabic_8\NN\6986894|with|gum|and|gm (r_nmod) treatment_5\NN\654885|concomitant|arabic (r_nsubj) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm_40\NN\13717155| (r_conj) cellulose_38\NN\14994004|with|and|gm (r_nmod) treated_36\VBN\2376958|cellulose (r_acl) rats_35\NNS\2329401|in|treated (r_nmod) %_30\NN\1740|to|432|,|respectively|,|rats (r_nmod) compared_25\VBN\644583|(|%|) (r_dep) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm_61\NN\13717155| (r_conj) cellulose_59\NN\14994004|plus|gm (r_compound) group_62\NN\2137|in|the|cellulose (r_nmod) %_56\NN\1740|to|27|group (r_nmod) compared_53\VBN\644583|% (r_prep) decreased_44\VBD\169651|that|%|(|compared (r_conj) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm-induced_65\JJ\1740| (r_amod) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm_78\NN\13717155| (r_dobj) given_77\VBN\2327200|gm|together|arabic (r_acl) rats_76\NNS\2329401|in|given (r_nmod) severe_74\JJ\1740|to|be|less|rats (r_xcomp) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D003404_D007683 NONE creatinine_13\NN\1740|and|urea (r_dobj) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D014508_D007683 NONE urea_15\NN\14727670| (r_conj) creatinine_13\NN\1740|and|urea (r_dobj) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
D005978_D007683 NONE gsh_48\NN\1740|of|cortical (r_nmod) that_45\DT\1740|gsh (r_dobj) decreased_44\VBD\169651|that|%|(|compared (r_conj) increased_12\VBD\169651|that|treatment|significantly|creatinine|%|,|respectively|compared|,|and|decreased|)|appeared (l_parataxis) appeared_69\VBD\2604760|necrosis|severe (l_nsubj) necrosis_68\NN\11444117|the|gm-induced|proximal|tubular
17111419
C102006_D064420 NONE citrate_1\NN\14850483| (r_compound) toxicity_2\NN\13576101|severe|citrate|complicating|.
C102006_D064420 NONE citrate_6\NN\14850483| (r_compound) toxicity_7\NN\13576101|of|severe|citrate|collection
C102006_D064420 NONE citrate_22\NN\14850483| (r_compound) toxicity_23\NN\13576101|due|citrate
D002125_C536214 NONE gluconate_5\NN\1740|with|intravenous|calcium (r_nmod) treatment_1\NN\654885|empirical|gluconate (r_nsubjpass) initiated_7\VBN\1617192|treatment|was|,|and|subsided (l_conj) subsided_13\VBD\223500|contractions|slowly|minutes|. (l_nsubj) contractions_11\NNS\358931|muscle
D002118_D006996 NONE calcium_9\NN\14625458| (r_compound) chelation_10\NN\29677|to|calcium|anticoagulant (r_nmod) reaction_7\NN\13446390|with|a|severe|chelation|resulting (l_acl) resulting_15\VBG\2633881|hypocalcemia (l_nmod) hypocalcemia_19\NN\14299637|in|symptomatic|systemic
C102006_D006996 CID citrate_13\NN\14850483| (r_compound) anticoagulant_14\NN\3740161|by|sodium|citrate (r_nmod) chelation_10\NN\29677|to|calcium|anticoagulant (r_nmod) reaction_7\NN\13446390|with|a|severe|chelation|resulting (l_acl) resulting_15\VBG\2633881|hypocalcemia (l_nmod) hypocalcemia_19\NN\14299637|in|symptomatic|systemic
C102006_D006996 CID citrate_22\NN\14850483| (r_compound) toxicity_23\NN\13576101|due|citrate (r_nmod) reactions_19\NNS\13446390|severe|toxicity (r_dobj) prevent_17\VB\1740|reactions (r_xcomp) help_16\VB\2556126|to|prevent (r_advcl) recommended_14\VBN\875394|that|screening|is|help (l_nsubjpass) screening_4\NN\6887726|careful|medications (l_nmod) medications_6\NNS\3247620|for|and|conditions|predisposing (l_acl) predisposing_10\VBG\680841|hypocalcemia (l_nmod) hypocalcemia_12\NN\14299637|to
D002034_D006996 NONE bumetanide_9\NN\1740| (r_nsubj) diuretic_13\NN\3247620|that|bumetanide|is|a|loop|cause (l_acl:relcl) cause_16\VB\1617192|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\14299637|significant
D049994_D006996 NONE diuretic_13\NN\3247620|that|bumetanide|is|a|loop|cause (l_acl:relcl) cause_16\VB\1617192|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\14299637|significant
9284778
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS\14603497|by|used (r_nmod) caused_4\VBN\1617192|hydrochlorofluorocarbons (r_acl) disease_3\NN\14061805|of|liver|caused
D010126_D008107 NONE ozone-sparing_9\NN\1740| (r_amod) substitutes_10\NNS\5695554|as|ozone-sparing|chlorofluorocarbons (r_nmod) used_7\VBN\1156834|substitutes (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|by|used (r_nmod) caused_4\VBN\1617192|hydrochlorofluorocarbons (r_acl) disease_3\NN\14061805|of|liver|caused
D017402_D008107 NONE chlorofluorocarbons_12\NNS\14871968|of (r_nmod) substitutes_10\NNS\5695554|as|ozone-sparing|chlorofluorocarbons (r_nmod) used_7\VBN\1156834|substitutes (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|by|used (r_nmod) caused_4\VBN\1617192|hydrochlorofluorocarbons (r_acl) disease_3\NN\14061805|of|liver|caused
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|repeated|accidental|mixture (r_nmod) workers_10\NNS\7846|in|nine|industrial|exposure (r_nmod) epidemic_3\NN\7435273|an|disease|workers (l_nmod) disease_6\NN\14061805|of|liver
C067411_D008107 CID 123_24\CD\1740| (r_nummod) hcfc_23\NN\14603497|(|123|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|repeated|accidental|mixture (r_nmod) workers_10\NNS\7846|in|nine|industrial|exposure (r_nmod) epidemic_3\NN\7435273|an|disease|workers (l_nmod) disease_6\NN\14061805|of|liver
C067411_D008107 CID 124_8\CD\1740| (r_conj) hcfcs_5\NNS\14603497|123|and|124 (r_nsubj) result_10\VB\2633881|whether|hcfcs|can|disease (l_nmod) disease_14\NN\14061805|in|serious|liver
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740|hcfc (r_conj) 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|repeated|accidental|mixture (r_nmod) workers_10\NNS\7846|in|nine|industrial|exposure (r_nmod) epidemic_3\NN\7435273|an|disease|workers (l_nmod) disease_6\NN\14061805|of|liver
C072959_D008107 CID 124_30\CD\1740| (r_nummod) hcfc_29\NN\14603497|(|124|) (r_appos) 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740|hcfc (r_conj) 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|repeated|accidental|mixture (r_nmod) workers_10\NNS\7846|in|nine|industrial|exposure (r_nmod) epidemic_3\NN\7435273|an|disease|workers (l_nmod) disease_6\NN\14061805|of|liver
C072959_D008107 CID 124_8\CD\1740| (r_conj) hcfcs_5\NNS\14603497|123|and|124 (r_nsubj) result_10\VB\2633881|whether|hcfcs|can|disease (l_nmod) disease_14\NN\14061805|in|serious|liver
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740|as|halothane (r_nmod) metabolised_3\VBN\1740|compounds|are|way|1-bromo-1-chloro-2,2,2-trifluoroethane|form|. (l_advcl) form_14\VB\1617192|to|intermediates (l_dobj) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_acl:relcl) implicated_23\VBN\2677097|which|have|been|hepatotoxicity (l_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D006221_D056486 NONE halothane_11\NN\3570838|(|) (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740|as|halothane (r_nmod) metabolised_3\VBN\1740|compounds|are|way|1-bromo-1-chloro-2,2,2-trifluoroethane|form|. (l_advcl) form_14\VB\1617192|to|intermediates (l_dobj) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_acl:relcl) implicated_23\VBN\2677097|which|have|been|hepatotoxicity (l_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D006221_D056486 NONE halothane_28\NN\3570838|of (r_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D014269_D056486 NONE trifluoroacetyl_16\NN\1740| (r_compound) halide_17\NN\15010703|trifluoroacetyl (r_compound) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_acl:relcl) implicated_23\VBN\2677097|which|have|been|hepatotoxicity (l_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D014269_D056486 NONE trifluoroacetyl-altered_17\JJ\1740| (r_amod) proteins_19\NNS\14944888|trifluoroacetyl-altered|liver (r_nsubjpass) involved_21\VBN\2676054|that|proteins|are (r_ccomp) suggest_15\VBP\1010118|known|,|results|involved|. (l_advcl) known_11\VBN\2110220|although|mechanism|is|not (l_nsubjpass) mechanism_3\NN\13446390|the|exact|hepatotoxicity (l_nmod) hepatotoxicity_5\NN\1740|of|agents
C067411_D056486 NONE 124_11\CD\1740| (r_conj) hcfcs_8\NNS\14603497|to|123|and|124 (r_nmod) exposure_3\NN\5042871|repeated|beings|hcfcs (r_nsubj) result_13\VB\2633881|exposure|can|injury|. (l_nmod) injury_17\NN\14052046|in|serious|liver|proportion
C072959_D056486 NONE 124_11\CD\1740| (r_conj) hcfcs_8\NNS\14603497|to|123|and|124 (r_nmod) exposure_3\NN\5042871|repeated|beings|hcfcs (r_nsubj) result_13\VB\2633881|exposure|can|injury|. (l_nmod) injury_17\NN\14052046|in|serious|liver|proportion
7834920
D012293_D005921 CID rifampin_6\NN\2716205| (r_compound) therapy_7\NN\657604|with|intermittent|rifampin|tuberculosis (r_nmod) associated_3\VBN\628491|therapy (r_acl) glomerulonephritis_2\NN\14113798|crescentic|fibrillary|associated|.
D012293_D005921 CID rifampin_17\NN\2716205|with (r_nmod) treated_15\VBN\2376958|rifampin (r_acl) patient_14\NN\9898892|in|a|treated|had (r_nmod) glomerulonephritis_11\NN\14113798|of|proliferative|crescentic|patient
D012293_D005921 CID rifampin_20\NN\2716205|with (r_nmod) treated_18\VBN\2376958|rifampin (r_acl) patient_17\NN\9898892|in|a|treated (r_nmod) occurrence_5\NN\29378|the|unusual|glomerulonephritis|patient (l_nmod) glomerulonephritis_9\NN\14113798|of|progressive|crescents
D012293_D005921 CID rifampin_20\NN\2716205|with (r_nmod) treated_18\VBN\2376958|rifampin (r_acl) patient_17\NN\9898892|in|a|treated (r_nmod) occurrence_5\NN\29378|the|unusual|glomerulonephritis|patient (l_nmod) glomerulonephritis_9\NN\14113798|of|progressive|crescents (l_nmod) crescents_11\NNS\13867641|with|and|glomerulonephritis (l_conj) glomerulonephritis_14\NN\14113798|fibrillar
D012293_D014397 NONE rifampin_6\NN\2716205| (r_compound) therapy_7\NN\657604|with|intermittent|rifampin|tuberculosis (l_nmod) tuberculosis_10\NN\14127211|for|pulmonary
D012293_D014397 NONE rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin (r_dobj) underwent_2\VBD\109660|patient|regimen|tuberculosis|and|discovered|. (l_nmod) tuberculosis_12\NN\14127211|for|pulmonary
D012293_D051437 CID rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin (r_dobj) underwent_2\VBD\109660|patient|regimen|tuberculosis|and|discovered|. (l_conj) discovered_15\VBN\2163746|was|developed (l_xcomp) developed_18\VBN\1753788|to|have|signs|completion (l_dobj) signs_19\NNS\6643763|failure (l_nmod) failure_23\NN\66216|of|severe|renal
D007538_D014397 NONE isoniazid_9\NN\2716205| (r_conj) rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin (r_dobj) underwent_2\VBD\109660|patient|regimen|tuberculosis|and|discovered|. (l_nmod) tuberculosis_12\NN\14127211|for|pulmonary
D007538_D051437 NONE isoniazid_9\NN\2716205| (r_conj) rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin (r_dobj) underwent_2\VBD\109660|patient|regimen|tuberculosis|and|discovered|. (l_conj) discovered_15\VBN\2163746|was|developed (l_xcomp) developed_18\VBN\1753788|to|have|signs|completion (l_dobj) signs_19\NNS\6643763|failure (l_nmod) failure_23\NN\66216|of|severe|renal
3564823
D008012_D013035 NONE lidocaine_5\NN\3681148|by (r_nmod) relieved_3\VBN\205885|lidocaine (r_acl) spasm_2\NN\14299637|drug-induced|arterial|relieved|.
D013874_D002545 NONE pentothal_10\NN\2792049|sodium (r_nsubjpass) infused_13\VBN\606335|surgery|,|pentothal|was|intravenously|minimize|. (l_xcomp) minimize_15\VB\441445|to|ischaemia (l_dobj) ischaemia_17\NN\14195315|cerebral
D008012_D020301 NONE lidocaine_11\NN\3681148| (r_nsubjpass) given_13\VBN\2327200|precluded|,|lidocaine|was|intra-arterially|,|monitoring|,|counteract|. (l_advcl) counteract_22\VB\2367363|to|vasospasm (l_dobj) vasospasm_24\NN\1740|the
8638206
D001279_D010243 CID atracurium_6\NN\1740|of (r_nmod) use_4\NN\407535|after|prolonged|atracurium|absence (r_nmod) paralysis_1\NN\14557898|persistent|use|.
D001279_D010243 CID besylate_1\NN\1740|atracurium|,|nmba|, (r_nsubjpass) associated_20\VBN\628491|besylate|has|also|been|paralysis|,|but|used|. (l_nmod) paralysis_23\NN\14557898|with|persistent
D001279_D010243 CID atracurium-related_5\JJ\1740| (r_amod) paralysis_6\NN\14557898|of|atracurium-related|persisting
D014673_D010243 CID bromide_19\NN\14904359|such|vecuronium (r_nmod) nmbas_15\NNS\1740|aminosteroid-based|bromide|,|used (r_dobj) involved_13\VBN\2676054|reports|have|often|nmbas|. (l_nsubj) reports_0\NNS\6470073|paralysis (l_nmod) paralysis_3\NN\14557898|of|persistent|discontinuance
-1_D010243 NONE benzylisoquinolinium_5\NN\1740| (r_compound) nmba_6\NN\1740|a|short-acting|benzylisoquinolinium|eliminated (r_appos) besylate_1\NN\1740|atracurium|,|nmba|, (r_nsubjpass) associated_20\VBN\628491|besylate|has|also|been|paralysis|,|but|used|. (l_nmod) paralysis_23\NN\14557898|with|persistent
18791946
D002939_D013921 CID ciprofloxacin_7\NN\2716866|with (r_nmod) associated_5\VBN\628491|ciprofloxacin (r_acl) thrombocytopenia_1\NN\14189204|severe|and|anaemia|associated|:|report
D002939_D013921 CID ciprofloxacin_5\NN\2716866| (r_nsubj) precipitate_7\VB\1642924|that|ciprofloxacin|may|thrombocytopenia|phases|exposures (l_dobj) thrombocytopenia_9\NN\14189204|life-threatening|and|anaemia|,
D002939_D000743 CID ciprofloxacin_7\NN\2716866|with (r_nmod) associated_5\VBN\628491|ciprofloxacin (r_acl) thrombocytopenia_1\NN\14189204|severe|and|anaemia|associated|:|report (l_conj) anaemia_4\NN\14299637|haemolytic
D002939_D000743 CID ciprofloxacin_5\NN\2716866| (r_nsubj) precipitate_7\VB\1642924|that|ciprofloxacin|may|thrombocytopenia|phases|exposures (l_dobj) thrombocytopenia_9\NN\14189204|life-threatening|and|anaemia|, (l_conj) anaemia_12\NN\14299637|haemolytic
D002939_D015746 CID ciprofloxacin_16\NN\2716866|of|oral (r_nmod) administration_13\NN\1133281|after|3-day|ciprofloxacin|suspect (r_nmod) reported_5\VBD\831651|man|pain|administration|. (l_nmod) pain_8\NN\14299637|with|abdominal|and|jaundice
D002939_D007565 CID ciprofloxacin_16\NN\2716866|of|oral (r_nmod) administration_13\NN\1133281|after|3-day|ciprofloxacin|suspect (r_nmod) reported_5\VBD\831651|man|pain|administration|. (l_nmod) pain_8\NN\14299637|with|abdominal|and|jaundice (l_conj) jaundice_10\NN\14299637|
D002939_D014552 NONE ciprofloxacin_16\NN\2716866|of|oral (r_nmod) administration_13\NN\1133281|after|3-day|ciprofloxacin|suspect (l_nmod) suspect_19\NN\7846|for|a|infection (l_nmod) infection_23\NN\14052046|of|tract
3358181
D012312_D014693 CID ritodrine_6\NN\1740| (r_compound) therapy_7\NN\657604|after|ritodrine (r_nmod) section_4\NN\7020895|during|cesarean|therapy (r_nmod) tachyarrhythmias_1\NNS\1740|ventricular|section|:|interaction
D012312_D007752 NONE ritodrine_6\NN\1740| (r_dobj) receiving_5\VBG\2210855|ritodrine|labor (l_nmod) labor_9\NN\7974025|for|preterm
D012312_D007752 NONE ritodrine_19\NN\1740|of (r_nmod) effects_17\NNS\13245626|between|the|residual|betamimetic|ritodrine|and|effects (r_nmod) interactions_12\NNS\37396|effects (r_dobj) risk_11\VB\2530167|that|patients|may|interactions (l_nsubj) patients_4\NNS\9898892|receiving (l_acl) receiving_5\VBG\2210855|ritodrine|labor (l_nmod) labor_9\NN\7974025|for|preterm
D012312_D002318 NONE ritodrine_15\NN\1740|of (r_nmod) infusion_13\NN\14589223|of|an|ritodrine (r_nmod) cessation_10\NN\7365849|after|infusion (r_nmod) result_3\VB\2633881|interactions|may|complications|cessation|. (l_nmod) complications_7\NNS\1073995|in|serious|cardiovascular
D010656_D007022 NONE phenylephrine_20\NN\2682038|such (r_nmod) vasopressor_17\NN\4522421|of|an|alpha-adrenergic|phenylephrine (r_nmod) use_13\NN\407535|to|the|vasopressor|treat (l_acl) treat_22\VB\2376958|to|patients (l_dobj) patients_24\NNS\9898892|hypotensive|tachycardia (l_amod) hypotensive_23\JJ\1740|
D010656_D013610 NONE phenylephrine_20\NN\2682038|such (r_nmod) vasopressor_17\NN\4522421|of|an|alpha-adrenergic|phenylephrine (r_nmod) use_13\NN\407535|to|the|vasopressor|treat (l_acl) treat_22\VB\2376958|to|patients (l_dobj) patients_24\NNS\9898892|hypotensive|tachycardia (l_nmod) tachycardia_26\NN\14110674|with
19300402
D001920_D006930 NONE bradykinin_0\NN\1740| (r_compound) receptors_1\NNS\5225602|bradykinin (r_compound) antagonists_2\NNS\7846|receptors|and|inhibitors|hyperalgesia|. (l_nmod) hyperalgesia_13\NN\1740|in|induced|model
D001920_D006930 NONE bradykinin_11\NN\1740| (r_compound) receptors_12\NNS\5225602|of|bradykinin (r_nmod) inhibition_9\NN\1068773|receptors|and|synthase (r_nsubj) reduces_23\VBZ\441445|that|inhibition|hyperalgesia (l_dobj) hyperalgesia_25\NN\1740|diabetic
D001920_D006930 NONE bradykinin_19\NN\1740| (r_conj) products_6\NNS\3076708|both|synthase|as|bradykinin (r_nsubjpass) involved_21\VBN\2676054|that|products|are|hyperalgesia (l_nmod) hyperalgesia_23\NN\1740|in|produced
D001920_D006930 NONE bradykinin_12\NN\1740|of (r_nmod) activity_10\NN\30358|in|pronociceptive|bradykinin (r_nmod) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D001920_D006930 NONE bradykinin_12\NN\1740|of (r_nmod) activity_10\NN\30358|in|pronociceptive|bradykinin (r_nmod) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_parataxis) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (l_nmod) hyperalgesia_17\NN\1740|in|vincristine-induced
D001920_D006930 NONE bradykinin_18\NN\1740| (r_nsubj) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (r_parataxis) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D001920_D006930 NONE bradykinin_18\NN\1740| (r_nsubj) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (l_nmod) hyperalgesia_17\NN\1740|in|vincristine-induced
D001920_D003929 NONE bradykinin_0\NN\1740| (r_compound) receptors_1\NNS\5225602|bradykinin (r_compound) antagonists_2\NNS\7846|receptors|and|inhibitors|hyperalgesia|. (l_nmod) hyperalgesia_13\NN\1740|in|induced|model (l_nmod) model_20\NN\5888929|in|chemotherapy|rat (l_compound) chemotherapy_15\NN\661091|and|neuropathy (l_conj) neuropathy_18\NN\14204950|diabetic
D001920_D003929 NONE bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|hoe (r_appos) antagonists_57\NNS\7846|of|selective|b2|receptors|:|bradykinin (r_nmod) action_54\NN\30358|on|antihyperalgesic|antagonists (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D009569_D006930 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\1740|nitric|oxide (r_compound) inhibitors_7\NNS\20090|synthase (r_conj) antagonists_2\NNS\7846|receptors|and|inhibitors|hyperalgesia|. (l_nmod) hyperalgesia_13\NN\1740|in|induced|model
D009569_D006930 NONE no_15\NN\7204911| (r_compound) synthase_16\NN\1740|inducible|no|not|activity (r_conj) inhibition_9\NN\1068773|receptors|and|synthase (r_nsubj) reduces_23\VBZ\441445|that|inhibition|hyperalgesia (l_dobj) hyperalgesia_25\NN\1740|diabetic
D009569_D006930 NONE no_20\NN\7204911| (r_compound) synthase_21\NN\1740|neuronal|no (r_compound) activity_22\NN\30358|synthase (r_conj) synthase_16\NN\1740|inducible|no|not|activity (r_conj) inhibition_9\NN\1068773|receptors|and|synthase (r_nsubj) reduces_23\VBZ\441445|that|inhibition|hyperalgesia (l_dobj) hyperalgesia_25\NN\1740|diabetic
D009569_D006930 NONE no_9\NN\7204911| (r_compound) synthase_10\NN\1740|of|inducible|no|and|activation (r_nmod) products_6\NNS\3076708|both|synthase|as|bradykinin (r_nsubjpass) involved_21\VBN\2676054|that|products|are|hyperalgesia (l_nmod) hyperalgesia_23\NN\1740|in|produced
D009569_D006930 NONE no_13\NN\7204911| (r_compound) synthase_14\NN\1740|neuronal|no (r_compound) activation_15\NN\13561719|synthase (r_conj) synthase_10\NN\1740|of|inducible|no|and|activation (r_nmod) products_6\NNS\3076708|both|synthase|as|bradykinin (r_nsubjpass) involved_21\VBN\2676054|that|products|are|hyperalgesia (l_nmod) hyperalgesia_23\NN\1740|in|produced
D009569_D006930 NONE no_5\NN\7204911| (r_compound) synthase_6\NN\1740|inducible|no (r_nsubj) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D009569_D006930 NONE no_5\NN\7204911| (r_compound) synthase_6\NN\1740|inducible|no (r_nsubj) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_parataxis) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (l_nmod) hyperalgesia_17\NN\1740|in|vincristine-induced
D009569_D006930 NONE no_23\NN\7204911| (r_compound) synthase_24\NN\1740|no (r_compound) pathway_25\NN\5483677|neuronal|synthase (r_dobj) activate_21\VB\1641914|to|pathway (r_xcomp) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (r_parataxis) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D009569_D006930 NONE no_23\NN\7204911| (r_compound) synthase_24\NN\1740|no (r_compound) pathway_25\NN\5483677|neuronal|synthase (r_dobj) activate_21\VB\1641914|to|pathway (r_xcomp) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (l_nmod) hyperalgesia_17\NN\1740|in|vincristine-induced
D009569_D003929 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\1740|nitric|oxide (r_compound) inhibitors_7\NNS\20090|synthase (r_conj) antagonists_2\NNS\7846|receptors|and|inhibitors|hyperalgesia|. (l_nmod) hyperalgesia_13\NN\1740|in|induced|model (l_nmod) model_20\NN\5888929|in|chemotherapy|rat (l_compound) chemotherapy_15\NN\661091|and|neuropathy (l_conj) neuropathy_18\NN\14204950|diabetic
D009569_D003929 NONE no_10\NN\7204911| (r_compound) synthase_11\NN\1740|of|constitutive|no (r_nmod) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|and|inhibitor (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D009569_D003929 NONE no_26\NN\7204911| (r_compound) synthase_27\NN\1740|of|inducible|no (r_nmod) inhibitor_23\NN\20090|a|selective|synthase|l-nil (r_conj) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|and|inhibitor (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D009569_D003929 NONE no_42\NN\7204911| (r_compound) synthase_43\NN\1740|of|neuronal|no (r_nmod) inhibitor_39\NN\20090|a|specific|synthase|7-ni (r_conj) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|and|inhibitor (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D014750_D006930 CID vincristine_9\NN\3917455|and|streptozotocin (r_nmod:npmod) induced_12\JJ\1740|vincristine (r_amod) hyperalgesia_13\NN\1740|in|induced|model
D014750_D006930 CID vincristine_26\NN\3917455|by (r_nmod) produced_24\VBN\1617192|vincristine (r_acl) hyperalgesia_23\NN\1740|in|produced
D014750_D006930 CID vincristine-induced_16\JJ\1740| (r_amod) hyperalgesia_17\NN\1740|in|vincristine-induced (r_nmod) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (r_parataxis) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D014750_D006930 CID vincristine-induced_16\JJ\1740| (r_amod) hyperalgesia_17\NN\1740|in|vincristine-induced
D014750_D003929 NONE vincristine_9\NN\3917455|and|streptozotocin (r_nmod:npmod) induced_12\JJ\1740|vincristine (r_amod) hyperalgesia_13\NN\1740|in|induced|model (l_nmod) model_20\NN\5888929|in|chemotherapy|rat (l_compound) chemotherapy_15\NN\661091|and|neuropathy (l_conj) neuropathy_18\NN\14204950|diabetic
D013311_D006930 CID streptozotocin_11\NN\1740| (r_conj) vincristine_9\NN\3917455|and|streptozotocin (r_nmod:npmod) induced_12\JJ\1740|vincristine (r_amod) hyperalgesia_13\NN\1740|in|induced|model
D013311_D006930 CID streptozotocin-induced_1\JJ\1740| (r_amod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D013311_D006930 CID streptozotocin-induced_1\JJ\1740| (r_amod) hyperalgesia_2\NN\1740|in|streptozotocin-induced (r_nmod) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|whereas|seemed (l_parataxis) seemed_19\VBD\2604760|hyperalgesia|bradykinin|activate|. (l_nmod) hyperalgesia_17\NN\1740|in|vincristine-induced
D013311_D003929 CID streptozotocin_11\NN\1740| (r_conj) vincristine_9\NN\3917455|and|streptozotocin (r_nmod:npmod) induced_12\JJ\1740|vincristine (r_amod) hyperalgesia_13\NN\1740|in|induced|model (l_nmod) model_20\NN\5888929|in|chemotherapy|rat (l_compound) chemotherapy_15\NN\661091|and|neuropathy (l_conj) neuropathy_18\NN\14204950|diabetic
D009569_D010523 NONE no_10\NN\7204911| (r_compound) synthase_11\NN\1740|of|constitutive|no (r_nmod) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|and|inhibitor (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D009569_D010523 NONE no_26\NN\7204911| (r_compound) synthase_27\NN\1740|of|inducible|no (r_nmod) inhibitor_23\NN\20090|a|selective|synthase|l-nil (r_conj) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|and|inhibitor (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D009569_D010523 NONE no_42\NN\7204911| (r_compound) synthase_43\NN\1740|of|neuronal|no (r_nmod) inhibitor_39\NN\20090|a|specific|synthase|7-ni (r_conj) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|and|inhibitor (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
D001920_D010523 NONE bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|hoe (r_appos) antagonists_57\NNS\7846|of|selective|b2|receptors|:|bradykinin (r_nmod) action_54\NN\30358|on|antihyperalgesic|antagonists (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
C065679_D003929 NONE 140_69\CD\1740| (r_nummod) hoe_68\NN\4451818|(|140|;|nmol/kg|) (r_appos) bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|hoe (r_appos) antagonists_57\NNS\7846|of|selective|b2|receptors|:|bradykinin (r_nmod) action_54\NN\30358|on|antihyperalgesic|antagonists (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
C065679_D010523 NONE 140_69\CD\1740| (r_nummod) hoe_68\NN\4451818|(|140|;|nmol/kg|) (r_appos) bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|hoe (r_appos) antagonists_57\NNS\7846|of|selective|b2|receptors|:|bradykinin (r_nmod) action_54\NN\30358|on|antihyperalgesic|antagonists (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
C065679_D010523 NONE 140_13\CD\1740| (r_nummod) hoe_12\NNP\4451818|of|140|or|des-arg10hoe (r_nmod) activity_10\NN\30358|antihyperalgesic|hoe (r_dobj) intensify_8\VBP\153263|moreover|,|l-noarg|activity|neuropathy|. (l_nmod) neuropathy_19\NN\14204950|in|toxic
C078665_D003929 NONE 140_79\CD\1740| (r_nummod) hoe_78\NN\4451818|des|arg10|140|nmol/kg (r_conj) bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|hoe (r_appos) antagonists_57\NNS\7846|of|selective|b2|receptors|:|bradykinin (r_nmod) action_54\NN\30358|on|antihyperalgesic|antagonists (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
C078665_D010523 NONE 140_79\CD\1740| (r_nummod) hoe_78\NN\4451818|des|arg10|140|nmol/kg (r_conj) bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|hoe (r_appos) antagonists_57\NNS\7846|of|selective|b2|receptors|:|bradykinin (r_nmod) action_54\NN\30358|on|antihyperalgesic|antagonists (r_nmod) influence_3\NN\5190804|the|inhibitor|,|action|respectively|,|model (l_nmod) model_88\NN\5888929|in|neuropathy (l_nmod) neuropathy_99\NN\14204950|of|diabetic|toxic
C078665_D010523 NONE 140_16\CD\1740| (r_nummod) des-arg10hoe_15\NN\1740|140 (r_conj) hoe_12\NNP\4451818|of|140|or|des-arg10hoe (r_nmod) activity_10\NN\30358|antihyperalgesic|hoe (r_dobj) intensify_8\VBP\153263|moreover|,|l-noarg|activity|neuropathy|. (l_nmod) neuropathy_19\NN\14204950|in|toxic
D001920_D009437 NONE bradykinin_8\NN\1740| (r_compound) antagonists_10\NNS\7846|of|bradykinin|receptor|and|inhibitors (r_nmod) doses_6\NNS\3740161|of|small|antagonists (r_nmod) administration_3\NN\1133281|concomitant|doses (r_nsubj) effective_17\JJ\1740|therefore|,|administration|can|be|alleviation|care|. (l_nmod) alleviation_19\NN\7492516|in|pain|, (l_nmod) pain_22\NN\14299637|of|neuropathic
D009569_D009437 NONE no_12\NN\7204911| (r_compound) inhibitors_14\NNS\20090|no|synthase (r_conj) antagonists_10\NNS\7846|of|bradykinin|receptor|and|inhibitors (r_nmod) doses_6\NNS\3740161|of|small|antagonists (r_nmod) administration_3\NN\1133281|concomitant|doses (r_nsubj) effective_17\JJ\1740|therefore|,|administration|can|be|alleviation|care|. (l_nmod) alleviation_19\NN\7492516|in|pain|, (l_nmod) pain_22\NN\14299637|of|neuropathic
3107448
D005905_D056486 CID glyburide-induced_0\JJ\1740| (r_amod) hepatitis_1\NN\14127211|glyburide-induced|.
D005905_D056486 CID glyburide_1\NN\2719105|for|,|sulfonylurea (r_nmod) exist_13\VBP\1740|glyburide|,|reports|. (l_nsubj) reports_10\NNS\6470073|two|brief|hepatotoxicity (l_nmod) hepatotoxicity_12\NN\1740|of
D005905_D056486 CID glyburide_16\NN\2719105| (r_compound) therapy_17\NN\657604|of|glyburide (r_nmod) initiation_14\NN\7450842|after|therapy (r_nmod) developed_7\VBD\1753788|patients|syndrome|initiation|. (l_dobj) syndrome_11\NN\5870365|an|acute|hepatitis-like
D005905_D056486 CID glyburide_0\NN\2719105| (r_nsubj) produce_2\VB\1617192|glyburide|can|illness|persons|. (l_dobj) illness_6\NN\14052046|an|acute|hepatitis-like
D013453_D056486 NONE sulfonylureas_12\NNS\2719105|with (r_nmod) reported_8\VBN\831651|hepatotoxicity|,|common|,|has|been|infrequently|sulfonylureas|. (l_nsubjpass) hepatotoxicity_1\NN\1740|drug-induced
D013453_D056486 NONE sulfonylurea_5\NN\2719105|a|second-generation (r_appos) glyburide_1\NN\2719105|for|,|sulfonylurea (r_nmod) exist_13\VBP\1740|glyburide|,|reports|. (l_nsubj) reports_10\NNS\6470073|two|brief|hepatotoxicity (l_nmod) hepatotoxicity_12\NN\1740|of
D005905_D003924 NONE glyburide_16\NN\2719105| (r_compound) therapy_17\NN\657604|of|glyburide (r_nmod) initiation_14\NN\7450842|after|therapy (r_nmod) developed_7\VBD\1753788|patients|syndrome|initiation|. (l_nsubj) patients_1\NNS\9898892|two|mellitus (l_nmod) mellitus_6\NN\1740|with|type|ii|diabetes
7292072
D003891_D017180 CID desipramine_4\NN\4482543| (r_compound) toxicity_5\NN\13576101|in|desipramine (r_nmod) tachycardia_2\NN\14110674|variant|ventricular|toxicity|.
D003891_D017180 CID desipramine_10\NN\4482543| (r_compound) toxicity_11\NN\13576101|by|desipramine (r_nmod) induced_8\VBN\1627355|toxicity (r_acl) tachycardia_7\NN\14110674|of|variant|ventricular|induced
D003891_D064420 NONE desipramine_4\NN\4482543| (r_compound) toxicity_5\NN\13576101|in|desipramine
D003891_D064420 NONE desipramine_10\NN\4482543| (r_compound) toxicity_11\NN\13576101|by|desipramine
1085609
D011736_D012640 NONE pyridoxine_1\NN\15090742| (r_nmod:npmod) responsive_2\JJ\1740|pyridoxine (r_amod) convulsions_3\NNS\14081375|neonatal|responsive|therapy|.
D011736_D012640 NONE pyridoxine_9\NN\15090742|intramuscular (r_dobj) administering_7\VBG\2436349|of|pyridoxine (r_advcl) hours_5\NNS\15118228|within|4|administering (r_nmod) ceased_2\VBD\1740|fits|hours|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D011736_D012640 NONE pyridoxine_15\NN\15090742| (r_compound) deficiency_16\NN\14449126|of|pyridoxine|secondary (r_nmod) aetiology_13\NN\7326557|an|deficiency (r_dobj) suggesting_11\VBG\1010118|aetiology (r_advcl) ceased_2\VBD\1740|fits|hours|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D007538_D012640 CID isoniazid_6\NN\2716205| (r_compound) therapy_7\NN\657604|due|isoniazid (r_nmod) convulsions_3\NNS\14081375|neonatal|responsive|therapy|.
D007538_D012640 CID isoniazid_4\NN\2716205| (r_compound) therapy_5\NN\657604|on|isoniazid|mg/kg (r_nmod) infant_2\NN\9918248|a|17-day-old|therapy|daily|birth|tuberculosis (r_nsubjpass) admitted_16\VBN\822367|infant|was|days|. (l_nmod) days_19\NNS\15140892|after|4|fits (l_nmod) fits_22\NNS\7518132|of|clonic
D007538_D012640 CID isoniazid_19\NN\2716205| (r_compound) medication_20\NN\3247620|to|isoniazid (r_nmod) secondary_17\JJ\1740|medication (r_amod) deficiency_16\NN\14449126|of|pyridoxine|secondary (r_nmod) aetiology_13\NN\7326557|an|deficiency (r_dobj) suggesting_11\VBG\1010118|aetiology (r_advcl) ceased_2\VBD\1740|fits|hours|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D007538_D014376 NONE isoniazid_4\NN\2716205| (r_compound) therapy_5\NN\657604|on|isoniazid|mg/kg (r_nmod) infant_2\NN\9918248|a|17-day-old|therapy|daily|birth|tuberculosis (l_nmod) tuberculosis_14\NN\14127211|because|maternal
19346865
D008795_D001927 CID metronidazole-induced_5\JJ\1740| (r_amod) encephalopathy_6\NN\14084880|in|metronidazole-induced (r_nmod) lesion_3\NN\14204950|reversible|colliculus|encephalopathy|:|findings
D008795_D001927 CID metronidazole-induced_5\JJ\1740| (r_amod) encephalopathy_6\NN\14084880|in|metronidazole-induced
D008795_D001927 CID metronidazole-induced_11\JJ\1740| (r_amod) encephalopathy_12\NN\14084880|in|metronidazole-induced (r_nmod) lesions_9\NNS\14204950|reversible|inferior|colliculus|encephalopathy
D008795_D001927 CID metronidazole-induced_11\JJ\1740| (r_amod) encephalopathy_12\NN\14084880|in|metronidazole-induced
D008795_D001927 CID metronidazole-induced_24\JJ\1740| (r_amod) encephalopathy_25\NN\14084880|metronidazole-induced
D008795_D001927 CID metronidazole-induced_13\JJ\1740| (r_amod) encephalopathy_14\NN\14084880|for|metronidazole-induced (r_nmod) characteristic_11\JJ\1740|as|the|encephalopathy|,|next (r_nmod) considered_8\VBN\689344|lesions|could|be|characteristic (l_nsubjpass) lesions_5\NNS\14204950|reversible|colliculus
D008795_D001927 CID metronidazole-induced_13\JJ\1740| (r_amod) encephalopathy_14\NN\14084880|for|metronidazole-induced
D008795_D007239 NONE metronidazole_4\NN\2723292|dosage (r_dobj) taking_3\VBG\2367363|they|had|been|metronidazole|treat|. (l_advcl) treat_23\VB\2376958|to|infection (l_dobj) infection_25\NN\14052046|the|organs
16298782
D019331_D006311 NONE ester_2\NN\14727670|nitro-l-arginine|methyl|:|protector|. (l_appos) protector_6\NN\10466918|a|potential|ototoxicity (l_nmod) ototoxicity_9\NN\1740|against|gentamicin
D005839_D006311 NONE gentamicin_8\NN\2716866| (r_compound) ototoxicity_9\NN\1740|against|gentamicin
D009569_D006316 NONE oxide_2\NN\14818238|nitric|no (r_compound) ester_9\NN\14727670|the|oxide|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D009569_D006316 NONE no_4\NN\7204911|(|) (r_appos) oxide_2\NN\14818238|nitric|no (r_compound) ester_9\NN\14727670|the|oxide|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D019331_D006316 NONE ester_9\NN\14727670|the|oxide|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D019331_D006316 NONE l-name_11\NN\1740|(|) (r_appos) ester_9\NN\14727670|the|oxide|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D005839_D006316 NONE gentamicin_24\NN\2716866|by (r_nmod) caused_22\VBN\1617192|gentamicin (r_acl) loss_21\NN\13252973|against|high-frequency|hearing|caused
D009569_D006311 NONE no_17\NN\7204911|of (r_nmod) production_15\NN\30358|the|no (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_nsubj) ototoxicity_1\NN\1740|their
D009569_D006311 NONE no_17\NN\7204911|of (r_nmod) production_15\NN\30358|the|no (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_amod) ototoxic_11\JJ\1740|
D009569_D006311 NONE no_26\NN\7204911| (r_compound) inhibitors_27\NNS\20090|of|no (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_nsubj) ototoxicity_1\NN\1740|their
D009569_D006311 NONE no_26\NN\7204911| (r_compound) inhibitors_27\NNS\20090|of|no (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_conj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_amod) ototoxic_11\JJ\1740|
D009569_D006319 NONE no_17\NN\7204911|of (r_nmod) production_15\NN\30358|the|no (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_conj) need_20\VBP\2604760|,|we|assess|. (l_xcomp) assess_22\VB\670261|to|use (l_dobj) use_24\NN\407535|the|inhibitors|prevention (l_nmod) prevention_30\NN\1073995|for|the|loss (l_nmod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing
D009569_D006319 NONE no_26\NN\7204911| (r_compound) inhibitors_27\NNS\20090|of|no (r_nmod) use_24\NN\407535|the|inhibitors|prevention (l_nmod) prevention_30\NN\1073995|for|the|loss (l_nmod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing
D000617_D006311 NONE aminoglycoside-induced_32\JJ\1740| (r_amod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing (r_nmod) prevention_30\NN\1073995|for|the|loss (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_nsubj) ototoxicity_1\NN\1740|their
D000617_D006311 NONE aminoglycoside-induced_32\JJ\1740| (r_amod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing (r_nmod) prevention_30\NN\1073995|for|the|loss (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_conj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_amod) ototoxic_11\JJ\1740|
D000617_D006319 NONE aminoglycoside-induced_32\JJ\1740| (r_amod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing
D019331_D034381 NONE l-name_0\NN\1740| (r_nsubj) reduced_1\VBD\441445|l-name|loss|range|,|but|gave|. (l_dobj) loss_4\NN\13252973|gentamicin-induced|hearing
D005839_D034381 CID gentamicin-induced_2\JJ\1740| (r_amod) loss_4\NN\13252973|gentamicin-induced|hearing
2396046
D002794_D006528 CID choline-supplemented_13\JJ\1740| (r_amod) diet_14\NN\7560652|the|plain|choline-supplemented (r_dobj) fed_10\VBN\1182709|diet (r_acl) rats_9\NNS\2329401|in|fed (r_nmod) developed_7\VBD\1753788|nodules|rats|,|developed|. (l_nsubj) nodules_3\NNS\5264913|no|hepatic|preneoplastic|or|carcinomas (l_conj) carcinomas_6\NNS\14239918|hepatocellular
D002794_D006528 CID choline-supplemented_13\JJ\1740| (r_amod) diet_14\NN\7560652|the|plain|choline-supplemented (r_dobj) fed_10\VBN\1182709|diet (r_acl) rats_9\NNS\2329401|in|fed (r_nmod) developed_7\VBD\1753788|nodules|rats|,|developed|. (l_advcl) developed_24\VBD\1753788|while|nodule|rats (l_nsubj) nodule_19\NN\5264913|one|preneoplastic|and|carcinoma (l_conj) carcinoma_23\NN\14239918|one|hepatocellular
D002794_D006528 CID choline-devoid_23\JJ\1740| (r_amod) diet_24\NN\7560652|the|plain|choline-devoid (r_dobj) fed_20\VBN\1182709|diet (r_acl) rats_19\NNS\2329401|in|fed (r_nmod) %_11\NN\1740|incidence|was|10|and|%|,|respectively|,|rats|,|and|%|. (l_nsubj) incidence_1\NN\13821570|the|nodules (l_nmod) nodules_4\NNS\5264913|of|preneoplastic|and|carcinomas (l_conj) carcinomas_8\NNS\14239918|of|hepatocellular
D002794_D006528 CID choline-devoid_38\JJ\1740| (r_amod) diet_39\NN\7560652|the|phenobarbital-containing|choline-devoid (r_dobj) fed_35\VBN\1182709|diet (r_acl) rats_34\NNS\2329401|in|fed (r_nmod) %_28\NN\1740|17|and|%|,|rats (r_conj) %_11\NN\1740|incidence|was|10|and|%|,|respectively|,|rats|,|and|%|. (l_nsubj) incidence_1\NN\13821570|the|nodules (l_nmod) nodules_4\NNS\5264913|of|preneoplastic|and|carcinomas (l_conj) carcinomas_8\NNS\14239918|of|hepatocellular
D010634_D006528 NONE phenobarbital_33\NN\2792049| (r_dobj) containing_32\VBG\2632940|phenobarbital (r_acl) diet_31\NN\7560652|the|same|containing (r_dobj) fed_28\VBN\1182709|diet (r_acl) rats_27\NNS\2329401|in|two|fed (r_nmod) developed_24\VBD\1753788|while|nodule|rats (r_advcl) developed_7\VBD\1753788|nodules|rats|,|developed|. (l_nsubj) nodules_3\NNS\5264913|no|hepatic|preneoplastic|or|carcinomas (l_conj) carcinomas_6\NNS\14239918|hepatocellular
D010634_D006528 NONE phenobarbital_33\NN\2792049| (r_dobj) containing_32\VBG\2632940|phenobarbital (r_acl) diet_31\NN\7560652|the|same|containing (r_dobj) fed_28\VBN\1182709|diet (r_acl) rats_27\NNS\2329401|in|two|fed (r_nmod) developed_24\VBD\1753788|while|nodule|rats (l_nsubj) nodule_19\NN\5264913|one|preneoplastic|and|carcinoma (l_conj) carcinoma_23\NN\14239918|one|hepatocellular
D010634_D006528 NONE phenobarbital-containing_37\JJ\1740| (r_amod) diet_39\NN\7560652|the|phenobarbital-containing|choline-devoid (r_dobj) fed_35\VBN\1182709|diet (r_acl) rats_34\NNS\2329401|in|fed (r_nmod) %_28\NN\1740|17|and|%|,|rats (r_conj) %_11\NN\1740|incidence|was|10|and|%|,|respectively|,|rats|,|and|%|. (l_nsubj) incidence_1\NN\13821570|the|nodules (l_nmod) nodules_4\NNS\5264913|of|preneoplastic|and|carcinomas (l_conj) carcinomas_8\NNS\14239918|of|hepatocellular
17344566
D019821_D003161 CID simvastatin-induced_0\JJ\1740| (r_amod) syndrome_4\NN\5870365|simvastatin-induced|bilateral|leg|compartment|and|myonecrosis|.
D019821_D003161 CID simvastatin_7\NN\3676175| (r_conj) thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\NN\15388|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBD\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis
D019821_D009135 NONE simvastatin-induced_0\JJ\1740| (r_amod) syndrome_4\NN\5870365|simvastatin-induced|bilateral|leg|compartment|and|myonecrosis|. (l_conj) myonecrosis_6\NN\11486708|associated
D019821_D009135 NONE simvastatin_7\NN\3676175| (r_conj) thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\NN\15388|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBD\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis (l_conj) myonecrosis_15\NN\11486708|
D019821_D007037 NONE simvastatin-induced_0\JJ\1740| (r_amod) syndrome_4\NN\5870365|simvastatin-induced|bilateral|leg|compartment|and|myonecrosis|. (l_conj) myonecrosis_6\NN\11486708|associated (l_acl) associated_7\VBN\628491|hypothyroidism (l_nmod) hypothyroidism_9\NN\14059928|with
D019821_D007037 NONE simvastatin_7\NN\3676175| (r_conj) thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\NN\15388|a|54-year-old|hypothyroid|taking (l_amod) hypothyroid_2\JJ\1740|
D013974_D007037 NONE thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\NN\15388|a|54-year-old|hypothyroid|taking (l_amod) hypothyroid_2\JJ\1740|
D013974_D003161 NONE thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\NN\15388|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBD\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis
D013974_D009135 NONE thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\NN\15388|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBD\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis (l_conj) myonecrosis_15\NN\11486708|
7269015
D002066_D006470 CID busulfan-induced_0\NN\1740| (r_compound) cystitis_2\NN\14566129|busulfan-induced|hemorrhagic|.
D002066_D006470 CID busulfan-induced_4\JJ\1740| (r_amod) cystitis_6\NN\14566129|of|a|busulfan-induced|hemorrhage
D002066_D003556 CID busulfan-induced_0\NN\1740| (r_compound) cystitis_2\NN\14566129|busulfan-induced|hemorrhagic|.
D002066_D003556 CID busulfan-induced_4\JJ\1740| (r_amod) cystitis_6\NN\14566129|of|a|busulfan-induced|hemorrhage
D002066_D003556 CID busulfan_7\NN\1740| (r_compound) cystitis_8\NN\14566129|of|busulfan|and|radiation
D002066_D003556 CID busulfan_7\NN\1740| (r_compound) cystitis_8\NN\14566129|of|busulfan|and|radiation (l_conj) radiation_11\NN\11452218|both|and|cystitis (l_conj) cystitis_14\NN\14566129|cyclophosphamide-induced
D003520_D003556 NONE cyclophosphamide-induced_13\JJ\1740| (r_amod) cystitis_14\NN\14566129|cyclophosphamide-induced (r_conj) radiation_11\NN\11452218|both|and|cystitis (r_conj) cystitis_8\NN\14566129|of|busulfan|and|radiation
D003520_D003556 NONE cyclophosphamide-induced_13\JJ\1740| (r_amod) cystitis_14\NN\14566129|cyclophosphamide-induced
D002066_D002277 NONE busulfan_7\NN\1740|of (r_nmod) tendency_5\NN\6193203|of|the|known|busulfan|induce (l_acl) induce_9\VB\1627355|to|atypia (l_dobj) atypia_11\NN\1740|cellular|and|carcinoma|sites (l_conj) carcinoma_13\NN\14239918|
11928786
D016642_D064420 NONE bupropion_0\NN\1740|zyban (r_compound) toxicity_4\NN\13576101|bupropion|.
D016642_D064420 NONE zyban_2\NN\1740|(|) (r_appos) bupropion_0\NN\1740|zyban (r_compound) toxicity_4\NN\13576101|bupropion|.
D003975_D012640 NONE diazepam_5\NN\2830852|with (r_nmod) treated_3\VBN\2376958|seizures|were|diazepam|and|treated (l_nsubjpass) seizures_1\NNS\14081375|recurrent
D003975_D013610 NONE diazepam_5\NN\2830852|with (r_nmod) treated_3\VBN\2376958|seizures|were|diazepam|and|treated (l_conj) treated_12\VBN\2376958|tachycardia|was|successfully|adenosine|. (l_nsubjpass) tachycardia_9\NN\14110674|broad|complex
D000241_D012640 NONE adenosine_14\NN\14964367|with (r_nmod) treated_12\VBN\2376958|tachycardia|was|successfully|adenosine|. (r_conj) treated_3\VBN\2376958|seizures|were|diazepam|and|treated (l_nsubjpass) seizures_1\NNS\14081375|recurrent
D000241_D013610 NONE adenosine_14\NN\14964367|with (r_nmod) treated_12\VBN\2376958|tachycardia|was|successfully|adenosine|. (l_nsubjpass) tachycardia_9\NN\14110674|broad|complex
D016642_D020258 NONE zyban_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|zyban|toxicity|. (l_dobj) toxicity_6\NN\13576101|significant|neurological|overdose
D016642_D002318 NONE zyban_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|zyban|toxicity|. (l_dobj) toxicity_6\NN\13576101|significant|neurological|overdose
D016642_D062787 NONE zyban_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|zyban|toxicity|. (l_dobj) toxicity_6\NN\13576101|significant|neurological|overdose (l_nmod) overdose_8\NN\1740|in
8231633
D002118_D064420 NONE calcium_2\NN\14625458| (r_compound) blockers_4\NNS\10101634|of|calcium|channel (r_nmod) effects_0\NNS\13245626|blockers|toxicity|. (l_nmod) toxicity_7\NN\13576101|on|bupivacaine-induced
D002118_D064420 NONE calcium_11\NN\14625458| (r_compound) blockers_13\NNS\10101634|of|calcium|channel (r_nmod) influence_9\NN\5190804|the|blockers|toxicity (l_nmod) toxicity_17\NN\13576101|on|bupivacaine-induced|acute
D002045_D064420 NONE bupivacaine-induced_6\JJ\1740| (r_amod) toxicity_7\NN\13576101|on|bupivacaine-induced
D002045_D064420 NONE bupivacaine-induced_15\JJ\1740| (r_amod) toxicity_17\NN\13576101|on|bupivacaine-induced|acute
D002045_D012640 CID bupivacaine_4\NN\1740|of (r_nmod) activity_2\NN\30358|the|convulsant|bupivacaine (r_nsubjpass) modified_8\VBN\109660|activity|was|not|significantly|but|decreased (l_conj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|latency (l_nmod) latency_17\NN\15269513|of|obtain (l_acl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_21\NNS\14081375|bupivacaine-induced
D002045_D012640 CID bupivacaine-induced_20\JJ\1740| (r_amod) convulsions_21\NNS\14081375|bupivacaine-induced
D002118_D012640 NONE calcium_10\NN\14625458| (r_compound) blockers_12\NNS\10101634|calcium|channel (r_nsubj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|latency (l_nmod) latency_17\NN\15269513|of|obtain (l_acl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_21\NNS\14081375|bupivacaine-induced
D015764_D012640 NONE bepridil_29\NN\1740|with (r_nmod) pronounced_27\JJ\1740|modified|;|effect|was|less|bepridil|. (l_ccomp) modified_8\VBN\109660|activity|was|not|significantly|but|decreased (l_conj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|latency (l_nmod) latency_17\NN\15269513|of|obtain (l_acl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_21\NNS\14081375|bupivacaine-induced
7423039
D004317_D066126 CID adriamycin_3\NN\1740| (r_compound) cardiotoxicity_4\NN\1740|in|adriamycin
D004317_D066126 CID adriamycin_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|the|cardiotoxic|adriamycin (l_amod) cardiotoxic_1\JJ\1740|
869641
D007980_D001919 NONE l-dopa_7\NN\14604959|by (r_nmod) mediation_0\NN\7148192|bradycardia|l-dopa|formation|. (l_nmod) bradycardia_5\NN\14110674|of|enhanced|reflex|vagal
D007980_D001919 NONE l-dopa_13\NN\14604959|by (r_nmod) enhanced_11\VBN\227165|bradycardia|was|significantly|l-dopa (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D007980_D001919 NONE l-dopa_20\NN\14604959|of (r_nmod) effect_18\NN\34213|reflex-enhancing|l-dopa (r_conj) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect (l_conj) bradycardia_15\NN\14110674|
D007980_D001919 NONE l-dopa_2\NN\14604959| (r_nsubj) restored_3\VBD\1631072|however|,|l-dopa|bradycardia|addition|. (l_dobj) bradycardia_5\NN\14110674|the|caused
D007980_D001919 NONE l-dopa_4\NN\14604959| (r_nsubj) enhances_5\VBZ\227165|that|l-dopa|bradycardia|stimulation (l_dobj) bradycardia_7\NN\14110674|reflex
D004298_D001919 NONE dopamine_10\NN\14807737| (r_compound) formation_11\NN\7938773|via|central|dopamine|dogs (r_nmod) mediation_0\NN\7148192|bradycardia|l-dopa|formation|. (l_nmod) bradycardia_5\NN\14110674|of|enhanced|reflex|vagal
D004298_D001919 NONE dopamine-beta-oxidase_3\NN\1740| (r_amod) inhibitor_4\NN\20090|a|dopamine-beta-oxidase (r_appos) fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect (l_conj) bradycardia_15\NN\14110674|
D009638_D001919 CID norepinephrine_8\NN\14807929|by|injected (r_nmod) caused_5\VBN\1617192|norepinephrine (r_acl) bradycardia_4\NN\14110674|reflex|caused
D009638_D001919 CID norepinephrine_29\NN\14807929|to (r_nmod) responses_27\NNS\11410625|reflex|norepinephrine (r_conj) pressure_21\NN\11419404|on|blood|,|rate|or|responses (r_nmod) effect_18\NN\34213|no|pressure (r_dobj) had_16\VBD\2108377|addition|,|enhanced|,|dl-threo-dihydroxyphenylserine|effect|. (l_ccomp) enhanced_11\VBN\227165|bradycardia|was|significantly|l-dopa (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D009638_D001919 CID norepinephrine_8\NN\14807929|by (r_nmod) caused_6\VBN\1617192|norepinephrine (r_acl) bradycardia_5\NN\14110674|the|caused
D009638_D001919 CID norepinephrine_18\NN\14807929|to (r_nmod) bradycardia_16\NN\14110674|the|reflex|norepinephrine
D015103_D001919 NONE dl-threo-dihydroxyphenylserine_15\NN\1740| (r_nsubj) had_16\VBD\2108377|addition|,|enhanced|,|dl-threo-dihydroxyphenylserine|effect|. (l_ccomp) enhanced_11\VBN\227165|bradycardia|was|significantly|l-dopa (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D005406_D007022 NONE fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect
D005406_D001919 NONE fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect (l_conj) bradycardia_15\NN\14110674|
D004298_D007022 NONE dopamine-beta-oxidase_3\NN\1740| (r_amod) inhibitor_4\NN\20090|a|dopamine-beta-oxidase (r_appos) fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect
D007980_D007022 NONE l-dopa_20\NN\14604959|of (r_nmod) effect_18\NN\34213|reflex-enhancing|l-dopa (r_conj) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect
D006916_D001919 NONE 5-htp_0\NN\1740|mg/kg (r_nsubj) decreased_6\VBD\169651|5-htp|pressure|and|decreased|. (l_conj) decreased_13\VBD\169651|bradycardia (l_dobj) bradycardia_16\NN\14110674|the|reflex|norepinephrine
12523465
C022189_D006212 CID zonisamide_4\NN\1740|with (r_nmod) associated_2\VBN\628491|zonisamide (r_acl) hallucinations_1\NNS\14376855|visual|associated|.
C022189_D006212 CID zonisamide_29\NN\1740| (r_compound) treatment_30\NN\654885|zonisamide (r_nsubjpass) begun_32\VBN\941990|after|treatment|was|or|increased (r_advcl) experienced_20\VBD\2108377|who|hallucinations|begun (r_acl:relcl) patients_18\NNS\9898892|three|experienced (r_dobj) describe_16\VBP\1001294|reported|,|we|patients|. (l_advcl) reported_6\VBN\831651|although|hallucinations|have|not|been|effect (l_nsubjpass) hallucinations_2\NNS\14376855|visual
C022189_D006212 CID zonisamide_29\NN\1740| (r_compound) treatment_30\NN\654885|zonisamide (r_nsubjpass) begun_32\VBN\941990|after|treatment|was|or|increased (r_advcl) experienced_20\VBD\2108377|who|hallucinations|begun (l_dobj) hallucinations_23\NNS\14376855|complex|visual|and|status
C022189_D012640 NONE zonisamide_0\NN\1740| (r_nsubj) drug_5\NN\14778436|zonisamide|is|a|broad-spectrum|antiepileptic|used|. (l_acl) used_6\VBN\1156834|treat (l_xcomp) treat_8\VB\2376958|to|types (l_dobj) types_10\NNS\5839024|various|seizures (l_nmod) seizures_12\NNS\14081375|of
16867021
D006632_D002375 NONE histamine_10\NN\14739004| (r_compound) ligands_12\NNS\20090|of|histamine|h(3)-receptor (r_nmod) effect_8\NN\34213|the|ligands|catalepsy (l_nmod) catalepsy_15\NN\14023236|on|neuroleptic-induced|,|behavior|and|activities|mice
D001058_D002375 NONE apomorphine-induced_17\JJ\1740| (r_amod) behavior_19\NN\407535|apomorphine-induced|climbing (r_conj) catalepsy_15\NN\14023236|on|neuroleptic-induced|,|behavior|and|activities|mice
D001058_D002375 NONE apomorphine_12\NN\3786417|mg/kg|and|amphetamine (r_nsubjpass) used_26\VBN\1156834|while|apomorphine|were|studying (r_advcl) induced_2\VBN\1627355|catalepsy|was|haloperidol|,|used|. (l_nsubjpass) catalepsy_0\NN\14023236|
D001058_D002375 NONE apomorphine-induced_15\JJ\1740| (r_amod) climbing_16\NN\7445480|apomorphine-induced|mice (r_dobj) reducing_14\VBG\441445|climbing (r_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (r_conj) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D000661_D002375 NONE amphetamine-induced_21\JJ\1740| (r_amod) activities_23\NNS\30358|amphetamine-induced|locomotor (r_conj) catalepsy_15\NN\14023236|on|neuroleptic-induced|,|behavior|and|activities|mice
D000661_D002375 NONE amphetamine_19\NN\3248958|s.c. (r_conj) apomorphine_12\NN\3786417|mg/kg|and|amphetamine (r_nsubjpass) used_26\VBN\1156834|while|apomorphine|were|studying (r_advcl) induced_2\VBN\1627355|catalepsy|was|haloperidol|,|used|. (l_nsubjpass) catalepsy_0\NN\14023236|
D000661_D002375 NONE amphetamine-induced_11\JJ\1740| (r_amod) hyperactivity_12\NN\14052403|amphetamine-induced (r_dobj) reducing_10\VBG\441445|hyperactivity|and|reducing (r_conj) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol_4\NN\3713736|by|p.o. (r_nmod) induced_2\VBN\1627355|catalepsy|was|haloperidol|,|used|. (l_nsubjpass) catalepsy_0\NN\14023236|
D006220_D002375 CID haloperidol_16\NN\3713736|prior (r_nmod) administration_0\NN\1133281|thp|haloperidol (r_nsubj) resulted_17\VBD\2633881|administration|increase|. (l_nmod) increase_21\NN\13576355|in|a|dose-dependent|times|p (l_nmod) times_25\NNS\15113229|in|the|catalepsy (l_amod) catalepsy_24\JJ\1740|
D006220_D002375 CID haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|haloperidol-induced
C069357_D002375 NONE (r)-alpha-methylhistamine_0\NN\1740|ramh|microg|and|thioperamide (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C069357_D002375 NONE ramh_2\NN\1740|(|) (r_appos) (r)-alpha-methylhistamine_0\NN\1740|ramh|microg|and|thioperamide (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C052075_D002375 CID thioperamide_10\NN\1740|thp|mg/kg|,|se (r_conj) (r)-alpha-methylhistamine_0\NN\1740|ramh|microg|and|thioperamide (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C052075_D002375 CID thp_12\NN\1740|(|) (r_appos) thioperamide_10\NN\1740|thp|mg/kg|,|se (r_conj) (r)-alpha-methylhistamine_0\NN\1740|ramh|microg|and|thioperamide (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C052075_D002375 CID thp_2\NN\1740|of|mg/kg (r_nmod) administration_0\NN\1133281|thp|haloperidol (r_nsubj) resulted_17\VBD\2633881|administration|increase|. (l_nmod) increase_21\NN\13576355|in|a|dose-dependent|times|p (l_nmod) times_25\NNS\15113229|in|the|catalepsy (l_amod) catalepsy_24\JJ\1740|
C052075_D002375 CID thp_0\NN\1740| (r_nsubj) exhibited_1\VBD\2632167|thp|profile|potentiating|. (l_advcl) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D000661_D006948 CID amphetamine-induced_1\JJ\1740| (r_amod) hyperactivity_2\NN\14052403|on|amphetamine-induced
D000661_D006948 CID amphetamine-induced_11\JJ\1740| (r_amod) hyperactivity_12\NN\14052403|amphetamine-induced
C052075_D006948 NONE thp_4\NN\1740|mg/kg (r_nsubj) reduced_12\VBD\441445|hyperactivity|,|thp|time|. (l_nmod) hyperactivity_2\NN\14052403|on|amphetamine-induced
C052075_D006948 NONE thp_0\NN\1740| (r_nsubj) exhibited_1\VBD\2632167|thp|profile|potentiating|. (l_advcl) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (l_dobj) hyperactivity_12\NN\14052403|amphetamine-induced
D006220_D006948 NONE haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|haloperidol-induced (r_dobj) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (l_dobj) hyperactivity_12\NN\14052403|amphetamine-induced
D001058_D006948 NONE apomorphine-induced_15\JJ\1740| (r_amod) climbing_16\NN\7445480|apomorphine-induced|mice (r_dobj) reducing_14\VBG\441445|climbing (r_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (l_dobj) hyperactivity_12\NN\14052403|amphetamine-induced
11250767
D011441_D014657 NONE propylthiouracil-induced_0\JJ\1740| (r_amod) vasculitis_5\NN\14336539|propylthiouracil-induced|perinuclear-staining|antineutrophil|autoantibody-positive|conjunction|.
D011441_D014657 NONE propylthiouracil-induced_7\JJ\1740| (r_amod) vasculitis_8\NN\14336539|of|propylthiouracil-induced|manifesting
D011441_D014657 NONE uracil_16\NN\14964590| (r_compound) therapy_17\NN\657604|with|propylthio-|uracil (r_nmod) associated_13\VBN\628491|therapy (r_acl) vasculitis_12\NN\14336539|in|anti-mpo|panca-positive|associated
D011441_D014657 NONE uracil_14\NN\14964590| (r_compound) therapy_15\NN\657604|to|propylthio-|uracil (r_nmod) attributable_11\JJ\1740|therapy (r_amod) vasculitis_10\NN\14336539|of|drug-induced|attributable
D011441_D010493 CID propylthiouracil-induced_0\JJ\1740| (r_amod) vasculitis_5\NN\14336539|propylthiouracil-induced|perinuclear-staining|antineutrophil|autoantibody-positive|conjunction|. (l_nmod) conjunction_7\NN\5048123|in|pericarditis (l_nmod) pericarditis_9\NN\14338942|with
D011441_D010493 CID propylthiouracil-induced_7\JJ\1740| (r_amod) vasculitis_8\NN\14336539|of|propylthiouracil-induced|manifesting (l_acl) manifesting_9\VBG\1015244|pericarditis (l_nmod) pericarditis_11\NN\14338942|with
D011441_D010493 CID propylthiouracil_15\NN\14727670|with (r_nmod) treated_13\VBN\2376958|propylthiouracil (r_acl) woman_10\NN\9605289|of|a|hyperthyroidism|treated|developed (l_acl:relcl) developed_27\VBD\1753788|whom|syndrome (l_nsubj) syndrome_19\NN\5870365|a|pericarditis (l_nmod) pericarditis_21\NN\14338942|of|,|fever|,|and|glomerulonephritis
D011441_D010493 CID uracil_16\NN\14964590| (r_compound) therapy_17\NN\657604|with|propylthio-|uracil (r_nmod) associated_13\VBN\628491|therapy (r_acl) vasculitis_12\NN\14336539|in|anti-mpo|panca-positive|associated (r_nmod) pericarditis_8\NN\14338942|of|vasculitis
D011441_D010493 CID uracil_14\NN\14964590| (r_compound) therapy_15\NN\657604|to|propylthio-|uracil (r_nmod) attributable_11\JJ\1740|therapy (r_amod) vasculitis_10\NN\14336539|of|drug-induced|attributable (r_nmod) manifestation_7\NN\7321772|:|pericarditis|may|be|the|initial|vasculitis (l_nsubj) pericarditis_2\NN\14338942|
D011441_D006980 NONE propylthiouracil_15\NN\14727670|with (r_nmod) treated_13\VBN\2376958|propylthiouracil (r_acl) woman_10\NN\9605289|of|a|hyperthyroidism|treated|developed (l_nmod) hyperthyroidism_12\NN\14059928|with
D011441_D005334 CID propylthiouracil_15\NN\14727670|with (r_nmod) treated_13\VBN\2376958|propylthiouracil (r_acl) woman_10\NN\9605289|of|a|hyperthyroidism|treated|developed (l_acl:relcl) developed_27\VBD\1753788|whom|syndrome (l_nsubj) syndrome_19\NN\5870365|a|pericarditis (l_nmod) pericarditis_21\NN\14338942|of|,|fever|,|and|glomerulonephritis (l_conj) fever_23\NN\14299637|
D011441_D005921 CID propylthiouracil_15\NN\14727670|with (r_nmod) treated_13\VBN\2376958|propylthiouracil (r_acl) woman_10\NN\9605289|of|a|hyperthyroidism|treated|developed (l_acl:relcl) developed_27\VBD\1753788|whom|syndrome (l_nsubj) syndrome_19\NN\5870365|a|pericarditis (l_nmod) pericarditis_21\NN\14338942|of|,|fever|,|and|glomerulonephritis (l_conj) glomerulonephritis_26\NN\14113798|
10457883
1992636
D009853_D000743 CID omeprazole_7\NN\14778019|of (r_nmod) use_5\NN\407535|with|the|omeprazole (r_nmod) associated_2\VBN\628491|use (r_acl) anemia_1\NN\14189204|hemolytic|associated|.
D009853_D000743 CID omeprazole_15\NN\14778019|of (r_nmod) use_13\NN\407535|with|the|omeprazole (r_nmod) reaction_10\NN\13446390|of|a|serious|short-term|adverse|use|: (r_nmod) case_4\NN\7283608|the|first|reaction|anemia (l_dep) anemia_18\NN\14189204|hemolytic
D009853_D000743 CID omeprazole_4\NN\14778019| (r_nsubj) caused_5\VBD\1617192|which|omeprazole|anemia (l_dobj) anemia_10\NN\14189204|patient|hemolytic
D009853_D053609 CID omeprazole_17\NN\14778019|with (r_nmod) therapy_15\NN\657604|omeprazole (r_dobj) starting_14\VBG\2009433|after|therapy (r_advcl) developed_2\VBD\1753788|patient|weakness|starting|. (l_dobj) weakness_3\NN\14462666|,|lethargy (l_conj) lethargy_5\NN\14014621|,|and|shortness
D009853_D004417 CID omeprazole_17\NN\14778019|with (r_nmod) therapy_15\NN\657604|omeprazole (r_dobj) starting_14\VBG\2009433|after|therapy (r_advcl) developed_2\VBD\1753788|patient|weakness|starting|. (l_dobj) weakness_3\NN\14462666|,|lethargy (l_conj) lethargy_5\NN\14014621|,|and|shortness (l_conj) shortness_8\NN\5129201|breath (l_nmod) breath_10\NN\13440063|of
9088814
D000527_D007022 CID e1-induced_5\JJ\1740|prostaglandin (r_amod) hypotension_6\NN\14057371|of|prolonged|e1-induced|and|haemodilution
D000527_D007022 CID e1_5\NN\1740|prolonged|prostaglandin (r_compound) (pge1)-induced_6\NN\1740|e1 (r_nummod) hypotension_7\NN\14057371|of|(pge1)-induced|and|haemodilution
D000527_D007022 CID (pge1)-induced_6\NN\1740|e1 (r_nummod) hypotension_7\NN\14057371|of|(pge1)-induced|and|haemodilution
D000527_D007022 CID pge1_10\NN\1740|with (r_nmod) induced_8\VBN\1627355|hypotension|was|pge1|maintain|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|a
D000527_D007022 CID pge1-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|pge1-induced
D000527_D020141 NONE e1-induced_5\JJ\1740|prostaglandin (r_amod) hypotension_6\NN\14057371|of|prolonged|e1-induced|and|haemodilution (l_conj) haemodilution_8\NN\1740|
D000527_D020141 NONE e1_5\NN\1740|prolonged|prostaglandin (r_compound) (pge1)-induced_6\NN\1740|e1 (r_nummod) hypotension_7\NN\14057371|of|(pge1)-induced|and|haemodilution (l_conj) haemodilution_9\NN\1740|
D000527_D020141 NONE (pge1)-induced_6\NN\1740|e1 (r_nummod) hypotension_7\NN\14057371|of|(pge1)-induced|and|haemodilution (l_conj) haemodilution_9\NN\1740|
D000527_D020141 NONE pge1-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|pge1-induced (r_nmod) min_11\NN\15154774|of|120|hypotension|and|haemodilution (l_conj) haemodilution_17\NN\1740|moderate
D003911_D020141 NONE dextran_23\NN\1740| (r_compound) solution_24\NN\14586258|of|dextran (r_nmod) amount_21\NN\13329641|with|the|same|solution (r_nmod) replacing_16\VBG\1631072|it|amount (r_conj) withdrawing_9\VBG\1835496|by|ml|and|replacing (r_advcl) produced_7\VBN\1617192|haemodilution|was|withdrawing|,|and|% (l_nsubjpass) haemodilution_0\NN\1740|groups
D001663_D007022 NONE bilirubin_50\NN\14756039|total (r_conj) sgot_43\NN\1740|,|sgpt|,|ldh|and|bilirubin (r_nsubj) showed_51\VBD\2137132|sgot|increases|operation|. (r_conj) showed_5\VBD\2137132|c|,|akbr|decrease|min|,|and|showed (l_nmod) min_11\NN\15154774|at|120|%|and|min (l_conj) min_19\NN\15154774|at|180|%|start|and|min (l_nmod) start_26\NN\7290905|after|the|hypotension (l_nmod) hypotension_28\NN\14057371|of
D000527_D008107 CID pge1-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|pge1-induced (r_nmod) min_11\NN\15154774|of|120|hypotension|and|haemodilution (r_nmod) combination_6\NN\7951464|a|prolonged|min (r_nsubj) cause_19\VB\1617192|that|combination|would|impairment (l_dobj) impairment_20\NN\7296428|function (l_nmod) function_23\NN\13783581|of|hepatic
6286738
D002762_D064420 NONE d3_1\NN\1740|vitamin (r_compound) toxicity_2\NN\13576101|d3|cows|.
D002762_D064420 NONE d3_3\NN\1740| (r_compound) toxicity_4\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_3\NN\1740| (r_compound) toxicity_4\NN\13576101|of|vitamin|d3 (r_nmod) signs_0\NNS\6643763|toxicity (r_nsubjpass) observed_7\VBN\2163746|signs|were|not|cows (r_ccomp) developed_18\VBD\1753788|observed|;|however|,|cows|commonly|signs|and|died (l_dobj) signs_20\NNS\6643763|severe|toxicity (l_nmod) toxicity_24\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_23\NN\1740| (r_compound) toxicity_24\NN\13576101|of|vitamin|d3 (r_nmod) signs_20\NNS\6643763|severe|toxicity (r_dobj) developed_18\VBD\1753788|observed|;|however|,|cows|commonly|signs|and|died (l_ccomp) observed_7\VBN\2163746|signs|were|not|cows (l_nsubjpass) signs_0\NNS\6643763|toxicity (l_nmod) toxicity_4\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_23\NN\1740| (r_compound) toxicity_24\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin
D002762_D064420 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (r_nmod) margin_15\NN\13903079|the|low|safety|doses (r_conj) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin
D002762_D064420 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (r_ccomp) concluded_35\VBD\628491|toxicity|,|we|used|. (l_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin
D002762_D006934 CID d3_5\NN\1740|of|vitamin (r_nmod) doses_2\NNS\3740161|large|parenteral|d3|iu (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|plasma
D002762_D006934 CID d3_15\NN\1740|vitamin (r_appos) iu_13\NN\1740|(|)|d3|) (r_dep) doses_2\NNS\3740161|large|parenteral|d3|iu (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|plasma
D002762_D006934 CID d3_30\NN\1740|of|vitamin|and|metabolites (r_nmod) increases_27\NNS\13576355|large|d3 (r_conj) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|plasma
D002762_D054559 CID d3_5\NN\1740|of|vitamin (r_nmod) doses_2\NNS\3740161|large|parenteral|d3|iu (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|plasma (l_conj) hyperphosphatemia_23\NN\1740|
D002762_D054559 CID d3_15\NN\1740|vitamin (r_appos) iu_13\NN\1740|(|)|d3|) (r_dep) doses_2\NNS\3740161|large|parenteral|d3|iu (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|plasma (l_conj) hyperphosphatemia_23\NN\1740|
D002762_D054559 CID d3_30\NN\1740|of|vitamin|and|metabolites (r_nmod) increases_27\NNS\13576355|large|d3 (r_conj) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|plasma (l_conj) hyperphosphatemia_23\NN\1740|
D002762_D010319 NONE d3_7\NN\1740|with|vitamin (r_nmod) treated_4\VBN\2376958|d3 (r_acl) cows_3\NNS\2402010|of|the|treated (r_nmod) none_0\NN\15228378|cows (r_nsubj) showed_8\VBD\2137132|none|signs|period (l_dobj) signs_9\NNS\6643763|fever (l_nmod) fever_12\NN\14299637|of|milk
D002762_D010319 NONE d3_7\NN\1740|with|vitamin (r_nmod) treated_4\VBN\2376958|d3 (r_acl) cows_3\NNS\2402010|of|the|treated (r_nmod) none_0\NN\15228378|cows (r_nsubj) showed_8\VBD\2137132|none|signs|period (r_ccomp) developed_26\VBD\1753788|showed|;|however|,|%|signs|period|. (l_dobj) signs_28\NNS\6643763|clinical|fever (l_nmod) fever_31\NN\14299637|of|milk
D002762_D010319 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (l_acl:relcl) prevent_24\VBP\1740|that|fever (l_dobj) fever_26\NN\14299637|milk
D002762_D010319 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (l_conj) doses_28\NNS\3740161|induce (l_acl:relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin (r_nmod) concluded_35\VBD\628491|toxicity|,|we|used|. (l_ccomp) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (l_xcomp) prevent_45\VB\1740|to|fever|injected (l_dobj) fever_47\NN\14299637|milk
D002762_D010319 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (l_acl:relcl) prevent_24\VBP\1740|that|fever (l_dobj) fever_26\NN\14299637|milk
D002762_D010319 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (l_conj) doses_28\NNS\3740161|induce (l_acl:relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (r_nmod) margin_15\NN\13903079|the|low|safety|doses (r_conj) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin (r_nmod) concluded_35\VBD\628491|toxicity|,|we|used|. (l_ccomp) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (l_xcomp) prevent_45\VB\1740|to|fever|injected (l_dobj) fever_47\NN\14299637|milk
D002762_D010319 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (r_ccomp) concluded_35\VBD\628491|toxicity|,|we|used|. (l_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (l_acl:relcl) prevent_24\VBP\1740|that|fever (l_dobj) fever_26\NN\14299637|milk
D002762_D010319 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (r_ccomp) concluded_35\VBD\628491|toxicity|,|we|used|. (l_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent|and|doses (l_conj) doses_28\NNS\3740161|induce (l_acl:relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (l_xcomp) prevent_45\VB\1740|to|fever|injected (l_dobj) fever_47\NN\14299637|milk
15145918
D004967_D007022 NONE estrogen_3\NN\14745635|by (r_nmod) modulation_1\NN\7044917|differential|estrogen|hypotension|. (l_nmod) hypotension_9\NN\14057371|of|alpha2-adrenergic|rats
D004967_D007022 NONE estrogen_5\NN\14745635| (r_nsubj) modulates_7\VBZ\1724459|that|estrogen|negatively|effect|and|implicates (l_dobj) effect_10\NN\34213|the|hypotensive|clonidine|rats (l_amod) hypotensive_9\JJ\1740|
D004967_D007022 NONE estrogen_4\NN\14745635| (r_nsubj) downregulates_5\VBZ\1740|that|estrogen|hypotension (l_dobj) hypotension_10\NN\14057371|alpha2-
D004967_D007022 NONE alpha-methyldopa-estrogen_21\JJ\1740| (r_compound) interaction_22\NN\37396|in|alpha-methyldopa-estrogen (r_nmod) role_14\NN\719494|a|control|interaction (r_dobj) highlight_12\VBP\514463|role (r_conj) suggest_2\VBP\1010118|findings|downregulates|and|highlight|. (l_ccomp) downregulates_5\VBZ\1740|that|estrogen|hypotension (l_dobj) hypotension_10\NN\14057371|alpha2-
D048288_D007022 NONE i1-imidazoline_7\NN\1740| (r_nmod:npmod) receptor-mediated_8\JJ\1740|i1-imidazoline (r_conj) alpha2-adrenergic_5\JJ\1740|and|receptor-mediated (r_amod) hypotension_9\NN\14057371|of|alpha2-adrenergic|rats
D003000_D007022 NONE clonidine_12\NN\2721160|of|agonist (r_nmod) effect_10\NN\34213|the|hypotensive|clonidine|rats (l_amod) hypotensive_9\JJ\1740|
C032302_D007022 CID rilmenidine_4\NN\1740|or|alpha-methyldopa (r_nsubj) elicited_7\VBD\1617192|rats|,|rilmenidine|hypotension|. (l_dobj) hypotension_9\NN\14057371|similar|lasted
C032302_D007022 CID rilmenidine_15\NN\1740| (r_compound) hypotension_16\NN\14057371|on|rilmenidine (r_nmod) effect_13\NN\34213|to|no|hypotension (r_nmod) contrast_10\NN\13854649|in|effect (r_nmod) enhanced_2\VBD\227165|ovx|significantly|response|,|contrast|. (l_dobj) response_5\NN\11410625|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_4\JJ\1740|
C032302_D007022 CID rilmenidine_15\NN\1740| (r_compound) hypotension_16\NN\14057371|on|rilmenidine
D008750_D007022 CID alpha-methyldopa_6\NN\1740| (r_conj) rilmenidine_4\NN\1740|or|alpha-methyldopa (r_nsubj) elicited_7\VBD\1617192|rats|,|rilmenidine|hypotension|. (l_dobj) hypotension_9\NN\14057371|similar|lasted
D008750_D007022 CID alpha-methyldopa_7\NN\1740|to (r_nmod) response_5\NN\11410625|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_4\JJ\1740|
D008750_D007022 CID alpha-methyldopa_7\NN\1740|to (r_nmod) response_5\NN\11410625|the|hypotensive|alpha-methyldopa (r_dobj) enhanced_2\VBD\227165|ovx|significantly|response|,|contrast|. (l_nmod) contrast_10\NN\13854649|in|effect (l_nmod) effect_13\NN\34213|to|no|hypotension (l_nmod) hypotension_16\NN\14057371|on|rilmenidine
D008750_D007022 CID alpha-methyldopa_2\NN\1740| (r_compound) hypotension_3\NN\14057371|the|enhanced|alpha-methyldopa|rats
D008750_D007022 CID alpha-methyldopa-estrogen_21\JJ\1740| (r_compound) interaction_22\NN\37396|in|alpha-methyldopa-estrogen (r_nmod) role_14\NN\719494|a|control|interaction (r_dobj) highlight_12\VBP\514463|role (r_conj) suggest_2\VBP\1010118|findings|downregulates|and|highlight|. (l_ccomp) downregulates_5\VBZ\1740|that|estrogen|hypotension (l_dobj) hypotension_10\NN\14057371|alpha2-
D008750_D001523 NONE alpha-methyldopa_2\NN\1740| (r_compound) hypotension_3\NN\14057371|the|enhanced|alpha-methyldopa|rats (r_nsubjpass) paralleled_8\VBN\2657219|hypotension|was|reduction|. (l_nmod) reduction_11\NN\351485|with|further|sdrr|and|activity (l_conj) activity_18\NN\30358|a|reduced|locomotor
17608141
D008694_D020258 NONE methamphetamine-induced_2\JJ\1740| (r_amod) neurotoxicity_5\NN\1740|of|methamphetamine-induced|nigrostriatal|dopaminergic|mice
D008694_D020258 NONE methamphetamine-induced_21\JJ\1740| (r_amod) neurotoxicity_24\NN\1740|the|methamphetamine-induced|nigrostriatal|dopamine
D008694_D020258 NONE methamphetamine-induced_15\JJ\1740| (r_amod) neurotoxicity_18\NN\1740|against|methamphetamine-induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_9\NN\1740| (r_compound) pretreatment_10\NN\1740|by|lipopolysaccharide (r_nmod) attenuation_0\NN\7427337|neurotoxicity|pretreatment|. (l_nmod) neurotoxicity_5\NN\1740|of|methamphetamine-induced|nigrostriatal|dopaminergic|mice
D008070_D020258 NONE lipopolysaccharide_9\NN\1740|of|,|factor|,|treatment (r_nmod) roles_7\NNS\719494|the|lipopolysaccharide|modulating (l_advcl) modulating_19\VBG\1724459|in|neurotoxicity (l_dobj) neurotoxicity_24\NN\1740|the|methamphetamine-induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_8\NN\1740| (r_compound) pretreatment_9\NN\1740|for|systemic|lipopolysaccharide|exerting (l_acl) exerting_11\VBG\1158872|in|protection (l_dobj) protection_13\NN\407535|effective|neurotoxicity (l_nmod) neurotoxicity_18\NN\1740|against|methamphetamine-induced|nigrostriatal|dopamine
D008694_D009422 NONE methamphetamine-induced_10\JJ\1740| (r_amod) damage_13\NN\7296428|in|methamphetamine-induced|dopaminergic|terminal
D004298_D020258 NONE dopamine_23\NN\14807737| (r_compound) neurotoxicity_24\NN\1740|the|methamphetamine-induced|nigrostriatal|dopamine
D004298_D020258 NONE dopamine_17\NN\14807737| (r_compound) neurotoxicity_18\NN\1740|against|methamphetamine-induced|nigrostriatal|dopamine
D008070_D005334 NONE lipopolysaccharide_0\NN\1740| (r_compound) pretreatment_1\NN\1740|lipopolysaccharide (r_nsubj) affect_4\VB\126264|pretreatment|did|not|temperature|later|. (l_dobj) temperature_8\NN\13575869|the|basal|body|or|hyperthermia (l_conj) hyperthermia_11\NN\14034177|methamphetamine-elicited
D008694_D005334 CID methamphetamine-elicited_10\JJ\1740| (r_amod) hyperthermia_11\NN\14034177|methamphetamine-elicited
4027862
D003891_D003693 CID desipramine-induced_0\JJ\1740| (r_amod) delirium_1\NN\14391660|desipramine-induced|concentrations|:|report
D003891_D003693 CID desipramine_7\NN\4482543|with|dose (r_nmod) treated_3\VBN\2376958|desipramine (r_acl) patient_2\NN\9898892|an|elderly|treated (r_nsubj) developed_8\VBD\1753788|patient|delirium|while|. (l_dobj) delirium_10\NN\14391660|a
6133211
D012460_D015212 NONE sulphasalazine_15\NN\1740|with (r_nmod) treatment_13\NN\654885|sulphasalazine (r_dobj) received_12\VBD\2210855|who|treatment|pregnancy (r_acl:relcl) mothers_6\NNS\10399491|of|two|disease|received (l_nmod) disease_10\NN\14061805|with|inflammatory|bowel
D012460_D000013 NONE sulphasalazine_15\NN\1740|with (r_nmod) treatment_13\NN\654885|sulphasalazine (r_dobj) received_12\VBD\2210855|who|treatment|pregnancy (r_acl:relcl) mothers_6\NNS\10399491|of|two|disease|received (r_nmod) born_3\VBN\2630189|mothers (r_acl) infants_1\NNS\9918248|three|,|born|, (r_nsubjpass) found_20\VBN\2426171|infants|were|have|. (l_xcomp) have_22\VB\2108377|to|anomalies (l_dobj) anomalies_25\NNS\14501726|major|congenital
17639754
D014859_D006470 CID warfarin_18\NN\2718259|between|and|levofloxacin (r_nmod) interaction_16\NN\37396|of|the|warfarin (r_nmod) result_13\NN\34213|to|be|the|interaction (r_xcomp) appear_9\VBP\2604760|that|result (r_acl:relcl) complications_7\NNS\1073995|of|serious|bleeding|appear (l_amod) bleeding_6\JJ\1740|
D064704_D006470 CID levofloxacin_20\NN\1740| (r_conj) warfarin_18\NN\2718259|between|and|levofloxacin (r_nmod) interaction_16\NN\37396|of|the|warfarin (r_nmod) result_13\NN\34213|to|be|the|interaction (r_xcomp) appear_9\VBP\2604760|that|result (r_acl:relcl) complications_7\NNS\1073995|of|serious|bleeding|appear (l_amod) bleeding_6\JJ\1740|
16574712
D018817_D003072 CID mdma_0\NN\3054098| (r_compound) users_2\NNS\7846|mdma|polydrug (r_nsubj) show_3\VBP\2137132|users|impairments|. (l_dobj) impairments_7\NNS\7296428|process-specific|central|executive|coupled (l_acl) coupled_8\VBN\1295275|processes (l_nmod) processes_15\NNS\407535|with|impaired|social|judgement
D018817_D008569 NONE mdma_12\NN\3054098|of|3,4-methylenedioxymethamphetamine (r_nmod) users_10\NNS\7846|in|mdma (r_nmod) reported_8\VBN\831651|years|deficits|have|been|users|. (l_nsubjpass) deficits_5\NNS\5113133|memory
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\NN\1740|(|,|ecstasy|) (r_appos) mdma_12\NN\3054098|of|3,4-methylenedioxymethamphetamine (r_nmod) users_10\NNS\7846|in|mdma (r_nmod) reported_8\VBN\831651|years|deficits|have|been|users|. (l_nsubjpass) deficits_5\NNS\5113133|memory
D018817_D008569 NONE ecstasy_16\NN\13985818| (r_appos) 3,4-methylenedioxymethamphetamine_14\NN\1740|(|,|ecstasy|) (r_appos) mdma_12\NN\3054098|of|3,4-methylenedioxymethamphetamine (r_nmod) users_10\NNS\7846|in|mdma (r_nmod) reported_8\VBN\831651|years|deficits|have|been|users|. (l_nsubjpass) deficits_5\NNS\5113133|memory
18083142
D009638_D001008 NONE norepinephrine_0\NN\14807929| (r_compound) signaling_1\NN\33020|norepinephrine|receptors (r_nsubj) critical_6\JJ\1740|signaling|is|expression|. (l_nmod) expression_8\NN\4679549|for|anxiety (l_nmod) anxiety_11\NN\14373582|of|cocaine-induced
D009638_D001008 NONE norepinephrine_22\NN\14807929|ne (r_dobj) lack_21\VBP\1740|which|norepinephrine (r_acl:relcl) mice_18\NNS\2329401|of|dopamine|beta-hydroxylase|knockout|)|,|lack|, (r_nmod) performance_9\NN\6619065|the|mice (r_dobj) evaluated_7\VBD\670261|study|,|we|performance|maze|examine|. (l_advcl) examine_36\VB\789138|to|contribution (l_dobj) contribution_38\NN\786195|the|signaling|anxiety (l_nmod) anxiety_44\NN\14373582|to|cocaine-induced
D009638_D001008 NONE ne_24\NN\14622893|(|) (r_appos) norepinephrine_22\NN\14807929|ne (r_dobj) lack_21\VBP\1740|which|norepinephrine (r_acl:relcl) mice_18\NNS\2329401|of|dopamine|beta-hydroxylase|knockout|)|,|lack|, (r_nmod) performance_9\NN\6619065|the|mice (r_dobj) evaluated_7\VBD\670261|study|,|we|performance|maze|examine|. (l_advcl) examine_36\VB\789138|to|contribution (l_dobj) contribution_38\NN\786195|the|signaling|anxiety (l_nmod) anxiety_44\NN\14373582|to|cocaine-induced
D003042_D001008 CID cocaine-induced_10\JJ\1740| (r_amod) anxiety_11\NN\14373582|of|cocaine-induced
D003042_D001008 CID cocaine_4\NN\3492717|'s (r_nmod:poss) effects_7\NNS\13245626|cocaine|rewarding (r_dobj) underlying_3\VBG\2604760|effects (r_acl) mechanisms_2\NNS\13446390|the|underlying (r_nsubjpass) studied_10\VBN\630380|while|mechanisms|have|been|extensively (r_advcl) paid_17\VBN\2199590|studied|,|attention|has|been|states|. (l_nmod) states_22\NNS\8491826|to|the|unpleasant|behavioral|induced|,|anxiety (l_nmod) anxiety_29\NN\14373582|such
D003042_D001008 CID cocaine_25\NN\3492717|by (r_nmod) induced_23\VBN\1627355|cocaine (r_acl) states_22\NNS\8491826|to|the|unpleasant|behavioral|induced|,|anxiety (l_nmod) anxiety_29\NN\14373582|such
D003042_D001008 CID cocaine-induced_43\JJ\1740| (r_amod) anxiety_44\NN\14373582|to|cocaine-induced
D003042_D001008 CID cocaine_5\NN\3492717| (r_nsubj) increased_7\VBD\169651|that|cocaine|dose-dependently|behavior|,|measured (l_dobj) behavior_9\NN\407535|anxiety-like|mice (l_amod) anxiety-like_8\JJ\1740|
D003042_D001008 CID cocaine-induced_0\JJ\1740| (r_amod) anxiety_1\NN\14373582|cocaine-induced
D003042_D001008 CID cocaine-induced_18\JJ\1740| (r_amod) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
D003042_D001008 CID cocaine-induced_14\JJ\1740| (r_amod) anxiety_15\NN\14373582|for|cocaine-induced|mice
D004298_D001008 NONE dopamine_11\NN\14807737| (r_compound) mice_18\NNS\2329401|of|dopamine|beta-hydroxylase|knockout|)|,|lack|, (r_nmod) performance_9\NN\6619065|the|mice (r_dobj) evaluated_7\VBD\670261|study|,|we|performance|maze|examine|. (l_advcl) examine_36\VB\789138|to|contribution (l_dobj) contribution_38\NN\786195|the|signaling|anxiety (l_nmod) anxiety_44\NN\14373582|to|cocaine-induced
D004298_D001008 NONE dopamine_15\NN\14807737| (r_compound) inhibitor_20\NN\20090|a|dopamine|beta-hydroxylase|dbh (r_appos) disulfiram_12\NN\3740161|of|,|inhibitor (r_nmod) administration_10\NN\1133281|following|disulfiram (r_nmod) attenuated_4\VBN\224901|anxiety|was|also|mice|administration|. (l_nsubjpass) anxiety_1\NN\14373582|cocaine-induced
D004221_D001008 NONE disulfiram_12\NN\3740161|of|,|inhibitor (r_nmod) administration_10\NN\1133281|following|disulfiram (r_nmod) attenuated_4\VBN\224901|anxiety|was|also|mice|administration|. (l_nsubjpass) anxiety_1\NN\14373582|cocaine-induced
D011433_D001008 NONE propranolol_16\NN\1740|with|the|beta-adrenergic|receptor|antagonist (r_nmod) pretreatment_10\NN\1740|propranolol (r_nsubj) blocked_17\VBD\1476483|that|pretreatment|behavior|dbh|,|had (l_dobj) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
D011224_D001008 NONE prazosin_34\NN\2698769|the|alpha(1|)|antagonist|and|yohimbine (r_nsubj) had_41\VBD\2108377|while|prazosin|effect (r_advcl) blocked_17\VBD\1476483|that|pretreatment|behavior|dbh|,|had (l_dobj) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
D015016_D001008 NONE yohimbine_40\NN\1740|the|alpha(2|)|antagonist (r_conj) prazosin_34\NN\2698769|the|alpha(1|)|antagonist|and|yohimbine (r_nsubj) had_41\VBD\2108377|while|prazosin|effect (r_advcl) blocked_17\VBD\1476483|that|pretreatment|behavior|dbh|,|had (l_dobj) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
3341566
D009599_D006470 NONE nitroprusside-induced_10\JJ\1740| (r_amod) hypotension_11\NN\14057371|during|sodium|nitroprusside-induced|dogs (r_nmod) than_7\IN\1740|hypotension (r_prep) greater_4\JJR\1740|variation|is|hemorrhage|than|. (l_nmod) hemorrhage_6\NN\14285662|during
D009599_D006470 NONE nitroprusside_28\NN\1740|of|sodium|snp (r_nmod) infusion_25\NN\14589223|by|continuous|nitroprusside (r_conj) hem_16\NN\3264542|(|,|=|or|infusion (r_appos) hemorrhage_14\NN\14285662|by|hem
D009599_D006470 NONE nitroprusside_28\NN\1740|of|sodium|snp (r_nmod) infusion_25\NN\14589223|by|continuous|nitroprusside (r_conj) hem_16\NN\3264542|(|,|=|or|infusion
D009599_D006470 NONE snp_30\NN\11493266|(|,|=|) (r_appos) nitroprusside_28\NN\1740|of|sodium|snp (r_nmod) infusion_25\NN\14589223|by|continuous|nitroprusside (r_conj) hem_16\NN\3264542|(|,|=|or|infusion (r_appos) hemorrhage_14\NN\14285662|by|hem
D009599_D006470 NONE snp_30\NN\11493266|(|,|=|) (r_appos) nitroprusside_28\NN\1740|of|sodium|snp (r_nmod) infusion_25\NN\14589223|by|continuous|nitroprusside (r_conj) hem_16\NN\3264542|(|,|=|or|infusion
D009599_D006470 NONE snp_19\NN\11493266| (r_compound) group_20\NN\2137|in|the|snp (r_nmod) that_16\DT\1740|with|group (r_nmod) compared_14\VBN\644583|that (r_prep) higher_13\JJR\1740|resistance|compared (r_conj) lower_8\JJR\1740|hypotension|output|was|significantly|and|higher|. (l_nmod) hypotension_2\NN\14057371|during|hem-induced (l_amod) hem-induced_1\JJ\1740|
D009599_D006470 NONE snp_24\NN\11493266| (r_compound) group_25\NN\2137|in|the|snp (r_nmod) hg_21\NN\14625458|with|9.1|mm|group (r_nmod) compared_15\VBN\644583|hg (r_prep) hg_9\NN\14625458|spv|was|15.7|mm|group|,|compared|p|. (l_nmod) group_13\NN\2137|in|the|hem (l_compound) hem_12\NNP\3264542|
D009599_D006470 NONE snp_31\NN\11493266| (r_conj) hem_29\NN\3264542|and|snp
D009599_D007022 CID nitroprusside-induced_10\JJ\1740| (r_amod) hypotension_11\NN\14057371|during|sodium|nitroprusside-induced|dogs
D009599_D007022 CID snp_19\NN\11493266| (r_compound) group_20\NN\2137|in|the|snp (r_nmod) that_16\DT\1740|with|group (r_nmod) compared_14\VBN\644583|that (r_prep) higher_13\JJR\1740|resistance|compared (r_conj) lower_8\JJR\1740|hypotension|output|was|significantly|and|higher|. (l_nmod) hypotension_2\NN\14057371|during|hem-induced
D009599_D007022 CID snp_24\NN\11493266| (r_compound) group_25\NN\2137|in|the|snp (r_nmod) hg_21\NN\14625458|with|9.1|mm|group (r_nmod) compared_15\VBN\644583|hg (r_prep) hg_9\NN\14625458|spv|was|15.7|mm|group|,|compared|p|. (l_nsubj) spv_1\NN\1740|the|hypotension (l_nmod) hypotension_3\NN\14057371|during
D009599_D007022 CID snp_31\NN\11493266| (r_conj) hem_29\NN\3264542|and|snp (r_compound) groups_32\NNS\2137|in|the|hem (r_nmod) hg_26\NN\14625458|20.3|mm|groups|,|respectively|,|hypotension|. (l_nmod) hypotension_37\NN\14057371|during|p
3714122
C005238_D020258 NONE mipafox-induced_7\JJ\1740| (r_amod) damage_9\NN\7296428|mipafox-induced|neuropathic|rats (r_conj) inhibition_5\NN\1068773|between|neurotoxic|esterase|and|damage (l_amod) neurotoxic_3\JJ\1740|
C005238_D020258 NONE mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition (l_conj) inhibition_6\NN\1068773|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\1740|
C005238_D020258 NONE mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (l_appos) organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\1740|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740|(|n|,|) (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition (l_conj) inhibition_6\NN\1068773|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\1740|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740|(|n|,|) (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (l_appos) organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\1740|
C005238_D009422 NONE mipafox-induced_7\JJ\1740| (r_amod) damage_9\NN\7296428|mipafox-induced|neuropathic|rats
C005238_D009422 NONE mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition
C005238_D009422 NONE mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition (l_conj) inhibition_6\NN\1068773|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|neuropathy|target|nte (l_compound) neuropathy_11\NN\14204950|
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740|(|n|,|) (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740|(|n|,|) (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition (l_conj) inhibition_6\NN\1068773|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|neuropathy|target|nte (l_compound) neuropathy_11\NN\14204950|
C005238_D009422 NONE mipafox_18\NN\1740| (r_compound) exposure_19\NN\5042871|after|mipafox (r_nmod) sampled_15\VBN\1156834|exposure (r_acl) percentage_6\NN\13815742|a|critical|inhibition|sampled (r_nsubj) predict_21\VB\916909|that|percentage|can|damage|later (l_dobj) damage_23\NN\7296428|neuropathic|rats
D010755_D009422 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition
D010755_D009422 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition (l_conj) inhibition_6\NN\1068773|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|neuropathy|target|nte (l_compound) neuropathy_11\NN\14204950|
D010755_D020258 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NN\1740|to|n'-diisopropylphosphorodiamidofluoridate|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition (l_conj) inhibition_6\NN\1068773|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\1740|
D010755_D020258 NONE organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\1740|
C005238_D013118 CID mipafox_5\NN\1740|of|(|than|)|inhibited (r_nmod) dosages_3\NNS\13576355|mipafox (r_nsubj) produced_39\VBD\1617192|contrast|,|dosages|degree|%|. (l_dobj) degree_41\NN\4916342|this|damage (l_nmod) damage_44\NN\7296428|of|cord
3125768
D015760_D009127 CID alfentanil-induced_4\JJ\1740| (r_amod) rigidity_5\NN\5023233|during|alfentanil-induced
D015760_D009127 CID alfentanil-induced_8\JJ\1740| (r_amod) rigidity_9\NN\5023233|during|alfentanil-induced|rats
D015760_D009127 CID alfentanil_9\NN\1740|,|and|,|presumably|,|opiates|, (r_nsubjpass) used_19\VBN\1156834|when|alfentanil|are|management (r_advcl) prevented_7\VBN\1740|that|rigidity|should|be|used (l_nsubjpass) rigidity_4\NN\5023233|
C032943_D009127 NONE metocurine_10\NN\1740|with (r_nmod) abolished_8\VBN\1740|when|rigidity|was|metocurine (l_nsubjpass) rigidity_6\NN\5023233|
9195768
D018170_D010292 CID sumatriptan_7\NN\1740|of|subcutaneous (r_nmod) use_4\NN\407535|the|sumatriptan (r_dobj) following_2\VBG\1835496|use (r_acl) sensations_1\NNS\5708432|atypical|following
1919871
D001241_D007681 CID aspirin_18\NN\2707683|with|and|paracetamol (r_nmod) treatment_16\NN\654885|during|continuous|long-term|aspirin|rats (r_nmod) developed_12\VBD\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability
D001241_D007681 CID aspirin_18\NN\2707683|with|and|paracetamol (r_nmod) treatment_16\NN\654885|during|continuous|long-term|aspirin|rats (r_nmod) developed_12\VBD\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability (l_appos) rpn_4\NN\1740|(|)
D000082_D007681 CID paracetamol_20\NN\1740| (r_conj) aspirin_18\NN\2707683|with|and|paracetamol (r_nmod) treatment_16\NN\654885|during|continuous|long-term|aspirin|rats (r_nmod) developed_12\VBD\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability
D000082_D007681 CID paracetamol_20\NN\1740| (r_conj) aspirin_18\NN\2707683|with|and|paracetamol (r_nmod) treatment_16\NN\654885|during|continuous|long-term|aspirin|rats (r_nmod) developed_12\VBD\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability (l_appos) rpn_4\NN\1740|(|)
15275829
D000109_D012640 NONE acetylcholine_5\NN\14807558| (r_compound) subunits_7\NNS\13604718|the|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) necessary_9\JJ\1740|subunits|are|seizures|. (l_nmod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice
D000109_D012640 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|to|nicotinic|acetylcholine|nachrs (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|,|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death
D000109_D006948 NONE acetylcholine_5\NN\14807558| (r_compound) subunits_7\NNS\13604718|the|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) necessary_9\JJ\1740|subunits|are|seizures|. (l_nmod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice (l_conj) hypolocomotion_14\NN\1740|
D009538_D012640 CID nicotine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice
D009538_D012640 CID nicotine_2\NN\14712692|of (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|,|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death
D009538_D012640 CID nicotine-induced_9\JJ\1740| (r_amod) seizures_10\NNS\14081375|in|nicotine-induced|and|hypolocomotion
D009538_D012640 CID nicotine_10\NN\14712692|of (r_nmod) effects_8\NNS\13245626|to|the|nicotine (r_nmod) sensitive_5\JJ\1740|mice|were|less|effects|both|. (l_advmod) both_11\CC\1740|doses (l_nmod) doses_14\NNS\3740161|at|low|,|measured|,|and|doses (l_conj) doses_28\NNS\3740161|at|high|,|measured (l_acl) measured_30\VBN\697589|sensitivity (l_nmod) sensitivity_32\NN\5651971|as|seizures (l_nmod) seizures_35\NNS\14081375|to|nicotine-induced
D009538_D012640 CID nicotine-induced_34\JJ\1740| (r_amod) seizures_35\NNS\14081375|to|nicotine-induced
D009538_D012640 CID nicotine-induced_7\JJ\1740| (r_amod) seizures_8\NNS\14081375|to|nicotine-induced
D009538_D012640 CID nicotine-induced_15\JJ\1740| (r_amod) seizures_16\NNS\14081375|of|nicotine-induced|and|hypolocomotion
D009538_D006948 NONE nicotine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice (l_conj) hypolocomotion_14\NN\1740|
D009538_D006948 NONE nicotine-induced_9\JJ\1740| (r_amod) seizures_10\NNS\14081375|in|nicotine-induced|and|hypolocomotion (l_conj) hypolocomotion_12\NN\1740|
D009538_D006948 NONE nicotine-induced_15\JJ\1740| (r_amod) seizures_16\NNS\14081375|of|nicotine-induced|and|hypolocomotion (l_conj) hypolocomotion_18\NN\1740|
D009538_D014202 NONE nicotine_2\NN\14712692|of (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|,|seizures (l_nmod) exploration_20\NN\309647|from|altered|,|sedation (l_conj) sedation_22\NN\14034177|,|and|tremors (l_conj) tremors_25\NNS\345926|
D009538_D003643 NONE nicotine_2\NN\14712692|of (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|,|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death (l_conj) death_30\NN\7296428|
D000109_D014202 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|to|nicotinic|acetylcholine|nachrs (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|,|seizures (l_nmod) exploration_20\NN\309647|from|altered|,|sedation (l_conj) sedation_22\NN\14034177|,|and|tremors (l_conj) tremors_25\NNS\345926|
D000109_D003643 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|to|nicotinic|acetylcholine|nachrs (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|,|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death (l_conj) death_30\NN\7296428|
7919560
D000667_D004892 CID ampicillin_7\NN\3910033|by (r_nmod) caused_5\VBN\1617192|ampicillin (r_acl) myocarditis_4\NN\14338942|hypersensitivity|caused|. (r_conj) multiforme_1\JJ\1740|erythema|and|myocarditis
D000667_D004892 CID ampicillin_14\NN\3910033|by (r_nmod) caused_12\VBN\1617192|ampicillin (r_acl) case_5\NN\7283608|a|multiforme|caused (l_nmod) multiforme_8\NN\1740|of|erythema|and|myocarditis
D000667_D009205 CID ampicillin_7\NN\3910033|by (r_nmod) caused_5\VBN\1617192|ampicillin (r_acl) myocarditis_4\NN\14338942|hypersensitivity|caused|.
D000667_D009205 CID ampicillin_14\NN\3910033|by (r_nmod) caused_12\VBN\1617192|ampicillin (r_acl) case_5\NN\7283608|a|multiforme|caused (l_nmod) multiforme_8\NN\1740|of|erythema|and|myocarditis (l_conj) myocarditis_11\NN\14338942|hypersensitivity
D000667_D018805 NONE ampicillin_9\NN\3910033|with|and|gentamicin (r_nmod) treated_7\VBN\2376958|:|boy|was|ampicillin|septicemia|. (l_nmod) septicemia_15\NN\14189204|because|suspected
D005839_D018805 NONE gentamicin_11\NN\2716866| (r_conj) ampicillin_9\NN\3910033|with|and|gentamicin (r_nmod) treated_7\VBN\2376958|:|boy|was|ampicillin|septicemia|. (l_nmod) septicemia_15\NN\14189204|because|suspected
D010406_D009205 NONE penicillins_13\NNS\2716866|to (r_nmod) allergy_11\NN\14533203|of|penicillins (r_nmod) manifestation_9\NN\7321772|myocarditis|is|a|rare|allergy (l_nsubj) myocarditis_3\NN\14338942|hypersensitivity
D010406_D004342 NONE penicillins_13\NNS\2716866|to (r_nmod) allergy_11\NN\14533203|of|penicillins
19269743
D002211_D010146 CID capsaicin-induced_7\JJ\1740| (r_amod) pain_8\NN\14299637|of|capsaicin-induced
D002211_D010146 CID capsaicin_19\NN\15032661|of (r_nmod) doses_17\NNS\3740161|of|three|capsaicin|microg|,|given (r_nmod) injections_14\NNS\320852|intradermal|doses (r_dobj) received_12\VBD\2210855|address|,|volunteers|injections|. (l_advcl) address_3\VB\740577|in|to|memory (l_dobj) memory_6\NN\5926676|long-term|pain (l_compound) pain_5\NN\14299637|
D002211_D010146 CID capsaicin_11\NN\15032661| (r_compound) doses_12\NNS\3740161|across|capsaicin|p<0.001 (r_nmod) discriminate_5\VB\650353|to|reliably|magnitude|doses (l_dobj) magnitude_7\NN\4916342|pain|and|duration (l_compound) pain_6\NN\14299637|
6640832
D004317_D001749 NONE adriamycin_2\NN\1740|early|adjuvant|carcinoma|. (l_nmod) carcinoma_6\NN\14239918|in|superficial|bladder
D004317_D001749 NONE adriamycin_0\NN\1740|ml|) (r_nsubjpass) administered_7\VBN\2436349|adriamycin|was|intravesically|h|. (l_nmod) h_11\NN\14622893|within|24|resection (l_nmod) resection_14\NN\671351|after|transurethral|tumors (l_nmod) tumors_21\NNS\14234074|of|ta-t1|(|o-a|bladder
D004317_D002277 NONE adriamycin_2\NN\1740|early|adjuvant|carcinoma|. (l_nmod) carcinoma_6\NN\14239918|in|superficial|bladder
8387218
D016049_D064420 NONE didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D016049_D064420 NONE ddi_7\NN\2725367|(|) (r_appos) didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D016049_D015658 NONE didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_nmod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D016049_D015658 NONE ddi_7\NN\2725367|(|) (r_appos) didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_nmod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D015215_D064420 NONE zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D015215_D064420 NONE azt_17\NN\3834836|(|) (r_appos) zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D015215_D015658 NONE zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D015215_D015658 NONE azt_17\NN\3834836|(|) (r_appos) zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D016049_D018149 CID didanosine_24\NN\2725367| (r_dobj) ceasing_23\VBG\1740|on|didanosine (r_advcl) returned_19\VBD\1835496|normal|ceasing (r_conj) mild_12\JJ\1740|these|were|,|require|and|returned|. (r_conj) developed_2\VBD\1753788|patients|curves|but|mild (l_dobj) curves_5\NNS\13863771|glucose|tolerance|characteristic
D016049_D003920 NONE didanosine_24\NN\2725367| (r_dobj) ceasing_23\VBG\1740|on|didanosine (r_advcl) returned_19\VBD\1835496|normal|ceasing (r_conj) mild_12\JJ\1740|these|were|,|require|and|returned|. (r_conj) developed_2\VBD\1753788|patients|curves|but|mild (l_dobj) curves_5\NNS\13863771|glucose|tolerance|characteristic (l_amod) characteristic_6\JJ\1740|diabetes (l_nmod) diabetes_8\NN\14075199|of
220563
C023470_D010523 CID maleate_1\NN\2718811|perhexiline|and|neuropathy (l_conj) neuropathy_4\NN\14204950|peripheral|.
C023470_D010523 CID maleate_12\NN\2718811|with|perhexiline|,|drug (r_nmod) therapy_9\NN\657604|of|maleate (r_nmod) complication_7\NN\1073995|as|a|therapy (r_nmod) noted_4\VBN\1009240|neuropathy|has|been|complication|treatment|. (l_nsubjpass) neuropathy_1\NN\14204950|peripheral
C023470_D000787 NONE maleate_12\NN\2718811|with|perhexiline|,|drug (r_nmod) therapy_9\NN\657604|of|maleate (r_nmod) complication_7\NN\1073995|as|a|therapy (r_nmod) noted_4\VBN\1009240|neuropathy|has|been|complication|treatment|. (l_nmod) treatment_33\NN\654885|for|the|prophylactic|pectoris (l_nmod) pectoris_36\NN\1740|of|angina
8170551
D000086_D053040 NONE acetazolamide-induced_0\JJ\1740| (r_amod) nephrolithiasis_1\NN\14115914|acetazolamide-induced|:|implications
D000086_D053040 NONE acetazolamide_5\NN\1740|of (r_nmod) complication_3\NN\1073995|nephrolithiasis|is|a|acetazolamide|but|preclude|. (l_nsubj) nephrolithiasis_0\NN\14115914|
D000086_D009468 NONE acetazolamide-induced_0\JJ\1740| (r_amod) nephrolithiasis_1\NN\14115914|acetazolamide-induced|:|implications (l_appos) implications_3\NNS\5774614|treatment|. (l_nmod) treatment_5\NN\654885|for|disorders (l_nmod) disorders_8\NNS\14034177|of|neuromuscular
D000086_D007669 CID acetazolamide_3\NN\1740|on|% (r_nmod) patients_1\NNS\9898892|three|acetazolamide (r_nsubj) developed_8\VBD\1753788|patients|calculi|. (l_dobj) calculi_10\NNS\9416076|renal
19803309
D013390_D009224 NONE suxamethonium_27\NN\1740|of|intravenous (r_nmod) dose_24\NN\3740161|following|a|standard|suxamethonium|induction (r_nmod) developed_16\VBD\1753788|who|spasm|dose (r_acl:relcl) primigravida_13\NN\10144838|in|a|24-year-old|healthy|,|developed (r_nmod) case_4\NN\7283608|an|undiagnosed|congenita|primigravida (l_nmod) congenita_7\NN\1740|of|myotonia
D013390_D014313 CID suxamethonium_27\NN\1740|of|intravenous (r_nmod) dose_24\NN\3740161|following|a|standard|suxamethonium|induction (r_nmod) developed_16\VBD\1753788|who|spasm|dose (l_dobj) spasm_20\NN\14299637|threatening|masseter
11426838
-1_D012640 NONE bd1018_8\NN\1740|with|,|bd1063|,|or|lr132 (r_nmod) pre-treatment_4\NN\1740|mice|bd1018 (r_nsubj) attenuated_15\VBD\224901|studies|,|pre-treatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
-1_D012640 NONE lr132_13\NN\1740| (r_conj) bd1018_8\NN\1740|with|,|bd1063|,|or|lr132 (r_nmod) pre-treatment_4\NN\1740|mice|bd1018 (r_nsubj) attenuated_15\VBD\224901|studies|,|pre-treatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
C093337_D012640 NONE bd1063_10\NN\1740| (r_conj) bd1018_8\NN\1740|with|,|bd1063|,|or|lr132 (r_nmod) pre-treatment_4\NN\1740|mice|bd1018 (r_nsubj) attenuated_15\VBD\224901|studies|,|pre-treatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
D003042_D012640 CID cocaine-induced_16\JJ\1740| (r_amod) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
D003042_D012640 CID anti-cocaine_7\JJ\1740| (r_amod) effects_8\NNS\13245626|the|anti-cocaine|ligands (r_nsubj) involved_13\VBD\2676054|that|effects|antagonism (r_acl) hypothesis_4\NN\7162194|the|involved (r_dobj) validate_2\VB\803325|to|further|hypothesis (r_advcl) shown_27\VBN\2137132|validate|,|oligodeoxynucleotide|was|also|attenuate|. (l_xcomp) attenuate_30\VB\224901|to|significantly|effects (l_dobj) effects_36\NNS\13245626|the|convulsive|cocaine (l_amod) convulsive_32\JJ\1740|and|locomotor|stimulatory
D003042_D012640 CID cocaine_38\NN\3492717|of (r_nmod) effects_36\NNS\13245626|the|convulsive|cocaine (l_amod) convulsive_32\JJ\1740|and|locomotor|stimulatory
C050232_D064420 NONE di-o-tolylguanidine_16\NN\1740|dtg|and|agonist (r_dep) agonist_15\NN\9613191|the|well-characterized|sigma|receptor|di-o-tolylguanidine|each (r_nsubj) worsened_31\VBD\146138|contrast|,|agonist|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
C050232_D064420 NONE dtg_18\NN\1740|(|) (r_appos) di-o-tolylguanidine_16\NN\1740|dtg|and|agonist (r_dep) agonist_15\NN\9613191|the|well-characterized|sigma|receptor|di-o-tolylguanidine|each (r_nsubj) worsened_31\VBD\146138|contrast|,|agonist|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
-1_D064420 NONE bd1031_26\NN\1740|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_dep) agonist_25\NN\9613191|the|novel|sigma|receptor|bd1031 (r_conj) di-o-tolylguanidine_16\NN\1740|dtg|and|agonist (r_dep) agonist_15\NN\9613191|the|well-characterized|sigma|receptor|di-o-tolylguanidine|each (r_nsubj) worsened_31\VBD\146138|contrast|,|agonist|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
-1_D064420 NONE 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_28\NN\1740|(|) (r_appos) bd1031_26\NN\1740|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_dep) agonist_25\NN\9613191|the|novel|sigma|receptor|bd1031 (r_conj) di-o-tolylguanidine_16\NN\1740|dtg|and|agonist (r_dep) agonist_15\NN\9613191|the|well-characterized|sigma|receptor|di-o-tolylguanidine|each (r_nsubj) worsened_31\VBD\146138|contrast|,|agonist|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
D003042_D064420 NONE cocaine_36\NN\3492717|of (r_nmod) toxicity_34\NN\13576101|the|behavioral|cocaine
D009838_D012640 NONE oligodeoxynucleotide_21\NN\1740|an|antisense|receptors (r_nsubjpass) shown_27\VBN\2137132|validate|,|oligodeoxynucleotide|was|also|attenuate|. (l_xcomp) attenuate_30\VB\224901|to|significantly|effects (l_dobj) effects_36\NNS\13245626|the|convulsive|cocaine (l_amod) convulsive_32\JJ\1740|and|locomotor|stimulatory
9869257
C087567_D000647 NONE pg-9_6\NN\1740|mg/kg|,|administered|, (r_nsubj) prevented_24\VBD\1740|test|,|pg-9|amnesia|. (l_dobj) amnesia_25\NN\5669934|induced
C087567_D000647 NONE pg-9_6\NN\1740|microg (r_nsubj) able_19\JJ\1740|conditions|,|pg-9|was|also|prevent|,|demonstrating|. (l_xcomp) prevent_21\VB\1740|to|amnesia (l_dobj) amnesia_23\NN\5669934|antimuscarine-induced
D012601_D000647 CID scopolamine_34\NN\14712692|by|both|the|drug|and|s-(-)-et-126 (r_nmod) induced_26\VBN\1627355|scopolamine (r_acl) amnesia_25\NN\5669934|induced
C098725_D000647 CID s-(-)-et-126_39\NN\1740|the|antagonist (r_conj) scopolamine_34\NN\14712692|by|both|the|drug|and|s-(-)-et-126 (r_nmod) induced_26\VBN\1627355|scopolamine (r_acl) amnesia_25\NN\5669934|induced
19759529
D004298_D012559 NONE dopamine_8\NN\14807737| (r_compound) neurotransmission_9\NN\1740|in|dopamine (r_nmod) dysfunction_6\NN\14204950|with|neurotransmission (r_nmod) associated_4\VBN\628491|schizophrenia|has|been|initially|dysfunction|. (l_nsubjpass) schizophrenia_0\NN\14398067|
D018698_D012559 NONE glutamate_8\NN\15010703| (r_compound) receptor_13\NN\5225602|of|the|glutamate|n-methyl-d-aspartate|nmda|) (r_nmod) antagonists_5\NNS\7846|receptor (r_nsubj) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
D016202_D012559 NONE n-methyl-d-aspartate_9\NN\1740| (r_compound) receptor_13\NN\5225602|of|the|glutamate|n-methyl-d-aspartate|nmda|) (r_nmod) antagonists_5\NNS\7846|receptor (r_nsubj) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
D016202_D012559 NONE nmda_11\NN\1740|( (r_compound) receptor_13\NN\5225602|of|the|glutamate|n-methyl-d-aspartate|nmda|) (r_nmod) antagonists_5\NNS\7846|receptor (r_nsubj) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
D016202_D012559 NONE nmda_33\NN\1740| (r_compound) receptor_34\NN\5225602|via|its|nmda (r_nmod) dysfunctioning_26\NN\1740|of|a|system|receptor (r_nmod) idea_23\NN\5809192|to|the|dysfunctioning (r_nmod) led_20\VBN\1752884|however|,|observation|has|idea|. (l_nsubj) observation_3\NN\996969|the|produce (l_acl) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
-1_D006948 NONE ssr103800_10\NN\1740|of (r_nmod) properties_8\NNS\32613|the|potential|antipsychotic-like|ssr103800 (r_dobj) investigating_4\VBG\644583|at|properties|,|focus (l_nmod) focus_15\NN\5704266|with|a|particular|models (l_nmod) models_17\NNS\5888929|on|hyperactivity|,|involving (l_nmod) hyperactivity_19\NN\14052403|of
-1_D006948 NONE ssr103800_3\NN\1740|p.o. (r_nsubj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|and|reversed (l_dobj) hyperactivity_12\NN\14052403|induced
-1_D006948 NONE ssr103800_3\NN\1740|p.o. (r_nsubj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|and|reversed (l_conj) reversed_24\VBD\109660|partially|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|spontaneous|mice
-1_D006948 NONE ssr103800_3\NN\1740| (r_nsubj) failed_4\VBD\1798936|contrast|,|ssr103800|affect|. (l_xcomp) affect_6\VB\126264|to|hyperactivity|or|observed (l_dobj) hyperactivity_7\NN\14052403|induced
D000661_D006948 CID amphetamine_28\NN\3248958|(|ie|,|and|mk-801|) (r_dep) challenge_24\NN\13927383|either|drug|amphetamine|or|mice (r_dobj) involving_21\VBG\2676054|challenge (r_acl) models_17\NNS\5888929|on|hyperactivity|,|involving (l_nmod) hyperactivity_19\NN\14052403|of
D000661_D006948 CID amphetamine_10\NN\3248958|by (r_nmod) induced_8\VBN\1627355|amphetamine (r_acl) hyperactivity_7\NN\14052403|induced
D016291_D006948 CID mk-801_30\NN\1740| (r_conj) amphetamine_28\NN\3248958|(|ie|,|and|mk-801|) (r_dep) challenge_24\NN\13927383|either|drug|amphetamine|or|mice (r_dobj) involving_21\VBG\2676054|challenge (r_acl) models_17\NNS\5888929|on|hyperactivity|,|involving (l_nmod) hyperactivity_19\NN\14052403|of
D016291_D006948 CID mk-801_21\NN\1740| (r_appos) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801 (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced
D016291_D006948 CID mk-801_21\NN\1740| (r_appos) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801 (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced (r_dobj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|and|reversed (l_conj) reversed_24\VBD\109660|partially|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|spontaneous|mice
D016202_D006948 NONE nmda_38\NN\1740| (r_compound) nr1(neo-/-_39\JJ\1740|(|ie|,|nmda|) (r_appos) mice_34\NNS\2329401|transgenic|nr1(neo-/-|and|dat(-/-|) (r_conj) challenge_24\NN\13927383|either|drug|amphetamine|or|mice (r_dobj) involving_21\VBG\2676054|challenge (r_acl) models_17\NNS\5888929|on|hyperactivity|,|involving (l_nmod) hyperactivity_19\NN\14052403|of
D016202_D006948 NONE nmda_17\NN\1740| (r_compound) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801 (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced
D016202_D006948 NONE nmda_17\NN\1740| (r_compound) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801 (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced (r_dobj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|and|reversed (l_conj) reversed_24\VBD\109660|partially|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|spontaneous|mice
D016202_D006948 NONE nmda_28\NN\1740|nr1(neo-/- (r_compound) mice_31\NNS\2329401|of|nmda (r_nmod) hyperactivity_26\NN\14052403|spontaneous|mice (r_dobj) reversed_24\VBD\109660|partially|hyperactivity (r_conj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|and|reversed (l_dobj) hyperactivity_12\NN\14052403|induced
D016202_D006948 NONE nmda_28\NN\1740|nr1(neo-/- (r_compound) mice_31\NNS\2329401|of|nmda (r_nmod) hyperactivity_26\NN\14052403|spontaneous|mice
D004298_D006948 NONE dopamine_15\NN\14807737| (r_compound) transporter_16\NN\4490091|dopamine|dat(-/- (r_compound) mice_22\NNS\2329401|in|transporter|)|knockout|p.o. (r_nmod) observed_13\VBN\2163746|naturally|mice (r_conj) affect_6\VB\126264|to|hyperactivity|or|observed (l_dobj) hyperactivity_7\NN\14052403|induced
D006220_D006948 NONE haloperidol_5\NN\3713736|(|) (r_dep) classical_3\JJ\1740|both|haloperidol|and|atypical (r_amod) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
C076029_D006948 NONE olanzapine_10\NN\1740|(|,|clozapine|and|aripiprazole|) (r_dep) atypical_8\JJ\1740|olanzapine (r_conj) classical_3\JJ\1740|both|haloperidol|and|atypical (r_amod) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
D003024_D006948 NONE clozapine_12\NN\3713736| (r_conj) olanzapine_10\NN\1740|(|,|clozapine|and|aripiprazole|) (r_dep) atypical_8\JJ\1740|olanzapine (r_conj) classical_3\JJ\1740|both|haloperidol|and|atypical (r_amod) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
C094645_D006948 NONE aripiprazole_14\NN\1740| (r_conj) olanzapine_10\NN\1740|(|,|clozapine|and|aripiprazole|) (r_dep) atypical_8\JJ\1740|olanzapine (r_conj) classical_3\JJ\1740|both|haloperidol|and|atypical (r_amod) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
-1_D002375 NONE ssr103800_6\NN\1740| (r_nsubj) produce_9\VB\1617192|however|,|latter|,|ssr103800|did|not|catalepsy|p.o.|show|. (l_dobj) catalepsy_10\NN\14023236|retention
-1_D002375 NONE ssr103800_32\NN\1740| (r_appos) inhibitor_30\NN\20090|the|glyt1|,|ssr103800|, (r_nsubj) produces_34\VBZ\1617192|that|inhibitor|effects|,|and|has (r_ccomp) show_26\VBP\2137132|together|findings|produces (r_advcl) produce_9\VB\1617192|however|,|latter|,|ssr103800|did|not|catalepsy|p.o.|show|. (l_dobj) catalepsy_10\NN\14023236|retention
20520283
C522667_D012559 NONE asenapine_4\NN\1740|of (r_nmod) efficacy_0\NN\5199286|and|safety|asenapine|trial|. (l_nmod) trial_10\NN\786195|in|a|placebo-|patients (l_nmod) patients_12\NNS\9898892|in|exacerbation (l_nmod) exacerbation_15\NN\374224|with|acute|schizophrenia (l_nmod) schizophrenia_17\NN\14398067|of
C522667_D012559 NONE asenapine_0\NN\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|adults|treatment|. (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes
C522667_D012559 NONE asenapine_18\NN\1740|with|mg|twice|daily|bid|) (r_nmod) treatment_16\NN\654885|to|fixed-dose|asenapine|,|asenapine (r_nmod) assigned_13\VBN\2475922|trial|,|patients|were|randomly|treatment|. (l_nsubjpass) patients_7\NNS\9898892|458|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|with|acute
C522667_D012559 NONE asenapine_28\NN\1740|bid|,|placebo|,|or|haloperidol (r_conj) treatment_16\NN\654885|to|fixed-dose|asenapine|,|asenapine (r_nmod) assigned_13\VBN\2475922|trial|,|patients|were|randomly|treatment|. (l_nsubjpass) patients_7\NNS\9898892|458|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|with|acute
D006220_D012559 NONE haloperidol-controlled_9\NN\1740| (r_conj) placebo-_7\NN\1740|and|haloperidol-controlled (r_nummod) trial_10\NN\786195|in|a|placebo-|patients (l_nmod) patients_12\NNS\9898892|in|exacerbation (l_nmod) exacerbation_15\NN\374224|with|acute|schizophrenia (l_nmod) schizophrenia_17\NN\14398067|of
D006220_D012559 NONE haloperidol_37\NN\3713736|bid|(|verify (r_conj) asenapine_28\NN\1740|bid|,|placebo|,|or|haloperidol (r_conj) treatment_16\NN\654885|to|fixed-dose|asenapine|,|asenapine (r_nmod) assigned_13\VBN\2475922|trial|,|patients|were|randomly|treatment|. (l_nsubjpass) patients_7\NNS\9898892|458|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|with|acute
C522667_D001714 NONE asenapine_0\NN\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|adults|treatment|. (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes (l_conj) episodes_21\NNS\7283608|of|manic|associated (l_amod) manic_18\JJ\1740|or|mixed
C522667_D001714 NONE asenapine_0\NN\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|adults|treatment|. (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes (l_conj) episodes_21\NNS\7283608|of|manic|associated (l_acl) associated_22\VBN\628491|disorder (l_nmod) disorder_26\NN\14034177|with|bipolar|i|with|features
C522667_D011618 NONE asenapine_0\NN\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|adults|treatment|. (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes (l_conj) episodes_21\NNS\7283608|of|manic|associated (l_acl) associated_22\VBN\628491|disorder (l_nmod) disorder_26\NN\14034177|with|bipolar|i|with|features (l_nmod) features_31\NNS\5849040|psychotic (l_amod) psychotic_30\JJ\1740|
C522667_D001480 CID asenapine_21\NN\1740|of|the (r_nmod) %_8\NN\1740|in|15|and|%|,|%|,|and|%|asenapine|groups (r_nmod) occurred_5\VBD\2623529|symptoms|%|,|respectively|. (l_nsubj) symptoms_1\NNS\5823932|extrapyramidal|reported
C522667_D001480 CID asenapine_9\NN\1740|with|and|haloperidol (r_nmod) similar_7\JJ\1740|that|efficacy|was|asenapine (r_ccomp) indicated_3\VBD\952524|analyses|similar (r_ccomp) seen_16\VBN\2106506|indicated|;|contrasts|were|aes|. (l_nmod) aes_18\NNS\1740|in|,|symptoms (l_appos) symptoms_22\NNS\5823932|especially|extrapyramidal
D006220_D001480 CID haloperidol_29\NN\3713736| (r_conj) bid_27\NN\7160883|at|mg|,|haloperidol|,|and|placebo (r_compound) groups_33\NNS\2137|bid (r_appos) %_8\NN\1740|in|15|and|%|,|%|,|and|%|asenapine|groups (r_nmod) occurred_5\VBD\2623529|symptoms|%|,|respectively|. (l_nsubj) symptoms_1\NNS\5823932|extrapyramidal|reported
D006220_D001480 CID haloperidol_11\NN\3713736| (r_conj) asenapine_9\NN\1740|with|and|haloperidol (r_nmod) similar_7\JJ\1740|that|efficacy|was|asenapine (r_ccomp) indicated_3\VBD\952524|analyses|similar (r_ccomp) seen_16\VBN\2106506|indicated|;|contrasts|were|aes|. (l_nmod) aes_18\NNS\1740|in|,|symptoms (l_appos) symptoms_22\NNS\5823932|especially|extrapyramidal
16167916
D020849_D054556 CID raloxifene_13\NN\1740| (r_compound) treatment_14\NN\654885|due|raloxifene (r_nmod) risk_7\NN\14541044|the|increased|thromboembolism|treatment (l_nmod) thromboembolism_10\NN\14100769|of|venous
12090760
D015215_D000740 CID azidothymidine-induced_9\JJ\1740| (r_amod) anemia_10\NN\14189204|with|azidothymidine-induced
D015215_D000740 CID azidothymidine_0\NN\1740| (r_compound) (azt)-induced_1\NN\1740|azidothymidine (r_compound) anemia_2\NN\14189204|(azt)-induced|mice
D015215_D000740 CID (azt)-induced_1\NN\1740|azidothymidine (r_compound) anemia_2\NN\14189204|(azt)-induced|mice
7083920
D000638_D006327 CID amiodarone_11\NN\2715941| (r_compound) treatment_12\NN\654885|under|amiodarone|tachycardia (r_nmod) occurring_9\VBG\2623529|treatment|patient (r_acl) block_8\NN\21939|of|a|reversible|intra-hisian|occurring
D000638_D013617 NONE amiodarone_11\NN\2715941| (r_compound) treatment_12\NN\654885|under|amiodarone|tachycardia (l_nmod) tachycardia_15\NN\14110674|for|atrial
D000638_D006345 NONE amiodarone_11\NN\2715941| (r_compound) treatment_12\NN\654885|under|amiodarone|tachycardia (r_nmod) occurring_9\VBG\2623529|treatment|patient (l_nmod) patient_18\NN\9898892|in|a|abnormalities (l_nmod) abnormalities_23\NNS\14034177|without|clear|intraventricular|conduction
D000638_D001282 NONE amiodarone_3\NN\2715941| (r_compound) discontinuation_4\NN\209943|days|amiodarone (r_nsubj) showed_9\VBD\2137132|discontinuation|,|electrograms|flutter|delay|. (l_dobj) flutter_11\NN\331950|atrial
18439803
C108761_D012640 NONE n-(2-propylpentanoyl)urea_3\NN\1740| (r_compound) neurotransmitters_8\NNS\14807410|of|n-(2-propylpentanoyl)urea|on|hippocampal|amino|acid|seizure (l_nmod) seizure_11\NN\14081375|in|pilocarpine-induced|rats
C108761_D012640 NONE vpu_0\NN\1740| (r_nsubj) potent_3\JJ\1740|vpu|was|more|vpa|,|exhibiting|mg/kg|. (l_advcl) exhibiting_7\VBG\2632167|dose (l_dobj) dose_11\NN\3740161|the|median|effective|ed(50|)|mg/kg|protecting (l_advcl) protecting_20\VBG\1127795|in|rats|seizure (l_nmod) seizure_24\NN\14081375|against|pilocarpine-induced
C108761_D012640 NONE vpu_5\NN\1740|and|vpa (r_nsubj) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\NN\14081375|against|pilocarpine-induced
C108761_D012640 NONE vpu_8\NN\1740| (r_nsubj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_acl) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|least|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D000596_D012640 NONE acid_7\NN\14818238| (r_compound) neurotransmitters_8\NNS\14807410|of|n-(2-propylpentanoyl)urea|on|hippocampal|amino|acid|seizure (l_nmod) seizure_11\NN\14081375|in|pilocarpine-induced|rats
D000596_D012640 NONE acid_24\NN\14818238| (r_compound) neurotransmitters_25\NNS\14807410|of|inhibitory|amino|acid (r_nmod) reduction_20\NN\351485|the|neurotransmitters (r_nsubj) minor_28\JJ\1740|that|reduction|was|comparatively|and|offset (r_ccomp) suggested_17\VBN\1010118|finding|it|is|minor|. (l_nmod) finding_3\NN\43195|based|on|the|protect (l_acl) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\NN\14081375|against|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_10\JJ\1740| (r_amod) seizure_11\NN\14081375|in|pilocarpine-induced|rats
D010862_D012640 CID pilocarpine-induced_23\JJ\1740| (r_amod) seizure_24\NN\14081375|against|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_13\JJ\1740| (r_amod) seizure_14\NN\14081375|against|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_12\JJ\1740| (r_amod) increases_13\NNS\13576355|pilocarpine-induced|glutamate (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_acl) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|least|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D010862_D012640 CID pilocarpine-induced_31\JJ\1740| (r_amod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D014635_D012640 NONE vpa_5\NN\1740|than (r_nmod) potent_3\JJ\1740|vpu|was|more|vpa|,|exhibiting|mg/kg|. (l_advcl) exhibiting_7\VBG\2632167|dose (l_dobj) dose_11\NN\3740161|the|median|effective|ed(50|)|mg/kg|protecting (l_advcl) protecting_20\VBG\1127795|in|rats|seizure (l_nmod) seizure_24\NN\14081375|against|pilocarpine-induced
D014635_D012640 NONE vpa_30\NN\1740|for (r_nmod) value_28\NN\5856066|the|corresponding|vpa (r_nsubj) mg/kg_33\NN\1740|whereas|value|was|322 (r_dep) potent_3\JJ\1740|vpu|was|more|vpa|,|exhibiting|mg/kg|. (l_advcl) exhibiting_7\VBG\2632167|dose (l_dobj) dose_11\NN\3740161|the|median|effective|ed(50|)|mg/kg|protecting (l_advcl) protecting_20\VBG\1127795|in|rats|seizure (l_nmod) seizure_24\NN\14081375|against|pilocarpine-induced
D014635_D012640 NONE vpa_7\NN\1740| (r_conj) vpu_5\NN\1740|and|vpa (r_nsubj) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\NN\14081375|against|pilocarpine-induced
D014635_D012640 NONE vpa_3\NN\1740|like (r_nmod) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|least|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D018698_D012640 NONE glutamate_36\NN\15010703|of|and|aspartate (r_nmod) reduction_34\NN\351485|by|a|pronounced|glutamate (r_nmod) offset_30\VBN\2673134|reduction (r_conj) minor_28\JJ\1740|that|reduction|was|comparatively|and|offset (r_ccomp) suggested_17\VBN\1010118|finding|it|is|minor|. (l_nmod) finding_3\NN\43195|based|on|the|protect (l_acl) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\NN\14081375|against|pilocarpine-induced
D018698_D012640 NONE glutamate_15\NN\15010703|in|and|aspartate (r_nmod) increases_13\NNS\13576355|pilocarpine-induced|glutamate (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_acl) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|least|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D001224_D012640 NONE aspartate_38\NN\1740| (r_conj) glutamate_36\NN\15010703|of|and|aspartate (r_nmod) reduction_34\NN\351485|by|a|pronounced|glutamate (r_nmod) offset_30\VBN\2673134|reduction (r_conj) minor_28\JJ\1740|that|reduction|was|comparatively|and|offset (r_ccomp) suggested_17\VBN\1010118|finding|it|is|minor|. (l_nmod) finding_3\NN\43195|based|on|the|protect (l_acl) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\NN\14081375|against|pilocarpine-induced
D001224_D012640 NONE aspartate_17\NN\1740| (r_conj) glutamate_15\NN\15010703|in|and|aspartate (r_nmod) increases_13\NNS\13576355|pilocarpine-induced|glutamate (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_acl) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|least|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
7248170
D010634_D006529 CID phenobarbitone-induced_0\JJ\1740| (r_amod) enlargement_1\NN\363260|phenobarbitone-induced|liver|:|relationship (l_nmod) liver_4\NN\5298729|of|the|rat
D010634_D006529 CID phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (r_nsubjpass) increased_61\VBN\169651|yield|was|%|%|giving|. (l_advcl) giving_69\VBG\2327200|by|dose (l_dobj) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (l_nmod) peak_81\NN\13758296|at|the|enlargement (l_nmod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D010634_D006529 CID phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D010634_D005355 NONE phenobarbitone-induced_0\JJ\1740| (r_amod) enlargement_1\NN\363260|phenobarbitone-induced|liver|:|relationship (l_appos) relationship_10\NN\31921|its|cirrhosis|. (l_nmod) cirrhosis_14\NN\14116321|to|carbon|tetrachloride-induced
D002251_D006529 NONE tetrachloride-induced_13\JJ\1740| (r_amod) cirrhosis_14\NN\14116321|to|carbon|tetrachloride-induced (r_nmod) relationship_10\NN\31921|its|cirrhosis|. (r_appos) enlargement_1\NN\363260|phenobarbitone-induced|liver|:|relationship (l_nmod) liver_4\NN\5298729|of|the|rat
D002251_D006529 NONE tetrachloride_53\NN\14818238|of|carbon (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (r_nsubjpass) increased_61\VBN\169651|yield|was|%|%|giving|. (l_advcl) giving_69\VBG\2327200|by|dose (l_dobj) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (l_nmod) peak_81\NN\13758296|at|the|enlargement (l_nmod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D002251_D006529 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (l_nmod) peak_81\NN\13758296|at|the|enlargement (l_nmod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D002251_D005355 NONE tetrachloride-induced_13\JJ\1740| (r_amod) cirrhosis_14\NN\14116321|to|carbon|tetrachloride-induced
D002251_D008103 CID tetrachloride_53\NN\14818238|of|carbon (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_nmod) liver_7\NN\5298729|of|the
D002251_D008103 CID tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_nmod) liver_7\NN\5298729|of|the
D002251_D001201 NONE tetrachloride_53\NN\14818238|of|carbon (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) ascites_20\NN\14204950|greater|,|albumin
D002251_D001201 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) ascites_20\NN\14204950|greater|,|albumin
D002251_D013163 NONE tetrachloride_53\NN\14818238|of|carbon (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) splenomegaly_33\NN\14366759|normal
D002251_D013163 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) splenomegaly_33\NN\14366759|normal
D002251_D001284 NONE tetrachloride_53\NN\14818238|of|carbon (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) atrophy_42\NN\14299637|testicular|weight
D002251_D001284 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) atrophy_42\NN\14299637|testicular|weight
D010634_D008103 CID phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_nmod) liver_7\NN\5298729|of|the
D010634_D008103 CID phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_nmod) liver_7\NN\5298729|of|the
D010634_D001201 NONE phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) ascites_20\NN\14204950|greater|,|albumin
D010634_D001201 NONE phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) ascites_20\NN\14204950|greater|,|albumin
D010634_D013163 NONE phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) splenomegaly_33\NN\14366759|normal
D010634_D013163 NONE phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) splenomegaly_33\NN\14366759|normal
D010634_D001284 NONE phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) doses_50\NNS\3740161|after|12|tetrachloride|given (r_nmod) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) atrophy_42\NN\14299637|testicular|weight
D010634_D001284 NONE phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|yield|was|%|%|giving|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis|doses (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver|defined (l_acl) defined_9\VBN\2604760|(|liver (l_nmod) liver_15\NN\5298729|as|a|shrunken|finely|nodular|histology|,|ascites|,|splenomegaly|,|and|atrophy|) (l_conj) atrophy_42\NN\14299637|testicular|weight
2234245
D003676_D014786 NONE desferrioxamine_8\NN\1740| (r_dobj) receiving_7\VBG\2210855|desferrioxamine (r_acl) patients_6\NNS\9898892|in|hemodialyzed|receiving (r_nmod) toxicity_3\NN\13576101|ocular|patients|.
D003676_D014786 NONE desferrioxamine_10\NN\1740|bw/3 (r_dobj) receiving_9\VBG\2210855|desferrioxamine|weekly|) (r_acl) patients_8\NNS\9898892|41|hemodialyzed|receiving|time (r_nsubjpass) monitored_25\VBN\2169352|period|patients|were|detection|. (l_nmod) detection_27\NN\5708432|for|toxicity (l_nmod) toxicity_30\NN\13576101|of|audiovisual
D003676_D014786 NONE desferrioxamine_15\NN\1740| (r_dobj) receiving_14\VBG\2210855|desferrioxamine (r_acl) patients_13\NNS\9898892|in|hemodialyzed|receiving (r_nmod) complication_10\NN\1073995|that|toxicity|is|not|an|infrequent|patients (l_nsubj) toxicity_5\NN\13576101|audiovisual
D003676_D006311 NONE desferrioxamine_8\NN\1740| (r_dobj) receiving_7\VBG\2210855|desferrioxamine (r_acl) patients_6\NNS\9898892|in|hemodialyzed|receiving (r_nmod) toxicity_3\NN\13576101|ocular|patients|.
D003676_D006311 NONE desferrioxamine_10\NN\1740|bw/3 (r_dobj) receiving_9\VBG\2210855|desferrioxamine|weekly|) (r_acl) patients_8\NNS\9898892|41|hemodialyzed|receiving|time (r_nsubjpass) monitored_25\VBN\2169352|period|patients|were|detection|. (l_nmod) detection_27\NN\5708432|for|toxicity (l_nmod) toxicity_30\NN\13576101|of|audiovisual
D003676_D006311 NONE desferrioxamine_15\NN\1740| (r_dobj) receiving_14\VBG\2210855|desferrioxamine (r_acl) patients_13\NNS\9898892|in|hemodialyzed|receiving (r_nmod) complication_10\NN\1073995|that|toxicity|is|not|an|infrequent|patients (l_nsubj) toxicity_5\NN\13576101|audiovisual
D003676_D034381 NONE desferrioxamine_0\NN\1740| (r_compound) withdrawal_1\NN\7206096|desferrioxamine (r_nsubj) resulted_2\VBD\2633881|withdrawal|recovery|. (l_nmod) recovery_6\NN\7357388|in|a|complete|function|patient|and|recovery|,|and|reversal (l_conj) reversal_22\NN\199130|a|complete|loss|patients|and|recovery (l_nmod) loss_25\NN\13252973|of|hearing
D003676_D064420 NONE desferrioxamine_10\NN\1740|of (r_nmod) doses_8\NNS\3740161|the|higher|desferrioxamine (r_dobj) receiving_5\VBG\2210855|doses (r_acl) patients_4\NNS\9898892|in|receiving (r_nmod) appeared_2\VBD\2604760|toxicity|patients|or|coincided|. (l_nsubj) toxicity_1\NN\13576101|this
-1_D064420 NONE aluminium_19\NN\14625458| (r_conj) ferritin_17\NN\14728724|or|aluminium (r_compound) levels_21\NNS\4916342|of|ferritin|serum (r_nmod) normalization_15\NN\1123598|with|the|levels (r_nmod) coincided_12\VBD\2604477|normalization (r_conj) appeared_2\VBD\2604760|toxicity|patients|or|coincided|. (l_nsubj) toxicity_1\NN\13576101|this
12574103
D003907_D006973 CID dexamethasone_1\NN\2721538|prenatal (r_nsubj) programs_2\VBZ\794981|dexamethasone|hypertension|. (l_dobj) hypertension_3\NN\14057371|and|injury|rat
D003907_D006973 CID dexamethasone_11\NN\2721538|prenatal (r_nsubj) programmed_12\VBD\794981|if|dexamethasone|increase (l_dobj) increase_15\NN\13576355|a|progressive|pressure|rats (l_nmod) pressure_18\NN\11419404|in|blood|and|injury
D003907_D006973 CID dexamethasone_5\NN\2721538|prenatal (r_dobj) received_3\VBD\2210855|that|dexamethasone|days (r_acl:relcl) rats_1\NNS\2329401|male|received (r_nsubj) had_22\VBD\2108377|rats|pressures|months (l_dobj) pressures_25\NNS\11419404|elevated|blood
D003907_D006973 CID dexamethasone_5\NN\2721538|prenatal|rats (r_nsubj) results_8\VBZ\2633881|that|dexamethasone|reduction|administered (l_nmod) reduction_11\NN\351485|in|a|number (l_nmod) number_14\NN\5107765|in|glomerular|,|glomerulosclerosis (l_conj) glomerulosclerosis_16\NN\1740|,|and|hypertension (l_conj) hypertension_19\NN\14057371|
D003907_D007674 CID dexamethasone_1\NN\2721538|prenatal (r_nsubj) programs_2\VBZ\794981|dexamethasone|hypertension|. (l_dobj) hypertension_3\NN\14057371|and|injury|rat (l_conj) injury_6\NN\14052046|renal
D003907_D007674 CID dexamethasone_11\NN\2721538|prenatal (r_nsubj) programmed_12\VBD\794981|if|dexamethasone|increase (l_dobj) increase_15\NN\13576355|a|progressive|pressure|rats (l_nmod) pressure_18\NN\11419404|in|blood|and|injury (l_conj) injury_21\NN\14052046|renal
D003907_D007674 CID dexamethasone_4\NN\2721538| (r_dobj) administered_3\VBN\2436349|dexamethasone|days (r_acl) rats_2\NNS\2329401|of|administered (r_nmod) offspring_0\NN\10235549|rats|gestation (r_nsubj) had_11\VBD\2108377|offspring|reduction|,|comparable|. (l_dobj) reduction_15\NN\351485|a|%|number|compared|527+/-509|,|p<0.05|) (l_nmod) number_18\NN\5107765|in|glomerular
D003907_D007674 CID dexamethasone_5\NN\2721538|prenatal (r_dobj) received_3\VBD\2210855|that|dexamethasone|days (r_acl:relcl) rats_1\NNS\2329401|male|received (r_nsubj) had_22\VBD\2108377|rats|pressures|months (r_ccomp) have_37\VB\2108377|had|;|group|did|not|reduction|. (l_dobj) reduction_39\NN\351485|a|number (l_nmod) number_42\NN\5107765|in|glomerular
D003907_D007674 CID dexamethasone_5\NN\2721538|prenatal|rats (r_nsubj) results_8\VBZ\2633881|that|dexamethasone|reduction|administered (l_nmod) reduction_11\NN\351485|in|a|number (l_nmod) number_14\NN\5107765|in|glomerular|,|glomerulosclerosis
D003907_D005921 NONE dexamethasone_3\NN\2721538| (r_dobj) given_2\VBN\2327200|dexamethasone|days (r_acl) rats_1\NNS\2329401|adult|given (r_nsubj) had_11\VBD\2108377|rats|glomeruli|rats|. (l_dobj) glomeruli_13\NNS\5425910|more|glomerulosclerosis (l_nmod) glomerulosclerosis_15\NN\1740|with
D003907_D005921 NONE dexamethasone_5\NN\2721538|prenatal|rats (r_nsubj) results_8\VBZ\2633881|that|dexamethasone|reduction|administered (l_nmod) reduction_11\NN\351485|in|a|number (l_nmod) number_14\NN\5107765|in|glomerular|,|glomerulosclerosis (l_conj) glomerulosclerosis_16\NN\1740|,|and|hypertension
9625142
D002443_D056486 CID ceftriaxone_11\NN\2996840|by (r_nmod) induced_9\VBN\1627355|ceftriaxone (r_acl) erythroblastocytopenia_8\NN\1740|induced (r_conj) anemia_5\NN\14189204|autoimmune|hemolytic|,|and|erythroblastocytopenia (r_conj) hepatitis_1\NN\14127211|acute|,|anemia|.
D002443_D056486 CID ceftriaxone_10\NN\2996840|oral (r_dobj) ingesting_8\VBG\597915|after|ceftriaxone (r_advcl) developed_3\VBD\1753788|man|hepatitis|ingesting|. (l_dobj) hepatitis_5\NN\14127211|acute
D002443_D000744 CID ceftriaxone_11\NN\2996840|by (r_nmod) induced_9\VBN\1627355|ceftriaxone (r_acl) erythroblastocytopenia_8\NN\1740|induced (r_conj) anemia_5\NN\14189204|autoimmune|hemolytic|,|and|erythroblastocytopenia
D002443_-1 NONE ceftriaxone_11\NN\2996840|by (r_nmod) induced_9\VBN\1627355|ceftriaxone (r_acl) erythroblastocytopenia_8\NN\1740|induced
D047090_D000744 NONE lactam_11\NN\1740| (r_compound) antibiotic_12\NN\2716205|the|beta|lactam (r_dobj) withholding_8\VBG\2212825|after|antibiotic (r_advcl) returned_4\VBD\1835496|although|transaminases|gradually|baseline|withholding (r_advcl) was_15\VBD\836236|returned|,|there|increase|. (l_attr) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia
D047090_-1 NONE lactam_11\NN\1740| (r_compound) antibiotic_12\NN\2716205|the|beta|lactam (r_dobj) withholding_8\VBG\2212825|after|antibiotic (r_advcl) returned_4\VBD\1835496|although|transaminases|gradually|baseline|withholding (r_advcl) was_15\VBD\836236|returned|,|there|increase|. (l_attr) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\1740|
D001663_D000744 NONE bilirubin_21\NN\14756039|in|serum (r_nmod) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia
D001663_-1 NONE bilirubin_21\NN\14756039|in|serum (r_nmod) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\1740|
17615423
D019821_D012206 CID simvastatin_11\NN\3676175|of|,|amiodarone|,|and|atazanavir (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|.
D019821_D012206 CID simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure
D019821_D012206 CID simvastatin_16\NN\3676175| (r_compound) metabolism_17\NN\13526110|simvastatin (r_dobj) inhibit_15\VBP\2510337|that|metabolism (r_acl:relcl) drugs_13\NNS\14778436|in|presence|of|concomitant|inhibit (r_nmod) increased_7\VBN\169651|discussion|risk|is|drugs|. (l_nsubjpass) risk_3\NN\14541044|the|rhabdomyolysis (l_nmod) rhabdomyolysis_5\NN\1740|of
D019821_D058186 CID simvastatin_11\NN\3676175|of|,|amiodarone|,|and|atazanavir (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|. (l_conj) failure_5\NN\66216|acute|renal
D019821_D058186 CID simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure (l_conj) failure_23\NN\66216|acute|renal
D000638_D012206 CID amiodarone_13\NN\2715941| (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone|,|and|atazanavir (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|.
D000638_D012206 CID amiodarone_13\NN\2715941| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure
D000638_D058186 CID amiodarone_13\NN\2715941| (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone|,|and|atazanavir (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|. (l_conj) failure_5\NN\66216|acute|renal
D000638_D058186 CID amiodarone_13\NN\2715941| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure (l_conj) failure_23\NN\66216|acute|renal
C413408_D012206 CID atazanavir_16\NN\1740| (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone|,|and|atazanavir (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|.
C413408_D012206 CID atazanavir_16\NN\1740| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure
C413408_D058186 CID atazanavir_16\NN\1740| (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone|,|and|atazanavir (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|. (l_conj) failure_5\NN\66216|acute|renal
C413408_D058186 CID atazanavir_16\NN\1740| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure (l_conj) failure_23\NN\66216|acute|renal
D019821_D015658 NONE simvastatin_0\NN\3676175|,|amiodarone|,|and|medications (l_conj) medications_11\NNS\3247620|patient|virus (l_compound) virus_10\NN\9312843|human|immunodeficiency
D000638_D015658 NONE amiodarone_2\NN\2715941| (r_conj) simvastatin_0\NN\3676175|,|amiodarone|,|and|medications (l_conj) medications_11\NNS\3247620|patient|virus (l_compound) virus_10\NN\9312843|human|immunodeficiency
6466532
D006024_D001919 NONE glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia|doses (l_nmod) bradycardia_10\NN\14110674|of|and|arrhythmias
D006024_D001919 NONE glycopyrrolate_5\NN\1740|of|5|kg-1|and|atropine (r_nmod) administration_3\NN\1133281|of|glycopyrrolate|i.v.|induction|, (r_nmod) effectiveness_1\NN\5190804|the|administration|prevent (l_acl) prevent_27\VB\1740|to|arrhythmia (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia|doses (l_conj) bradycardia_30\NN\14110674|
D006024_D001145 NONE glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia|doses (l_nmod) bradycardia_10\NN\14110674|of|and|arrhythmias (l_conj) arrhythmias_12\NNS\14103288|
D006024_D001145 NONE glycopyrrolate_5\NN\1740|of|5|kg-1|and|atropine (r_nmod) administration_3\NN\1133281|of|glycopyrrolate|i.v.|induction|, (r_nmod) effectiveness_1\NN\5190804|the|administration|prevent (l_acl) prevent_27\VB\1740|to|arrhythmia (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia|doses
D001285_D001919 NONE atropine_5\NN\14712692| (r_conj) glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia|doses (l_nmod) bradycardia_10\NN\14110674|of|and|arrhythmias
D001285_D001919 NONE atropine_12\NN\14712692|10|kg-1 (r_conj) glycopyrrolate_5\NN\1740|of|5|kg-1|and|atropine (r_nmod) administration_3\NN\1133281|of|glycopyrrolate|i.v.|induction|, (r_nmod) effectiveness_1\NN\5190804|the|administration|prevent (l_acl) prevent_27\VB\1740|to|arrhythmia (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia|doses (l_conj) bradycardia_30\NN\14110674|
D001285_D001145 NONE atropine_5\NN\14712692| (r_conj) glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia|doses (l_nmod) bradycardia_10\NN\14110674|of|and|arrhythmias (l_conj) arrhythmias_12\NNS\14103288|
D001285_D001145 NONE atropine_12\NN\14712692|10|kg-1 (r_conj) glycopyrrolate_5\NN\1740|of|5|kg-1|and|atropine (r_nmod) administration_3\NN\1133281|of|glycopyrrolate|i.v.|induction|, (r_nmod) effectiveness_1\NN\5190804|the|administration|prevent (l_acl) prevent_27\VB\1740|to|arrhythmia (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia|doses
D013390_D001919 CID suxamethonium_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) prevention_8\NN\1073995|in|the|bradycardia|doses (l_nmod) bradycardia_10\NN\14110674|of|and|arrhythmias
D013390_D001919 CID suxamethonium_35\NN\1740|of (r_nmod) doses_33\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) arrhythmia_28\NN\14103288|and|bradycardia|doses (l_conj) bradycardia_30\NN\14110674|
D013390_D001145 NONE suxamethonium_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) prevention_8\NN\1073995|in|the|bradycardia|doses (l_nmod) bradycardia_10\NN\14110674|of|and|arrhythmias (l_conj) arrhythmias_12\NNS\14103288|
D013390_D001145 NONE suxamethonium_35\NN\1740|of (r_nmod) doses_33\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) arrhythmia_28\NN\14103288|and|bradycardia|doses
9862868
D004997_D002780 CID estradiol_9\NN\14749794|ethinyl|ee (r_compound) treatment_13\NN\654885|by|estradiol (r_nmod) cholestasis_6\NN\14052403|of|intrahepatic|treatment|and|cholestasis
D004997_D002780 CID ee_11\NN\6125041|(|) (r_appos) estradiol_9\NN\14749794|ethinyl|ee (r_compound) treatment_13\NN\654885|by|estradiol (r_nmod) cholestasis_6\NN\14052403|of|intrahepatic|treatment|and|cholestasis
D004997_D001651 NONE estradiol_9\NN\14749794|ethinyl|ee (r_compound) treatment_13\NN\654885|by|estradiol (r_nmod) cholestasis_6\NN\14052403|of|intrahepatic|treatment|and|cholestasis (l_conj) cholestasis_16\NN\14052403|extrahepatic|ligation
D004997_D001651 NONE ee_11\NN\6125041|(|) (r_appos) estradiol_9\NN\14749794|ethinyl|ee (r_compound) treatment_13\NN\654885|by|estradiol (r_nmod) cholestasis_6\NN\14052403|of|intrahepatic|treatment|and|cholestasis (l_conj) cholestasis_16\NN\14052403|extrahepatic|ligation
88336
D002719_D013375 NONE chlormethiazole_6\NN\1740|of (r_nmod) doses_4\NNS\3740161|high|chlormethiazole|symptoms (l_nmod) symptoms_10\NNS\5823932|for|withdrawal
D002719_D062787 NONE chlormethiazole_6\NN\1740|of (r_nmod) doses_4\NNS\3740161|high|chlormethiazole|symptoms (r_dobj) received_2\VBD\2210855|patients|doses|,|and|took (l_conj) took_14\VBD\2367363|one|overdose|. (l_dobj) overdose_17\NN\1740|a|suicidal|nitrazepam
D002719_D062787 NONE chlormethiazole_10\NN\1740| (r_compound) intoxication_11\NN\14034177|with|chlormethiazole (r_nmod) those_8\DT\1740|of|intoxication (r_nmod) two_6\CD\13741022|those (r_conj) patient_1\NN\9898892|the|overdose|and|two (l_nmod) overdose_4\NN\1740|with|nitrazepam
D000431_D013375 NONE alcohol_8\NN\7881800| (r_compound) withdrawal_9\NN\7206096|alcohol (r_compound) symptoms_10\NNS\5823932|for|withdrawal
D000431_D062787 NONE alcohol_8\NN\7881800| (r_compound) withdrawal_9\NN\7206096|alcohol (r_compound) symptoms_10\NNS\5823932|for|withdrawal (r_nmod) doses_4\NNS\3740161|high|chlormethiazole|symptoms (r_dobj) received_2\VBD\2210855|patients|doses|,|and|took (l_conj) took_14\VBD\2367363|one|overdose|. (l_dobj) overdose_17\NN\1740|a|suicidal|nitrazepam
D009567_D013375 NONE nitrazepam_19\NN\2830852|of (r_nmod) overdose_17\NN\1740|a|suicidal|nitrazepam (r_dobj) took_14\VBD\2367363|one|overdose|. (r_conj) received_2\VBD\2210855|patients|doses|,|and|took (l_dobj) doses_4\NNS\3740161|high|chlormethiazole|symptoms (l_nmod) symptoms_10\NNS\5823932|for|withdrawal
D009567_D062787 CID nitrazepam_19\NN\2830852|of (r_nmod) overdose_17\NN\1740|a|suicidal|nitrazepam
D009567_D062787 CID nitrazepam_3\NN\2830852| (r_compound) overdose_4\NN\1740|with|nitrazepam
D009567_D003128 CID nitrazepam_3\NN\2830852| (r_compound) overdose_4\NN\1740|with|nitrazepam (r_nmod) patient_1\NN\9898892|the|overdose|and|two (r_nsubj) conformed_12\VBD\109660|patient|criteria|,|showing|. (l_nmod) criteria_15\NNS\13577171|to|the|coma (l_nmod) coma_19\NN\5678932|of|'|alpha|'
D002719_D003128 CID chlormethiazole_10\NN\1740| (r_compound) intoxication_11\NN\14034177|with|chlormethiazole (r_nmod) those_8\DT\1740|of|intoxication (r_nmod) two_6\CD\13741022|those (r_conj) patient_1\NN\9898892|the|overdose|and|two (r_nsubj) conformed_12\VBD\109660|patient|criteria|,|showing|. (l_nmod) criteria_15\NNS\13577171|to|the|coma (l_nmod) coma_19\NN\5678932|of|'|alpha|'
8701950
D016559_D000743 CID fk506_4\NN\1740|tacrolimus (r_compound) therapy_8\NN\657604|fk506 (r_dobj) complicating_3\VBG\126264|therapy (r_acl) anemia_2\NN\14189204|microangiopathic|hemolytic|complicating|.
D016559_D000743 CID tacrolimus_6\NN\1740|(|) (r_appos) fk506_4\NN\1740|tacrolimus (r_compound) therapy_8\NN\657604|fk506 (r_dobj) complicating_3\VBG\126264|therapy (r_acl) anemia_2\NN\14189204|microangiopathic|hemolytic|complicating|.
D016559_D000743 CID fk506_17\NN\1740|tacrolimus (r_compound) therapy_21\NN\657604|under|fk506 (r_nmod) describe_1\VBP\1001294|we|episodes|therapy|. (l_dobj) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha
D016559_D000743 CID fk506_17\NN\1740|tacrolimus (r_compound) therapy_21\NN\657604|under|fk506 (r_nmod) describe_1\VBP\1001294|we|episodes|therapy|. (l_dobj) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha (l_appos) maha_9\NN\9654687|(|)
D016559_D000743 CID tacrolimus_19\NN\1740|(|) (r_appos) fk506_17\NN\1740|tacrolimus (r_compound) therapy_21\NN\657604|under|fk506 (r_nmod) describe_1\VBP\1001294|we|episodes|therapy|. (l_dobj) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha
D016559_D000743 CID tacrolimus_19\NN\1740|(|) (r_appos) fk506_17\NN\1740|tacrolimus (r_compound) therapy_21\NN\657604|under|fk506 (r_nmod) describe_1\VBP\1001294|we|episodes|therapy|. (l_dobj) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha (l_appos) maha_9\NN\9654687|(|)
D016559_D000743 CID fk506_6\NN\1740|of (r_nmod) discontinuation_4\NN\209943|fk506|and|treatment (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D016559_D000743 CID fk506_6\NN\1740|of (r_nmod) reintroduction_4\NN\7217349|fk506 (r_nsubj) led_7\VBD\1752884|patient|,|reintroduction|recurrence|. (l_nmod) recurrence_10\NN\7342049|to|rapid|maha (l_nmod) maha_12\NN\9654687|of
D016559_D000743 CID fk506-associated_0\JJ\1740| (r_amod) maha_1\NN\9654687|fk506-associated
D016559_D000743 CID fk506_9\NN\1740| (r_nsubj) seem_12\VB\2604760|experience|literature|,|fk506|does|not|cross-react|. (l_xcomp) cross-react_14\VB\1740|to|a (l_nmod) a_17\NN\13649268|with|cyclosporin|cya|,|drug (l_appos) drug_24\NN\14778436|an|immuno-suppressive|known (l_acl) known_26\VBN\2110220|already|induce (l_xcomp) induce_28\VB\1627355|to|maha (l_dobj) maha_29\NN\9654687|
D000305_D000743 NONE corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|plasma|,|corticosteroids (r_conj) exchange_11\NN\11409059|with|plasma|,|replacement (r_nmod) treatment_8\NN\654885|exchange (r_conj) discontinuation_4\NN\209943|fk506|and|treatment (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D001241_D000743 NONE aspirin_20\NN\2707683|,|and|dipyridamole (r_conj) corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|plasma|,|corticosteroids (r_conj) exchange_11\NN\11409059|with|plasma|,|replacement (r_nmod) treatment_8\NN\654885|exchange (r_conj) discontinuation_4\NN\209943|fk506|and|treatment (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D004176_D000743 NONE dipyridamole_23\NN\1740| (r_conj) aspirin_20\NN\2707683|,|and|dipyridamole (r_conj) corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|plasma|,|corticosteroids (r_conj) exchange_11\NN\11409059|with|plasma|,|replacement (r_nmod) treatment_8\NN\654885|exchange (r_conj) discontinuation_4\NN\209943|fk506|and|treatment (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D016572_D000743 NONE a_17\NN\13649268|with|cyclosporin|cya|,|drug (l_appos) drug_24\NN\14778436|an|immuno-suppressive|known (l_acl) known_26\VBN\2110220|already|induce (l_xcomp) induce_28\VB\1627355|to|maha (l_dobj) maha_29\NN\9654687|
D016572_D000743 NONE cya_19\NN\1740|(|) (r_appos) a_17\NN\13649268|with|cyclosporin|cya|,|drug (l_appos) drug_24\NN\14778436|an|immuno-suppressive|known (l_acl) known_26\VBN\2110220|already|induce (l_xcomp) induce_28\VB\1627355|to|maha (l_dobj) maha_29\NN\9654687|
7890216
D015282_D042882 CID octreotide_7\NN\1740|with (r_nmod) associated_5\VBN\628491|octreotide (r_acl) stones_4\NNS\19128|of|bladder|associated
D015282_D042882 CID octreotide_0\NN\1740|,|treatment|, (r_nsubj) induces_8\VBZ\1627355|octreotide|stones|%|. (l_dobj) stones_11\NNS\19128|bladder
D015282_D042882 CID octreotide_28\NN\1740| (r_nmod:npmod) treated_29\JJ\1740|octreotide (r_amod) patients_31\NNS\9898892|in|14|treated|acromegalic|stones (l_nmod) stones_34\NNS\19128|with|gall
D015282_D042882 CID octreotide_3\NN\1740| (r_nmod:npmod) induced_4\JJ\1740|octreotide (r_amod) stones_6\NNS\19128|induced|gall
D015282_D042882 CID octreotide_3\NN\1740| (r_nmod:npmod) induced_4\JJ\1740|octreotide (r_amod) stones_6\NNS\19128|induced|gall (r_nsubj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|have|. (l_advcl) have_31\VB\2108377|although|,|in|,|presentation|patients|will|duct (l_dep) in_18\IN\13603305|common (l_amod) common_19\JJ\1740|disease (l_nmod) disease_24\NN\14061805|with|spontaneous|gall|stone
D015282_D042882 CID octreotide_3\NN\1740| (r_nmod:npmod) induced_4\JJ\1740|octreotide (r_amod) stones_6\NNS\19128|induced|gall (r_nsubj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|have|. (l_advcl) have_31\VB\2108377|although|,|in|,|presentation|patients|will|duct (l_dobj) duct_35\NN\5248181|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\19128|some|gall|containing
D014580_D042882 NONE acid_13\NN\14818238|to|oral|ursodeoxycholic (r_nmod) response_9\NN\11410625|acid (r_dep) composition_0\NN\5075602|stones|:|response|. (l_nmod) stones_4\NNS\19128|of|bladder|associated
D015282_D000172 NONE octreotide_0\NN\1740|,|treatment|, (l_appos) treatment_4\NN\654885|an|effective|acromegaly (l_nmod) acromegaly_6\NN\14366759|for
D015282_D000172 NONE octreotide_28\NN\1740| (r_nmod:npmod) treated_29\JJ\1740|octreotide (r_amod) patients_31\NNS\9898892|in|14|treated|acromegalic|stones (l_amod) acromegalic_30\JJ\1740|
D002784_D042882 NONE cholesterol_21\NN\15058310|%|weight (r_dobj) contained_15\VBD\2632940|that|they|cholesterol (r_ccomp) showed_12\VBD\2137132|analysis|,|contained|. (l_nsubj) analysis_1\NN\633864|chemical|stones (l_nmod) stones_4\NNS\19128|of|gall|retrieved
D002784_D042882 NONE cholesterol_36\NN\15058310| (r_nmod:npmod) rich_37\JJ\1740|that|stones|were|cholesterol (r_ccomp) suggesting_31\VBG\1010118|rich (r_advcl) showed_12\VBD\2137132|year|,|five|partial|,|suggesting|. (l_dobj) partial_14\JJ\1740|either|=|or|complete|dissolution (l_dep) dissolution_29\NN\13518963|stone (l_compound) stone_28\NN\19128|gall
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_nmod:npmod) rich_15\JJ\1740|cholesterol (r_conj) multiple_11\JJ\1740|,|and|rich (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|have|. (l_nsubj) stones_6\NNS\19128|induced|gall
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_nmod:npmod) rich_15\JJ\1740|cholesterol (r_conj) multiple_11\JJ\1740|,|and|rich (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|have|. (l_advcl) have_31\VB\2108377|although|,|in|,|presentation|patients|will|duct (l_dep) in_18\IN\13603305|common (l_amod) common_19\JJ\1740|disease (l_nmod) disease_24\NN\14061805|with|spontaneous|gall|stone
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_nmod:npmod) rich_15\JJ\1740|cholesterol (r_conj) multiple_11\JJ\1740|,|and|rich (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|have|. (l_advcl) have_31\VB\2108377|although|,|in|,|presentation|patients|will|duct (l_dobj) duct_35\NN\5248181|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\19128|some|gall|containing
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing (r_conj) duct_35\NN\5248181|a|blocked|cystic|and|stones (r_dobj) have_31\VB\2108377|although|,|in|,|presentation|patients|will|duct (r_advcl) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|have|. (l_nsubj) stones_6\NNS\19128|induced|gall
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing (r_conj) duct_35\NN\5248181|a|blocked|cystic|and|stones (r_dobj) have_31\VB\2108377|although|,|in|,|presentation|patients|will|duct (l_dep) in_18\IN\13603305|common (l_amod) common_19\JJ\1740|disease (l_nmod) disease_24\NN\14061805|with|spontaneous|gall|stone
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing
18726058
D010208_D020301 NONE hydrochloride_3\NN\14817592|papaverine (r_nsubj) vasodilator_7\NN\3198383|:|hydrochloride|is|a|direct-acting|used (l_acl) used_8\VBN\1156834|manage (l_xcomp) manage_10\VB\2524171|to|vasospasm|operations (l_dobj) vasospasm_11\NN\1740|
D010208_D020301 NONE papaverine_20\NN\3800001|topical (r_dobj) received_18\VBD\2210855|who|papaverine|vasospasm (l_nmod) vasospasm_22\NN\1740|for
D010208_D020301 NONE papaverine_1\NN\3800001|topical (r_nsubjpass) used_3\VBN\1156834|papaverine|was|action|manage|. (l_xcomp) manage_10\VB\2524171|to|vasospasm|total (l_dobj) vasospasm_11\NN\1740|
D010208_D020301 NONE papaverine_3\NN\3800001|topical|treatment (l_nmod) treatment_6\NN\654885|for|the|vasospasm (l_nmod) vasospasm_8\NN\1740|of
D010208_D003389 NONE papaverine_13\NN\3800001|with|topical (r_nmod) described_6\VBN\1001294|dysfunction|has|been|cases|papaverine|. (l_nsubjpass) dysfunction_3\NN\14204950|nerve
D010208_D003389 NONE papaverine_8\NN\3800001|from (r_nmod) deficits_6\NNS\5113133|potential|nerve|papaverine
16274958
D017255_D055154 CID acitretin_3\NN\1740| (r_conj) dysphonia_1\NN\14400677|recurrent|and|acitretin|.
D017255_D055154 CID acitretin_15\NN\1740|by (r_nmod) treated_13\VBN\2376958|while|she|was|acitretin (r_advcl) complaining_7\VBG\843959|dysphonia|treated (l_nmod) dysphonia_9\NN\14400677|of
D017255_D055154 CID acitretin-induced_10\JJ\1740| (r_amod) dysphonia_11\NN\14400677|of|acitretin-induced
12820454
D016729_D000740 CID acetate_6\NN\15010703|[|leuprolide|lhrh-a|intramuscularly|,|days|plus|flutamide|] (r_dep) cab_3\NN\3079741|acetate (r_dobj) received_2\VBD\2210855|patients|cab|and|evaluated|. (l_conj) evaluated_30\VBN\670261|were|anemia|examination|baseline (l_nmod) anemia_32\NN\14189204|for
D016729_D000740 CID lhrh-a_8\NN\1740|(|)|mg (r_appos) acetate_6\NN\15010703|[|leuprolide|lhrh-a|intramuscularly|,|days|plus|flutamide|] (r_dep) cab_3\NN\3079741|acetate (r_dobj) received_2\VBD\2210855|patients|cab|and|evaluated|. (l_conj) evaluated_30\VBN\670261|were|anemia|examination|baseline (l_nmod) anemia_32\NN\14189204|for
D005485_D000740 CID flutamide_21\NN\1740|mg|,|tid|,|os (r_conj) acetate_6\NN\15010703|[|leuprolide|lhrh-a|intramuscularly|,|days|plus|flutamide|] (r_dep) cab_3\NN\3079741|acetate (r_dobj) received_2\VBD\2210855|patients|cab|and|evaluated|. (l_conj) evaluated_30\VBN\670261|were|anemia|examination|baseline (l_nmod) anemia_32\NN\14189204|for
18417364
D009538_D009759 CID nicotine-induced_0\JJ\1740| (r_amod) nystagmus_1\NN\337486|nicotine-induced
D009538_D009759 CID nicotine-induced_3\JJ\1740| (r_amod) nystagmus_4\NN\337486|of|nicotine-induced|nin
D009538_D009759 CID nicotine-induced_3\JJ\1740| (r_amod) nystagmus_4\NN\337486|of|nicotine-induced|nin (l_appos) nin_6\NN\1740|(|)
D010100_D009759 NONE oxygen_4\NN\14622893| (r_nmod:npmod) level-dependent_5\JJ\1740|blood|oxygen|bold (r_amod) levels_10\NNS\4916342|with|level-dependent|activity|site (r_nmod) correlated_1\VBD\2657219|nin|levels|. (l_nsubj) nin_0\NNP\1740|
2334618
D009020_D001049 NONE morphine_17\NN\2707683|of (r_nmod) infusion_15\NN\14589223|a|continuous|i.v.|morphine|mg (r_dobj) receiving_11\VBG\2210855|infusion (r_acl) patients_10\NNS\9898892|between|five|receiving|and|patients (r_nmod) compared_7\VBN\644583|incidence|was|patients|. (l_nsubjpass) incidence_1\NN\13821570|the|apnoea (l_nmod) apnoea_5\NN\1740|of|postoperative|respiratory
D002045_D001049 NONE bupivacaine_34\NN\1740|of|%|mg (r_nmod) infusion_30\NN\14589223|a|continuous|extradural|bupivacaine (r_dobj) receiving_26\VBG\2210855|infusion|period (r_acl) patients_25\NNS\9898892|five|receiving (r_conj) patients_10\NNS\9898892|between|five|receiving|and|patients (r_nmod) compared_7\VBN\644583|incidence|was|patients|. (l_nsubjpass) incidence_1\NN\13821570|the|apnoea (l_nmod) apnoea_5\NN\1740|of|postoperative|respiratory
D009020_D020181 CID morphine_25\NN\2707683| (r_compound) infusion_26\NN\14589223|a|morphine (r_dobj) had_23\VBD\2108377|who|infusion (r_acl:relcl) patients_21\NNS\9898892|in|had (r_nmod) occurred_17\VBD\2623529|obstructive|frequently|patients|. (l_nsubj) obstructive_1\JJ\1740|both|p|and|apnoea (l_conj) apnoea_10\NN\1740|central|p
D009020_D020182 CID morphine_25\NN\2707683| (r_compound) infusion_26\NN\14589223|a|morphine (r_dobj) had_23\VBD\2108377|who|infusion (r_acl:relcl) patients_21\NNS\9898892|in|had (r_nmod) occurred_17\VBD\2623529|obstructive|frequently|patients|. (l_nsubj) obstructive_1\JJ\1740|both|p|and|apnoea (l_conj) apnoea_10\NN\1740|central|p
D009020_D013610 NONE morphine_26\NN\2707683| (r_compound) infusion_27\NN\14589223|morphine (r_compound) group_28\NN\2137|in|the|infusion (r_nmod) was_1\VBD\836236|there|also|incidence|group|. (l_attr) incidence_5\NN\13821570|a|higher|tachyarrhythmias (l_nmod) tachyarrhythmias_7\NNS\1740|of|p|and|beats
D009020_D018879 CID morphine_26\NN\2707683| (r_compound) infusion_27\NN\14589223|morphine (r_compound) group_28\NN\2137|in|the|infusion (r_nmod) was_1\VBD\836236|there|also|incidence|group|. (l_attr) incidence_5\NN\13821570|a|higher|tachyarrhythmias (l_nmod) tachyarrhythmias_7\NNS\1740|of|p|and|beats (l_conj) beats_17\NNS\8289449|ventricular|ectopic|p
18703024
D006220_D002375 CID haloperidol-induced_3\JJ\1740| (r_amod) catalepsy_4\NN\14023236|in|haloperidol-induced|or|locomotion
D016291_D002375 NONE mk-801-induced_6\JJ\1740| (r_amod) locomotion_7\NN\4773351|mk-801-induced (r_conj) catalepsy_4\NN\14023236|in|haloperidol-induced|or|locomotion
9587734
D013390_D006323 CID suxamethonium-induced_0\NN\1740| (r_compound) arrest_2\NN\88481|suxamethonium-induced|cardiac|and|death|days|.
D013390_D006323 CID suxamethonium_21\NN\1740|of (r_nmod) use_19\NN\407535|following|the|suxamethonium|woman (r_nmod) hyperkalaemia_16\NN\1740|of|use (r_nmod) result_14\NN\34213|as|a|hyperkalaemia (r_nmod) case_5\NN\7283608|a|arrest|result (l_nmod) arrest_8\NN\88481|of|cardiac|and|death
D013390_D006323 CID suxamethonium_5\NN\1740|of (r_nmod) injection_3\NN\320852|after|suxamethonium (r_nmod) occurred_11\VBD\2623529|injection|,|bradycardia|. (l_nsubj) bradycardia_7\NN\14110674|and|arrest (l_conj) arrest_10\NN\88481|cardiac
D013390_D003643 NONE suxamethonium-induced_0\NN\1740| (r_compound) arrest_2\NN\88481|suxamethonium-induced|cardiac|and|death|days|. (l_conj) death_4\NN\7296428|
D013390_D003643 NONE suxamethonium_21\NN\1740|of (r_nmod) use_19\NN\407535|following|the|suxamethonium|woman (r_nmod) hyperkalaemia_16\NN\1740|of|use (r_nmod) result_14\NN\34213|as|a|hyperkalaemia (r_nmod) case_5\NN\7283608|a|arrest|result (l_nmod) arrest_8\NN\88481|of|cardiac|and|death (l_conj) death_11\NN\7296428|subsequent
D013390_D003643 NONE suxamethonium_11\NN\1740|to (r_nmod) hypersensitivity_9\NN\14531772|by|suxamethonium|,|associated (r_nmod) caused_7\VBN\1617192|that|death|was|hypersensitivity (l_nsubjpass) death_5\NN\7296428|her
D013390_D006947 CID suxamethonium_21\NN\1740|of (r_nmod) use_19\NN\407535|following|the|suxamethonium|woman (r_nmod) hyperkalaemia_16\NN\1740|of|use
D013390_D006947 CID suxamethonium_35\NN\1740|of (r_nmod) administration_33\NN\1133281|following|the|suxamethonium (r_nmod) hyperkalaemia_30\NN\1740|for|administration
D013390_D001919 CID suxamethonium_5\NN\1740|of (r_nmod) injection_3\NN\320852|after|suxamethonium (r_nmod) occurred_11\VBD\2623529|injection|,|bradycardia|. (l_nsubj) bradycardia_7\NN\14110674|and|arrest
D013390_D004342 CID suxamethonium_11\NN\1740|to (r_nmod) hypersensitivity_9\NN\14531772|by|suxamethonium|,|associated
14513889
D007654_D009422 NONE ketoconazole-induced_0\NN\1740| (r_compound) sequelae_2\NNS\14501726|ketoconazole-induced|neurologic|.
D007654_D018908 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|h|ketoconazole (r_dep) developed_3\VBD\1753788|patient|weakness|ingestion|time|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis
D007654_D010243 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|h|ketoconazole (r_dep) developed_3\VBD\1753788|patient|weakness|ingestion|time|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis (l_conj) paralysis_9\NN\14557898|legs|,|dysarthria
D007654_D004401 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|h|ketoconazole (r_dep) developed_3\VBD\1753788|patient|weakness|ingestion|time|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis (l_conj) paralysis_9\NN\14557898|legs|,|dysarthria (l_conj) dysarthria_11\NN\14400677|and|tremor
D007654_D014202 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|h|ketoconazole (r_dep) developed_3\VBD\1753788|patient|weakness|ingestion|time|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis (l_conj) paralysis_9\NN\14557898|legs|,|dysarthria (l_conj) dysarthria_11\NN\14400677|and|tremor (l_conj) tremor_13\NN\345926|
435349
D013390_D005207 CID suxamethonium_0\NN\1740| (r_compound) rate_2\NN\13815152|suxamethonium|infusion|and|observed (l_conj) observed_4\VBN\2163746|fasciculations|. (l_dobj) fasciculations_5\NNS\14361664|
D013390_D013746 NONE sch_20\NNP\1740| (r_compound) mg_22\NN\13717155|sch|120 (r_nsubjpass) exceeded_24\VBN\2673965|when|mg|was (r_conj) was_7\VBD\836236|either|when|there|response|or|exceeded (l_attr) response_10\NN\11410625|no|muscular|stimulation (l_nmod) stimulation_13\NN\242808|to|tetanic|nerve (l_amod) tetanic_12\JJ\1740|
7582165
D000305_D004342 NONE corticosteroids_3\NNS\14745635|to (r_nmod) reactions_1\NNS\13446390|pseudo-allergic|corticosteroids|:|diagnosis
D010248_D004342 NONE paramethasone_3\NNS\1740|from (r_nmod) different_1\JJ\1740|paramethasone (r_amod) corticosteroids_0\NNS\14745635|different (r_nsubj) produced_5\VBD\1617192|corticosteroids|also|reactions|patients (l_dobj) reactions_7\NNS\13446390|hypersensitivity (l_compound) hypersensitivity_6\NN\14531772|
D010248_D004342 NONE paramethasone_14\NN\1740|by (r_nmod) caused_12\VBN\1617192|paramethasone (r_acl) pseudo-allergy_11\NN\1740|of|a|caused
6518066
D008094_D004437 CID lithium_1\NN\14625458|maternal|and|anomaly|: (l_conj) anomaly_6\NN\14501726|neonatal|ebstein
D008094_D006331 NONE lithium_7\NN\14625458|to (r_nmod) exposed_5\VBN\2110927|lithium|gestation (r_acl) newborns_4\NNS\9827683|of|exposed (r_nmod) screening_2\NN\6887726|cross-sectional|echocardiographic|newborns (r_nsubj) provide_11\VB\2199590|screening|can|assessment|. (l_dobj) assessment_16\NN\5732756|accurate|,|noninvasive|presence (l_nmod) presence_19\NN\13954253|of|the|or|absence|malformations (l_nmod) malformations_25\NNS\14213199|of|lithium-induced|cardiac
D008094_D006331 NONE lithium-induced_23\JJ\1740| (r_amod) malformations_25\NNS\14213199|of|lithium-induced|cardiac
16403073
D007654_D016171 CID ketoconazole_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|ketoconazole|pointes|use|. (l_dobj) pointes_4\NNS\1740|torsades|de
D007654_D016171 CID ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|taking (l_dobj) interval_14\NN\33615|a|prolonged|qt|and|pointes (l_conj) pointes_18\NNS\1740|torsades|de|tdp
D007654_D016171 CID ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|taking (l_dobj) interval_14\NN\33615|a|prolonged|qt|and|pointes (l_conj) pointes_18\NNS\1740|torsades|de|tdp (l_appos) tdp_20\NN\1740|(|)
D007654_D016171 CID ketoconazole_13\NN\1740|alone (r_nsubj) prolong_16\VB\317700|that|virtue|,|ketoconazole|may|interval|and|induce (l_conj) induce_20\VB\1627355|tdp. (l_dobj) tdp._21\NN\1740|
D007654_D016171 CID ketoconazole_27\NN\1740| (r_nsubjpass) administered_29\VBN\2436349|when|ketoconazole|is|patients (r_advcl) calls_23\VBZ\1029852|this|attention|administered (r_ccomp) postulate_1\VBP\756338|we|prolong|calls|. (l_ccomp) prolong_16\VB\317700|that|virtue|,|ketoconazole|may|interval|and|induce (l_conj) induce_20\VB\1627355|tdp. (l_dobj) tdp._21\NN\1740|
D007654_D003324 NONE ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|taking (r_acl:relcl) woman_3\NN\9605289|a|disease|developed (l_nmod) disease_7\NN\14061805|with|coronary|artery
D007654_D008133 CID ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|taking (l_dobj) interval_14\NN\33615|a|prolonged|qt|and|pointes
D007654_D008133 CID ketoconazole_13\NN\1740|alone (r_nsubj) prolong_16\VB\317700|that|virtue|,|ketoconazole|may|interval|and|induce (r_ccomp) postulate_1\VBP\756338|we|prolong|calls|. (l_ccomp) calls_23\VBZ\1029852|this|attention|administered (l_advcl) administered_29\VBN\2436349|when|ketoconazole|is|patients (l_nmod) patients_31\NNS\9898892|to|factors (l_nmod) factors_34\NNS\7326557|with|risk|syndrome (l_nmod) syndrome_39\NN\5870365|for|acquired|long|qt
D007654_D008133 CID ketoconazole_27\NN\1740| (r_nsubjpass) administered_29\VBN\2436349|when|ketoconazole|is|patients (l_nmod) patients_31\NNS\9898892|to|factors (l_nmod) factors_34\NNS\7326557|with|risk|syndrome (l_nmod) syndrome_39\NN\5870365|for|acquired|long|qt
D007654_D009181 NONE ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (l_nmod) treatment_26\NN\654885|for|infection (l_nmod) infection_29\NN\14052046|of|fungal
16330766
C040029_D009437 NONE gabapentin_11\NN\2718469|of|,|drug (l_appos) drug_14\NN\14778436|a|effective (l_amod) effective_15\JJ\1740|patients (l_nmod) patients_19\NNS\9898892|in|neuropathic|pain (l_compound) pain_18\NN\14299637|
C040029_D006930 NONE gabapentin-induced_15\JJ\1740| (r_amod) modulation_16\NN\7044917|the|gabapentin-induced|activity|response (l_nmod) response_21\NN\11410625|in|stimulation (l_nmod) stimulation_25\NN\242808|to|nociceptive|mechanical|skin|and|hyperalgesia (l_conj) hyperalgesia_32\NN\1740|capsaicin-induced|secondary
D002211_D006930 CID capsaicin-induced_30\JJ\1740| (r_amod) hyperalgesia_32\NN\1740|capsaicin-induced|secondary
18754075
D004164_D011507 NONE bisphosphonate_8\NN\1740|alendronate (r_compound) administration_12\NN\1133281|after|oral|bisphosphonate|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|.
D004164_D011507 NONE bisphosphonates_11\NNS\1740|intravenous|oral (r_nsubj) aggravate_13\VB\126264|that|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\14299637|and|failure
D004164_D058186 NONE bisphosphonate_8\NN\1740|alendronate (r_compound) administration_12\NN\1133281|after|oral|bisphosphonate|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|. (l_conj) failure_5\NN\66216|acute|renal
D004164_D058186 NONE bisphosphonate_18\NN\1740|sodium (r_compound) administration_23\NN\1133281|of|the|oral|bisphosphonate (r_nmod) days_14\NNS\15140892|within|14|administration (r_nmod) decreased_6\VBD\169651|amount|15.6|g.|days|increased (l_parataxis) increased_31\VBD\169651|,|amount|rapidly|g|failure|. (l_nmod) failure_40\NN\66216|with|acute|renal
D004164_D058186 NONE bisphosphonates_11\NNS\1740|intravenous|oral (r_nsubj) aggravate_13\VB\126264|that|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\14299637|and|failure (l_conj) failure_18\NN\66216|acute|renal
D004164_D005923 NONE bisphosphonate_8\NN\1740|alendronate (r_compound) administration_12\NN\1133281|after|oral|bisphosphonate|patient (l_nmod) patient_15\NN\9898892|in|a|glomerulosclerosis (l_nmod) glomerulosclerosis_19\NN\1740|with|focal|segmental
D019386_D011507 CID alendronate_10\NN\3740161|(|) (r_appos) bisphosphonate_8\NN\1740|alendronate (r_compound) administration_12\NN\1133281|after|oral|bisphosphonate|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|.
D019386_D058186 CID alendronate_10\NN\3740161|(|) (r_appos) bisphosphonate_8\NN\1740|alendronate (r_compound) administration_12\NN\1133281|after|oral|bisphosphonate|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|. (l_conj) failure_5\NN\66216|acute|renal
D019386_D058186 CID sodium_21\NN\14625458|(|alendronate|) (r_appos) bisphosphonate_18\NN\1740|sodium (r_compound) administration_23\NN\1133281|of|the|oral|bisphosphonate (r_nmod) days_14\NNS\15140892|within|14|administration (r_nmod) decreased_6\VBD\169651|amount|15.6|g.|days|increased (l_parataxis) increased_31\VBD\169651|,|amount|rapidly|g|failure|. (l_nmod) failure_40\NN\66216|with|acute|renal
D019386_D005923 NONE alendronate_10\NN\3740161|(|) (r_appos) bisphosphonate_8\NN\1740|alendronate (r_compound) administration_12\NN\1133281|after|oral|bisphosphonate|patient (l_nmod) patient_15\NN\9898892|in|a|glomerulosclerosis (l_nmod) glomerulosclerosis_19\NN\1740|with|focal|segmental
D013256_D009404 NONE steroid_17\NN\14727670| (r_compound) therapy_18\NN\657604|to|steroid (r_nmod) responding_14\VBG\2367363|man|was|initially|well|therapy|. (l_nsubj) man_3\NN\9605289|a|61-year-old|japanese|syndrome (l_nmod) syndrome_6\NN\5870365|with|nephrotic|glomerulosclerosis
D013256_D005923 NONE steroid_17\NN\14727670| (r_compound) therapy_18\NN\657604|to|steroid (r_nmod) responding_14\VBG\2367363|man|was|initially|well|therapy|. (l_nsubj) man_3\NN\9605289|a|61-year-old|japanese|syndrome (l_nmod) syndrome_6\NN\5870365|with|nephrotic|glomerulosclerosis (l_nmod) glomerulosclerosis_11\NN\1740|due|focal|segmental
7628595
D014805_D064420 NONE b12_6\NN\1740|of|vitamin|and|supplementation (r_nmod) role_3\NN\719494|of|the|b12|preventing (l_advcl) preventing_12\VBG\1740|in|toxicity (l_dobj) toxicity_14\NN\13576101|hematologic|zidovudine
D002955_D064420 NONE acid_9\NN\14818238|folinic (r_compound) supplementation_10\NN\5108947|acid (r_conj) b12_6\NN\1740|of|vitamin|and|supplementation (r_nmod) role_3\NN\719494|of|the|b12|preventing (l_advcl) preventing_12\VBG\1740|in|toxicity (l_dobj) toxicity_14\NN\13576101|hematologic|zidovudine
D015215_D064420 NONE zidovudine_16\NN\3834836|of (r_nmod) toxicity_14\NN\13576101|hematologic|zidovudine
D014805_D001855 NONE b12_13\NN\1740|of|vitamin|and|supplementation (r_nmod) role_10\NN\719494|the|b12|preventing (l_advcl) preventing_19\VBG\1740|in|suppression (l_dobj) suppression_24\NN\13489037|zidovudine|bone|marrow
D014805_D001855 NONE b12_6\NN\1740|vitamin|or|folate (r_compound) levels_9\NNS\4916342|between|b12|and|development (l_conj) development_11\NN\248977|myelosuppression (l_nmod) myelosuppression_13\NN\1740|of
D014805_D001855 NONE b12_1\NN\1740|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|preventing|,|excluded|. (l_advcl) preventing_14\VBG\1740|in|or|reducing|myelotoxicity (l_dobj) myelotoxicity_18\NN\1740|zdv-induced|population
D002955_D001855 NONE acid_16\NN\14818238|folinic (r_compound) supplementation_17\NN\5108947|acid (r_conj) b12_13\NN\1740|of|vitamin|and|supplementation (r_nmod) role_10\NN\719494|the|b12|preventing (l_advcl) preventing_19\VBG\1740|in|suppression (l_dobj) suppression_24\NN\13489037|zidovudine|bone|marrow
D002955_D001855 NONE acid_4\NN\14818238|folinic (r_compound) supplementation_5\NN\5108947|acid|therapy (r_conj) b12_1\NN\1740|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|preventing|,|excluded|. (l_advcl) preventing_14\VBG\1740|in|or|reducing|myelotoxicity (l_dobj) myelotoxicity_18\NN\1740|zdv-induced|population
D015215_D001855 CID zidovudine_20\NN\3834836|(zdv)-induced (r_compound) suppression_24\NN\13489037|zidovudine|bone|marrow
D015215_D001855 CID (zdv)-induced_21\NN\1740| (r_dep) zidovudine_20\NN\3834836|(zdv)-induced (r_compound) suppression_24\NN\13489037|zidovudine|bone|marrow
D015215_D001855 CID zdv_7\NN\3834836| (r_compound) therapy_8\NN\657604|of|zdv (r_nmod) supplementation_5\NN\5108947|acid|therapy (r_conj) b12_1\NN\1740|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|preventing|,|excluded|. (l_advcl) preventing_14\VBG\1740|in|or|reducing|myelotoxicity (l_dobj) myelotoxicity_18\NN\1740|zdv-induced|population
D015215_D001855 CID zdv-induced_17\JJ\1740| (r_amod) myelotoxicity_18\NN\1740|zdv-induced|population
D015215_D015658 NONE zdv_18\NN\3834836|either|mg|alone|group|or|combination|group (r_dobj) receive_16\VB\2210855|to|zdv (r_xcomp) randomized_14\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_5\NNS\9898892|(hiv)-infected|counts (l_nummod) (hiv)-infected_4\NN\1740|seventy-five|virus
D002955_D015658 NONE acid_38\NN\14818238|with|folinic|mg|and|b12 (r_nmod) combination_35\NN\7951464|in|acid (r_conj) zdv_18\NN\3834836|either|mg|alone|group|or|combination|group (r_dobj) receive_16\VB\2210855|to|zdv (r_xcomp) randomized_14\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_5\NNS\9898892|(hiv)-infected|counts (l_nummod) (hiv)-infected_4\NN\1740|seventy-five|virus
D014805_D015658 NONE b12_47\NN\1740|intramascular|vitamin|micrograms (r_conj) acid_38\NN\14818238|with|folinic|mg|and|b12 (r_nmod) combination_35\NN\7951464|in|acid (r_conj) zdv_18\NN\3834836|either|mg|alone|group|or|combination|group (r_dobj) receive_16\VB\2210855|to|zdv (r_xcomp) randomized_14\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_5\NNS\9898892|(hiv)-infected|counts (l_nummod) (hiv)-infected_4\NN\1740|seventy-five|virus
D005492_D001855 NONE folate_8\NN\15090742| (r_conj) b12_6\NN\1740|vitamin|or|folate (r_compound) levels_9\NNS\4916342|between|b12|and|development (l_conj) development_11\NN\248977|myelosuppression (l_nmod) myelosuppression_13\NN\1740|of
17261653
D003000_D001919 CID clonidine-induced_0\JJ\1740| (r_amod) bradycardia_1\NN\14110674|clonidine-induced|mice
20633755
D013390_D001049 CID suxamethonium_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|suxamethonium|apnea|patient|. (l_dobj) apnea_3\NN\14299637|prolonged
D013390_D001049 CID suxamethonium_0\NN\1740| (r_nsubj) causes_1\VBZ\1617192|suxamethonium|apnea|patients|. (l_dobj) apnea_3\NN\14299637|prolonged
D009943_D001049 CID poisons_17\NNS\20090|by|organophosphorus (r_nmod) deactivated_11\VBN\1097743|whom|enzyme|gets|poisons (r_acl:relcl) patients_5\NNS\9898892|in|deactivated (r_nmod) causes_1\VBZ\1617192|suxamethonium|apnea|patients|. (l_dobj) apnea_3\NN\14299637|prolonged
D009943_D001049 CID compound_14\NN\5869584|by|op (r_nmod) attempt_11\NN\407535|about|suicidal|compound (r_nmod) information_8\NN\6598915|the|attempt (r_nsubjpass) concealed_16\VBN\1740|because|information|was|team (r_advcl) ensued_5\VBD\2633881|apnea|concealed|. (l_nsubj) apnea_1\NN\14299637|prolonged|case
10526274
C056507_D002289 NONE gemcitabine_0\NN\1740|plus|vinorelbine|patients|. (l_nmod) patients_8\NNS\9898892|in|carcinoma|age|or|patients (l_compound) carcinoma_7\NN\14239918|nonsmall|cell|lung
C056507_D002289 NONE gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination|patients (l_nmod) patients_17\NNS\9898892|in|elderly|nsclc|or|those (l_nmod) nsclc_20\NN\1740|with|advanced
C030852_D002289 NONE vinorelbine_2\NN\1740| (r_conj) gemcitabine_0\NN\1740|plus|vinorelbine|patients|. (l_nmod) patients_8\NNS\9898892|in|carcinoma|age|or|patients (l_compound) carcinoma_7\NN\14239918|nonsmall|cell|lung
C030852_D002289 NONE vnb_14\NN\1740| (r_conj) gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination|patients (l_nmod) patients_17\NNS\9898892|in|elderly|nsclc|or|those (l_nmod) nsclc_20\NN\1740|with|advanced
D002945_D002289 NONE cisplatin_20\NN\1740| (r_dobj) receive_19\VB\2210855|who|can|not|cisplatin (r_acl:relcl) patients_15\NNS\9898892|receive (r_conj) patients_8\NNS\9898892|in|carcinoma|age|or|patients (l_compound) carcinoma_7\NN\14239918|nonsmall|cell|lung
D002945_D002289 NONE cisplatin_28\NN\1740| (r_dobj) receiving_27\VBG\2210855|to|cisplatin (r_advcl) contraindication_25\NN\5819149|with|some|receiving (r_nmod) those_22\DT\1740|contraindication (r_conj) patients_17\NNS\9898892|in|elderly|nsclc|or|those (l_nmod) nsclc_20\NN\1740|with|advanced
D002945_D002289 NONE cisplatin_33\NN\1740| (r_dobj) receiving_32\VBG\2210855|to|cisplatin (r_advcl) contraindication_30\NN\5819149|some|receiving (r_dobj) had_28\VBD\2108377|who|contraindication (r_conj) age_14\NN\4916342|38|were|/=|years|and|age|but|had (r_parataxis) included_8\VBN\690614|patients|were|,|age|. (l_nsubjpass) patients_3\NNS\9898892|forty-nine|nsclc (l_nmod) nsclc_6\NN\1740|with|advanced
C030852_D064420 NONE vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement
C030852_D064420 NONE vnb_10\NN\1740|(|) (r_appos) vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement
C030852_D064420 NONE vnb_14\NN\1740| (r_conj) gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination|patients (l_conj) toxicity_7\NN\13576101|
C056507_D064420 NONE gemcitabine_13\NN\1740|gem (r_conj) vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement
C056507_D064420 NONE gem_15\NN\2743547|(|) (r_appos) gemcitabine_13\NN\1740|gem (r_conj) vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement
C056507_D064420 NONE gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination|patients (l_conj) toxicity_7\NN\13576101|
D002945_D064420 NONE cisplatin_28\NN\1740| (r_dobj) receiving_27\VBG\2210855|to|cisplatin (r_advcl) contraindication_25\NN\5819149|with|some|receiving (r_nmod) those_22\DT\1740|contraindication (r_conj) patients_17\NNS\9898892|in|elderly|nsclc|or|those (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination|patients (l_conj) toxicity_7\NN\13576101|
322550
D009599_D007022 CID nitroprusside-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|during|nitroprusside-induced
D009599_D007022 CID nitroprusside_5\NN\1740| (r_compound) infusion_6\NN\14589223|before|nitroprusside (r_nmod) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_dobj) decrease_10\NN\7296428|a|further|pressure (l_nmod) pressure_14\NN\11419404|in|arterial|blood
D009599_D007022 CID nitroprusside_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|nitroprusside|decreases|,|but|change|. (l_dobj) decreases_3\NNS\7296428|significant|pressure|and|increases (l_nmod) pressure_7\NN\11419404|in|arterial|blood|and|resistance
D009599_D007022 NONE nitroprusside_1\NN\1740| (r_compound) infusion_2\NN\14589223|during|nitroprusside (r_nmod) alter_10\VB\126264|infusion|levels|do|not|markedly|dynamics|,|but|produce (l_conj) produce_29\VBP\1617192|levels|decreasing|,|decreases|. (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
D014867_D007022 NONE h2o_2\NN\14618834| (r_compound) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_dobj) decrease_10\NN\7296428|a|further|pressure (l_nmod) pressure_14\NN\11419404|in|arterial|blood
D014867_D007022 NONE h2o_22\NN\14618834|(|cm|) (r_appos) cpap_18\NN\1740|of|h2o (r_nmod) levels_16\NNS\4916342|high|cpap|, (r_nsubj) produce_29\VBP\1617192|levels|decreasing|,|decreases|. (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
D014867_D002303 NONE h2o_2\NN\14618834| (r_compound) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_conj) increased_17\VBD\169651|significantly|rate|and|decreased (l_conj) decreased_21\VBD\169651|output (l_dobj) output_23\NN\4007894|cardiac|and|qs/qt
D014867_D002303 NONE h2o_22\NN\14618834|(|cm|) (r_appos) cpap_18\NN\1740|of|h2o (r_nmod) levels_16\NNS\4916342|high|cpap|, (r_nsubj) produce_29\VBP\1617192|levels|decreasing|,|decreases|. (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
D009599_D002303 NONE nitroprusside_5\NN\1740| (r_compound) infusion_6\NN\14589223|before|nitroprusside (r_nmod) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_conj) increased_17\VBD\169651|significantly|rate|and|decreased (l_conj) decreased_21\VBD\169651|output (l_dobj) output_23\NN\4007894|cardiac|and|qs/qt
D009599_D002303 NONE nitroprusside_1\NN\1740| (r_compound) infusion_2\NN\14589223|during|nitroprusside (r_nmod) alter_10\VB\126264|infusion|levels|do|not|markedly|dynamics|,|but|produce (l_conj) produce_29\VBP\1617192|levels|decreasing|,|decreases|. (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
19729346
D010098_D010146 NONE oxycodone_16\NN\1740|of|immediate-release (r_nmod) dose_13\NN\3740161|of|a|single|10-mg|oxycodone (r_nmod) effects_8\NNS\13245626|the|objective|neurocognitive|dose|adults (l_nmod) adults_35\NNS\7846|in|healthy|suffering (l_acl:relcl) suffering_39\VBG\2110220|who|were|not|pain (l_nmod) pain_45\NN\14299637|from|chronic|daily
D010098_D059350 NONE oxycodone_28\NN\1740|of|immediate-release (r_nmod) dose_25\NN\3740161|to|a|10-mg|oxycodone (r_nmod) response_21\NN\11410625|in|dose (r_nmod) changes_19\NNS\7283608|neurocognitive|response (r_nsubj) similar_30\JJ\1740|that|adults|,|changes|are|those (l_nmod) adults_7\NNS\7846|for|healthy|older|suffering (l_acl:relcl) suffering_11\VBG\2110220|who|are|not|pain (l_nmod) pain_14\NN\14299637|from|chronic
891050
D003276_D006463 CID contraceptives_17\NNS\3183080|oral (r_dobj) taking_15\VBG\2367363|contraceptives (r_acl) woman_14\NN\9605289|in|a|taking (r_nmod) syndrome_8\NN\5870365|of|the|hemolytic|uremic|hus|woman
D003276_D006463 CID contraceptives_17\NNS\3183080|oral (r_dobj) taking_15\VBG\2367363|contraceptives (r_acl) woman_14\NN\9605289|in|a|taking (r_nmod) syndrome_8\NN\5870365|of|the|hemolytic|uremic|hus|woman (l_appos) hus_10\NN\1740|(|)
D006493_D001002 NONE heparin_4\NN\2718259|with|,|dipyridamole|and|hemodialysis (r_nmod) treated_2\VBN\2376958|she|was|heparin|;|and|rose (l_conj) rose_20\VBD\1835496|months|,|output|ml|;|and|stopped (l_conj) stopped_37\VBN\2452885|onset|,|treatment|was|. (l_nmod) onset_30\NN\7325190|after|the|anuria (l_nmod) anuria_32\NN\14061805|of
D004176_D001002 NONE dipyridamole_6\NN\1740| (r_conj) heparin_4\NN\2718259|with|,|dipyridamole|and|hemodialysis (r_nmod) treated_2\VBN\2376958|she|was|heparin|;|and|rose (l_conj) rose_20\VBD\1835496|months|,|output|ml|;|and|stopped (l_conj) stopped_37\VBN\2452885|onset|,|treatment|was|. (l_nmod) onset_30\NN\7325190|after|the|anuria (l_nmod) anuria_32\NN\14061805|of
17147461
D020123_D011507 CID sirolimus-associated_0\JJ\1740| (r_amod) proteinuria_1\NN\14299637|sirolimus-associated|and|dysfunction|.
D020123_D011507 CID sirolimus_11\NN\1740| (r_nsubjpass) associated_13\VBN\628491|that|,|circumstances|,|sirolimus|is|proteinuria (l_nmod) proteinuria_15\NN\14299637|with|and|dysfunction
D020123_D011507 CID sirolimus-associated_3\JJ\1740| (r_amod) proteinuria_4\NN\14299637|of|sirolimus-associated
D020123_D011507 CID sirolimus_21\NN\1740|of (r_nmod) effects_19\NNS\13245626|of|the|molecular|sirolimus|kidney (r_nmod) knowledge_15\NN\23100|by|effects|,|use (l_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|and|withdrawal (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D020123_D011507 CID sirolimus_21\NN\1740|of (r_nmod) effects_19\NNS\13245626|of|the|molecular|sirolimus|kidney (r_nmod) knowledge_15\NN\23100|by|effects|,|use (l_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|and|withdrawal (l_conj) use_43\NN\407535|inhibitors|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria (l_nsubj) proteinuria_54\NN\14299637|
D020123_D011507 CID sirolimus_29\NN\1740|of (r_nmod) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|and|withdrawal (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D020123_D011507 CID sirolimus_29\NN\1740|of (r_nmod) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|and|withdrawal (l_conj) use_43\NN\407535|inhibitors|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria (l_nsubj) proteinuria_54\NN\14299637|
D020123_D007674 CID sirolimus-associated_0\JJ\1740| (r_amod) proteinuria_1\NN\14299637|sirolimus-associated|and|dysfunction|. (l_conj) dysfunction_4\NN\14204950|renal
D020123_D007674 CID sirolimus_0\NN\1740| (r_nsubj) represents_1\VBZ\2664769|sirolimus|advance|. (l_dobj) advance_5\NN\7311115|a|major|therapeutic|prevention (l_nmod) prevention_8\NN\1073995|in|the|rejection (l_nmod) rejection_13\NN\30358|of|acute|renal|allograft|and|nephropathy (l_conj) nephropathy_17\NN\14573196|chronic|allograft
D020123_D007674 CID sirolimus_1\NN\1740| (r_nsubj) share_4\VB\2660631|because|sirolimus|does|not|effects (r_advcl) designated_18\VBN\2475922|share|,|it|has|been|drug|. (l_xcomp) drug_22\NN\14778436|a|'|non-nephrotoxic|' (l_amod) non-nephrotoxic_21\JJ\1740|
D020123_D058186 NONE sirolimus_11\NN\1740| (r_nsubjpass) associated_13\VBN\628491|that|,|circumstances|,|sirolimus|is|proteinuria (l_nmod) proteinuria_15\NN\14299637|with|and|dysfunction (l_conj) dysfunction_19\NN\14204950|acute|renal
D020123_D058186 NONE sirolimus_6\NN\1740|with (r_nmod) associated_4\VBN\628491|sirolimus|(|function (r_acl) dysfunction_3\NN\14204950|the|acute|renal|associated|)
D000809_D011507 NONE angiotensin-converting_45\JJ\1740| (r_amod) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors|occurs (r_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|and|withdrawal (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D000809_D011507 NONE angiotensin-converting_45\JJ\1740| (r_amod) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria (l_nsubj) proteinuria_54\NN\14299637|
D000804_D011507 NONE ii_50\CD\13741022| (r_nummod) blockers_52\NNS\10101634|angiotensin|ii|receptor (r_conj) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors|occurs (r_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|and|withdrawal (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D000804_D011507 NONE ii_50\CD\13741022| (r_nummod) blockers_52\NNS\10101634|angiotensin|ii|receptor (r_conj) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria (l_nsubj) proteinuria_54\NN\14299637|
1749407
D003042_D009203 CID cocaine-induced_0\JJ\1740| (r_amod) infarction_2\NN\14204950|cocaine-induced|myocardial|:|observations
D003042_D009203 CID cocaine_13\NN\3492717| (r_nsubj) result_15\VB\2633881|which|cocaine|may|infarction (l_nmod) infarction_19\NN\14204950|in|acute|myocardial
D003042_D009203 CID cocaine-induced_24\JJ\1740| (r_amod) increase_25\NN\13576355|with|cocaine-induced|product (r_nmod) associated_22\VBN\628491|increase (r_acl) increase_17\NN\13576355|from|an|demand|associated (r_nmod) result_14\VB\2633881|individuals|,|infarction|may|increase|. (l_nsubj) infarction_12\NN\14204950|acute|myocardial
D010100_D009203 NONE oxygen_20\NN\14622893| (r_compound) demand_21\NN\6513366|in|myocardial|oxygen (r_nmod) increase_17\NN\13576355|from|an|demand|associated (r_nmod) result_14\VB\2633881|individuals|,|infarction|may|increase|. (l_nsubj) infarction_12\NN\14204950|acute|myocardial
D003042_D013035 NONE cocaine-induced_16\JJ\1740| (r_amod) vasoconstriction_17\NN\1149911|of|cocaine-induced (r_nmod) locus_14\NN\8645963|the|vasoconstriction (r_nsubj) remains_18\VBZ\2604760|locus|speculative|. (r_conj) circumstantial_10\JJ\1740|regard|,|findings|are|largely|,|and|remains (l_nmod) regard_1\NN\5817845|with|spasm (l_nmod) spasm_3\NN\14299637|to
D003042_D013927 NONE cocaine_11\NN\3492717|of (r_nmod) effect_9\NN\34213|of|a|primary|,|thrombotic|cocaine (l_amod) thrombotic_8\JJ\1740|
8996652
D000617_D006311 NONE aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_appos) drugs_14\NNS\14778436|of|ototoxic|,|aminoglycosides (r_nmod) administration_7\NN\1133281|to|a|prolonged|and|dose|drugs (r_nmod) related_3\JJ\1740|closely|administration (r_xcomp) appeared_1\VBD\2604760|ototoxicity|related|. (l_nsubj) ototoxicity_0\NN\1740|
D000617_D006311 NONE aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_appos) drugs_14\NNS\14778436|of|ototoxic|,|aminoglycosides (l_amod) ototoxic_13\JJ\1740|
D005665_D006311 NONE furosemide_19\NN\3214670| (r_conj) aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_appos) drugs_14\NNS\14778436|of|ototoxic|,|aminoglycosides (r_nmod) administration_7\NN\1133281|to|a|prolonged|and|dose|drugs (r_nmod) related_3\JJ\1740|closely|administration (r_xcomp) appeared_1\VBD\2604760|ototoxicity|related|. (l_nsubj) ototoxicity_0\NN\1740|
D005665_D006311 NONE furosemide_19\NN\3214670| (r_conj) aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_appos) drugs_14\NNS\14778436|of|ototoxic|,|aminoglycosides (l_amod) ototoxic_13\JJ\1740|
3800626
D010423_D009408 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous (r_nmod) neuropathy_1\NN\14204950|compression|nerve|myopathy|. (l_nmod) nerve_5\NN\5475681|of|the|radial
D010423_D009408 CID pentazocine-induced_10\JJ\1740| (r_amod) myopathy_11\NN\14204950|by|pentazocine-induced (r_nmod) affected_8\VBN\126264|myopathy (r_acl) muscle_7\NN\5289601|due|fibrotic|affected (r_nmod) neuropathy_3\NN\14204950|compression|muscle
D010423_D020425 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous (r_nmod) neuropathy_1\NN\14204950|compression|nerve|myopathy|. (l_nmod) nerve_5\NN\5475681|of|the|radial
D010423_D005355 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous
D010423_D005355 CID pentazocine_11\NN\2707683| (r_compound) injection_12\NN\320852|of|repeated|pentazocine (r_nmod) effect_8\NN\34213|myopathy|is|a|common|,|well-known|side|injection|. (l_nsubj) myopathy_1\NN\14204950|fibrous
D010423_D005355 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|muscles|bilaterally|and|history
D010423_D005355 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|muscles|bilaterally|and|history (r_nmod) woman_3\NN\9605289|in|a|37-year-old|myopathy (r_nmod) showed_26\VBD\2137132|woman|,|examination|lesion|,|addition|. (l_nmod) addition_46\NN\3081021|in|myopathy (l_nmod) myopathy_50\NN\14204950|to|the|fibrous
D010423_D009135 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous
D010423_D009135 CID pentazocine_11\NN\2707683| (r_compound) injection_12\NN\320852|of|repeated|pentazocine (r_nmod) effect_8\NN\34213|myopathy|is|a|common|,|well-known|side|injection|. (l_nsubj) myopathy_1\NN\14204950|fibrous
D010423_D009135 CID pentazocine-induced_10\JJ\1740| (r_amod) myopathy_11\NN\14204950|by|pentazocine-induced
D010423_D009135 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|muscles|bilaterally|and|history
D010423_D009135 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|muscles|bilaterally|and|history (r_nmod) woman_3\NN\9605289|in|a|37-year-old|myopathy (r_nmod) showed_26\VBD\2137132|woman|,|examination|lesion|,|addition|. (l_nmod) addition_46\NN\3081021|in|myopathy (l_nmod) myopathy_50\NN\14204950|to|the|fibrous
19387625
D002211_D010146 NONE capsaicin-induced_7\JJ\1740| (r_amod) hyperalgesia_9\NN\1740|in|capsaicin-induced|secondary (r_nmod) modulation_1\NN\7044917|attentional|intensity|hyperalgesia|. (l_nmod) intensity_5\NN\5090441|of|perceived|pain (l_compound) pain_4\NN\14299637|
D002211_D010146 NONE capsaicin-induced_16\JJ\1740| (r_amod) hyperalgesia_18\NN\1740|in|capsaicin-induced|secondary (r_nmod) affected_12\VBN\126264|that|how|ratings|are|attention|hyperalgesia (l_nsubjpass) ratings_10\NNS\5733583|intensity (l_compound) intensity_9\NN\5090441|pain (l_compound) pain_8\NN\14299637|
D002211_D010146 NONE capsaicin_7\NN\15032661| (r_compound) treatment_8\NN\654885|between|capsaicin|and|modulation (r_nmod) interaction_5\NN\37396|no|treatment (r_dobj) showing_3\VBG\2137132|interaction (r_acl) findings_1\NNS\7951464|our|,|showing (r_nsubj) suggest_12\VBP\1010118|findings|affect|. (l_ccomp) affect_20\VB\126264|that|hyperalgesia|might|pain|mechanisms (l_dobj) pain_22\NN\14299637|mechanical
D002211_D010146 NONE capsaicin-induced_14\JJ\1740| (r_amod) hyperalgesia_16\NN\1740|capsaicin-induced|secondary|and|attention (r_nsubj) affect_20\VB\126264|that|hyperalgesia|might|pain|mechanisms (l_dobj) pain_22\NN\14299637|mechanical
D002211_D006930 CID capsaicin-induced_7\JJ\1740| (r_amod) hyperalgesia_9\NN\1740|in|capsaicin-induced|secondary
D002211_D006930 CID capsaicin-induced_16\JJ\1740| (r_amod) hyperalgesia_18\NN\1740|in|capsaicin-induced|secondary
D002211_D006930 CID capsaicin-untreated_20\NN\1740| (r_amod) condition_23\NN\24720|of|capsaicin-untreated|control (r_nmod) that_18\DT\1740|to|condition (r_nmod) similar_16\JJ\1740|that|magnitude|is|very|that (l_nsubj) magnitude_7\NN\4916342|the|modulation (l_nmod) modulation_10\NN\7044917|of|attentional|hyperalgesia (l_nmod) hyperalgesia_13\NN\1740|in|secondary
D002211_D006930 CID capsaicin_7\NN\15032661| (r_compound) treatment_8\NN\654885|between|capsaicin|and|modulation (r_nmod) interaction_5\NN\37396|no|treatment (r_dobj) showing_3\VBG\2137132|interaction (r_acl) findings_1\NNS\7951464|our|,|showing (r_nsubj) suggest_12\VBP\1010118|findings|affect|. (l_ccomp) affect_20\VB\126264|that|hyperalgesia|might|pain|mechanisms (l_nsubj) hyperalgesia_16\NN\1740|capsaicin-induced|secondary|and|attention
D002211_D006930 CID capsaicin-induced_14\JJ\1740| (r_amod) hyperalgesia_16\NN\1740|capsaicin-induced|secondary|and|attention
3070035
D002216_D051437 NONE captopril-induced_2\JJ\1740| (r_amod) insufficiency_4\NN\14462946|of|captopril-induced|renal
D002216_D051437 NONE captopril-induced_4\JJ\1740| (r_amod) failure_6\NN\66216|in|captopril-induced|renal
D002216_D006978 NONE captopril-induced_2\JJ\1740| (r_amod) insufficiency_4\NN\14462946|of|captopril-induced|renal (r_nmod) reversibility_0\NN\4733640|insufficiency|use|. (l_nmod) use_7\NN\407535|after|prolonged|case (l_nmod) case_11\NN\7283608|in|an|unusual|hypertension (l_nmod) hypertension_14\NN\14057371|of|renovascular
D002216_D006973 NONE captopril_27\NN\2673637|with (r_nmod) treatment_25\NN\654885|following|captopril (r_nmod) developed_18\VBD\1753788|who|deterioration|treatment (r_acl:relcl) hypertension_6\NN\14057371|of|severe|artery|,|developed
D002216_D058186 CID captopril_27\NN\2673637|with (r_nmod) treatment_25\NN\654885|following|captopril (r_nmod) developed_18\VBD\1753788|who|deterioration|treatment (l_dobj) deterioration_20\NN\14560612|sudden|function (l_nmod) function_23\NN\13783581|of|renal
17020434
D014859_D020521 NONE warfarin_12\NN\2718259| (r_nsubj) reduces_13\VBZ\441445|that|warfarin|risk|%|,|and|reduces (l_dobj) risk_15\NN\14541044|the|stroke (l_nmod) stroke_17\NN\556313|of
D014859_D020521 NONE warfarin_6\NN\2718259| (r_nsubj) superior_8\JJ\1740|overall|,|patients|,|warfarin|is|aspirin|preventing|,|reduction|. (l_advcl) preventing_12\VBG\1740|in|strokes (l_dobj) strokes_13\NNS\556313|
D001241_D020521 NONE aspirin_24\NN\2707683|alone (r_nsubj) reduces_26\VBZ\441445|that|aspirin|risk|% (r_conj) reduces_13\VBZ\441445|that|warfarin|risk|%|,|and|reduces (l_dobj) risk_15\NN\14541044|the|stroke (l_nmod) stroke_17\NN\556313|of
D001241_D020521 NONE aspirin_10\NN\2707683|to (r_nmod) superior_8\JJ\1740|overall|,|patients|,|warfarin|is|aspirin|preventing|,|reduction|. (l_advcl) preventing_12\VBG\1740|in|strokes (l_dobj) strokes_13\NNS\556313|
C426686_D004617 NONE ximelagatran_0\NN\1740|,|inhibitor|, (r_nsubjpass) found_9\VBN\2426171|ximelagatran|was|efficient|. (l_xcomp) efficient_13\JJ\1740|to|be|as|drugs|prevention|,|but|withdrawn (l_nmod) prevention_21\NN\1073995|in|the|events (l_nmod) events_24\NNS\23100|of|embolic
C426686_D056486 CID ximelagatran_0\NN\1740|,|inhibitor|, (r_nsubjpass) found_9\VBN\2426171|ximelagatran|was|efficient|. (l_xcomp) efficient_13\JJ\1740|to|be|as|drugs|prevention|,|but|withdrawn (l_conj) withdrawn_30\VBN\1835496|has|been|recently|tests (l_nmod) tests_36\NNS\5798043|because|abnormal|liver|function (l_compound) function_35\NN\13783581|
D014812_D004617 NONE k_16\NN\13608598| (r_compound) drugs_18\NNS\14778436|as|vitamin|k|antagonist (r_nmod) efficient_13\JJ\1740|to|be|as|drugs|prevention|,|but|withdrawn (l_nmod) prevention_21\NN\1073995|in|the|events (l_nmod) events_24\NNS\23100|of|embolic
D014812_D056486 NONE k_16\NN\13608598| (r_compound) drugs_18\NNS\14778436|as|vitamin|k|antagonist (r_nmod) efficient_13\JJ\1740|to|be|as|drugs|prevention|,|but|withdrawn (l_conj) withdrawn_30\VBN\1835496|has|been|recently|tests (l_nmod) tests_36\NNS\5798043|because|abnormal|liver|function (l_compound) function_35\NN\13783581|
C055162_D001281 NONE clopidogrel_5\NNP\1740| (r_compound) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (l_compound) fibrillation_4\NN\14361664|atrial
C055162_D001281 NONE clopidogrel_26\NN\1740|(|plus|aspirin|) (r_appos) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (r_ccomp) demonstrated_17\VBN\2137132|study|has|superior|. (l_nsubj) study_15\NN\635850|the|trial (l_compound) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (l_compound) fibrillation_4\NN\14361664|atrial
C055162_D004617 NONE clopidogrel_5\NNP\1740| (r_compound) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (r_compound) study_15\NN\635850|the|trial (r_nsubj) demonstrated_17\VBN\2137132|study|has|superior|. (l_ccomp) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
C055162_D004617 NONE clopidogrel_26\NN\1740|(|plus|aspirin|) (r_appos) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
C081309_D001281 NONE irbesartan_8\NN\1740|with (r_nmod) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (l_compound) fibrillation_4\NN\14361664|atrial
C081309_D004617 NONE irbesartan_8\NN\1740|with (r_nmod) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (r_compound) study_15\NN\635850|the|trial (r_nsubj) demonstrated_17\VBN\2137132|study|has|superior|. (l_ccomp) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
D014859_D001281 NONE warfarin_19\NN\2718259| (r_nsubj) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (r_ccomp) demonstrated_17\VBN\2137132|study|has|superior|. (l_nsubj) study_15\NN\635850|the|trial (l_compound) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (l_compound) fibrillation_4\NN\14361664|atrial
D014859_D004617 NONE warfarin_19\NN\2718259| (r_nsubj) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
D001241_D001281 NONE aspirin_28\NN\2707683| (r_conj) clopidogrel_26\NN\1740|(|plus|aspirin|) (r_appos) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (r_ccomp) demonstrated_17\VBN\2137132|study|has|superior|. (l_nsubj) study_15\NN\635850|the|trial (l_compound) trial_6\NNP\786195|active-w|(|fibrillation|clopidogrel|irbesartan|prevention|) (l_compound) fibrillation_4\NN\14361664|atrial
D001241_D004617 NONE aspirin_28\NN\2707683| (r_conj) clopidogrel_26\NN\1740|(|plus|aspirin|) (r_appos) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
C479958_D001281 NONE idraparinux_0\NN\1740|,|inhibitor|, (r_nsubjpass) evaluated_9\VBN\670261|idraparinux|is|being|patients|. (l_nmod) patients_11\NNS\9898892|in|fibrillation (l_nmod) fibrillation_14\NN\14361664|with|atrial
D000809_D001281 NONE angiotensin-converting_0\JJ\1740| (r_amod) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) fibrillation_12\NN\14361664|in|atrial
D000809_D020257 NONE angiotensin-converting_0\JJ\1740| (r_amod) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) remodelling_15\NN\1740|through|cardiac
D000804_D001281 NONE ii_5\CD\13741022| (r_nummod) drugs_7\NNS\14778436|angiotensin|ii|receptor-blocking (r_conj) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) fibrillation_12\NN\14361664|in|atrial
D000804_D020257 NONE ii_5\CD\13741022| (r_nummod) drugs_7\NNS\14778436|angiotensin|ii|receptor-blocking (r_conj) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) remodelling_15\NN\1740|through|cardiac
7516729
D014700_D001919 CID verapamil_4\NN\2938514|by (r_nmod) induced_2\VBN\1627355|verapamil (r_acl) bradycardia_1\NN\14110674|dose-dependent|induced
20084309
D008874_D020521 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) age_15\NN\4916342|,|sex|,|stroke|,|myocardiopathy|,|duration|,|regurgitation|and|dose (l_conj) stroke_19\NN\556313|
D008874_D009202 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) age_15\NN\4916342|,|sex|,|stroke|,|myocardiopathy|,|duration|,|regurgitation|and|dose (l_conj) myocardiopathy_21\NN\14103288|mp
D008874_D009202 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) age_15\NN\4916342|,|sex|,|stroke|,|myocardiopathy|,|duration|,|regurgitation|and|dose (l_conj) myocardiopathy_21\NN\14103288|mp (l_appos) mp_23\NN\10249459|(|)
D008874_D009202 NONE mz_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|high|mz|mg (r_conj) mr_6\NN\6339416|severe|,|mp|and|doses (l_conj) mp_8\NN\10249459|%
D008874_D008944 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) age_15\NN\4916342|,|sex|,|stroke|,|myocardiopathy|,|duration|,|regurgitation|and|dose (l_conj) regurgitation_32\NN\7406350|mitral|mr
D008874_D008944 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) age_15\NN\4916342|,|sex|,|stroke|,|myocardiopathy|,|duration|,|regurgitation|and|dose (l_conj) regurgitation_32\NN\7406350|mitral|mr (l_appos) mr_34\NN\6339416|(|)
D008874_D008944 NONE mz_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|high|mz|mg (r_conj) mr_6\NN\6339416|severe|,|mp|and|doses
D008874_D000860 CID mz_44\NN\1740| (r_compound) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused (r_nmod) 8_34\CD\13741022|%|hypoxia (r_conj) presented_22\VBD\2137132|patients|hypoxia|obstruction|and|8|. (r_dep) event_10\NN\23100|hypoxia|was|the|common|patients|;|presented (l_nsubj) hypoxia_1\NN\14035298|mild|%
D008874_D000860 CID mz_44\NN\1740| (r_compound) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused (r_nmod) 8_34\CD\13741022|%|hypoxia (r_conj) presented_22\VBD\2137132|patients|hypoxia|obstruction|and|8|. (l_dobj) hypoxia_24\NN\14035298|transient
D008874_D000860 CID mz_44\NN\1740| (r_compound) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused
D008874_D000402 NONE mz_44\NN\1740| (r_compound) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused (r_nmod) 8_34\CD\13741022|%|hypoxia (r_conj) presented_22\VBD\2137132|patients|hypoxia|obstruction|and|8|. (l_nmod) obstruction_29\NN\4341686|due|airway|introduction
4812392
D001379_D011565 NONE azathioprine_4\NN\3740161|with (r_nmod) treatment_0\NN\654885|psoriasis|azathioprine|. (l_nmod) psoriasis_2\NN\14219661|of
D001379_D011565 NONE azathioprine_0\NN\3740161| (r_compound) treatment_1\NN\654885|azathioprine (r_nsubj) benefited_2\VBD\2210855|treatment|19|patients|. (l_dobj) patients_11\NNS\9898892|29|suffering (l_acl) suffering_12\VBG\2110220|psoriasis (l_nmod) psoriasis_15\NN\14219661|from|severe
D001379_D056486 NONE azathioprine_9\NN\3740161| (r_compound) therapy_10\NN\657604|azathioprine (r_nsubjpass) continued_12\VBN\2367363|if|therapy|is|detected (l_advcl) detected_20\VBN\2163746|so|that|damage|may|be|stage (l_nsubjpass) damage_17\NN\7296428|structural|liver
11431197
D011899_D009395 CID ranitidine-induced_0\JJ\1740| (r_amod) nephritis_3\NN\14113228|ranitidine-induced|acute|interstitial|allograft|.
D011899_D009395 CID ranitidine-induced_5\JJ\1740| (r_amod) nephritis_8\NN\14113228|of|ranitidine-induced|acute|interstitial|recipient
9766615
D003024_D001480 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (r_conj) gain_27\NN\13576355|weight|,|dysfunction|,|threshold (r_conj) sedation_18\NN\14034177|with|,|effects|,|effects|,|gain (r_nmod) associated_13\VBN\628491|are|degrees|sedation (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|. (l_dobj) risk_7\NN\14541044|a|lower|eps (l_nmod) eps_9\NN\1740|of
D003024_D001480 NONE clozapine_46\NN\3713736|(|only|) (r_dep) agranulocytosis_44\NN\14189204|clozapine (r_conj) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (r_conj) gain_27\NN\13576355|weight|,|dysfunction|,|threshold (r_conj) sedation_18\NN\14034177|with|,|effects|,|effects|,|gain (r_nmod) associated_13\VBN\628491|are|degrees|sedation (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|. (l_dobj) risk_7\NN\14541044|a|lower|eps (l_nmod) eps_9\NN\1740|of
D003024_D015430 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (r_conj) gain_27\NN\13576355|weight|,|dysfunction|,|threshold
D003024_D015430 NONE clozapine_46\NN\3713736|(|only|) (r_dep) agranulocytosis_44\NN\14189204|clozapine (r_conj) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (r_conj) gain_27\NN\13576355|weight|,|dysfunction|,|threshold
D003024_D012735 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (r_conj) gain_27\NN\13576355|weight|,|dysfunction|,|threshold (l_conj) dysfunction_30\NN\14204950|sexual|,|effects
D003024_D012735 NONE clozapine_46\NN\3713736|(|only|) (r_dep) agranulocytosis_44\NN\14189204|clozapine (r_conj) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (r_conj) gain_27\NN\13576355|weight|,|dysfunction|,|threshold (l_conj) dysfunction_30\NN\14204950|sexual|,|effects
D003024_D012640 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (l_compound) seizure_36\NN\14081375|
D003024_D012640 NONE clozapine_46\NN\3713736|(|only|) (r_dep) agranulocytosis_44\NN\14189204|clozapine (r_conj) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (l_compound) seizure_36\NN\14081375|
D003024_D000380 CID clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|lowered|seizure|clozapine|,|and|agranulocytosis (l_conj) agranulocytosis_44\NN\14189204|clozapine
D003024_D000380 CID clozapine_46\NN\3713736|(|only|) (r_dep) agranulocytosis_44\NN\14189204|clozapine
1786266
D000928_D001480 NONE antidepressant_3\JJ\1740| (r_amod) use_4\NN\407535|antidepressant|,|and|findings (r_conj) syndrome_1\NN\5870365|rabbit|,|use|.
10193204
C009438_D013927 NONE tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice|and|aggregation
C009438_D013927 NONE tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation
C009438_D013927 NONE tet_15\NN\15157225|of|and|fan (r_nmod) mg/kg_10\NN\1740|(|50|,|i.p.|)|tet (r_appos) administration_7\NN\1133281|the|mg/kg|mice (r_nsubj) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
C009438_D001791 NONE tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice|and|aggregation (l_conj) aggregation_13\NN\31264|human|platelet
C009438_D001791 NONE tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
C009438_D001791 NONE tet_14\NNP\15157225|and|fan (r_nsubj) showed_17\VBD\2137132|aggregations|,|tet|inhibitions|dose|dependently|. (l_nmod) aggregations_5\NNS\31264|in|vitro|human|platelet|induced
C060802_D013927 NONE fangchinoline_4\NN\1740| (r_conj) tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice|and|aggregation
C060802_D013927 NONE fan_12\NN\3183080| (r_conj) tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation
C060802_D013927 NONE fan_17\NN\3183080| (r_conj) tet_15\NN\15157225|of|and|fan (r_nmod) mg/kg_10\NN\1740|(|50|,|i.p.|)|tet (r_appos) administration_7\NN\1133281|the|mg/kg|mice (r_nsubj) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
C060802_D001791 NONE fangchinoline_4\NN\1740| (r_conj) tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice|and|aggregation (l_conj) aggregation_13\NN\31264|human|platelet
C060802_D001791 NONE fan_12\NN\3183080| (r_conj) tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
C060802_D001791 NONE fan_16\NN\3183080| (r_conj) tet_14\NNP\15157225|and|fan (r_nsubj) showed_17\VBD\2137132|aggregations|,|tet|inhibitions|dose|dependently|. (l_nmod) aggregations_5\NNS\31264|in|vitro|human|platelet|induced
C009438_D001778 NONE tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
C060802_D001778 NONE fan_12\NN\3183080| (r_conj) tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
D004837_D013927 CID epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation
D004837_D013927 CID ep_23\NN\1740|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation
D004837_D001791 NONE epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
D004837_D001791 NONE ep_23\NN\1740|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
D004837_D001778 NONE epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
D004837_D001778 NONE ep_23\NN\1740|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced|,|and|aggregation (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
D001241_D013927 NONE acid_36\NN\14818238|acetylsalicylic|asa (r_nsubj) showed_50\VBD\2137132|while|acid|inhibition (r_advcl) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
D001241_D013927 NONE asa_38\NN\1740|(|,|mg/kg|i.p.|)|,|control|, (r_appos) acid_36\NN\14818238|acetylsalicylic|asa (r_nsubj) showed_50\VBD\2137132|while|acid|inhibition (r_advcl) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
2522601
D002220_D004342 CID carbamazepine_2\NN\1740|to (r_nmod) hypersensitivity_0\NN\14531772|carbamazepine|presenting|.
D002220_D004342 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine
D002220_D007955 CID carbamazepine_2\NN\1740|to (r_nmod) hypersensitivity_0\NN\14531772|carbamazepine|presenting|. (l_acl) presenting_3\VBG\2137132|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia
D002220_D007955 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBD\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) reaction_17\NN\13446390|a|severe|leukemoid
D002220_D004802 NONE carbamazepine_2\NN\1740|to (r_nmod) hypersensitivity_0\NN\14531772|carbamazepine|presenting|. (l_acl) presenting_3\VBG\2137132|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia (l_conj) eosinophilia_9\NN\14299637|,|erythroderma
D002220_D004802 NONE carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBD\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) eosinophilia_19\NN\14299637|
D002220_D003873 CID carbamazepine_2\NN\1740|to (r_nmod) hypersensitivity_0\NN\14531772|carbamazepine|presenting|. (l_acl) presenting_3\VBG\2137132|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia (l_conj) eosinophilia_9\NN\14299637|,|erythroderma (l_conj) erythroderma_11\NN\14219661|,|and|failure
D002220_D003873 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBD\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure
D002220_D051437 CID carbamazepine_2\NN\1740|to (r_nmod) hypersensitivity_0\NN\14531772|carbamazepine|presenting|. (l_acl) presenting_3\VBG\2137132|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia (l_conj) eosinophilia_9\NN\14299637|,|erythroderma (l_conj) erythroderma_11\NN\14219661|,|and|failure (l_conj) failure_15\NN\66216|renal
D002220_D051437 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBD\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) failure_25\NN\66216|renal
D002220_D007010 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBD\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) hyponatremia_21\NN\14299637|
18221780
D016202_D010146 NONE nmda_3\NN\1740| (r_compound) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia|model (l_nmod) model_12\NN\5888929|in|a|capsaicin|pain (l_nmod) pain_15\NN\14299637|of|persistent
D016202_D010146 NONE nmda_7\NN\1740| (r_compound) antagonists_8\NNS\7846|between|nmda|and|morphine (r_nmod) interaction_5\NN\37396|a|sexually-dimorphic|antagonists|model (l_nmod) model_15\NN\5888929|in|a|persistent|pain|distinguished (l_compound) pain_14\NN\14299637|
D016202_D059787 NONE nmda_3\NN\1740| (r_compound) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia|model (r_nmod) differences_1\NNS\4723816|sex|enhancement|:|comparisons (l_dep) comparisons_17\NNS\635850|models|. (l_nmod) models_20\NNS\5888929|to|two|pain (l_nmod) pain_23\NN\14299637|of|acute
D016202_D059787 NONE n-methyl-d-aspartate_5\NN\1740|nmda (r_compound) antagonists_9\NNS\7846|n-methyl-d-aspartate (r_nsubj) enhance_10\VBP\227165|models|,|antagonists|effects|extent|. (l_nmod) models_3\NNS\5888929|in|acute|pain (l_compound) pain_2\NN\14299637|
D016202_D059787 NONE nmda_7\NN\1740|(|) (r_appos) n-methyl-d-aspartate_5\NN\1740|nmda (r_compound) antagonists_9\NNS\7846|n-methyl-d-aspartate (r_nsubj) enhance_10\VBP\227165|models|,|antagonists|effects|extent|. (l_nmod) models_3\NNS\5888929|in|acute|pain (l_compound) pain_2\NN\14299637|
D016202_D059787 NONE nmda_7\NN\1740| (r_compound) antagonists_8\NNS\7846|between|nmda|and|morphine (r_nmod) interaction_5\NN\37396|a|sexually-dimorphic|antagonists|model (l_nmod) model_15\NN\5888929|in|a|persistent|pain|distinguished (l_acl:relcl) distinguished_19\VBN\618878|that|can|be|those (l_nmod) those_21\DT\1740|from|observed (l_acl) observed_22\VBN\2163746|models (l_nmod) models_26\NNS\5888929|in|acute|pain (l_compound) pain_25\NN\14299637|
D009020_D010146 NONE morphine_7\NN\2707683| (r_compound) antihyperalgesia_8\NN\1740|of|morphine (r_nmod) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia|model (l_nmod) model_12\NN\5888929|in|a|capsaicin|pain (l_nmod) pain_15\NN\14299637|of|persistent
D009020_D010146 NONE morphine_10\NN\2707683| (r_conj) antagonists_8\NNS\7846|between|nmda|and|morphine (r_nmod) interaction_5\NN\37396|a|sexually-dimorphic|antagonists|model (l_nmod) model_15\NN\5888929|in|a|persistent|pain|distinguished (l_compound) pain_14\NN\14299637|
D009020_D059787 NONE morphine_7\NN\2707683| (r_compound) antihyperalgesia_8\NN\1740|of|morphine (r_nmod) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia|model (r_nmod) differences_1\NNS\4723816|sex|enhancement|:|comparisons (l_dep) comparisons_17\NNS\635850|models|. (l_nmod) models_20\NNS\5888929|to|two|pain (l_nmod) pain_23\NN\14299637|of|acute
D009020_D059787 NONE morphine_15\NN\2707683|of (r_nmod) effects_13\NNS\13245626|the|antinociceptive|morphine (r_dobj) enhance_10\VBP\227165|models|,|antagonists|effects|extent|. (l_nmod) models_3\NNS\5888929|in|acute|pain (l_compound) pain_2\NN\14299637|
D009020_D059787 NONE morphine_2\NN\2707683| (r_compound) antinociception_3\NN\1740|of|morphine (r_nmod) enhancement_0\NN\248977|antinociception|dextromethorphan (r_nsubjpass) seen_7\VBN\2106506|enhancement|was|males|models|,|greater|. (l_nmod) models_17\NNS\5888929|in|the|acute|pain (l_compound) pain_16\NN\14299637|
D009020_D059787 NONE morphine_10\NN\2707683| (r_conj) antagonists_8\NNS\7846|between|nmda|and|morphine (r_nmod) interaction_5\NN\37396|a|sexually-dimorphic|antagonists|model (l_nmod) model_15\NN\5888929|in|a|persistent|pain|distinguished (l_acl:relcl) distinguished_19\VBN\618878|that|can|be|those (l_nmod) those_21\DT\1740|from|observed (l_acl) observed_22\VBN\2163746|models (l_nmod) models_26\NNS\5888929|in|acute|pain (l_compound) pain_25\NN\14299637|
D002211_D010146 NONE capsaicin_11\NN\15032661| (r_compound) model_12\NN\5888929|in|a|capsaicin|pain (l_nmod) pain_15\NN\14299637|of|persistent
D002211_D059787 NONE capsaicin_11\NN\15032661| (r_compound) model_12\NN\5888929|in|a|capsaicin|pain (r_nmod) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia|model (r_nmod) differences_1\NNS\4723816|sex|enhancement|:|comparisons (l_dep) comparisons_17\NNS\635850|models|. (l_nmod) models_20\NNS\5888929|to|two|pain (l_nmod) pain_23\NN\14299637|of|acute
D002211_D006930 CID capsaicin_11\NN\15032661|of (r_nmod) administration_9\NN\1133281|by|capsaicin|tail (r_nmod) induced_7\VBN\1627355|end|,|hyperalgesia|was|administration|,|immersed|,|and|measured|. (l_nsubjpass) hyperalgesia_5\NN\1740|persistent
D003915_D059787 NONE dextromethorphan_5\NN\1740|by (r_nmod) enhancement_0\NN\248977|antinociception|dextromethorphan (r_nsubjpass) seen_7\VBN\2106506|enhancement|was|males|models|,|greater|. (l_nmod) models_17\NNS\5888929|in|the|acute|pain (l_compound) pain_16\NN\14299637|
16337777
D010862_D004827 NONE pilocarpine_12\NN\14712692|by (r_nmod) induced_10\VBN\1627355|pilocarpine (r_acl) model_7\NN\5888929|in|the|experimental|epilepsy|induced (l_nmod) epilepsy_9\NN\14085708|of
D010862_D013226 NONE pilocarpine_49\NN\14712692| (r_compound) model_50\NN\5888929|of|the|pilocarpine|epilepsy (r_nmod) phase_46\NN\15113229|in|the|chronic|model (r_nmod) provoke_18\VB\1617192|to|abnormalities|phase (r_xcomp) sufficient_16\JJ\1740|whether|generation|would|be|provoke (l_nsubj) generation_8\NN\7942152|increased|fr|epilepticus (l_nmod) epilepticus_13\NN\1740|during|status
D010862_D004833 CID pilocarpine_49\NN\14712692| (r_compound) model_50\NN\5888929|of|the|pilocarpine|epilepsy (l_nmod) epilepsy_54\NN\14085708|of|temporal|lobe
7352670
D009599_D006973 NONE nitroprusside_4\NN\1740|after|sodium (r_nmod) hypertensive_1\JJ\1740|rebound|nitroprusside|prevented
D009599_D006973 NONE snp_2\NN\11493266| (r_compound) infusion_3\NN\14589223|during|the|snp (r_nmod) demonstrated_7\VBD\2137132|infusion|animals|increase|,|whereas|showed|. (l_dobj) increase_10\NN\13576355|a|progressive|pressure|torr (l_nmod) pressure_13\NN\11419404|in|blood
D012504_D006973 NONE saralasin_7\NN\1740|by (r_nmod) prevented_5\VBN\1740|saralasin|rats|. (r_dep) hypertensive_1\JJ\1740|rebound|nitroprusside|prevented
D012504_D006973 NONE saralasin-treated_20\JJ\1740| (r_amod) animals_21\NNS\4475|the|saralasin-treated (r_nsubj) showed_22\VBD\2137132|animals|change (r_parataxis) demonstrated_7\VBD\2137132|infusion|animals|increase|,|whereas|showed|. (l_dobj) increase_10\NN\13576355|a|progressive|pressure|torr (l_nmod) pressure_13\NN\11419404|in|blood
D000809_D007022 NONE angiotensin_6\JJ\1740| (r_amod) system_7\NN\3575240|of|the|renin|--|angiotensin (r_nmod) role_1\NN\719494|the|system|maintenance (l_nmod) maintenance_10\NN\266806|in|the|pressure|anesthesia (l_nmod) anesthesia_16\NN\14034177|during|halothane|and|hypotension (l_conj) hypotension_21\NN\14057371|(snp)-induced
D000809_D007022 NONE angiotensin_8\JJ\1740| (r_amod) system_9\NN\3575240|of|the|renin|angiotensin (r_nmod) participation_3\NN\1080366|the|system|antagonizing (l_advcl) antagonizing_11\VBG\1787955|in|effects (l_dobj) effects_15\NNS\13245626|the|combined|hypotensive|halothane (l_amod) hypotensive_14\JJ\1740|
D006221_D007022 CID halothane_15\NN\3570838| (r_compound) anesthesia_16\NN\14034177|during|halothane|and|hypotension (l_conj) hypotension_21\NN\14057371|(snp)-induced
D006221_D007022 CID halothane_17\NN\3570838|of|and|snp (r_nmod) effects_15\NNS\13245626|the|combined|hypotensive|halothane (l_amod) hypotensive_14\JJ\1740|
D009599_D007022 CID nitroprusside_19\NN\1740|sodium (r_compound) (snp)-induced_20\NN\1740|nitroprusside (r_nummod) hypotension_21\NN\14057371|(snp)-induced
D009599_D007022 CID (snp)-induced_20\NN\1740|nitroprusside (r_nummod) hypotension_21\NN\14057371|(snp)-induced
D009599_D007022 CID snp_19\NN\11493266| (r_conj) halothane_17\NN\3570838|of|and|snp (r_nmod) effects_15\NNS\13245626|the|combined|hypotensive|halothane (l_amod) hypotensive_14\JJ\1740|
11807648
D014148_D004827 NONE acid_10\NN\14818238|tranexamic (r_dobj) containing_8\VBG\2632940|acid|rats (r_acl) sealants_7\NNS\14705533|of|fibrin|containing (r_nmod) application_4\NN\947128|following|cortical|sealants (r_nmod) seizures_1\NNS\14081375|epileptic|application|.
D014148_D004827 NONE tamca_2\NNP\1740| (r_nsubjpass) shown_5\VBN\2137132|however|,|tamca|has|been|cause|. (l_xcomp) cause_7\VB\1617192|to|seizures (l_dobj) seizures_9\NNS\14081375|epileptic
D014148_D012640 CID tamca_5\NNP\1740| (r_nsubj) retains_6\VBZ\2700867|whether|tamca|action|incorporated (l_dobj) action_9\NN\30358|its|convulsive (l_amod) convulsive_8\JJ\1740|
D014148_D012640 CID tamca_4\NN\1740| (r_dobj) containing_3\VBG\2632940|tamca (r_acl) fs_2\NN\13714184|containing (r_nsubj) caused_5\VBD\1617192|fs|activity|. (l_dobj) activity_8\NN\30358|paroxysmal|brain|associated (l_acl:relcl) associated_11\VBN\628491|which|was|behaviours (l_nmod) behaviours_15\NNS\14006945|with|distinct|convulsive (l_amod) convulsive_14\JJ\1740|
D014148_D012640 CID tamca_10\NN\1740|of (r_nmod) concentration_8\NN\4916342|with|increasing|tamca (r_nmod) increased_5\VBD\169651|degree|concentration|. (l_nsubj) degree_1\NN\4916342|the|seizures (l_nmod) seizures_4\NNS\14081375|of|these
D014148_D012640 CID tamca_6\NN\1740|mg/ml (r_dobj) containing_3\VBG\2632940|tamca (r_acl) fs_2\NN\13714184|containing (r_nsubj) evoked_7\VBD\1617192|thus|,|fs|seizures|rats|n=6|evoked|. (l_dobj) seizures_9\NNS\14081375|generalized
D014148_D012640 CID tamca_6\NN\1740|mg/ml (r_dobj) containing_3\VBG\2632940|tamca (r_acl) fs_2\NN\13714184|containing (r_nsubj) evoked_7\VBD\1617192|thus|,|fs|seizures|rats|n=6|evoked|. (l_advcl) evoked_28\VBD\1617192|while|concentration|only|episodes|rats (l_dobj) episodes_30\NNS\7283608|brief|potentials (l_nmod) potentials_34\NNS\14481929|of|jerk-correlated|convulsive (l_amod) convulsive_33\JJ\1740|
D014148_D012640 CID tamca_22\NN\1740|of (r_nmod) concentration_20\NN\4916342|the|lowest|tamca|mg/ml (r_nsubj) evoked_28\VBD\1617192|while|concentration|only|episodes|rats (r_advcl) evoked_7\VBD\1617192|thus|,|fs|seizures|rats|n=6|evoked|. (l_dobj) seizures_9\NNS\14081375|generalized
D014148_D012640 CID tamca_22\NN\1740|of (r_nmod) concentration_20\NN\4916342|the|lowest|tamca|mg/ml (r_nsubj) evoked_28\VBD\1617192|while|concentration|only|episodes|rats (l_dobj) episodes_30\NNS\7283608|brief|potentials (l_nmod) potentials_34\NNS\14481929|of|jerk-correlated|convulsive (l_amod) convulsive_33\JJ\1740|
D014148_D012640 CID acid_3\NN\14818238|tranexamic (r_nsubj) retains_4\VBZ\2700867|interpretation|:|acid|action|. (l_dobj) action_7\NN\30358|its|convulsive|fs (l_amod) convulsive_6\JJ\1740|
15325671
D003520_D066126 NONE cyclophosphamide-based_7\JJ\1740| (r_amod) chemotherapy_8\NN\661091|with|high-dose|cyclophosphamide-based|cancer (r_nmod) association_4\NN\8008335|in|chemotherapy (r_nmod) observed_2\VBN\2163746|association (r_acl) toxicity_1\NN\13576101|cardiac|observed|.
D003520_D066126 NONE cyclophosphamide-related_3\JJ\1740| (r_amod) toxicity_5\NN\13576101|of|transient|cyclophosphamide-related|cardiac|%
D003520_D001943 NONE cyclophosphamide-based_7\JJ\1740| (r_amod) chemotherapy_8\NN\661091|with|high-dose|cyclophosphamide-based|cancer (l_nmod) cancer_12\NN\14239425|for|metastatic|breast
D003520_D001943 NONE cyclophosphamide_10\NN\1740|high-dose|,|thiotepa|,|and|carboplatin (r_conj) paclitaxel_5\NN\1740|,|melphalan|and|cyclophosphamide (r_dobj) combined_4\VBD\2630189|:|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|triple|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D003520_D001943 NONE cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide|part (r_acl) women_5\NNS\9605289|on|61|cancer|receiving (l_nmod) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast
D017239_D001943 NONE paclitaxel_5\NN\1740|,|melphalan|and|cyclophosphamide (r_dobj) combined_4\VBD\2630189|:|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|triple|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D008558_D001943 NONE melphalan_7\NN\2722458| (r_conj) paclitaxel_5\NN\1740|,|melphalan|and|cyclophosphamide (r_dobj) combined_4\VBD\2630189|:|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|triple|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D013852_D001943 NONE thiotepa_12\NN\2722458| (r_conj) cyclophosphamide_10\NN\1740|high-dose|,|thiotepa|,|and|carboplatin (r_conj) paclitaxel_5\NN\1740|,|melphalan|and|cyclophosphamide (r_dobj) combined_4\VBD\2630189|:|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|triple|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D016190_D001943 NONE carboplatin_15\NN\1740| (r_conj) cyclophosphamide_10\NN\1740|high-dose|,|thiotepa|,|and|carboplatin (r_conj) paclitaxel_5\NN\1740|,|melphalan|and|cyclophosphamide (r_dobj) combined_4\VBD\2630189|:|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|triple|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D003520_D006333 CID cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide|part (r_acl) women_5\NNS\9605289|on|61|cancer|receiving (r_nmod) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_advcl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure|and|characteristics (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf
D003520_D006333 CID cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide|part (r_acl) women_5\NNS\9605289|on|61|cancer|receiving (r_nmod) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_advcl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure|and|characteristics (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf (l_appos) chf_34\NN\1740|(|)
D003520_D006333 CID cyclophosphamide_18\NN\1740|following|infusional|decline (r_nmod) developed_10\VBD\1753788|women|chf|cyclophosphamide|. (l_dobj) chf_15\NN\1740|reversible|grade|3
D003520_D006333 CID cyclophosphamide_5\NN\1740|during|infusional (r_nmod) monitoring_2\NN\879759|routine|ekg|cyclophosphamide (r_nsubj) predict_8\VB\916909|monitoring|did|not|development|. (l_dobj) development_10\NN\248977|chf (l_compound) chf_9\NN\1740|
D003520_D006973 NONE cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide|part (r_acl) women_5\NNS\9605289|on|61|cancer|receiving (r_nmod) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_dep) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (l_conj) hypertension_52\NN\14057371|
D003520_D003920 NONE cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide|part (r_acl) women_5\NNS\9605289|on|61|cancer|receiving (r_nmod) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_dep) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (l_conj) mellitus_61\NN\1740|diabetes
D018943_D001943 NONE anthracyclines_66\NNS\1740|of (r_nmod) use_64\NN\407535|prior|anthracyclines (r_conj) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (r_dep) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_nmod) women_5\NNS\9605289|on|61|cancer|receiving (l_nmod) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast
D018943_D006333 NONE anthracyclines_66\NNS\1740|of (r_nmod) use_64\NN\407535|prior|anthracyclines (r_conj) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (r_dep) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_advcl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure|and|characteristics (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf
D018943_D006333 NONE anthracyclines_66\NNS\1740|of (r_nmod) use_64\NN\407535|prior|anthracyclines (r_conj) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (r_dep) performed_2\VBN\2367363|analysis|was|women|assess|presence|. (l_advcl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure|and|characteristics (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf (l_appos) chf_34\NN\1740|(|)
D018943_D006973 NONE anthracyclines_66\NNS\1740|of (r_nmod) use_64\NN\407535|prior|anthracyclines (r_conj) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (l_conj) hypertension_52\NN\14057371|
D018943_D003920 NONE anthracyclines_66\NNS\1740|of (r_nmod) use_64\NN\407535|prior|anthracyclines (r_conj) presence_42\NN\13954253|abnormalities|,|age|,|hypertension|,|history|,|smoking|,|mellitus|,|use|,|and|irradiation (l_conj) mellitus_61\NN\1740|diabetes
11147747
D018490_D014549 CID antidepressants_1\NNS\3740161|serotonergic|and|incontinence|. (l_conj) incontinence_4\NN\13473097|urinary
D018490_D014549 CID antidepressants_8\NNS\3740161|to|serotonergic (r_nmod) secondary_5\JJ\1740|antidepressants (r_amod) incontinence_4\NN\13473097|secondary
C047426_D014549 CID venlafaxine_10\NN\1740| (r_dobj) taking_9\VBG\2367363|while|venlafaxine (r_advcl) experienced_6\VBD\2108377|who|incontinence|taking (l_dobj) incontinence_7\NN\13473097|
C047426_D014549 CID venlafaxine_35\NN\1740|on (r_nmod) effect_33\NN\34213|this|side|venlafaxine (r_dobj) developed_30\VBD\1753788|who|effect (r_acl:relcl) third_28\NN\13732295|a|developed (r_conj) patients_9\NNS\9898892|2|female|developed|,|as|third (l_acl:relcl) developed_11\VBD\1753788|who|incontinence (l_dobj) incontinence_12\NN\13473097|secondary
D012701_D014549 NONE serotonin_17\NN\14807737| (r_compound) inhibitors_19\NNS\20090|to|the|selective|serotonin|reuptake|paroxetine (r_nmod) secondary_13\JJ\1740|inhibitors (r_amod) incontinence_12\NN\13473097|secondary
D017374_D014549 CID paroxetine_20\NN\1740|and|sertraline (r_dep) inhibitors_19\NNS\20090|to|the|selective|serotonin|reuptake|paroxetine (r_nmod) secondary_13\JJ\1740|inhibitors (r_amod) incontinence_12\NN\13473097|secondary
D020280_D014549 CID sertraline_22\NN\4169152| (r_conj) paroxetine_20\NN\1740|and|sertraline (r_dep) inhibitors_19\NNS\20090|to|the|selective|serotonin|reuptake|paroxetine (r_nmod) secondary_13\JJ\1740|inhibitors (r_amod) incontinence_12\NN\13473097|secondary
D016651_D014549 CID carbonate_12\NN\15010703|lithium|and|beta-blockers|,|contributed (l_acl:relcl) contributed_21\VBN\126264|both|could|have|incontinence (l_nmod) incontinence_24\NN\13473097|to|the
14659530
D009569_D008881 NONE no-induced_0\JJ\1740| (r_amod) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D015740_D008881 NONE peptide_10\NN\14724264|plasma|calcitonin|gene-related|cgrp (r_compound) concentration_14\NN\4916342|in|peptide (r_nmod) increase_5\NN\13576355|strong|concentration|and|correlation (r_dep) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D015740_D008881 NONE cgrp_12\NN\1740|(|) (r_appos) peptide_10\NN\14724264|plasma|calcitonin|gene-related|cgrp (r_compound) concentration_14\NN\4916342|in|peptide (r_nmod) increase_5\NN\13576355|strong|concentration|and|correlation (r_dep) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D015740_D008881 NONE peptide_15\NN\14724264|plasma|calcitonin|gene-related|cgrp (r_compound) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D015740_D008881 NONE cgrp_17\NN\1740|(|) (r_appos) peptide_15\NN\14724264|plasma|calcitonin|gene-related|cgrp (r_compound) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D015740_D008881 NONE cgrp_1\NN\1740| (r_compound) concentration_2\NN\4916342|plasma|cgrp (r_nsubj) increased_3\VBD\169651|concentration|significantly|p<0.01|attack|and|returned|. (l_nmod) attack_11\NN\955060|during|the|migraine (l_compound) migraine_10\NN\14326607|
D015740_D008881 NONE cgrp_1\NN\1740| (r_compound) concentration_2\NN\4916342|plasma|cgrp (r_nsubj) increased_3\VBD\169651|concentration|significantly|p<0.01|attack|and|returned|. (l_conj) returned_13\VBD\1835496|baseline|cessation (l_nmod) cessation_18\NN\7365849|after|the|migraine (l_nmod) migraine_21\NN\14326607|of|the
D015740_D008881 NONE cgrp_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|plasma|cgrp (r_nsubj) failed_5\VBD\1798936|however|,|concentrations|change|. (l_xcomp) change_7\VB\46534|to|headache|subjects (l_nmod) subjects_14\NNS\6598915|in|the|attack (l_nmod) attack_18\NN\955060|with|no|migraine (l_compound) migraine_17\NN\14326607|
D015740_D008881 NONE cgrp_1\NN\1740| (r_compound) concentration_2\NN\4916342|basal|cgrp (r_nsubj) higher_5\JJR\1740|concentration|was|significantly|and|tended (l_conj) tended_10\VBD\2604760|content|lower|. (l_xcomp) lower_13\JJR\1740|to|be|subjects (l_nmod) subjects_15\NNS\6598915|in|experienced (l_acl:relcl) experienced_17\VBD\2108377|who|attack (l_dobj) attack_20\NN\955060|a|migraine (l_compound) migraine_19\NN\14326607|
D015740_D008881 NONE cgrp_7\NN\1740| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity|headache (l_nmod) headache_18\NN\5829480|of|a|migraine (l_compound) migraine_17\NN\14326607|
D015740_D008881 NONE cgrp_7\NN\1740| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\2657219|that|concentration|timing (r_acl) fact_4\NN\5816287|the|correlates (r_nsubj) suggests_19\VBZ\1010118|conclusion|,|fact|relationship|. (l_dobj) relationship_22\NN\31921|a|direct|cgrp (l_nmod) cgrp_24\NN\1740|between|and|migraine (l_conj) migraine_26\NN\14326607|
D015740_D008881 NONE cgrp_24\NN\1740|between|and|migraine (r_nmod) relationship_22\NN\31921|a|direct|cgrp (r_dobj) suggests_19\VBZ\1010118|conclusion|,|fact|relationship|. (l_nsubj) fact_4\NN\5816287|the|correlates (l_acl) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity|headache (l_nmod) headache_18\NN\5829480|of|a|migraine (l_compound) migraine_17\NN\14326607|
D015740_D008881 NONE cgrp_24\NN\1740|between|and|migraine (l_conj) migraine_26\NN\14326607|
D015740_D008881 NONE cgrp_21\NN\1740| (r_compound) release_22\NN\3748886|the|concomitant|cgrp (r_conj) headache_17\NN\5829480|the|and|release|model (r_dobj) counteract_15\VB\2367363|contrast|,|provoke|,|it|may|even|headache|. (l_ccomp) provoke_9\VB\1617192|release|does|not|migraine (l_dobj) migraine_10\NN\14326607|
D012701_D008881 NONE serotonin_20\NN\14807737| (r_compound) release_21\NN\3748886|with|platelet|serotonin (r_nmod) correlation_17\NN\13841213|negative|release (r_conj) increase_5\NN\13576355|strong|concentration|and|correlation (r_dep) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D012701_D008881 NONE serotonin_22\NN\14807737| (r_compound) content_28\NN\7951464|platelet|serotonin|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D012701_D008881 NONE 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_compound) content_28\NN\7951464|platelet|serotonin|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D012701_D008881 NONE 5-ht_26\NN\1740| (r_appos) 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_compound) content_28\NN\7951464|platelet|serotonin|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D012701_D008881 NONE 5-ht_8\NN\1740| (r_compound) content_9\NN\7951464|platelet|5-ht (r_nsubj) tended_10\VBD\2604760|content|lower|. (l_xcomp) lower_13\JJR\1740|to|be|subjects (l_nmod) subjects_15\NNS\6598915|in|experienced (l_acl:relcl) experienced_17\VBD\2108377|who|attack (l_dobj) attack_20\NN\955060|a|migraine (l_compound) migraine_19\NN\14326607|
D012701_D008881 NONE serotonin_1\NN\14807737| (r_compound) content_2\NN\7951464|platelet|serotonin (r_nsubj) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|subjects|but|observed (l_nmod) subjects_11\NNS\6598915|in|attack (l_nmod) attack_15\NN\955060|with|no|migraine (l_compound) migraine_14\NN\14326607|
D012701_D008881 NONE serotonin_1\NN\14807737| (r_compound) content_2\NN\7951464|platelet|serotonin (r_nsubj) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|subjects|but|observed (l_conj) observed_21\VBN\2163746|change|was|patients|. (l_nmod) patients_23\NNS\9898892|in|attack (l_nmod) attack_26\NN\955060|with|migraine (l_compound) migraine_25\NN\14326607|
D012701_D008881 NONE serotonin_3\NN\14807737| (r_compound) release_4\NN\3748886|serotonin|platelets (r_nsubj) provoke_9\VB\1617192|release|does|not|migraine (l_dobj) migraine_10\NN\14326607|
D015740_D006261 NONE peptide_15\NN\14724264|plasma|calcitonin|gene-related|cgrp (r_compound) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack
D015740_D006261 NONE cgrp_17\NN\1740|(|) (r_appos) peptide_15\NN\14724264|plasma|calcitonin|gene-related|cgrp (r_compound) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack
D015740_D006261 NONE cgrp_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|plasma|cgrp (r_nsubj) failed_5\VBD\1798936|however|,|concentrations|change|. (l_xcomp) change_7\VB\46534|to|headache|subjects (l_nmod) headache_10\NN\5829480|during|immediate|and
D015740_D006261 NONE cgrp_7\NN\1740| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity|headache (l_nmod) headache_18\NN\5829480|of|a|migraine
D015740_D006261 NONE cgrp_24\NN\1740|between|and|migraine (r_nmod) relationship_22\NN\31921|a|direct|cgrp (r_dobj) suggests_19\VBZ\1010118|conclusion|,|fact|relationship|. (l_nsubj) fact_4\NN\5816287|the|correlates (l_acl) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity|headache (l_nmod) headache_18\NN\5829480|of|a|migraine
D015740_D006261 NONE cgrp_21\NN\1740| (r_compound) release_22\NN\3748886|the|concomitant|cgrp (r_conj) headache_17\NN\5829480|the|and|release|model
D012701_D006261 NONE serotonin_22\NN\14807737| (r_compound) content_28\NN\7951464|platelet|serotonin|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack
D012701_D006261 NONE 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_compound) content_28\NN\7951464|platelet|serotonin|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack
D012701_D006261 NONE 5-ht_26\NN\1740| (r_appos) 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_compound) content_28\NN\7951464|platelet|serotonin|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|and|content (r_nmod) changes_9\NNS\7283608|concentration|headache (l_nmod) headache_32\NN\5829480|during|the|immediate|and|attack
D012701_D006261 NONE serotonin_3\NN\14807737| (r_compound) release_4\NN\3748886|serotonin|platelets (r_nsubj) provoke_9\VB\1617192|release|does|not|migraine (r_ccomp) counteract_15\VB\2367363|contrast|,|provoke|,|it|may|even|headache|. (l_dobj) headache_17\NN\5829480|the|and|release|model
D005996_D006261 NONE nitroglycerin_41\NN\15015501|by (r_nmod) provoked_39\VBN\1617192|nitroglycerin (r_acl) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (r_conj) headache_32\NN\5829480|during|the|immediate|and|attack
D005996_D008881 NONE nitroglycerin_41\NN\15015501|by (r_nmod) provoked_39\VBN\1617192|nitroglycerin (r_acl) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D005996_D008881 NONE nitroglycerin_16\NN\15015501| (r_compound) application_17\NN\947128|the|nitroglycerin (r_nmod) min_11\NN\15154774|60|before|application|,|and|min|mean (l_conj) min_23\NN\15154774|60|after|beginning (l_nmod) beginning_26\NN\7283608|the|attack (l_nmod) attack_30\NN\955060|of|the|migraine (l_compound) migraine_29\NN\14326607|
D005996_D008881 NONE nitroglycerin_9\NN\15015501|after (r_nmod) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|subjects|but|observed (l_nmod) subjects_11\NNS\6598915|in|attack (l_nmod) attack_15\NN\955060|with|no|migraine (l_compound) migraine_14\NN\14326607|
D005996_D008881 NONE nitroglycerin_9\NN\15015501|after (r_nmod) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|subjects|but|observed (l_conj) observed_21\VBN\2163746|change|was|patients|. (l_nmod) patients_23\NNS\9898892|in|attack (l_nmod) attack_26\NN\955060|with|migraine (l_compound) migraine_25\NN\14326607|
567256
D004054_D006394 CID diethylstilbestrol_6\NN\14749794|with (r_nmod) associated_4\VBN\628491|diethylstilbestrol (r_acl) angiosarcoma_0\NN\14239425|liver|associated|. (l_nmod) liver_3\NN\5298729|of|the
D004054_D006394 CID diethylstilbestrol_21\NN\14749794|with (r_nmod) treated_12\VBN\2376958|who|had|been|adenocarcinoma|diethylstilbestrol|years (r_acl:relcl) man_8\NN\9605289|in|a|76-year-old|treated (r_nmod) occurred_4\VBD\2623529|angiosarcoma|man|. (l_nsubj) angiosarcoma_0\NN\14239425|liver (l_nmod) liver_3\NN\5298729|of|the
D004054_D008113 CID diethylstilbestrol_6\NN\14749794|with (r_nmod) associated_4\VBN\628491|diethylstilbestrol (r_acl) angiosarcoma_0\NN\14239425|liver|associated|. (l_nmod) liver_3\NN\5298729|of|the
D004054_D008113 CID diethylstilbestrol_21\NN\14749794|with (r_nmod) treated_12\VBN\2376958|who|had|been|adenocarcinoma|diethylstilbestrol|years (r_acl:relcl) man_8\NN\9605289|in|a|76-year-old|treated (r_nmod) occurred_4\VBD\2623529|angiosarcoma|man|. (l_nsubj) angiosarcoma_0\NN\14239425|liver (l_nmod) liver_3\NN\5298729|of|the
D004054_D008113 NONE diethylstilbestrol_21\NN\14749794|with (r_nmod) treated_12\VBN\2376958|who|had|been|adenocarcinoma|diethylstilbestrol|years (l_nmod) adenocarcinoma_16\NN\14242337|for|a|well-differentiated|liver (l_nmod) liver_19\NN\5298729|of|the
D004054_D000230 NONE diethylstilbestrol_21\NN\14749794|with (r_nmod) treated_12\VBN\2376958|who|had|been|adenocarcinoma|diethylstilbestrol|years (l_nmod) adenocarcinoma_16\NN\14242337|for|a|well-differentiated|liver (l_nmod) liver_19\NN\5298729|of|the
12789195
D008914_D004194 NONE minoxidil_7\NN\4522904|of (r_nmod) use_5\NN\407535|by|the|long-term|minoxidil (r_nmod) induced_1\VBN\1627355|use (r_acl) pseudoacromegaly_0\NN\1740|induced|.
D008914_D004194 NONE minoxidil_13\NN\4522904|of (r_nmod) use_11\NN\407535|from|the|long-term|minoxidil|dose (r_nmod) resulted_7\VBD\2633881|that|use (r_acl:relcl) pseudoacromegaly_5\NN\1740|with|resulted
D008914_D004194 NONE minoxidil_13\NN\4522904| (r_compound) use_14\NN\407535|of|minoxidil (r_nmod) effect_11\NN\34213|as|a|side|use (r_nmod) report_5\NN\6470073|this|is|the|first|case|pseudoacromegaly|effect|. (l_nmod) pseudoacromegaly_7\NN\1740|of
17931375
D006493_D003288 CID heparin_10\NN\2718259| (r_compound) injection_11\NN\320852|of|subcutaneous|heparin (r_nmod) duration_7\NN\15113229|of|the|injection (r_nmod) effect_4\NN\34213|on|the|duration|bruising (l_nmod) bruising_13\NN\1740|on|and|pain
D006493_D003288 CID heparin_26\NN\2718259|of (r_nmod) injection_24\NN\320852|of|the|subcutaneous|heparin (r_nmod) administration_20\NN\1133281|following|the|injection (r_nmod) bruising_15\NN\1740|on|and|pain|administration
D006493_D003288 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) bruising_7\NN\1740|and|pain|injection
D006493_D003288 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) bruising_7\NN\1740|and|pain|injection (r_dobj) prevent_6\VB\1740|to|bruising (r_acl) methods_4\NNS\5616786|different|prevent (r_nsubjpass) studied_19\VBN\630380|although|methods|have|been|widely|and|described (r_advcl) background_0\NN\4921011|:|studied (r_nsubjpass) documented_37\VBN\1000214|background|,|effect|is|little|. (l_nsubjpass) effect_24\NN\34213|the|duration|occurrence (l_nmod) occurrence_30\NN\29378|on|the|bruising (l_nmod) bruising_32\NN\1740|of|and|pain
D006493_D003288 CID heparin_6\NN\2718259| (r_nmod:npmod) applied_7\VBN\2676054|heparin (r_amod) areas_8\NNS\8630985|on|the|applied (r_nmod) bruising_3\NN\1740|of|the|areas
D006493_D003288 CID heparin_20\NN\2718259|of (r_nmod) administration_18\NN\1133281|following|the|subcutaneous|heparin (r_nmod) had_8\VBD\2108377|that|duration|effect|administration (l_dobj) effect_10\NN\34213|an|bruising (l_nmod) bruising_12\NN\1740|on|and|pain
D006493_D010146 CID heparin_10\NN\2718259| (r_compound) injection_11\NN\320852|of|subcutaneous|heparin (r_nmod) duration_7\NN\15113229|of|the|injection (r_nmod) effect_4\NN\34213|on|the|duration|bruising (l_nmod) bruising_13\NN\1740|on|and|pain (l_conj) pain_15\NN\14299637|
D006493_D010146 CID heparin_26\NN\2718259|of (r_nmod) injection_24\NN\320852|of|the|subcutaneous|heparin (r_nmod) administration_20\NN\1133281|following|the|injection (r_nmod) bruising_15\NN\1740|on|and|pain|administration (l_conj) pain_17\NN\14299637|
D006493_D010146 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) bruising_7\NN\1740|and|pain|injection (l_conj) pain_9\NN\14299637|
D006493_D010146 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) bruising_7\NN\1740|and|pain|injection (r_dobj) prevent_6\VB\1740|to|bruising (r_acl) methods_4\NNS\5616786|different|prevent (r_nsubjpass) studied_19\VBN\630380|although|methods|have|been|widely|and|described (r_advcl) background_0\NN\4921011|:|studied (r_nsubjpass) documented_37\VBN\1000214|background|,|effect|is|little|. (l_nsubjpass) effect_24\NN\34213|the|duration|occurrence (l_nmod) occurrence_30\NN\29378|on|the|bruising (l_nmod) bruising_32\NN\1740|of|and|pain (l_conj) pain_34\NN\14299637|
D006493_D010146 CID heparin_20\NN\2718259|of (r_nmod) administration_18\NN\1133281|following|the|subcutaneous|heparin (r_nmod) had_8\VBD\2108377|that|duration|effect|administration (l_dobj) effect_10\NN\34213|an|bruising (l_nmod) bruising_12\NN\1740|on|and|pain (l_conj) pain_14\NN\14299637|
17562951
D007479_D051436 NONE iopamidol_16\NN\1740|of|and|iodixanol (r_nmod) comparison_14\NN\635850|study|is|a|multicenter|,|double-blind|iopamidol|patients (l_nmod) patients_20\NNS\9898892|in|disease (l_nmod) disease_24\NN\14061805|with|chronic|kidney|rate
C044834_D051436 NONE iodixanol_18\NN\1740| (r_conj) iopamidol_16\NN\1740|of|and|iodixanol (r_nmod) comparison_14\NN\635850|study|is|a|multicenter|,|double-blind|iopamidol|patients (l_nmod) patients_20\NNS\9898892|in|disease (l_nmod) disease_24\NN\14061805|with|chronic|kidney|rate
D000111_D003920 NONE n-acetylcysteine_14\NN\1740|of (r_nmod) use_12\NN\407535|n-acetylcysteine (r_conj) volume_5\NN\33615|contrast|,|presence|,|use|,|scr|,|and|rate (l_conj) presence_7\NN\13954253|mellitus (l_nmod) mellitus_10\NN\1740|of|diabetes
D007479_D003920 NONE iopamidol_22\NN\1740|with (r_nmod) %_14\NN\1740|patients|,|increases|were|5.1|patients|iopamidol|and|%|,|whereas|%|. (l_nmod) patients_1\NNS\9898892|in|diabetes (l_nmod) diabetes_3\NN\14075199|with
D007479_D003920 NONE iopamidol_7\NN\1740|with (r_nmod) less_5\JJR\1740|increases|were|significantly|iopamidol|patients (l_dep) patients_10\NNS\9898892|(|all|:|mg/dl|,|micromol/l|,|p=0.03|;|patients|. (l_dep) patients_24\NNS\9898892|diabetes|:|mg/dl|,|micromol/l|,|p=0.01|) (l_nmod) diabetes_26\NN\14075199|with
D007479_D003920 NONE iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (l_nmod) patients_28\NNS\9898892|to|high-risk|,|with|mellitus (l_appos) mellitus_34\NN\1740|diabetes
C044834_D003920 NONE iodixanol_33\NN\1740|with (r_nmod) %_25\NN\1740|13.0|patients|iodixanol|p=0.11 (r_conj) %_14\NN\1740|patients|,|increases|were|5.1|patients|iopamidol|and|%|,|whereas|%|. (l_nmod) patients_1\NNS\9898892|in|diabetes (l_nmod) diabetes_3\NN\14075199|with
C044834_D003920 NONE iodixanol_25\NN\1740| (r_conj) iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (l_nmod) patients_28\NNS\9898892|to|high-risk|,|with|mellitus (l_appos) mellitus_34\NN\1740|diabetes
D007479_D007674 CID iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (r_nmod) different_17\JJ\1740|rate|is|not|statistically|administration (l_nsubj) rate_3\NN\13815152|the|nephropathy|, (l_nmod) nephropathy_6\NN\14573196|of|contrast-induced|,|defined
C044834_D007674 CID iodixanol_25\NN\1740| (r_conj) iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (r_nmod) different_17\JJ\1740|rate|is|not|statistically|administration (l_nsubj) rate_3\NN\13815152|the|nephropathy|, (l_nmod) nephropathy_6\NN\14573196|of|contrast-induced|,|defined
2070391
D008012_D010146 CID lidocaine_6\NN\3681148|buffered (r_dobj) using_4\VBG\1156834|lidocaine|anesthetic|catheterization (r_acl) reduction_0\NN\351485|pain|using|. (l_nmod) pain_3\NN\14299637|in|injection
D008012_D010146 CID lidocaine_11\NN\3681148|of (r_nmod) injection_9\NN\320852|with|the|lidocaine (r_nmod) associated_6\VBN\628491|injection (r_acl) pain_5\NN\14299637|associated
D008012_D010146 CID lidocaine_14\NN\3681148|of (r_nmod) ph_12\NN\5038959|the|lidocaine (r_dobj) adjust_10\VB\126264|to|ph|range (r_acl) addition_4\NN\3081021|the|solution|adjust (r_nsubj) reduce_20\VB\441445|if|addition|would|pain (l_dobj) pain_21\NN\14299637|injection
D008012_D010146 CID lidocaine_13\NN\3681148|standard|area (r_dobj) receiving_11\VBG\2210855|after|lidocaine|and|lidocaine (r_advcl) quantify_5\VB\947077|to|severity|receiving (l_dobj) severity_7\NN\5036394|the|pain (l_nmod) pain_9\NN\14299637|of
D008012_D010146 CID lidocaine_20\NN\3681148|buffered|area (r_conj) receiving_11\VBG\2210855|after|lidocaine|and|lidocaine (r_advcl) quantify_5\VB\947077|to|severity|receiving (l_dobj) severity_7\NN\5036394|the|pain (l_nmod) pain_9\NN\14299637|of
D008012_D010146 CID lidocaine_6\NN\3681148|for|buffered (r_nmod) score_3\NN\5736149|the|mean|pain|lidocaine (l_compound) pain_2\NN\14299637|
D008012_D010146 CID lidocaine_16\NN\3681148|for|standard (r_nmod) score_13\NN\5736149|than|the|mean|lidocaine (r_nmod) lower_9\JJR\1740|score|was|significantly|score|2.7|. (l_nsubj) score_3\NN\5736149|the|mean|pain|lidocaine (l_compound) pain_2\NN\14299637|
D008012_D010146 CID lidocaine_5\NN\3681148|of|standard (r_nmod) adjustment_2\NN\7357388|the|ph|lidocaine (r_nsubjpass) accomplished_8\VBN\484166|adjustment|can|be|easily|laboratory|injection|and|results|. (l_conj) results_17\VBZ\2633881|reduction (l_nmod) reduction_20\NN\351485|in|a|pain (l_nmod) pain_23\NN\14299637|of|the|occurring
9653867
D013974_D013971 CID thyroxine_0\JJ\1740| (r_amod) abuse_1\NN\418025|thyroxine|:|case (l_appos) case_5\NN\7283608|an|unusual|thyrotoxicosis|. (l_nmod) thyrotoxicosis_7\NN\14059928|of|pregnancy
D013974_D013971 CID thyroxine_28\NN\5413241| (r_compound) abuse_29\NN\418025|thyroxine (r_nsubjpass) considered_32\VBN\689344|that|remains|,|abuse|should|be|and|explored (l_advcl) remains_25\VBZ\2604760|when|cause|obscure (l_nsubj) cause_22\NN\7323922|a|thyrotoxicosis (l_nmod) thyrotoxicosis_24\NN\14059928|for
D013974_D001068 NONE thyroxine_28\NN\5413241| (r_compound) abuse_29\NN\418025|thyroxine (r_nsubjpass) considered_32\VBN\689344|that|remains|,|abuse|should|be|and|explored (r_ccomp) reminds_17\VBZ\831651|us|considered (r_conj) illustrates_3\VBZ\955601|particular|it|derangements|and|reminds|. (l_dobj) derangements_5\NNS\14395018|the|function|seen (l_acl) seen_9\VBN\2106506|women (l_nmod) women_12\NNS\9605289|in|pregnant|disorders (l_nmod) disorders_15\NNS\14034177|with|eating
18217897
D013792_D008228 NONE thalidomide_0\NN\4166841| (r_nsubj) has_1\VBZ\2108377|thalidomide|activity|:|trial (l_dobj) activity_4\NN\30358|limited|single-agent|lymphomas (l_nmod) lymphomas_11\NNS\14239918|in|relapsed|indolent|non-hodgkin
D013792_D009369 NONE thalidomide_0\NN\4166841| (r_nsubj) has_1\VBZ\2108377|thalidomide|activity|:|trial (l_dobj) trial_16\NN\786195|a|phase|ii|b. (l_nmod) b._23\.\1740|of|the|group (l_compound) group_22\NNP\2137|cancer (l_compound) cancer_19\NNP\14239425|and|leukemia
D013792_D007938 NONE thalidomide_0\NN\4166841| (r_nsubj) has_1\VBZ\2108377|thalidomide|activity|:|trial (l_dobj) trial_16\NN\786195|a|phase|ii|b. (l_nmod) b._23\.\1740|of|the|group (l_compound) group_22\NNP\2137|cancer (l_compound) cancer_19\NNP\14239425|and|leukemia (l_conj) leukemia_21\NNP\14239918|
D013792_D009101 NONE thalidomide_0\NN\4166841| (r_nsubj) agent_4\NN\7347|thalidomide|is|an|immunomodulatory|activity|. (l_nmod) activity_7\NN\30358|with|demonstrated|myeloma (l_nmod) myeloma_10\NN\14239425|in|multiple|,|lymphoma|and|lymphoma
D013792_D020522 NONE thalidomide_0\NN\4166841| (r_nsubj) agent_4\NN\7347|thalidomide|is|an|immunomodulatory|activity|. (l_nmod) activity_7\NN\30358|with|demonstrated|myeloma (l_nmod) myeloma_10\NN\14239425|in|multiple|,|lymphoma|and|lymphoma (l_conj) lymphoma_14\NN\14239918|mantle|cell
D013792_D008223 NONE thalidomide_0\NN\4166841| (r_nsubj) agent_4\NN\7347|thalidomide|is|an|immunomodulatory|activity|. (l_nmod) activity_7\NN\30358|with|demonstrated|myeloma (l_nmod) myeloma_10\NN\14239425|in|multiple|,|lymphoma|and|lymphoma (l_conj) lymphoma_17\NN\14239918|lymphoplasmacytic
D013792_D008223 NONE thalidomide_14\NN\4166841|mg (r_dobj) received_13\VBD\2210855|july|,|patients|thalidomide|escalation|. (l_nsubj) patients_8\NNS\9898892|24|lymphomas (l_nmod) lymphomas_12\NNS\14239918|with|relapsed/refractory|indolent
D013792_D008223 NONE thalidomide_12\NN\4166841|to|agent (r_nmod) rate_8\NN\13815152|an|important|response|thalidomide|lymphomas (l_nmod) lymphomas_15\NNS\14239918|in|indolent
C467567_D008223 NONE lenalidomide_31\NN\1740| (r_appos) agent_29\NN\7347|with|the|generation|immunomodulatory|,|lenalidomide (r_nmod) reported_23\VBN\831651|agent (r_acl) level_22\NN\4916342|with|the|higher|activity|reported (r_nmod) contrast_17\NN\13854649|level (r_conj) demonstrate_4\VB\2137132|to|rate|and|contrast (l_dobj) rate_8\NN\13815152|an|important|response|thalidomide|lymphomas (l_nmod) lymphomas_15\NNS\14239918|in|indolent
17491223
D004280_D017202 CID dobutamine-induced_12\JJ\1740| (r_amod) ischemia_14\NN\14195315|of|dobutamine-induced|myocardial
D004280_D017202 CID dobutamine-induced_10\JJ\1740| (r_amod) ischemia_12\NN\14195315|dobutamine-induced|myocardial
D004280_D017202 CID dobutamine-induced_35\JJ\1740| (r_amod) ischemia_37\NN\14195315|dobutamine-induced|myocardial
D004280_D007511 NONE dobutamine-induced_35\JJ\1740| (r_amod) ischemia_37\NN\14195315|dobutamine-induced|myocardial (r_dobj) detecting_34\VBG\2163746|for|ischemia (r_advcl) assess_3\VB\670261|to|value|detecting|,|using (l_advcl) using_39\VBG\1156834|tomography|standard|assess (l_advcl) assess_52\VB\670261|to|presence (l_dobj) presence_54\NN\13954253|the|or|absence|ischemia (l_nmod) ischemia_58\NN\14195315|of
D017256_D017202 NONE tc99m-sestamibi_40\JJ\1740| (r_amod) tomography_44\NN\900375|tc99m-sestamibi|single-photon|emission|computed (r_dobj) using_39\VBG\1156834|tomography|standard|assess (r_advcl) assess_3\VB\670261|to|value|detecting|,|using (l_advcl) detecting_34\VBG\2163746|for|ischemia (l_dobj) ischemia_37\NN\14195315|dobutamine-induced|myocardial
D017256_D007511 NONE tc99m-sestamibi_40\JJ\1740| (r_amod) tomography_44\NN\900375|tc99m-sestamibi|single-photon|emission|computed (r_dobj) using_39\VBG\1156834|tomography|standard|assess (l_advcl) assess_52\VB\670261|to|presence (l_dobj) presence_54\NN\13954253|the|or|absence|ischemia (l_nmod) ischemia_58\NN\14195315|of
12063090
D004177_D003248 NONE metamizol_0\NN\1740| (r_nsubj) potentiates_1\VBZ\229605|metamizol|antinociception|treatment|. (l_dobj) antinociception_3\NN\1740|morphine|not|constipation (l_conj) constipation_6\NN\14299637|
D004177_D003248 NONE metamizol_20\NN\1740|with|mg/kg|s.c. (r_nmod) combination_10\NN\7951464|of|the|morphine|metamizol|day|days|) (r_nmod) effects_7\NNS\13245626|the|antinociceptive|combination (l_amod) antinociceptive_4\JJ\1740|and|constipating (l_conj) constipating_6\JJ\1740|
D004177_D003248 NONE metamizol_20\NN\1740| (r_nsubj) potentiate_23\VB\229605|that|metamizol|did|not|constipation (l_dobj) constipation_25\NN\14299637|morphine-induced
D009020_D003248 CID morphine_2\NN\2707683| (r_compound) antinociception_3\NN\1740|morphine|not|constipation (l_conj) constipation_6\NN\14299637|
D009020_D003248 CID morphine_15\NN\2707683|of|mg/kg|s.c. (r_nmod) combination_10\NN\7951464|of|the|morphine|metamizol|day|days|) (r_nmod) effects_7\NNS\13245626|the|antinociceptive|combination (l_amod) antinociceptive_4\JJ\1740|and|constipating (l_conj) constipating_6\JJ\1740|
D009020_D003248 CID morphine_4\NN\2707683| (r_nsubj) inhibited_5\VBD\2510337|groups|,|morphine|transit|%|acute|,|respectively|,|suggesting|. (l_advcl) suggesting_23\VBG\1010118|develop (l_ccomp) develop_28\VB\1753788|that|tolerance|did|not|effects (l_nmod) effects_32\NNS\13245626|to|the|constipating (l_amod) constipating_31\JJ\1740|
D009020_D003248 CID morphine_10\NN\2707683|by (r_nmod) produced_8\VBN\1617192|morphine (r_acl) that_7\DT\1740|to|produced (r_nmod) similar_5\JJ\1740|that (r_amod) transit_4\NN\4365484|intestinal|similar (r_dobj) inhibited_2\VBD\2510337|combination|transit|regardless|,|suggesting|. (l_advcl) suggesting_18\VBG\1010118|potentiate (l_ccomp) potentiate_23\VB\229605|that|metamizol|did|not|constipation (l_dobj) constipation_25\NN\14299637|morphine-induced
D009020_D003248 CID morphine-induced_24\JJ\1740| (r_amod) constipation_25\NN\14299637|morphine-induced
D002606_D010146 NONE charcoal_23\NN\14633206| (r_compound) meal_24\NN\7570720|charcoal (r_compound) test_25\NN\5798043|the|meal (r_nsubjpass) used_27\VBN\1156834|test|was|evaluate|. (r_conj) assessed_8\VBN\670261|day|,|effects|were|using|and|used (l_xcomp) using_9\VBG\1156834|model (l_dobj) model_11\NN\5888929|a|nociception|,|model|, (l_conj) model_19\NN\5888929|pain-induced|functional|impairment (l_amod) pain-induced_16\JJ\1740|
D009020_D059350 NONE morphine_7\NN\2707683|between|and|metamizol (r_nmod) interaction_5\NN\37396|a|significant|morphine|rats (r_dobj) show_2\VBP\2137132|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|useful (l_ccomp) useful_21\JJ\1740|that|combination|could|be|treatment (l_nmod) treatment_24\NN\654885|for|the|pain (l_nmod) pain_27\NN\14299637|of|chronic
D004177_D059350 NONE metamizol_9\NN\1740| (r_conj) morphine_7\NN\2707683|between|and|metamizol (r_nmod) interaction_5\NN\37396|a|significant|morphine|rats (r_dobj) show_2\VBP\2137132|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|useful (l_ccomp) useful_21\JJ\1740|that|combination|could|be|treatment (l_nmod) treatment_24\NN\654885|for|the|pain (l_nmod) pain_27\NN\14299637|of|chronic
1420741
D005672_D003424 NONE acid_7\NN\14818238|with|fusidic|: (r_nmod) treatment_0\NN\654885|disease|acid|antibiotic|. (l_nmod) disease_4\NN\14061805|of|crohn
D005672_D003424 NONE acid_28\NN\14818238|fusidic (r_compound) treatment_29\NN\654885|of|acid|patients (r_nmod) pharmacodynamics_23\NNS\1740|the|and|tolerability|treatment (r_dobj) estimate_21\VB\637259|to|pharmacodynamics (r_xcomp) undertaken_19\VBN\1641914|need|,|study|was|estimate|. (l_nmod) need_3\NN\13920835|because|the|development (l_nmod) development_6\NN\248977|for|the|treatments (l_nmod) treatments_9\NNS\654885|of|new|disease (l_nmod) disease_13\NN\14061805|for|crohn|'s
D005672_D003424 NONE acid_9\NN\14818238|fusidic (r_nsubj) benefit_13\NN\13278375|that|acid|may|be|of|patients (l_nmod) patients_21\NNS\9898892|in|selected|disease|ineffective (l_compound) disease_20\NN\14061805|chronic|active|crohn
D016572_D003424 NONE cyclosporin_16\NN\1740|to (r_nmod) similar_14\JJ\1740|cyclosporin (r_amod) properties_13\NNS\32613|with|immunosuppressive|similar (r_nmod) antibiotic_10\NN\2716205|an|properties (r_dep) treatment_0\NN\654885|disease|acid|antibiotic|. (l_nmod) disease_4\NN\14061805|of|crohn
D005672_D015212 NONE acid_13\NN\14818238|of|fusidic (r_nmod) use_10\NN\407535|for|the|acid|level|disease (l_nmod) disease_21\NN\14061805|in|inflammatory|bowel
14568327
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids (l_appos) lids_3\NNS\5313679|(|)
D007980_D004409 CID levodopa_32\NN\14604959| (r_compound) therapy_33\NN\657604|of|levodopa (r_nmod) response_27\NN\11410625|to|and|duration|therapy (r_conj) rate_18\NN\13815152|progression|and|response (r_nsubjpass) involved_36\VBN\2676054|which|rate|may|be|development (l_nmod) development_39\NN\248977|in|the|lids (l_nmod) lids_41\NNS\5313679|of
D007980_D004409 CID levodopa_20\NN\14604959| (r_compound) therapy_21\NN\657604|of|levodopa (r_nmod) initiation_18\NN\7450842|prior|therapy (r_nmod) exposure_7\NN\5042871|with|acute|(|short-term|)|mptp|,|onset|initiation (r_nmod) monkeys_0\NNS\2469914|exposure (r_nsubj) developed_22\VBD\1753788|monkeys|dyskinesia|days|. (l_dobj) dyskinesia_23\NN\14084880|
D007980_D004409 CID levodopa_31\NN\14604959| (r_compound) administration_32\NN\1133281|of|daily|levodopa (r_nmod) days_28\NNS\15140892|between|11|administration (r_nmod) developed_22\VBD\1753788|monkeys|dyskinesia|days|. (l_dobj) dyskinesia_23\NN\14084880|
D007980_D004409 CID levodopa_20\NN\14604959| (r_compound) therapy_21\NN\657604|of|levodopa (r_nmod) initiation_18\NN\7450842|prior|therapy (r_nmod) exposure_7\NN\5042871|with|long-term|mptp|,|progression|initiation (r_nmod) monkeys_3\NNS\2469914|exposure (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developing_26\VBG\1753788|to|lids (l_dobj) lids_27\NNS\5313679|
D007980_D004409 CID levodopa_20\NN\14604959| (r_compound) therapy_21\NN\657604|of|levodopa (r_nmod) initiation_18\NN\7450842|prior|therapy (r_nmod) exposure_7\NN\5042871|with|long-term|mptp|,|progression|initiation (r_nmod) monkeys_3\NNS\2469914|exposure (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_dep) developed_32\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_31\NN\14084880|
D007980_D004409 CID levodopa_40\NN\14604959| (r_compound) administration_41\NN\1133281|of|chronic|levodopa (r_nmod) days_37\NNS\15140892|than|146|administration (r_nmod) sooner_34\RBR\1740|no|days (r_advmod) developed_32\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (r_dep) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developing_26\VBG\1753788|to|lids (l_dobj) lids_27\NNS\5313679|
D007980_D004409 CID levodopa_40\NN\14604959| (r_compound) administration_41\NN\1133281|of|chronic|levodopa (r_nmod) days_37\NNS\15140892|than|146|administration (r_nmod) sooner_34\RBR\1740|no|days (r_advmod) developed_32\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_31\NN\14084880|
D007980_D004409 CID levodopa_24\NN\14604959|to (r_nmod) prior_22\RB\1740|levodopa (r_advmod) develop_9\VB\1753788|to|lids|prior (l_dobj) lids_10\NNS\5313679|monkeys
D007980_D004409 CID levodopa_24\NN\14604959|to (r_nmod) prior_22\RB\1740|levodopa (r_advmod) develop_9\VB\1753788|to|lids|prior (r_acl) propensity_7\NN\7498854|in|the|develop (r_nmod) differences_4\NNS\4723816|distinct|propensity (r_dobj) suggest_2\VBP\1010118|data|differences|and|demonstrate|. (l_conj) demonstrate_26\VBP\2137132|value (l_dobj) value_28\NN\5856066|the|models|studying (l_advcl) studying_34\VBG\630380|for|further|pathophysiology (l_dobj) pathophysiology_36\NN\1740|the|lids (l_nmod) lids_38\NNS\5313679|of
D007980_D010300 NONE levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced (r_nmod) development_0\NN\248977|dyskinesias|monkeys (l_nmod) monkeys_6\NNS\2469914|in|parkinsonian (l_amod) parkinsonian_5\JJ\1740|
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids (r_nsubj) present_5\VBP\2137132|dyskinesias|problem|. (l_dobj) problem_8\NN\14408086|a|major|management (l_nmod) management_12\NN\1123598|for|the|long-term|patients (l_nmod) patients_20\NNS\9898892|of|disease (l_compound) disease_16\NN\14061805|parkinson|pd
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids (r_nsubj) present_5\VBP\2137132|dyskinesias|problem|. (l_dobj) problem_8\NN\14408086|a|major|management (l_nmod) management_12\NN\1123598|for|the|long-term|patients (l_nmod) patients_20\NNS\9898892|of|disease (l_compound) disease_16\NN\14061805|parkinson|pd (l_appos) pd_18\NN\14625458|(|)
D015632_D010302 CID mptp-induced_7\JJ\1740| (r_amod) parkinsonism_8\NN\14085708|of|mptp-induced
D015632_D004409 NONE mptp-induced_7\JJ\1740| (r_amod) parkinsonism_8\NN\14085708|of|mptp-induced (r_nmod) types_5\NNS\5839024|with|different|parkinsonism (r_nmod) monkeys_2\NNS\2469914|macaque|types (r_dobj) using_0\VBG\1156834|monkeys (r_advcl) evaluated_13\VBD\670261|using|,|study|degree|. (l_dobj) degree_15\NN\4916342|the|involved (l_acl:relcl) involved_36\VBN\2676054|which|rate|may|be|development (l_nmod) development_39\NN\248977|in|the|lids (l_nmod) lids_41\NNS\5313679|of
D015632_D004409 NONE mptp_6\NN\1740| (r_compound) exposure_7\NN\5042871|with|acute|(|short-term|)|mptp|,|onset|initiation (r_nmod) monkeys_0\NNS\2469914|exposure (r_nsubj) developed_22\VBD\1753788|monkeys|dyskinesia|days|. (l_dobj) dyskinesia_23\NN\14084880|
D015632_D004409 NONE mptp_6\NN\1740| (r_compound) exposure_7\NN\5042871|with|long-term|mptp|,|progression|initiation (r_nmod) monkeys_3\NNS\2469914|exposure (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developing_26\VBG\1753788|to|lids (l_dobj) lids_27\NNS\5313679|
D015632_D004409 NONE mptp_6\NN\1740| (r_compound) exposure_7\NN\5042871|with|long-term|mptp|,|progression|initiation (r_nmod) monkeys_3\NNS\2469914|exposure (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_dep) developed_32\VBD\1753788|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_31\NN\14084880|
D007980_D010302 NONE levodopa_32\NN\14604959| (r_compound) therapy_33\NN\657604|of|levodopa (r_nmod) response_27\NN\11410625|to|and|duration|therapy (r_conj) rate_18\NN\13815152|progression|and|response (r_nsubjpass) involved_36\VBN\2676054|which|rate|may|be|development (r_acl:relcl) degree_15\NN\4916342|the|involved (r_dobj) evaluated_13\VBD\670261|using|,|study|degree|. (l_advcl) using_0\VBG\1156834|monkeys (l_dobj) monkeys_2\NNS\2469914|macaque|types (l_nmod) types_5\NNS\5839024|with|different|parkinsonism (l_nmod) parkinsonism_8\NN\14085708|of|mptp-induced
11745184
D002945_D001943 NONE cisplatin_5\NN\1740|of|plus|wr-2721 (r_nmod) trial_3\NN\786195|a|phase|ii|cisplatin|carcinoma|:|study|. (l_nmod) carcinoma_14\NN\14239918|for|metastatic|breast
D002945_D001943 NONE cisplatin_2\NN\1740| (r_nsubj) has_3\VBZ\2108377|:|cisplatin|activity|used (l_advcl) used_8\VBN\1156834|when|treatment (l_dobj) treatment_13\NN\654885|second-|carcinoma (l_nmod) carcinoma_17\NN\14239918|of|metastatic|breast
D002945_D001943 NONE cisplatin_8\NN\1740|with (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|,|toxicities|have|use|. (l_dobj) use_29\NN\407535|its|treatment (l_nmod) treatment_32\NN\654885|as|a|carcinoma (l_nmod) carcinoma_35\NN\14239918|for|breast
D002945_D001943 NONE cisplatin_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (r_nsubj) limited_27\VBN\2510337|observed|,|toxicities|have|use|. (l_dobj) use_29\NN\407535|its|treatment (l_nmod) treatment_32\NN\654885|as|a|carcinoma (l_nmod) carcinoma_35\NN\14239918|for|breast
D002945_D001943 NONE cisplatin_10\NN\1740|of|plus|amifostine (r_nmod) combination_8\NN\7951464|of|the|cisplatin (r_nmod) study_5\NN\635850|a|phase|ii|combination (r_nsubjpass) conducted_14\VBN\2436349|study|was|patients|. (l_nmod) patients_16\NNS\9898892|in|carcinoma|received (l_nmod) carcinoma_21\NN\14239918|with|progressive|metastatic|breast
D004999_D001943 NONE wr-2721_7\NN\1740|amifostine (r_conj) cisplatin_5\NN\1740|of|plus|wr-2721 (r_nmod) trial_3\NN\786195|a|phase|ii|cisplatin|carcinoma|:|study|. (l_nmod) carcinoma_14\NN\14239918|for|metastatic|breast
D004999_D001943 NONE amifostine_9\NN\1740|(|) (r_appos) wr-2721_7\NN\1740|amifostine (r_conj) cisplatin_5\NN\1740|of|plus|wr-2721 (r_nmod) trial_3\NN\786195|a|phase|ii|cisplatin|carcinoma|:|study|. (l_nmod) carcinoma_14\NN\14239918|for|metastatic|breast
D004999_D001943 NONE amifostine_12\NN\1740| (r_conj) cisplatin_10\NN\1740|of|plus|amifostine (r_nmod) combination_8\NN\7951464|of|the|cisplatin (r_nmod) study_5\NN\635850|a|phase|ii|combination (r_nsubjpass) conducted_14\VBN\2436349|study|was|patients|. (l_nmod) patients_16\NNS\9898892|in|carcinoma|received (l_nmod) carcinoma_21\NN\14239918|with|progressive|metastatic|breast
D002945_D064420 NONE cisplatin_8\NN\1740|with (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|,|toxicities|have|use|. (l_nsubj) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity
D002945_D064420 NONE cisplatin_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity
D002945_D064420 NONE cisplatin_18\NN\1740|to (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_conj) toxicity_6\NN\13576101|reduced|tissues
D002945_D007674 CID cisplatin_8\NN\1740|with (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|,|toxicities|have|use|. (l_nsubj) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (l_dep) nephrotoxicity_19\NN\1740|(|e.g.|,|,|ototoxicity|,|and|neurotoxicity|)
D002945_D007674 CID cisplatin_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (l_dep) nephrotoxicity_19\NN\1740|(|e.g.|,|,|ototoxicity|,|and|neurotoxicity|)
D002945_D007674 CID cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy
D002945_D007674 CID cisplatin-induced_14\JJ\1740| (r_amod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy
D002945_D006311 CID cisplatin_8\NN\1740|with (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|,|toxicities|have|use|. (l_nsubj) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (l_dep) nephrotoxicity_19\NN\1740|(|e.g.|,|,|ototoxicity|,|and|neurotoxicity|) (l_conj) ototoxicity_21\NN\1740|
D002945_D006311 CID cisplatin_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (l_dep) nephrotoxicity_19\NN\1740|(|e.g.|,|,|ototoxicity|,|and|neurotoxicity|) (l_conj) ototoxicity_21\NN\1740|
D002945_D006311 CID cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy (l_conj) ototoxicity_17\NN\1740|,
D002945_D006311 CID cisplatin-induced_14\JJ\1740| (r_amod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy (l_conj) ototoxicity_17\NN\1740|,
D002945_D020258 NONE cisplatin_8\NN\1740|with (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|,|toxicities|have|use|. (l_nsubj) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (l_dep) nephrotoxicity_19\NN\1740|(|e.g.|,|,|ototoxicity|,|and|neurotoxicity|) (l_conj) neurotoxicity_24\NN\1740|
D002945_D020258 NONE cisplatin_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated|nephrotoxicity (l_dep) nephrotoxicity_19\NN\1740|(|e.g.|,|,|ototoxicity|,|and|neurotoxicity|) (l_conj) neurotoxicity_24\NN\1740|
D002945_D009422 CID cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy (l_conj) neuropathy_20\NN\14204950|
D002945_D009422 CID cisplatin-induced_14\JJ\1740| (r_amod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy (l_conj) neuropathy_20\NN\14204950|
D004999_D007674 NONE amifostine_5\NN\1740| (r_conj) cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy
D004999_D006311 NONE amifostine_5\NN\1740| (r_conj) cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy (l_conj) ototoxicity_17\NN\1740|,
D004999_D009422 NONE amifostine_5\NN\1740| (r_conj) cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|and|neuropathy (l_conj) neuropathy_20\NN\14204950|
D004999_D009369 NONE amifostine_16\NN\1740|of (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_amod) tumor-protective_2\JJ\1740|
D004999_D064420 NONE amifostine_16\NN\1740|of (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_conj) toxicity_6\NN\13576101|reduced|tissues
D002945_D009369 NONE cisplatin_18\NN\1740|to (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_amod) tumor-protective_2\JJ\1740|
15572383
D004317_D007674 NONE adriamycin-induced_12\JJ\1740| (r_amod) damage_14\NN\7296428|to|adriamycin-induced|renal
D004317_D007674 NONE adriamycin_23\NN\1740|of (r_nmod) injection_21\NN\320852|by|a|single|adriamycin|rats (r_nmod) induced_17\VBN\1627355|injection (r_acl) damage_16\NN\7296428|of|renal|induced
D004317_D007674 NONE adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|results|anticipated|,|adriamycin|proteinuria|. (l_dobj) proteinuria_9\NN\14299637|range|,|damage|and|glomerulosclerosis (l_conj) damage_13\NN\7296428|renal|interstitial
D004317_D007674 NONE adriamycin-induced_12\JJ\1740| (r_amod) damage_14\NN\7296428|of|adriamycin-induced|renal|strain
D004317_D011507 CID adriamycin_10\NN\1740|by|= (r_nmod) induced_8\VBN\1627355|week|,|proteinuria|was|adriamycin|]|. (l_nsubjpass) proteinuria_6\NN\14299637|
D004317_D011507 CID adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|results|anticipated|,|adriamycin|proteinuria|. (l_dobj) proteinuria_9\NN\14299637|range|,|damage|and|glomerulosclerosis
D004317_D011507 CID adriamycin_12\NN\1740|after|= (r_nmod) rise_8\NN\7324673|with|the|relative|proteinuria|adriamycin|,|actin (l_nmod) proteinuria_10\NN\14299637|in
D004317_D009404 NONE adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|results|anticipated|,|adriamycin|proteinuria|. (l_dobj) proteinuria_9\NN\14299637|range|,|damage|and|glomerulosclerosis (l_compound) range_8\NN\5123416|nephrotic (l_amod) nephrotic_7\JJ\1740|
D004317_D005923 NONE adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|results|anticipated|,|adriamycin|proteinuria|. (l_dobj) proteinuria_9\NN\14299637|range|,|damage|and|glomerulosclerosis (l_conj) glomerulosclerosis_17\NN\1740|mild|focal
2024540
D004656_D006333 NONE enalapril_9\NN\2673637|of|and|prazosin (r_nmod) safety_7\NN\13920835|enalapril|phase (l_nmod) phase_16\NN\15113229|in|the|initial|treatment|patients (l_nmod) patients_18\NNS\9898892|of|failure (l_nmod) failure_22\NN\66216|with|congestive|heart
D011224_D006333 NONE prazosin_11\NN\2698769| (r_conj) enalapril_9\NN\2673637|of|and|prazosin (r_nmod) safety_7\NN\13920835|enalapril|phase (l_nmod) phase_16\NN\15113229|in|the|initial|treatment|patients (l_nmod) patients_18\NNS\9898892|of|failure (l_nmod) failure_22\NN\66216|with|congestive|heart
D000806_D006333 NONE inhibitors_10\NNS\20090|of|enzyme (r_nmod) introduction_2\NN\235435|since|the|inhibitors|treatment (l_nmod) treatment_14\NN\654885|into|the|adjunctive|patients (l_nmod) patients_16\NNS\9898892|of|failure (l_nmod) failure_20\NN\66216|with|congestive|heart
D000806_D007022 CID inhibitors_10\NNS\20090|of|enzyme (r_nmod) introduction_2\NN\235435|since|the|inhibitors|treatment (r_nmod) reported_38\VBN\831651|introduction|,|cases|have|occasionally|been|. (l_nsubjpass) cases_22\NNS\7283608|hypotension|,|day|, (l_nmod) hypotension_25\NN\14057371|of|severe
D000806_D007022 CID inhibitor_7\NN\20090| (r_compound) enalapril_8\NN\2673637|of|the|ace|inhibitor (r_nmod) safety_3\NN\13920835|the|enalapril (r_dobj) assess_1\VB\670261|to|safety|designed (l_parataxis) designed_17\VBN\1631534|trial|was|compared|. (l_ccomp) compared_19\VBD\644583|that|incidence (l_dobj) incidence_21\NN\13821570|the|and|severity|hypotension|day (l_nmod) hypotension_26\NN\14057371|of|symptomatic
D004656_D007022 NONE enalapril_8\NN\2673637|of|the|ace|inhibitor (r_nmod) safety_3\NN\13920835|the|enalapril (r_dobj) assess_1\VB\670261|to|safety|designed (l_parataxis) designed_17\VBN\1631534|trial|was|compared|. (l_ccomp) compared_19\VBD\644583|that|incidence (l_dobj) incidence_21\NN\13821570|the|and|severity|hypotension|day (l_nmod) hypotension_26\NN\14057371|of|symptomatic
D004656_D007022 NONE enalapril_3\NN\2673637| (r_dobj) received_2\VBD\2210855|who|enalapril (r_acl:relcl) patients_0\NNS\9898892|received (r_nsubj) experienced_4\VBD\2108377|patients|hypotension|patients|. (l_dobj) hypotension_11\NN\14057371|symptomatic|%
D011224_D007022 CID prazosin-controlled_14\JJ\1740| (r_amod) trial_15\NN\786195|a|multicenter|,|randomized|,|prazosin-controlled (r_nsubjpass) designed_17\VBN\1631534|trial|was|compared|. (l_ccomp) compared_19\VBD\644583|that|incidence (l_dobj) incidence_21\NN\13821570|the|and|severity|hypotension|day (l_nmod) hypotension_26\NN\14057371|of|symptomatic
D011224_D007022 CID prazosin_21\NN\2698769| (r_dobj) received_20\VBD\2210855|who|prazosin (r_acl:relcl) patients_18\NNS\9898892|than|the|received|% (r_nmod) experienced_4\VBD\2108377|patients|hypotension|patients|. (l_dobj) hypotension_11\NN\14057371|symptomatic|%
12695819
D016559_D020258 NONE tacrolimus-induced_7\JJ\1740| (r_amod) neurotoxicity_8\NN\1740|of|tacrolimus-induced|patients
D016559_D020258 NONE tacrolimus-induced_13\JJ\1740| (r_amod) neurotoxicity_14\NN\1740|of|tacrolimus-induced
D016559_D009422 NONE tacrolimus_17\NN\1740| (r_dobj) receiving_16\VBG\2210855|tacrolimus (r_acl) patients_15\NNS\9898892|in|14|transplant|receiving|developed (l_acl:relcl) developed_19\VBD\1753788|who|complications (l_dobj) complications_21\NNS\1073995|neurologic
17466854
D008775_D002386 NONE methylprednisolone_15\NN\1740|of|and|gentamicin (r_nmod) administration_13\NN\1133281|after|the|methylprednisolone|space|end (l_nmod) end_26\NN\8568978|at|the|surgery (l_nmod) surgery_30\NN\6045562|of|routine|cataract (l_compound) cataract_29\NN\14252864|
D005839_D002386 NONE gentamicin_17\NN\2716866| (r_conj) methylprednisolone_15\NN\1740|of|and|gentamicin (r_nmod) administration_13\NN\1133281|after|the|methylprednisolone|space|end (l_nmod) end_26\NN\8568978|at|the|surgery (l_nmod) surgery_30\NN\6045562|of|routine|cataract (l_compound) cataract_29\NN\14252864|
D008775_D020250 CID methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubjpass) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) vomiting_26\NN\116687|
D008775_D006261 CID methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubjpass) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) headache_29\NN\5829480|
D005839_D020250 CID gentamicin_7\NN\2716866| (r_conj) methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubjpass) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) vomiting_26\NN\116687|
D005839_D006261 CID gentamicin_7\NN\2716866| (r_conj) methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubjpass) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) headache_29\NN\5829480|
3437726
D013034_D064420 NONE sparteine/debrisoquine_9\NN\1740| (r_compound) polymorphism_10\NN\11418750|of|sparteine/debrisoquine|metabolism|,|constitutes (r_nmod) phenotype_7\NN\4933544|to|the|poor-metabolizer|polymorphism (r_nmod) belonging_3\VBG\2604760|phenotype (r_acl) patients_2\NNS\9898892|belonging|, (r_nsubj) experience_25\VB\2108377|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_28\NNS\13446390|adverse|drug
D003647_D064420 NONE sparteine/debrisoquine_9\NN\1740| (r_compound) polymorphism_10\NN\11418750|of|sparteine/debrisoquine|metabolism|,|constitutes (r_nmod) phenotype_7\NN\4933544|to|the|poor-metabolizer|polymorphism (r_nmod) belonging_3\VBG\2604760|phenotype (r_acl) patients_2\NNS\9898892|belonging|, (r_nsubj) experience_25\VB\2108377|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_28\NNS\13446390|adverse|drug
8643971
D017239_D006258 NONE paclitaxel_5\NN\1740|of|plus|cisplatin (r_nmod) study_3\NN\635850|a|phase|paclitaxel|therapy|:|results (l_nmod) therapy_10\NN\657604|as|first-line|cancers (l_nmod) cancers_15\NNS\14239425|for|head
D017239_D006258 NONE paclitaxel_11\NN\1740|of|single-agent|taxol (r_nmod) study_8\NN\635850|of|an|group|paclitaxel (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|cancer (l_nmod) cancer_35\NN\14239425|with|head
D017239_D006258 NONE taxol_13\NN\1740|(|;|company|) (r_appos) paclitaxel_11\NN\1740|of|single-agent|taxol (r_nmod) study_8\NN\635850|of|an|group|paclitaxel (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|cancer (l_nmod) cancer_35\NN\14239425|with|head
D017239_D006258 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved|. (r_conj) reported_23\VBD\831651|results|rate|,|and|used (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|cancer (l_nmod) cancer_35\NN\14239425|with|head
D017239_D006258 NONE paclitaxel_14\NN\1740| (r_compound) doses_15\NNS\3740161|of|escalating|paclitaxel|combined (r_nmod) response_9\NN\11410625|the|and|toxicity|doses|patients (l_nmod) patients_26\NNS\9898892|in|carcinoma (l_nmod) carcinoma_35\NN\14239918|with|untreated|advanced|inoperable|head
D017239_D006258 NONE paclitaxel/cisplatin_0\NN\1740| (r_nsubj) regimen_5\NN\5898568|paclitaxel/cisplatin|is|an|effective|first-line|cancer|and|warranted (l_nmod) cancer_12\NN\14239425|for|advanced|head
D002945_D006258 NONE cisplatin_7\NN\1740| (r_conj) paclitaxel_5\NN\1740|of|plus|cisplatin (r_nmod) study_3\NN\635850|a|phase|paclitaxel|therapy|:|results (l_nmod) therapy_10\NN\657604|as|first-line|cancers (l_nmod) cancers_15\NNS\14239425|for|head
D002945_D006258 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved|. (r_conj) reported_23\VBD\831651|results|rate|,|and|used (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|cancer (l_nmod) cancer_35\NN\14239425|with|head
D002945_D006258 NONE cisplatin_19\NN\1740|with|fixed-dose|support (r_nmod) combined_16\VBN\2630189|cisplatin (r_acl) doses_15\NNS\3740161|of|escalating|paclitaxel|combined (r_nmod) response_9\NN\11410625|the|and|toxicity|doses|patients (l_nmod) patients_26\NNS\9898892|in|carcinoma (l_nmod) carcinoma_35\NN\14239918|with|untreated|advanced|inoperable|head
D002945_D006258 NONE paclitaxel/cisplatin_0\NN\1740| (r_nsubj) regimen_5\NN\5898568|paclitaxel/cisplatin|is|an|effective|first-line|cancer|and|warranted (l_nmod) cancer_12\NN\14239425|for|advanced|head
D017239_D010051 NONE paclitaxel_11\NN\1740|of|single-agent|taxol (r_nmod) study_8\NN\635850|of|an|group|paclitaxel (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used (l_conj) used_43\VBN\1156834|combination|has|been|successfully|and|improved|. (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D017239_D010051 NONE taxol_13\NN\1740|(|;|company|) (r_appos) paclitaxel_11\NN\1740|of|single-agent|taxol (r_nmod) study_8\NN\635850|of|an|group|paclitaxel (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used (l_conj) used_43\VBN\1156834|combination|has|been|successfully|and|improved|. (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D017239_D010051 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved|. (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D002945_D010051 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved|. (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D017239_D064420 NONE paclitaxel_14\NN\1740| (r_compound) doses_15\NNS\3740161|of|escalating|paclitaxel|combined (r_nmod) response_9\NN\11410625|the|and|toxicity|doses|patients (l_conj) toxicity_11\NN\13576101|
D017239_D064420 NONE paclitaxel_5\NN\1740| (r_compound) doses_6\NNS\3740161|escalating|paclitaxel (r_dobj) incorporate_3\VBP\1461328|levels|doses|,|and|permitted (l_conj) permitted_17\VBN\797697|escalations|are|permits|. (l_advcl) permits_20\VBZ\797697|if|toxicity (l_nsubj) toxicity_19\NN\13576101|
D002945_D064420 NONE cisplatin_19\NN\1740|with|fixed-dose|support (r_nmod) combined_16\VBN\2630189|cisplatin (r_acl) doses_15\NNS\3740161|of|escalating|paclitaxel|combined (r_nmod) response_9\NN\11410625|the|and|toxicity|doses|patients (l_conj) toxicity_11\NN\13576101|
4071154
D007213_D051437 NONE indomethacin-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|indomethacin-induced|renal|:|recurrence|.
D007213_D051437 NONE indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) reported_2\VBN\831651|we|have|case|therapy|. (l_dobj) case_4\NN\7283608|a|failure|patient (l_nmod) failure_9\NN\66216|of|acute|oliguric|renal|hyperkalemia
D007213_D006947 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) reported_2\VBN\831651|we|have|case|therapy|. (l_dobj) case_4\NN\7283608|a|failure|patient (l_nmod) failure_9\NN\66216|of|acute|oliguric|renal|hyperkalemia (l_nmod) hyperkalemia_11\NN\14299637|with
D007213_D005355 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) reported_2\VBN\831651|we|have|case|therapy|. (l_dobj) case_4\NN\7283608|a|failure|patient (l_nmod) patient_14\NN\9898892|in|a|cirrhosis (l_nmod) cirrhosis_16\NN\14116321|with|,|ascites
D007213_D001201 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) reported_2\VBN\831651|we|have|case|therapy|. (l_dobj) case_4\NN\7283608|a|failure|patient (l_nmod) patient_14\NN\9898892|in|a|cirrhosis (l_nmod) cirrhosis_16\NN\14116321|with|,|ascites (l_conj) ascites_18\NN\14204950|,|and|pulmonale
D007213_D011660 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) reported_2\VBN\831651|we|have|case|therapy|. (l_dobj) case_4\NN\7283608|a|failure|patient (l_nmod) patient_14\NN\9898892|in|a|cirrhosis (l_nmod) cirrhosis_16\NN\14116321|with|,|ascites (l_conj) ascites_18\NN\14204950|,|and|pulmonale (l_conj) pulmonale_22\NN\1740|cor
D007213_D009846 CID indomethacin_16\NN\3828465|of (r_nmod) dose_14\NN\3740161|to|a|single|indomethacin (r_nmod) re-exposure_10\NN\1740|dose (r_nsubj) caused_17\VBD\1617192|while|re-exposure|recurrence (l_dobj) recurrence_18\NN\7342049|oliguria (l_nmod) oliguria_22\NN\14299637|of|acute|reversible
20477932
D003042_D008569 CID cocaine_0\NN\3492717| (r_nsubj) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|. (l_dobj) impairments_5\NNS\7296428|memory|rats
D003042_D007859 CID cocaine_0\NN\3492717| (r_nsubj) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|. (l_dobj) impairments_5\NNS\7296428|memory|rats
C052342_D008569 NONE topiramate_22\NN\1740|by (r_nmod) prevention_20\NN\1073995|topiramate (r_conj) involvement_9\NN\1080366|b|and|stress|,|and|prevention (r_dep) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|. (l_dobj) impairments_5\NNS\7296428|memory|rats
C052342_D007859 NONE topiramate_22\NN\1740|by (r_nmod) prevention_20\NN\1073995|topiramate (r_conj) involvement_9\NN\1080366|b|and|stress|,|and|prevention (r_dep) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|. (l_dobj) impairments_5\NNS\7296428|memory|rats
D003042_D064420 NONE cocaine_6\NN\3492717| (r_compound) toxicity_7\NN\13576101|for|cocaine
D003042_D064420 NONE cocaine_24\NN\3492717| (r_compound) induced-behaviour_25\NN\1740|cocaine (r_conj) status_19\NN\24720|between|oxidative|brain|and|induced-behaviour (r_nmod) association_16\NN\8008335|the|status (r_nsubjpass) understood_28\VBN\588888|association|is|poorly|. (r_conj) suggested_4\VBN\1010118|mechanisms|have|been|toxicity|increase|but|understood (l_nmod) toxicity_7\NN\13576101|for|cocaine
D009569_D019970 NONE oxide_9\NN\14818238| (r_compound) synthase_10\NN\1740|neuronal|nitric|oxide|nnos (r_compound) activity_14\NN\30358|synthase (r_conj) activity_2\NN\30358|nfkappab|,|stress|,|activity|,|learning|as|effect (l_conj) effect_24\NN\34213|the|topiramate (l_nmod) topiramate_26\NN\1740|of|,|therapy|, (l_appos) therapy_31\NN\657604|a|proposed|addiction (l_nmod) addiction_34\NN\14034177|for|cocaine
C052342_D019970 NONE topiramate_26\NN\1740|of|,|therapy|, (l_appos) therapy_31\NN\657604|a|proposed|addiction (l_nmod) addiction_34\NN\14034177|for|cocaine
D003042_D019970 NONE cocaine_43\NN\3492717| (r_compound) administration_44\NN\1133281|of|cocaine|rats (r_nmod) model_41\NN\5888929|in|an|experimental|administration (r_nmod) evaluated_37\VBN\670261|therefore|activity|were|model|. (l_nsubjpass) activity_2\NN\30358|nfkappab|,|stress|,|activity|,|learning|as|effect (l_conj) effect_24\NN\34213|the|topiramate (l_nmod) topiramate_26\NN\1740|of|,|therapy|, (l_appos) therapy_31\NN\657604|a|proposed|addiction (l_nmod) addiction_34\NN\14034177|for|cocaine
7881871
D011692_D007674 CID aminonucleoside-induced_7\JJ\1740|puromycin (r_amod) nephropathy_8\NN\14573196|in|aminonucleoside-induced
D011692_D007674 CID aminonucleoside_12\NN\1740|puromycin (r_compound) (pan)-induced_13\JJ\1740|acute|aminonucleoside (r_nummod) nephropathy_14\NN\14573196|of|(pan)-induced
D011692_D007674 CID (pan)-induced_13\JJ\1740|acute|aminonucleoside (r_nummod) nephropathy_14\NN\14573196|of|(pan)-induced
D011692_D007674 CID pan_14\NN\3101986| (r_compound) nephropathy_15\NN\14573196|in|pan
D010100_D007674 NONE oxygen_1\NN\14622893| (r_compound) species_2\NNS\7992450|reactive|oxygen (r_nsubjpass) implicated_5\VBN\2677097|species|have|been|pathogenesis|,|reducing|. (l_nmod) pathogenesis_8\NN\13533470|in|the|nephropathy (l_nmod) nephropathy_14\NN\14573196|of|(pan)-induced
D010100_D011507 NONE oxygen_1\NN\14622893| (r_compound) species_2\NNS\7992450|reactive|oxygen (r_nsubjpass) implicated_5\VBN\2677097|species|have|been|pathogenesis|,|reducing|. (l_advcl) reducing_19\VBG\441445|with|antioxidants|significantly|proteinuria (l_dobj) proteinuria_21\NN\14299637|the
D011692_D011507 CID aminonucleoside_12\NN\1740|puromycin (r_compound) (pan)-induced_13\JJ\1740|acute|aminonucleoside (r_nummod) nephropathy_14\NN\14573196|of|(pan)-induced (r_nmod) pathogenesis_8\NN\13533470|in|the|nephropathy (r_nmod) implicated_5\VBN\2677097|species|have|been|pathogenesis|,|reducing|. (l_advcl) reducing_19\VBG\441445|with|antioxidants|significantly|proteinuria (l_dobj) proteinuria_21\NN\14299637|the
D011692_D011507 CID (pan)-induced_13\JJ\1740|acute|aminonucleoside (r_nummod) nephropathy_14\NN\14573196|of|(pan)-induced (r_nmod) pathogenesis_8\NN\13533470|in|the|nephropathy (r_nmod) implicated_5\VBN\2677097|species|have|been|pathogenesis|,|reducing|. (l_advcl) reducing_19\VBG\441445|with|antioxidants|significantly|proteinuria (l_dobj) proteinuria_21\NN\14299637|the
D011692_D011507 CID pan_14\NN\3101986| (r_compound) nephropathy_15\NN\14573196|in|pan (r_nmod) injury_12\NN\14052046|the|proteinuric|nephropathy
11135224
D017239_D002289 NONE paclitaxel_0\NN\1740|,|cisplatin|gemcitabine (r_compound) chemotherapy_7\NN\661091|paclitaxel|combination|approach|. (l_nmod) approach_12\NN\940842|within|a|multidisciplinary|therapeutic|carcinoma (l_nmod) carcinoma_18\NN\14239918|in|metastatic|nonsmall|cell|lung
D017239_D002289 NONE paclitaxel_20\NN\1740|,|cisplatin (r_compound) combination_26\NN\7951464|of|a|paclitaxel|treat (l_acl) treat_28\VB\2376958|to|nsclc (l_dobj) nsclc_30\NN\1740|metastatic
D017239_D002289 NONE paclitaxel_26\NN\1740|of|mg/m(2|given|)|day|,|cisplatin|day|,|and|gemcitabine|days|,|weeks (r_nmod) combination_24\NN\7951464|with|a|paclitaxel (r_nmod) treated_21\VBN\2376958|patients|were|combination|. (l_nsubjpass) patients_3\NNS\9898892|thirty-five|consecutive|chemotherapy-naive|nsclc|and|status (l_nmod) nsclc_7\NN\1740|with|stage|iv
D017239_D002289 NONE paclitaxel_5\NN\1740|of|,|cisplatin (r_nmod) combination_3\NN\7951464|the|paclitaxel (r_nsubjpass) tolerated_13\VBN\802318|combination|is|well|and|shows (l_conj) shows_15\VBZ\2137132|activity (l_dobj) activity_17\NN\30358|high|nsclc (l_nmod) nsclc_20\NN\1740|in|metastatic
D002945_D002289 NONE cisplatin_2\NN\1740|,|and (r_conj) paclitaxel_0\NN\1740|,|cisplatin|gemcitabine (r_compound) chemotherapy_7\NN\661091|paclitaxel|combination|approach|. (l_nmod) approach_12\NN\940842|within|a|multidisciplinary|therapeutic|carcinoma (l_nmod) carcinoma_18\NN\14239918|in|metastatic|nonsmall|cell|lung
D002945_D002289 NONE cisplatin-based_2\JJ\1740| (r_amod) combinations_4\NNS\7951464|cisplatin-based|chemotherapy (r_nsubj) improve_5\VBP\126264|:|combinations|quality (l_dobj) quality_6\NN\24264|life|and|survival|carcinoma (l_nmod) carcinoma_16\NN\14239918|in|advanced|nonsmall|cell|lung|nsclc
D002945_D002289 NONE cisplatin-based_2\JJ\1740| (r_amod) combinations_4\NNS\7951464|cisplatin-based|chemotherapy (r_nsubj) improve_5\VBP\126264|:|combinations|quality (l_dobj) quality_6\NN\24264|life|and|survival|carcinoma (l_nmod) carcinoma_16\NN\14239918|in|advanced|nonsmall|cell|lung|nsclc (l_appos) nsclc_18\NN\1740|(|)
D002945_D002289 NONE cisplatin_22\NN\1740|,|and|gemcitabine (r_conj) paclitaxel_20\NN\1740|,|cisplatin (r_compound) combination_26\NN\7951464|of|a|paclitaxel|treat (l_acl) treat_28\VB\2376958|to|nsclc (l_dobj) nsclc_30\NN\1740|metastatic
D002945_D002289 NONE cisplatin_41\NN\1740|mg/m(2|given|) (r_conj) paclitaxel_26\NN\1740|of|mg/m(2|given|)|day|,|cisplatin|day|,|and|gemcitabine|days|,|weeks (r_nmod) combination_24\NN\7951464|with|a|paclitaxel (r_nmod) treated_21\VBN\2376958|patients|were|combination|. (l_nsubjpass) patients_3\NNS\9898892|thirty-five|consecutive|chemotherapy-naive|nsclc|and|status (l_nmod) nsclc_7\NN\1740|with|stage|iv
D002945_D002289 NONE cisplatin_7\NN\1740|,|and|gemcitabine (r_conj) paclitaxel_5\NN\1740|of|,|cisplatin (r_nmod) combination_3\NN\7951464|the|paclitaxel (r_nsubjpass) tolerated_13\VBN\802318|combination|is|well|and|shows (l_conj) shows_15\VBZ\2137132|activity (l_dobj) activity_17\NN\30358|high|nsclc (l_nmod) nsclc_20\NN\1740|in|metastatic
C056507_D002289 NONE gemcitabine_5\NN\1740| (r_dep) paclitaxel_0\NN\1740|,|cisplatin|gemcitabine (r_compound) chemotherapy_7\NN\661091|paclitaxel|combination|approach|. (l_nmod) approach_12\NN\940842|within|a|multidisciplinary|therapeutic|carcinoma (l_nmod) carcinoma_18\NN\14239918|in|metastatic|nonsmall|cell|lung
C056507_D002289 NONE gemcitabine_25\NN\1740| (r_conj) cisplatin_22\NN\1740|,|and|gemcitabine (r_conj) paclitaxel_20\NN\1740|,|cisplatin (r_compound) combination_26\NN\7951464|of|a|paclitaxel|treat (l_acl) treat_28\VB\2376958|to|nsclc (l_dobj) nsclc_30\NN\1740|metastatic
C056507_D002289 NONE gemcitabine_57\NN\1740|mg/m(2|given|) (r_conj) paclitaxel_26\NN\1740|of|mg/m(2|given|)|day|,|cisplatin|day|,|and|gemcitabine|days|,|weeks (r_nmod) combination_24\NN\7951464|with|a|paclitaxel (r_nmod) treated_21\VBN\2376958|patients|were|combination|. (l_nsubjpass) patients_3\NNS\9898892|thirty-five|consecutive|chemotherapy-naive|nsclc|and|status (l_nmod) nsclc_7\NN\1740|with|stage|iv
C056507_D002289 NONE gemcitabine_10\NN\1740| (r_conj) cisplatin_7\NN\1740|,|and|gemcitabine (r_conj) paclitaxel_5\NN\1740|of|,|cisplatin (r_nmod) combination_3\NN\7951464|the|paclitaxel (r_nsubjpass) tolerated_13\VBN\802318|combination|is|well|and|shows (l_conj) shows_15\VBZ\2137132|activity (l_dobj) activity_17\NN\30358|high|nsclc (l_nmod) nsclc_20\NN\1740|in|metastatic
D017239_D064420 NONE paclitaxel_20\NN\1740|,|cisplatin (r_compound) combination_26\NN\7951464|of|a|paclitaxel|treat (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|combination (l_conj) toxicity_17\NN\13576101|
D002945_D064420 NONE cisplatin_22\NN\1740|,|and|gemcitabine (r_conj) paclitaxel_20\NN\1740|,|cisplatin (r_compound) combination_26\NN\7951464|of|a|paclitaxel|treat (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|combination (l_conj) toxicity_17\NN\13576101|
C056507_D064420 NONE gemcitabine_25\NN\1740| (r_conj) cisplatin_22\NN\1740|,|and|gemcitabine (r_conj) paclitaxel_20\NN\1740|,|cisplatin (r_compound) combination_26\NN\7951464|of|a|paclitaxel|treat (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|combination (l_conj) toxicity_17\NN\13576101|
8073369
C007112_D001176 CID coniine_2\NN\1740| (r_nsubj) failed_4\VBN\1798936|however|,|coniine|has|produce|and|teratogenic|. (l_xcomp) produce_6\VB\1617192|to|arthrogryposis|rats (l_dobj) arthrogryposis_7\NN\1740|
C007112_D001176 CID coniine-induced_15\JJ\1740| (r_amod) arthrogryposis_16\NN\1740|of|coniine-induced
C007112_D009140 NONE coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused
C007112_D009140 NONE coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused (r_nsubj) flexion_11\NN\14034177|deformations|were|excessive|or|extension|toes|. (l_nmod) toes_18\NNS\5566097|of|one
D009538_D009140 NONE nicotine_7\NN\14712692| (r_compound) sulfate_8\NN\15010703|nicotine (r_conj) coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused
D009538_D009140 NONE nicotine_7\NN\14712692| (r_compound) sulfate_8\NN\15010703|nicotine (r_conj) coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused (r_nsubj) flexion_11\NN\14034177|deformations|were|excessive|or|extension|toes|. (l_nmod) toes_18\NNS\5566097|of|one
D009538_D002543 CID nicotine_30\NN\14712692| (r_nmod:npmod) sulfate-treated_31\JJ\1740|nicotine (r_amod) chicks_32\NNS\1791625|in|all|sulfate-treated (r_nmod) occurred_27\VBD\2623529|seen|;|however|,|hemorrhage|chicks|. (l_nsubj) hemorrhage_26\NN\14285662|extensive|cranial
11672959
D012460_D003872 CID sulphasalazine_25\NN\1740|of|oral (r_nmod) course_22\NN\883297|of|a|sulphasalazine|arthritis (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_5\NN\5728678|a|dermatitis (l_nmod) dermatitis_7\NN\14226056|of|,|fever|,|lymphadenopathy
D012460_D005334 CID sulphasalazine_25\NN\1740|of|oral (r_nmod) course_22\NN\883297|of|a|sulphasalazine|arthritis (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_5\NN\5728678|a|dermatitis (l_nmod) dermatitis_7\NN\14226056|of|,|fever|,|lymphadenopathy (l_conj) fever_9\NN\14299637|
D012460_D008206 CID sulphasalazine_25\NN\1740|of|oral (r_nmod) course_22\NN\883297|of|a|sulphasalazine|arthritis (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_5\NN\5728678|a|dermatitis (l_nmod) dermatitis_7\NN\14226056|of|,|fever|,|lymphadenopathy (l_conj) lymphadenopathy_11\NN\14204950|and|hepatitis
D012460_D056486 CID sulphasalazine_25\NN\1740|of|oral (r_nmod) course_22\NN\883297|of|a|sulphasalazine|arthritis (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|,|beginning|. (l_dobj) constellation_5\NN\5728678|a|dermatitis (l_nmod) dermatitis_7\NN\14226056|of|,|fever|,|lymphadenopathy (l_conj) lymphadenopathy_11\NN\14204950|and|hepatitis (l_conj) hepatitis_13\NN\14127211|
D012460_D001172 NONE sulphasalazine_25\NN\1740|of|oral (r_nmod) course_22\NN\883297|of|a|sulphasalazine|arthritis (l_nmod) arthritis_29\NN\14171682|for|sero-negative|rheumatoid
1428568
D013999_D005901 NONE timolol_6\NN\2832168|with|0.5%/12h (r_nmod) treated_4\VBN\2376958|chronically|timolol (r_acl) patients_2\NNS\9898892|eight|glaucomatous|treated|,|suffering|, (l_amod) glaucomatous_1\JJ\1740|
D013999_D003866 CID timolol_6\NN\2832168|with|0.5%/12h (r_nmod) treated_4\VBN\2376958|chronically|timolol (r_acl) patients_2\NNS\9898892|eight|glaucomatous|treated|,|suffering|, (l_acl) suffering_9\VBG\2110220|depression (l_nmod) depression_11\NN\14373582|from|diagnosed
D013999_D003866 CID timolol_13\NN\2832168| (r_compound) treatment_14\NN\654885|under|timolol (r_nmod) patients_11\NNS\9898892|the|treatment (r_nsubj) presented_15\VBD\2137132|study|,|patients|values|p|. (l_dobj) values_18\NNS\5941423|higher|depression|measured (l_compound) depression_17\NN\14373582|
D013999_D003866 CID timolol_12\NN\2832168|than|patients (r_nmod) less_7\JJR\1740|that|betaxolol|could|be|depression-inducer|timolol (l_nmod) depression-inducer_10\NN\1740|of|a
D015784_D003866 NONE betaxolol_4\NN\1740| (r_nsubj) less_7\JJR\1740|that|betaxolol|could|be|depression-inducer|timolol (l_nmod) depression-inducer_10\NN\1740|of|a
16858720
D014859_D002543 CID warfarin_4\NN\2718259|by (r_nmod) induced_2\VBN\1627355|warfarin (r_acl) haemorrhage_1\NN\14285662|cerebral|induced|-|influence|.
D014859_D002543 CID warfarin-induced_11\JJ\1740| (r_amod) haemorrhages_13\NNS\14285662|of|warfarin-induced|cerebral|warfarin
D014859_D002543 CID warfarin_16\NN\2718259|due|and|interactions (r_nmod) haemorrhages_13\NNS\14285662|of|warfarin-induced|cerebral|warfarin
D014859_D002543 CID warfarin-drug_18\NN\1740| (r_compound) interactions_19\NNS\37396|warfarin-drug (r_conj) warfarin_16\NN\2718259|due|and|interactions (r_nmod) haemorrhages_13\NNS\14285662|of|warfarin-induced|cerebral|warfarin
D014859_D002543 CID warfarin_8\NN\2718259|and|interactions (r_nsubj) caused_14\VBN\1617192|whether|warfarin|could|have|haemorrhage (l_dobj) haemorrhage_17\NN\14285662|the|cerebral
D014859_D002543 CID warfarin-drug_10\NN\1740| (r_compound) interactions_11\NNS\37396|warfarin-drug (r_conj) warfarin_8\NN\2718259|and|interactions (r_nsubj) caused_14\VBN\1617192|whether|warfarin|could|have|haemorrhage (l_dobj) haemorrhage_17\NN\14285662|the|cerebral
D014859_D002543 CID warfarin_19\NN\2718259| (r_compound) treatment_20\NN\654885|to|warfarin (r_nmod) related_17\JJ\1740|as|treatment (r_advcl) assessed_15\VBN\670261|,|59|were|related|. (r_dep) results_0\NNS\34213|:|patients|assessed (l_nmod) patients_4\NNS\9898892|among|593|haemorrhage (l_nmod) haemorrhage_7\NN\14285662|with|cerebral
D014859_D002543 CID warfarin-induced_2\JJ\1740| (r_amod) haemorrhages_4\NNS\14285662|warfarin-induced|cerebral
D014859_D002543 CID warfarin-related_4\JJ\1740| (r_amod) haemorrhages_6\NNS\14285662|of|warfarin-related|cerebral
D014859_D002543 CID warfarin_24\NN\2718259|with (r_nmod) interact_22\VB\2367363|to|warfarin (r_xcomp) known_20\VBN\2110220|interact (r_acl) drugs_19\NNS\14778436|known (r_dobj) prescribing_18\VBG\748282|when|drugs (r_advcl) taken_16\VBN\2367363|if|caution|had|been|prescribing (r_advcl) prevented_10\VBN\1740|proportion|might|have|been|taken|. (l_nsubjpass) proportion_2\NN\13824815|a|significant|haemorrhages (l_nmod) haemorrhages_6\NNS\14285662|of|warfarin-related|cerebral
D014859_D006470 NONE warfarin-drug_1\NN\1740| (r_compound) interaction_2\NN\37396|a|warfarin-drug (r_nsubj) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|and|considered (l_nmod) haemorrhage_8\NN\14285662|to|the
D014859_D006470 NONE warfarin-drug_1\NN\1740| (r_compound) interaction_2\NN\37396|a|warfarin-drug (r_nsubj) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|and|considered (l_conj) considered_32\VBN\689344|7|complication|was|possible|. (l_nsubjpass) complication_30\NN\1073995|the|bleeding (l_compound) bleeding_29\NN\14285662|
D014859_D006470 NONE warfarin_17\NN\2718259| (r_compound) patients_18\NNS\9898892|of|the|warfarin (r_nmod) 24_10\CD\13745420|in|%|patients (r_nmod) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|and|considered (l_nmod) haemorrhage_8\NN\14285662|to|the
D014859_D006470 NONE warfarin_17\NN\2718259| (r_compound) patients_18\NNS\9898892|of|the|warfarin (r_nmod) 24_10\CD\13745420|in|%|patients (r_nmod) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|and|considered (l_conj) considered_32\VBN\689344|7|complication|was|possible|. (l_nsubjpass) complication_30\NN\1073995|the|bleeding (l_compound) bleeding_29\NN\14285662|
19299179
D015662_D002779 NONE co-trimoxazole_7\NN\1740| (r_compound) treatment_8\NN\654885|after|high-dose|co-trimoxazole|pneumonia (r_nmod) cholestasis_4\NN\14052403|severe|treatment|--|report
D015662_D011020 NONE co-trimoxazole_7\NN\1740| (r_compound) treatment_8\NN\654885|after|high-dose|co-trimoxazole|pneumonia (l_nmod) pneumonia_11\NN\14145095|for|pneumocystis|patients
D015662_D011020 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|,
D015662_D011020 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|, (l_appos) pcp_3\NN\10480253|(|)
D015662_D011020 NONE co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (l_nmod) pcp_34\NN\10480253|for
D015662_D015658 NONE co-trimoxazole_7\NN\1740| (r_compound) treatment_8\NN\654885|after|high-dose|co-trimoxazole|pneumonia (l_nmod) pneumonia_11\NN\14145095|for|pneumocystis|patients (l_nmod) patients_14\NNS\9898892|in|hiv-infected (l_amod) hiv-infected_13\JJ\1740|
D015662_D015658 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|, (l_appos) infection_9\NN\14052046|a|common|opportunistic|individuals (l_nmod) individuals_12\NNS\7347|in|hiv-infected (l_amod) hiv-infected_11\JJ\1740|
D015662_D015658 NONE co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (r_nmod) mimicking_22\VBG\1742886|formation|exams|,|treatment (r_acl) lesions_21\NNS\14204950|patient|mimicking (r_conj) cases_5\NNS\7283608|two|patients|,|and|lesions (l_nmod) patients_10\NNS\9898892|of|immunocompromised|hiv-infected|developed (l_amod) hiv-infected_9\JJ\1740|
D015662_D009894 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|, (l_appos) infection_9\NN\14052046|a|common|opportunistic|individuals
D015662_D002780 CID co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (r_nmod) mimicking_22\VBG\1742886|formation|exams|,|treatment (r_acl) lesions_21\NNS\14204950|patient|mimicking (r_conj) cases_5\NNS\7283608|two|patients|,|and|lesions (l_nmod) patients_10\NNS\9898892|of|immunocompromised|hiv-infected|developed (l_acl:relcl) developed_12\VBD\1753788|who|cholestasis (l_dobj) cholestasis_15\NN\14052403|severe|intrahepatic
D015662_D008100 NONE co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (r_nmod) mimicking_22\VBG\1742886|formation|exams|,|treatment (l_dobj) formation_25\NN\7938773|liver|abscess (l_compound) abscess_24\NN\14299637|
7449470
D004317_D066126 NONE doxorubicin_3\NN\2716866| (r_compound) cardiotoxicity_4\NN\1740|late|,|late|doxorubicin|.
D004317_D066126 NONE adriamycin_11\NN\1740|of (r_nmod) use_9\NN\407535|the|adriamycin|agent (r_dobj) limits_7\VBZ\2510337|which|use (r_acl:relcl) complication_5\NN\1073995|toxicity|is|a|major|limits|. (l_nsubj) toxicity_1\NN\13576101|cardiac
9672936
D008614_D012640 CID pethidine-associated_0\NN\1740| (r_compound) seizure_1\NN\14081375|pethidine-associated|adolescent|.
D008614_D012640 CID pethidine_7\NN\1740| (r_dobj) receiving_6\VBG\2210855|pethidine|control (r_acl) adolescent_5\NN\9622049|in|a|healthy|receiving (r_nmod) seizure_1\NN\14081375|pethidine-associated|adolescent|.
D008614_D010149 NONE pethidine-associated_0\NN\1740| (r_compound) seizure_1\NN\14081375|pethidine-associated|adolescent|. (l_nmod) adolescent_5\NN\9622049|in|a|healthy|receiving (l_acl) receiving_6\VBG\2210855|pethidine|control (l_nmod) control_11\NN\5190804|for|postoperative|pain (l_compound) pain_10\NN\14299637|
D008614_D010149 NONE pethidine_7\NN\1740| (r_dobj) receiving_6\VBG\2210855|pethidine|control (l_nmod) control_11\NN\5190804|for|postoperative|pain (l_compound) pain_10\NN\14299637|
D008614_D010149 NONE pethidine_9\NN\1740|of (r_nmod) doses_7\NNS\3740161|standard|intermittent|pethidine (r_dobj) received_4\VBD\2210855|male|doses|pump|management|. (l_nmod) management_19\NN\1123598|for|control (l_nmod) control_23\NN\5190804|of|postoperative|pain (l_compound) pain_22\NN\14299637|
16680561
D003891_D009325 CID desipramine_8\NN\4482543|with|alone (r_nmod) treatment_6\NN\654885|following|desipramine|receiving (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|%|,|reported|. (l_parataxis) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
D003891_D009325 CID desipramine_13\NN\4482543| (r_dobj) receiving_12\VBG\2210855|than|when|desipramine|cinacalcet (r_advcl) treatment_6\NN\654885|following|desipramine|receiving (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|%|,|reported|. (l_parataxis) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
D003891_D009325 CID desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
D003891_D006261 CID desipramine_8\NN\4482543|with|alone (r_nmod) treatment_6\NN\654885|following|desipramine|receiving (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|%|,|reported|. (l_parataxis) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
D003891_D006261 CID desipramine_13\NN\4482543| (r_dobj) receiving_12\VBG\2210855|than|when|desipramine|cinacalcet (r_advcl) treatment_6\NN\654885|following|desipramine|receiving (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|%|,|reported|. (l_parataxis) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
D003891_D006261 CID desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
C476217_D009325 CID cinacalcet_15\NN\1740|with (r_nmod) receiving_12\VBG\2210855|than|when|desipramine|cinacalcet (r_advcl) treatment_6\NN\654885|following|desipramine|receiving (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|%|,|reported|. (l_parataxis) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
C476217_D009325 CID cinacalcet_43\NN\1740| (r_conj) desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
C476217_D006261 CID cinacalcet_15\NN\1740|with (r_nmod) receiving_12\VBG\2210855|than|when|desipramine|cinacalcet (r_advcl) treatment_6\NN\654885|following|desipramine|receiving (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|%|,|reported|. (l_parataxis) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
C476217_D006261 CID cinacalcet_43\NN\1740| (r_conj) desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|frequent|have|been|patients (l_nsubjpass) frequent_25\JJ\1740|the|most|which|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
10579464
C121249_D006948 NONE nra0160_0\NN\1740|and|clozapine (r_nsubj) antagonized_3\VBD\1787955|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN\14052403|locomotor|induced
D003024_D006948 NONE clozapine_2\NN\3713736| (r_conj) nra0160_0\NN\1740|and|clozapine (r_nsubj) antagonized_3\VBD\1787955|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN\14052403|locomotor|induced
D008694_D006948 CID methamphetamine_8\NN\2704153|by|map (r_nmod) induced_6\VBN\1627355|methamphetamine|mice (r_acl) hyperactivity_5\NN\14052403|locomotor|induced
D008694_D006948 CID map_10\NN\4076846|(|) (r_appos) methamphetamine_8\NN\2704153|by|map (r_nmod) induced_6\VBN\1627355|methamphetamine|mice (r_acl) hyperactivity_5\NN\14052403|locomotor|induced
C121249_D002375 CID nra0160_0\NN\1740|and|clozapine (r_nsubj) induced_4\VBD\1627355|nra0160|significantly|catalepsy|rats|,|exceed|. (l_dobj) catalepsy_5\NN\14023236|
D003024_D002375 CID clozapine_2\NN\3713736| (r_conj) nra0160_0\NN\1740|and|clozapine (r_nsubj) induced_4\VBD\1627355|nra0160|significantly|catalepsy|rats|,|exceed|. (l_dobj) catalepsy_5\NN\14023236|
3782049
D008972_D012206 CID molindone_6\NN\3713736| (r_compound) administration_7\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_4\NN\1740|of|massive|administration
D008972_D012206 CID molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_11\NN\1740|massive|and|failure|administration
D008972_D012559 NONE molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_11\NN\1740|massive|and|failure|administration (r_dobj) illustrate_9\VB\955601|to|rhabdomyolysis (r_xcomp) reported_7\VBN\831651|case|is|illustrate|. (l_nsubjpass) case_1\NN\7283608|the|patient (l_nmod) patient_5\NN\9898892|of|a|schizophrenic (l_amod) schizophrenic_4\JJ\1740|
D008972_D058186 CID molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_11\NN\1740|massive|and|failure|administration (l_conj) failure_16\NN\66216|subsequent|acute|renal
7444978
D013307_D020258 NONE streptomycin_9\NN\2716866|of (r_nmod) effects_7\NNS\13245626|to|neurotoxic|streptomycin (l_amod) neurotoxic_6\JJ\1740|
D013307_D004409 CID streptomycin_48\NN\2716866|to (r_nmod) sensitive_46\JJ\1740|that|cochlea|is|more|streptomycin|site (r_ccomp) indicating_40\VBG\952524|sensitive (r_advcl) occurred_23\VBD\2623529|occurred|;|period|sensitivities|17|,|respectively|,|indicating|. (l_ccomp) occurred_4\VBD\2623529|movements|rats (l_nsubj) movements_1\NNS\191142|abnormal|and|deafness
D013307_D004409 CID streptomycin_48\NN\2716866|to (r_nmod) sensitive_46\JJ\1740|that|cochlea|is|more|streptomycin|site (l_nmod) site_51\NN\8673395|than|the|vestibular|responsible (l_amod) responsible_57\JJ\1740|dyskinesias (l_nmod) dyskinesias_60\NNS\14084880|for|the
D013307_D003638 CID streptomycin_48\NN\2716866|to (r_nmod) sensitive_46\JJ\1740|that|cochlea|is|more|streptomycin|site (r_ccomp) indicating_40\VBG\952524|sensitive (r_advcl) occurred_23\VBD\2623529|occurred|;|period|sensitivities|17|,|respectively|,|indicating|. (l_ccomp) occurred_4\VBD\2623529|movements|rats (l_nsubj) movements_1\NNS\191142|abnormal|and|deafness (l_conj) deafness_3\NN\14550797|
2273650
D012601_D000647 CID scopolamine_3\NN\14712692|by|and|cycloheximide (r_nmod) produced_1\VBN\1617192|scopolamine (r_acl) amnesia_0\NN\5669934|produced
D012601_D000647 CID scopolamine_3\NN\14712692|pre-test (r_nsubj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|significantly|;|and|failed (l_dobj) amnesia_8\NN\5669934|the|scopolamine-induced|,|but
D012601_D000647 CID scopolamine_3\NN\14712692|pre-test (r_nsubj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|significantly|;|and|failed (l_conj) failed_17\VBD\1798936|cycloheximide|reverse|. (l_xcomp) reverse_19\VB\109660|to|amnesia (l_dobj) amnesia_22\NN\5669934|the|cycloheximide-induced
D012601_D000647 CID scopolamine-induced_7\JJ\1740| (r_amod) amnesia_8\NN\5669934|the|scopolamine-induced|,|but
D012601_D000647 CID scopolamine-induced_7\JJ\1740| (r_amod) amnesia_8\NN\5669934|the|scopolamine-induced|,|but (r_dobj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|significantly|;|and|failed (l_conj) failed_17\VBD\1798936|cycloheximide|reverse|. (l_xcomp) reverse_19\VB\109660|to|amnesia (l_dobj) amnesia_22\NN\5669934|the|cycloheximide-induced
D003513_D000647 CID cycloheximide_5\NN\1740| (r_conj) scopolamine_3\NN\14712692|by|and|cycloheximide (r_nmod) produced_1\VBN\1617192|scopolamine (r_acl) amnesia_0\NN\5669934|produced
D003513_D000647 CID cycloheximide_16\NN\1740|pre-test (r_nsubj) failed_17\VBD\1798936|cycloheximide|reverse|. (r_conj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|significantly|;|and|failed (l_dobj) amnesia_8\NN\5669934|the|scopolamine-induced|,|but
D003513_D000647 CID cycloheximide_16\NN\1740|pre-test (r_nsubj) failed_17\VBD\1798936|cycloheximide|reverse|. (l_xcomp) reverse_19\VB\109660|to|amnesia (l_dobj) amnesia_22\NN\5669934|the|cycloheximide-induced
D003513_D000647 CID cycloheximide-induced_21\JJ\1740| (r_amod) amnesia_22\NN\5669934|the|cycloheximide-induced (r_dobj) reverse_19\VB\109660|to|amnesia (r_xcomp) failed_17\VBD\1798936|cycloheximide|reverse|. (r_conj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|significantly|;|and|failed (l_dobj) amnesia_8\NN\5669934|the|scopolamine-induced|,|but
D003513_D000647 CID cycloheximide-induced_21\JJ\1740| (r_amod) amnesia_22\NN\5669934|the|cycloheximide-induced
D009020_D000647 NONE morphine_9\NN\2707683|by|given (r_nmod) reversed_7\VBN\109660|amnesia|were|morphine|pre-test|,|and|facilitated (l_nsubjpass) amnesia_0\NN\5669934|produced
D009020_D000647 NONE morphine_23\NN\2707683|pre-test (r_nsubj) facilitated_25\VBD\2547586|morphine|also|retrieval|. (r_conj) reversed_7\VBN\109660|amnesia|were|morphine|pre-test|,|and|facilitated (l_nsubjpass) amnesia_0\NN\5669934|produced
D009270_D000647 NONE naloxone_33\NN\3808977| (r_dobj) administered_32\VBN\2436349|naloxone|trial (r_acl) animals_31\NNS\4475|in|the|administered (r_nmod) retrieval_28\NN\13450862|the|memory|animals (r_dobj) facilitated_25\VBD\2547586|morphine|also|retrieval|. (r_conj) reversed_7\VBN\109660|amnesia|were|morphine|pre-test|,|and|facilitated (l_nsubjpass) amnesia_0\NN\5669934|produced
